n
(:LKP_GENE_DETAILS {GeneMasterName: "ASXL1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PHOXB2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:syndrome {name: "Acrodysostosis 1 with or without hormone resistance", types: ["Dominant"], verbiages: ["The PRKAR1A gene is associated with autosomal dominant Carney complex (CNC) (MedGen UID: Acrodysostosis (MedGen UID: 477858).  	

Autosomal dominant acrodysostosis is characterized by variable skeletal, endocrine, and neurological abnormalities that are present in childhood (PMID: 22464252). The most common features include brachydactyly, dysmorphic facies, short stature, and intellectual disability and/or developmental delays (PMID: 26763073). Other symptoms may include advanced bone age, peripheral dysostosis with shortened bones of the hands and feet, cone-shaped epiphyses, lumbar stenosis, hypothyroidism, multiple hormone resistance, cryptorchidism, hypospadias, deafness and rhinitis (PMID: 22464252, 23033274, 26763073).

Loss of function variants are associated with CNC (PMID: 19293268, 11115848). Some further genotype-phenotype correlations have been suggested for acrodysostosis versus CNC (PMID: 10974026, 10973256, 22464250, 22464252), but these correlations remain preliminary."]})
(:syndrome {name: "Limb-girdle muscular dystrophy"})
(:syndrome {name: "3-Methylglutaconic aciduria type 2"})
(:syndrome {name: "Emery-Dreifuss muscular dystrophy 7, autosomal dominant"})
(:syndrome {name: "Familial restrictive cardiomyopathy"})
(:syndrome {name: "Choreoathetosis and Congenital Hypothyroidism with or Without Pulmonary Dysfunction"})
(:syndrome {name: "IMAGe syndrome", types: ["Dominant"], verbiages: ["IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) (MedGen UID: 337364).  

IMAGe syndrome is also characterized by growth abnormality; however, unlike BWS, affected individuals present with growth restriction. In addition to the clinical findings indicated by the acronym (Intrauterine growth restriction, Metaphyseal dysplasia, congenital Adrenal hypoplasia, and Genital anomalies), some may present with craniofacial features such as low-set ears, flat nasal bridge and short nose (PMID: 24098681, 10599684, 14760276). Genital anomalies occur mostly in males and include micropenis, undescended testes and hypospadias (PMID: 14760276)."]})
(:syndrome {name: "Familial Erythrocytosis"})
(:syndrome {name: "Hereditary Retinoblastoma"})
(:syndrome {name: "Serrated Polyposis Syndrome"})
(:syndrome {name: "VACTERL association with hydrocephaly, X-linked"})
(:syndrome {name: "Coats Plus Syndrome"})
(:syndrome {name: "Xeroderma pigmentosum, group B"})
(:syndrome {name: "Overgrowth and Neurodevelopmental Delay Syndrome"})
(:syndrome {name: "x-linked"})
(:syndrome {name: "Primary Immunodeficiency Syndrome"})
(:syndrome {name: "GAPPS", types: ["Dominant"], verbiages: ["Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414)."]})
(:syndrome {name: "Autosomal dominant hypocalcemia with Bartter syndrome", types: ["Dominant"], verbiages: ["A subset of GOF variants in CASR can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130)."]})
(:syndrome {name: "Autosomal dominant hypocalcemia", types: ["Dominant"], verbiages: ["Pathogenic gain-of-function (GOF) variants in CASR cause ADH. ADH is characterized by hypoparathyroidism, hypocalcemia and hypercalciuria although approximately half of affected individuals have no associated health problems (PMID: 31189130). A subset of GOF variants can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130)."]})
(:syndrome {name: "Hereditary Lung Cancer", types: ["Dominant"], verbiages: ["LOF variants in EGFR are not known to be associated with autosomal dominant predisposition to lung cancer.

Pathogenic gain-of-function (GOF) EGFR variants are associated with an increased risk of lung cancer (PMID: 16258541, 24736066, 24736080, 21252721, 23380224, 25176975, 18355544, 23358982). One study estimated the risk of lung cancer to be 15-31% (PMID: 24736066), although data are limited."]})
(:syndrome {name: "Autosomal recessive deafness"})
(:syndrome {name: "COMMAD syndrome", types: ["Recessive"], verbiages: ["Autosomal recessive COMMAD syndrome (coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness) (MedGen UID: 934592).  
COMMAD syndrome is a rare condition characterized by iris coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism and deafness. Due to the limited cases described in the literature, the clinical features and natural history of COMMAD are still unclear and will likely evolve over time. Clinical correlation is advised."]})
(:syndrome {name: "Small cell carcinoma of the ovary, hypercalcemic type", types: ["Dominant"], verbiages: ["Autosomal dominant small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PMID: 24658002, 24658001).   SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established."]})
(:syndrome {name: "Congenital ocular motor apraxia", types: ["Dominant"], verbiages: ["Autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317)."]})
(:syndrome {name: "Familial isolated pituitary adenoma (FIPA)", types: ["Dominant"], verbiages: ["(MedGen UID: 489979).  FIPA presents in early adulthood with the development of pituitary adenomas in the absence of other syndromic findings. These pituitary adenomas may be of various types including somatotropinoma (growth hormone-secreting), prolactinoma (prolactin-secreting), somatomammotropinoma (growth hormone and prolactin co-secreting) and nonfunctioning pituitary adenomas (NFPA). Other types of adenomas have also been observed (PMID: 22720333, 26186299)."]})
(:syndrome {name: "Congenital central hypoventilation syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant congenital central hypoventilation syndrome (CCHS) (MedGen UID: 347052). Most cases of CCHS are due to a polyalanine repeat expansion, which is not analyzed by this test.											  CCHS is a disorder of autonomic regulation characterized by alveolar hypoventilation and symptoms of autonomic dysregulation presenting in the newborn period. Dysmorphic features include downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears (PMID: 23465774,18579454, 20208042). A subset of affected individuals may develop Hirschsprung disease and/or tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma)."]})
(:syndrome {name: "MSH3-associated Polyposis"})
(:syndrome {name: "Emberger Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Emberger syndrome (MedGen UID: 481294).  Emberger syndrome is a related GATA2 deficiency condition associated with lymphedema of the lower extremities and predisposition to AML; hearing loss has been reported in some cases (PMID: 23223431, 21892158, 20803646)."]})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Kidney (Benign)", PredominantCancerSubtype: "Nephrotic Syndrome", GeneMasterName: "WT1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Diaphragmatic Hernia", GeneMasterName: "WT1", Gender: "Either", Organ: "Diaphragm"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Genitourinary (Benign)", PredominantCancerSubtype: "Cryptorchidism, ectopic ureter", GeneMasterName: "WT1", Gender: "Male", Organ: "Genitals"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intellectual Disability", GeneMasterName: "WT1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "WT1", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Mesothelioma", PredominantCancerSubtype: "Pleura", GeneMasterName: "WT1", Gender: "Either", Organ: "Mesothelium"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "WT1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "WT1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "XRCC2", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "XRCC2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "XRCC2", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Endocrine", PredominantCancerSubtype: "Familial Hypocalciuric Hypercalcemia", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Endocrine"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Skin Pigmentation", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Cardiovascular Neoplasm", PredominantCancerSubtype: "Cardiac Myxoma", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Lentigines", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Skin Neoplasm", PredominantCancerSubtype: "Mucocutaneous myoma", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PDGFRA", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FGFR3", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FLT3", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TRRAP", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FANCA", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ELAC2", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MITF", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EHBP1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "IGF2R", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "FAT4", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "HPC1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PCAP", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "NTRK", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH3", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Subependymal giant cell astrocytomas", GeneMasterName: "TSC1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas", GeneMasterName: "TSC1", Gender: "Either", Organ: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Angiomyolipomas", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Hamartoma", PredominantCancerSubtype: "Retinal nodular hamartomas", GeneMasterName: "TSC1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC2", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Angiomyolipomas", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Subependymal giant cell astrocytomas", GeneMasterName: "TSC2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Subependymal nodules", GeneMasterName: "TSC2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Cortical tubers", GeneMasterName: "TSC2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Cardiovascular Neoplasm", PredominantCancerSubtype: "Rhabdomyomas", GeneMasterName: "TSC2", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Hamartoma", PredominantCancerSubtype: "Retinal nodular hamartomas", GeneMasterName: "TSC2", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Hamartoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC2", Gender: "Either", Organ: "Multiple organs"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Lymphangiomyomatosis", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC2", Gender: "Either", Organ: "Lymphatic"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Hamartomas Of Tongue", GeneMasterName: "TSC2", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas", GeneMasterName: "TSC2", Gender: "Either", Organ: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Tuberous sclerosis complex (TSC)", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC2", Gender: "Either", Organ: "General"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "FAMM", GeneMasterName: "CDKN2A"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Congenital tufting enteropathy", GeneMasterName: "EPCAM-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Constitutional Mismatch Repair Deficiency Syndrome", GeneMasterName: "MLH1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Constitutional Mismatch Repair Deficiency Syndrome", GeneMasterName: "PMS2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MDPL Syndrome", GeneMasterName: "POLD1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "FILS Syndrome", GeneMasterName: "POLE-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Myhre Syndrome", GeneMasterName: "SMAD4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Watson Syndrome", GeneMasterName: "NF1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Nijmegen Breakage Syndrome", GeneMasterName: "NBN-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Marinesco-Sj√∂gren syndrome", GeneMasterName: "SIL1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cowden Syndrome", GeneMasterName: "PTEN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cowden Syndrome", GeneMasterName: "SDHB"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cowden Syndrome", GeneMasterName: "SDHD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "BRCA2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "BRIP1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "PALB2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "RAD51C-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "RAD51-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Diffuse Gastric Cancer Syndrome", GeneMasterName: "CDH1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Diffuse Gastric Cancer Syndrome", GeneMasterName: "IL1B"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Diffuse Gastric Cancer Syndrome", GeneMasterName: "IL1RN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Diffuse Gastric Cancer Syndrome", GeneMasterName: "KRAS"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "BCS1L"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "COX10"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "COX15"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "FOXRED1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFA10"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFA12"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFA2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFA9"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFAF2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFAF6"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFS3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFS4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFS7"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NDUFS8"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "SURF1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "MSH2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Constitutional Mismatch Repair Deficiency Syndrome", GeneMasterName: "MSH2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Hemorrhagic Telangiectasia (HHT)", GeneMasterName: "SMAD4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Neurofibromatosis, type 2", GeneMasterName: "NF2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Nijmegen Breakage Syndrome-Like Disorder", GeneMasterName: "RAD50-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Peutz-Jeghers Syndrome", GeneMasterName: "STK11"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Constitutional Mismatch Repair Deficiency Syndrome", GeneMasterName: "MSH6-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "PMS2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Birt-Hogg-Dube Syndrome", GeneMasterName: "FLCN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Gardner Syndrome", GeneMasterName: "APC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Mixed Polyposis Syndrome", GeneMasterName: "GREM1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Juvenile Polyposis Syndrome", GeneMasterName: "BMPR1A"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Juvenile Polyposis Syndrome", GeneMasterName: "SMAD4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", GeneMasterName: "SDHA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", GeneMasterName: "SDHAF2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", GeneMasterName: "SDHB"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", GeneMasterName: "SDHC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", GeneMasterName: "SDHD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Ataxia telangiectasia", GeneMasterName: "ATM-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Carney-Stratakis Syndrome", GeneMasterName: "SDHB"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Breast and Ovary Cancer Syndrome", GeneMasterName: "BRCA2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "MSH6"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "EPCAM"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Li-Fraumeni Syndrome", GeneMasterName: "TP53"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "PMS1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "MLH1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MEN1", GeneMasterName: "MEN1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MEN2b", GeneMasterName: "RET"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MEN4", GeneMasterName: "CDKN1B"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Neurofibromatosis, type 1", GeneMasterName: "NF1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Von Hippel Lindau Syndrome", GeneMasterName: "VHL"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Attenuated FAP", GeneMasterName: "APC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Breast Cancer Syndrome", GeneMasterName: "ATM"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MUTYH-Associated Polyposis Syndrome", GeneMasterName: "MUTYH-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Breast and Ovary Cancer Syndrome", GeneMasterName: "BRCA1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Neurofibromatosis-Noonan syndrome", GeneMasterName: "NF1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "FAP", GeneMasterName: "APC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MEN2a", GeneMasterName: "RET"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Von Hippel Lindau Syndrome", GeneMasterName: "CCND1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lynch Syndrome", GeneMasterName: "MLH3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Bannayan-Riley-Ruvalcaba syndrome", GeneMasterName: "PTEN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Medullary Thyroid Carcinoma Syndrome", GeneMasterName: "RET"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Blepharocheilodontic Syndrome", GeneMasterName: "CDH1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Juvenile polyposis_hereditary hemorrhagic telangiectasia syndrome", GeneMasterName: "SMAD4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Melanoma astrocytoma syndrome", GeneMasterName: "CDKN2A"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Muir-Torre syndrome", GeneMasterName: "MLH1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MUTYH-related AFAP", GeneMasterName: "MUTYH-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPL11"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPL26"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPL35A"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPL5"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPS10"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPS19"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPS24"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPS26"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPS7"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Atrial fibrillation, familial", GeneMasterName: "ABCC9"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "ABCC9"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cantu Syndrome", GeneMasterName: "ABCC9"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "ACTN2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "ACTN2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "BRCA1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Muir-Torre syndrome", GeneMasterName: "MSH2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Bloom Syndrome", GeneMasterName: "BLM-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Mosaic Variegated Aneuploidy Syndrome", GeneMasterName: "BUB1B-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Neonatal Severe Hyperparathyroidism", GeneMasterName: "CASR-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Mosaic Variegated Aneuploidy Syndrome", GeneMasterName: "CEP57-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cystic Fibrosis & Congenital Absence Of The Vas Deferens (CAVD),", GeneMasterName: "CFTR-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dyskeratosis Congenita", GeneMasterName: "CTC1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Perlman Syndrome", GeneMasterName: "DIS3L2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cockayne Syndrome", GeneMasterName: "ERCC4-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCA-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCC-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCD2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCE-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCF-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCG-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCL-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "FANCM-Biallelic"})
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
(:LKP_GENE_SYNDROME {SyndromeMasterName: "fumarate hydratase deficiency", GeneMasterName: "FH-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Ataxia-Telangiectasia-Like Disorder (ATLD)", GeneMasterName: "MRE11-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Colonic Polyposis And Colorectal Cancer", GeneMasterName: "MSH3-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dyskeratosis Congenita", GeneMasterName: "NHP2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dyskeratosis Congenita", GeneMasterName: "NOP10-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Tuberous Sclerosis Complex", GeneMasterName: "TSC1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "BRIP1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "CFTR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "CEP57"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "CTC1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "DDB2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "LDLRAP1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NBN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NHP2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "NTHL1 Tumor Syndrome", GeneMasterName: "NTHL1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NOP10"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RAD50"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RAD51"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RAD51C"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RECQL"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "SLX4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "SPINK1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "WRN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "XPA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Baller-Gerold Syndrome", GeneMasterName: "RECQL4-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Rapadilino Syndrome", GeneMasterName: "RECQL4-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Turcot Syndrome", GeneMasterName: "APC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Turcot Syndrome", GeneMasterName: "MLH1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Turcot Syndrome", GeneMasterName: "PMS2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Arrhythmogenic right ventricular dysplasia", GeneMasterName: "TMEM43"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "arrhythmogenic right ventricular dysplasia", GeneMasterName: "PKP2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "arrhythmogenic right ventricular dysplasia", GeneMasterName: "JUP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "arrhythmogenic right ventricular dysplasia", GeneMasterName: "DSP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "arrhythmogenic right ventricular dysplasia", GeneMasterName: "DSG2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "arrhythmogenic right ventricular dysplasia", GeneMasterName: "DSC2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Carney Complex", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Trichohepatoenteric Syndrome", GeneMasterName: "TTC37"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Trichohepatoenteric Syndrome", GeneMasterName: "SKIV2L"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Colonic Polyposis And Colorectal Cancer", GeneMasterName: "NTHL1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Rothmund-Thomson Syndrome", GeneMasterName: "RECQL4-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Mitochondrial Complex II Deficiency", GeneMasterName: "SDHA-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Mitochondrial Complex II Deficiency", GeneMasterName: "SDHB-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "SLX4-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Pancreatitis", GeneMasterName: "SPINK1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Erythrocytosis Type 2", GeneMasterName: "VHL-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Werner Syndrome", GeneMasterName: "WRN-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Androgen Insensitivity Syndrome", GeneMasterName: "AR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Blepharocheilodontic syndrome", GeneMasterName: "CTNND1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Brugada syndrome", GeneMasterName: "SCN5A"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Clouston syndrome", GeneMasterName: "GJB6"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Danon disease", GeneMasterName: "LAMP2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fabry disease", GeneMasterName: "GLA-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "HUTCHINSON-GILFORD PROGERIA SYNDROME", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "CDC73-related conditions", GeneMasterName: "CDC73"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome", GeneMasterName: "FOXP3-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "McLeod neuroacanthocytosis syndrome", GeneMasterName: "XK-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cutaneous telangiectasia and cancer syndrome, familial", GeneMasterName: "ATR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Seckel syndrome 1", GeneMasterName: "ATR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Oligodontia-Colorectal Cancer Syndrome", GeneMasterName: "AXIN2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "BAP1 Tumor Predisposition Syndrome", GeneMasterName: "BAP1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Hypocalciuric Hypercalcemia", GeneMasterName: "CASR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Isolated Hyperparathyroidism", GeneMasterName: "CASR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "FAMM", GeneMasterName: "CDK4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Beckwith-Wiedemann Syndrome", GeneMasterName: "CDKN1C"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Acute Myeloid Leukemia", GeneMasterName: "CEBPA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Spiegler-Brooke syndrome", GeneMasterName: "CYLD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Scapuloperoneal syndrome, neurogenic, Kaeser type", GeneMasterName: "DES"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "DICER1-Pleuropulmonary Blastoma Familial Tumor Predisposition Syndrome", GeneMasterName: "DICER1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "X-Linked Dyskeratosis Congenita", GeneMasterName: "DKC1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Skin fragility woolly hair syndrome", GeneMasterName: "DSP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "neonatal inflammatory skin and bowel disease", GeneMasterName: "EGFR-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Pulmonary Arterial Hypertension (PAH)", GeneMasterName: "ENG"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cerebrooculofacioskeletal syndrome", GeneMasterName: "ERCC2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MEN2", GeneMasterName: "RET"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Howel-Evans syndrome", GeneMasterName: "RHBDF2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Sessile serrated polyposis cancer syndrome", GeneMasterName: "RNF43"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Platelet Disorder With Associated Myeloid Malignancy", GeneMasterName: "RUNX1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Shwachman syndrome", GeneMasterName: "SBDS"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Leigh Syndrome", GeneMasterName: "SDHA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cowden-Like Syndrome", GeneMasterName: "SDHD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Rhabdoid Tumor Predisposition Syndrome 2", GeneMasterName: "SMARCA4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Rhabdoid Tumor Predisposition Syndrome 1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Schwannomatosis", GeneMasterName: "SMARCB1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Coffin-Siris Syndrome", GeneMasterName: "SMARCE1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Meningioma", GeneMasterName: "SMARCE1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Legius Syndrome", GeneMasterName: "SPRED1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Gorlin Syndrome", GeneMasterName: "SUFU"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Joubert Syndrome", GeneMasterName: "SUFU-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Tuberous Sclerosis Complex", GeneMasterName: "TSC2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Denys-Drash Syndrome", GeneMasterName: "WT1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Frasier Syndrome", GeneMasterName: "WT1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Meacham syndrome", GeneMasterName: "WT1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "WAGR Syndrome", GeneMasterName: "WT1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Breast Cancer Syndrome", GeneMasterName: "XRCC2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "CSRP3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "CSRP3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Macular dystrophy, patterned, 2", GeneMasterName: "CTNNA1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "xeroderma pigmentosum complementation group E", GeneMasterName: "DDB2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy", GeneMasterName: "DES"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Arrhythmogenic right ventricular cardiomyopathy", GeneMasterName: "DSC2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Arrhythmogenic right ventricular cardiomyopathy", GeneMasterName: "DSG2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "XFE progeroid syndrome", GeneMasterName: "ERCC4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cerebrooculofacioskeletal syndrome", GeneMasterName: "ERCC5"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Seizures, scoliosis, and macrocephaly syndrome", GeneMasterName: "EXT2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Weaver Syndrome", GeneMasterName: "EZH2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "X-Linked Fanconi Anemia", GeneMasterName: "FANCB-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Leiomyomatosis And Renal Cell Cancer (HLRCC)", GeneMasterName: "FH"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Diamond-Blackfan Anemia", GeneMasterName: "GATA1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "X-Linked GATA1-Related Cytopenia", GeneMasterName: "GATA1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "GATA2 Deficiency", GeneMasterName: "GATA2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Simpson-Golabi-Behmel syndrome", GeneMasterName: "GPC3-X-Linked Recessive"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Costello Syndrome", GeneMasterName: "HRAS"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Heart-hand syndrome, Slovenian type", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Lethal tight skin contracture syndrome", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "FAMM", GeneMasterName: "MC1R"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Isolated Hyperparathyroidism", GeneMasterName: "MEN1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Papillary Renal Cell Carcinoma", GeneMasterName: "MET"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Tietz syndrome", GeneMasterName: "MITF"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Waardenburg syndrome type 2A", GeneMasterName: "MITF"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Joubert Syndrome", GeneMasterName: "MRE11"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "PALB2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "GIST-plus syndrome", GeneMasterName: "PDGFRA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Colonic Polyposis And Colorectal Cancer", GeneMasterName: "POLD1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Gorlin Syndrome", GeneMasterName: "PTCH1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Gorlin Syndrome", GeneMasterName: "PTCH2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Macrocephaly/autism syndrome", GeneMasterName: "PTEN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Proteus Syndrome", GeneMasterName: "PTEN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Proteus-Like Syndrome", GeneMasterName: "PTEN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "DSG2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Arrhythmogenic right ventricular cardiomyopathy", GeneMasterName: "DSP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Cardiomyopathy, dilated, with woolly hair, keratoderma, and tooth agenesis", GeneMasterName: "DSP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy with woolly hair and keratoderma", GeneMasterName: "DSP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Emery-Dreifuss muscular dystrophy 1, X-linked", GeneMasterName: "EMD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Trichothiodystrophy 1, photosensitive", GeneMasterName: "ERCC2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Xeroderma Pigmentosa", GeneMasterName: "ERCC2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Trichothiodystrophy 2, photosensitive", GeneMasterName: "ERCC3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "ERCC2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Prostate Cancer", GeneMasterName: "HOXB13"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Partial albinism", GeneMasterName: "KIT"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy", GeneMasterName: "LDB3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypercholesterolemia, autosomal recessive", GeneMasterName: "LDLRAP1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Benign scapuloperoneal muscular dystrophy with cardiomyopathy", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Congenital muscular dystrophy, LMNA-related", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Emery-Dreifuss muscular dystrophy 3, autosomal recessive", GeneMasterName: "LMNA-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial partial lipodystrophy 2", GeneMasterName: "LMNA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "MYBPC3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "MYBPC3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy", GeneMasterName: "MYH7"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Myopathy, myosin storage, autosomal recessive", GeneMasterName: "MYH7"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Myosin storage myopathy", GeneMasterName: "MYH7"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Scapuloperoneal myopathy, MYH7-related", GeneMasterName: "MYH7"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "MYL2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "MYL3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary insensitivity to pain with anhidrosis", GeneMasterName: "NTRK1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypercholesterolemia, autosomal dominant, 3", GeneMasterName: "PCSK9"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Arrhythmogenic right ventricular cardiomyopathy", GeneMasterName: "PKP2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "PLN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "PLN"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "CRC12", GeneMasterName: "POLE"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "POT1 tumor predisposition syndrome", GeneMasterName: "POT1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "PRKAG2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Acrodysostosis 1 with or without hormone resistance", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy", GeneMasterName: "SGCD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Limb-girdle muscular dystrophy", GeneMasterName: "SGCD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "3-Methylglutaconic aciduria type 2", GeneMasterName: "TAZ"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "TAZ"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "TCAP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "TCAP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Limb-girdle muscular dystrophy", GeneMasterName: "TCAP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dyskeratosis Congenita", GeneMasterName: "TERC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dyskeratosis Congenita", GeneMasterName: "TERT"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Arrhythmogenic right ventricular cardiomyopathy", GeneMasterName: "TMEM43"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Emery-Dreifuss muscular dystrophy 7, autosomal dominant", GeneMasterName: "TMEM43"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated cardiomyopathy", GeneMasterName: "TNNI3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial restrictive cardiomyopathy", GeneMasterName: "TNNI3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "TNNI3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "TNNT2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial restrictive cardiomyopathy", GeneMasterName: "TNNT2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "TNNT2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "TPM1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "TPM1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dilated Cardiomyopathy", GeneMasterName: "VCL"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hypertrophic Cardiomyopathy", GeneMasterName: "VCL"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Xeroderma Pigmentosa", GeneMasterName: "XPA-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "XRCC2-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Choreoathetosis and Congenital Hypothyroidism with or Without Pulmonary Dysfunction", GeneMasterName: "NKX2-1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "IMAGe syndrome", GeneMasterName: "CDKN1C"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial Erythrocytosis", GeneMasterName: "EGLN1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Retinoblastoma", GeneMasterName: "SDHD"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Rhabdoid Tumor Predisposition Syndrome 1", GeneMasterName: "RF1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Rhabdoid Tumor Predisposition Syndrome 2", GeneMasterName: "SMARCB1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Serrated Polyposis Syndrome", GeneMasterName: "SMARCA4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "VACTERL association with hydrocephaly, X-linked", GeneMasterName: "FANCB"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "ANKRD26"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "ARMC5"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "ASXL1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "BLM"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "DIS3L2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "FANCA"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "FANCC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "FANCM"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "GALNT12"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "GPC3"})
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "KIF1B"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "LZTR1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "PHOXB2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "PRSS1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RAD51D"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RPS20"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "TRIM37"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Coats Plus Syndrome", GeneMasterName: "CTC1-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Xeroderma pigmentosum, group B", GeneMasterName: "ERCC3-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Overgrowth and Neurodevelopmental Delay Syndrome", GeneMasterName: "CDKN1B-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "ERCC5-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "x-linked", GeneMasterName: "GPC3-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Primary Immunodeficiency Syndrome", GeneMasterName: "MYD88-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "GAPPS", GeneMasterName: "APC"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Autosomal dominant hypocalcemia with Bartter syndrome", GeneMasterName: "CASR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Autosomal dominant hypocalcemia", GeneMasterName: "CASR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Lung Cancer", GeneMasterName: "EGFR"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Autosomal recessive deafness", GeneMasterName: "MET-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "COMMAD syndrome", GeneMasterName: "MITF-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RAD51C-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Small cell carcinoma of the ovary, hypercalcemic type", GeneMasterName: "SMARCA4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Coffin-Siris Syndrome", GeneMasterName: "SMARCA4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Congenital ocular motor apraxia", GeneMasterName: "SUFU"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Familial isolated pituitary adenoma (FIPA)", GeneMasterName: "AIP"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "ALK"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "BARD1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "CHEK2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", GeneMasterName: "MAX"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "MSH3"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "NTHL1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Congenital central hypoventilation syndrome", GeneMasterName: "PHOX2B"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Fanconi Anemia", GeneMasterName: "RAD51D-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RB1"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Unknown", GeneMasterName: "RECQL4"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", GeneMasterName: "TMEM127"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Constitutional Mismatch Repair Deficiency Syndrome", GeneMasterName: "EPCAM-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MSH3-associated Polyposis", GeneMasterName: "MSH3-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Mitochondrial Complex II Deficiency", GeneMasterName: "SDHD-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Dyskeratosis Congenita", GeneMasterName: "TERT-Biallelic"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "Emberger Syndrome", GeneMasterName: "GATA2"})
(:LKP_GENE_SYNDROME {SyndromeMasterName: "MSH3-associated Polyposis", GeneMasterName: "MLH3-Biallelic"})
(:LKP_GENE_CARD_REFERENCES {Id: "1", PubmedId: "10419612"})
(:LKP_GENE_CARD_REFERENCES {Id: "2", PubmedId: "10433620"})
(:LKP_GENE_CARD_REFERENCES {Id: "3", PubmedId: "10599684"})
(:LKP_GENE_CARD_REFERENCES {Id: "4", PubmedId: "10612394"})
(:LKP_GENE_CARD_REFERENCES {Id: "5", PubmedId: "10864200"})
(:LKP_GENE_CARD_REFERENCES {Id: "6", PubmedId: "10956390"})
(:LKP_GENE_CARD_REFERENCES {Id: "7", PubmedId: "10973256"})
(:LKP_GENE_CARD_REFERENCES {Id: "8", PubmedId: "10974026"})
(:LKP_GENE_CARD_REFERENCES {Id: "9", PubmedId: "11113065"})
(:LKP_GENE_CARD_REFERENCES {Id: "10", PubmedId: "11115848"})
(:LKP_GENE_CARD_REFERENCES {Id: "11", PubmedId: "11136714"})
(:LKP_GENE_CARD_REFERENCES {Id: "12", PubmedId: "11471165"})
(:LKP_GENE_CARD_REFERENCES {Id: "13", PubmedId: "11719428"})
(:LKP_GENE_CARD_REFERENCES {Id: "14", PubmedId: "11729114"})
(:LKP_GENE_CARD_REFERENCES {Id: "15", PubmedId: "11755638"})
(:LKP_GENE_CARD_REFERENCES {Id: "16", PubmedId: "11920808"})
(:LKP_GENE_CARD_REFERENCES {Id: "17", PubmedId: "12072543"})
(:LKP_GENE_CARD_REFERENCES {Id: "18", PubmedId: "12213668"})
(:LKP_GENE_CARD_REFERENCES {Id: "19", PubmedId: "12221036"})
(:LKP_GENE_CARD_REFERENCES {Id: "20", PubmedId: "12242432"})
(:LKP_GENE_CARD_REFERENCES {Id: "21", PubmedId: "12393516"})
(:LKP_GENE_CARD_REFERENCES {Id: "22", PubmedId: "12434154"})
(:LKP_GENE_CARD_REFERENCES {Id: "23", PubmedId: "12647800"})
(:LKP_GENE_CARD_REFERENCES {Id: "24", PubmedId: "12699448"})
(:LKP_GENE_CARD_REFERENCES {Id: "25", PubmedId: "12750283"})
(:LKP_GENE_CARD_REFERENCES {Id: "26", PubmedId: "14641934"})
(:LKP_GENE_CARD_REFERENCES {Id: "27", PubmedId: "14684699"})
(:LKP_GENE_CARD_REFERENCES {Id: "28", PubmedId: "14699510"})
(:LKP_GENE_CARD_REFERENCES {Id: "29", PubmedId: "14760276"})
(:LKP_GENE_CARD_REFERENCES {Id: "30", PubmedId: "14981712"})
(:LKP_GENE_CARD_REFERENCES {Id: "31", PubmedId: "14985373"})
(:LKP_GENE_CARD_REFERENCES {Id: "32", PubmedId: "14996857"})
(:LKP_GENE_CARD_REFERENCES {Id: "33", PubmedId: "15042511"})
(:LKP_GENE_CARD_REFERENCES {Id: "34", PubmedId: "15098033"})
(:LKP_GENE_CARD_REFERENCES {Id: "35", PubmedId: "15241338"})
(:LKP_GENE_CARD_REFERENCES {Id: "36", PubmedId: "15279807"})
(:LKP_GENE_CARD_REFERENCES {Id: "37", PubmedId: "15279810"})
(:LKP_GENE_CARD_REFERENCES {Id: "38", PubmedId: "15492928"})
(:LKP_GENE_CARD_REFERENCES {Id: "39", PubmedId: "15695377"})
(:LKP_GENE_CARD_REFERENCES {Id: "40", PubmedId: "15699726"})
(:LKP_GENE_CARD_REFERENCES {Id: "41", PubmedId: "15880589"})
(:LKP_GENE_CARD_REFERENCES {Id: "42", PubmedId: "16116422"})
(:LKP_GENE_CARD_REFERENCES {Id: "43", PubmedId: "16234564"})
(:LKP_GENE_CARD_REFERENCES {Id: "44", PubmedId: "16258541"})
(:LKP_GENE_CARD_REFERENCES {Id: "45", PubmedId: "16448984"})
(:LKP_GENE_CARD_REFERENCES {Id: "46", PubmedId: "16461775"})
(:LKP_GENE_CARD_REFERENCES {Id: "47", PubmedId: "16492921"})
(:LKP_GENE_CARD_REFERENCES {Id: "48", PubmedId: "16497624"})
(:LKP_GENE_CARD_REFERENCES {Id: "49", PubmedId: "16542390"})
(:LKP_GENE_CARD_REFERENCES {Id: "50", PubmedId: "16673358"})
(:LKP_GENE_CARD_REFERENCES {Id: "51", PubmedId: "16691589"})
(:LKP_GENE_CARD_REFERENCES {Id: "52", PubmedId: "16720667"})
(:LKP_GENE_CARD_REFERENCES {Id: "53", PubmedId: "16756677"})
(:LKP_GENE_CARD_REFERENCES {Id: "54", PubmedId: "16763388"})
(:LKP_GENE_CARD_REFERENCES {Id: "55", PubmedId: "16770759"})
(:LKP_GENE_CARD_REFERENCES {Id: "56", PubmedId: "16825431"})
(:LKP_GENE_CARD_REFERENCES {Id: "57", PubmedId: "17033622"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Familial Meningioma", VerbiageFromMedneonAug2022: "Autosomal dominant familial meningioma (MedGen UID: 232281)  Pathogenic loss-of-function (LOF) SMARCE1 variants are associated with familial meningioma. Meningiomas are typically slow growing benign tumors derived from the meningeal tissue of the brain and spinal cord (PMID: 23377182, 25143307).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Familial Platelet Disorder With Associated Myeloid Malignancy", VerbiageFromMedneonAug2022: "Autosomal dominant familial platelet disorder with associated myeloid malignancy (MedGen UID: 321945).  Familial platelet disorder is characterized by mild to moderate thrombocytopenia, platelet abnormalities, and a predisposition to develop myelodysplasia and/or acute myeloid leukemia (PMID: 19357396, 18723428). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired RUNX1 variants and additional testing may be appropriate.", HereditaryType: "Dominant"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MEN2B", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MTC1", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTC", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "rearranged during transfection", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RET-ELE1", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ret proto-oncogene", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RET/PTC", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RET51", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RET_HUMAN", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMD1GG", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DHSA_HUMAN", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "flavoprotein subunit of complex II", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FP", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH1", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH2", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDHF", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase flavoprotein subunit, mitochondrial", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase complex flavoprotein subunit", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase complex subunit A, flavoprotein", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "succinate dehydrogenase complex, subunit A, flavoprotein", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C11orf79", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FLJ20487", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hSDH5", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PGL2", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH assembly factor 2", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH5", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDHF2_HUMAN", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase assembly factor 2, mitochondrial", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase subunit 5, mitochondrial", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DHSB_HUMAN", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FLJ92337", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IP", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "iron-sulfur subunit of complex II", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PGL4", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH1", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH2", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDHIP", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase iron-sulfur subunit, mitochondrial", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase iron-sulfur subunit, mitochondrial precursor", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase complex subunit B, iron sulfur", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "succinate dehydrogenase complex, subunit B, iron sulfur", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C560_HUMAN", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CYB560", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CYBL", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cytochrome B large subunit of complex II", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "integral membrane protein CII-3", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "integral membrane protein CII-3b", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PGL3", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "QPs-1", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "QPS1", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH3", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase cytochrome b560 subunit, mitochondrial", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "succinate-ubiquinone oxidoreducatase cytochrome B large subunit", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate-ubiquinone oxidoreductase cytochrome B large subunit", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CBT1", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CII-4", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cybS", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DHSD_HUMAN", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PGL", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PGL1", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "QPs3", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDH4", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "succinate dehydrogenase complex subunit D, integral membrane protein", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase complex, subunit D, integral membrane protein", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate dehydrogenase ubiquinone cytochrome B small subunit", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate-ubiquinone oxidoreductase cytochrome b small subunit", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "succinate-ubiquinone reductase membrane anchor subunit", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "elongin binding protein", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "pVHL", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "VHL1", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "VHL_HUMAN", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATM-Biallellic", GeneMasterName: "ATM-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BLM-Biallellic", GeneMasterName: "BLM-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1-Biallellic", GeneMasterName: "BRCA1-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA2-Biallellic", GeneMasterName: "BRCA2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRIP1-Biallellic", GeneMasterName: "BRIP1-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LDLRAP1", GeneMasterName: "LDLRAP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRE11", GeneMasterName: "MRE11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NTRK1", GeneMasterName: "NTRK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PCSK9", GeneMasterName: "PCSK9"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51B", GeneMasterName: "RAD51B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RHBDF2", GeneMasterName: "RHBDF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SBDS", GeneMasterName: "SBDS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XPA", GeneMasterName: "XPA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XPC1", GeneMasterName: "XPC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RNF43", GeneMasterName: "RNF43"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ACD", GeneMasterName: "ACD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ETV6", GeneMasterName: "ETV6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PARK2", GeneMasterName: "PARK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS3", GeneMasterName: "PMS3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL", GeneMasterName: "RECQL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "bone morphogenetic protein receptor, type IA", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "bone morphogenetic protein receptor, type IA precursor", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1 gene", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 1, early onset", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "brca 2 gene", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA2_HUMAN", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 2, early onset", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cadherin 1, E-cadherin", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cadherin 1, type 1, E-cadherin", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDKN4", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDN1B_HUMAN", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase inhibitor 1B", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase inhibitor 1B (p27, Kip1)", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KIP1", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P27KIP1", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDK4 inhibitor p16-INK4", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CHK2 checkpoint homolog", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MEAI", GeneMasterName: "MEN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MEN1_HUMAN", GeneMasterName: "MEN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "multiple endocrine neoplasia I", GeneMasterName: "MEN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutL homolog 1, colon cancer, nonpolyposis type 2", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC7", GeneMasterName: "MLH3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutS homolog 2, colon cancer, nonpolyposis type 1", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "mutS homolog 6", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Neurofibromatosis-related protein NF-1", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Neurofibromatosis Type 1 Protein", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "neurofibromin 1", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NF1-GAP-Related Protein", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NF1 GRP", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NF1 Protein", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NF1_HUMAN", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ACN", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BANF", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MERL_HUMAN", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "merlin", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "moesin-ezrin-radixin-like protein", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SCH", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "schwannomerlin", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "schwannomin", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC3", GeneMasterName: "PMS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MLH2", GeneMasterName: "PMS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMSL1", GeneMasterName: "PMS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BUB1B-Biallellic", GeneMasterName: "BUB1B-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CASR-Biallellic", GeneMasterName: "CASR-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDKN1B-Biallellic", GeneMasterName: "CDKN1B-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CEP57-Biallellic", GeneMasterName: "CEP57-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CFTR-Biallellic", GeneMasterName: "CFTR-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTC1-Biallellic", GeneMasterName: "CTC1-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DDB2-Biallelic", GeneMasterName: "DDB2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DIS3L2-Biallellic", GeneMasterName: "DIS3L2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EPCAM-Biallelic", GeneMasterName: "EPCAM-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC2-Biallelic", GeneMasterName: "ERCC2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC3-Biallelic", GeneMasterName: "ERCC3-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC4-Biallelic", GeneMasterName: "ERCC4-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC4-Biallellic", GeneMasterName: "ERCC4-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC5-Biallelic", GeneMasterName: "ERCC5-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCA-Biallellic", GeneMasterName: "FANCA-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCC-Biallellic", GeneMasterName: "FANCC-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCD2-Biallellic", GeneMasterName: "FANCD2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCE-Biallellic", GeneMasterName: "FANCE-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCF-Biallellic", GeneMasterName: "FANCF-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCG-Biallellic", GeneMasterName: "FANCG-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCL-Biallellic", GeneMasterName: "FANCL-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCM-Biallellic", GeneMasterName: "FANCM-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FH-Biallellic", GeneMasterName: "FH-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GPC3-Biallellic", GeneMasterName: "GPC3-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LDLRAP1-Biallelic", GeneMasterName: "LDLRAP1-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LMNA-Biallelic", GeneMasterName: "LMNA-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MLH1-Biallelic", GeneMasterName: "MLH1-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRE11-Biallellic", GeneMasterName: "MRE11-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH2-Biallelic", GeneMasterName: "MSH2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH3-Biallellic", GeneMasterName: "MSH3-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH6-Biallelic", GeneMasterName: "MSH6-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBN-Biallellic", GeneMasterName: "NBN-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NHP2-Biallellic", GeneMasterName: "NHP2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NOP10-Biallellic", GeneMasterName: "NOP10-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NTHL1-Biallellic", GeneMasterName: "NTHL1-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PALB2-Biallellic", GeneMasterName: "PALB2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS2-Biallelic", GeneMasterName: "PMS2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD50-Biallellic", GeneMasterName: "RAD50-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51-Biallellic", GeneMasterName: "RAD51-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51C-Biallellic", GeneMasterName: "RAD51C-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL4-Biallellic", GeneMasterName: "RECQL4-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDHA-Biallellic", GeneMasterName: "SDHA-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDHB-Biallellic", GeneMasterName: "SDHB-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SLX4-Biallellic", GeneMasterName: "SLX4-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SPINK1-Biallellic", GeneMasterName: "SPINK1-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "VHL-Biallellic", GeneMasterName: "VHL-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WRN-Biallellic", GeneMasterName: "WRN-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XPA-Biallelic", GeneMasterName: "XPA-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XRCC2-Biallelic", GeneMasterName: "XRCC2-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "POLE-Biallelic", GeneMasterName: "POLE-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SIL1", GeneMasterName: "SIL1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IL1B", GeneMasterName: "IL1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IL1RN", GeneMasterName: "IL1RN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KRAS", GeneMasterName: "KRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BCS1L", GeneMasterName: "BCS1L"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "COX10", GeneMasterName: "COX10"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "COX15", GeneMasterName: "COX15"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FOXRED1", GeneMasterName: "FOXRED1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFA10", GeneMasterName: "NDUFA10"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFA12", GeneMasterName: "NDUFA12"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFA2", GeneMasterName: "NDUFA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFA9", GeneMasterName: "NDUFA9"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFAF2", GeneMasterName: "NDUFAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFAF6", GeneMasterName: "NDUFAF6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFS3", GeneMasterName: "NDUFS3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFS4", GeneMasterName: "NDUFS4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFS7", GeneMasterName: "NDUFS7"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDUFS8", GeneMasterName: "NDUFS8"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SURF1", GeneMasterName: "SURF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CCND1", GeneMasterName: "CCND1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPL11", GeneMasterName: "RPL11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPL26", GeneMasterName: "RPL26"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPL35A", GeneMasterName: "RPL35A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPL5", GeneMasterName: "RPL5"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPS10", GeneMasterName: "RPS10"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPS19", GeneMasterName: "RPS19"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPS24", GeneMasterName: "RPS24"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPS26", GeneMasterName: "RPS26"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPS7", GeneMasterName: "RPS7"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CFTR", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CEP57", GeneMasterName: "CEP57"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTC1", GeneMasterName: "CTC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NHP2", GeneMasterName: "NHP2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NOP10", GeneMasterName: "NOP10"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "JUP", GeneMasterName: "JUP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TTC37", GeneMasterName: "TTC37"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SKIV2L", GeneMasterName: "SKIV2L"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AR", GeneMasterName: "AR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTNND1", GeneMasterName: "CTNND1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SCN5A", GeneMasterName: "SCN5A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GJB6", GeneMasterName: "GJB6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FOXP3", GeneMasterName: "FOXP3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XK", GeneMasterName: "XK"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DKC1", GeneMasterName: "DKC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ENG", GeneMasterName: "ENG"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EZH2", GeneMasterName: "EZH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCB", GeneMasterName: "FANCB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GATA1", GeneMasterName: "GATA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MC1R", GeneMasterName: "MC1R"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTCH2", GeneMasterName: "PTCH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SPRED1", GeneMasterName: "SPRED1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATRX", GeneMasterName: "ATRX"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD54L", GeneMasterName: "RAD54L"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDK12", GeneMasterName: "CDK12"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DMC1", GeneMasterName: "DMC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PPP2R2A", GeneMasterName: "PPP2R2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD52", GeneMasterName: "RAD52"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EME1", GeneMasterName: "EME1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EME2", GeneMasterName: "EME2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAM175A¬†", GeneMasterName: "ABRAXAS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FLCN", GeneMasterName: "FLCN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GEN1", GeneMasterName: "GEN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MUS81", GeneMasterName: "MUS81"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RBBP8", GeneMasterName: "RBBP8"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SLX1A", GeneMasterName: "SLX1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XRCC3", GeneMasterName: "XRCC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TP53BP1", GeneMasterName: "TP53BP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XPC", GeneMasterName: "XPC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WWP1", GeneMasterName: "WWP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FOXE1", GeneMasterName: "FOXE1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HABP2", GeneMasterName: "HABP2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRE11A", GeneMasterName: "MRE11A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSR1", GeneMasterName: "MSR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NKX2-1", GeneMasterName: "NKX2-1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SEC23B", GeneMasterName: "SEC23B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SRGAP1", GeneMasterName: "SRGAP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ABRAXAS1", GeneMasterName: "ABRAXAS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGLN1", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ABC35", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KIF1B", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LZTR1", GeneMasterName: "LZTR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PALLD", GeneMasterName: "PALLD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CCDC98", GeneMasterName: "ABRAXAS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SIH002", GeneMasterName: "PALLD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PNCA1", GeneMasterName: "PALLD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MYN", GeneMasterName: "PALLD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CGI151", GeneMasterName: "PALLD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CGI-151", GeneMasterName: "PALLD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BTBD29", GeneMasterName: "LZTR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "leucine-zipper-like transcriptional regulator 1", GeneMasterName: "LZTR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LZTR-1", GeneMasterName: "LZTR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NS10", GeneMasterName: "LZTR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SWNTS2", GeneMasterName: "LZTR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMT2", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMT2A", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HMSNII", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KIAA0591", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KIAA1488", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KIF1B_HUMAN", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KLP", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ECYT3", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ZMYND6", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "zinc finger MYND domain-containing protein 6", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "prolyl hydroxylase domain-containing protein 2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PHD2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hypoxia-inducible factor prolyl hydroxylase 2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HPH2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HPH-2
HIFPH2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "egl nine homolog 1", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGLN1_HUMAN", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HIF-prolyl hydroxylase 2
egl nine homolog 1 (C. elegans)", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "egl nine-like protein 1", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HIF-PH2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HIF prolyl hydroxylase 2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "egl-9 family hypoxia-inducible factor 1", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HIF PH2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC1", GeneMasterName: "ERCC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAN1", GeneMasterName: "FAN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "POLH", GeneMasterName: "POLH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WRAP53", GeneMasterName: "WRAP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SLC45A2", GeneMasterName: "SLC45A2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TINF2", GeneMasterName: "TINF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TYR", GeneMasterName: "TYR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MAP3K6", GeneMasterName: "MAP3K6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTCSC3", GeneMasterName: "PTCSC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTCSC2", GeneMasterName: "PTCSC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTCSC1", GeneMasterName: "PTCSC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FBXO24", GeneMasterName: "FBXO24"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DOT1L", GeneMasterName: "DOT1L"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "INSR", GeneMasterName: "INSR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EHBP1", GeneMasterName: "EHBP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ELAC2", GeneMasterName: "ELAC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAT4", GeneMasterName: "FAT4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FGFR3", GeneMasterName: "FGFR3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FLT3", GeneMasterName: "FLT3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HPC1", GeneMasterName: "HPC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IGF2R", GeneMasterName: "IGF2R"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ABCC7", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CFTR/MRP", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TNR-CFTR", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "dJ760C5.1", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CAP", GeneMasterName: "CAP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CAP1-PEN", GeneMasterName: "CAP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAM6A", GeneMasterName: "DIS3L2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PRLMNS", GeneMasterName: "DIS3L2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hDIS3L2", GeneMasterName: "DIS3L2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERBB", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HER1", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mENA", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERBB1", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PIG61", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NISBD2", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ANKRD26", GeneMasterName: "ANKRD26"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ARMC5", GeneMasterName: "ARMC5"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ASXL1", GeneMasterName: "ASXL1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PHOXB2", GeneMasterName: "PHOXB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRIM37", GeneMasterName: "TRIM37"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "10q23del", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "10q23del", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ABRA1", GeneMasterName: "ABRAXAS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ACRDYS1", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ADOHR", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ALK1", GeneMasterName: "ALK"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AML1", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AML1-EVI-1", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AMLCR1", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AUTS9", GeneMasterName: "MET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "aviD", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AWT1", GeneMasterName: "WT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BAF190", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BAF190A", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BAF47", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BAF57", GeneMasterName: "SMARCE1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BCDS1", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BCNS", GeneMasterName: "PTCH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BerEp4", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Ber-Ep4", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BHD", GeneMasterName: "FLCN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "bHLHd4", GeneMasterName: "MAX"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "bHLHe32", GeneMasterName: "MITF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BMFS5", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA2_HUMAN
BRCC2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRG1", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BS", GeneMasterName: "BLM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C1orf12", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CAP102", GeneMasterName: "CTNNA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C-BAS/HAS", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CBF2alpha", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CBFA2", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CCHS", GeneMasterName: "PHOX2B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD117", GeneMasterName: "KIT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD140A", GeneMasterName: "PDGFRA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C-HA-RAS1", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C-H-RAS", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C-Kit", GeneMasterName: "KIT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "c-Met", GeneMasterName: "MET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMM10", GeneMasterName: "POT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMM8", GeneMasterName: "MITF"})
(:LKP_GENE_DETAILS {GeneMasterName: "TRIM37", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ATP7B¬†", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPE65", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "GAA", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "HNF1A", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TRDN", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ACVRL1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TTN", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FLNC", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CASQ2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "BTD", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MLH1, MSH2, PMS2, MSH6", GeneFullName: "LynchGenesMinusEPCAM_ForPrevalenceQueryUse", In_Invitae84: 1, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TSC1/2", GeneFullName: "_ForPrevalenceQueryUse", In_Invitae84: 1, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "GPC3", GeneFullName: "Glypican 3", In_Invitae84: 1, Mechanism: "Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "HRAS", GeneFullName: "GTPase Hras", In_Invitae84: 1, Mechanism: "HRAS encodes a protein part of the RAS/MAPK pathway. This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus."})
(:LKP_GENE_DETAILS {GeneMasterName: "KIT", GeneFullName: "KIT Proto-Oncogene, Receptor Tyrosine Kinase", In_Invitae84: 1, Mechanism: "This gene encodes a receptor tyrosine kinase. This gene was initially identified as a homolog of the feline sarcoma viral oncogene v-kit and is often referred to as proto-oncogene c-Kit. The canonical form of this glycosylated transmembrane protein has an N-terminal extracellular region with five immunoglobulin-like domains, a transmembrane region, and an intracellular tyrosine kinase domain at the C-terminus. Upon activation by its cytokine ligand, stem cell factor (SCF), this protein phosphorylates multiple intracellular proteins that play a role in in the proliferation, differentiation, migration and apoptosis of many cell types and thereby plays an important role in hematopoiesis, stem cell maintenance, gametogenesis, melanogenesis, and in mast cell development, migration and function. This protein can be a membrane-bound or soluble protein. Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2020]"})
(:LKP_GENE_DETAILS {GeneMasterName: "BRCA2", GeneFullName: "Breast Cancer 2 Early Onset Protein", In_Invitae84: 1, Mechanism: "The protein product of BRCA2 is a nuclear phosphoprotein which forms part of the homologous recombination pathway for double-stranded DNA repair via binding with RAD51."})
(:LKP_GENE_DETAILS {GeneMasterName: "MSH2", GeneFullName: "MutS Homolog 2", In_Invitae84: 1, Mechanism: "Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Recruits DNA helicase MCM9 to chromatin which unwinds the mismatch containing DNA strand (PubMed:26300262). ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis"})
(:LKP_GENE_DETAILS {GeneMasterName: "MSH6", GeneFullName: "MutS Homolog 6", In_Invitae84: 1, Mechanism: "This gene encodes a member of the DNA mismatch repair MutS family. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein heterodimerizes with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene may be associated with hereditary nonpolyposis colon cancer, colorectal cancer, and endometrial cancer. Transcripts variants encoding different isoforms have been described. [provided by RefSeq, Jul 2013]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MUTYH", GeneFullName: "MutY DNA Glycosylase", In_Invitae84: 1, Mechanism: "This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene."})
(:LKP_GENE_DETAILS {GeneMasterName: "NBN", GeneFullName: "Nibrin", In_Invitae84: 1, Mechanism: "Nibrin, the protein product of NBN, plays a role in the cellular response to DNA double-strand damage, in addition to regulating cell division and cell proliferation."})
(:LKP_GENE_DETAILS {GeneMasterName: "PALB2", GeneFullName: "Partner And Localizer Of BRCA2", In_Invitae84: 1, Mechanism: "This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PMS1", GeneFullName: "PMS1 Homolog 1, Mismatch Repair System Component", In_Invitae84: 0, Mechanism: "This gene encodes a protein belonging to the DNA mismatch repair mutL/hexB family. This protein is thought to be involved in the repair of DNA mismatches, and it can form heterodimers with MLH1, a known DNA mismatch repair protein. Mutations in this gene cause hereditary nonpolyposis colorectal cancer type 3 (HNPCC3) either alone or in combination with mutations in other genes involved in the HNPCC phenotype, which is also known as Lynch syndrome. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PMS2", GeneFullName: "PMS1 Homolog 2, Mismatch Repair System Component", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a key component of the mismatch repair system that functions to correct DNA mismatches and small insertions and deletions that can occur during DNA replication and homologous recombination. This protein forms heterodimers with the gene product of the mutL homolog 1 (MLH1) gene to form the MutL-alpha heterodimer. The MutL-alpha heterodimer possesses an endonucleolytic activity that is activated following recognition of mismatches and insertion/deletion loops by the MutS-alpha and MutS-beta heterodimers, and is necessary for removal of the mismatched DNA. There is a DQHA(X)2E(X)4E motif found at the C-terminus of the protein encoded by this gene that forms part of the active site of the nuclease. Mutations in this gene have been associated with hereditary nonpolyposis colorectal cancer (HNPCC; also known as Lynch syndrome) and Turcot syndrome. [provided by RefSeq, Apr 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "POLD1", GeneFullName: "Polymerase (DNA-Directed), Delta 1, Catalytic Subunit; POLD1", In_Invitae84: 1, Mechanism: "POLD1 codes for the catalytic subunit of DNA polymerase delta, which is essential for DNA replication."})
(:LKP_GENE_DETAILS {GeneMasterName: "BRIP1", GeneFullName: "BRCA1 Interacting Protein C-Terminal Helicase 1", In_Invitae84: 1, Mechanism: "The protein product of BRIP1 is a helicase which interacts with BRCA1 via BRCT repeats. It is essential to the role of BRCA1 in double-stranded DNA repair."})
(:LKP_GENE_DETAILS {GeneMasterName: "CDH1", GeneFullName: "Cadherin 1", In_Invitae84: 1, Mechanism: "CDH1 codes for a transmembrane epithelial cadherin protein which plays a role in cell adhesion. Loss of function can lead to cancer through heightened cell proliferation and mobility."})
(:LKP_GENE_DETAILS {GeneMasterName: "CDK4", GeneFullName: "Cyclin Dependent Kinase 4", In_Invitae84: 1, Mechanism: "CDK4 encodes cyclin-dependent kinase 4, a serine/threonine kinase which helps regulate the cell cycle at the G1 phase."})
(:LKP_GENE_DETAILS {GeneMasterName: "CDKN2A", GeneFullName: "Cyclin Dependent Kinase Inhibitor 2A", In_Invitae84: 1, Mechanism: "Via alternative splicing, CDKN2A can produce two major proteins, p14 and p16. Both act as tumor suppressors: p14 activates the p53 tumor suppressor protein, while p16 helps regulate the cell cycle by activating the RB1 protein via inhibition of CDK4 and CDK6. Thus, p16 helps keep the cell in the G1 phase of the cell cycle."})
(:LKP_GENE_DETAILS {GeneMasterName: "CHEK1", GeneFullName: "Checkpoint Kinase 1", In_Invitae84: 0, Mechanism: "The protein encoded by this gene belongs to the Ser/Thr protein kinase family. It is required for checkpoint mediated cell cycle arrest in response to DNA damage or the presence of unreplicated DNA. This protein acts to integrate signals from ATM and ATR, two cell cycle proteins involved in DNA damage responses, that also associate with chromatin in meiotic prophase I. Phosphorylation of CDC25A protein phosphatase by this protein is required for cells to delay cell cycle progression in response to double-strand DNA breaks. Several alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Oct 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CHEK2", GeneFullName: "Checkpoint Kinase 2", In_Invitae84: 1, Mechanism: "When DNA double-stranded breaks occur, the protein product of CHEK2 inhibits CDC25C phosphatase and stabilizes the p53 tumor suppressor protein, thus keeping the cell in the G1 phase of the cell cycle. CHEK2 also phosphorylates BRCA1, which allows BRCA1 to ensure survival after DNA damage."})
(:LKP_GENE_DETAILS {GeneMasterName: "EPCAM", GeneFullName: "Epithelial Cell Adhesion Molecule", In_Invitae84: 1, Mechanism: "EPCAM codes for a cellular adhesion antigen molecule which is involved in embryonic stem cell proliferation and differentiation. 3' deletions cause EPCAM mRNA to be combined with mRNA of the downstream MSH2 gene, causing loss of function of MSH2."})
(:LKP_GENE_DETAILS {GeneMasterName: "GREM1", GeneFullName: "Gremlin 1, DAN Family BMP Antagonis", In_Invitae84: 1, Mechanism: "This gene encodes a member of the BMP (bone morphogenic protein) antagonist family. Like BMPs, BMP antagonists contain cystine knots and typically form homo- and heterodimers. The CAN (cerberus and dan) subfamily of BMP antagonists, to which this gene belongs, is characterized by a C-terminal cystine knot with an eight-membered ring. The antagonistic effect of the secreted glycosylated protein encoded by this gene is likely due to its direct binding to BMP proteins. As an antagonist of BMP, this gene may play a role in regulating organogenesis, body patterning, and tissue differentiation. In mouse, this protein has been shown to relay the sonic hedgehog (SHH) signal from the polarizing region to the apical ectodermal ridge during limb bud outgrowth. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MLH1", GeneFullName: "MutL Homolog 1", In_Invitae84: 1, Mechanism: "The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MLH3", GeneFullName: "MutL Homolog 3", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TERC", GeneFullName: "Telomerase RNA Component", In_Invitae84: 1, Mechanism: "TERC encodes a component of telomerase which is involved with maintaining telomeric integrity"})
(:LKP_GENE_DETAILS {GeneMasterName: "MAX", GeneFullName: "MYC-Associated Factor X", In_Invitae84: 1, Mechanism: "MAX encodes a tumor suppressor part of the MYC-MAX-MXD2 complex, which regulates cell proliferation, differentiation, and apoptosis."})
(:LKP_GENE_DETAILS {GeneMasterName: "ACTA2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SMAD3", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FBN1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "APOB", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "KCNH2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "KCNE1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "KCNQ1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "HFE", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "COL3A1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RYR1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TGFBR2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TGFBR1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "APC", GeneFullName: "APC regulator of WNT signaling pathway", In_Invitae84: 1, Mechanism: "APC functions as an antagonist to the Wnt (Wingless-related integration site) signaling pathway. It regulates cell division, adhesion, migration, and apoptosis, among other processes."})
(:LKP_GENE_DETAILS {GeneMasterName: "ATM", GeneFullName: "Ataxia Telangiectasia Mutated", In_Invitae84: 1, Mechanism: "ATM encodes a phosphorylating cell cycle checkpoint kinase in the PI3/PI4-kinase family which regulates downstream tumor suppressor proteins. It is involved with the cellular response to DNA damage."})
(:LKP_GENE_DETAILS {GeneMasterName: "BARD1", GeneFullName: "BRCA-Associated RING Domain 1", In_Invitae84: 1, Mechanism: "The protein product of BARD1 forms a heterodimer with BRCA1 at the N-terminal to regulate various processes, including transcriptional regulation, DNA damage repair, and ubiquitination."})
(:LKP_GENE_DETAILS {GeneMasterName: "BMPR1A", GeneFullName: "Bone Morphogenetic Protein Receptor Type 1A", In_Invitae84: 1, Mechanism: "BMPR1A encodes transmembrane serine/threonine kinases which repress the Wnt (Wingless-related integration site) signaling pathway."})
(:LKP_GENE_DETAILS {GeneMasterName: "BRCA1", GeneFullName: "Breast Cancer 1 Early Onset Protein", In_Invitae84: 1, Mechanism: "The protein product of BRCA1 is a nuclear phosphoprotein which forms the BRCA1-associated genome surveillance complex (BASC) with other proteins and can also form a heterodimer with BARD1. BRCA1 helps regulate the cell cycle and plays a role in homologous recombination repair of double-stranded DNA breaks, transcription, recombination, and ubiquitination."})
(:LKP_GENE_DETAILS {GeneMasterName: "EGFR", GeneFullName: "Epidermal Growth Factor Receptor", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. EGFR is a component of the cytokine storm that sometimes results from a severe form of human infection of SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). [provided by RefSeq, Jun 2020]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FH", GeneFullName: "Fumerate Hydratase", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FLCN", GeneFullName: "Folliculin", In_Invitae84: 1, Mechanism: "FLCN encodes a tumor suppressor involved in the AMPK and mTOR pathways"})
(:LKP_GENE_DETAILS {GeneMasterName: "GATA2", GeneFullName: "GATA Binding Protein 2", In_Invitae84: 1, Mechanism: "This gene encodes a member of the GATA family of zinc-finger transcription factors that are named for the consensus nucleotide sequence they bind in the promoter regions of target genes. The encoded protein plays an essential role in regulating transcription of genes involved in the development and proliferation of hematopoietic and endocrine cell lineages. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Mar 2009].GATA2 encodes a transcription factor that regulates transcription of genes involved in development and proliferation of hematopoietic and endocrine cells."})
(:LKP_GENE_DETAILS {GeneMasterName: "POLE", GeneFullName: "DNA Polymerase Epsilon, Catalytic Subunit", In_Invitae84: 1, Mechanism: "POLE codes for the catalytic subunit of DNA polymerase epsilon, which is essential for DNA replication."})
(:LKP_GENE_DETAILS {GeneMasterName: "PTEN", GeneFullName: "Phosphatase and Tensin Homolog", In_Invitae84: 1, Mechanism: "PTEN codes for a phosphatase which is an antagonist for intracellular phosphatidylinositol-3,4,5-triphosphate levels and for the AKT/PKB signaling pathway. It is involved in cellular migration, adhesion, and angiogenesis."})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD50", GeneFullName: "RAD50 Double Strand Break Repair Protein", In_Invitae84: 1, Mechanism: "The protein product for RAD50 forms the MRN complex with MRE11 and NBS1. It plays a role in nonhomologous repair of double-stranded DNA breaks, as well as serving as a checkpoint in the cell cycle."})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD51", GeneFullName: "RAD51 Recombinase", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD51C", GeneFullName: "RAD51 Paralog C", In_Invitae84: 1, Mechanism: "The protein product of RAD51C is pivotal in homologous recombination repair of double-stranded DNA breaks. In collaboration with other proteins, it plays a role in Holliday junction resolution."})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD51D", GeneFullName: "RAD51 Paralog D", In_Invitae84: 1, Mechanism: "The protein product of RAD51D is pivotal in homologous recombination repair of double-stranded DNA breaks. In collaboration with other proteins, it plays a role in Holliday junction resolution."})
(:LKP_GENE_DETAILS {GeneMasterName: "RHBDF2", GeneFullName: "Rhomboid 5 Homolog 2", In_Invitae84: 0, Mechanism: "RHBDF2 (Rhomboid 5 Homolog 2) is a Protein Coding gene. Diseases associated with RHBDF2 include¬†Tylosis With Esophageal Cancer¬†and¬†Palmoplantar Keratoderma, Nonepidermolytic, Focal 1. Gene Ontology (GO) annotations related to this gene include¬†serine-type endopeptidase activity¬†and¬†growth factor binding. An important paralog of this gene is¬†RHBDF1."})
(:LKP_GENE_DETAILS {GeneMasterName: "SMAD4", GeneFullName: "SMAD Family Member 4", In_Invitae84: 1, Mechanism: "SMAD4 codes for a signal transduction protein in the SMAD family, which is activated by transmembrane serine-threonine kinases. SMAD4 conglomerates with other SMAD proteins, building up in the nucleus. SMAD4 also helps regulate cell growth and proliferati"})
(:LKP_GENE_DETAILS {GeneMasterName: "STK11", GeneFullName: "Serine/Threonine Kinase 11", In_Invitae84: 1, Mechanism: "STK11 codes for a serine/threonine protein kinase which regulates AMP-activated protein kinases. As a result, STK11 plays a role in controlling cell apoptosis, division, metabolism, and polarization, along with DNA damage repair."})
(:LKP_GENE_DETAILS {GeneMasterName: "TP53", GeneFullName: "Tumor Protein P53", In_Invitae84: 1, Mechanism: "TP53 codes for a regulatory protein which controls expression of other genes. In this capacity, TP53 plays a role in the cell cycle, apoptosis, DNA repair, cell metabolism, and cellular senescence."})
(:LKP_GENE_DETAILS {GeneMasterName: "HOXB13", GeneFullName: "Homeobox B13", In_Invitae84: 1, Mechanism: "This gene encodes a transcription factor that belongs to the homeobox gene family. Genes of this family are highly conserved among vertebrates and essential for vertebrate embryonic development. This gene has been implicated to play a role in fetal skin development and cutaneous regeneration. In mice, a similar gene was shown to exhibit temporal and spatial colinearity in the main body axis of the embryo, but was not expressed in the secondary axes, which suggests functions in body patterning along the axis. This gene and other HOXB genes form a gene cluster at chromosome the 17q21-22 region."})
(:LKP_GENE_DETAILS {GeneMasterName: "RECQL", GeneFullName: "RecQ like helicase", In_Invitae84: 0, Mechanism: "The protein encoded by RECQL is  involved in the processing of Holliday junctions, the suppression of sister chromatid exchanges, telomere maintenance, and is required for genotoxic stress resistance."})
(:LKP_GENE_DETAILS {GeneMasterName: "INSR", GeneFullName: "insulin receptor", In_Invitae84: 0, Mechanism: "This gene encodes a member of the receptor tyrosine kinase family of proteins. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that form a heterotetrameric receptor. Binding of insulin or other ligands to this receptor activates the insulin signaling pathway, which regulates glucose uptake and release, as well as the synthesis and storage of carbohydrates, lipids and protein.¬†"})
(:LKP_GENE_DETAILS {GeneMasterName: "MAP3K6", GeneFullName: "Mitogen-Activated Protein Kinase Kinase Kinase 6", In_Invitae84: 0, Mechanism: "This gene encodes a serine/threonine protein kinase that forms a component of protein kinase-mediated signal transduction cascades. The encoded kinase participates in the regulation of vascular endothelial growth factor (VEGF) expression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2014]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FOXE1", GeneFullName: "forkhead box E1", In_Invitae84: 0, Mechanism: "This intronless gene encodes a protein that belongs to the forkhead family of transcription factors. Members of this family contain a conserved 100-amino acid DNA-binding 'forkhead' domain. The encoded protein functions as a thyroid transcription factor that plays a role in thyroid morphogenesis.¬†"})
(:LKP_GENE_DETAILS {GeneMasterName: "MRE11", GeneFullName: "MRE11 Homolog", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MSR1", GeneFullName: "Macrophage Scavenger Receptor 1", In_Invitae84: 0, Mechanism: "This gene encodes the class A macrophage scavenger receptors, which include three different types (1, 2, 3) generated by alternative splicing of this gene. These receptors or isoforms are macrophage-specific trimeric integral membrane glycoproteins and have been implicated in many macrophage-associated physiological and pathological processes including atherosclerosis, Alzheimer's disease, and host defense. The isoforms type 1 and type 2 are functional receptors and are able to mediate the endocytosis of modified low density lipoproteins (LDLs). The isoform type 3 does not internalize modified LDL (acetyl-LDL) despite having the domain shown to mediate this function in the types 1 and 2 isoforms. It has an altered intracellular processing and is trapped within the endoplasmic reticulum, making it unable to perform endocytosis. The isoform type 3 can inhibit the function of isoforms type 1 and type 2 when co-expressed, indicating a dominant negative effect and suggesting a mechanism for regulation of scavenger receptor activity in macrophages. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "XRCC2", GeneFullName: "X-ray repair cross complementing 2", In_Invitae84: 0, Mechanism: "This gene encodes a member of the RecA/Rad51-related protein family that participates in homologous recombination to maintain chromosome stability and repair DNA damage. This gene is involved in the repair of DNA double-strand breaks by homologous recombi"})
(:LKP_GENE_DETAILS {GeneMasterName: "CTNND1", GeneFullName: "catenin delta 1", In_Invitae84: 0, Mechanism: "This gene encodes a member of the Armadillo protein family, which function in adhesion between cells and signal transduction. Multiple translation initiation codons and alternative splicing result in many different isoforms being translated. Not all of the full-length natures of the described transcript variants have been determined. Read-through transcription also exists between this gene and the neighboring upstream thioredoxin-related transmembrane protein 2 (TMX2) gene. [provided by RefSeq, Dec 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "DOT1L", GeneFullName: "DOT1 Like Histone Lysine Methyltransferase", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a histone methyltransferase that methylates lysine-79 of histone H3. It is inactive against free core histones, but shows significant histone methyltransferase activity against nucleosomes. [provided by RefSeq, Aug 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FBXO24", GeneFullName: "F-box protein 24", In_Invitae84: 0, Mechanism: "This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class. Multiple transcript variants encoding different isoforms have been found for this gene."})
(:LKP_GENE_DETAILS {GeneMasterName: "NKX2-1", GeneFullName: "NK2 Homeobox 1", In_Invitae84: 0, Mechanism: "This gene encodes a protein initially identified as a thyroid-specific transcription factor. The encoded protein binds to the thyroglobulin promoter and regulates the expression of thyroid-specific genes but has also been shown to regulate the expression of genes involved in morphogenesis. Mutations and deletions in this gene are associated with benign hereditary chorea, choreoathetosis, congenital hypothyroidism, and neonatal respiratory distress, and may be associated with thyroid cancer. Multiple transcript variants encoding different isoforms have been found for this gene. This gene shares the symbol/alias 'TTF1' with another gene, transcription termination factor 1, which plays a role in ribosomal gene transcription. [provided by RefSeq, Feb 2014]"})
(:LKP_GENE_DETAILS {GeneMasterName: "BUB1B", GeneFullName: "Mitotic Checkpoint Serine/Threonine Kinase B", In_Invitae84: 0, Mechanism: "This gene encodes a kinase involved in spindle checkpoint function. The protein has been localized to the kinetochore and plays a role in the inhibition of the anaphase-promoting complex/cyclosome (APC/C), delaying the onset of anaphase and ensuring proper chromosome segregation. Impaired spindle checkpoint function has been found in many forms of cancer. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "DSG2", GeneFullName: "Desmoglein¬†", In_Invitae84: 0, Mechanism: "This gene encodes a member of the desmoglein family and cadherin cell adhesion molecule superfamily of proteins. Desmogleins are calcium-binding transmembrane glycoprotein components of desmosomes, cell-cell junctions between epithelial, myocardial, and other cell types. The encoded preproprotein is proteolytically processed to generate the mature glycoprotein. This gene is present in a gene cluster with other desmoglein gene family members on chromosome 18. Mutations in this gene have been associated with arrhythmogenic right ventricular dysplasia, familial, 10. [provided by RefSeq, Jan 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "DSP", GeneFullName: "Desmoplakin", In_Invitae84: 0, Mechanism: "This gene encodes a protein that anchors intermediate filaments to desmosomal plaques and forms an obligate component of functional desmosomes. Mutations in this gene are the cause of several cardiomyopathies and keratodermas, including skin fragility-woolly hair syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "EMD", GeneFullName: "Emerin", In_Invitae84: 0, Mechanism: "Emerin is a serine-rich nuclear membrane protein and a member of the nuclear lamina-associated protein family. It mediates membrane anchorage to the cytoskeleton. Dreifuss-Emery muscular dystrophy is an X-linked inherited degenerative myopathy resulting from mutation in the emerin gene. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ENG", GeneFullName: "Endoglin", In_Invitae84: 0, Mechanism: "This gene encodes a homodimeric transmembrane protein which is a major glycoprotein of the vascular endothelium. This protein is a component of the transforming growth factor beta receptor complex and it binds to the beta1 and beta3 peptides with high affinity. Mutations in this gene cause hereditary hemorrhagic telangiectasia, also known as Osler-Rendu-Weber syndrome 1, an autosomal dominant multisystemic vascular dysplasia. This gene may also be involved in preeclampsia and several types of cancer. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2013]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC2", GeneFullName: "ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit", In_Invitae84: 0, Mechanism: "The nucleotide excision repair pathway is a mechanism to repair damage to DNA. The protein encoded by this gene is involved in transcription-coupled nucleotide excision repair and is an integral member of the basal transcription factor BTF2/TFIIH complex. The gene product has ATP-dependent DNA helicase activity and belongs to the RAD3/XPD subfamily of helicases. Defects in this gene can result in three different disorders, the cancer-prone syndrome xeroderma pigmentosum complementation group D, trichothiodystrophy, and Cockayne syndrome. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Aug 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC3", GeneFullName: "ERCC Excision Repair 3, TFIIH Core Complex Helicase Subuni", In_Invitae84: 0, Mechanism: "This gene encodes an ATP-dependent DNA helicase that functions in nucleotide excision repair. The encoded protein is a subunit of basal transcription factor 2 (TFIIH) and, therefore, also functions in class II transcription. Mutations in this gene are associated with Xeroderma pigmentosum B, Cockayne's syndrome, and trichothiodystrophy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCA", GeneFullName: "FA Complementation Group A", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group A. Alternative splicing results in multiple transcript variants encoding different isoforms. Mutations in this gene are the most common cause of Fanconi anemia. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCB", GeneFullName: "FA Complementation Group B", In_Invitae84: 0, Mechanism: "This gene encodes a member of the Fanconi anemia complementation group B. This protein is assembled into a nucleoprotein complex that is involved in the repair of DNA lesions. Mutations in this gene can cause chromosome instability and VACTERL syndrome with hydrocephalus. [provided by RefSeq, Apr 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCC", GeneFullName: "FA Complementation Group C", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group C. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCD2", GeneFullName: "FA Complementation Group D2", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group D2. This protein is monoubiquinated in response to DNA damage, resulting in its localization to nuclear foci with other proteins (BRCA1 AND BRCA2) involved in homology-directed DNA repair. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCE", GeneFullName: "FA Complementation Group E", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group E. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCF", GeneFullName: "FA Complementation Group F", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group F. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCG", GeneFullName: "FA Complementation Group G", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group G. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCI", GeneFullName: "FA Complementation Group I", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group I. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCL", GeneFullName: "FA Complementation Group L", In_Invitae84: 0, Mechanism: "This gene encodes a ubiquitin ligase that is a member of the Fanconi anemia complementation group (FANC). Members of this group are related by their assembly into a common nuclear protein complex rather than by sequence similarity. This gene encodes the protein for complementation group L that mediates monoubiquitination of FANCD2 as well as FANCI. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2018]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCM", GeneFullName: "FA Complementation Group M", In_Invitae84: 0, Mechanism: "The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group M. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FOXP3", GeneFullName: "Foxheadbox P3", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a member of the forkhead/winged-helix family of transcriptional regulators. Defects in this gene are the cause of immunodeficiency polyendocrinopathy, enteropathy, X-linked syndrome (IPEX), also known as X-linked autoimmunity-immunodeficiency syndrome. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FOXRED1", GeneFullName: "FAD Dependent Oxidoreductase Domain Containing 1", In_Invitae84: 0, Mechanism: "This gene encodes a protein that contains a FAD-dependent oxidoreductase domain. The encoded protein is localized to the mitochondria and may function as a chaperone protein required for the function of mitochondrial complex I. Mutations in this gene are associated with mitochondrial complex I deficiency. Alternatively spliced transcript variants have been observed for this gene. [provided by RefSeq, Dec 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "GALNT12", GeneFullName: "Polypeptide N-Acetylgalactosaminyltransferase 1", In_Invitae84: 0, Mechanism: "This gene encodes a member of the UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family of enzymes. GalNAc-Ts initiate mucin-type O-linked glycosylation in the Golgi apparatus by catalyzing the transfer of GalNAc to serine and threonine residues on target proteins. They are characterized by an N-terminal transmembrane domain, a stem region, a lumenal catalytic domain containing a GT1 motif and Gal/GalNAc transferase motif, and a C-terminal ricin/lectin-like domain. GalNAc-Ts have different, but overlapping, substrate specificities and patterns of expression. Transcript variants derived from this gene that utilize alternative polyA signals have been described in the literature. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CTRC", GeneFullName: "Chymotrpsin C", In_Invitae84: 0, Mechanism: "his gene encodes a member of the peptidase S1 family. The encoded protein is a serum calcium-decreasing factor that has chymotrypsin-like protease activity. Alternatively spliced transcript variants have been observed, but their full-length nature has not been determined. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CYLD", GeneFullName: "CYLD Lysine 63 Deubiquitinase", In_Invitae84: 0, Mechanism: "his gene is encodes a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme. Mutations in this gene have been associated with cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "DDB2", GeneFullName: "Damage Specific DNA Binding Protein 2", In_Invitae84: 0, Mechanism: "This gene encodes a protein that is necessary for the repair of ultraviolet light-damaged DNA. This protein is the smaller subunit of a heterodimeric protein complex that participates in nucleotide excision repair, and this complex mediates the ubiquitylation of histones H3 and H4, which facilitates the cellular response to DNA damage. This subunit appears to be required for DNA binding. Mutations in this gene cause xeroderma pigmentosum complementation group E, a recessive disease that is characterized by an increased sensitivity to UV light and a high predisposition for skin cancer development, in some cases accompanied by neurological abnormalities. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2014]"})
(:LKP_GENE_DETAILS {GeneMasterName: "DES", GeneFullName: "Desmin", In_Invitae84: 0, Mechanism: "his gene encodes a muscle-specific class III intermediate filament. Homopolymers of this protein form a stable intracytoplasmic filamentous network connecting myofibrils to each other and to the plasma membrane. Mutations in this gene are associated with desmin-related myopathy, a familial cardiac and skeletal myopathy (CSM), and with distal myopathies. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "DKC1", GeneFullName: "Dyskerin Pseudouridine Synthase 1", In_Invitae84: 0, Mechanism: "his gene functions in two distinct complexes. It plays an active role in telomerase stabilization and maintenance, as well as recognition of snoRNAs containing H/ACA sequences which provides stability during biogenesis and assembly into H/ACA small nucleolar RNA ribonucleoproteins (snoRNPs). This gene is highly conserved and widely expressed, and may play additional roles in nucleo-cytoplasmic shuttling, DNA damage response, and cell adhesion. Mutations have been associated with X-linked dyskeratosis congenita. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2014]"})
(:LKP_GENE_DETAILS {GeneMasterName: "DSC2", GeneFullName: "Desmocollin 2", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a histone methyltransferase that methylates lysine-79 of histone H3. It is inactive against free core histones, but shows significant histone methyltransferase activity against nucleosomes."})
(:LKP_GENE_DETAILS {GeneMasterName: "GATA1", GeneFullName: "GATA Binding Protein 1", In_Invitae84: 0, Mechanism: "This gene encodes a protein which belongs to the GATA family of transcription factors. The protein plays an important role in erythroid development by regulating the switch of fetal hemoglobin to adult hemoglobin. Mutations in this gene have been associated with X-linked dyserythropoietic anemia and thrombocytopenia. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "GJB6", GeneFullName: "Gap Junction Protein Beta 6", In_Invitae84: 0, Mechanism: "Gap junctions allow the transport of ions and metabolites between the cytoplasm of adjacent cells. They are formed by two hemichannels, made up of six connexin proteins assembled in groups. Each connexin protein has four transmembrane segments, two extracellular loops, a cytoplasmic loop formed between the two inner transmembrane segments, and the N- and C-terminus both being in the cytoplasm. The specificity of the gap junction is determined by which connexin proteins comprise the hemichannel. In the past, connexin protein names were based on their molecular weight, however the new nomenclature uses sequential numbers based on which form (alpha or beta) of the gap junction is present. This gene encodes one of the connexin proteins. Mutations in this gene have been found in some forms of deafness and in some families with hidrotic ectodermal dysplasia. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "GLA", GeneFullName: "Galactosidase Alpha", In_Invitae84: 0, Mechanism: "This gene encodes a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. A variety of mutations in this gene affect the synthesis, processing, and stability of this enzyme, which causes Fabry disease, a rare lysosomal storage disorder that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "IL1B", GeneFullName: "HRas proto-oncogene, GTPase", In_Invitae84: 0, Mechanism: "This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus."})
(:LKP_GENE_DETAILS {GeneMasterName: "IL1RN", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "JUP", GeneFullName: "Junction Plakoglobin", In_Invitae84: 0, Mechanism: "This gene encodes a major cytoplasmic protein which is the only known constituent common to submembranous plaques of both desmosomes and intermediate junctions. This protein forms distinct complexes with cadherins and desmosomal cadherins and is a member of the catenin family since it contains a distinct repeating amino acid motif called the armadillo repeat. Mutation in this gene has been associated with Naxos disease. Alternative splicing occurs in this gene; however, not all transcripts have been fully described. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MC1R", GeneFullName: "Melanocortin 1 Receptor", In_Invitae84: 0, Mechanism: "This intronless gene encodes the receptor protein for melanocyte-stimulating hormone (MSH). The encoded protein, a seven pass transmembrane G protein coupled receptor, controls melanogenesis. Two types of melanin exist: red pheomelanin and black eumelanin. Gene mutations that lead to a loss in function are associated with increased pheomelanin production, which leads to lighter skin and hair color. Eumelanin is photoprotective but pheomelanin may contribute to UV-induced skin damage by generating free radicals upon UV radiation. Binding of MSH to its receptor activates the receptor and stimulates eumelanin synthesis. This receptor is a major determining factor in sun sensitivity and is a genetic risk factor for melanoma and non-melanoma skin cancer. Over 30 variant alleles have been identified which correlate with skin and hair color, providing evidence that this gene is an important component in determining normal human pigment variation. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MSI", GeneFullName: "MutS Homolog 6", In_Invitae84: 0, Mechanism: "The protein product of MSH6 forms a heterodimer with MSH2, which helps repair DNA replication errors. Loss of MSH6 function increases risk of tumor formation."})
(:LKP_GENE_DETAILS {GeneMasterName: "MYBPC3", GeneFullName: "MutY DNA Glycosylase", In_Invitae84: 0, Mechanism: "The protein product of MUTYH is a DNA glycosylase which plays a role in oxidative DNA damage repair. At DNA sites where adenine is improperly paired, this glycosylase excises the adenine base to correct the error."})
(:LKP_GENE_DETAILS {GeneMasterName: "MYH7", GeneFullName: "Myosin Heavy Chain 7", In_Invitae84: 0, Mechanism: "Muscle myosin is a hexameric protein containing 2 heavy chain subunits, 2 alkali light chain subunits, and 2 regulatory light chain subunits. This gene encodes the beta (or slow) heavy chain subunit of cardiac myosin. It is expressed predominantly in normal human ventricle. It is also expressed in skeletal muscle tissues rich in slow-twitch type I muscle fibers. Changes in the relative abundance of this protein and the alpha (or fast) heavy subunit of cardiac myosin correlate with the contractile velocity of cardiac muscle. Its expression is also altered during thyroid hormone depletion and hemodynamic overloading. Mutations in this gene are associated with familial hypertrophic cardiomyopathy, myosin storage myopathy, dilated cardiomyopathy, and Laing early-onset distal myopathy. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MYL2", GeneFullName: "Myosin Light Chain 2", In_Invitae84: 0, Mechanism: "Thus gene encodes the regulatory light chain associated with cardiac myosin beta (or slow) heavy chain. Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction. Mutations in this gene are associated with mid-left ventricular chamber type hypertrophic cardiomyopathy. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MYL3", GeneFullName: "Myosin Light Chain 3", In_Invitae84: 0, Mechanism: "MYL3 encodes myosin light chain 3, an alkali light chain also referred to in the literature as both the ventricular isoform and the slow skeletal muscle isoform. Mutations in MYL3 have been identified as a cause of mid-left ventricular chamber type hypertrophic cardiomyopathy. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFA10", GeneFullName: "NADH:Ubiquinone Oxidoreductase Subunit A10", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a component of 42 kDa complex I, the first enzyme complex in the electron transport chain of mitochondria. This protein has NADH dehydrogenase activity and oxidoreductase activity. It transfers electrons from NADH to the respiratory chain. A mutation in this gene was found in an individual with Leigh syndrome. [provided by RefSeq, Apr 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFA12", GeneFullName: "NADH:Ubiquinone Oxidoreductase Subunit A12", In_Invitae84: 0, Mechanism: "This gene encodes a protein which is part of mitochondrial complex 1, part of the oxidative phosphorylation system in mitochondria. Complex 1 transfers electrons to ubiquinone from NADH which establishes a proton gradient for the generation of ATP. Mutations in this gene are associated with Leigh syndrome due to mitochondrial complex 1 deficiency. Pseudogenes of this gene are located on chromosomes 5 and 13. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2012]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFA2", GeneFullName: "NADH:Ubiquinone Oxidoreductase Subunit A2", In_Invitae84: 0, Mechanism: "The encoded protein is a subunit of the hydrophobic protein fraction of the NADH:ubiquinone oxidoreductase (complex 1), the first enzyme complex in the electron transport chain located in the inner mitochondrial membrane, and may be involved in regulating complex I activity or its assembly via assistance in redox processes. Mutations in this gene are associated with Leigh syndrome, an early-onset progressive neurodegenerative disorder. Alternative splicing results in multiple transcript variants.[provided by RefSeq, May 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFA9", GeneFullName: "NADH:Ubiquinone Oxidoreductase Subunit A9", In_Invitae84: 0, Mechanism: "The encoded protein is a subunit of the hydrophobic protein fraction of the NADH:ubiquinone oxidoreductase (complex I), the first enzyme complex in the electron transport chain located in the inner mitochondrial membrane. A pseudogene has been identified on chromosome 12. [provided by RefSeq, May 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFAF2", GeneFullName: "NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 2", In_Invitae84: 0, Mechanism: "NADH:ubiquinone oxidoreductase (complex I) catalyzes the transfer of electrons from NADH to ubiquinone (coenzyme Q) in the first step of the mitochondrial respiratory chain, resulting in the translocation of protons across the inner mitochondrial membrane. This gene encodes a complex I assembly factor. Mutations in this gene cause progressive encephalopathy resulting from mitochondrial complex I deficiency. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CDKN1B", GeneFullName: "Cyclin Dependent Kinase Inhibitor 1B", In_Invitae84: 1, Mechanism: "This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state."})
(:LKP_GENE_DETAILS {GeneMasterName: "CDKN1C", GeneFullName: "Cyclin Dependent Kinase Inhibitor 1C", In_Invitae84: 1, Mechanism: "This gene is imprinted, with preferential expression of the maternal allele. The encoded protein is a tight-binding, strong inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation. Mutations in this gene are implicated in sporadic cancers and Beckwith-Wiedemann syndorome, suggesting that this gene is a tumor suppressor candidate. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Oct 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CEBPA", GeneFullName: "CAAT Enhancer Binding Protein Alpha", In_Invitae84: 1, Mechanism: "This intronless gene encodes a transcription factor that contains a basic leucine zipper (bZIP) domain and recognizes the CCAAT motif in the promoters of target genes. The encoded protein functions in homodimers and also heterodimers with CCAAT/enhancer-binding proteins beta and gamma. Activity of this protein can modulate the expression of genes involved in cell cycle regulation as well as in body weight homeostasis. Mutation of this gene is associated with acute myeloid leukemia. The use of alternative in-frame non-AUG (GUG) and AUG start codons results in protein isoforms with different lengths. Differential translation initiation is mediated by an out-of-frame, upstream open reading frame which is located between the GUG and the first AUG start codons. [provided by RefSeq, Dec 2013]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CTNNA1", GeneFullName: "Catenin Alpha 1", In_Invitae84: 1, Mechanism: "CTNNA1 encodes a protein of the same name that may play a role in cell differentiation."})
(:LKP_GENE_DETAILS {GeneMasterName: "MEN1", GeneFullName: "Menin¬†", In_Invitae84: 1, Mechanism: "MEN1 encodes a tumor suppressor that plays a role in cell proliferation, genomic stability, and cell cycle control."})
(:LKP_GENE_DETAILS {GeneMasterName: "MET", GeneFullName: "MET Proto-Oncogene, Receptor Tyrosine Kinase", In_Invitae84: 1, Mechanism: "This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFAF6", GeneFullName: "NADH:Ubiquinone Oxidoreductase Complex Assembly Factor 6", In_Invitae84: 0, Mechanism: "This gene encodes a protein that localizes to mitochondria and contains a predicted phytoene synthase domain. The encoded protein plays an important role in the assembly of complex I (NADH-ubiquinone oxidoreductase) of the mitochondrial respiratory chain through regulation of subunit ND1 biogenesis. Mutations in this gene are associated with complex I enzymatic deficiency. [provided by RefSeq, Nov 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFS3", GeneFullName: "NADH:Ubiquinone Oxidoreductase Core Subunit S3", In_Invitae84: 0, Mechanism: "This gene encodes one of the iron-sulfur protein (IP) components of mitochondrial NADH:ubiquinone oxidoreductase (complex I). Mutations in this gene are associated with Leigh syndrome resulting from mitochondrial complex I deficiency.[provided by RefSeq, Apr 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFS4", GeneFullName: "NADH:Ubiquinone Oxidoreductase Subunit S4", In_Invitae84: 0, Mechanism: "This gene encodes an nuclear-encoded accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I, or NADH:ubiquinone oxidoreductase). Complex I removes electrons from NADH and passes them to the electron acceptor ubiquinone. Mutations in this gene can cause mitochondrial complex I deficiencies such as Leigh syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2015]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFS7", GeneFullName: "NADH:Ubiquinone Oxidoreductase Core Subunit S", In_Invitae84: 0, Mechanism: "This gene encodes a protein that is a subunit of one of the complexes that forms the mitochondrial respiratory chain. This protein is one of over 40 subunits found in complex I, the nicotinamide adenine dinucleotide (NADH):ubiquinone oxidoreductase. This complex functions in the transfer of electrons from NADH to the respiratory chain, and ubiquinone is believed to be the immediate electron acceptor for the enzyme. Mutations in this gene cause Leigh syndrome due to mitochondrial complex I deficiency, a severe neurological disorder that results in bilaterally symmetrical necrotic lesions in subcortical brain regions. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NDUFS8", GeneFullName: "NADH:Ubiquinone Oxidoreductase Core Subunit S8", In_Invitae84: 0, Mechanism: "This gene encodes a subunit of mitochondrial NADH:ubiquinone oxidoreductase, or Complex I, a multimeric enzyme of the respiratory chain responsible for NADH oxidation, ubiquinone reduction, and the ejection of protons from mitochondria. The encoded protein is involved in the binding of two of the six to eight iron-sulfur clusters of Complex I and, as such, is required in the electron transfer process. Mutations in this gene have been associated with Leigh syndrome. [provided by RefSeq, Mar 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PMS3", GeneFullName: "PMS1 Homolog 2", In_Invitae84: 0, Mechanism: "The protein product of PMS2 exhibits C-terminal interaction with MLH1 to form a heterodimer which helps repair DNA replication errors via exonuclease degradation. Loss of function of PMS2 increases risk of tumor formation."})
(:LKP_GENE_DETAILS {GeneMasterName: "PRKAG2", GeneFullName: "Protein Kinase AMP-Activated Non-Catalytic Subunit Gamma 2", In_Invitae84: 0, Mechanism: "AMP-activated protein kinase (AMPK) is a heterotrimeric protein composed of a catalytic alpha subunit, a noncatalytic beta subunit, and a noncatalytic regulatory gamma subunit. Various forms of each of these subunits exist, encoded by different genes. AMPK is an important energy-sensing enzyme that monitors cellular energy status and functions by inactivating key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This gene is a member of the AMPK gamma subunit family. Mutations in this gene have been associated with Wolff-Parkinson-White syndrome, familial hypertrophic cardiomyopathy, and glycogen storage disease of the heart. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jan 2015]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PTCH2", GeneFullName: "Patched 2", In_Invitae84: 0, Mechanism: "This gene encodes a transmembrane receptor of the patched gene family. The encoded protein may function as a tumor suppressor in the hedgehog signaling pathway. Alterations in this gene have been associated with nevoid basal cell carcinoma syndrome, basal cell carcinoma, medulloblastoma, and susceptibility to congenital macrostomia. Alternatively spliced transcript variants have been described.[provided by RefSeq, Oct 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD51B", GeneFullName: "RAD51 Paralog B", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a member of the RAD51 protein family. RAD51 family members are evolutionarily conserved proteins essential for DNA repair by homologous recombination. This protein has been shown to form a stable heterodimer with the family member RAD51C, which further interacts with the other family members, such as RAD51, XRCC2, and XRCC3. Overexpression of this gene was found to cause cell cycle G1 delay and cell apoptosis, which suggested a role of this protein in sensing DNA damage. Rearrangements between this locus and high mobility group AT-hook 2 (HMGA2, GeneID 8091) have been observed in uterine leiomyomata. [provided by RefSeq, Mar 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RET", GeneFullName: "Ret Proto-Oncogene", In_Invitae84: 1, Mechanism: "This gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis. [provided by RefSeq, Sep 2017]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RINT1", GeneFullName: "RAD50 Interactor 1", In_Invitae84: 0, Mechanism: "This gene encodes a protein first identified for its ability to interact with the RAD50 double strand break repair protein, with the resulting interaction implicated in the regulation of cell cycle progression and telomere length. The encoded protein may also play a role in trafficking of cellular cargo from the endosome to the trans-Golgi network. Mutations in this gene may be associated with breast cancer in human patients. [provided by RefSeq, Oct 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPL11", GeneFullName: "Ribosomal Protein L11", In_Invitae84: 0, Mechanism: "Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs to the L5P family of ribosomal proteins. It is located in the cytoplasm. The protein probably associates with the 5S rRNA. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Dec 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PTCSC3", GeneFullName: "¬†papillary thyroid carcinoma susceptibility candidate 3", In_Invitae84: 0, Mechanism: "PTCSC3 (Papillary Thyroid Carcinoma Susceptibility Candidate 3) is an RNA Gene, and is affiliated with the lncRNA class"})
(:LKP_GENE_DETAILS {GeneMasterName: "PTCSC1", GeneFullName: "¬†papillary thyroid carcinoma susceptibility candidate 1", In_Invitae84: 0, Mechanism: "Long noncoding RNAs, such as¬†PTCSC1, have over 200 nucleotides and play major roles in gene regulation.¬†PTCSC1¬†functions as a critical scaffold for proteins involved in cell signaling"})
(:LKP_GENE_DETAILS {GeneMasterName: "AIP", GeneFullName: "Aryl Hydrocarbon Receptor Interacting Protein", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a receptor for aryl hydrocarbons and a ligand-activated transcription factor. The encoded protein is found in the cytoplasm as part of a multiprotein complex, but upon binding of ligand is transported to the nucleus. This protein can regulate the expression of many xenobiotic metabolizing enzymes. Also, the encoded protein can bind specifically to and inhibit the activity of hepatitis B virus. Three transcript variants encoding different isoforms have been found for this gene. AIP encodes a protein that binds and stabilizes the AHR in the cytoplasm, and helps to regulate its subcellular localization."})
(:LKP_GENE_DETAILS {GeneMasterName: "ALK", GeneFullName: "Anaplastic Lymphoma Receptor Tyrosine Kinase", In_Invitae84: 1, Mechanism: "This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system.. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011] ALK encodes a tyrosine kinase receptor which plays a role in brain development."})
(:LKP_GENE_DETAILS {GeneMasterName: "AR", GeneFullName: "Androgen receptor", In_Invitae84: 0, Mechanism: "The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract from the normal 9-34 repeats to the pathogenic 38-62 repeats causes spinal bulbar muscular atrophy (SBMA, also known as Kennedy's disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jan 2017]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ATR", GeneFullName: "ATR¬†Serine/Tnreonine Kinase", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a serine/threonine kinase and DNA damage sensor, activating cell cycle checkpoint signaling upon DNA stress. The encoded protein can phosphorylate and activate several proteins involved in the inhibition of DNA replication and mitosis, and can promote DNA repair, recombination, and apoptosis. This protein is also important for fragile site stability and centrosome duplication. Defects in this gene are a cause of Seckel syndrome 1. [provided by RefSeq, Aug 2017]"})
(:LKP_GENE_DETAILS {GeneMasterName: "BCS1L", GeneFullName: "BCS1 Homolog, Ubiquinol-Cytochrome C Reductase Complex Chaperone", In_Invitae84: 0, Mechanism: "This gene encodes a homolog of the S. cerevisiae bcs1 protein which is involved in the assembly of complex III of the mitochondrial respiratory chain. The encoded protein does not contain a mitochondrial targeting sequence but experimental studies confirm that it is imported into mitochondria. Mutations in this gene are associated with mitochondrial complex III deficiency and the GRACILE syndrome. Several alternatively spliced transcripts encoding two different isoforms have been described. [provided by RefSeq, Jan 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC4", GeneFullName: "ERCC Excision Repair 4, Endonuclease Catalytic Subunit", In_Invitae84: 0, Mechanism: "The protein encoded by this gene forms a complex with ERCC1 and is involved in the 5' incision made during nucleotide excision repair. This complex is a structure specific DNA repair endonuclease that interacts with EME1. Defects in this gene are a cause of xeroderma pigmentosum complementation group F (XP-F), or xeroderma pigmentosum VI (XP6).[provided by RefSeq, Mar 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC5", GeneFullName: "ERCC Excision Repair 5, Endonuclease", In_Invitae84: 0, Mechanism: "his gene encodes a single-strand specific DNA endonuclease that makes the 3' incision in DNA excision repair following UV-induced damage. The protein may also function in other cellular processes, including RNA polymerase II transcription, and transcription-coupled DNA repair. Mutations in this gene cause xeroderma pigmentosum complementation group G (XP-G), which is also referred to as xeroderma pigmentosum VII (XP7), a skin disorder characterized by hypersensitivity to UV light and increased susceptibility for skin cancer development following UV exposure. Some patients also develop Cockayne syndrome, which is characterized by severe growth defects, cognitive disability, and cachexia. Read-through transcription exists between this gene and the neighboring upstream BIVM (basic, immunoglobulin-like variable motif containing) gene. [provided by RefSeq, Feb 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ETV6", GeneFullName: "ETS Variant Transcription Factor 6", In_Invitae84: 0, Mechanism: "This gene encodes an ETS family transcription factor. The product of this gene contains two functional domains: a N-terminal pointed (PNT) domain that is involved in protein-protein interactions with itself and other proteins, and a C-terminal DNA-binding domain. Gene knockout studies in mice suggest that it is required for hematopoiesis and maintenance of the developing vascular network. This gene is known to be involved in a large number of chromosomal rearrangements associated with leukemia and congenital fibrosarcoma. [provided by RefSeq, Sep 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "EXT1", GeneFullName: "Exostosin Glycosyltransferase¬†", In_Invitae84: 0, Mechanism: "This gene encodes an endoplasmic reticulum-resident type II transmembrane glycosyltransferase involved in the chain elongation step of heparan sulfate biosynthesis. Mutations in this gene cause the type I form of multiple exostoses. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "EXT2", GeneFullName: "Exostosin Glycosyltransferase 2", In_Invitae84: 0, Mechanism: "This gene encodes one of two glycosyltransferases involved in the chain elongation step of heparan sulfate biosynthesis. Mutations in this gene cause the type II form of multiple exostoses. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "EZH2", GeneFullName: "Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit", In_Invitae84: 0, Mechanism: "This gene encodes a member of the Polycomb-group (PcG) family. PcG family members form multimeric protein complexes, which are involved in maintaining the transcriptional repressive state of genes over successive cell generations. This protein associates with the embryonic ectoderm development protein, the VAV1 oncoprotein, and the X-linked nuclear protein. This protein may play a role in the hematopoietic and central nervous systems. Multiple alternatively splcied transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Feb 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FAH", GeneFullName: "Fumarylacetoacetate Hydrolase", In_Invitae84: 0, Mechanism: "his gene encodes the last enzyme in the tyrosine catabolism pathway. FAH deficiency is associated with Type 1 hereditary tyrosinemia (HT). [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NHP2", GeneFullName: "NHP2 Ribonucleoprotein", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "NOP10", GeneFullName: "NK2 homeobox 1", In_Invitae84: 0, Mechanism: "This gene encodes a protein initially identified as a thyroid-specific transcription factor. The encoded protein binds to the thyroglobulin promoter and regulates the expression of thyroid-specific genes but has also been shown to regulate the expression of genes involved in morphogenesis.¬†"})
(:LKP_GENE_DETAILS {GeneMasterName: "NTRK1", GeneFullName: "Neurotrophic Receptor Tyrosine Kinase 1", In_Invitae84: 0, Mechanism: "This gene encodes a member of the neurotrophic tyrosine kinase receptor (NTKR) family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, phosphorylates itself and members of the MAPK pathway. The presence of this kinase leads to cell differentiation and may play a role in specifying sensory neuron subtypes. Mutations in this gene have been associated with congenital insensitivity to pain, anhidrosis, self-mutilating behavior, cognitive disability and cancer. Alternate transcriptional splice variants of this gene have been found, but only three have been characterized to date. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PARK2", GeneFullName: "Parkinson Disease 2, Autosomal Recessive Juvinile", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PCSK9", GeneFullName: "Proprotein Convertase Subtilisin/Kexin Type 9", In_Invitae84: 0, Mechanism: "This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PIK3CA", GeneFullName: "Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha", In_Invitae84: 0, Mechanism: "Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PKP2", GeneFullName: "Plakophilin 2", In_Invitae84: 0, Mechanism: "This gene encodes a member of the arm-repeat (armadillo) and plakophilin gene families. Plakophilin proteins contain numerous armadillo repeats, localize to cell desmosomes and nuclei, and participate in linking cadherins to intermediate filaments in the cytoskeleton. This gene product may regulate the signaling activity of beta-catenin. Two alternately spliced transcripts encoding two protein isoforms have been identified. A processed pseudogene with high similarity to this locus has been mapped to chromosome 12p13. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PLN", GeneFullName: "Phospholamban", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is found as a pentamer and is a major substrate for the cAMP-dependent protein kinase in cardiac muscle. The encoded protein is an inhibitor of cardiac muscle sarcoplasmic reticulum Ca(2+)-ATPase in the unphosphorylated state, but inhibition is relieved upon phosphorylation of the protein. The subsequent activation of the Ca(2+) pump leads to enhanced muscle relaxation rates, thereby contributing to the inotropic response elicited in heart by beta-agonists. The encoded protein is a key regulator of cardiac diastolic function. Mutations in this gene are a cause of inherited human dilated cardiomyopathy with refractory congestive heart failure, and also familial hypertrophic cardiomyopathy. [provided by RefSeq, Apr 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPL26", GeneFullName: "Ribosomal Protein L2", In_Invitae84: 0, Mechanism: "Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs to the L24P family of ribosomal proteins. It is located in the cytoplasm. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. Mutations in this gene result in Diamond-Blackfan anemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2015]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPL35A", GeneFullName: "Ribosomal Protein L35a", In_Invitae84: 0, Mechanism: "Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs to the L35AE family of ribosomal proteins. It is located in the cytoplasm. The rat protein has been shown to bind to both initiator and elongator tRNAs, and thus, it is located at the P site, or P and A sites, of the ribosome. Although this gene was originally mapped to chromosome 18, it has been established that it is located at 3q29-qter. Alternative splicing results in multiple transcript variants. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Oct 2015]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPL5", GeneFullName: "Ribosomal Protein L5", In_Invitae84: 0, Mechanism: "Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of four RNA species and approximately 80 structurally distinct proteins. This gene encodes a member of the L18P family of ribosomal proteins and component of the 60S subunit. The encoded protein binds 5S rRNA to form a stable complex called the 5S ribonucleoprotein particle (RNP), which is necessary for the transport of nonribosome-associated cytoplasmic 5S rRNA to the nucleolus for assembly into ribosomes. The encoded protein may also function to inhibit tumorigenesis through the activation of downstream tumor suppressors and the downregulation of oncoprotein expression. Mutations in this gene have been identified in patients with Diamond-Blackfan Anemia (DBA). This gene is co-transcribed with the small nucleolar RNA gene U21, which is located in its fifth intron. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed throughout the genome. [provided by RefSeq, Mar 2017]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPS10", GeneFullName: "Ribosomal Protein S10", In_Invitae84: 0, Mechanism: "Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 40S subunit. The protein belongs to the S10E family of ribosomal proteins. It is located in the cytoplasm. Variable expression of this gene in colorectal cancers compared to adjacent normal tissues has been observed, although no correlation between the level of expression and the severity of the disease has been found. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. Alternate splicing results in multiple transcript variants that encode the same protein. Naturally occurring read-through transcription occurs between this locus and the neighboring locus NUDT3 (nudix (nucleoside diphosphate linked moiety X)-type motif 3).[provided by RefSeq, Feb 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPS19", GeneFullName: "Ribosomal Protein S19", In_Invitae84: 0, Mechanism: "Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 40S subunit. The protein belongs to the S19E family of ribosomal proteins. It is located in the cytoplasm. Mutations in this gene cause Diamond-Blackfan anemia (DBA), a constitutional erythroblastopenia characterized by absent or decreased erythroid precursors, in a subset of patients. This suggests a possible extra-ribosomal function for this gene in erythropoietic differentiation and proliferation, in addition to its ribosomal function. Higher expression levels of this gene in some primary colon carcinomas compared to matched normal colon tissues has been observed. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Jul 2008"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPS20", GeneFullName: "Ribosomal Protein S20", In_Invitae84: 0, Mechanism: "Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 40S subunit. The protein belongs to the S10P family of ribosomal proteins. It is located in the cytoplasm. This gene is co-transcribed with the small nucleolar RNA gene U54, which is located in its second intron. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. Two transcript variants encoding different isoforms have been identified for this gene. [provided by RefSeq, Apr 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPS24", GeneFullName: "Ribosomal Protein S24", In_Invitae84: 0, Mechanism: "Required for processing of pre-rRNA and maturation of 40S ribosomal subunits"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPS26", GeneFullName: "Ribosomal Protein S26", In_Invitae84: 0, Mechanism: "40S ribosomal protein S26,12kDa"})
(:LKP_GENE_DETAILS {GeneMasterName: "RPS7", GeneFullName: "Ribosomal Protein S7", In_Invitae84: 0, Mechanism: "Required for rRNA maturation."})
(:LKP_GENE_DETAILS {GeneMasterName: "SURF1", GeneFullName: "SURF1 Cytochrome C Oxidase Assembly Factor", In_Invitae84: 0, Mechanism: "Component of the MITRAC (mitochondrial translation regulation assembly intermediate of cytochrome c oxidase complex) complex, that regulates cytochrome c oxidase assembly."})
(:LKP_GENE_DETAILS {GeneMasterName: "TAZ", GeneFullName: "Tafazzin", In_Invitae84: 0, Mechanism: "Some isoforms may be involved in cardiolipin (CL) metabolism"})
(:LKP_GENE_DETAILS {GeneMasterName: "TCAP", GeneFullName: "Titin-Cap", In_Invitae84: 0, Mechanism: "Muscle assembly regulating factor. Mediates the antiparallel assembly of titin (TTN) molecules at the sarcomeric Z-disk."})
(:LKP_GENE_DETAILS {GeneMasterName: "TMEM43", GeneFullName: "transmembrane Protein 43", In_Invitae84: 0, Mechanism: "May have an important role in maintaining nuclear envelope structure by organizing protein complexes at the inner nuclear membrane. Required for retaining emerin at the inner nuclear membrane (By similarity)."})
(:LKP_GENE_DETAILS {GeneMasterName: "TNNI3", GeneFullName: "Troponin I3, Cardiac Type", In_Invitae84: 0, Mechanism: "Troponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity"})
(:LKP_GENE_DETAILS {GeneMasterName: "TNNT2", GeneFullName: "roponin T2, Cardiac Type", In_Invitae84: 0, Mechanism: "Troponin T is the tropomyosin-binding subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity"})
(:LKP_GENE_DETAILS {GeneMasterName: "TPM1", GeneFullName: "Tropomyosin 1", In_Invitae84: 0, Mechanism: "Binds to actin filaments in muscle and non-muscle cells (PubMed:23170982). Plays a central role, in association with the troponin complex, in the calcium dependent regulation of vertebrate striated muscle contraction (PubMed:23170982). Smooth muscle contr"})
(:LKP_GENE_DETAILS {GeneMasterName: "TTC37", GeneFullName: "etratricopeptide Repeat Domain 37", In_Invitae84: 0, Mechanism: "Component of the SKI complex which is thought to be involved in exosome-mediated RNA decay and associates with transcriptionally active genes in a manner dependent on PAF1 complex (PAF1C)"})
(:LKP_GENE_DETAILS {GeneMasterName: "VCL", GeneFullName: "Vinculin", In_Invitae84: 0, Mechanism: "Vinculin is a cytoskeletal protein associated with cell-cell and cell-matrix junctions, where it is thought to function as one of several interacting proteins involved in anchoring F-actin to the membrane. Defects in VCL are the cause of cardiomyopathy di"})
(:LKP_GENE_DETAILS {GeneMasterName: "XK", GeneFullName: "Membrane transport protein XK", In_Invitae84: 0, Mechanism: "XK (X-Linked Kx Blood Group) is a Protein Coding gene. Diseases associated with XK include Mcleod Syndrome and Choreoacanthocytosis. Among its related pathways are Signaling by GPCR and Peptide ligand-binding receptors. Gene Ontology (GO) annotations rela"})
(:LKP_GENE_DETAILS {GeneMasterName: "XPA", GeneFullName: "XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A;¬†XPA", In_Invitae84: 0, Mechanism: "Xeroderma pigmentosum is a genetically heterogeneous autosomal recessive disorder characterized by increased sensitivity to sunlight with the development of carcinomas at an early age. Some patients develop neurologic symptoms or a more severe clinical ph"})
(:LKP_GENE_DETAILS {GeneMasterName: "XPC1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RNF43", GeneFullName: "Ring Finger Protein 43", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a RING-type E3 ubiquitin ligase and is predicted to contain a transmembrane domain, a protease-associated domain, an ectodomain, and a cytoplasmic RING domain. This protein is thought to negatively regulate Wnt signaling, and expression of this gene results in an increase in ubiquitination of frizzled receptors, an alteration in their subcellular distribution, resulting in reduced surface levels of these receptors. Mutations in this gene have been reported in multiple tumor cells, including colorectal and endometrial cancers. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Mar 2015]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ABRAXAS1", GeneFullName: "Coiled-Coil Domain-Containing protein 98;", In_Invitae84: 0, Mechanism: "This gene encodes a protein that binds to the C-terminal repeats of breast cancer 1 (BRCA1) through a phospho-SXXF motif. The encoded protein recruits ubiquitin interaction motif containing 1 protein to BRCA1 protein and is required for DNA damage resistance, DNA repair, and cell cycle checkpoint control. Pseudogenes of this gene are found on chromosomes 3 and 8. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "EGLN1", GeneFullName: "Egl-9 Family Hypoxia Inducible Factor 1", In_Invitae84: 0, Mechanism: "The protein encoded by this gene catalyzes the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. HIF is a transcriptional complex that plays a central role in mammalian oxygen homeostasis. This protein functions as a cellular oxygen sensor, and under normal oxygen concentration, modification by prolyl hydroxylation is a key regulatory event that targets HIF subunits for proteasomal destruction via the von Hippel-Lindau ubiquitylation complex. Mutations in this gene are associated with erythrocytosis familial type 3 (ECYT3). [provided by RefSeq, Nov 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "KIF1B", GeneFullName: "Kinesin Family Member 1B", In_Invitae84: 0, Mechanism: "This gene encodes a motor protein that transports mitochondria and synaptic vesicle precursors. Mutations in this gene cause Charcot-Marie-Tooth disease, type 2A1. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "LZTR1", GeneFullName: "Leucine Zipper Like Transcription Regulator 1", In_Invitae84: 0, Mechanism: "This gene encodes a member of the BTB-kelch superfamily. Initially described as a putative transcriptional regulator based on weak homology to members of the basic leucine zipper-like family, the encoded protein subsequently has been shown to localize exclusively to the Golgi network where it may help stabilize the Gogli complex. Deletion of this gene may be associated with DiGeorge syndrome. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PALLD", GeneFullName: "Partner and Localizer of BRCA2", In_Invitae84: 0, Mechanism: "The protein product of PALB2 is the partner and localizer of BRCA2, facilitating its accumulation in the nucleus. As such, PALB2 is involved with cell growth and division, along with DNA damage repair."})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC1", GeneFullName: "ERCC Excision Repair 1, Endonuclease Non-Catalytic Subunit", In_Invitae84: 0, Mechanism: "The product of this gene functions in the nucleotide excision repair pathway, and is required for the repair of DNA lesions such as those induced by UV light or formed by electrophilic compounds including cisplatin. The encoded protein forms a heterodimer with the XPF endonuclease (also known as ERCC4), and the heterodimeric endonuclease catalyzes the 5' incision in the process of excising the DNA lesion. The heterodimeric endonuclease is also involved in recombinational DNA repair and in the repair of inter-strand crosslinks. Mutations in this gene result in cerebrooculofacioskeletal syndrome, and polymorphisms that alter expression of this gene may play a role in carcinogenesis. Multiple transcript variants encoding different isoforms have been found for this gene. The last exon of this gene overlaps with the CD3e molecule, epsilon associated protein gene on the opposite strand. [provided by RefSeq, Oct 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "FAN1", GeneFullName: "FANCD2 And FANCI Associated Nuclease 1", In_Invitae84: 0, Mechanism: "This gene plays a role in DNA interstrand cross-link repair and encodes a protein with 5' flap endonuclease and 5'-3' exonuclease activity. Mutations in this gene cause karyomegalic interstitial nephritis. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Feb 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "POLH", GeneFullName: "DNA Polymerase Epsilon, Catalytic Subunit", In_Invitae84: 0, Mechanism: "This gene encodes a member of the Y family of specialized DNA polymerases. It copies undamaged DNA with a lower fidelity than other DNA-directed polymerases. However, it accurately replicates UV-damaged DNA; when thymine dimers are present, this polymerase inserts the complementary nucleotides in the newly synthesized DNA, thereby bypassing the lesion and suppressing the mutagenic effect of UV-induced DNA damage. This polymerase is thought to be involved in hypermutation during immunoglobulin class switch recombination. Mutations in this gene result in XPV, a variant type of xeroderma pigmentosum. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2014]"})
(:LKP_GENE_DETAILS {GeneMasterName: "SLC45A2", GeneFullName: "Solute Carrier Family 45 Member 2", In_Invitae84: 0, Mechanism: "Melanocyte differentiation antigen. May transport substances required for melanin biosynthesis (By similarity)."})
(:LKP_GENE_DETAILS {GeneMasterName: "TINF2", GeneFullName: "TERF1 Interacting Nuclear Factor 2", In_Invitae84: 0, Mechanism: "Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded TTAGGG repeats added by telomerase and protects chromosome ends; without its protective"})
(:LKP_GENE_DETAILS {GeneMasterName: "WRAP53", GeneFullName: "WD Repeat Containing Antisense To TP53", In_Invitae84: 0, Mechanism: "RNA chaperone that plays a key role in telomere maintenance and RNA localization to Cajal bodies (PubMed:29804836, PubMed:29695869). Specifically recognizes and binds the Cajal body box (CAB box) present in both small Cajal body RNAs (scaRNAs) and telomer"})
(:LKP_GENE_DETAILS {GeneMasterName: "TYR", GeneFullName: "Tyrosinase", In_Invitae84: 0, Mechanism: "This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine. In add"})
(:LKP_GENE_DETAILS {GeneMasterName: "ATRX", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CAP1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CDK12", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CTFR", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "DMC1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "EHBP1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ELAC2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "EME1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "BRCA1-Biallelic", GeneFullName: "Breast Cancer 1 Early Onset Protein", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "BRCA2-Biallelic", GeneFullName: "Breast Cancer 2 Early Onset Protein", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "BRIP1-Biallelic", GeneFullName: "BRCA1 Interacting Protein C-Terminal Helicase 1", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "BUB1B-Biallelic", GeneFullName: "BRCA1 Interacting Protein C-Terminal Helicase 1", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CASR-Biallelic", GeneFullName: "Calcium Sensing Receptor", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CDKN1B-Biallelic", GeneFullName: "Calcium Sensing Receptor", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CEP57-Biallelic", GeneFullName: "Centrosomal Protein 57", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CFTR-Biallelic", GeneFullName: "CF Transmembrane Conductance Regulator", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CTC1-Biallelic", GeneFullName: "CST Telomere Replication Complex Component 1", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "DDB2-Biallelic", GeneFullName: "Damage Specific DNA Binding Protein 2", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "DIS3L2-Biallelic", GeneFullName: "DIS3 Like 3'-5' Exoribonuclease 2", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "EPCAM-Biallelic", GeneFullName: "Epithelial Cell Adhesion Molecule", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC2-Biallelic", GeneFullName: "ERCC Excision Repair 2, TFIIH Core Complex Helicase Subunit", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC3-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC4-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ERCC5-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCA-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCC-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCD2-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCE-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCF-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCG-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCL-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FANCM-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FH-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "GPC3-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "LDLRAP1-Biallelic", GeneFullName: "Low Density Lipoprotein Receptor Adaptor Protein 1", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "LMNA-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MRE11-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MSH3-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "NBN-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "NHP2-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "NOP10-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "NTHL1-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PALB2-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "POLE-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD50-Biallelic", GeneFullName: "RAD50 Double Strand Break Repair Protein", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD51-Biallelic", GeneFullName: "RAD51 Paralog B", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD51C-Biallelic", GeneFullName: "RAD51 Paralog C", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RECQL4-Biallelic", GeneFullName: "RecQ like helicase¬†4", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SDHA-Biallelic", GeneFullName: "Succinate Dehydrogenase Complex Flavoprotein Subunit A", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SDHB-Biallelic", GeneFullName: "Succinate Dehydrogenase Complex Iron Sulfur Subunit B", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SLX4-Biallelic", GeneFullName: "SLX4 Structure-Specific Endonuclease Subunit", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SPINK1-Biallelic", GeneFullName: "Serine Peptidase Inhibitor Kazal Type 1", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "VHL-Biallelic", GeneFullName: "Von Hippel-Lindau Tumor Suppressor", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "WRN-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "XPA-Biallelic", GeneFullName: "XERODERMA PIGMENTOSUM, COMPLEMENTATION GROUP A;¬†XPA", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "XRCC2-Biallelic", GeneFullName: "X-ray repair cross complementing 2", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MUTYH-Biallelic/Compound Heterozygous
MUTYH-Biallelic/Compound Heterozygous", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PTCSC2", GeneFullName: "papillary thyroid carcinoma susceptibility candidate 2", In_Invitae84: 0, Mechanism: "PTCSC2 (Papillary Thyroid Carcinoma Susceptibility Candidate 2) is an RNA Gene, and is affiliated with the lncRNA class"})
(:LKP_GENE_DETAILS {GeneMasterName: "SEC23B", GeneFullName: "SEC23 homolog B, COPII coat complex component", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a member of the SEC23 subfamily of the SEC23/SEC24 family, which is involved in vesicle trafficking. The encoded protein has similarity to yeast Sec23p component of COPII. COPII is the coat protein complex responsible f"})
(:LKP_GENE_DETAILS {GeneMasterName: "SRGAP1", GeneFullName: "SLIT-ROBO Rho GTPase activating protein 1", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a GTPase activator, working with the GTPase CDC42 to negatively regulate neuronal migration. The encoded protein interacts with the transmembrane receptor ROBO1 to inactivate CDC42."})
(:LKP_GENE_DETAILS {GeneMasterName: "ABCC9", GeneFullName: "ATP Binding Cassette Subfamily C Member 9", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MRP subfamily which is involved in multi-drug resistance. This protein is thought to form ATP-sensitive potassium channels in cardiac, skeletal, and vascular and non-vascular smooth muscle. Protein structure suggests a role as the drug-binding channel-modulating subunit of the extra-pancreatic ATP-sensitive potassium channels. Mutations in this gene are associated with cardiomyopathy dilated type 1O. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ACD", GeneFullName: "Shelterin Complex Subunit And Telomerase Recruitment Factor", In_Invitae84: 0, Mechanism: "This gene encodes a protein that is involved in telomere function. This protein is one of six core proteins in the telosome/shelterin telomeric complex, which functions to maintain telomere length and to protect telomere ends. Through its interaction with other components, this protein plays a key role in the assembly and stabilization of this complex, and it mediates the access of telomerase to the telomere. Multiple transcript variants encoding different isoforms have been found for this gene. This gene, which is also referred to as TPP1, is distinct from the unrelated TPP1 gene on chromosome 11, which encodes tripeptidyl-peptidase I. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ACTC", GeneFullName: "Actin Alpha Cardiac Muscle 1", In_Invitae84: 0, Mechanism: "ctins are highly conserved proteins that are involved in various types of cell motility. Polymerization of globular actin (G-actin) leads to a structural filament (F-actin) in the form of a two-stranded helix. Each actin can bind to four others. The protein encoded by this gene belongs to the actin family which is comprised of three main groups of actin isoforms, alpha, beta, and gamma. The alpha actins are found in muscle tissues and are a major constituent of the contractile apparatus. Defects in this gene have been associated with idiopathic dilated cardiomyopathy (IDC) and familial hypertrophic cardiomyopathy (FHC). [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ACTN2", GeneFullName: "ACITIN ALPHA 2", In_Invitae84: 0, Mechanism: "Alpha actinins belong to the spectrin gene superfamily which represents a diverse group of cytoskeletal proteins, including the alpha and beta spectrins and dystrophins. Alpha actinin is an actin-binding protein with multiple roles in different cell types. In nonmuscle cells, the cytoskeletal isoform is found along microfilament bundles and adherens-type junctions, where it is involved in binding actin to the membrane. In contrast, skeletal, cardiac, and smooth muscle isoforms are localized to the Z-disc and analogous dense bodies, where they help anchor the myofibrillar actin filaments. This gene encodes a muscle-specific, alpha actinin isoform that is expressed in both skeletal and cardiac muscles. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2013]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CCND1", GeneFullName: "Cyclin D1", In_Invitae84: 0, Mechanism: "The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with tumor suppressor protein Rb and the expression of this gene is regulated positively by Rb. Mutations, amplification and overexpression of this gene, which alters cell cycle progression, are observed frequently in a variety of human cancers.¬†"})
(:LKP_GENE_DETAILS {GeneMasterName: "CEP57", GeneFullName: "Centrosomal Protein 57", In_Invitae84: 0, Mechanism: "This gene encodes a cytoplasmic protein called Translokin. This protein localizes to the centrosome and has a function in microtubular stabilization. The N-terminal half of this protein is required for its centrosome localization and for its multimerization, and the C-terminal half is required for nucleating, bundling and anchoring microtubules to the centrosomes. This protein specifically interacts with fibroblast growth factor 2 (FGF2), sorting nexin 6, Ran-binding protein M and the kinesins KIF3A and KIF3B, and thus mediates the nuclear translocation and mitogenic activity of the FGF2. It also interacts with cyclin D1 and controls nucleocytoplasmic distribution of the cyclin D1 in quiescent cells. This protein is crucial for maintaining correct chromosomal number during cell division. Mutations in this gene cause mosaic variegated aneuploidy syndrome, a rare autosomal recessive disorder. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2011]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CFTR", GeneFullName: "CF Transmembrane Conductance Regulator", In_Invitae84: 0, Mechanism: "This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]"})
(:LKP_GENE_DETAILS {GeneMasterName: "COX10", GeneFullName: "Cytochrome C Oxidase Assembly Factor Heme A:Farnesyltransferase COX10", In_Invitae84: 0, Mechanism: "Cytochrome c oxidase (COX), the terminal component of the mitochondrial respiratory chain, catalyzes the electron transfer from reduced cytochrome c to oxygen. This component is a heteromeric complex consisting of 3 catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The mitochondrially-encoded subunits function in electron transfer, and the nuclear-encoded subunits may function in the regulation and assembly of the complex. This nuclear gene encodes heme A:farnesyltransferase, which is not a structural subunit but required for the expression of functional COX and functions in the maturation of the heme A prosthetic group of COX. This protein is predicted to contain 7-9 transmembrane domains localized in the mitochondrial inner membrane. A gene mutation, which results in the substitution of a lysine for an asparagine (N204K), is identified to be responsible for cytochrome c oxidase deficiency. In addition, this gene is disrupted in patients with CMT1A (Charcot-Marie-Tooth type 1A) duplication and with HNPP (hereditary neuropathy with liability to pressure palsies) deletion. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "COX15", GeneFullName: "Cytochrome C Oxidase Assembly Homolog", In_Invitae84: 0, Mechanism: "Cytochrome c oxidase (COX), the terminal component of the mitochondrial respiratory chain, catalyzes the electron transfer from reduced cytochrome c to oxygen. This component is a heteromeric complex consisting of 3 catalytic subunits encoded by mitochondrial genes and multiple structural subunits encoded by nuclear genes. The mitochondrially-encoded subunits function in electron transfer, and the nuclear-encoded subunits may function in the regulation and assembly of the complex. This nuclear gene encodes a protein which is not a structural subunit, but may be essential for the biogenesis of COX formation and may function in the hydroxylation of heme O, according to the yeast mutant studies. This protein is predicted to contain 5 transmembrane domains localized in the mitochondrial inner membrane. Alternative splicing of this gene generates two transcript variants diverging in the 3' region. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CPA1", GeneFullName: "Carboxypeptidase A1", In_Invitae84: 0, Mechanism: "This gene encodes a member of the carboxypeptidase A family of zinc metalloproteases. This enzyme is produced in the pancreas and preferentially cleaves C-terminal branched-chain and aromatic amino acids from dietary proteins. This gene and several family members are present in a gene cluster on chromosome 7. Mutations in this gene may be linked to chronic pancreatitis, while elevated protein levels may be associated with pancreatic cancer. [provided by RefSeq, Jan 2015]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CSRP3", GeneFullName: "Cysteine And Glycine Rich Protein 3", In_Invitae84: 0, Mechanism: "This gene encodes a member of the CSRP family of LIM domain proteins, which may be involved in regulatory processes important for development and cellular differentiation. The LIM/double zinc-finger motif found in this protein is found in a group of proteins with critical functions in gene regulation, cell growth, and somatic differentiation. Mutations in this gene are thought to cause heritable forms of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) in humans. Alternatively spliced transcript variants with different 5' UTR, but encoding the same protein, have been found for this gene. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CTC1", GeneFullName: "CST Telomere Replication Complex Component 1", In_Invitae84: 0, Mechanism: "This gene encodes a component of the CST complex. This complex plays an essential role in protecting telomeres from degradation. This protein also forms a heterodimer with the CST complex subunit STN1 to form the enzyme alpha accessory factor. This enzyme regulates DNA replication. Mutations in this gene are the cause of cerebroretinal microangiopathy with calcifications and cysts. Alternate splicing results in both coding and non-coding variants. [provided by RefSeq, Mar 2012]"})
(:LKP_GENE_DETAILS {GeneMasterName: "CTF1", GeneFullName: "Cardiotrophin 1", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a secreted cytokine that induces cardiac myocyte hypertrophy in vitro. It has been shown to bind and activate the ILST/gp130 receoptor. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "KRAS", GeneFullName: "KRAS Proto-Oncogene, GTPase", In_Invitae84: 0, Mechanism: "his gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "LAMP2", GeneFullName: "Lysosomal Associated Membrane Protein 2", In_Invitae84: 0, Mechanism: "he protein encoded by this gene is a member of a family of membrane glycoproteins. This glycoprotein provides selectins with carbohydrate ligands. It may play a role in tumor cell metastasis. It may also function in the protection, maintenance, and adhesion of the lysosome. Alternative splicing of this gene results in multiple transcript variants encoding distinct proteins. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "LDB3", GeneFullName: "LIM Domain Binding 3", In_Invitae84: 0, Mechanism: "This gene encodes a PDZ domain-containing protein. PDZ motifs are modular protein-protein interaction domains consisting of 80-120 amino acid residues. PDZ domain-containing proteins interact with each other in cytoskeletal assembly or with other proteins involved in targeting and clustering of membrane proteins. The protein encoded by this gene interacts with alpha-actinin-2 through its N-terminal PDZ domain and with protein kinase C via its C-terminal LIM domains. The LIM domain is a cysteine-rich motif defined by 50-60 amino acids containing two zinc-binding modules. This protein also interacts with all three members of the myozenin family. Mutations in this gene have been associated with myofibrillar myopathy and dilated cardiomyopathy. Alternatively spliced transcript variants encoding different isoforms have been identified; all isoforms have N-terminal PDZ domains while only longer isoforms (1, 2 and 5) have C-terminal LIM domains. [provided by RefSeq, Jan 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "LDLR", GeneFullName: "Low Density Lipoprotein Receptor", In_Invitae84: 0, Mechanism: "he low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Sep 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "LDLRAP1", GeneFullName: "Low Density Lipoprotein Receptor Adaptor Protein 1", In_Invitae84: 0, Mechanism: "The protein encoded by this gene is a cytosolic protein which contains a phosphotyrosine binding (PTD) domain. The PTD domain has been found to interact with the cytoplasmic tail of the LDL receptor. Mutations in this gene lead to LDL receptor malfunction and cause the disorder autosomal recessive hypercholesterolaemia. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "LKB1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "LMNA", GeneFullName: "Lamin A/C", In_Invitae84: 0, Mechanism: "The nuclear lamina consists of a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, Apr 2012]"})
(:LKP_GENE_DETAILS {GeneMasterName: "SBDS", GeneFullName: "SBDS Ribosome Maturation Factor", In_Invitae84: 0, Mechanism: "Required for the assembly of mature ribosomes and ribosome biogenesis. Together with EFL1, triggers the GTP-dependent release of EIF6 from 60S pre-ribosomes in the cytoplasm, thereby activating ribosomes for translation competence by allowing 80S ribosome"})
(:LKP_GENE_DETAILS {GeneMasterName: "SCN5A", GeneFullName: "Sodium Voltage-Gated Channel Alpha Subunit 5", In_Invitae84: 0, Mechanism: "This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+)"})
(:LKP_GENE_DETAILS {GeneMasterName: "SGCD", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SIL1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SKIV2L", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SLX4", GeneFullName: "SLX4 Structure-Specific Endonuclease Subunit", In_Invitae84: 0, Mechanism: "Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replicatio"})
(:LKP_GENE_DETAILS {GeneMasterName: "SPRED1", GeneFullName: "Sprouty Related EVH1 Domain Containing 1", In_Invitae84: 0, Mechanism: "Tyrosine kinase substrate that inhibits growth-factor-mediated activation of MAP kinase (By similarity). Negatively regulates hematopoiesis of bone marrow (By similarity). Inhibits fibroblast growth factor (FGF)-induced retinal lens fiber differentiation,"})
(:LKP_GENE_DETAILS {GeneMasterName: "EME2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FAT4", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FGFR3", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "FLT3", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "GEN1", GeneFullName: "GEN1 Holliday Junction 5' Flap Endonuclease", In_Invitae84: 0, Mechanism: "This gene encodes a member of the Rad2/xeroderma pigmentosum group G nuclease family, whose members are characterized by N-terminal and internal xeroderma pigmentosum group G nuclease domains followed by helix-hairpin-helix domains and disordered C-terminal domains. The protein encoded by this gene is involved in resolution of Holliday junctions, which are intermediate four-way structures that covalently link DNA during homologous recombination and double-strand break repair. The protein resolves Holliday junctions by creating dual incisions across the junction to produce nicked duplex products that can be ligated. In addition, this protein has been found to localize to centrosomes where it has been implicated in regulation of centrosome integrity. Alternative splicing results in multiple transcript variants"})
(:LKP_GENE_DETAILS {GeneMasterName: "HABP2", GeneFullName: "Hyaluronan Binding Protein 2", In_Invitae84: 0, Mechanism: "This gene encodes a member of the peptidase S1 family of serine proteases. The encoded preproprotein is secreted by hepatocytes and proteolytically processed to generate heavy and light chains that form the mature heterodimer. Further autoproteolysis leads to smaller, inactive peptides. This extracellular protease binds hyaluronic acid and may play a role in the coagulation and fibrinolysis systems. Mutations in this gene are associated with nonmedullary thyroid cancer and susceptibility to venous thromboembolism. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. [provided by RefSeq, Jan 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "HPC1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "IGF2R", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MCPH1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MUS81", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MYD88", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "NTRK", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PCAP", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PMS2P1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PPP2R2A", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD52", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RAD54L", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RBBP8", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "SLX1A", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TP53BP1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "TRRAP", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "WWP1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "XPC", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "XRCC3", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MLH1-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MSH2-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MSH6-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MUTYH-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MUTYH-Biallelic/Compound Heterozygous
MUTYH-Biallelic/Compound Heterozygous", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MUTYH-Biallelic/G396D", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MYD88-Biallelic", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "PMS2-Biallelic", GeneFullName: "PMS1 Homolog 2, Mismatch Repair System Component", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ATM-Biallelic", GeneFullName: "Ataxia Telangiectasia Mutated", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "BLM-Biallelic", GeneFullName: "RecQ Like Helicase", In_Invitae84: 0, Mechanism: "The Bloom syndrome is an autosomal recessive disorder characterized by growth deficiency, microcephaly and immunodeficiency among others. It is caused by homozygous or compound heterozygous mutation in the gene encoding DNA helicase RecQ protein on chromosome 15q26. This Bloom-associated helicase unwinds a variety of DNA substrates including Holliday junction, and is involved in several pathways contributing to the maintenance of genome stability. Identification of pathogenic Bloom variants is required for heterozygote testing in at-risk families. [provided by RefSeq, May 2020]"})
(:LKP_GENE_DETAILS {GeneMasterName: "NF2", GeneFullName: "Neurofibromin 2", In_Invitae84: 1, Mechanism: "This gene encodes a protein that is similar to some members of the ERM (ezrin, radixin, moesin) family of proteins that are thought to link cytoskeletal components with proteins in the cell membrane. This gene product has been shown to interact with cell-surface proteins, proteins involved in cytoskeletal dynamics and proteins involved in regulating ion transport. This gene is expressed at high levels during embryonic development; in adults, significant expression is found in Schwann cells, meningeal cells, lens and nerve."})
(:LKP_GENE_DETAILS {GeneMasterName: "NTHL1", GeneFullName: "Nth Like DNA Glycosylase 1", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a DNA N-glycosylase of the endonuclease III family. Like a similar protein in E. coli, the encoded protein has DNA glycosylase activity on DNA substrates containing oxidized pyrimidine residues and has apurinic/apyrimidinic lyase activity. [provided by RefSeq, Oct 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PDGFRA", GeneFullName: "Platelet Derived Growth Factor Receptor Alpha", In_Invitae84: 1, Mechanism: "This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers. [provided by RefSeq, Mar 2012]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PHOX2B", GeneFullName: "Paired Like Homeobox 2B", In_Invitae84: 1, Mechanism: "The DNA-associated protein encoded by this gene is a member of the paired family of homeobox proteins localized to the nucleus. The protein functions as a transcription factor involved in the development of several major noradrenergic neuron populations and the determination of neurotransmitter phenotype. The gene product is linked to enhancement of second messenger-mediated activation of the dopamine beta-hydroylase, c-fos promoters and several enhancers, including cyclic amp-response element and serum-response element. Expansion of a 20 amino acid polyalanine tract in this protein by 5-13 aa has been associated with congenital central hypoventilation syndrome. [provided by RefSeq, Jul 2016]"})
(:LKP_GENE_DETAILS {GeneMasterName: "POT1", GeneFullName: "Protection Of Telomeres 1", In_Invitae84: 1, Mechanism: "This gene is a member of the telombin family and encodes a nuclear protein involved in telomere maintenance. Specifically, this protein functions as a member of a multi-protein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation. Increased transcriptional expression of this gene is associated with stomach carcinogenesis and its progression. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PRKAR1A", GeneFullName: "Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha", In_Invitae84: 1, Mechanism: "cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. This gene encodes one of the regulatory subunits. This protein was found to be a tissue-specific extinguisher that down-regulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Mutations in this gene cause Carney complex (CNC). This gene can fuse to the RET protooncogene by gene rearrangement and form the thyroid tumor-specific chimeric oncogene known as PTC2. A nonconventional nuclear localization sequence (NLS) has been found for this protein which suggests a role in DNA replication via the protein serving as a nuclear transport protein for the second subunit of the Replication Factor C (RFC40). Several alternatively spliced transcript variants encoding two different isoforms have been observed. [provided by RefSeq, Jan 2013]"})
(:LKP_GENE_DETAILS {GeneMasterName: "SDHAF2", GeneFullName: "Succinate Dehydrogenase Complex Assembly Factor 2", In_Invitae84: 1, Mechanism: "SDHAF2 encodes a protein involved with the flavination of a succinate dehydrogenase complex subunit."})
(:LKP_GENE_DETAILS {GeneMasterName: "SDHB", GeneFullName: "Succinate Dehydrogenase Complex Iron Sulfur Subunit B", In_Invitae84: 1, Mechanism: "SDHB encodes a tumor suppressor involved in complex II of the mitochondrial electron transport chain."})
(:LKP_GENE_DETAILS {GeneMasterName: "SDHC", GeneFullName: "Succinate Dehydrogenase Complex Subunit C", In_Invitae84: 1, Mechanism: "SDHC encodes a component of the succinate dehydrogenase enzyme which is involved in the electron transport chain."})
(:LKP_GENE_DETAILS {GeneMasterName: "SDHD", GeneFullName: "Succinate Dehydrogenase Complex Subunit D", In_Invitae84: 1, Mechanism: "SDHD encodes a tumor-suppressor that is involved in complex II of the mitochondrial electron transport chain."})
(:LKP_GENE_DETAILS {GeneMasterName: "SMARCA4", GeneFullName: "SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4", In_Invitae84: 1, Mechanism: "Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structur"})
(:LKP_GENE_DETAILS {GeneMasterName: "SMARCB1", GeneFullName: "SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1", In_Invitae84: 1, Mechanism: "Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to c"})
(:LKP_GENE_DETAILS {GeneMasterName: "SMARCE1", GeneFullName: "SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily E, Member 1", In_Invitae84: 1, Mechanism: "Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structur"})
(:LKP_GENE_DETAILS {GeneMasterName: "SPINK1", GeneFullName: "Serine Peptidase Inhibitor Kazal Type 1", In_Invitae84: 0, Mechanism: "Serine protease inhibitor which exhibits anti-trypsin activity (PubMed:7142173). In the pancreas, protects against trypsin-catalyzed premature activation of zymogens (By similarity)."})
(:LKP_GENE_DETAILS {GeneMasterName: "SUFU", GeneFullName: "SUFU negative regulator of hedgehog signaling", In_Invitae84: 1, Mechanism: "The SUFU gene is important  in early development as it plays a role in pattern formation and cellular proliferation.  This gene encodes a negative regulator of the hedgehog signaling pathway."})
(:LKP_GENE_DETAILS {GeneMasterName: "TERT", GeneFullName: "Telomerase Reverse Transcriptase", In_Invitae84: 1, Mechanism: "Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoen"})
(:LKP_GENE_DETAILS {GeneMasterName: "TMEM127", GeneFullName: "Transmembrane Protein 127", In_Invitae84: 1, Mechanism: "Controls cell proliferation acting as a negative regulator of TOR signaling pathway mediated by mTORC1. May act as a tumor suppressor."})
(:LKP_GENE_DETAILS {GeneMasterName: "TSC1", GeneFullName: "TSC Complex Subunit 1", In_Invitae84: 1, Mechanism: "This gene is a tumor suppressor gene that encodes the growth inhibitory protein hamartin. The encoded protein interacts with and stabilizes the GTPase activating protein tuberin. This hamartin-tuberin complex negatively regulates mammalian target of rapam"})
(:LKP_GENE_DETAILS {GeneMasterName: "TSC2", GeneFullName: "TSC Complex Subunit 2", In_Invitae84: 1, Mechanism: "In complex with TSC1, this tumor suppressor inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling (PubMed:12271141, PubMed:28215400). Acts as a GTPase-activating protein ("})
(:LKP_GENE_DETAILS {GeneMasterName: "VHL", GeneFullName: "Von Hippel-Lindau Tumor Suppressor", In_Invitae84: 1, Mechanism: "VHL encodes a tumor suppressor that is involved in transcriptional repression."})
(:LKP_GENE_DETAILS {GeneMasterName: "WRN", GeneFullName: "ATP-dependent helicase", In_Invitae84: 1, Mechanism: "Multifunctional enzyme that has both magnesium and ATP-dependent DNA-helicase activity and 3'->5' exonuclease activity towards double-stranded DNA with a 5'-overhang. Has no nuclease activity towards single-stranded DNA or blunt-ended double-stranded DNA."})
(:LKP_GENE_DETAILS {GeneMasterName: "WT1", GeneFullName: "WT1 Transcription Factor", In_Invitae84: 1, Mechanism: "Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:7862533, PubMed:17716689, PubMed:25258363). Regulates the expression of nume"})
(:LKP_GENE_DETAILS {GeneMasterName: "AXIN2", GeneFullName: "Axis Inhibitor 2", In_Invitae84: 1, Mechanism: "The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin. Apparently, the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "BAP1", GeneFullName: "BRCA1 associated protein 1", In_Invitae84: 1, Mechanism: "This gene belongs to the ubiquitin C-terminal hydrolase subfamily of deubiquitinating enzymes that are involved in the removal of ubiquitin from proteins. The encoded enzyme binds to the breast cancer type 1 susceptibility protein (BRCA1) via the RING finger domain of the latter and acts as a tumor suppressor. In addition, the enzyme may be involved in regulation of transcription, regulation of cell cycle and growth, response to DNA damage and chromatin dynamics."})
(:LKP_GENE_DETAILS {GeneMasterName: "BLM", GeneFullName: "BLM RecQ Like Helicase", In_Invitae84: 1, Mechanism: "BLM encodes a helicase that works to maintain genomic stability."})
(:LKP_GENE_DETAILS {GeneMasterName: "CASR", GeneFullName: "Calcium Sensing Receptor", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a plasma membrane G protein-coupled receptor that senses small changes in circulating calcium concentration. The encoded protein couples this information to intracellular signaling pathways that modify parathyroid hormone secretion or renal cation handling, and thus this protein plays an essential role in maintaining mineral ion homeostasis."})
(:LKP_GENE_DETAILS {GeneMasterName: "CDC73", GeneFullName: "Cell Division Cycle 73", In_Invitae84: 1, Mechanism: "This gene encodes a tumor suppressor that is involved in transcriptional and post-transcriptional control pathways. The protein is a component of the the PAF protein complex, which associates with the RNA polymerase II subunit POLR2A and with a histone methyltransferase complex. This protein appears to facilitate the association of 3' mRNA processing factors with actively-transcribed chromatin. Mutations in this gene have been linked to hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism, and parathyroid carcinoma. [provided by RefSeq, Jul 2009]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MITF", GeneFullName: "Melanocyte Inducing Transcription Factor", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a transcription factor that contains both basic helix-loop-helix and leucine zipper structural features. The encoded protein regulates melanocyte development and is responsible for pigment cell-specific transcription of the melanogenesis enzyme genes. Heterozygous mutations in the this gene cause auditory-pigmentary syndromes, such as Waardenburg syndrome type 2 and Tietz syndrome. [provided by RefSeq, Aug 2017]"})
(:LKP_GENE_DETAILS {GeneMasterName: "MSH3", GeneFullName: "MutS Homolog 3", In_Invitae84: 1, Mechanism: "MSH3 encodes a protein involved in DNA mismatch repair.The protein encoded by this gene forms a heterodimer with MSH2 to form MutS beta, part of the post-replicative DNA mismatch repair system. MutS beta initiates mismatch repair by binding to a mismatch and then forming a complex with MutL alpha heterodimer. This gene contains a polymorphic 9 bp tandem repeat sequence in the first exon. The repeat is present 6 times in the reference genome sequence and 3-7 repeats have been reported. Defects in this gene are a cause of susceptibility to endometrial cancer."})
(:LKP_GENE_DETAILS {GeneMasterName: "NF1", GeneFullName: "Neurofibromin 1", In_Invitae84: 1, Mechanism: "This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "PRSS1", GeneFullName: "protein kinase cAMP-dependent type I regulatory subunit alpha", In_Invitae84: 0, Mechanism: "cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. This gene encodes one of the regulatory subunits. This protein was found to be a tissue-specific extinguisher that down-regulates the expression of seven liver genes in hepatoma x fibroblast hybrids."})
(:LKP_GENE_CARD_REFERENCES {Id: "58", PubmedId: "17047042"})
(:LKP_GENE_CARD_REFERENCES {Id: "59", PubmedId: "17087943"})
(:LKP_GENE_DETAILS {GeneMasterName: "PTCH1", GeneFullName: "serine protease 1", In_Invitae84: 1, Mechanism: "This gene encodes a trypsinogen, which is a member of the trypsin family of serine proteases. This enzyme is secreted by the pancreas and cleaved to its active form in the small intestine. It is active on peptide linkages involving the carboxyl group of lysine or arginine. Mutations in this gene are associated with hereditary pancreatitis. This gene and several other trypsinogen genes are localized to the T cell receptor beta locus on chromosome 7"})
(:LKP_GENE_DETAILS {GeneMasterName: "RB1", GeneFullName: "RB Transcriptional Corepressor 1", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma. [provided by RefSeq, Jul 2008]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RECQL4", GeneFullName: "RecQ like helicase¬†4", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is a DNA helicase that belongs to the RecQ helicase family. DNA helicases unwind double-stranded DNA into single-stranded DNAs and may modulate chromosome segregation. This gene is predominantly expressed in thymus and testis. Mutations in this gene are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes. [provided by RefSeq, Jan 2010]"})
(:LKP_GENE_DETAILS {GeneMasterName: "RUNX1", GeneFullName: "RUNX Family Transcription Factor 1", In_Invitae84: 1, Mechanism: "Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory"})
(:LKP_GENE_DETAILS {GeneMasterName: "SDHA", GeneFullName: "Succinate Dehydrogenase Complex Flavoprotein Subunit A", In_Invitae84: 1, Mechanism: "SDHA encodes a component of the succinate dehydrogenase enzyme which is involved in the electron transport chain"})
(:LKP_GENE_DETAILS {GeneMasterName: "DICER1", GeneFullName: "dicer 1, ribonuclease III", In_Invitae84: 1, Mechanism: "This gene encodes a protein possessing an RNA helicase motif containing a DEXH box in its amino terminus and an RNA motif in the carboxy terminus. The encoded protein functions as a ribonuclease and is required by the RNA interference and small temporal RNA (stRNA) pathways to produce the active small RNA component that represses gene expression. Alternative splicing results in multiple transcript variants."})
(:LKP_GENE_DETAILS {GeneMasterName: "DIS3L2", GeneFullName: "DIS3 Like 3'-5' Exoribonuclease 2", In_Invitae84: 1, Mechanism: "The protein encoded by this gene is similar in sequence to 3'/5' exonucleolytic subunits of the RNA exosome. The exosome is a large multimeric ribonucleotide complex responsible for degrading various RNA substrates. Several transcript variants, some protein-coding and some not, have been found for this gene. [provided by RefSeq, Mar 2012]"})
(:LKP_GENE_DETAILS {GeneMasterName: "ACTC1", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ATP7B", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "CACNA1S", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "MYH11", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "OTC", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "RYR2", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ANKRD26", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENE_DETAILS {GeneMasterName: "ARMC5", GeneFullName: "Unknown", In_Invitae84: 0, Mechanism: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Bronchiectasis", GeneMasterName: "CFTR", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Cystic fibrosis", PredominantCancerSubtype: "Metabolic", GeneMasterName: "CFTR", Gender: "Either", Organ: "Metabolic"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Genitourinary (Benign)", PredominantCancerSubtype: "Congenital bilateral absence of the vas deferens", GeneMasterName: "CFTR", Gender: "Male", Organ: "Genitals"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Familial erythrocytosis", GeneMasterName: "EGLN1", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "EGLN1", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Uterus Neoplasm", PredominantCancerSubtype: "Uterine Tumors", GeneMasterName: "CDC73", Gender: "Either", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Kidney (Benign)", PredominantCancerSubtype: "Renal cysts", GeneMasterName: "CDC73", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "AXIN2", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Kidney Neoplasm", PredominantCancerSubtype: "Renal hamartomas", GeneMasterName: "CDC73", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "CDC73", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Coarse facial features, curly or sparse, fine hair, loose, soft skin", GeneMasterName: "HRAS", Gender: "Either", Organ: "Face"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "ALK", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Peripheral Nervous System Benign", PredominantCancerSubtype: "Ganglioneuroma", GeneMasterName: "ALK", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Ganglioneuroblastoma", GeneMasterName: "ALK", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "acrochordons, angiofibromas", GeneMasterName: "FLCN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Parathyroid Neoplasm", PredominantCancerSubtype: "Parathyroid Adenoma", GeneMasterName: "FLCN", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Pituitary Adenoma", GeneMasterName: "FLCN", Gender: "Either", Organ: "Pituitary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Peripheral Nervous System Neoplasm", PredominantCancerSubtype: "neural tissue tumor", GeneMasterName: "FLCN", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Peripheral Nervous System Neoplasm", PredominantCancerSubtype: "connective tissue nevus", GeneMasterName: "FLCN", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Lipoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "FLCN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Multinodular Goiter", GeneMasterName: "FLCN", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "focal cutaneous mucinosis", GeneMasterName: "FLCN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Syndrome", DiseaseName: "Simpson-Golabi-Behmel syndrome", PredominantCancerSubtype: "characteristic facies, cognitive impairment, pre- and postnatal overgrowth, macrosomia, and skeletal, genitourinary, cardiac, and renal anomalies", GeneMasterName: "GPC3", Gender: "Male", Organ: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Failure to thrive", GeneMasterName: "HRAS", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intellectual Disability", GeneMasterName: "HRAS", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Papillomata of the face and perianal region", GeneMasterName: "HRAS", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Diffuse hypotonia and joint laxity, tight achilles tendons", GeneMasterName: "HRAS", Gender: "Either", Organ: "Connective Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Cardiac hypertrophy, congenital heart defect, arrhythmia", GeneMasterName: "HRAS", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Acral lentiginous melanomas", GeneMasterName: "WRN", Gender: "Either", Organ: "Skin"})
(:LKP_GENE_CARD_REFERENCES {Id: "60", PubmedId: "17287723"})
(:LKP_GENE_CARD_REFERENCES {Id: "61", PubmedId: "17368238"})
(:LKP_GENE_CARD_REFERENCES {Id: "62", PubmedId: "17392301"})
(:LKP_GENE_CARD_REFERENCES {Id: "63", PubmedId: "17392703"})
(:LKP_GENE_CARD_REFERENCES {Id: "64", PubmedId: "17539897"})
(:LKP_GENE_CARD_REFERENCES {Id: "65", PubmedId: "17545690"})
(:LKP_GENE_CARD_REFERENCES {Id: "66", PubmedId: "17603801"})
(:LKP_GENE_CARD_REFERENCES {Id: "67", PubmedId: "17667967"})
(:LKP_GENE_CARD_REFERENCES {Id: "68", PubmedId: "1770531"})
(:LKP_GENE_CARD_REFERENCES {Id: "69", PubmedId: "17957789"})
(:LKP_GENE_CARD_REFERENCES {Id: "70", PubmedId: "18042939"})
(:LKP_GENE_CARD_REFERENCES {Id: "71", PubmedId: "18172190"})
(:LKP_GENE_CARD_REFERENCES {Id: "72", PubmedId: "18211978"})
(:LKP_GENE_CARD_REFERENCES {Id: "73", PubmedId: "18234728"})
(:LKP_GENE_CARD_REFERENCES {Id: "74", PubmedId: "18334619"})
(:LKP_GENE_CARD_REFERENCES {Id: "75", PubmedId: "18355544"})
(:LKP_GENE_CARD_REFERENCES {Id: "76", PubmedId: "18398828"})
(:LKP_GENE_CARD_REFERENCES {Id: "77", PubmedId: "18572020"})
(:LKP_GENE_CARD_REFERENCES {Id: "78", PubmedId: "18579454"})
(:LKP_GENE_CARD_REFERENCES {Id: "79", PubmedId: "18602922"})
(:LKP_GENE_CARD_REFERENCES {Id: "80", PubmedId: "18614535"})
(:LKP_GENE_CARD_REFERENCES {Id: "81", PubmedId: "18670346"})
(:LKP_GENE_CARD_REFERENCES {Id: "82", PubmedId: "18709565"})
(:LKP_GENE_CARD_REFERENCES {Id: "83", PubmedId: "18723428"})
(:LKP_GENE_CARD_REFERENCES {Id: "84", PubmedId: "18724359"})
(:LKP_GENE_CARD_REFERENCES {Id: "85", PubmedId: "18728283"})
(:LKP_GENE_CARD_REFERENCES {Id: "86", PubmedId: "18756473"})
(:LKP_GENE_CARD_REFERENCES {Id: "87", PubmedId: "18759107"})
(:LKP_GENE_CARD_REFERENCES {Id: "88", PubmedId: "18780370"})
(:LKP_GENE_CARD_REFERENCES {Id: "89", PubmedId: "18923523"})
(:LKP_GENE_CARD_REFERENCES {Id: "90", PubmedId: "18946494"})
(:LKP_GENE_CARD_REFERENCES {Id: "91", PubmedId: "19205158"})
(:LKP_GENE_CARD_REFERENCES {Id: "92", PubmedId: "19245865"})
(:LKP_GENE_CARD_REFERENCES {Id: "93", PubmedId: "19265751"})
(:LKP_GENE_CARD_REFERENCES {Id: "94", PubmedId: "19293268"})
(:LKP_GENE_CARD_REFERENCES {Id: "95", PubmedId: "19357396"})
(:LKP_GENE_CARD_REFERENCES {Id: "96", PubmedId: "19372699"})
(:LKP_GENE_CARD_REFERENCES {Id: "97", PubmedId: "19394335"})
(:LKP_GENE_CARD_REFERENCES {Id: "98", PubmedId: "19409520"})
(:LKP_GENE_CARD_REFERENCES {Id: "99", PubmedId: "19453252"})
(:LKP_GENE_CARD_REFERENCES {Id: "100", PubmedId: "19476995"})
(:LKP_GENE_CARD_REFERENCES {Id: "101", PubmedId: "19555431"})
(:LKP_GENE_CARD_REFERENCES {Id: "102", PubmedId: "19556618"})
(:LKP_GENE_CARD_REFERENCES {Id: "103", PubmedId: "19617566"})
(:LKP_GENE_CARD_REFERENCES {Id: "104", PubmedId: "19620482"})
(:LKP_GENE_CARD_REFERENCES {Id: "105", PubmedId: "19671848"})
(:LKP_GENE_CARD_REFERENCES {Id: "106", PubmedId: "19732775"})
(:LKP_GENE_CARD_REFERENCES {Id: "107", PubmedId: "19802898"})
(:LKP_GENE_CARD_REFERENCES {Id: "108", PubmedId: "19898272"})
(:LKP_GENE_CARD_REFERENCES {Id: "109", PubmedId: "19900449"})
(:LKP_GENE_CARD_REFERENCES {Id: "110", PubmedId: "20028993"})
(:LKP_GENE_CARD_REFERENCES {Id: "111", PubmedId: "20071235"})
(:LKP_GENE_CARD_REFERENCES {Id: "112", PubmedId: "20082463"})
(:LKP_GENE_CARD_REFERENCES {Id: "113", PubmedId: "20127975"})
(:LKP_GENE_CARD_REFERENCES {Id: "114", PubmedId: "20208042"})
(:LKP_GENE_CARD_REFERENCES {Id: "115", PubmedId: "20392993"})
(:LKP_GENE_CARD_REFERENCES {Id: "116", PubmedId: "20400963"})
(:LKP_GENE_CARD_REFERENCES {Id: "117", PubmedId: "20442441"})
(:LKP_GENE_CARD_REFERENCES {Id: "118", PubmedId: "20503338"})
(:LKP_GENE_CARD_REFERENCES {Id: "119", PubmedId: "20507306"})
(:LKP_GENE_CARD_REFERENCES {Id: "120", PubmedId: "20522427"})
(:LKP_GENE_CARD_REFERENCES {Id: "121", PubmedId: "2069856"})
(:LKP_GENE_CARD_REFERENCES {Id: "122", PubmedId: "20803646"})
(:LKP_GENE_CARD_REFERENCES {Id: "123", PubmedId: "20859198"})
(:LKP_GENE_CARD_REFERENCES {Id: "124", PubmedId: "21150883"})
(:LKP_GENE_CARD_REFERENCES {Id: "125", PubmedId: "21173220"})
(:LKP_GENE_CARD_REFERENCES {Id: "126", PubmedId: "21208904"})
(:LKP_GENE_CARD_REFERENCES {Id: "127", PubmedId: "21224366"})
(:LKP_GENE_CARD_REFERENCES {Id: "128", PubmedId: "21285249"})
(:LKP_GENE_CARD_REFERENCES {Id: "129", PubmedId: "21356067"})
(:LKP_GENE_CARD_REFERENCES {Id: "130", PubmedId: "21386872"})
(:LKP_GENE_CARD_REFERENCES {Id: "131", PubmedId: "21416598"})
(:LKP_GENE_CARD_REFERENCES {Id: "132", PubmedId: "21436073"})
(:LKP_GENE_CARD_REFERENCES {Id: "133", PubmedId: "21505157"})
(:LKP_GENE_CARD_REFERENCES {Id: "134", PubmedId: "21514219"})
(:LKP_GENE_CARD_REFERENCES {Id: "135", PubmedId: "21521328"})
(:LKP_GENE_CARD_REFERENCES {Id: "136", PubmedId: "21552134"})
(:LKP_GENE_CARD_REFERENCES {Id: "137", PubmedId: "21626677"})
(:LKP_GENE_CARD_REFERENCES {Id: "138", PubmedId: "21642682"})
(:LKP_GENE_CARD_REFERENCES {Id: "139", PubmedId: "21685915"})
(:LKP_GENE_CARD_REFERENCES {Id: "140", PubmedId: "21706002"})
(:LKP_GENE_CARD_REFERENCES {Id: "141", PubmedId: "21807500"})
(:LKP_GENE_CARD_REFERENCES {Id: "142", PubmedId: "21813476"})
(:LKP_GENE_CARD_REFERENCES {Id: "143", PubmedId: "21844754"})
(:LKP_GENE_CARD_REFERENCES {Id: "144", PubmedId: "21876083"})
(:LKP_GENE_CARD_REFERENCES {Id: "145", PubmedId: "21892158"})
(:LKP_GENE_CARD_REFERENCES {Id: "146", PubmedId: "21937622"})
(:LKP_GENE_CARD_REFERENCES {Id: "147", PubmedId: "22006311"})
(:LKP_GENE_CARD_REFERENCES {Id: "148", PubmedId: "22058428"})
(:LKP_GENE_CARD_REFERENCES {Id: "149", PubmedId: "22071890"})
(:LKP_GENE_CARD_REFERENCES {Id: "150", PubmedId: "22241717"})
(:LKP_GENE_CARD_REFERENCES {Id: "151", PubmedId: "22341969"})
(:LKP_GENE_CARD_REFERENCES {Id: "152", PubmedId: "22355046"})
(:LKP_GENE_CARD_REFERENCES {Id: "153", PubmedId: "22357538"})
(:LKP_GENE_CARD_REFERENCES {Id: "154", PubmedId: "22373003"})
(:LKP_GENE_CARD_REFERENCES {Id: "155", PubmedId: "22452945"})
(:LKP_GENE_CARD_REFERENCES {Id: "156", PubmedId: "22464250"})
(:LKP_GENE_CARD_REFERENCES {Id: "157", PubmedId: "22464251"})
(:LKP_GENE_CARD_REFERENCES {Id: "158", PubmedId: "22464252"})
(:LKP_GENE_CARD_REFERENCES {Id: "159", PubmedId: "22561515"})
(:LKP_GENE_CARD_REFERENCES {Id: "160", PubmedId: "22692063"})
(:LKP_GENE_CARD_REFERENCES {Id: "161", PubmedId: "22723327"})
(:LKP_GENE_CARD_REFERENCES {Id: "162", PubmedId: "22846733"})
(:LKP_GENE_CARD_REFERENCES {Id: "163", PubmedId: "22863007"})
(:LKP_GENE_CARD_REFERENCES {Id: "164", PubmedId: "22935333"})
(:LKP_GENE_CARD_REFERENCES {Id: "165", PubmedId: "22972948"})
(:LKP_GENE_CARD_REFERENCES {Id: "166", PubmedId: "22974104"})
(:LKP_GENE_CARD_REFERENCES {Id: "167", PubmedId: "23029104"})
(:LKP_GENE_CARD_REFERENCES {Id: "168", PubmedId: "23033274"})
(:LKP_GENE_CARD_REFERENCES {Id: "169", PubmedId: "23047742"})
(:LKP_GENE_CARD_REFERENCES {Id: "170", PubmedId: "23060355"})
(:LKP_GENE_CARD_REFERENCES {Id: "171", PubmedId: "23083876"})
(:LKP_GENE_CARD_REFERENCES {Id: "172", PubmedId: "23091106"})
(:LKP_GENE_CARD_REFERENCES {Id: "173", PubmedId: "23140918"})
(:LKP_GENE_CARD_REFERENCES {Id: "174", PubmedId: "23208944"})
(:LKP_GENE_CARD_REFERENCES {Id: "175", PubmedId: "23223431"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Osteosarcoma", GeneMasterName: "WRN", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "WRN", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "WRN", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Bronchiectasis", GeneMasterName: "PTCH21", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Metabolic", PredominantCancerSubtype: "Cystic fibrosis", GeneMasterName: "RPS17", Gender: "Either", Organ: "Metabolic"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic/Compound Heterozygous", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ABRAXAS1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BLM", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BLM", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Cholangiocarcinoma", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Bile Duct"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Cholangiocarcinoma", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Bile Duct"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Hearing loss", PredominantCancerSubtype: "Unknown", GeneMasterName: "GATA2", Gender: "Either", Organ: "Auditory"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Arthrogryposis", PredominantCancerSubtype: "Unknown", GeneMasterName: "Unknown", Gender: "Unknown", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Inflammatory fibroid polyps", PredominantCancerSubtype: "Unknown", GeneMasterName: "PDGFRA", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Fibroid tumors", PredominantCancerSubtype: "Unknown", GeneMasterName: "PDGFRA", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Coarse skin and facial features in addition to broad hands and feet", PredominantCancerSubtype: "Unknown", GeneMasterName: "PDGFRA", Gender: "Either", Organ: "General"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears", GeneMasterName: "PHOX2B", Gender: "Either", Organ: "General"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Coffin-Siris syndrome", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCA4", Gender: "Either", Organ: "General"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Rhabdoid Tumour", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCA4", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Rhabdoid Tumour", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCB1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Polyp", PredominantCancerSubtype: "Unknown", GeneMasterName: "FLCN", Gender: "Either", Organ: "Colon"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Kidney Cysts", PredominantCancerSubtype: "Unknown", GeneMasterName: "FLCN", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FLCN", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Cirrhosis", PredominantCancerSubtype: "Unknown", GeneMasterName: "TERT", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Unknown", DiseaseName: "Coffin-Siris syndrome", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCE1", Gender: "Unknown", Organ: "General"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Tuberous sclerosis complex (TSC)", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC1", Gender: "Either", Organ: "General"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Cortical tubers", GeneMasterName: "TSC1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Hamartoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC1", Gender: "Either", Organ: "Multiple organs"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Unknown", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Subependymal nodules", GeneMasterName: "TSC1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Hemihyperplasia", GeneMasterName: "WT1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "TERT", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "MRE11A", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "RPS20", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "RAD50", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "ABRAXAS1", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Cleft palate
- Bifid epiglottis", GeneMasterName: "PTCSC2", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Hypothyroid", GeneMasterName: "PTCSC2", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "PTCSC2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioma", GeneMasterName: "PTCSC3", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Papillary Thyroid Cancer", GeneMasterName: "PTCSC1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Kidney (Benign)", PredominantCancerSubtype: "Cystic Nephroma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Thyroid Neoplasm", PredominantCancerSubtype: "Thyroid Adenoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Sarcoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Eye Neoplasm", PredominantCancerSubtype: "ciliary body medulloepithelioma (CBME)", GeneMasterName: "DICER1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Nasopharyngeal Neoplasm", PredominantCancerSubtype: "nasal chondromesenchymal hamartoma (NCMH)", GeneMasterName: "DICER1", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Flat face , High forehead , Asymmetric face (in some patients), High anterior hairline", GeneMasterName: "CDH1", Gender: "Either", Organ: "Face"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Hypertelorism 
- Ectropion of lower eyelids
- Lagophthalmia
- Megaloblepharon
- Distichiasis", GeneMasterName: "CDH1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Parathyroid (Benign)", PredominantCancerSubtype: "Primary Hyperparathyroidism", GeneMasterName: "RET", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Kidney (Benign)", PredominantCancerSubtype: "Renal malformations (Renal Agenesis)", GeneMasterName: "RET", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Cutaneous Lichen Amyloidosis", GeneMasterName: "RET", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Gastrinoma", GeneMasterName: "MEN1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "MEN1", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MEN1", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Adrenal Neoplasm", PredominantCancerSubtype: "Adrenal Adenoma", GeneMasterName: "MEN1", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Nasopharyngeal Neoplasm", PredominantCancerSubtype: "Angiofibroma", GeneMasterName: "MEN1", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Ependymoma", GeneMasterName: "MEN1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lipoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MEN1", Gender: "Either", Organ: "Lipid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Carcinoid", GeneMasterName: "MEN1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "MEN1", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Pancreatic Neuroendocrine Tumor", GeneMasterName: "MEN1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Parathyroid (Benign)", PredominantCancerSubtype: "Primary Hyperparathyroidism", GeneMasterName: "MEN1", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Anterior Pituitary Neuroendocrine Tumors", GeneMasterName: "MEN1", Gender: "Either", Organ: "Pituitary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MEN1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BAP1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Nose (Benign)", PredominantCancerSubtype: "Choanal atresia", GeneMasterName: "CDH1", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Teeth (Benign)", PredominantCancerSubtype: "Conical teeth
- Hypodontia
- Delayed dentition", GeneMasterName: "CDH1", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Clinodactyly 
- Syndactyly", GeneMasterName: "CDH1", Gender: "Either", Organ: "Hand"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Imperforate anus", GeneMasterName: "CDH1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Nails (Benign)", PredominantCancerSubtype: "Hypoplastic nails", GeneMasterName: "CDH1", Gender: "Either", Organ: "Nails"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Hair (Benign)", PredominantCancerSubtype: "Distichiasis
- Sparse hair", GeneMasterName: "CDH1", Gender: "Either", Organ: "Hair"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Neural tube defect", GeneMasterName: "CDH1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Thyroid hypoplasia", GeneMasterName: "CDH1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "Juvenile myelomonocytic leukemia", GeneMasterName: "NF1", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Glaucoma
- Hypertelorism 
- Hyperreflective choroidal spots", GeneMasterName: "NF1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Blood Vessel (Benign)", PredominantCancerSubtype: "Renal artery stenosis
- Hypertension", GeneMasterName: "NF1", Gender: "Either", Organ: "Blood Vessel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Scoliosis and Bone Dysplasia
- Spina bifida", GeneMasterName: "NF1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Meningioma", GeneMasterName: "NF1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Hypothalamic tumor", GeneMasterName: "NF1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Carcinoid", GeneMasterName: "NF1", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Parathyroid Neoplasm", PredominantCancerSubtype: "Parathyroid Adenoma", GeneMasterName: "NF1", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Non-Small Cell Lung Adenocarcinoma", GeneMasterName: "BAP1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Unknown", GeneMasterName: "BAP1", Gender: "Either", Organ: "Neuroendocrine"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Megacolon", GeneMasterName: "RET", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Peripheral Nervous System Neoplasm", PredominantCancerSubtype: "Mucosal Neuromas", GeneMasterName: "RET", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Marfanoid Body Habitus", GeneMasterName: "RET", Gender: "Either", Organ: "Connective tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GI Neoplasm", PredominantCancerSubtype: "Intestinal Ganglioneuroma", GeneMasterName: "RET", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Medullated corneal nerve fibers", GeneMasterName: "RET", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Ectopic Lenses", GeneMasterName: "RET", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Parathyroid Neoplasm", PredominantCancerSubtype: "Parathyroid Adenoma", GeneMasterName: "RET", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Carcinoid", GeneMasterName: "MEN1", Gender: "Either", Organ: "Thymus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Adrenal Cortical (Benign)", PredominantCancerSubtype: "Adrenal Hyperplasia", GeneMasterName: "MEN1", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Meningioma", GeneMasterName: "MEN1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Pancreatic Adenocarcinoma", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Dyskeratosis Congenita", GeneMasterName: "ACD", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "ACD", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "ACD", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "ACD", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Inflammatory Myofibroblastic Tumor", PredominantCancerSubtype: "Unknown", GeneMasterName: "ALK", Gender: "Either", Organ: "Wound healing"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ALK", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Anaplastic Large Cell Lymphoma", GeneMasterName: "ALK", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "ALK", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Rhabdomyosarcoma", GeneMasterName: "ALK", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Adrenal Cortical (Benign)", PredominantCancerSubtype: "Primary Macronodular Adrenal Hyperplasia", GeneMasterName: "APC", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Bicuspid Aortic Valve", GeneMasterName: "APC", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Bone Neoplasm", PredominantCancerSubtype: "Osteoma", GeneMasterName: "APC", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "APC", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "CHRPE", PredominantCancerSubtype: "Congenital retinal pigment epithelial hypertrophy", GeneMasterName: "APC", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Colorectal Polyps", GeneMasterName: "APC", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Teeth (Benign)", PredominantCancerSubtype: "Supranummary teeth (Odontoma)", GeneMasterName: "APC", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Soft Tissue Neoplasm", PredominantCancerSubtype: "Desmoid", GeneMasterName: "APC", Gender: "Either", Organ: "Soft tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Duodenum Neoplasm", PredominantCancerSubtype: "Duodenal Polyps", GeneMasterName: "APC", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Duodenum Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Epidermoid Cysts", GeneMasterName: "APC", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Facial Palsy", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Gastric Neoplasm", PredominantCancerSubtype: "Gastric Polyps", GeneMasterName: "APC", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatoblastoma", GeneMasterName: "APC", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Pilomatrixoma", GeneMasterName: "APC", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "APC", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Papillary Thyroid Cancer", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "ATM", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "T cell prolymphocytic leukemia", GeneMasterName: "ATM", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "NSCLC", GeneMasterName: "ATM", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Mantle Cell", GeneMasterName: "ATM", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATM", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Bifid Rib", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Abnormal Facies, Webbed neck , Midface hypoplasia 
- Prominent nasolabial folds
- Low-set ears
- Posteriorly rotated ears", GeneMasterName: "NF1", Gender: "Either", Organ: "Face"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Abnormal Facies, Birdlike' facies, Short nose 
- Depressed nasal bridge 
- Hypoplastic mandible (uncommon)
- Hypoplastic maxilla (uncommon)
- Broad forehead 
- Square outline
- Frontal bossing 
- 'Dished out' midface
- Long philtrum", GeneMasterName: "PTEN", Gender: "Either", Organ: "Face"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Ear (Benign)", PredominantCancerSubtype: "Hearing Loss", GeneMasterName: "PTEN", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Cataract
- Angioid streaks
- Myopia", GeneMasterName: "PTEN", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Microstomia 
- High-arched palate
- Scrotal tongue 
- Oral papillomas", GeneMasterName: "PTEN", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Liver (Benign)", PredominantCancerSubtype: "Hepatomegaly", GeneMasterName: "PTEN", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Spleen (Benign)", PredominantCancerSubtype: "Splenomegaly", GeneMasterName: "PTEN", Gender: "Either", Organ: "Spleen"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Cervical Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Female", Organ: "Cervix"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Genitourinary (Benign)", PredominantCancerSubtype: "Hydrocele
- Varicocele", GeneMasterName: "PTEN", Gender: "Male", Organ: "Genitals"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Meningioma", GeneMasterName: "PTEN", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Nose (Benign)", PredominantCancerSubtype: "Nasal Polyps", GeneMasterName: "STK11", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Bronchial Polyps", GeneMasterName: "STK11", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Ovarian (Benign)", PredominantCancerSubtype: "Ovarian Cyst", GeneMasterName: "STK11", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bladder (Benign)", PredominantCancerSubtype: "Bladder Polyps", GeneMasterName: "STK11", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Short Stature", GeneMasterName: "TP53", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Non-Medullary  thyroid carcinoma", GeneMasterName: "FOXE1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Papillary Thyroid Cancer", GeneMasterName: "PTCSC2", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Papillary Thyroid Cancer", GeneMasterName: "PTCSC3", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Non-Medullary  thyroid carcinoma", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Short Stature", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Ear (Benign)", PredominantCancerSubtype: "Hearing Loss", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Epicanthal folds
- Hypertelorism 
- Optic atrophy
- Strabismus
- Blue eyes (Japanese patients)
- Conjunctival and scleral pigmentation", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye Neoplasm", PredominantCancerSubtype: "Eyelid myxoma", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Abnormal Facies, Hypoplastic maxilla 
- Prognathism Low nasal bridge 
- Broad, upturned nose
- Dimpled nasal tip", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Face"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Teeth (Benign)", PredominantCancerSubtype: "Malocclusion
- Delayed tooth eruption
- Hypodontia", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Spinal canal stenosis
- Scoliosis
- Narrow interpediculate distances
- Small vertebrae", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Short, broad hands
- Short metacarpals
- Short phalanges
- Cone-shaped epiphyses", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Hand"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Large halluces
- Short metatarsals", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Nevi
- Ephelides
Centrofacial/mucosal -lentigines
- Blue nevi
- Thin skin
- Striae
- Easy bruising", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intellectual Disability", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Pituitary Adenoma", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Pituitary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Thyroid follicular hyperplasia", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "CNS Tumor", PredominantCancerSubtype: "Schwannoma, Psammomatous melanotic schwannomas", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Goiter", GeneMasterName: "FOXE1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "BAP1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Uveal Melanoma", GeneMasterName: "BAP1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Mesothelioma", PredominantCancerSubtype: "Peritoneal", GeneMasterName: "BAP1", Gender: "Either", Organ: "Mesothelium"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Spitz Nevus (Atypical)", GeneMasterName: "BAP1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Basal Cell Carcinoma", GeneMasterName: "BAP1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BAP1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BARD1", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Unknown", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Goiter", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Hashimoto thyroiditis", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMM9", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMT2A1", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CNC", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CNC1", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "COMMAD", GeneMasterName: "MITF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CPA", GeneMasterName: "CPA1"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Neoplasm", DiseaseName: "GI Neoplasm", PredominantCancerSubtype: "Hamartomatous Polyps", GeneMasterName: "SEC23B", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Epileptic encephalopathy", GeneMasterName: "SEC23B", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Lentigines", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Ephelides", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BARD1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BARD1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "BARD1", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BARD1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Psychiatric", PredominantCancerSubtype: "Schizophrenia", GeneMasterName: "BARD1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Tetralogy Of Fallot", GeneMasterName: "BARD1", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BLM", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BLM", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Atrioventricular Septum Defect", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Duodenum Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Facial Dysmorphism", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Face"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Juvenile Polyps", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Tetralogy Of Fallot", GeneMasterName: "BMPR1A", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "BRCA1", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Psychiatric", PredominantCancerSubtype: "Autism", GeneMasterName: "BRCA2", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Esophageal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Esophagus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Uveal Melanoma", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRCA2", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Ewing Sarcoma", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRIP1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Cervical Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRIP1", Gender: "Female", Organ: "Cervix"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRIP1", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRIP1", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRIP1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "BRIP1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Epilepsy", GeneMasterName: "CASR", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Endocrine", PredominantCancerSubtype: "Neonatal Severe Hyperparathyroid", GeneMasterName: "CASR", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Endocrine", PredominantCancerSubtype: "Autosomal Dominant Hypocalcemia Type 1", GeneMasterName: "CASR", Gender: "Either", Organ: "Endocrine"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Endocrine", PredominantCancerSubtype: "Hypocalciuric Hypercalcemia", GeneMasterName: "CASR", Gender: "Either", Organ: "Endocrine"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Endocrine", PredominantCancerSubtype: "Familial Isolated Hyperparathyroid", GeneMasterName: "CASR", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Kidney (Benign)", PredominantCancerSubtype: "Kidney Stone", GeneMasterName: "CASR", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "CASR", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Parathyroid (Benign)", PredominantCancerSubtype: "Hyperparathyroid", GeneMasterName: "CDC73", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Bone Neoplasm", PredominantCancerSubtype: "Jaw Tumor", GeneMasterName: "CDC73", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Parathyroid Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDC73", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Parathyroid Neoplasm", PredominantCancerSubtype: "Parathyroid Adenoma", GeneMasterName: "CDC73", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Invasive Lobular Breast Cancer", GeneMasterName: "CDH1", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Nasopharyngeal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "cleft palate", GeneMasterName: "CDH1", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Macrocephaly", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Oral Mucosal Papillomatosis", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Breast (Benign)", PredominantCancerSubtype: "Fibroadenoma", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Blood Vessel (Benign)", PredominantCancerSubtype: "Hemangioma", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Blood Vessel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Breast (Benign)", PredominantCancerSubtype: "Atypical ductal hyperplasia", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Gastrointestinal polyps", GeneMasterName: "SEC23B", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Trichilemmoma", GeneMasterName: "SEC23B", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Uterus (Benign)", PredominantCancerSubtype: "Uterine Fibroids", GeneMasterName: "SEC23B", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDH1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDK4", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Head And Neck Cancer", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "CDK4", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDK4", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDK4", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Plasma Cell Cancer", PredominantCancerSubtype: "Multiple Myeloma", GeneMasterName: "CDK4", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDK4", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Liposarcoma", GeneMasterName: "CDK4", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Atypical Nevi", GeneMasterName: "CDK4", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN1B", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN1B", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Parathyroid (Benign)", PredominantCancerSubtype: "Hyperparathyroid", GeneMasterName: "CDKN1B", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Pancreatic Neuroendocrine Tumor", GeneMasterName: "CDKN1B", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Parathyroid Neoplasm", PredominantCancerSubtype: "Parathyroid Adenoma", GeneMasterName: "CDKN1B", Gender: "Either", Organ: "Parathyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Pituitary Adenoma", GeneMasterName: "CDKN1B", Gender: "Either", Organ: "Pituitary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Adrenal Cortical (Benign)", PredominantCancerSubtype: "Adrenal Hypoplasia", GeneMasterName: "CDKN1C", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Genitourinary (Benign)", PredominantCancerSubtype: "Cryptorchidism, Hypospadias", GeneMasterName: "CDKN1C", Gender: "Male", Organ: "Genitals"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intrauterine Growth Restriction", GeneMasterName: "CDKN1C", Gender: "Either", Organ: "Developmental"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Metaphyseal Dysplasia", GeneMasterName: "CDKN1C", Gender: "Either", Organ: "Bone"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CRCS1", GeneMasterName: "GALNT12"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CSS3", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CSS4", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CSS5", GeneMasterName: "SMARCE1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTLO", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CWS2", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DCML", GeneMasterName: "GATA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DCR1", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DENND8B", GeneMasterName: "FLCN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DESMD", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DFNB97", GeneMasterName: "MET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DGSX", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Dicer", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Dicer1e", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DKCA1", GeneMasterName: "TERC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DKCA2", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DKCB4", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DUP", GeneMasterName: "MSH3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGP314", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERRP", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EST2", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EVI-1", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FA3", GeneMasterName: "FANCC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAC", GeneMasterName: "FANCC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FACC", GeneMasterName: "FANCC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCU", GeneMasterName: "XRCC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAP3", GeneMasterName: "NTHL1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAP4", GeneMasterName: "MSH3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FLCL", GeneMasterName: "FLCN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FMRD", GeneMasterName: "FH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GalNAc-T12", GeneMasterName: "GALNT12"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GLM9", GeneMasterName: "POT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GLOW", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GTR2-2", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GUD", GeneMasterName: "WT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HALAH", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HAMSV", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HERNA", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hEST2", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HGFR", GeneMasterName: "MET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HIFPH2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HIF-prolyl hydroxylase 2
egl nine homolog 1 (C. elegans)", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HLRCC", GeneMasterName: "FH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MI", GeneMasterName: "MITF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MITF-A", GeneMasterName: "MITF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MLH-1", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MMRCS1", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MMRCS2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MMRCS3", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MMRCS4", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MNG1", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MONOMAC", GeneMasterName: "GATA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRD15", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRD16", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRP1", GeneMasterName: "MSH3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH-2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH-6", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MXR7", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBCCS", GeneMasterName: "PTCH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBLST1", GeneMasterName: "KIF1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBLST2", GeneMasterName: "PHOX2B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBPhox", GeneMasterName: "PHOX2B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NDAXOA", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NFE1B", GeneMasterName: "GATA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NFNS", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NPHS4", GeneMasterName: "WT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NS2", GeneMasterName: "LZTR1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NTH1", GeneMasterName: "NTHL1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "OCI-5", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "OCTS3", GeneMasterName: "NTHL1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "OF", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "OSRC", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "p105-Rb", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "p110-RB1", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "p21ras", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PBT", GeneMasterName: "KIT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PCTT", GeneMasterName: "SPINK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PDGFR2", GeneMasterName: "PDGFRA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PDGFR-2", GeneMasterName: "PDGFRA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PEBP2aB", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PEBP2alpha", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PFBMFT1", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PFBMFT2", GeneMasterName: "TERC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PGL5", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PKR1", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS-2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMX2B", GeneMasterName: "PHOX2B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "POF17", GeneMasterName: "XRCC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "pp110", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PPNAD1", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PPP1R130", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PPP1R144", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PPP1R160", GeneMasterName: "TSC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "pRb", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PRKAR1", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PRO1280", GeneMasterName: "SUFU"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PSTI", GeneMasterName: "SPINK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTC1", GeneMasterName: "PTCH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTCH", GeneMasterName: "PTCH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RASH1", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RB", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RCA1", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RCCP2", GeneMasterName: "MET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RDT", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RecQ1", GeneMasterName: "RECQL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQ2", GeneMasterName: "BLM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQ3", GeneMasterName: "WRN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQ4", GeneMasterName: "RECQL4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL1", GeneMasterName: "RECQL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL2", GeneMasterName: "BLM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL2", GeneMasterName: "WRN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL3", GeneMasterName: "BLM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL3", GeneMasterName: "WRN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RINT-1", GeneMasterName: "RINT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RMSE2", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RTPS1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RTPS2", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "S20", GeneMasterName: "RPS20"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SCARNA19", GeneMasterName: "TERC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SCFR", GeneMasterName: "KIT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SCG2", GeneMasterName: "MEN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SDYS", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Sfh1p", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SGB", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SGBS", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SGBS1", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SM20", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SNF2", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SNF2-beta", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SNF2L4", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SNF2LB", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SNF5", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SNF5L1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Snr1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SPGF50", GeneMasterName: "XRCC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Spink3", GeneMasterName: "SPINK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SUFUH", GeneMasterName: "SUFU"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SUFUXL", GeneMasterName: "SUFU"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SWI2", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SWNTS1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TATI", GeneMasterName: "SPINK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TCP", GeneMasterName: "SPINK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TCS1", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TP2", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TR", GeneMasterName: "TERC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRC3", GeneMasterName: "TERC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRP1", GeneMasterName: "PRSS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRT", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRY1", GeneMasterName: "PRSS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRY4", GeneMasterName: "PRSS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRYP1", GeneMasterName: "PRSS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TSC", GeneMasterName: "TSC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TSC4", GeneMasterName: "TSC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TSE1", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "uS10", GeneMasterName: "RPS20"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "VRNF", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WAGR", GeneMasterName: "WT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WIT-2", GeneMasterName: "WT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WS2", GeneMasterName: "MITF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WS2A", GeneMasterName: "MITF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WSS", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WT-1", GeneMasterName: "WT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WT33", GeneMasterName: "WT1"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "FAMM", VerbiageFromMedneonAug2022: "Autosomal dominant predisposition to cutaneous melanoma (MedGen UID: 268851).  CDK4-related cutaneous melanoma is characterized by early presentation of atypical nevi and early-onset melanoma (PMID: 15880589, 23384855, 30775140). In a study of individuals with pathogenic CDK4 variants, the penetrance at age 50 was 74% (PMID: 23384855). Additional risk factors including pale skin and excessive sun exposure may amplify lifetime risks.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Fanconi Anemia", VerbiageFromMedneonAug2022: "Fanconi anemia is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life.", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "FAP", VerbiageFromMedneonAug2022: "FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935)", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "FILS Syndrome", VerbiageFromMedneonAug2022: "Autosomal recessive FILS syndrome (facial dysmorphism, immunodeficiency, livedo, and short stature) (MedGen UID: 767490).  FILS syndrome is characterized by mild facial dysmorphism and immunodeficiency resulting in recurrent infections, livedo on the skin present at birth and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Frasier Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Frasier syndrome (MedGen UID: 215533).  Frasier syndrome, which is more often associated with gonadoblastoma and less often with Wilms tumor (PMID: 23295293, 9529364).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "fumarate hydratase deficiency", VerbiageFromMedneonAug2022: "Autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).  FHD is an inborn error of metabolism that causes infantile encephalopathy, failure to thrive, hypotonia, lethargy and seizures. Affected individuals often have microcephaly, distinctive facial features, structural brain abnormalities and developmental delay.", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "GAPPS", VerbiageFromMedneonAug2022: "Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "GATA2 Deficiency", VerbiageFromMedneonAug2022: "The GATA2 gene is associated with autosomal dominant GATA2 deficiency (MedGen UID: 481660) and Emberger syndrome (MedGen UID: 481294).  GATA2 deficiency is an immunodeficiency syndrome that typically presents in late adolescence or early adulthood with neutropenia and recurrent infections. GATA2 deficiency is associated with an increased risk of myelodysplastic syndrome and acute myelogenous leukemia (AML).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "GIST-plus syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant GIST-plus syndrome (MedGen UID: 357402).  GIST-plus syndrome is associated with inflammatory fibroid polyps and fibroid tumors in the gastrointestinal tract in addition to gastrointestinal stromal tumors (GIST) that most often develop in the stomach and small intestines. GIST may be noncancerous but have malignant potential; however, specific lifetime cancer risks are not established. Some affected individuals may also have coarse skin and facial features in addition to broad hands and feet (PMID: 14699510, 18670346, 17087943).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Gorlin Syndrome", VerbiageFromMedneonAug2022: "The PTCH1 gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554). There is also evidence suggesting PTCH1 is associated with autosomal dominant holoprosencephaly (HPE) (MedGen: 372134). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  PTCH1-associated BCNS is an early-onset condition characterized by up to a 90% risk of developing multiple skin cancers, specifically basal cell carcinomas (BCCs). Approximately 90% will develop odontogenic keratocysts. BCNS is also associated with cardiac fibromas and ovarian fibromas in affected females. Additional findings include palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. Medulloblastomas occur in up to 5% of children with PTCH1-associated BCNS (PMID: 33066274).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Breast and Ovary Cancer Syndrome", VerbiageFromMedneonAug2022: "The BRCA2 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793)", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Diffuse Gastric Cancer Syndrome", VerbiageFromMedneonAug2022: "The CDH1 gene is associated with autosomal dominant predisposition to diffuse gastric cancer and lobular breast cancer, collectively known as hereditary diffuse gastric cancer (HDGC) syndrome (MedGen UID: 310839).  The estimated lifetime risk of diffuse gastric cancer in individuals with a pathogenic CDH1 variant is 67-83% (PMID: 11729114), although recent studies suggest the risk may be lower, at 33-42% (PMID: 31246251, 31296550). The lifetime risk of lobular cancer in females is 27%-52% (PMID: 17545690, 11729114, 33471974).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Hemorrhagic Telangiectasia (HHT)", VerbiageFromMedneonAug2022: "Hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400).  HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Leiomyomatosis And Renal Cell Cancer (HLRCC)", VerbiageFromMedneonAug2022: "The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771).  HLRCC is characterized by cutaneous leiomyomas, early onset uterine leiomyomas, kidney tumors and kidney cancer. Uterine leiomyomas, also known as fibroids, are present in nearly all affected females. The lifetime risk for renal cell carcinoma is approximately 21% (PMID: 31831373). Some individuals with a clinically significant change in FH may also develop paragangliomas (PGL) and pheochromocytomas (PCC). PGL are nervous system tumors that often form in the head, neck, spine or abdomen. PCC are adrenal gland tumors that may cause symptoms including tachycardia and hypertension. Most PGL and PCC are benign and while there is malignant potential, lifetime cancer risks are not clear.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Lung Cancer", VerbiageFromMedneonAug2022: "LOF variants in EGFR are not known to be associated with autosomal dominant predisposition to lung cancer.

Pathogenic gain-of-function (GOF) EGFR variants are associated with an increased risk of lung cancer (PMID: 16258541, 24736066, 24736080, 21252721, 23380224, 25176975, 18355544, 23358982). One study estimated the risk of lung cancer to be 15-31% (PMID: 24736066), although data are limited.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Mixed Polyposis Syndrome", VerbiageFromMedneonAug2022: "The GREM1 gene is associated with autosomal dominant hereditary mixed polyposis syndrome (HMPS) in individuals who carry a duplication spanning the 3' end of the adjacent SCG5 gene and a region upstream of the GREM1 locus (MedGen UID: 430218, PMID: 22561515).  Hereditary mixed polyposis syndrome is an adult-onset condition associated with various types of colon polyps which may subsequently become malignant (PMID: 22561515). Lifetime cancer risks are currently not well established.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Papillary Renal Cell Carcinoma", VerbiageFromMedneonAug2022: "Autosomal dominant predisposition to hereditary papillary renal cell carcinoma (HPRCC) (MedGen UID: 766). HPRCC is a rare, highly penetrant hereditary cancer syndrome characterized by an increased lifetime risk of developing type 1 papillary renal cell carcinoma (PRCC) (PMID: 24710684, 9563489, 12647800). These tumors are typically multifocal and bilateral (PMID: 8308957).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", VerbiageFromMedneonAug2022: "Hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 313270). PGL-PCC syndrome is characterized by malignant or benign PGL and PCC tumors. PGLs are nervous system tumors that often develop within the head, neck, spine, or abdomen. PCCs are adrenal gland tumors that may cause symptoms related to increased hormone secretion, such as rapid heartbeat and high blood pressure (PMID: 21685915, 22452945, 23666964).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Hereditary Prostate Cancer", VerbiageFromMedneonAug2022: "The HOXB13 gene is associated with autosomal dominant predisposition to prostate cancer (PMID: 31629417).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "IMAGe syndrome", VerbiageFromMedneonAug2022: "IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) (MedGen UID: 337364).  

IMAGe syndrome is also characterized by growth abnormality; however, unlike BWS, affected individuals present with growth restriction. In addition to the clinical findings indicated by the acronym (Intrauterine growth restriction, Metaphyseal dysplasia, congenital Adrenal hypoplasia, and Genital anomalies), some may present with craniofacial features such as low-set ears, flat nasal bridge and short nose (PMID: 24098681, 10599684, 14760276). Genital anomalies occur mostly in males and include micropenis, undescended testes and hypospadias (PMID: 14760276).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Joubert Syndrome", VerbiageFromMedneonAug2022: "Autosomal recessive Joubert syndrome (MedGen UID: 1626697), and autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).  

Joubert syndrome (JS) is a highly variable condition associated with a specific anomaly of the cerebellar vermis and brainstem causing the characteristic \"molar tooth sign\" (MTS) on magnetic resonance imaging. Additional findings include ataxia, polydactyly, distinctive facial features, episodic tachypnea or apnea and abnormal eye movements (PMID: 24360807). Cognitive abilities may range from normal to severely impaired. The term \"Joubert syndrome and related disorders (JSRD)\" is used to describe JS and other conditions that have MTS as well as other overlapping clinical features (PMID: 17603801, 14981712). While the SUFU gene is associated with JS, LOF variants in this gene have not been observed in individuals with this condition.", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Juvenile Polyposis Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518)  .  JPS is characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Juvenile polyposis_hereditary hemorrhagic telangiectasia syndrome", VerbiageFromMedneonAug2022: "Hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400).  LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.      The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400) and Myhre syndrome (MedGen UID: 167103).  Loss-of-function (LOF) variants in SMAD4 are associated with juvenile polyposis syndrome (JPS), a condition characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469). LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.   Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Li-Fraumeni Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Li-Fraumeni syndrome (LFS) (MedGen UID: 322656).  LFS is a cancer predisposition syndrome associated with sarcoma, brain cancer, breast cancer, adrenocortical carcinoma and other malignancies. Affected individuals often develop cancers in childhood or early adulthood, and are at increased risk for multiple primary cancers. Overall lifetime cancer risks have been reported as high as 73% for males and nearly 100% for females (PMID: 10864200). It is estimated that 7-20% of LFS cases are due to a de novo pathogenic variant (PMID: 19556618). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired TP53 variants and additional testing may be appropriate.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Lynch Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 232603).  Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the uterus/endometrium, ovary, stomach, bladder, biliary tract, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks for individuals with a pathogenic variant in MSH2 and/or EPCAM include a 33-52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain/central nervous system cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Macular dystrophy, patterned, 2", VerbiageFromMedneonAug2022: "Autosomal dominant butterfly-shaped pigmentary macular dystrophy (MedGen UID: 332348). To date, loss-of-function variants in CTNNA1 have not been associated with butterfly-shaped pigmentary macular dystrophy.  Butterfly-shaped pigmentary macular dystrophy is a form of patterned dystrophies of the retinal pigment epithelium, characterized by accumulation of pigment in the macula that resembles the wings of a butterfly (PMID: 12724643). Affected individuals typically present from middle age with mildly reduced visual acuity and color vision. The activity of the RPE measured by electrooculogram (EOG) recordings may be abnormal (PMID: 26691986). Retinitis pigmentosa-like changes have been observed in some cases (PMID: 22466463). The disease is relatively benign, but can progress to atrophy of the choroid and retina, resulting in severe vision loss, though the severity of the disease is highly variable, even within the same family (PMID: 26691986).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "MDPL Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant MDPL syndrome (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) (MedGen UID: 811623). MDPL syndrome is a rare, systemic disorder characterized by loss of subcutaneous fat, distinctive facial features and metabolic abnormalities including insulin resistance and diabetes. Sensorineural hearing loss is also a common finding, typically presenting in the first or second decades of life (PMID: 25131834, 23770608).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "MEN1", VerbiageFromMedneonAug2022: "Autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome (MedGen UID: 9957). Multiple endocrine neoplasia type 1 is a highly penetrant condition associated with endocrine tumors in the parathyroid, anterior pituitary, thymus, gastro-entero-pancreatic tract and adrenal glands. Affected individuals may also have facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. While most MEN1-associated tumors are noncancerous, there is an increased risk of malignant transformation. Parathyroid tumors are the primary MEN1-associated endocrinopathy with symptoms typically developing at 20-25 years of age (PMID: 32971521).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "MEN2", VerbiageFromMedneonAug2022: "Autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501). In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area. 

Pathogenic loss-of-function (LOF) RET variants are associated with Hirschsprung disease (HD), a condition characterized by congenital agenesis of ganglion in the colon. HD is typically diagnosed in early infancy, although less severe cases may be diagnosed later in childhood (PMID: 16448984).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "MEN2a", VerbiageFromMedneonAug2022: "The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "MEN2b", VerbiageFromMedneonAug2022: "The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B.  In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "MEN4", VerbiageFromMedneonAug2022: "Autosomal dominant multiple endocrine neoplasia type 4 (MEN4) (MedGen UID: 373469).  MEN4 is characterized by parathyroid and pituitary tumors as well as tumors of the adrenal glands, kidney and reproductive organs (PMID: 23933118, 23140918).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Mitochondrial Complex II Deficiency", VerbiageFromMedneonAug2022: "Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy (PMID: 22972948, 23322652, 27683074). Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy (PMID: 22972948, 23322652). The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 23322652). Clinical correlation is advised.", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Myhre Syndrome", VerbiageFromMedneonAug2022: "Myhre syndrome (MedGen UID: 167103).  Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Acrodysostosis 1 with or without hormone resistance", VerbiageFromMedneonAug2022: "The PRKAR1A gene is associated with autosomal dominant Carney complex (CNC) (MedGen UID: Acrodysostosis (MedGen UID: 477858).  	

Autosomal dominant acrodysostosis is characterized by variable skeletal, endocrine, and neurological abnormalities that are present in childhood (PMID: 22464252). The most common features include brachydactyly, dysmorphic facies, short stature, and intellectual disability and/or developmental delays (PMID: 26763073). Other symptoms may include advanced bone age, peripheral dysostosis with shortened bones of the hands and feet, cone-shaped epiphyses, lumbar stenosis, hypothyroidism, multiple hormone resistance, cryptorchidism, hypospadias, deafness and rhinitis (PMID: 22464252, 23033274, 26763073).

Loss of function variants are associated with CNC (PMID: 19293268, 11115848). Some further genotype-phenotype correlations have been suggested for acrodysostosis versus CNC (PMID: 10974026, 10973256, 22464250, 22464252), but these correlations remain preliminary.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Ataxia telangiectasia", VerbiageFromMedneonAug2022: "A-T is characterized by progressive cerebellar ataxia beginning in early childhood, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections and increased malignancy risk, particularly leukemia and lymphoma (PMID: 15279807, 26050521).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Attenuated FAP", VerbiageFromMedneonAug2022: "Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Autosomal dominant hypocalcemia", VerbiageFromMedneonAug2022: "Pathogenic gain-of-function (GOF) variants in CASR cause ADH. ADH is characterized by hypoparathyroidism, hypocalcemia and hypercalciuria although approximately half of affected individuals have no associated health problems (PMID: 31189130). A subset of GOF variants can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Autosomal dominant hypocalcemia with Bartter syndrome", VerbiageFromMedneonAug2022: "A subset of GOF variants in CASR can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Bannayan-Riley-Ruvalcaba syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Bannayan-Riley-Ruvalcaba syndrome", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "BAP1 Tumor Predisposition Syndrome", VerbiageFromMedneonAug2022: "(MedGen UID: 482122). BAP1 tumor predisposition syndrome is associated with an increased risk for cutaneous and uveal melanoma, malignant pleural mesothelioma and renal cell carcinoma; lifetime cancer risks are unclear (PMID: 22935333, 23684012).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Beckwith-Wiedemann Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Beckwith-Wiedemann syndrome (BWS) (MedGen UID: 2562).  BWS is an overgrowth disorder characterized by macrosomia, macroglossia, visceromegaly, hemihyperplasia, omphalocele, neonatal hypoglycemia, and renal abnormalities. There is an increased risk for neoplasia, particularly Wilms tumor, hepatoblastoma, neuroblastoma, adrenocortical carcinoma and rhabdomyosarcoma; these risks are highest in the newborn period through eight years of age (PMID: 24335096, 24911853, 20301568).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Birt-Hogg-Dube Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Birt-Hogg-Dub√© (BHD) syndrome (MedGen UID: 91070). There is also evidence suggesting BHD is associated with an increased risk of colon polyps and colorectal cancer (PMID: 20522427, 20392993). The data, however, are preliminary and insufficient to made a determination regarding this relationship.  BHD is characterized by an increased risk to develop noncancerous cysts in the lungs (70% risk) and kidneys (12-34% risk) in addition to acrochordons, fibrofolliculomas and trichodiscomas on the face neck and upper body. There is a 24-38% risk of developing one or more spontaneous pneumothorax. Affected individuals also have an increased risk of kidney cancer; however, lifetime risks are not established (PMID: 25519092, 25519458, 18234728).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Bloom Syndrome", VerbiageFromMedneonAug2022: "Bloom syndrome is characterized by proportionate small stature, microcephaly, abnormal skin pigmentation, facial anomalies, sun-sensitive facial erythema, infertility, immunodeficiency, and a predisposition to a wide variety of cancers (PMID: 16763388, 5770175).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Carney Complex", VerbiageFromMedneonAug2022: "Autosomal dominant Carney complex (CNC) (MedGen UID: 388559).			  CNC is characterized by myxomas, endocrine tumors and schwannomas. Pigmentary skin lesions are a defining feature, present in over 80% of cases. Primary pigmented nodular adrenocortical disease (PPNAD), which can lead to Cushing's syndrome, develops in 25-60% of affected individuals. CNC is associated with an increased risk of developing thyroid nodules, thyroid cancer, myxomas in the heart, breast, skin, throat and female genital tract in addition to psammomatous melanotic schwannomas (PMS) and ovarian tumors. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in nearly all affected males (PMID: 26130139, 16756677).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Carney-Stratakis Syndrome", VerbiageFromMedneonAug2022: "Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "CDC73-related conditions", VerbiageFromMedneonAug2022: "Autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid carcinoma, and familial isolated hyperparathyroidism (FIH) (MedGen UID: 310065, 146361, 333554), collectively referred to as CDC73-related conditions. There is also evidence suggesting CDC73 is associated with autosomal dominant predisposition to malignant uterine tumors (PMID: 23293331, 12434154, 23029104). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  CDC73-related conditions are characterized by primary hyperparathyroidism, which occurs in over 70% of cases (PMID: 16720667, 20301744). This primary hyperparathyroidism is typically caused by benign parathyroid adenomas, though it can also be due to an underlying parathyroid carcinoma (PMID: 20301744). Additional features include ossifying jaw fibromas, uterine fibroids, renal cysts, hamartomas and Wilms tumor.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Coffin-Siris syndrome", VerbiageFromMedneonAug2022: "Coffin-Siris syndrome (CSS) (MedGen UID: 766163).  
Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Colonic Polyposis And Colorectal Cancer", VerbiageFromMedneonAug2022: "Autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 436445). Individuals with a pathogenic POLD1 variant typically presents with 10-100 colonic polyps and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 23263490, 26133394, 24501277).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "COMMAD syndrome", VerbiageFromMedneonAug2022: "Autosomal recessive COMMAD syndrome (coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness) (MedGen UID: 934592).  
COMMAD syndrome is a rare condition characterized by iris coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism and deafness. Due to the limited cases described in the literature, the clinical features and natural history of COMMAD are still unclear and will likely evolve over time. Clinical correlation is advised.", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Congenital central hypoventilation syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant congenital central hypoventilation syndrome (CCHS) (MedGen UID: 347052). Most cases of CCHS are due to a polyalanine repeat expansion, which is not analyzed by this test.											  CCHS is a disorder of autonomic regulation characterized by alveolar hypoventilation and symptoms of autonomic dysregulation presenting in the newborn period. Dysmorphic features include downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears (PMID: 23465774,18579454, 20208042). A subset of affected individuals may develop Hirschsprung disease and/or tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Congenital ocular motor apraxia", VerbiageFromMedneonAug2022: "Autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Congenital tufting enteropathy", VerbiageFromMedneonAug2022: "The EPCAM gene is associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031).  Congenital tufting enteropathy (CTE) is a gastrointestinal insufficiency syndrome presenting early in infancy as severe watery diarrhea. CTE is usually treated by daily nutritional supplements and occasionally, intestinal transplantation (PMID: 8057225, 18572020).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Constitutional Mismatch Repair Deficiency Syndrome", VerbiageFromMedneonAug2022: "Autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as caf√©-au-lait spots (PMID: 18709565, 20442441, 17539897).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Costello Syndrome", VerbiageFromMedneonAug2022: "Costello syndrome (MedGen UID: 108454).  Costello syndrome is characterized by intellectual disability, failure to thrive, cardiac malformations, short stature, loose skin with deep palmar and plantar creases, cerebellar overgrowth, predisposition to malignancy, and dysmorphic facial features including coarse facies, epicanthal folds, long eyelashes, sparse/curly hair, full lips, and a wide nasal bridge.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Cowden Syndrome", VerbiageFromMedneonAug2022: "The PTEN gene is associated with autosomal dominant PTEN hamartoma tumor syndrome (PHTS), including the clinical subtypes of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and PTEN-related autism spectrum disorder (MedGen UID: 368366). Other PTEN-associated conditions have also been described (PMID: 11755638, 17392703, 27890237).  PHTS is a highly variable hamartomatous condition characterized by macrocephaly, Lhermitte-Duclos disease, mucocutaneous lesions, gastrointestinal hamartomas, lipomas, benign thyroid lesions, macular pigmentation of the glans penis, cerebrovascular malformations and several types of cancer. Associated cancers include breast (up to 85% risk), thyroid (typically follicular, up to 38% risk), renal (up to 34%), endometrial (up to 28% risk), colorectal (9-16% risk) and melanoma (6% risk) (PMID: 31216739, 33471991). PHTS is also associated with developmental delay, intellectual disability and autism spectrum disorder (PMID: 26564076, 19265751, 25288137).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "CRC12", VerbiageFromMedneonAug2022: "The POLE gene is associated with an autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 767374).  Individuals with a pathogenic POLE variant typically present with 10-100 adenomas and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 26133394, 29120461, 32424176).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Denys-Drash Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Denys-Drash syndrome (MedGen UID: 181980)  Denys-Drash syndrome, which has a high risk of Wilms tumor and genitourinary anomalies", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "DICER1-Pleuropulmonary Blastoma Familial Tumor Predisposition Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome (MedGen UID: 449020).  DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome is associated with an increased risk for certain types of rare tumors and cancers that may present in childhood. Noncancerous neoplasias include cystic nephroma, nasal chondromesenchymal hamartomas, thyroid adenomas and goiter. There is also an increased risk of certain malignancies including pleuropulmonary blastoma, ovarian sex cord-stromal tumors, Sertoli-Leydig cell tumors, genitourinary embryonal rhabdomyosarcoma, renal sarcoma, Wilms tumor, thyroid cancer, ciliary body medulloepithelioma, pituitary blastoma and pineoblastoma.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Dyskeratosis Congenita", VerbiageFromMedneonAug2022: "The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793  Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual‚Äôs telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Dyskeratosis Congenita", VerbiageFromMedneonAug2022: "The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793  Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual‚Äôs telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Emberger Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Emberger syndrome (MedGen UID: 481294).  Emberger syndrome is a related GATA2 deficiency condition associated with lymphedema of the lower extremities and predisposition to AML; hearing loss has been reported in some cases (PMID: 23223431, 21892158, 20803646).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Familial Acute Myeloid Leukemia", VerbiageFromMedneonAug2022: "(MedGen UID: 9730).  Familial AML is characterized by multiple diagnoses of this cancer type within a family. The age at diagnosis can be variable; however, it appears to have an earlier onset than sporadic cases (PMID: 18946494, 26162409).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Familial Erythrocytosis Type 2", VerbiageFromMedneonAug2022: "Autosomal recessive familial erythrocytosis, type 2 (MedGen UID: 332974).  Familial erythrocytosis is characterized by the abnormally high production of red blood cells (erythrocytes), which can cause headaches, dizziness, nosebleeds, shortness of breath and predisposition to excessive clotting. Familial erythrocytosis has incomplete penetrance; many individuals with biallelic pathogenic variants will never develop clinical symptoms (PMID: 24115288, 23733342).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Familial Hypocalciuric Hypercalcemia", VerbiageFromMedneonAug2022: "Characterized by hypercalcemia and hypocalciuria, although most affected individuals are asymptomatic (PMID: 31189130).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Familial Isolated Hyperparathyroidism", VerbiageFromMedneonAug2022: "Familial isolated hyperparathyroidism (FIHP) (OMIM: 145000). Autosomal dominant familial isolated hyperparathyroidism (FIHP), characterized by parathyroid adenomas or hyperplasia without other associated tumors or endocrinopathies (PMID: 12213668, 12699448). Individuals with FIHP often present with one or more hyperplastic parathyroid glands, resulting in elevated parathyroid hormone and hypercalemia; like FHH, most individuals are asymptomatic due to early diagnosis and treatment (PMID: 31189130).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Familial isolated pituitary adenoma (FIPA)", VerbiageFromMedneonAug2022: "(MedGen UID: 489979).  FIPA presents in early adulthood with the development of pituitary adenomas in the absence of other syndromic findings. These pituitary adenomas may be of various types including somatotropinoma (growth hormone-secreting), prolactinoma (prolactin-secreting), somatomammotropinoma (growth hormone and prolactin co-secreting) and nonfunctioning pituitary adenomas (NFPA). Other types of adenomas have also been observed (PMID: 22720333, 26186299).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "neonatal inflammatory skin and bowel disease", VerbiageFromMedneonAug2022: "Pathogenic loss-of-function (LOF) variants in EGFR are associated with neonatal inflammatory skin and bowel disease, a rare condition affecting the skin, hair, kidney, growth, gastrointestinal and respiratory systems. Skin manifestations include erosions, scaling, inflammatory rash and infection. Recurrent respiratory and gastrointestinal infections as well as severe diarrhea and vomiting may occur (PMID: 32602142, 29899996, 26436111, 24691054). GOF variants in EGFR are not known to be associated with autosomal recessive neonatal inflammatory skin and bowel disease.", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Neonatal Severe Hyperparathyroidism", VerbiageFromMedneonAug2022: "NSHPT presents in infancy with parathyroid hyperplasia, elevated parathyroid hormone levels and hypercalcemia, which can result in bone demineralization and failure to thrive. Untreated NSHPT may lead to a severe, life-threatening neurological disorder (PMID: 31189130). There are reports of homozygous CASR variants causing a milder FHH-like phenotype (PMID: 31189130).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Neurofibromatosis, type 1", VerbiageFromMedneonAug2022: "Autosomal dominant neurofibromatosis type 1 (NF1) (MedGen UID: 18013).   NF1 is a neurocutaneous disorder associated with an increased risk of several types of benign and malignant tumors. Primary features include multiple cafe-au-lait spots, inguinal freckling and neurofibromas. NF1 is highly variable in its expression, even among affected members of the same family. There is an increased risk for tumors of the central nervous system neoplasms and other malignancies including female breast cancer, gastrointestinal stromal tumors, pheochromocytoma and soft tissue sarcomas (PMID: 20301288). Approximately one-half of NF1 cases are inherited, and the remainder are the result of de novo mutations (PMID: 20082463).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Neurofibromatosis, type 2", VerbiageFromMedneonAug2022: "Autosomal dominant neurofibromatosis type 2 (NF2) (MedGen UID: 18014).										  Neurofibromatosis type 2 is a highly penetrant condition characterized by multiple tumors throughout the central and peripheral nervous systems including schwannomas, meningiomas, ependymomas and rarely, astrocytomas and neurofibromas (PMID: 20082463, 15699726, 19476995). The hallmark tumors associated with this condition are bilateral vestibular schwannomas causing symptoms of tinnitus, hearing loss, balance difficulties and facial nerve weakness (PMID: 19671848, 24724714). Neurofibromatosis type 2 generally presents in the third to fourth decade of life, although this may be influenced by mutation type (PMID: 19476995).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Neurofibromatosis-Noonan syndrome", VerbiageFromMedneonAug2022: "Neurofibromatosis-Noonan syndrome (NFNS) (MedGen UID: 419089).  NFNS is characterized by classic neurofibromatosis in addition to short stature, distinctive facial features, broad neck, congenital heart defects, speech delay and pectus anomaly (PMID: 16542390, 24357598, 26178382).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Nijmegen Breakage Syndrome", VerbiageFromMedneonAug2022: "Autosomal recessive Nijmegen breakage syndrome (NBS) (MedGen UID: 140771).  NBS is a progressive multisystemic disorder characterized by physical abnormalities, immunodeficiency, increased cancer risk and cognitive impairment. Physical abnormalities may include progressive microcephaly, early growth restriction leading to short stature and distinctive facial features. Immunodeficiency often results in recurrent pulmonary infections. B-cell lymphomas are the most common malignancy, although T-cell lymphomas, medulloblastomas, gliomas and rhabdomyosarcomas may also occur (PMID: 22373003, 26271390).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Nijmegen Breakage Syndrome-Like Disorder", VerbiageFromMedneonAug2022: "Autosomal recessive Nijmegen breakage syndrome-like disorder (NBSLD) (PMID: 19409520).  NBSLD is characterized by a clinical phenotype resembling Nijmegen breakage syndrome including chromosomal instability, radiosensitivity, neurodevelopmental disease, and immunodeficiency but with a milder clinical presentation.", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Oligodontia-Colorectal Cancer Syndrome", VerbiageFromMedneonAug2022: "(MedGen UID: 324868).								  Oligodontia-colorectal cancer syndrome is associated with colon polyps and colorectal cancer as well as features of ectodermal dysplasia including severe oligodontia and sparse eyebrows, scalp and body hair (PMID: 15042511, 21416598, 21626677).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Perlman Syndrome", VerbiageFromMedneonAug2022: "The DIS3L2 gene is associated with autosomal recessive Perlman syndrome (MedGen UID: 162909).  Perlman syndrome is an overgrowth disorder characterized by macrosomia, renal dysplasia, nephroblastomatosis and Wilms tumor (PMID: 23613427). Affected infants have a high rate of neonatal morbidity; the incidence of Wilms tumor in those who survive the neonatal period has been estimated at 64% (PMID: 18780370).", HereditaryType: "Recessive"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Peutz-Jeghers Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Peutz-Jeghers syndrome (PJS) (MedGen UID: 18404).  PJS is characterized by gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation of the lips, and increased risk of cancer. Affected individuals have increased risk of developing a wide variety of cancers including breast (19-54% risk), ovarian (18-21% risk), testicular (9% risk), endometrial/uterine (9% risk), cervical (10% risk), colon (39% risk), gastric (29% risk), small bowel (13% risk), pancreatic (11-36% risk) and lung (7-17% risk) (PMID: 11113065, 33471991).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "POT1 tumor predisposition syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant POT1 tumor predisposition syndrome (MedGen UID: 862913).  POT1 tumor predisposition syndrome is associated with predisposition to familial malignant melanoma (PMID: 24686846, 24686849, 26337759). Melanoma most often occurs in the skin, but may also develop in the eyes, ears, gastrointestinal tract, and oral and genital membranes. POT1 has also been associated with a susceptibility to additional cancers including glioma and angiosarcoma, among others; specific lifetime cancer risks are not clear (PMID: 25482530, 30165405, 25252913, 28853721, 27528712). Although consensus guidelines have not been published for individuals with pathogenic variants in POT1, evaluation and surveillance considerations are available in PMID: 33119245.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Rhabdoid Tumor Predisposition Syndrome 1", VerbiageFromMedneonAug2022: "Autosomal dominant rhabdoid tumor predisposition syndrome 1 (RTPS1) (MedGen UID: 322892)  RTPS is associated with an increased risk of rhabdoid tumors, a rare type of childhood cancer that most often develops in the kidneys and central nervous system.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Rhabdoid Tumor Predisposition Syndrome 2", VerbiageFromMedneonAug2022: "Rhabdoid tumor predisposition syndrome, type 2.  Loss-of-function (LOF) variants in SMARCA4 are associated with RTPS2, a childhood-onset condition associated with rhabdoid tumors that typically develop in the kidneys and central nervous system. SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Schwannomatosis", VerbiageFromMedneonAug2022: "Schwannomatosis (MedGen UID: 234775). Schwannomatosis is characterized by the development of multiple spinal, peripheral, and cranial nerve schwannomas. The absence of vestibular schwannomas distinguishes schwannomatosis from neurofibromatosis type 2 (PMID: 24933152, 19898272, 21208904).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Small cell carcinoma of the ovary, hypercalcemic type", VerbiageFromMedneonAug2022: "Autosomal dominant small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PMID: 24658002, 24658001).   SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established.", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Tuberous Sclerosis Complex", VerbiageFromMedneonAug2022: "Autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 344288).  (MedGen UID: 348170).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Von Hippel Lindau Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant von Hippel-Lindau (VHL) syndrome (MedGen UID: 42458).  Von Hippel-Lindau syndrome is associated with an increased risk of developing various noncancerous tumors throughout the body including hemangioblastomas of the central nervous system and retina, head and neck paragangliomas, pheochromocytomas, endolymphatic sac tumors and epididymal cystadenomas. Although most tumors are benign, there is a 17-70% risk of developing clear cell renal cell carcinoma and an 8-17% risk for pancreatic neuroendocrine tumors (PMID: 20301636, 28620007, 31095066). Approximately 20% of VHL cases are de novo (PMID: 21386872, 25611110). Although genotype-phenotype correlations have been suggested, their diagnostic relevance is unclear and therefore should not impact medical management (PMID: 21386872, 20301636).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Waardenburg syndrome type 2A", VerbiageFromMedneonAug2022: "Waardenburg syndrome, type 2a (MedGen UID: 349786).  Waardenburg syndrome, type 2a (WS2a) is characterized by congenital deafness and abnormal pigmentation of the iris, hair and skin. Additional neurologic manifestations including intellectual disability and myelination abnormalities have been described. WS2a is distinguished from Waardenburg type 1 by the absence of dystopia canthorum (PMID: 20127975).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "WAGR Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant WAGR syndrome (MedGen UID: 64512) Deletions of WT1 along with the neighboring PAX6 gene are associated with WAGR (Wilms tumor-aniridia-genital anomalies-retardation) syndrome, characterized by Wilms tumor, genitourinary anomalies, intellectual disability, and aniridia (PMID: 22692063).", HereditaryType: "Dominant"})
(:LKP_SYNDROME_VERBIAGE {SyndromeMasterName: "Watson Syndrome", VerbiageFromMedneonAug2022: "Autosomal dominant Watson syndrome (MedGen UID: 107817).   Watson syndrome is characterized by pulmonic stenosis, cafe-au-lait spots, macrocephaly, Lisch nodules, intellectual disability and short stature (PMID: 1770531, 23047742).", HereditaryType: "Dominant"})
(:NCCN_GUIDELINES {GuidelineName: "Unknown", OrganSystem: "Unknown", Gene: "Gene", GuidelineVersion: "Unknown", GuidelineBody: "Unknown", Gender: "Unknown", GuidelineYear: "Unknown", Modality: "Unknown", OriginalAction: "OriginalAction"})
(:NCCN_GUIDELINES {GuidelineName: "Myelodysplastic Syndromes", OrganSystem: "General", Gene: "ANKRD26", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Gene Insight", GuidelineYear: "2021", OriginalAction: ":w"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "For probands with the I1307K variant who are unaffected by CRC and with a first-degree relative with CRC: Colonoscopy screening every 5 y, beginning at age 40 or 10 y prior to age of first-degree relative's age at CRC diagnosis. 

For probands with the I1307K variant who are unaffected by CRC and no first-degree relative with CRC: Colonoscopy screening every 5 y, beginning at age 40.

For probands with CRC and the I1307K variant: See surveillance recommendations for post-CRC resection: NCCN Guidelines for Colon Cancer and NCCN Guidelines for Rectal Cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Body", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Annual physical examination."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "High-quality colonoscopy and polypectomy beginning in late teens, then every 1-2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Risk-Reducing Colectomy", GuidelineYear: "2021", OriginalAction: "Three different surgical options are available for individuals with classical FAP and AFAP: total proctocolectomy with IPAA (TPC/IPAA) (recommended for FAP), total abdominal colectomy with IRA (TAC/IRA) (recommended for AFAP), and TPC with permanent end ileostomy (TPC/EI). The prime factors to consider when choosing an operation for FAP and AFAP are the personal and familial phenotype, including the rectal polyp burden (i.e., distribution and number) and whether colon or rectal cancer is present at diagnosis. In patients presenting with the classical FAP phenotype, TPC/IPAA is generally recommended because it prevents both colon and rectal cancers. For patients with AFAP, TAC/IRA is generally recommended; TPC/IPAA can also be considered in cases of dense rectal polyposis not manageable with polypectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Discuss advantages of genetic testing, including avoidance of costs, burden, and risks associated with frequent colonoscopy if APC mutation ruled out. FAP genetic testing in children should be done by age 10-12 years when colon screening would be initiated. If there is intent to do hepatoblastoma screening, FAP genetic testing should be considered in infancy. FAP: If genetic testing not completed, colonoscopy (preferred) or flexible sigmoidoscopy every 12 months beginning at age 10-15 years AFAP: If genetic testing not completed, colonoscopy beginning in late teens, then every 2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Discuss advantages of genetic testing, including avoidance of costs, burden, and risks associated with frequent colonoscopy if APC mutation ruled out. FAP genetic testing in children should be done by age 10-12 years when colon screening would be initiated. If there is intent to do hepatoblastoma screening, FAP genetic testing should be considered in infancy. FAP: If genetic testing not completed, colonoscopy (preferred) or flexible sigmoidoscopy every 12 months beginning at age 10-15 years AFAP: If genetic testing not completed, colonoscopy beginning in late teens, then every 2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Discuss advantages of genetic testing, including avoidance of costs, burden, and risks associated with frequent colonoscopy if APC mutation ruled out. FAP genetic testing in children should be done by age 10-12 years when colon screening would be initiated. If there is intent to do hepatoblastoma screening, FAP genetic testing should be considered in infancy. FAP: If genetic testing not completed, colonoscopy (preferred) or flexible sigmoidoscopy every 12 months beginning at age 10-15 years AFAP: If genetic testing not completed, colonoscopy beginning in late teens, then every 2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Referral", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "It is recommended that patients be managed by physicians or centers with expertise in FAP and that management be individualized to account for genotype, phenotype, and personal considerations."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Referral", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "It is recommended that patients be managed by physicians or centers with expertise in FAP and that management be individualized to account for genotype, phenotype, and personal considerations."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Referral", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "It is recommended that patients be managed by physicians or centers with expertise in FAP and that management be individualized to account for genotype, phenotype, and personal considerations."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Thyroid", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Ultrasound at baseline starting in late teenage years. If normal, consider repeating ultrasound every 2-5 years and if abnormal, consider referral to a thyroid specialist. Shorter intervals may be considered for individuals with a family history of thyroid cancer. Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Thyroid", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Ultrasound at baseline starting in late teenage years. If normal, consider repeating ultrasound every 2-5 years and if abnormal, consider referral to a thyroid specialist. Shorter intervals may be considered for individuals with a family history of thyroid cancer. Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Thyroid", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Ultrasound at baseline starting in late teenage years. If normal, consider repeating ultrasound every 2-5 years and if abnormal, consider referral to a thyroid specialist. Shorter intervals may be considered for individuals with a family history of thyroid cancer. Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "UGI", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Duodenal or periampullary cancer: Upper endoscopy (including complete visualization of the ampulla of Vater) starting at around age 20-25 years. Consider baseline upper endoscopy earlier, if family history of aggressive duodenal adenoma burden or cancer. Cap-assisted endoscopy may be adequate for visualization of the ampulla. (Kallenberg F, et al. Endoscopy 2017;49:181-185.) There is no clear evidence to support screening for gastric cancer in FAP/AFAP. However, given the increased risk for duodenal cancer in FAP/AFAP, the stomach should be examined at the same time of duodenoscopy. Fundic gland polyps occur in a majority of FAP patients, and focal low-grade dysplasia can occur but is typically non- progressive. The risk of gastric cancer in FAP patients appears to be increased in patients from geographic areas with high gastric cancer risk and may be elevated in the setting of certain endoscopic findings, including carpeting of fundic gland polyps, solitary polyps larger than 20 mm, and mounds of polyps. High-risk histologic features include tubular adenomas, polyps with high-grade dysplasia, and pyloric gland adenomas. Need for specialized surveillance or surgery should be considered in presence of high-risk histologic features, preferably at a center of expertise.Patients with high-risk lesions that cannot be removed endoscopically should be referred to a specialized center for consideration of gastrectomy.Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "UGI", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Duodenal or periampullary cancer: Upper endoscopy (including complete visualization of the ampulla of Vater) starting at around age 20-25 years. Consider baseline upper endoscopy earlier, if family history of aggressive duodenal adenoma burden or cancer. Cap-assisted endoscopy may be adequate for visualization of the ampulla. (Kallenberg F, et al. Endoscopy 2017;49:181-185.) There is no clear evidence to support screening for gastric cancer in FAP/AFAP. However, given the increased risk for duodenal cancer in FAP/AFAP, the stomach should be examined at the same time of duodenoscopy. Fundic gland polyps occur in a majority of FAP patients, and focal low-grade dysplasia can occur but is typically non- progressive. The risk of gastric cancer in FAP patients appears to be increased in patients from geographic areas with high gastric cancer risk and may be elevated in the setting of certain endoscopic findings, including carpeting of fundic gland polyps, solitary polyps larger than 20 mm, and mounds of polyps. High-risk histologic features include tubular adenomas, polyps with high-grade dysplasia, and pyloric gland adenomas. Need for specialized surveillance or surgery should be considered in presence of high-risk histologic features, preferably at a center of expertise.Patients with high-risk lesions that cannot be removed endoscopically should be referred to a specialized center for consideration of gastrectomy.Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "UGI", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "Duodenal or periampullary cancer: Upper endoscopy (including complete visualization of the ampulla of Vater) starting at around age 20-25 years. Consider baseline upper endoscopy earlier, if family history of aggressive duodenal adenoma burden or cancer. Cap-assisted endoscopy may be adequate for visualization of the ampulla. (Kallenberg F, et al. Endoscopy 2017;49:181-185.) There is no clear evidence to support screening for gastric cancer in FAP/AFAP. However, given the increased risk for duodenal cancer in FAP/AFAP, the stomach should be examined at the same time of duodenoscopy. Fundic gland polyps occur in a majority of FAP patients, and focal low-grade dysplasia can occur but is typically non- progressive. The risk of gastric cancer in FAP patients appears to be increased in patients from geographic areas with high gastric cancer risk and may be elevated in the setting of certain endoscopic findings, including carpeting of fundic gland polyps, solitary polyps larger than 20 mm, and mounds of polyps. High-risk histologic features include tubular adenomas, polyps with high-grade dysplasia, and pyloric gland adenomas. Need for specialized surveillance or surgery should be considered in presence of high-risk histologic features, preferably at a center of expertise.Patients with high-risk lesions that cannot be removed endoscopically should be referred to a specialized center for consideration of gastrectomy.Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "If patient had an ileostomy, consider careful visualization and stoma inspection by ileoscopy to evaluate for polyps or malignancy annually; evidence to support this recommendation is limited.

If patient had TPC with ileal pouch-anal anastomosis (IPAA), then endoscopic evaluations of the ileal pouch and rectal cuff annually depending on polyp burden. Surveillance frequency should be shortened to every 6 months for large, flat polyps with villous histology and/or high-grade dysplasia identified.

If patient had colectomy with ileorectal anastomosis, then endoscopic evaluation of the rectum every 6-12 months depending on polyp burden."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "If patient had an ileostomy, consider careful visualization and stoma inspection by ileoscopy to evaluate for polyps or malignancy annually; evidence to support this recommendation is limited.

If patient had TPC with ileal pouch-anal anastomosis (IPAA), then endoscopic evaluations of the ileal pouch and rectal cuff annually depending on polyp burden. Surveillance frequency should be shortened to every 6 months for large, flat polyps with villous histology and/or high-grade dysplasia identified.

If patient had colectomy with ileorectal anastomosis, then endoscopic evaluation of the rectum every 6-12 months depending on polyp burden."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "If patient had an ileostomy, consider careful visualization and stoma inspection by ileoscopy to evaluate for polyps or malignancy annually; evidence to support this recommendation is limited.

If patient had TPC with ileal pouch-anal anastomosis (IPAA), then endoscopic evaluations of the ileal pouch and rectal cuff annually depending on polyp burden. Surveillance frequency should be shortened to every 6 months for large, flat polyps with villous histology and/or high-grade dysplasia identified.

If patient had colectomy with ileorectal anastomosis, then endoscopic evaluation of the rectum every 6-12 months depending on polyp burden."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MUTYH biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "If patient had an ileostomy, consider careful visualization and stoma inspection by ileoscopy to evaluate for polyps or malignancy annually; evidence to support this recommendation is limited.

If patient had TPC with ileal pouch-anal anastomosis (IPAA), then endoscopic evaluations of the ileal pouch and rectal cuff annually depending on polyp burden. Surveillance frequency should be shortened to every 6 months for large, flat polyps with villous histology and/or high-grade dysplasia identified.

If patient had colectomy with ileorectal anastomosis, then endoscopic evaluation of the rectum every 6-12 months depending on polyp burden."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Small Bowel", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "High-level evidence to support routine small bowel screening distal to the duodenum is lacking. However, may consider small bowel visualization (e.g., capsule endoscopy), especially if advanced duodenal polyposis. Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Small Bowel", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "High-level evidence to support routine small bowel screening distal to the duodenum is lacking. However, may consider small bowel visualization (e.g., capsule endoscopy), especially if advanced duodenal polyposis. Other than colon cancer, screening recommendations are expert opinion rather than evidence-based."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "CNS", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Patients should be educated regarding signs and symptoms of neurologic cancer and the importance of prompt reporting of abnormal symptoms to their physicians."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "CNS", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Patients should be educated regarding signs and symptoms of neurologic cancer and the importance of prompt reporting of abnormal symptoms to their physicians."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Colonoscopy (preferred) or flexible sigmoidoscopy every 12 months beginning at age 10-15 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "Colonoscopy (preferred) or flexible sigmoidoscopy every 12 months beginning at age 10-15 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Desmoid", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "FAP is associated with an increased risk for intra-abdominal desmoid tumors, the majority of which present within 5 years of colectomy. Suggestive abdominal symptoms should prompt immediate abdominal imaging. If personal history of symptomatic desmoids, consider imaging with abdominal MRI with and without contrast or CT with contrast no less frequently than annually."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Desmoid", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "FAP is associated with an increased risk for intra-abdominal desmoid tumors, the majority of which present within 5 years of colectomy. Suggestive abdominal symptoms should prompt immediate abdominal imaging. If personal history of symptomatic desmoids, consider imaging with abdominal MRI with and without contrast or CT with contrast no less frequently than annually."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Liver", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "High-level evidence to support routine hepatoblastoma screening is lacking. However, may consider liver palpation, abdominal ultrasound, and measurement of AFP every 3-6 months during the first 5 years of life."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Liver", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "High-level evidence to support routine hepatoblastoma screening is lacking. However, may consider liver palpation, abdominal ultrasound, and measurement of AFP every 3-6 months during the first 5 years of life."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "High-level evidence to support routine pancreatic screening is lacking. However, screening may be individualized based on family history of pancreatic cancer."})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "AXIN2", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Adenomatous Polyps", GeneMasterName: "AXIN2", Gender: "Either", Organ: "Colorectal"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "High-level evidence to support routine pancreatic screening is lacking. However, screening may be individualized based on family history of pancreatic cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Gastrectomy", GuidelineYear: "2021", OriginalAction: "High-risk histologic features include tubular adenomas, polyps with high-grade dysplasia, and pyloric gland adenomas. need for specialized surveillance or surgery should be considered in presence of high-risk histologic features, preferably at a center of expertise. Presence of fundic gland polyps with low-grade dysplasia alone in the absence of high-risk features does not require specialized surveillance. 

Patients with high-risk lesions that cannot be removed endoscopically should be referred to specialized center for consideration of gastrectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Gastrectomy", OriginalAction: "High-risk histologic features include tubular adenomas, polyps with high-grade dysplasia, and pyloric gland adenomas. need for specialized surveillance or surgery should be considered in presence of high-risk histologic features, preferably at a center of expertise. Presence of fundic gland polyps with low-grade dysplasia alone in the absence of high-risk features does not require specialized surveillance. 

Patients with high-risk lesions that cannot be removed endoscopically should be referred to specialized center for consideration of gastrectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Personal Cancer Management", GuidelineYear: "2021", OriginalAction: "If cancer found, see appropriate NCCN Guidelines for Treatment of Cancer by Site"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Personal Cancer Management", GuidelineYear: "2021", OriginalAction: "If cancer found, see appropriate NCCN Guidelines for Treatment of Cancer by Site"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Personal Cancer Management", GuidelineYear: "2021", OriginalAction: "If cancer found, see appropriate NCCN Guidelines for Treatment of Cancer by Site"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-FAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "NSAIDs and aspirin may be as effective for chemoprevention in FAP. Some evidence suggests utility for NSAIDs when used in combination with other agents. Post-Colectomy: Chemoprevention may be considered to facilitate management of the remaining rectum or pouch post-surgery in select patients with progressive polyp burden (e.g., based on size, number, and pathology). There are no FDA-approved medications for this indication at present. While there are data to suggest that sulindac is the most potent polyp regression medication, it is not known if the decrease in polyp burden decreases cancer risk. Patients interested in chemoprevention may consider referral to an expert center and enrollment in a clinical trial."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "NSAIDs and aspirin may be as effective for chemoprevention in FAP. Some evidence suggests utility for NSAIDs when used in combination with other agents. Post-Colectomy: Chemoprevention may be considered to facilitate management of the remaining rectum or pouch post-surgery in select patients with progressive polyp burden (e.g., based on size, number, and pathology). There are no FDA-approved medications for this indication at present. While there are data to suggest that sulindac is the most potent polyp regression medication, it is not known if the decrease in polyp burden decreases cancer risk. Patients interested in chemoprevention may consider referral to an expert center and enrollment in a clinical trial."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "APC-AFAP", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "NSAIDs and aspirin may be as effective for chemoprevention in FAP. Some evidence suggests utility for NSAIDs when used in combination with other agents. Post-Colectomy: Chemoprevention may be considered to facilitate management of the remaining rectum or pouch post-surgery in select patients with progressive polyp burden (e.g., based on size, number, and pathology). There are no FDA-approved medications for this indication at present. While there are data to suggest that sulindac is the most potent polyp regression medication, it is not known if the decrease in polyp burden decreases cancer risk. Patients interested in chemoprevention may consider referral to an expert center and enrollment in a clinical trial."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "General", Gene: "ASXL1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Both", Modality: "Gene Insight", GuidelineYear: "2021", OriginalAction: "Bohring-Opitz Syndrome is a malformation syndrome characterized by severe intrauterine growth retardation, poor feeding, profound mental retardation, trigonocephaly, prominent metopic suture, exophthalmos, nevus flammeus of the face, upslanting palpebral fissures, hirsutism, and flexion of the elbow and wrists with deviation of the wrists and metacarpophalangeal joints."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "Kidney", Gene: "ASXL1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Both", Modality: "Ultrasound", GuidelineYear: "2021", OriginalAction: "The Pediatric Cancer Working Group of the American Association for Cancer Research recommends renal US every 3 months up to age 8 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong. Absolute risk: 15-40%. Management: Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 40 years. Heterozygous ATM mutation should not lead to a recommendation to avoid radiation therapy at this time. Screening and risk-reduction management is extrapolated from BRCA1/2 data based on levels of risk. May be modified based on family history (typically beginning screening 5-10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene pathogenic/likely pathogenic variant. For women with pathogenic/likely pathogenic variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Mastectomy", GuidelineYear: "2021", OriginalAction: "Risk Reduction: Evidence insufficient for RRM, manage based on family history."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "General", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Genotype-Phenotype Correlation", GuidelineYear: "2021", OriginalAction: "A meta-analysis including five studies showed that ATM mutation carriers have a 38% lifetime risk of developing breast cancer, with carriers of the c.7271T>G missense mutation having a 69% risk of developing cancer by 70 years of age.  An analysis from a case-control study (42,671 breast cancer cases and 42,164 controls) showed a significant association between the c.7271T>G variant and breast cancer risk (OR, 11.60; 95% CI, 1.50-89.90; P = .001). An analysis of 27 families in which pathogenic ATM variants were identified showed an association between the c.7271T>G variant and increased risk for breast cancer (HR, 8.0; 95% CI, 2.3-27.4; P < .001)."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong. Absolute risk: <3%. Management: Risk reduction: Evidence insufficient for RRSO; manage based on family history."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Transvaginal ultrasound combined with serum CA-125 for ovarian cancer screening, although of uncertain benefit, may be considered at the clinician-s discretion."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong. Absolute risk: ~5-10%. Management: Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in -1 first- or second-degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. Abe T, et al. J Clin Oncol 2019;37:1070-1080. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Treatment", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Personal Cancer Management", GuidelineYear: "2021", OriginalAction: "Results of the case-control WECARE study suggested that radiation exposure may be associated with increased risk for contralateral breast cancer in women who are carriers of very rare ATM missense variants predicted to be deleterious. However, a meta-analysis including five studies showed that radiation therapy (with conventional dosing) is not contraindicated in patients with a heterozygous ATM mutation. Therefore, radiation therapy does not need to be avoided in these carriers who are diagnosed with cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "ATM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "Strength of Evidence: Not well-established. Risk level for CTC: Uncertain. Heterozygous mutations in ATM may also increase the risk for CRC."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "CHEK2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "RAD51D", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "PALB2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "ATR", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "NBN", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "PMS2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "GEN1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "MSH2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "MSH6", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "RAD51C", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "MRE11A", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "BRIP1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "FAM175A", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "HOXB13", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Male", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Clinical breast exam, every 12 months, starting at age 35 years."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "ATM", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "CHEK2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "RAD51D", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "PALB2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "ATR", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "NBN", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "PMS2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "GEN1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "MSH2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "MSH6", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "RAD51C", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "MRE11A", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "BRIP1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "FAM175A", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "HOXB13", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Breast Screening: Age 25-29 years, annual breast MRI screening with contrast (or mammogram with consideration of tomosynthesis, only if MRI is unavailable) or individualized based on family history if a breast cancer diagnosis before age 30 is present. Age 30-75 years, annual mammogram with consideration of tomosynthesis and breast MRI screening with contrast. Age >75 years, management should be considered on an individual basis. For individuals with a BRCA pathogenic/likely pathogenic variant who are treated for breast cancer and have not had a bilateral mastectomy, screening with annual mammogram with consideration of tomosynthesis and breast MRI should continue as described above. The appropriateness of imaging modalities and scheduling is still under study. Lehman CD, et al. J Natl Cancer Inst 2016;108. Breast MRI is preferred due to the theoretical risk of radiation exposure in pathogenic/likely pathogenic variant carriers. The criteria for high-quality breast MRI include a dedicated breast coil, the ability to perform biopsy under guidance, radiologists experienced in breast MRI, and regional availability. Breast MRI is preferably performed on days 7-15 of a menstrual cycle for premenopausal patients."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "AXIN2", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Surgery Consideration", GuidelineYear: "2021", OriginalAction: "For carriers of AXIN2 mutations, the panel recommends initiation of colonoscopy surveillance at ages 25 to 30 years and if no polyps are detected, to repeat colonoscopy every 2 to 3 years. If polyps are found, colonoscopy surveillance every 1 to 2 years is recommended, with consideration of surgical interventions if the polyp burden becomes unmanageable by colonoscopy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "AXIN2", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Genotype-Phenotype Correlation", GuidelineYear: "2021", OriginalAction: "A report described a family with an inherited AXIN2 mutation (c.1989G>A) segregating in an autosomal dominant pattern with oligodontia and other findings including colonic polyposis, gastric polyps, a mild ectodermal dysplasia phenotype, and early-onset colorectal and breast cancers. A study of 23 families with FAP resulted in the identification of a novel AXIN2 variant (c.1387C>T) in one family with attenuated polyposis. Carriers of the variant had a variable number of polyps, but no oligodontia or ectodermal dysplasia."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "General", Gene: "BAP1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Gene Insight", OriginalAction: "Syndrome: BAP1 tumor predisposition syndrome (TPDS). Histology: clear cell, chromophobe. Inheritance Pattern: Autosomal Dominant. Major Clinical Manifestations: melanoma (uveal and cutaneous), kidney cancer, mesothelioma. Other specialists Involved in Screening: dermatology, ophthalmology, thoracic oncology."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "BAP1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 2 y starting at age 30 y. If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Star P, Goodwin A, Kapoor R, et al. Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy. Eur J Cancer 2018;92:48-53."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "BAP1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "No specific guidelines in surgical management for this syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "BAP1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Female", Modality: "Pregnancy Considerations", GuidelineYear: "2021", OriginalAction: "Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BARD1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Evidence for increased risk: Strong for triple-negative disease. Absolute risk: 15%-40%. Management: Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 40 years. Risk reduction: Evidence insufficient for RRM, manage based on family history. May be modified based on family history (typically beginning screening 5-10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene pathogenic/likely pathogenic variant. For women with pathogenic/likely pathogenic variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "BARD1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "General", OriginalAction: "Evidence of increased risk: No established association."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "BLM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Strength of evidence: Not well-established. Risk level for CRC: uncertain. Possible increased risk for CRC. Available data are insufficient to provide specialized colorectal cancer screening recommendations at this time"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "BMPR1A", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Initiation: 12-15 years. Endoscopy should be initiated at an earlier age or repeated more frequently if signs/symptoms of GI blood loss.  High-quality colonoscopy with polypectomy: If polyps are found, repeat every 2-3 years. Shorter intervals may be indicated based on polyp size, number and pathology. If no polyps, then resume at 18 years. At 18 years, increase colonoscopy frequency to every 1-3 years. 

If polyp burden or polyp-related symptoms (i.e., anemia) cannot be controlled endoscopically or prevent optimal surveillance for cancer considerations should be given to gastrectomy and/or colectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Referral", Gene: "BMPR1A", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "For patients who meet clinical criteria for JPS or with a pathogenic variant in BMPR1A or SMAD4, we recommend referral to a specialized team and encourage participation in any available clinical trials."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Small Bowel", Gene: "BMPR1A", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: Rare, undefined 


No recommendations have been made."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "BMPR1A", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Initiation: 12-15 years.  Upper Endoscopy with polypectomy: If polyps are found, repeat every 2-3 years. Shorter intervals may be indicated based on polyp size, number, and pathology. If no polyps, then resume at 18 years.  at 18 years, resume upper endoscopy every 1-3 years. Intervals should be based on polyp size, number, and pathology. 

If polyp burden or polyp-related symptoms (i.e., anemia) cannot be controlled endoscopically or prevents optimal surveillance for cancer, consideration should be given to gastrectomy and/or colectomy.

BMRP1A carriers may have a less severe upper gastrointestinal tract phenotype and 
may merit lengthened surveillance intervals in the absence of polyps. Latchford A, et al. Dis Colon Rectum 2012;55:1038-1043. Aytac E, et al. Br J Surg 2015;102:114- 118."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Breast Self Examination", OriginalAction: "Breast awareness starting at age 18 years. Women should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent breast self exam (BSE) may facilitate breast self awareness. Premenopausal women may find BSE most informative when performed at the end of menses."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Chemoprevention", OriginalAction: "Consider risk reduction agents as options for breast and ovarian cancer, including discussion of risks and benefits. Case-control studies from the Hereditary Breast Cancer Clinical Study Group reported that the use of tamoxifen protected against contralateral breast cancer with an odds ratio (OR) of 0.38 (95% CI, 0.19-0.74) to 0.50 (95% CI, 0.30-0.85) among BRCA1 mutation carriers and 0.42 (95% CI, 0.17-1.02) to 0.63 (95% CI, 0.20-1.50) among BRCA2 carriers. This translates to an approximately 45% to 60% reduction in risk for contralateral tumors among BRCA1/2 mutation carriers with breast cancer. The data were not consistent in regard to the protective effects of tamoxifen in the subset of BRCA1/2 mutation carriers who also underwent oophorectomy. The aromatase inhibitors (AIs) exemestane and anastrozole have been demonstrated to be effective in preventing breast cancer in postmenopausal women considered to be high risk of developing breast cancer. However, to date, there is little evidence supporting the use of AIs as an effective chemopreventive approach for individuals with a BRCA1/2 pathogenic or likely pathogenic variant. With respect to the evidence regarding the effect of oral contraceptives on cancer risks in women with a known BRCA1/2 pathogenic or likely pathogenic variant, case-control studies have demonstrated that oral contraceptives reduced the risk for ovarian cancer by 45% to 50% in BRCA1 mutation carriers and by 60% in BRCA2 mutation carriers."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Clinical breast exam, every 6-12 months, starting at age 25 years. Randomized trials comparing clinical breast exam versus no screening have not been performed. Rationale for recommending clinical breast exam every 6-12 months is the concern for interval breast cancers."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Risk Reducing Mastectomy", OriginalAction: "Discuss option of risk-reducing mastectomy. Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling. Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Male", GuidelineYear: "2021", Modality: "Breast Self Examination", OriginalAction: "Breast self-exam training and education starting at age 35 years"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Breast Screening: Age 25-29 years, annual breast MRI screening with contrast (or mammogram with consideration of tomosynthesis, only if MRI is unavailable) or individualized based on family history if a breast cancer diagnosis before age 30 is present. Age 30-75 years, annual mammogram with consideration of tomosynthesis and breast MRI screening with contrast. Age >75 years, management should be considered on an individual basis. For individuals with a BRCA pathogenic/likely pathogenic variant who are treated for breast cancer and have not had a bilateral mastectomy, screening with annual mammogram with consideration of tomosynthesis and breast MRI should continue as described above. The appropriateness of imaging modalities and scheduling is still under study. Lehman CD, et al. J Natl Cancer Inst 2016;108. Breast MRI is preferred due to the theoretical risk of radiation exposure in pathogenic/likely pathogenic variant carriers. The criteria for high-quality breast MRI include a dedicated breast coil, the ability to perform biopsy under guidance, radiologists experienced in breast MRI, and regional availability. Breast MRI is preferably performed on days 7-15 of a menstrual cycle for premenopausal patients."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Male", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Consider annual mammogram screening in men with gynecomastia starting at age 50 or 10 years before the earliest known male breast cancer in the family (whichever comes first).There are only limited data to support screening for breast cancer in men. Gao Y, et al Radiology 2019;293:282-291."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Breast Self Examination", OriginalAction: "Breast awareness starting at age 18 years. Women should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent breast self exam (BSE) may facilitate breast self awareness. Premenopausal women may find BSE most informative when performed at the end of menses."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Recommend risk-reducing Salpingo-oophorectomy (RRSO), typically between 35 and 40 years, and upon completion of childbearing. Counseling includes a discussion of reproductive desires, extent of cancer risk, degree of protection for breast and ovarian cancer, management of menopausal symptoms, hormone replacement therapy, and related medical issues. Address psychosocial and quality-of-life aspects of undergoing Salpingo-oophorectomy. Salpingectomy alone is not the standard of care for risk reduction, although clinical trials of interval salpingectomy and delayed oophorectomy are ongoing. The concern for risk-reducing salpingectomy alone is that women are still at risk for developing ovarian cancer. In addition, in premenopausal women, oophorectomy likely reduces the risk of developing breast cancer but the magnitude is uncertain and may be gene-specific."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Chemoprevention", OriginalAction: "Consider risk reduction agents as options for breast and ovarian cancer, including discussion of risks and benefits. Case-control studies from the Hereditary Breast Cancer Clinical Study Group reported that the use of tamoxifen protected against contralateral breast cancer with an odds ratio (OR) of 0.38 (95% CI, 0.19-0.74) to 0.50 (95% CI, 0.30-0.85) among BRCA1 mutation carriers and 0.42 (95% CI, 0.17-1.02) to 0.63 (95% CI, 0.20-1.50) among BRCA2 carriers. This translates to an approximately 45% to 60% reduction in risk for contralateral tumors among BRCA1/2 mutation carriers with breast cancer. The data were not consistent in regard to the protective effects of tamoxifen in the subset of BRCA1/2 mutation carriers who also underwent oophorectomy. The aromatase inhibitors (AIs) exemestane and anastrozole have been demonstrated to be effective in preventing breast cancer in postmenopausal women considered to be high risk of developing breast cancer. However, to date, there is little evidence supporting the use of AIs as an effective chemopreventive approach for individuals with a BRCA1/2 pathogenic or likely pathogenic variant. With respect to the evidence regarding the effect of oral contraceptives on cancer risks in women with a known BRCA1/2 pathogenic or likely pathogenic variant, case-control studies have demonstrated that oral contraceptives reduced the risk for ovarian cancer by 45% to 50% in BRCA1 mutation carriers and by 60% in BRCA2 mutation carriers."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "For those patients who have not elected RRSO, transvaginal ultrasound combined with serum CA-125 for ovarian cancer screening, although of uncertain benefit, may be considered at the clinician-s discretion starting at age 30-35 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Clinical breast exam, every 6-12 months, starting at age 25 years. Randomized trials comparing clinical breast exam versus no screening have not been performed. Rationale for recommending clinical breast exam every 6-12 months is the concern for interval breast cancers."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in -1 first- or second-degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. Abe T, et al. J Clin Oncol 2019;37:1070-1080. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Risk Reducing Mastectomy", OriginalAction: "Discuss option of risk-reducing mastectomy. Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling. Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Referral", OriginalAction: "If there is a known or suspected cancer susceptibility gene, referral to a cancer genetics professional is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Male", GuidelineYear: "2021", Modality: "Breast Self Examination", OriginalAction: "Breast self-exam training and education starting at age 35 years"})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Men with these inherited syndromes may have an increased risk for prostate cancer: BRCA2, ATM, CHEK2, BRCA1, RAD51D, PALB2, ATR, NBN, PMS2, GEN1, MSH2, MSH6, RAD51C, MRE11A, BRIP1, or RAM175A. Mutations carriers have an increased risk of prostate cancer before age 65 years, and prostate cancer in men with germline BRCA2 or HOXB13 mutations occurs earlier and is more likely to be associated with prostate cancer mortality. For men with BRCA1, ATM, or mismatch repair (MLH1, MSH2, MSH6, PMS2) germline gene mutations timing of testing is less clear. Consequently, prostate cancer screening is recommended at age 40 years for BRCA2 carriers, and it is reasonable for men with other germline mutations to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. In addition, the panel believes that men with a family history of prostate cancer (defined as brother or father or multiple family members who were diagnosed with prostate cancer [but not clinically localized Grade Group 1] at <60 years of age or who died from prostate cancer) should begin shared decision-making about PSA screening at the age corresponding to 10 years prior to the age of the youngest family diagnosis. Men of African American ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45.Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Male", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Consider annual mammogram screening in men with gynecomastia starting at age 50 or 10 years before the earliest known male breast cancer in the family (whichever comes first).There are only limited data to support screening for breast cancer in men. Gao Y, et al Radiology 2019;293:282-291."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Genetic Testing", OriginalAction: "For individuals of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies. There are rare reports of compound heterozygous or homozygous BRCA1 mutations causing Fanconi anemia complementation group S (FANCS). FANCS is characterized by developmental delay apparent from infancy, short stature, microcephaly, and coarse dysmorphic features. It is associated with defective DNA repair and increased chromosomal breakage."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "For those patients who have not elected RRSO, transvaginal ultrasound combined with serum CA-125 for ovarian cancer screening, although of uncertain benefit, may be considered at the clinician-s discretion starting at age 30-35 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Skin", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "No specific screening guidelines exist for melanoma, but general melanoma risk management is appropriate, such as annual full-body skin examination and minimizing UV exposure."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in -1 first- or second-degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. Abe T, et al. J Clin Oncol 2019;37:1070-1080. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Uterine", Gene: "BRCA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Hysterectomy", GuidelineYear: "2021", OriginalAction: "Limited data suggest that there may be a slightly increased risk of serous uterine cancer among individuals with a BRCA1 pathogenic/likely pathogenic variant. The clinical significance of these findings is unclear. Further evaluation of the risk of serous uterine cancer in the BRCA population needs to be undertaken. The provider and patient should discuss the risks and benefits of concurrent hysterectomy at the time of RRSO for women with a BRCA1 pathogenic/likely pathogenic variant prior to surgery. Women who undergo hysterectomy at the time of RRSO are candidates for estrogen alone hormone replacement therapy, which is associated with a decreased risk of breast cancer compared to combined estrogen and progesterone, which is required when the uterus is left in situ (Chlebowski R, et al. JAMA Oncol 2015;1:296-305)."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Skin", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "No specific screening guidelines exist for melanoma, but general melanoma risk management is appropriate, such as annual full-body skin examination and minimizing UV exposure."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Male", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Clinical breast exam, every 12 months, starting at age 35 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "General", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Cascade Testing", OriginalAction: "Advise patient to advise at-risk relatives to consider testing."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Recommend risk-reducing Salpingo-oophorectomy (RRSO). Because ovarian cancer onset in patients with BRCA2 pathogenic/likely pathogenic variants is an average of 8-10 years later than in patients with BRCA1 pathogenic/likely pathogenic variants, it is reasonable to delay RRSO for management of ovarian cancer risk until age 40-45 years in patients with BRCA2 pathogenic/likely pathogenic variants unless age at diagnosis in the family warrants earlier age for consideration of prophylactic surgery. Counseling includes a discussion of reproductive desires, extent of cancer risk, degree of protection for breast and ovarian cancer, management of menopausal symptoms, hormone replacement therapy, and related medical issues. Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy and/or Salpingo-oophorectomy. Salpingectomy alone is not the standard of care for risk reduction, although clinical trials of interval salpingectomy and delayed oophorectomy are ongoing. The concern for risk-reducing salpingectomy alone is that women are still at risk for developing ovarian cancer. In addition, in premenopausal women, oophorectomy likely reduces the risk of developing breast cancer but the magnitude is uncertain and may be gene-specific. Given the high rate of occult neoplasms, special attention should be given to sampling and pathologic review of the ovaries and fallopian tubes."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "BRCA2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Genetic Testing", OriginalAction: "For individuals of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies. Fanconi anemia is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life. Biallelic pathogenic variants in BRCA2 are associated with early-onset acute leukemia and solid tumors with a cumulative probability of any malignancy of 97% by age 6 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "BRIP1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Evidence for increased risk: Limited; potential increase in female breast cancer (including triple negative). Absolute risk: Insufficient data to define. Management: Insufficient data; managed based on family history."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "BRIP1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong. Absolute risk: >10%. Management: Risk reduction: Consider RRSO at 45-50 years. Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of pathogenic/likely pathogenic variants in BRIP1 appears to be sufficient to justify consideration of risk-reducing Salpingo- oophorectomy. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45-50 years or earlier based on a specific family history of an earlier onset of ovarian cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "BRIP1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Genetic Testing", OriginalAction: "Counsel for risk of autosomal recessive condition in offspring. Fanconi anemia is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "CASR", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "For individuals with pathogenic/likely pathogenic variants in PRSS1 or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis: Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier. The panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in PRSS1, SPINK1, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the panel recommends germline testing for PRSS1, SPINK1, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention. Abe T, et al. J Clin Oncol 2019;37:1070-1080."})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Teeth (Benign)", PredominantCancerSubtype: "Oligodontia", GeneMasterName: "AXIN2", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Meningioma", GeneMasterName: "BAP1", Gender: "Either", Organ: "Brain"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "CFTR", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "For individuals with pathogenic/likely pathogenic variants in PRSS1 or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis: Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier. The panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in PRSS1, SPINK1, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the panel recommends germline testing for PRSS1, SPINK1, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention. Abe T, et al. J Clin Oncol 2019;37:1070-1080."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "CPA1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "For individuals with pathogenic/likely pathogenic variants in PRSS1 or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis: Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier. The panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in PRSS1, SPINK1, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the panel recommends germline testing for PRSS1, SPINK1, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention. Abe T, et al. J Clin Oncol 2019;37:1070-1080."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "CTCR", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "For individuals with pathogenic/likely pathogenic variants in PRSS1 or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis: Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier. The panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in PRSS1, SPINK1, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the panel recommends germline testing for PRSS1, SPINK1, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention. Abe T, et al. J Clin Oncol 2019;37:1070-1080."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "PRSS1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "For individuals with pathogenic/likely pathogenic variants in PRSS1 or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis: Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier. The panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in PRSS1, SPINK1, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the panel recommends germline testing for PRSS1, SPINK1, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention. Abe T, et al. J Clin Oncol 2019;37:1070-1080."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "SPINK1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "For individuals with pathogenic/likely pathogenic variants in PRSS1 or other hereditary pancreatitis genes AND a clinical phenotype consistent with hereditary pancreatitis: Consider pancreatic cancer screening 20 years after onset of pancreatitis, or at age 40 years, whichever is earlier. The panel recognizes that patients with hereditary pancreatitis (sometimes caused by pathogenic germline variants in PRSS1, SPINK1, and other genes) have increased lifetime risks of pancreatic cancer. The clinical significance of pathogenic germline variants in these genes is unclear, when such variants are identified in individuals lacking a clinical history of pancreatitis. As such, the panel recommends germline testing for PRSS1, SPINK1, and other pancreatitis genes in individuals with a personal and/or family history of exocrine pancreatic cancer only if there is a personal and/or family history suggestive of hereditary pancreatitis. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention. Abe T, et al. J Clin Oncol 2019;37:1070-1080."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "CDH1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong (with predisposition to lobular disease). Absolute risk: 41-60%. Management: Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 30 years. Screening and risk-reduction management is extrapolated from BRCA1/2 data based on levels of risk. May be modified based on family history (typically beginning screening 5-10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene pathogenic/likely pathogenic variant. For women with pathogenic/likely pathogenic variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "CDH1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Mastectomy", GuidelineYear: "2021", OriginalAction: "Discuss option of risk-reducing mastectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "CDH1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "Cleft lip with or without cleft palate has been associated with CDH1 pathogenic/likely pathogenic variants (Frebourg T, et al. J Med Genet 2006;43:138-142)."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "CDH1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Evidence of increased risk: No established association."})
(:NCCN_GUIDELINES {GuidelineName: "Gastric", OrganSystem: "Stomach", Gene: "CDH1", GuidelineVersion: "4.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Risk Reducing Surgery", GuidelineYear: "2021", OriginalAction: "There is controversy over how to manage gastric cancer risk in individuals with pathogenic/likely pathogenic variants in CDH1 in the absence of a family history of gastric cancer. However, one small study found that >50% of such individuals had gastric cancer identified at the time of risk-reducing total gastrectomy (Jacobs MF, et al. Gastroenterology 2019;157:87-96). The lifetime risk for gastric cancer by age 80 is estimated to be at 67% for men and 83% for women. Average age at diagnosis of gastric cancer is 37 years. Prophylactic total gastrectomy is recommended between ages 18 years and 40 years for CDH1 mutation carriers. A baseline endoscopy is indicated prior to prophylactic total gastrectomy. Intraoperative frozen sections should be performed to verify that the proximal margin contains esophageal squamous mucosa and the distal margin contains duodenal mucosa, to ensure complete removal of gastric tissue. A D2 lymph node dissection is not necessary for prophylactic total gastrectomy. Prophylactic gastrectomy prior to 18 years of age is not recommended, but may be considered for certain patients, especially those with family members diagnosed with gastric cancer before 25 years of age. CDH1 mutation carriers, who elect not to undergo prophylactic gastrectomy, should be offered screening every 6-12 months by upper endoscopy with multiple random biopsies."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, and Pancreatic", OrganSystem: "Breast", Gene: "CDKN2A", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Evidence of increased risk: No established association."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, and Pancreatic", OrganSystem: "Ovary", Gene: "CDKN2A", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Evidence of increased risk: No established association."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "CDKN2A", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Evidence for increased risk: Very strong. 
Absolute risk >15%
Management: Consider pancreatic cancer screening beginning at age 40 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier). For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Skin", Gene: "CDKN2A", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Strength of Evidence: Strong. Absolute risk: 28-76% depending on other risk factors, including family history, geographic location, and other genetic modifiers. General melanoma risk management is appropriate, such as annual full-body skin examination and minimizing UV exposure."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "CHEK2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Evidence for increased risk: Strong (with predisposition to ER+ disease).Absolute risk: 15%-40%. Management: Screening: Annual mammogram with consideration of tomosynthesis and consider breast MRI with contrast starting at age 40 years. Risk reduction: Evidence insufficient for RRM, manage based on family history. Screening and risk-reduction management is extrapolated from BRCA1/2 data based on levels of risk. May be modified based on family history (typically beginning screening 5-10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene pathogenic/likely pathogenic variant. For women with pathogenic/likely pathogenic variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described. Note: Risk data are based only on frameshift pathogenic/likely pathogenic variants. The risks for most missense variants are unclear but for some pathogenic/likely pathogenic variants, such as IIe157Thr, the risk for breast cancer appears to be lower. Management should be based on best estimates of cancer risk for the specific pathogenic/likely pathogenic variant."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "CHEK2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Evidence of increased risk: No established association."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "CHEK2", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "For probands with CRC and a CHEK2 pathogenic variant: See surveillance recommendations for post-CRC resection: NCCN Guidelines for Colon Cancer and NCCN Guidelines for Rectal Cancer

For probands with a CHEK2 pathogenic variant who are unaffected by CRC and with a first-degree relative with CRC: Colonoscopy screening every 5 y, beginning at age 40 or 10 y prior to age of first-degree relative age at CRC diagnosis.

For probands with a CHEK2 pathogenic variant who are unaffected by CRC and no first-degree relative with CRC: Colonoscopy screening every 5 y, beginning at age 40.
Heterogeneity in CRC risk may exist based on type of pathogenic CHEK2 variant (Han F, Guo C, Liu L. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol 2013;32:329-335; Liu C, Wang Q, Wang Y. The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis. Asian Pac J Cancer Prev 2012;13:2051-2055; Xiang H, Geng X, Ge W, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer 2011;47:2546-2551); some patients may elect for less aggressive screening based on shared decision-making. One model has suggested that earlier screening than the average risk initiation may be justified for CHEK2 1100delC and I157T carriers based on reaching same risk for CRC at an earlier age than observed among average-risk persons initiating screening at age 50 (Katona B, Yurgelun M, Garber J, et al. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 2018;20:1324-1327.).The panel recognizes that data to support the surveillance recommendations for these particular genes are evolving at this time. Caution should be used when implementing final colonoscopy surveillance regimens in context of patient preferences and new knowledge that may emerge."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "General", Gene: "DIS3L2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Both", Modality: "Gene Insight", GuidelineYear: "2021", OriginalAction: "Affected children are large at birth, are hypotonic, and show organomegaly, characteristic facial dysmorphisms (inverted V-shaped upper lip, prominent forehead, deep-set eyes, broad and flat nasal bridge, and low-set ears), renal anomalies (nephromegaly and hydronephrosis), frequent neurodevelopmental delay, and high neonatal mortality."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "Kidney", Gene: "DIS3L2", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Both", Modality: "Ultrasound", GuidelineYear: "2021", OriginalAction: "The Pediatric Cancer Working Group of the American Association for Cancer Research recommends renal US every 3 months up to age 8 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "High-quality colonoscopy at age 20-25 years or 2-5 years prior to the earliest colon cancer if it is diagnosed before age 25 years and repeat every 1-2 years. Patients who may benefit from a shorter 1-year versus longer 2-year interval include those with risk factors such as history of CRC, male sex, MLH1/MSH2 pathogenic variant, age >40 years, and history of adenoma. The panel recognizes that there are limited population-based studies on the lifetime risk for most of the cancers related to each of these genes. Although there are some pathogenic variant-specific data available, a generalized screening approach is suggested for many surveillance strategies. Screening and the option of risk-reducing surgeries should be individualized after risk assessment and counseling."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Skin", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Dermatologic Exam", GuidelineYear: "2021", OriginalAction: "Frequency of malignant and benign skin tumors such as sebaceous adenocarcinomas, sebaceous adenomas, and keratoacanthomas has been reported to be increased among patients with Lynch syndrome, but cumulative lifetime risk and median age of presentation are uncertain. Consider skin exam every 1-2 years with a health care provider skilled in identifying Lynch syndrome-associated skin manifestations. Age to start surveillance is uncertain and can be individualized."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Advise patients to tell relatives about possible inherited cancer risk, options for risk assessment and management. Recommend genetic counseling and considerations of genetic testing for at-risk relatives."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in >1 first-or second- degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of benign or indeterminate pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. The panel recommends that screening be considered using annual contrast-enhancing MRI/MRCP and/or EUS, with considerations of shorter screening intervals for individuals found to have potentially concerning abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in >1 first-or second- degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of benign or indeterminate pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. The panel recommends that screening be considered using annual contrast-enhancing MRI/MRCP and/or EUS, with considerations of shorter screening intervals for individuals found to have potentially concerning abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in >1 first-or second- degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of benign or indeterminate pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. The panel recommends that screening be considered using annual contrast-enhancing MRI/MRCP and/or EUS, with considerations of shorter screening intervals for individuals found to have potentially concerning abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in >1 first-or second- degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of benign or indeterminate pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. The panel recommends that screening be considered using annual contrast-enhancing MRI/MRCP and/or EUS, with considerations of shorter screening intervals for individuals found to have potentially concerning abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, and Pancreatic", OrganSystem: "Breast", Gene: "FANCC", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Lower penetrance genes that may be included as part of multi gene testing but for which there is currently insufficient evidence of an association with breast and/or ovarian cancer include: FANCC, MRE11A, MUTYH heterozygotes, RECQL4, RAD50, RINT1, SLX4, SMARCA4, and XRCC2. Risk management recommendations for these genes should take into account family history and other clinical factors."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "FANCC", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "MRE11A", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "MUTYH heterozygotes", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "RECQL4", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "RAD50", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "RINT1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "SLX4", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "SMARCA4", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "XRCC2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "MUTYH biallelic", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "The following genes and others are found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for:
FANCC, MRE11A, MUTYH heterozygotes, RAD50, RECQL, RINT1, SLX4, SMARCA4, or XRCC2."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FH", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast annually starting at age 8-10 if there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Menko F, Maher E, Schmidt L, et al. Hereditary Leiomyomatosis and renal cell cancer (HLRCC): Renal cancer risk, surveillance and treatment. Fam Cancer 2014;13:637-644."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FH", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Gene insight", OriginalAction: "Syndrome: Hereditary Leiomyomatosis and renal cell carcinoma (HLRCC).

Histology: FLRCC or FH-associated RCC; type 2 papillary

Inheritance Pattern: Autosomal Dominant

Major Clinical Manifestations: Leiomyomas of skin and uterus, unilateral, solitary, and aggressive renal cell tumors. PET-positive adrenal adenomas

Other specialists Involved in Screening: gynecology, dermatology"})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FH", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "As these tumors can be aggressive, surveillance of renal tumors it not recommended, and total radical nephrectomy should be considered. Menko FH, Maher ER, Schmidt LS, et al. Hereditary Leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer 2014;13:6376-44."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FH", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Therapy", OriginalAction: "There are no specific FDA-approved therapies for HLRCC. Treatment with erlotinib plus bevacizumab demonstrated benefit in patients with metastatic RCC from HLRCC. An FDA-approved biosimilar is an appropriate substitution for bevacizumab. Srinivasan R, Su D, Stamatakis L, et al. Mechanism based targeted therapy for hereditary Leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib [abstract]. Eur J Cancer 2014; Abstract 50."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "General", Gene: "FLCN", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Gene Insight", OriginalAction: "Syndrome: Birt-Hogg-Dube Syndrome (BHDS). Histology: chromophobe, hybrid oncocytoma. Inheritance Pattern: Autosomal Dominant. Major Clinical Manifestations: Cutaneous fibrofolliculoma or trichodiscoma, pulmonary cysts, and spontaneous pneumothorax. Other specialists Involved in Screening: pulmonology, dermatology."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FLCN", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 3 y starting at age 20 y. If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Menko F, van Steensel M, Giraud S, et al. Birt-Hogg-Dube syndrome: Diagnosis and management. Lancet Oncol 2009;10:1199-1206."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FLCN", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Nephron-sparing surgery is the treatment of choice for renal tumors whenever possible, with consideration that an individual may have multiple tumors during their lifetime. Ablative treatment options may be considered for those with significant medical or surgical risk to undergo an operation. Pavlovich CP, Grubb RL 3rd, Hurley K, et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 2005;173:1482-1486."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "GALNT12", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Colonoscopy", GuidelineYear: "2021", OriginalAction: "Available data are insufficient to provide specialized colorectal cancer screening recommendations at this time."})
(:NCCN_GUIDELINES {GuidelineName: "Myelodysplastic Syndromes", OrganSystem: "General", Gene: "GATA2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Gene Insight", GuidelineYear: "2021", OriginalAction: "Bone marrow failure; B-/NK-/CD4-cell lymphocytopenia, monocytopenia/AML/MDS(highly penetrant). Other features: immune deficiency (viral infections, warts, disseminated nontuberculous mycobacterial infections), wide range of extra-hematopoietic manifestations (e.g., lymphedema, sensorineural hearing loss, pulmonary alveolar proteinosis)."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "GREM1", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Begin colonoscopy at age 25-30 years and every 2-3 years if negative. If polyps are found, colonoscopy every 1-2 years with consideration of surgery if the polyp burden becomes unmanageable by colonoscopy. Surgical evaluation if appropriate. The panel recognizes that data to support the surveillance recommendations for these particular genes are evolving at this time. Caution should be used when implementing final colonoscopy surveillance regimens in context of patient preferences and new knowledge that may emerge."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "General", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Gene Insight", GuidelineYear: "2021", OriginalAction: "MAX patients are primarily at risk for adrenal tumors. Therefore, consideration can be given to more targeted imaging."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "General", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Parent of Origin Effect", GuidelineYear: "2021", OriginalAction: "MAX patients are most at risk if the pathogenic variant was paternally inherited. Recommend following the screening recommendations if the parent of origin is unknown. Consider screening for patients with maternally inherited variants as case reports of tumor occurrence exist."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "General", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Genetic counseling and MEN1 genetic testing should be offered to individuals with a clinical diagnosis of MEN1 and to at-risk relatives of individuals with known germline MEN1 mutations."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Lung", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Consider chest CT or MRI with contrast every 1-3 y. For prolonged surveillance, studies without radiation are preferred. Bronchial NETs occur more frequently in women, while thymic NETs occur more frequently in men. In addition, smokers appear to be at increased risk for the development of thymic NETs."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Pancreas", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Follow previously elevated serum hormones as symptoms indicate."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Pancreas", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Screening for Pancreatic Neuroendocrine Tumors (NETs). Follow previously elevated serum hormones or as symptoms indicate. Consider abdominal/pelvic CT or MRI with contrast every 1-3 years. Consider serial EUS. For prolonged surveillance, studies without radiation are preferred."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Pancreas", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2020", OriginalAction: "In general, surgical management of patients with MEN1 is similar to those with sporadic tumors. However, one notable exception is the multi-focality of pancreaticoduodenal NETs in patients with MEN1. The role of surgery remains controversial in patients with multifocal tumors. Decision to resect a pancreatic or duodenal NET in the setting of multifocal disease is complex. If surgery is performed to resect hormonally functional tumor(s), attempts should be made to preoperatively localize the site of the functional tumor. Surgical resection can be considered in the following scenarios: symptomatic functional tumors refractory to medical management, tumor larger than 2 cm in size, Tumor with relatively rapid rate of growth over 6-12 months. Endoscopy with EUS is recommended prior to pancreatic surgery in order to preoperatively assess the localized tumors. MEN1-associated metastatic PanNETs are often slower growing than metastatic sporadic tumors. Observation can be considered for non-functioning indolent tumors. Yates CJ, Newey PJ, Thakker RV. Challenges and controversies in management of pancreatic neuroendocrine tumors in patients with MEN1. Lancet Diabetes Endocrinol 2015;3:895-905.Frost M, Lines KE, Thakker RV. Current and emerging therapies for PNETs in patients with or without MEN1. Nat Rev Endocrinol 2018;14(4):216-227."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Parathyroid", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Measure serum calcium levels annually. If calcium elevated, measure PTH and 25-OH vitamin D levels and obtain imaging via neck ultrasound, parathyroid sestamibi with SPECT scan, or 4D-CT. Preference of scan will depend on institutional practice/protocol. Sestamibi may not be as sensitive since often the patient has hyperplasia. For prolonged surveillance, studies without radiation are preferred."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Pituitary", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Prolactin, IGF-1, and other previously abnormal pituitary hormones every 3-5 y or as symptoms indicate."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Pituitary", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Pituitary or sella MRI with contrast of pituitary every 3-5 y"})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Referral", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Referral", GuidelineYear: "2020", OriginalAction: "A consultation with an endocrinologist for all patients with MEN1 should be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Thymus", Gene: "MEN1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Consider chest CT or MRI with contrast every 1-3 y. For prolonged surveillance, studies without radiation are preferred. Bronchial NETs occur more frequently in women, while thymic NETs occur more frequently in men. In addition, smokers appear to be at increased risk for the development of thymic NETs."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "General", Gene: "MET", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Gene Insight", OriginalAction: "Syndrome: Hereditary papillary renal carcinoma (HPRC). Histology: Type 1 papillary. Inheritance Pattern: Autosomal Dominant. Major Clinical Manifestations: Multifocal, bilateral renal cell tumors. Other specialists Involved in Screening: Nephrology"})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "MET", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 1-2 y starting at age 30 y. If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Ornstein DK, Lubensky IA, Venzon D, et al. Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol 2000;163:431-433.Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23:e68-e75."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "MET", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Nephron-sparing surgery is the treatment of choice for renal tumors whenever possible, with consideration that an individual may have multiple tumors during their lifetime. Ablative treatment options may be considered for those with significant medical or surgical risk to undergo an operation."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Advise patients to tell relatives about possible inherited cancer risk, options for risk assessment and management. Recommend genetic counseling and consideration of genetic testing for at-risk relatives."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Skin", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Dermatologic Exam", GuidelineYear: "2021", OriginalAction: "Frequency of malignant and benign skin tumors such as sebaceous adenocarcinomas, sebaceous adenomas, and keratoacanthomas has been reported to be increased among patients with Lynch syndrome, but cumulative lifetime risk and median age of presentation are uncertain. Consider skin exam every 1-2 years with a health care provider skilled in identifying Lynch syndrome-associated skin manifestations. Age to start surveillance is uncertain and can be individualized."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "High-quality colonoscopy at age 20-25 years or 2-5 years prior to the earliest colon cancer if it is diagnosed before age 25 years and repeat every 1-2 years.  Patients who may benefit from a shorter 1-year versus longer 2-year interval include those with risk factors such as history of CRC, male sex, MLH1/MSH2 pathogenic variant, age >40 years, and history of adenoma. The panel recognizes that there are limited population-based studies on the lifetime risk for most of the cancers related to each of these genes. Although there are some pathogenic variant-specific data available, a generalized screening approach is suggested for many surveillance strategies. Screening and the option of risk-reducing surgeries should be individualized after risk assessment and counseling."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "High-quality colonoscopy at age 20-25 years or 2-5 years prior to the earliest colon cancer if it is diagnosed before age 25 years and repeat every 1-2 years.  Patients who may benefit from a shorter 1-year versus longer 2-year interval include those with risk factors such as history of CRC, male sex, MLH1/MSH2 pathogenic variant, age >40 years, and history of adenoma. The panel recognizes that there are limited population-based studies on the lifetime risk for most of the cancers related to each of these genes. Although there are some pathogenic variant-specific data available, a generalized screening approach is suggested for many surveillance strategies. Screening and the option of risk-reducing surgeries should be individualized after risk assessment and counseling."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Bilateral Salpingo-oophorectomy (BSO) may reduce the incidence of ovarian cancer. The decision to have a BSO as a risk-reducing option should be individualized. Timing of BSO should be individualized based on whether childbearing is complete, menopause status, comorbidities, family history, and LS gene, as risks for ovarian cancer vary by pathogenic variant. Estrogen replacement after premenopausal oophorectomy may be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Bilateral Salpingo-oophorectomy (BSO) may reduce the incidence of ovarian cancer. The decision to have a BSO as a risk-reducing option should be individualized. Timing of BSO should be individualized based on whether childbearing is complete, menopause status, comorbidities, family history, and LS gene, as risks for ovarian cancer vary by pathogenic variant. Estrogen replacement after premenopausal oophorectomy may be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Bilateral Salpingo-oophorectomy (BSO) may reduce the incidence of ovarian cancer. The decision to have a BSO as a risk-reducing option should be individualized. Timing of BSO should be individualized based on whether childbearing is complete, menopause status, comorbidities, family history, and LS gene, as risks for ovarian cancer vary by pathogenic variant. Estrogen replacement after premenopausal oophorectomy may be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "CNS", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Patients should be educated regarding signs and symptoms of neurologic cancer and the importance of prompt reporting of abnormal symptoms to their physicians."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "CNS", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Patients should be educated regarding signs and symptoms of neurologic cancer and the importance of prompt reporting of abnormal symptoms to their physicians."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "CNS", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Patients should be educated regarding signs and symptoms of neurologic cancer and the importance of prompt reporting of abnormal symptoms to their physicians."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "CNS", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Patients should be educated regarding signs and symptoms of neurologic cancer and the importance of prompt reporting of abnormal symptoms to their physicians."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "CNS", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Examination", OriginalAction: "Patients should be educated regarding signs and symptoms of neurologic cancer and the importance of prompt reporting of abnormal symptoms to their physicians."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Breast", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "There have been suggestions that there is an increased risk for breast cancer in LS patients; however, there is not enough evidence to support increased screening above average-risk breast cancer screening recommendations or those based on personal/family history of breast cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Breast", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "There have been suggestions that there is an increased risk for breast cancer in LS patients; however, there is not enough evidence to support increased screening above average-risk breast cancer screening recommendations or those based on personal/family history of breast cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Breast", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "There have been suggestions that there is an increased risk for breast cancer in LS patients; however, there is not enough evidence to support increased screening above average-risk breast cancer screening recommendations or those based on personal/family history of breast cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Breast", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "There have been suggestions that there is an increased risk for breast cancer in LS patients; however, there is not enough evidence to support increased screening above average-risk breast cancer screening recommendations or those based on personal/family history of breast cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Breast", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "There have been suggestions that there is an increased risk for breast cancer in LS patients; however, there is not enough evidence to support increased screening above average-risk breast cancer screening recommendations or those based on personal/family history of breast cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "The panel recommends that all individuals with LS who have a future colorectal cancer (i.e., excluding those with prior total proctocolectomy) consider using daily aspirin to reduce their future risk of colorectal cancer. The decision to use aspirin for reduction of colorectal cancer risk in LS and the dose chosen should be made on an individual basis, including discussion of individual risks, benefits, adverse effects, and childbearing plans. In determining whether an individual with LS should take aspirin and in deciding on the appropriate dosing, the panel recommends that providers carefully review patient-specific factors that may increase the risk of aspirin therapy - including, but not limited to increased age, prior allergy, concurrent use of antiplatelets/anticoagulants, and untreated H. pylori or unconfirmed H. pylori eradication - as well as patient-specific factors that indicate a comparably low future cumulative risk of colorectal cancer and who may thus be less likely to experience significant benefit."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "The panel recommends that all individuals with LS who have a future colorectal cancer (i.e., excluding those with prior total proctocolectomy) consider using daily aspirin to reduce their future risk of colorectal cancer. The decision to use aspirin for reduction of colorectal cancer risk in LS and the dose chosen should be made on an individual basis, including discussion of individual risks, benefits, adverse effects, and childbearing plans. In determining whether an individual with LS should take aspirin and in deciding on the appropriate dosing, the panel recommends that providers carefully review patient-specific factors that may increase the risk of aspirin therapy - including, but not limited to increased age, prior allergy, concurrent use of antiplatelets/anticoagulants, and untreated H. pylori or unconfirmed H. pylori eradication - as well as patient-specific factors that indicate a comparably low future cumulative risk of colorectal cancer and who may thus be less likely to experience significant benefit."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "The panel recommends that all individuals with LS who have a future colorectal cancer (i.e., excluding those with prior total proctocolectomy) consider using daily aspirin to reduce their future risk of colorectal cancer. The decision to use aspirin for reduction of colorectal cancer risk in LS and the dose chosen should be made on an individual basis, including discussion of individual risks, benefits, adverse effects, and childbearing plans. In determining whether an individual with LS should take aspirin and in deciding on the appropriate dosing, the panel recommends that providers carefully review patient-specific factors that may increase the risk of aspirin therapy - including, but not limited to increased age, prior allergy, concurrent use of antiplatelets/anticoagulants, and untreated H. pylori or unconfirmed H. pylori eradication - as well as patient-specific factors that indicate a comparably low future cumulative risk of colorectal cancer and who may thus be less likely to experience significant benefit."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "The panel recommends that all individuals with LS who have a future colorectal cancer (i.e., excluding those with prior total proctocolectomy) consider using daily aspirin to reduce their future risk of colorectal cancer. The decision to use aspirin for reduction of colorectal cancer risk in LS and the dose chosen should be made on an individual basis, including discussion of individual risks, benefits, adverse effects, and childbearing plans. In determining whether an individual with LS should take aspirin and in deciding on the appropriate dosing, the panel recommends that providers carefully review patient-specific factors that may increase the risk of aspirin therapy - including, but not limited to increased age, prior allergy, concurrent use of antiplatelets/anticoagulants, and untreated H. pylori or unconfirmed H. pylori eradication - as well as patient-specific factors that indicate a comparably low future cumulative risk of colorectal cancer and who may thus be less likely to experience significant benefit."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "The panel recommends that all individuals with LS who have a future colorectal cancer (i.e., excluding those with prior total proctocolectomy) consider using daily aspirin to reduce their future risk of colorectal cancer. The decision to use aspirin for reduction of colorectal cancer risk in LS and the dose chosen should be made on an individual basis, including discussion of individual risks, benefits, adverse effects, and childbearing plans. In determining whether an individual with LS should take aspirin and in deciding on the appropriate dosing, the panel recommends that providers carefully review patient-specific factors that may increase the risk of aspirin therapy - including, but not limited to increased age, prior allergy, concurrent use of antiplatelets/anticoagulants, and untreated H. pylori or unconfirmed H. pylori eradication - as well as patient-specific factors that indicate a comparably low future cumulative risk of colorectal cancer and who may thus be less likely to experience significant benefit."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Data do not support routine ovarian cancer screening for LS. Transvaginal ultrasound for ovarian cancer screen has not been shown to be sufficiently sensitive or specific to support routine recommendation, but may be considered at the clinician's discretion. Serum CA-125 is an additional ovarian screening test with caveats similar to transvaginal ultrasound."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Data do not support routine ovarian cancer screening for LS. Transvaginal ultrasound for ovarian cancer screen has not been shown to be sufficiently sensitive or specific to support routine recommendation, but may be considered at the clinician's discretion. Serum CA-125 is an additional ovarian screening test with caveats similar to transvaginal ultrasound."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Data do not support routine ovarian cancer screening for LS. Transvaginal ultrasound for ovarian cancer screen has not been shown to be sufficiently sensitive or specific to support routine recommendation, but may be considered at the clinician's discretion. Serum CA-125 is an additional ovarian screening test with caveats similar to transvaginal ultrasound."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Data do not support routine ovarian cancer screening for LS. Transvaginal ultrasound for ovarian cancer screen has not been shown to be sufficiently sensitive or specific to support routine recommendation, but may be considered at the clinician's discretion. Serum CA-125 is an additional ovarian screening test with caveats similar to transvaginal ultrasound."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Data do not support routine ovarian cancer screening for LS. Transvaginal ultrasound for ovarian cancer screen has not been shown to be sufficiently sensitive or specific to support routine recommendation, but may be considered at the clinician's discretion. Serum CA-125 is an additional ovarian screening test with caveats similar to transvaginal ultrasound."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Since there is no effective screening for ovarian cancer, women should be educated on the symptoms that might be associated with the development of ovarian cancer, such as pelvic or abdominal pain, bloating, increased abdominal girth, difficulty eating, early satiety, or urinary frequency or urgency. Symptoms that persist for several weeks and are a change from a woman's baseline should prompt evaluation by her physician."})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Cholangiocarcinoma", GeneMasterName: "BAP1", Gender: "Either", Organ: "Bile Duct"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Clear Cell Carcinoma", GeneMasterName: "BAP1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "CDKN1C", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Esophageal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Esophagus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "ALL", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Orolaryngeal Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CDKN2A", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Head And Neck Cancer", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Atypical Nevi", GeneMasterName: "CDKN2A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "CEBPA", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "CLL", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "CHEK2", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Polycythaemia Vera", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Osteosarcoma", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Thrombocythaemia", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Papillary Thyroid Cancer", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "CTNNA1", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Macular Dystrophy", GeneMasterName: "CTNNA1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Pineoblastoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "DICER1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "DICER1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Neoplasm", DiseaseName: "GI Neoplasm", PredominantCancerSubtype: "Hamartomatous Polyps", GeneMasterName: "DICER1", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Global Development Delay", GeneMasterName: "DICER1", Gender: "Either", Organ: "Developmental"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Intussusception", GeneMasterName: "DICER1", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Liver (Benign)", PredominantCancerSubtype: "Mesenchymal Hamartoma Of The Liver", GeneMasterName: "DICER1", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Pleuropulmonary blastoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Meckel‚Äôs Diverticulum", GeneMasterName: "DICER1", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Ovarian Neoplasm", PredominantCancerSubtype: "Sex Cord Tumor", GeneMasterName: "DICER1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Pituitary Blastoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Pituitary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Embryonal Rhabdomyosarcoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Dysplastic Nevus", GeneMasterName: "DICER1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Multinodular Goiter", GeneMasterName: "DICER1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENE_CARD_REFERENCES {Id: "176", PubmedId: "23230001"})
(:LKP_GENE_CARD_REFERENCES {Id: "177", PubmedId: "23263490"})
(:LKP_GENE_CARD_REFERENCES {Id: "178", PubmedId: "23293331"})
(:LKP_GENE_CARD_REFERENCES {Id: "179", PubmedId: "23295293"})
(:LKP_GENE_CARD_REFERENCES {Id: "180", PubmedId: "23322652"})
(:LKP_GENE_CARD_REFERENCES {Id: "181", PubmedId: "23334666"})
(:LKP_GENE_CARD_REFERENCES {Id: "182", PubmedId: "23335200"})
(:LKP_GENE_CARD_REFERENCES {Id: "183", PubmedId: "23377182"})
(:LKP_GENE_CARD_REFERENCES {Id: "184", PubmedId: "23380224"})
(:LKP_GENE_CARD_REFERENCES {Id: "185", PubmedId: "23384855"})
(:LKP_GENE_CARD_REFERENCES {Id: "186", PubmedId: "23401320"})
(:LKP_GENE_CARD_REFERENCES {Id: "187", PubmedId: "23409019"})
(:LKP_GENE_CARD_REFERENCES {Id: "188", PubmedId: "23465774"})
(:LKP_GENE_CARD_REFERENCES {Id: "189", PubmedId: "23613427"})
(:LKP_GENE_CARD_REFERENCES {Id: "190", PubmedId: "23648119"})
(:LKP_GENE_CARD_REFERENCES {Id: "191", PubmedId: "23652375"})
(:LKP_GENE_CARD_REFERENCES {Id: "192", PubmedId: "23666964"})
(:LKP_GENE_CARD_REFERENCES {Id: "193", PubmedId: "23684012"})
(:LKP_GENE_CARD_REFERENCES {Id: "194", PubmedId: "23713947"})
(:LKP_GENE_CARD_REFERENCES {Id: "195", PubmedId: "23733342"})
(:LKP_GENE_CARD_REFERENCES {Id: "196", PubmedId: "23765759"})
(:LKP_GENE_CARD_REFERENCES {Id: "197", PubmedId: "23770608"})
(:LKP_GENE_CARD_REFERENCES {Id: "198", PubmedId: "23929686"})
(:LKP_GENE_CARD_REFERENCES {Id: "199", PubmedId: "23933118"})
(:LKP_GENE_CARD_REFERENCES {Id: "200", PubmedId: "24098681"})
(:LKP_GENE_CARD_REFERENCES {Id: "201", PubmedId: "24115288"})
(:LKP_GENE_CARD_REFERENCES {Id: "202", PubmedId: "24115482"})
(:LKP_GENE_CARD_REFERENCES {Id: "203", PubmedId: "24335096"})
(:LKP_GENE_CARD_REFERENCES {Id: "204", PubmedId: "24357598"})
(:LKP_GENE_CARD_REFERENCES {Id: "205", PubmedId: "24360807"})
(:LKP_GENE_CARD_REFERENCES {Id: "206", PubmedId: "24362817"})
(:LKP_GENE_CARD_REFERENCES {Id: "207", PubmedId: "24367056"})
(:LKP_GENE_CARD_REFERENCES {Id: "208", PubmedId: "24401204"})
(:LKP_GENE_CARD_REFERENCES {Id: "209", PubmedId: "24424121"})
(:LKP_GENE_CARD_REFERENCES {Id: "210", PubmedId: "24444654"})
(:LKP_GENE_CARD_REFERENCES {Id: "211", PubmedId: "24451042"})
(:LKP_GENE_CARD_REFERENCES {Id: "212", PubmedId: "24501277"})
(:LKP_GENE_CARD_REFERENCES {Id: "213", PubmedId: "24549055"})
(:LKP_GENE_CARD_REFERENCES {Id: "214", PubmedId: "24658001"})
(:LKP_GENE_CARD_REFERENCES {Id: "215", PubmedId: "24658002"})
(:LKP_GENE_CARD_REFERENCES {Id: "216", PubmedId: "24686846"})
(:LKP_GENE_CARD_REFERENCES {Id: "217", PubmedId: "24686849"})
(:LKP_GENE_CARD_REFERENCES {Id: "218", PubmedId: "24691054"})
(:LKP_GENE_CARD_REFERENCES {Id: "219", PubmedId: "24694336"})
(:LKP_GENE_CARD_REFERENCES {Id: "220", PubmedId: "24715504"})
(:LKP_GENE_CARD_REFERENCES {Id: "221", PubmedId: "24724714"})
(:LKP_GENE_CARD_REFERENCES {Id: "222", PubmedId: "24736066"})
(:LKP_GENE_CARD_REFERENCES {Id: "223", PubmedId: "24736080"})
(:LKP_GENE_CARD_REFERENCES {Id: "224", PubmedId: "24886695"})
(:LKP_GENE_CARD_REFERENCES {Id: "225", PubmedId: "24894818"})
(:LKP_GENE_CARD_REFERENCES {Id: "226", PubmedId: "24899893"})
(:LKP_GENE_CARD_REFERENCES {Id: "227", PubmedId: "24911853"})
(:LKP_GENE_CARD_REFERENCES {Id: "228", PubmedId: "24933152"})
(:LKP_GENE_CARD_REFERENCES {Id: "229", PubmedId: "24935963"})
(:LKP_GENE_CARD_REFERENCES {Id: "230", PubmedId: "24941021"})
(:LKP_GENE_CARD_REFERENCES {Id: "231", PubmedId: "24960165"})
(:LKP_GENE_CARD_REFERENCES {Id: "232", PubmedId: "25050558"})
(:LKP_GENE_CARD_REFERENCES {Id: "233", PubmedId: "25099575"})
(:LKP_GENE_CARD_REFERENCES {Id: "234", PubmedId: "25131834"})
(:LKP_GENE_CARD_REFERENCES {Id: "235", PubmedId: "25143307"})
(:LKP_GENE_CARD_REFERENCES {Id: "236", PubmedId: "25168959"})
(:LKP_GENE_CARD_REFERENCES {Id: "237", PubmedId: "25169878"})
(:LKP_GENE_CARD_REFERENCES {Id: "238", PubmedId: "25170203"})
(:LKP_GENE_CARD_REFERENCES {Id: "239", PubmedId: "25170286"})
(:LKP_GENE_CARD_REFERENCES {Id: "240", PubmedId: "25176975"})
(:LKP_GENE_CARD_REFERENCES {Id: "241", PubmedId: "25237198"})
(:LKP_GENE_CARD_REFERENCES {Id: "242", PubmedId: "25238977"})
(:LKP_GENE_CARD_REFERENCES {Id: "243", PubmedId: "25252913"})
(:LKP_GENE_CARD_REFERENCES {Id: "244", PubmedId: "25288137"})
(:LKP_GENE_CARD_REFERENCES {Id: "245", PubmedId: "25288723"})
(:LKP_GENE_CARD_REFERENCES {Id: "246", PubmedId: "25300370"})
(:LKP_GENE_CARD_REFERENCES {Id: "247", PubmedId: "25403219"})
(:LKP_GENE_CARD_REFERENCES {Id: "248", PubmedId: "25426838"})
(:LKP_GENE_CARD_REFERENCES {Id: "249", PubmedId: "25431674"})
(:LKP_GENE_CARD_REFERENCES {Id: "250", PubmedId: "25452441"})
(:LKP_GENE_CARD_REFERENCES {Id: "251", PubmedId: "25480913"})
(:LKP_GENE_CARD_REFERENCES {Id: "252", PubmedId: "25482530"})
(:LKP_GENE_CARD_REFERENCES {Id: "253", PubmedId: "25519092"})
(:LKP_GENE_CARD_REFERENCES {Id: "254", PubmedId: "25519458"})
(:LKP_GENE_CARD_REFERENCES {Id: "255", PubmedId: "25611110"})
(:LKP_GENE_CARD_REFERENCES {Id: "256", PubmedId: "25818337"})
(:LKP_GENE_CARD_REFERENCES {Id: "257", PubmedId: "25921057"})
(:LKP_GENE_CARD_REFERENCES {Id: "258", PubmedId: "25938944"})
(:LKP_GENE_CARD_REFERENCES {Id: "259", PubmedId: "25940403"})
(:LKP_GENE_CARD_REFERENCES {Id: "260", PubmedId: "25951892"})
(:LKP_GENE_CARD_REFERENCES {Id: "261", PubmedId: "26008905"})
(:LKP_GENE_CARD_REFERENCES {Id: "262", PubmedId: "26022962"})
(:LKP_GENE_CARD_REFERENCES {Id: "263", PubmedId: "26050521"})
(:LKP_GENE_CARD_REFERENCES {Id: "264", PubmedId: "26050940"})
(:LKP_GENE_CARD_REFERENCES {Id: "265", PubmedId: "26130139"})
(:LKP_GENE_CARD_REFERENCES {Id: "266", PubmedId: "26133394"})
(:LKP_GENE_CARD_REFERENCES {Id: "267", PubmedId: "26162409"})
(:LKP_GENE_CARD_REFERENCES {Id: "268", PubmedId: "26175287"})
(:LKP_GENE_CARD_REFERENCES {Id: "269", PubmedId: "26178382"})
(:LKP_GENE_CARD_REFERENCES {Id: "270", PubmedId: "26182300"})
(:LKP_GENE_CARD_REFERENCES {Id: "271", PubmedId: "26186299"})
(:LKP_GENE_CARD_REFERENCES {Id: "272", PubmedId: "26259135"})
(:LKP_GENE_CARD_REFERENCES {Id: "273", PubmedId: "26271390"})
(:LKP_GENE_CARD_REFERENCES {Id: "274", PubmedId: "26315354"})
(:LKP_GENE_CARD_REFERENCES {Id: "275", PubmedId: "26337759"})
(:LKP_GENE_CARD_REFERENCES {Id: "276", PubmedId: "26347711"})
(:LKP_GENE_CARD_REFERENCES {Id: "277", PubmedId: "26358404"})
(:LKP_GENE_CARD_REFERENCES {Id: "278", PubmedId: "26364555"})
(:LKP_GENE_CARD_REFERENCES {Id: "279", PubmedId: "26380542"})
(:LKP_GENE_CARD_REFERENCES {Id: "280", PubmedId: "26385421"})
(:LKP_GENE_CARD_REFERENCES {Id: "281", PubmedId: "26424751"})
(:LKP_GENE_CARD_REFERENCES {Id: "282", PubmedId: "26436111"})
(:LKP_GENE_CARD_REFERENCES {Id: "283", PubmedId: "26446362"})
(:LKP_GENE_CARD_REFERENCES {Id: "284", PubmedId: "26483394"})
(:LKP_GENE_CARD_REFERENCES {Id: "285", PubmedId: "26559593"})
(:LKP_GENE_CARD_REFERENCES {Id: "286", PubmedId: "26564076"})
(:LKP_GENE_CARD_REFERENCES {Id: "287", PubmedId: "26636501"})
(:LKP_GENE_CARD_REFERENCES {Id: "288", PubmedId: "26657901"})
(:LKP_GENE_CARD_REFERENCES {Id: "289", PubmedId: "26681312"})
(:LKP_GENE_CARD_REFERENCES {Id: "290", PubmedId: "26691986"})
(:LKP_GENE_CARD_REFERENCES {Id: "291", PubmedId: "26700119"})
(:LKP_GENE_CARD_REFERENCES {Id: "292", PubmedId: "26712909"})
(:LKP_GENE_CARD_REFERENCES {Id: "293", PubmedId: "26720728"})
(:LKP_GENE_CARD_REFERENCES {Id: "294", PubmedId: "26722403"})
(:LKP_GENE_CARD_REFERENCES {Id: "295", PubmedId: "26763073"})
(:LKP_GENE_CARD_REFERENCES {Id: "296", PubmedId: "26833487"})
(:LKP_GENE_CARD_REFERENCES {Id: "297", PubmedId: "26905905"})
(:LKP_GENE_CARD_REFERENCES {Id: "298", PubmedId: "27013479"})
(:LKP_GENE_CARD_REFERENCES {Id: "299", PubmedId: "2705469"})
(:LKP_GENE_CARD_REFERENCES {Id: "300", PubmedId: "27087319"})
(:LKP_GENE_CARD_REFERENCES {Id: "301", PubmedId: "27112364"})
(:LKP_GENE_CARD_REFERENCES {Id: "302", PubmedId: "27264197"})
(:LKP_GENE_CARD_REFERENCES {Id: "303", PubmedId: "27296296"})
(:LKP_GENE_CARD_REFERENCES {Id: "304", PubmedId: "27302097"})
(:LKP_GENE_CARD_REFERENCES {Id: "305", PubmedId: "27306910"})
(:LKP_GENE_CARD_REFERENCES {Id: "306", PubmedId: "27343414"})
(:LKP_GENE_CARD_REFERENCES {Id: "307", PubmedId: "27433846"})
(:LKP_GENE_CARD_REFERENCES {Id: "308", PubmedId: "27476653"})
(:LKP_GENE_CARD_REFERENCES {Id: "309", PubmedId: "27528712"})
(:LKP_GENE_CARD_REFERENCES {Id: "310", PubmedId: "27562837"})
(:LKP_GENE_CARD_REFERENCES {Id: "311", PubmedId: "27572829"})
(:LKP_GENE_CARD_REFERENCES {Id: "312", PubmedId: "27632928"})
(:LKP_GENE_CARD_REFERENCES {Id: "313", PubmedId: "27683074"})
(:LKP_GENE_CARD_REFERENCES {Id: "314", PubmedId: "27777718"})
(:LKP_GENE_CARD_REFERENCES {Id: "315", PubmedId: "27836952"})
(:LKP_GENE_CARD_REFERENCES {Id: "316", PubmedId: "27890237"})
(:LKP_GENE_CARD_REFERENCES {Id: "317", PubmedId: "27900359"})
(:LKP_GENE_CARD_REFERENCES {Id: "318", PubmedId: "27989354"})
(:LKP_GENE_CARD_REFERENCES {Id: "319", PubmedId: "28031180"})
(:LKP_GENE_CARD_REFERENCES {Id: "320", PubmedId: "28099933"})
(:LKP_GENE_CARD_REFERENCES {Id: "321", PubmedId: "28374168"})
(:LKP_GENE_CARD_REFERENCES {Id: "322", PubmedId: "28418444"})
(:LKP_GENE_CARD_REFERENCES {Id: "323", PubmedId: "28620007"})
(:LKP_GENE_CARD_REFERENCES {Id: "324", PubmedId: "28657667"})
(:LKP_GENE_CARD_REFERENCES {Id: "325", PubmedId: "28724667"})
(:LKP_GENE_CARD_REFERENCES {Id: "326", PubmedId: "28754778"})
(:LKP_GENE_CARD_REFERENCES {Id: "327", PubmedId: "28767289"})
(:LKP_GENE_CARD_REFERENCES {Id: "328", PubmedId: "28772289"})
(:LKP_GENE_CARD_REFERENCES {Id: "329", PubmedId: "28837157"})
(:LKP_GENE_CARD_REFERENCES {Id: "330", PubmedId: "28837162"})
(:LKP_GENE_CARD_REFERENCES {Id: "331", PubmedId: "28853721"})
(:LKP_GENE_CARD_REFERENCES {Id: "332", PubmedId: "28888541"})
(:LKP_GENE_CARD_REFERENCES {Id: "333", PubmedId: "28973655"})
(:LKP_GENE_CARD_REFERENCES {Id: "334", PubmedId: "29120461"})
(:LKP_GENE_CARD_REFERENCES {Id: "335", PubmedId: "29177515"})
(:LKP_GENE_CARD_REFERENCES {Id: "336", PubmedId: "29186568"})
(:LKP_GENE_CARD_REFERENCES {Id: "337", PubmedId: "29231814"})
(:LKP_GENE_CARD_REFERENCES {Id: "338", PubmedId: "29386252"})
(:LKP_GENE_CARD_REFERENCES {Id: "339", PubmedId: "29478780"})
(:LKP_GENE_CARD_REFERENCES {Id: "340", PubmedId: "29895858"})
(:LKP_GENE_CARD_REFERENCES {Id: "341", PubmedId: "29899996"})
(:LKP_GENE_CARD_REFERENCES {Id: "342", PubmedId: "29922827"})
(:LKP_GENE_CARD_REFERENCES {Id: "343", PubmedId: "29978154"})
(:LKP_GENE_CARD_REFERENCES {Id: "344", PubmedId: "29978187"})
(:LKP_GENE_CARD_REFERENCES {Id: "345", PubmedId: "29988077"})
(:LKP_GENE_CARD_REFERENCES {Id: "346", PubmedId: "30075111"})
(:LKP_GENE_CARD_REFERENCES {Id: "347", PubmedId: "30161022"})
(:LKP_GENE_CARD_REFERENCES {Id: "348", PubmedId: "30201732"})
(:LKP_GENE_CARD_REFERENCES {Id: "349", PubmedId: "30499906"})
(:LKP_GENE_CARD_REFERENCES {Id: "350", PubmedId: "30517737"})
(:LKP_GENE_CARD_REFERENCES {Id: "351", PubmedId: "30536464"})
(:LKP_GENE_CARD_REFERENCES {Id: "352", PubmedId: "30608029"})
(:LKP_GENE_CARD_REFERENCES {Id: "353", PubmedId: "30610487"})
(:LKP_GENE_CARD_REFERENCES {Id: "354", PubmedId: "30733081"})
(:LKP_GENE_CARD_REFERENCES {Id: "355", PubmedId: "30775140"})
(:LKP_GENE_CARD_REFERENCES {Id: "356", PubmedId: "30777867"})
(:LKP_GENE_CARD_REFERENCES {Id: "357", PubmedId: "30858171"})
(:LKP_GENE_CARD_REFERENCES {Id: "358", PubmedId: "30862463"})
(:LKP_GENE_CARD_REFERENCES {Id: "359", PubmedId: "30900310"})
(:LKP_GENE_CARD_REFERENCES {Id: "360", PubmedId: "31070935"})
(:LKP_GENE_CARD_REFERENCES {Id: "361", PubmedId: "31095066"})
(:LKP_GENE_CARD_REFERENCES {Id: "362", PubmedId: "31189130"})
(:LKP_GENE_CARD_REFERENCES {Id: "363", PubmedId: "31204389"})
(:LKP_GENE_CARD_REFERENCES {Id: "364", PubmedId: "31216739"})
(:LKP_GENE_CARD_REFERENCES {Id: "365", PubmedId: "31243857"})
(:LKP_GENE_CARD_REFERENCES {Id: "366", PubmedId: "31246251"})
(:LKP_GENE_CARD_REFERENCES {Id: "367", PubmedId: "31296550"})
(:LKP_GENE_CARD_REFERENCES {Id: "368", PubmedId: "31337882"})
(:LKP_GENE_CARD_REFERENCES {Id: "369", PubmedId: "31406321"})
(:LKP_GENE_CARD_REFERENCES {Id: "370", PubmedId: "31490007"})
(:LKP_GENE_CARD_REFERENCES {Id: "371", PubmedId: "31629014"})
(:LKP_GENE_CARD_REFERENCES {Id: "372", PubmedId: "31629417"})
(:LKP_GENE_CARD_REFERENCES {Id: "373", PubmedId: "31831373"})
(:LKP_GENE_CARD_REFERENCES {Id: "374", PubmedId: "31841383"})
(:LKP_GENE_CARD_REFERENCES {Id: "375", PubmedId: "31881331"})
(:LKP_GENE_CARD_REFERENCES {Id: "376", PubmedId: "31944473"})
(:LKP_GENE_CARD_REFERENCES {Id: "377", PubmedId: "32051609"})
(:LKP_GENE_CARD_REFERENCES {Id: "378", PubmedId: "32091585"})
(:LKP_GENE_CARD_REFERENCES {Id: "379", PubmedId: "32107557"})
(:LKP_GENE_CARD_REFERENCES {Id: "380", PubmedId: "32130200"})
(:LKP_GENE_CARD_REFERENCES {Id: "381", PubmedId: "32359370"})
(:LKP_GENE_CARD_REFERENCES {Id: "382", PubmedId: "32422154"})
(:LKP_GENE_CARD_REFERENCES {Id: "383", PubmedId: "32424176"})
(:LKP_GENE_CARD_REFERENCES {Id: "384", PubmedId: "32602142"})
(:LKP_GENE_CARD_REFERENCES {Id: "385", PubmedId: "32676552"})
(:LKP_GENE_CARD_REFERENCES {Id: "386", PubmedId: "32708810"})
(:LKP_GENE_CARD_REFERENCES {Id: "387", PubmedId: "32758476"})
(:LKP_GENE_CARD_REFERENCES {Id: "388", PubmedId: "32853339"})
(:LKP_GENE_CARD_REFERENCES {Id: "389", PubmedId: "32923861"})
(:LKP_GENE_CARD_REFERENCES {Id: "390", PubmedId: "32953421"})
(:LKP_GENE_CARD_REFERENCES {Id: "391", PubmedId: "32971521"})
(:LKP_GENE_CARD_REFERENCES {Id: "392", PubmedId: "33024317"})
(:LKP_GENE_CARD_REFERENCES {Id: "393", PubmedId: "33051659"})
(:LKP_GENE_CARD_REFERENCES {Id: "394", PubmedId: "33059073"})
(:LKP_GENE_CARD_REFERENCES {Id: "395", PubmedId: "33066274"})
(:LKP_GENE_CARD_REFERENCES {Id: "396", PubmedId: "33099839"})
(:LKP_GENE_CARD_REFERENCES {Id: "397", PubmedId: "33471974"})
(:LKP_GENE_CARD_REFERENCES {Id: "398", PubmedId: "33471991"})
(:LKP_GENE_CARD_REFERENCES {Id: "399", PubmedId: "33493868"})
(:LKP_GENE_CARD_REFERENCES {Id: "400", PubmedId: "33812987"})
(:LKP_GENE_CARD_REFERENCES {Id: "401", PubmedId: "5770175"})
(:LKP_GENE_CARD_REFERENCES {Id: "402", PubmedId: "7525736"})
(:LKP_GENE_CARD_REFERENCES {Id: "403", PubmedId: "7529964"})
(:LKP_GENE_CARD_REFERENCES {Id: "404", PubmedId: "8308957"})
(:LKP_GENE_CARD_REFERENCES {Id: "405", PubmedId: "8522331"})
(:LKP_GENE_CARD_REFERENCES {Id: "406", PubmedId: "8655134"})
(:LKP_GENE_CARD_REFERENCES {Id: "407", PubmedId: "9438854"})
(:LKP_GENE_CARD_REFERENCES {Id: "408", PubmedId: "9529364"})
(:LKP_GENE_CARD_REFERENCES {Id: "409", PubmedId: "9563489"})
(:LKP_GENE_CARD_REFERENCES {Id: "410", PubmedId: "9622062"})
(:LKP_GENE_CARD_REFERENCES {Id: "411", PubmedId: "9869523"})
(:LKP_GENE_CARD_REFERENCES {Id: "412", PubmedId: "8057225"})
(:LKP_GENE_CARD_REFERENCES {Id: "413", PubmedId: "8986277"})
(:LKP_GENE_CARD_REFERENCES {Id: "414", PubmedId: "11729110"})
(:LKP_GENE_CARD_REFERENCES {Id: "415", PubmedId: "12120221"})
(:LKP_GENE_CARD_REFERENCES {Id: "416", PubmedId: "12393424"})
(:LKP_GENE_CARD_REFERENCES {Id: "417", PubmedId: "12724643"})
(:LKP_GENE_CARD_REFERENCES {Id: "418", PubmedId: "14757854"})
(:LKP_GENE_CARD_REFERENCES {Id: "419", PubmedId: "17003641"})
(:LKP_GENE_CARD_REFERENCES {Id: "420", PubmedId: "17681820"})
(:LKP_GENE_CARD_REFERENCES {Id: "421", PubmedId: "18059268"})
(:LKP_GENE_CARD_REFERENCES {Id: "422", PubmedId: "18172691"})
(:LKP_GENE_CARD_REFERENCES {Id: "423", PubmedId: "18242317"})
(:LKP_GENE_CARD_REFERENCES {Id: "424", PubmedId: "18652530"})
(:LKP_GENE_CARD_REFERENCES {Id: "425", PubmedId: "18755888"})
(:LKP_GENE_CARD_REFERENCES {Id: "426", PubmedId: "18923503"})
(:LKP_GENE_CARD_REFERENCES {Id: "427", PubmedId: "19423727"})
(:LKP_GENE_CARD_REFERENCES {Id: "428", PubmedId: "20301288"})
(:LKP_GENE_CARD_REFERENCES {Id: "429", PubmedId: "20301428"})
(:LKP_GENE_CARD_REFERENCES {Id: "430", PubmedId: "20301568"})
(:LKP_GENE_CARD_REFERENCES {Id: "431", PubmedId: "20977904"})
(:LKP_GENE_CARD_REFERENCES {Id: "432", PubmedId: "21211618"})
(:LKP_GENE_CARD_REFERENCES {Id: "433", PubmedId: "21252721"})
(:LKP_GENE_CARD_REFERENCES {Id: "434", PubmedId: "21520337"})
(:LKP_GENE_CARD_REFERENCES {Id: "435", PubmedId: "21681190"})
(:LKP_GENE_CARD_REFERENCES {Id: "436", PubmedId: "22232082"})
(:LKP_GENE_CARD_REFERENCES {Id: "437", PubmedId: "22461326"})
(:LKP_GENE_CARD_REFERENCES {Id: "438", PubmedId: "22466463"})
(:LKP_GENE_CARD_REFERENCES {Id: "439", PubmedId: "22942235"})
(:LKP_GENE_CARD_REFERENCES {Id: "440", PubmedId: "23358982"})
(:LKP_GENE_CARD_REFERENCES {Id: "441", PubmedId: "24030261"})
(:LKP_GENE_CARD_REFERENCES {Id: "442", PubmedId: "24469107"})
(:LKP_GENE_CARD_REFERENCES {Id: "443", PubmedId: "24522117"})
(:LKP_GENE_CARD_REFERENCES {Id: "444", PubmedId: "24628296"})
(:LKP_GENE_CARD_REFERENCES {Id: "445", PubmedId: "24710684"})
(:LKP_GENE_CARD_REFERENCES {Id: "446", PubmedId: "25206283"})
(:LKP_GENE_CARD_REFERENCES {Id: "447", PubmedId: "25426837"})
(:LKP_GENE_CARD_REFERENCES {Id: "448", PubmedId: "27133828"})
(:LKP_GENE_CARD_REFERENCES {Id: "449", PubmedId: "29749045"})
(:LKP_GENE_CARD_REFERENCES {Id: "450", PubmedId: "30165405"})
(:LKP_GENE_CARD_REFERENCES {Id: "451", PubmedId: "30373780"})
(:LKP_GENE_CARD_REFERENCES {Id: "452", PubmedId: "31204009"})
(:LKP_GENE_CARD_REFERENCES {Id: "453", PubmedId: "31882447"})
(:LKP_GENE_CARD_REFERENCES {Id: "454", PubmedId: "32201880"})
(:LKP_GENE_CARD_REFERENCES {Id: "455", PubmedId: "33482595"})
(:LKP_GENE_CARD_REFERENCES {Id: "456", PubmedId: "33864022"})
(:LKP_GENE_CARD_REFERENCES {Id: "457", PubmedId: "23035301"})
(:LKP_GENE_CARD_REFERENCES {Id: "458", PubmedId: "24624459"})
(:LKP_GENE_CARD_REFERENCES {Id: "459", PubmedId: "31390501"})
(:LKP_GENE_CARD_REFERENCES {Id: "460", PubmedId: "20301636"})
(:LKP_GENE_CARD_REFERENCES {Id: "461", PubmedId: "20301687"})
(:LKP_GENE_CARD_REFERENCES {Id: "462", PubmedId: "20301715"})
(:LKP_GENE_CARD_REFERENCES {Id: "463", PubmedId: "20301744"})
(:LKP_GENE_CARD_REFERENCES {Id: "464", PubmedId: "20301772"})
(:LKP_GENE_CARD_REFERENCES {Id: "465", PubmedId: "20417588"})
(:LKP_GENE_CARD_REFERENCES {Id: "466", PubmedId: "22720333"})
(:LKP_GENE_CARD_REFERENCES {Id: "467", PubmedId: "35172496"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "Concatenated", Pmids: "Unknown", Gene_Name: "Gene", References: "Unknown"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The ABRAXAS1 gene, formerly known as FAM175A, currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22357538).", Pmids: "22357538", Gene_Name: "ABRAXAS1", References: "22357538) Solyom S,Aressy B,Pylk√É¬§s K,Patterson-Fortin J,Hartikainen JM,Kallioniemi A,Kauppila S,Nikkil√É¬§ J,Kosma VM,Mannermaa A,Greenberg RA,Winqvist R. Breast cancer-associated Abraxas mutation disrupts nuclear localization and DNA damage response functions. Sci Transl Med.. 2012;4(122):122ra23."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The AIP gene is associated with autosomal dominant predisposition to familial isolated pituitary adenoma (FIPA) (MedGen UID: 489979).  FIPA presents in early adulthood with the development of pituitary adenomas in the absence of other syndromic findings. These pituitary adenomas may be of various types including somatotropinoma (growth hormone-secreting), prolactinoma (prolactin-secreting), somatomammotropinoma (growth hormone and prolactin co-secreting) and nonfunctioning pituitary adenomas (NFPA). Other types of adenomas have also been observed (PMID: 22720333, 26186299).", Pmids: "22720333|26186299", Gene_Name: "AIP", References: "26186299) Hern√É¬°ndez-Ram√É¬≠rez LC,Gabrovska P,D√É¬©nes J,Stals K,Trivellin G,Tilley D,Ferrau F,Evanson J,Ellard S,Grossman AB,Roncaroli F,Gadelha MR,Korbonits M, . Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab.. 2015;100(9):E1242-54.|22720333) AIP Familial Isolated Pituitary Adenomas"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The ALK gene is associated with autosomal dominant predisposition to neuroblastoma (MedGen UID: 414083).  Neuroblastoma is a tumor affecting developing nerve cells, and therefore most often affects infants and young children (PMID: 18242317). Studies have identified pathogenic ALK variants in families exhibiting a predisposition to neuroblastoma (PMID: 18724359, 18923523, 22071890) with incomplete penetrance (PMID: 18923503).", Pmids: "18242317|18724359|18923503|18923523|22071890", Gene_Name: "ALK", References: "18724359) Moss√É¬© YP,Laudenslager M,Longo L,Cole KA,Wood A,Attiyeh EF,Laquaglia MJ,Sennett R,Lynch JE,Perri P,Laureys G,Speleman F,Kim C,Hou C,Hakonarson H,Torkamani A,Schork NJ,Brodeur GM,Tonini GP,Rappaport E,Devoto M,Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature.. 2008;455(7215):930-5.|18923523) Janoueix-Lerosey I,Lequin D,Brugi√É¬®res L,Ribeiro A,de Pontual L,Combaret V,Raynal V,Puisieux A,Schleiermacher G,Pierron G,Valteau-Couanet D,Frebourg T,Michon J,Lyonnet S,Amiel J,Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature.. 2008;455(7215):967-70.|22071890) Bourdeaut F,Ferrand S,Brugi√É¬®res L,Hilbert M,Ribeiro A,Lacroix L,B√É¬©nard J,Combaret V,Michon J,Valteau-Couanet D,Isidor B,Rialland X,Poir√É¬©e M,Defachelles AS,Peuchmaur M,Schleiermacher G,Pierron G,Gauthier-Villars M,Janoueix-Lerosey I,Delattre O, . ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. Eur J Hum Genet.. 2012;20(3):291-7.|18242317) Neuroblastoma biology,prognosis,and treatment|18923503) Cancer a ringleader identified"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The ANKRD26 gene is associated with isolated, non-syndromic autosomal dominant thrombocytopenia (MedGen UID: 349976). Additionally, the ANKRD26 gene has preliminary evidence supporting a correlation with autosomal dominant familial leukemia (PMID: 24628296, 24030261).  Inherited thrombocytopenia is associated with mild-to-severe tendency to bruising and bleeding due to a decreased platelet count (PMID: 21211618). Laboratory studies reveal increased total white blood count and plasma thrombopoietin (TPO) (PMID: 24628296, 21211618). Bone marrow examination reveals dysmegakaryopoiesis, suggesting defective platelet production (PMID: 21211618, 26175287). Some studies have identified a pathogenic ANKRD26 variant in individuals with increased susceptibility to myeloid malignancies (PMID: 24030261, 24628296).", Pmids: "21211618|24030261|24628296|26175287", Gene_Name: "ANKRD26", References: "26175287) Ouchi-Uchiyama M,Sasahara Y,Kikuchi A,Goi K,Nakane T,Ikeno M,Noguchi Y,Uike N,Miyajima Y,Matsubara K,Koh K,Sugita K,Imaizumi M,Kure S. Analyses of Genetic and Clinical Parameters for Screening Patients With Inherited Thrombocytopenia with Small or Normal-Sized Platelets. Pediatr Blood Cancer.. 2015;62(12):2082-8.|21211618) Mutations in the5'utr of ankrd26, the ankirin repeat domain26 gene, cause an autosomal dominant form of inherited thrombocytopenia, thc2|24030261) ANKRD26-related thrombocytopenia and myeloid malignancies|24628296) A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).", Pmids: "8522331|8655134|16461775|21813476|27087319|27343414|31070935", Gene_Name: "APC - Classic FAP", References: "16461775) Sieber OM,Segditsas S,Knudsen AL,Zhang J,Luz J,Rowan AJ,Spain SL,Thirlwell C,Howarth KM,Jaeger EE,Robinson J,Volikos E,Silver A,Kelly G,Aretz S,Frayling I,Hutter P,Dunlop M,Guenther T,Neale K,Phillips R,Heinimann K,Tomlinson IP. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut.. 2006;55(10):1440-8.|21813476) Worthley DL,Phillips KD,Wayte N,Schrader KA,Healey S,Kaurah P,Shulkes A,Grimpen F,Clouston A,Moore D,Cullen D,Ormonde D,Mounkley D,Wen X,Lindor N,Carneiro F,Huntsman DG,Chenevix-Trench G,Suthers GK. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut.. 2012;61(5):774-9.|27087319) Li J,Woods SL,Healey S,Beesley J,Chen X,Lee JS,Sivakumaran H,Wayte N,Nones K,Waterfall JJ,Pearson J,Patch AM,Senz J,Ferreira MA,Kaurah P,Mackenzie R,Heravi-Moussavi A,Hansford S,Lannagan TRM,Spurdle AB,Simpson PT,da Silva L,Lakhani SR,Clouston AD,Bettington M,Grimpen F,Busuttil RA,Di Costanzo N,Boussioutas A,Jeanjean M,Chong G,Fabre A,Olschwang S,Faulkner GJ,Bellos E,Coin L,Rioux K,Bathe OF,Wen X,Martin HC,Neklason DW,Davis SR,Walker RL,Calzone KA,Avital I,Heller T,Koh C,Pineda M,Rudloff U,Quezado M,Pichurin PN,Hulick PJ,Weissman SM,Newlin A,Rubinstein WS,Sampson JE,Hamman K,Goldgar D,Poplawski N,Phillips K,Schofield L,Armstrong J,Kiraly-Borri C,Suthers GK,Huntsman DG,Foulkes WD,Carneiro F,Lindor NM,Edwards SL,French JD,Waddell N,Meltzer PS,Worthley DL,Schrader KA,Chenevix-Trench G. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet.. 2016;98(5):830-842.|27343414) Repak R,Kohoutova D,Podhola M,Rejchrt S,Minarik M,Benesova L,Lesko M,Bures J. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of√Ç¬†the literature. Gastrointest Endosc.. 2016;84(4):718-25.|31070935) Dinarvand P,Davaro EP,Doan JV,Ising ME,Evans NR,Phillips NJ,Lai J,Guzman MA. Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations. Arch Pathol Lab Med.. 2019;143(11):1382-1398.|8522331) van der Luijt RB,Vasen HF,Tops CM,Breukel C,Fodde R,Meera Khan P. APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet.. 1995;96(6):705-10.|8655134) Friedl W,Meuschel S,Caspari R,Lamberti C,Krieger S,Sengteller M,Propping P. Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet.. 1996;97(5):579-84."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).", Pmids: "8522331|8655134|16461775|21813476|27087319|27343414|31070935", Gene_Name: "APC - Attenuated FAP", References: "16461775) Sieber OM,Segditsas S,Knudsen AL,Zhang J,Luz J,Rowan AJ,Spain SL,Thirlwell C,Howarth KM,Jaeger EE,Robinson J,Volikos E,Silver A,Kelly G,Aretz S,Frayling I,Hutter P,Dunlop M,Guenther T,Neale K,Phillips R,Heinimann K,Tomlinson IP. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut.. 2006;55(10):1440-8.|21813476) Worthley DL,Phillips KD,Wayte N,Schrader KA,Healey S,Kaurah P,Shulkes A,Grimpen F,Clouston A,Moore D,Cullen D,Ormonde D,Mounkley D,Wen X,Lindor N,Carneiro F,Huntsman DG,Chenevix-Trench G,Suthers GK. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut.. 2012;61(5):774-9.|27087319) Li J,Woods SL,Healey S,Beesley J,Chen X,Lee JS,Sivakumaran H,Wayte N,Nones K,Waterfall JJ,Pearson J,Patch AM,Senz J,Ferreira MA,Kaurah P,Mackenzie R,Heravi-Moussavi A,Hansford S,Lannagan TRM,Spurdle AB,Simpson PT,da Silva L,Lakhani SR,Clouston AD,Bettington M,Grimpen F,Busuttil RA,Di Costanzo N,Boussioutas A,Jeanjean M,Chong G,Fabre A,Olschwang S,Faulkner GJ,Bellos E,Coin L,Rioux K,Bathe OF,Wen X,Martin HC,Neklason DW,Davis SR,Walker RL,Calzone KA,Avital I,Heller T,Koh C,Pineda M,Rudloff U,Quezado M,Pichurin PN,Hulick PJ,Weissman SM,Newlin A,Rubinstein WS,Sampson JE,Hamman K,Goldgar D,Poplawski N,Phillips K,Schofield L,Armstrong J,Kiraly-Borri C,Suthers GK,Huntsman DG,Foulkes WD,Carneiro F,Lindor NM,Edwards SL,French JD,Waddell N,Meltzer PS,Worthley DL,Schrader KA,Chenevix-Trench G. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet.. 2016;98(5):830-842.|27343414) Repak R,Kohoutova D,Podhola M,Rejchrt S,Minarik M,Benesova L,Lesko M,Bures J. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of√Ç¬†the literature. Gastrointest Endosc.. 2016;84(4):718-25.|31070935) Dinarvand P,Davaro EP,Doan JV,Ising ME,Evans NR,Phillips NJ,Lai J,Guzman MA. Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations. Arch Pathol Lab Med.. 2019;143(11):1382-1398.|8522331) van der Luijt RB,Vasen HF,Tops CM,Breukel C,Fodde R,Meera Khan P. APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet.. 1995;96(6):705-10.|8655134) Friedl W,Meuschel S,Caspari R,Lamberti C,Krieger S,Sengteller M,Propping P. Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet.. 1996;97(5):579-84."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).", Pmids: "8522331|8655134|16461775|21813476|27087319|27343414|31070935", Gene_Name: "APC - I1307K Variant", References: "16461775) Sieber OM,Segditsas S,Knudsen AL,Zhang J,Luz J,Rowan AJ,Spain SL,Thirlwell C,Howarth KM,Jaeger EE,Robinson J,Volikos E,Silver A,Kelly G,Aretz S,Frayling I,Hutter P,Dunlop M,Guenther T,Neale K,Phillips R,Heinimann K,Tomlinson IP. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut.. 2006;55(10):1440-8.|21813476) Worthley DL,Phillips KD,Wayte N,Schrader KA,Healey S,Kaurah P,Shulkes A,Grimpen F,Clouston A,Moore D,Cullen D,Ormonde D,Mounkley D,Wen X,Lindor N,Carneiro F,Huntsman DG,Chenevix-Trench G,Suthers GK. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut.. 2012;61(5):774-9.|27087319) Li J,Woods SL,Healey S,Beesley J,Chen X,Lee JS,Sivakumaran H,Wayte N,Nones K,Waterfall JJ,Pearson J,Patch AM,Senz J,Ferreira MA,Kaurah P,Mackenzie R,Heravi-Moussavi A,Hansford S,Lannagan TRM,Spurdle AB,Simpson PT,da Silva L,Lakhani SR,Clouston AD,Bettington M,Grimpen F,Busuttil RA,Di Costanzo N,Boussioutas A,Jeanjean M,Chong G,Fabre A,Olschwang S,Faulkner GJ,Bellos E,Coin L,Rioux K,Bathe OF,Wen X,Martin HC,Neklason DW,Davis SR,Walker RL,Calzone KA,Avital I,Heller T,Koh C,Pineda M,Rudloff U,Quezado M,Pichurin PN,Hulick PJ,Weissman SM,Newlin A,Rubinstein WS,Sampson JE,Hamman K,Goldgar D,Poplawski N,Phillips K,Schofield L,Armstrong J,Kiraly-Borri C,Suthers GK,Huntsman DG,Foulkes WD,Carneiro F,Lindor NM,Edwards SL,French JD,Waddell N,Meltzer PS,Worthley DL,Schrader KA,Chenevix-Trench G. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet.. 2016;98(5):830-842.|27343414) Repak R,Kohoutova D,Podhola M,Rejchrt S,Minarik M,Benesova L,Lesko M,Bures J. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of√Ç¬†the literature. Gastrointest Endosc.. 2016;84(4):718-25.|31070935) Dinarvand P,Davaro EP,Doan JV,Ising ME,Evans NR,Phillips NJ,Lai J,Guzman MA. Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations. Arch Pathol Lab Med.. 2019;143(11):1382-1398.|8522331) van der Luijt RB,Vasen HF,Tops CM,Breukel C,Fodde R,Meera Khan P. APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet.. 1995;96(6):705-10.|8655134) Friedl W,Meuschel S,Caspari R,Lamberti C,Krieger S,Sengteller M,Propping P. Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet.. 1996;97(5):579-84."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The APC gene is associated with autosomal dominant familial adenomatous polyposis (FAP) (MedGen UID: 398651), attenuated FAP (AFAP) (MedGen UID: 436213) and gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) (MedGen UID: 1657285).                                                                                                  FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935). Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134).  Pathogenic variants in promoter 1B of APC are associated with GAPPS, a condition characterized by fundic gland polyposis and gastric cancer. Unlike FAP or AFAP, the risk of colorectal polyposis and cancer appears to be lower (PMID: 21813476, 27087319, 27343414).", Pmids: "8522331|8655134|16461775|21813476|27087319|27343414|31070935", Gene_Name: "APC - GAPPS", References: "16461775) Sieber OM,Segditsas S,Knudsen AL,Zhang J,Luz J,Rowan AJ,Spain SL,Thirlwell C,Howarth KM,Jaeger EE,Robinson J,Volikos E,Silver A,Kelly G,Aretz S,Frayling I,Hutter P,Dunlop M,Guenther T,Neale K,Phillips R,Heinimann K,Tomlinson IP. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut.. 2006;55(10):1440-8.|21813476) Worthley DL,Phillips KD,Wayte N,Schrader KA,Healey S,Kaurah P,Shulkes A,Grimpen F,Clouston A,Moore D,Cullen D,Ormonde D,Mounkley D,Wen X,Lindor N,Carneiro F,Huntsman DG,Chenevix-Trench G,Suthers GK. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut.. 2012;61(5):774-9.|27087319) Li J,Woods SL,Healey S,Beesley J,Chen X,Lee JS,Sivakumaran H,Wayte N,Nones K,Waterfall JJ,Pearson J,Patch AM,Senz J,Ferreira MA,Kaurah P,Mackenzie R,Heravi-Moussavi A,Hansford S,Lannagan TRM,Spurdle AB,Simpson PT,da Silva L,Lakhani SR,Clouston AD,Bettington M,Grimpen F,Busuttil RA,Di Costanzo N,Boussioutas A,Jeanjean M,Chong G,Fabre A,Olschwang S,Faulkner GJ,Bellos E,Coin L,Rioux K,Bathe OF,Wen X,Martin HC,Neklason DW,Davis SR,Walker RL,Calzone KA,Avital I,Heller T,Koh C,Pineda M,Rudloff U,Quezado M,Pichurin PN,Hulick PJ,Weissman SM,Newlin A,Rubinstein WS,Sampson JE,Hamman K,Goldgar D,Poplawski N,Phillips K,Schofield L,Armstrong J,Kiraly-Borri C,Suthers GK,Huntsman DG,Foulkes WD,Carneiro F,Lindor NM,Edwards SL,French JD,Waddell N,Meltzer PS,Worthley DL,Schrader KA,Chenevix-Trench G. Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant. Am J Hum Genet.. 2016;98(5):830-842.|27343414) Repak R,Kohoutova D,Podhola M,Rejchrt S,Minarik M,Benesova L,Lesko M,Bures J. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of√Ç¬†the literature. Gastrointest Endosc.. 2016;84(4):718-25.|31070935) Dinarvand P,Davaro EP,Doan JV,Ising ME,Evans NR,Phillips NJ,Lai J,Guzman MA. Familial Adenomatous Polyposis Syndrome: An Update and Review of Extraintestinal Manifestations. Arch Pathol Lab Med.. 2019;143(11):1382-1398.|8522331) van der Luijt RB,Vasen HF,Tops CM,Breukel C,Fodde R,Meera Khan P. APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet.. 1995;96(6):705-10.|8655134) Friedl W,Meuschel S,Caspari R,Lamberti C,Krieger S,Sengteller M,Propping P. Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene. A clue for understanding the function of the APC protein. Hum Genet.. 1996;97(5):579-84."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The ARMC5 gene is associated with autosomal dominant primary bilateral macronodular adrenal hyperplasia (PBMAH) (MedGen UID: 863240).  Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a condition that primarily affects the adrenal glands. The adrenal glands are glands on top of the kidneys that produce hormones regulating many essential functions in the body. PBMAH is a condition that can cause lumps (nodules) to form in the adrenal glands leading them to enlarge and produce too much of a certain hormone (cortisol). Increased cortisol can result in weight gain, high blood pressure (hypertension), diabetes, fatigue and bone loss. When symptoms of PBMAH are present, they usually begin in middle age. However, some with PBMAH may not have any obvious symptoms (incomplete penetrance). Specific laboratory tests and imaging are typically used to diagnose PBMAH. A dexamethasone suppression test measures the response of the adrenal glands to the hormone ACTH (adrenocorticotropic hormone); affected individuals often have elevated cortisol levels in blood and urine as well as low levels of ACTH in blood following this test. Imaging often shows large, nodular adrenal glands. Treatment for severe cases may include the surgical removal of one or both adrenal glands. Otherwise treatment is supportive and focused on managing the individual's symptoms.", Pmids: "Unknown", Gene_Name: "ARMC5", References: "Unknown"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The ASXL1 gene is associated with autosomal dominant Bohring-Opitz syndrome (BOS), which is also known as C-like syndrome (MedGen UID: 208678).  BOS is characterized by multiple congenital malformations, intrauterine growth restriction, feeding difficulties, severe intellectual disability, and distinctive facial features (PMID: 16691589). Associated congenital malformations include palate abnormalities, microcephaly, trigonocephaly, and structural brain anomalies. Reported craniofacial features include exophthalmos, upslanting palpebral fissures, depressed and wide nasal bridge, hypertelorism, low-set posteriorly rotated ears, and facial nevus flammeus. A characteristic limb posture of flexion of the elbows, wrists, and metacarpophalangeal joints has been described. Other features including hypertrichosis, myopia, seizures, central obesity, Wilms tumor, and cardiac, ophthalmologic and gastrointestinal anomalies have been described (PMID: 21706002, 25921057, 26364555). For a review of clinical management for BOS, please refer to Russell et al., 2015 (PMID: 25921057).", Pmids: "16691589|21706002|25921057|26364555", Gene_Name: "ASXL1", References: "16691589) Bohring A,Oudesluijs GG,Grange DK,Zampino G,Thierry P. New cases of Bohring-Opitz syndrome, update, and critical review of the literature. Am J Med Genet A.. 2006;140(12):1257-63.|21706002) Hoischen A,van Bon BW,Rodr√É¬≠guez-Santiago B,Gilissen C,Vissers LE,de Vries P,Janssen I,van Lier B,Hastings R,Smithson SF,Newbury-Ecob R,Kjaergaard S,Goodship J,McGowan R,Bartholdi D,Rauch A,Peippo M,Cobben JM,Wieczorek D,Gillessen-Kaesbach G,Veltman JA,Brunner HG,de Vries BB. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet.. 2011;43(8):729-31.|25921057) Russell B,Johnston JJ,Biesecker LG,Kramer N,Pickart A,Rhead W,Tan WH,Brownstein CA,Kate Clarkson L,Dobson A,Rosenberg AZ,Vergano SA,Helm BM,Harrison RE,Graham JM. Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance. Am J Med Genet A.. 2015;167A(9):2122-31.|26364555) Dangiolo SB,Wilson A,Jobanputra V,Anyane-Yeboa K. Bohring-Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome. Am J Med Genet A.. 2015;167A(12):3161-6."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The ATM gene is associated with autosomal dominant predisposition to breast, ovarian, pancreatic (PMID: 26483394, 28888541, 30733081) and prostate cancer (PMID: 27989354, 28657667). ATM is also associated with autosomal recessive ataxia-telangiectasia (A-T) (MedGen UID: 439). Additionally, there is evidence suggesting ATM is associated with autosomal dominant predisposition to gastric (PMID: 26182300) and colon cancer (PMID: 30862463). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with one pathogenic ATM variant is approximately 21-33% (PMID: 30733081, 33471974, 27112364). There is also an increased risk of ovarian, pancreatic and prostate cancer; however, lifetime risks are not established (PMID: 30733081, 28767289, 27989354).  A-T is characterized by progressive cerebellar ataxia beginning in early childhood, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections and increased malignancy risk, particularly leukemia and lymphoma (PMID: 15279807, 26050521).

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results using specimens containing leukocytes may not distinguish between germline and acquired variants and additional testing may be appropriate.", Pmids: "15279807|25426837|25426838|26050521|26182300|26483394|27112364|27989354|28657667|28767289|28888541|30733081|30862463|33471974|33864022", Gene_Name: "ATM", References: "15279807) Chun HH,Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst).. ;3(8-9):1187-96.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|26050521) Teive HA,Moro A,Moscovich M,Arruda WO,Munhoz RP,Raskin S,Ashizawa T. Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome. J Neurol Sci.. 2015;355(1-2):3-6.|26182300) Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor NM,Pennell E,MacMillan A,Fernandez B,Keller G,Lynch H,Shah SP,Guilford P,Gallinger S,Corso G,Roviello F,Caldas C,Oliveira C,Pharoah PD,Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol.. 2015;1(1):23-32.|26483394) Hu C,Hart SN,Bamlet WR,Moore RM,Nandakumar K,Eckloff BW,Lee YK,Petersen GM,McWilliams RR,Couch FJ. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev.. 2016;25(1):207-11.|27112364) Marabelli M,Cheng SC,Parmigiani G. Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk. Genet Epidemiol.. 2016;40(5):425-31.|27989354) Na R,Zheng SL,Han M,Yu H,Jiang D,Shah S,Ewing CM,Zhang L,Novakovic K,Petkewicz J,Gulukota K,Helseth DL,Quinn M,Humphries E,Wiley KE,Isaacs SD,Wu Y,Liu X,Zhang N,Wang CH,Khandekar J,Hulick PJ,Shevrin DH,Cooney KA,Shen Z,Partin AW,Carter HB,Carducci MA,Eisenberger MA,Denmeade SR,McGuire M,Walsh PC,Helfand BT,Brendler CB,Ding Q,Xu J,Isaacs WB. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol.. 2017;71(5):740-747.|28657667) Pili√É¬© PG,Johnson AM,Hanson KL,Dayno ME,Kapron AL,Stoffel EM,Cooney KA. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer.. 2017;123(20):3925-3932.|28767289) Shindo K,Yu J,Suenaga M,Fesharakizadeh S,Cho C,Macgregor-Das A,Siddiqui A,Witmer PD,Tamura K,Song TJ,Navarro Almario JA,Brant A,Borges M,Ford M,Barkley T,He J,Weiss MJ,Wolfgang CL,Roberts NJ,Hruban RH,Klein AP,Goggins M. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. J Clin Oncol.. 2017;35(30):3382-3390.|28888541) Lilyquist J,LaDuca H,Polley E,Davis BT,Shimelis H,Hu C,Hart SN,Dolinsky JS,Couch FJ,Goldgar DE. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol.. 2017;147(2):375-380.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|30862463) Valle L,de Voer RM,Goldberg Y,Sjursen W,F√É¬∂rsti A,Ruiz-Ponte C,Cald√É¬©s T,Garr√É¬© P,Olsen MF,Nordling M,Castellvi-Bel S,Hemminki K. Update on genetic predisposition to colorectal cancer and polyposis. Mol Aspects Med.. 2019;69():10-26.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|25426837) Age-related clonal hematopoiesis associated with adverse outcomes|33864022) Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG)"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The ATR gene is associated with autosomal recessive Seckel syndrome 1 (MedGen UID: 830512). There is also evidence suggesting ATR is associated with autosomal dominant predisposition to prostate (PMID: 27433846) and oropharyngeal cancer (PMID: 22341969). The data, however, are preliminary and insufficient to make a determination regarding these relationships.                                                          Seckel syndrome is characterized by microcephaly and absence of visceral malformations (PMID: 20301772). Microcephaly may become apparent in the second trimester of gestation, is typically non-progressive, and is associated with varying degrees of cognitive impairment and developmental delay (PMID: 25951892, 26050940). Severe pre- and post-natal growth failure is common (PMID: 25951892, 20301772). Structural brain malformations, craniosynostosis, seizures and pancytopenia have also been described (PMID: 26050940, 20301772).", Pmids: "20301772|22341969|25951892|26050940|27433846", Gene_Name: "ATR", References: "22341969) Tanaka A,Weinel S,Nagy N,O'Driscoll M,Lai-Cheong JE,Kulp-Shorten CL,Knable A,Carpenter G,Fisher SA,Hiragun M,Yanase Y,Hide M,Callen J,McGrath JA. Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome. Am J Hum Genet.. 2012;90(3):511-7.|25951892) Faheem M,Naseer MI,Rasool M,Chaudhary AG,Kumosani TA,Ilyas AM,Pushparaj P,Ahmed F,Algahtani HA,Al-Qahtani MH,Saleh Jamal H. Molecular genetics of human primary microcephaly: an overview. BMC Med Genomics.. 2015;8 Suppl 1(Suppl 1):S4.|26050940) Morris-Rosendahl DJ,Kaindl AM. What next-generation sequencing (NGS) technology has enabled us to learn about primary autosomal recessive microcephaly (MCPH). Mol Cell Probes.. 2015;29(5):271-81.|27433846) Pritchard CC,Mateo J,Walsh MF,De Sarkar N,Abida W,Beltran H,Garofalo A,Gulati R,Carreira S,Eeles R,Elemento O,Rubin MA,Robinson D,Lonigro R,Hussain M,Chinnaiyan A,Vinson J,Filipenko J,Garraway L,Taplin ME,AlDubayan S,Han GC,Beightol M,Morrissey C,Nghiem B,Cheng HH,Montgomery B,Walsh T,Casadei S,Berger M,Zhang L,Zehir A,Vijai J,Scher HI,Sawyers C,Schultz N,Kantoff PW,Solit D,Robson M,Van Allen EM,Offit K,de Bono J,Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.. 2016;375(5):443-53.|20301772) Primary Autosomal Recessive Microcephalies and Seckel Syndrome Spectrum Disorders"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The AXIN2 gene is associated with autosomal dominant oligodontia-colorectal cancer syndrome (MedGen UID: 324868).								  Oligodontia-colorectal cancer syndrome is associated with colon polyps and colorectal cancer as well as features of ectodermal dysplasia including severe oligodontia and sparse eyebrows, scalp and body hair (PMID: 15042511, 21416598, 21626677).", Pmids: "15042511|21416598|21626677", Gene_Name: "AXIN2", References: "15042511) Lammi L,Arte S,Somer M,Jarvinen H,Lahermo P,Thesleff I,Pirinen S,Nieminen P. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet.. 2004;74(5):1043-50.|21416598) Marvin ML,Mazzoni SM,Herron CM,Edwards S,Gruber SB,Petty EM. AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am J Med Genet A.. 2011;155A(4):898-902.|21626677) Bergendal B,Klar J,Stecks√É¬©n-Blicks C,Norderyd J,Dahl N. Isolated oligodontia associated with mutations in EDARADD, AXIN2, MSX1, and PAX9 genes. Am J Med Genet A.. 2011;155A(7):1616-22."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The BAP1 gene is associated with autosomal dominant BAP1 tumor predisposition syndrome (MedGen UID: 482122). There is also evidence suggesting BAP1 is associated with autosomal dominant predisposition to meningioma (PMID: 30517737). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  BAP1 tumor predisposition syndrome is associated with an increased risk for cutaneous and uveal melanoma, malignant pleural mesothelioma and renal cell carcinoma; lifetime cancer risks are unclear (PMID: 22935333, 23684012).", Pmids: "22935333|23684012|30517737", Gene_Name: "BAP1", References: "22935333) Carbone M,Ferris LK,Baumann F,Napolitano A,Lum CA,Flores EG,Gaudino G,Powers A,Bryant-Greenwood P,Krausz T,Hyjek E,Tate R,Friedberg J,Weigel T,Pass HI,Yang H. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med.. 2012;10():179.|23684012) Popova T,Hebert L,Jacquemin V,Gad S,Caux-Moncoutier V,Dubois-d'Enghien C,Richaudeau B,Renaudin X,Sellers J,Nicolas A,Sastre-Garau X,Desjardins L,Gyapay G,Raynal V,Sinilnikova OM,Andrieu N,Mani√É¬© E,de Pauw A,Gesta P,Bonadona V,Maugard CM,Penet C,Avril MF,Barillot E,Cabaret O,Delattre O,Richard S,Caron O,Benfodda M,Hu HH,Soufir N,Bressac-de Paillerets B,Stoppa-Lyonnet D,Stern MH. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet.. 2013;92(6):974-80.|30517737) Walpole S,Pritchard AL,Cebulla CM,Pilarski R,Stautberg M,Davidorf FH,de la Fouchardi√É¬®re A,Cabaret O,Golmard L,Stoppa-Lyonnet D,Garfield E,Njauw CN,Cheung M,Turunen JA,Repo P,J√É¬§rvinen RS,van Doorn R,Jager MJ,Luyten GPM,Marinkovic M,Chau C,Potrony M,H√É¬∂iom V,Helgadottir H,Pastorino L,Bruno W,Andreotti V,Dalmasso B,Ciccarese G,Queirolo P,Mastracci L,Wadt K,Kiilgaard JF,Speicher MR,van Poppelen N,Kilic E,Al-Jamal RT,Dianzani I,Betti M,Bergmann C,Santagata S,Dahiya S,Taibjee S,Burke J,Poplawski N,O'Shea SJ,Newton-Bishop J,Adlard J,Adams DJ,Lane AM,Kim I,Klebe S,Racher H,Harbour JW,Nickerson ML,Murali R,Palmer JM,Howlie M,Symmons J,Hamilton H,Warrier S,Glasson W,Johansson P,Robles-Espinoza CD,Ossio R,de Klein A,Puig S,Ghiorzo P,Nielsen M,Kivel√É¬§ TT,Tsao H,Testa JR,Gerami P,Stern MH,Paillerets BB,Abdel-Rahman MH,Hayward NK. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst.. 2018;110(12):1328-1341."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The BARD1 gene is associated with autosomal dominant predisposition to breast cancer (MedGen UID: 87542). Elevated risks for ovarian cancer and neuroblastoma have also been suggested (PMID: 22006311, 23334666). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.  Females with a pathogenic BARD1 variant have an increased risk of breast cancer; the lifetime risk is 22-29% (PMID: 28418444, 32091585, Kurian et al. 2017).", Pmids: "22006311|23334666|28418444|32091585", Gene_Name: "BARD1", References: "22006311) Walsh T,Casadei S,Lee MK,Pennil CC,Nord AS,Thornton AM,Roeb W,Agnew KJ,Stray SM,Wickramanayake A,Norquist B,Pennington KP,Garcia RL,King MC,Swisher EM. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A.. 2011;108(44):18032-7.|23334666) Pugh TJ,Morozova O,Attiyeh EF,Asgharzadeh S,Wei JS,Auclair D,Carter SL,Cibulskis K,Hanna M,Kiezun A,Kim J,Lawrence MS,Lichenstein L,McKenna A,Pedamallu CS,Ramos AH,Shefler E,Sivachenko A,Sougnez C,Stewart C,Ally A,Birol I,Chiu R,Corbett RD,Hirst M,Jackman SD,Kamoh B,Khodabakshi AH,Krzywinski M,Lo A,Moore RA,Mungall KL,Qian J,Tam A,Thiessen N,Zhao Y,Cole KA,Diamond M,Diskin SJ,Mosse YP,Wood AC,Ji L,Sposto R,Badgett T,London WB,Moyer Y,Gastier-Foster JM,Smith MA,Guidry Auvil JM,Gerhard DS,Hogarty MD,Jones SJ,Lander ES,Gabriel SB,Getz G,Seeger RC,Khan J,Marra MA,Meyerson M,Maris JM. The genetic landscape of high-risk neuroblastoma. Nat Genet.. 2013;45(3):279-84.|28418444) Couch FJ,Shimelis H,Hu C,Hart SN,Polley EC,Na J,Hallberg E,Moore R,Thomas A,Lilyquist J,Feng B,McFarland R,Pesaran T,Huether R,LaDuca H,Chao EC,Goldgar DE,Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol.. 2017;3(9):1190-1196.|32091585) Hu C,Polley EC,Yadav S,Lilyquist J,Shimelis H,Na J,Hart SN,Goldgar DE,Shah S,Pesaran T,Dolinsky JS,LaDuca H,Couch FJ. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. J Natl Cancer Inst.. 2020;112(12):1231-1241."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The BLM gene is associated with autosomal recessive Bloom syndrome (MedGen UID: 2685). Studies have also suggested BLM may be associated with autosomal dominant predisposition to colorectal cancer (PMID: 12242432, 26358404). The evidence, however, is preliminary and insufficient to make a determination regarding this relationship.                                                                          Bloom syndrome is characterized by proportionate small stature, microcephaly, abnormal skin pigmentation, facial anomalies, sun-sensitive facial erythema, infertility, immunodeficiency, and a predisposition to a wide variety of cancers (PMID: 16763388, 5770175).", Pmids: "5770175|12242432|16763388|26358404", Gene_Name: "BLM", References: "12242432) Gruber SB,Ellis NA,Scott KK,Almog R,Kolachana P,Bonner JD,Kirchhoff T,Tomsho LP,Nafa K,Pierce H,Low M,Satagopan J,Rennert H,Huang H,Greenson JK,Groden J,Rapaport B,Shia J,Johnson S,Gregersen PK,Harris CC,Boyd J,Rennert G,Offit K. BLM heterozygosity and the risk of colorectal cancer. Science.. 2002;297(5589):2013.|16763388) Diaz A,Vogiatzi MG,Sanz MM,German J. Evaluation of short stature, carbohydrate metabolism and other endocrinopathies in Bloom's syndrome. Horm Res.. 2006;66(3):111-7.|26358404) de Voer RM,Hahn MM,Mensenkamp AR,Hoischen A,Gilissen C,Henkes A,Spruijt L,van Zelst-Stams WA,Kets CM,Verwiel ET,Nagtegaal ID,Schackert HK,van Kessel AG,Hoogerbrugge N,Ligtenberg MJ,Kuiper RP. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep.. 2015;5():14060.|5770175) ValidYN,LastName,ForeName,Initials. Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients. Am J Hum Genet.. 1969;21(2):196-227."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The BMPR1A gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518).  JPS is characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. There is an increased risk of developing colon cancer and stomach cancer (PMID: 20859198, 2705469). The risk of colon cancer is 40-50% (PMID: 22846733, 9869523) and the risk of gastric cancer is up to 21% (PMID: 12221036).", Pmids: "2705469|9869523|12221036|20859198|22846733", Gene_Name: "BMPR1A", References: "12221036) Dunlop MG, , . Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut.. 2002;51 Suppl 5():V21-7.|20859198) Pollock J,Welsh JS. Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol.. 2011;34(3):332-6.|22846733) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Genetic testing by cancer site: colon (polyposis syndromes). Cancer J.. ;18(4):328-33.|2705469) Walpole IR,Cullity G. Juvenile polyposis: a case with early presentation and death attributable to adenocarcinoma of the pancreas. Am J Med Genet.. 1989;32(1):1-8.|9869523) Howe JR,Mitros FA,Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol.. 1998;5(8):751-6."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The BRCA1 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793). Additionally, the BRCA1 gene has preliminary evidence supporting a correlation with autosomal recessive Fanconi anemia (MedGen UID: 1632414).  HBOC due to a clinically significant change in the BRCA1 gene is characterized by an increased risk of breast cancer (in both females and males), ovarian cancer, prostate cancer, pancreatic cancer and possibly melanoma when compared to individuals in the general population. The lifetime risk of breast cancer for females with a positive BRCA1 variant is 53-78% (PMID: 32676552, 33471974) and the chance of developing breast cancer again in their other breast (contralateral breast cancer) within 10 years after the first diagnosis is estimated to be 20-42% (PMID: 26700119). The lifetime risk to develop ovarian or fallopian tube cancer is 44-65% (PMID: 32676552). Males with HBOC due to a change in the BRCA1 gene have a 1-2% lifetime risk of developing breast cancer (PMID: 18042939) and an increased risk of prostate cancer, although specific lifetime risks are not clear (PMID: 30900310). Both males and females with a positive BRCA1 variant have a 3-4% lifetime risk of pancreatic cancer (PMID: 29922827, 27306910).", Pmids: "18042939|26700119|27306910|29922827|30900310|32676552|33471974", Gene_Name: "BRCA1", References: "18042939) Tai YC,Domchek S,Parmigiani G,Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst.. 2007;99(23):1811-4.|26700119) van den Broek AJ,van 't Veer LJ,Hooning MJ,Cornelissen S,Broeks A,Rutgers EJ,Smit VT,Cornelisse CJ,van Beek M,Janssen-Heijnen ML,Seynaeve C,Westenend PJ,Jobsen JJ,Siesling S,Tollenaar RA,van Leeuwen FE,Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol.. 2016;34(5):409-18.|27306910) Streff H,Profato J,Ye Y,Nebgen D,Peterson SK,Singletary C,Arun BK,Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist.. 2016;21(7):869-74.|29922827) Hu C,Hart SN,Polley EC,Gnanaolivu R,Shimelis H,Lee KY,Lilyquist J,Na J,Moore R,Antwi SO,Bamlet WR,Chaffee KG,DiCarlo J,Wu Z,Samara R,Kasi PM,McWilliams RR,Petersen GM,Couch FJ. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA.. 2018;319(23):2401-2409.|30900310) Oh M,Alkhushaym N,Fallatah S,Althagafi A,Aljadeed R,Alsowaida Y,Jeter J,Martin JR,Babiker HM,McBride A,Abraham I. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate.. 2019;79(8):880-895.|32676552) Chen J,Bae E,Zhang L,Hughes K,Parmigiani G,Braun D,Rebbeck TR. Penetrance of Breast and Ovarian Cancer in Women Who Carry a  Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectr.. 2020;4(4):pkaa029.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The BRCA2 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793) and autosomal recessive Fanconi anemia, type D1 (FA-D1) (MedGen UID: 325420).  Females with a pathogenic BRCA2 variant have a 44-80% lifetime risk of breast cancer (PMID: 32676552, 33471974). The risk for contralateral breast cancer 10 years after primary diagnosis is 10-30% (PMID: 26700119). The lifetime risk for ovarian, fallopian tube or peritoneal cancer is 19-46% (PMID: 32676552). Males have a 7-8% risk of breast cancer (PMID: 18042939) and a 22-32% risk of prostate cancer (PMID: 30900310). Both males and females have an increased risk of pancreatic cancer (4-9% lifetime risk) (PMID: 29922827, 27306910) and melanoma (lifetime risks are not established) (PMID: 10433620).  Biallelic pathogenic variants in BRCA2 are associated with a particularly severe form of Fanconi anemia (PMID: 16825431) characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). Risks of leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516), with up to a 97% risk of malignancy by 5 years of age (PMID: 16825431).", Pmids: "8986277|10433620|12393424|12393516|16825431|18042939|20417588|20507306|26700119|27306910|29922827|30900310|32676552|33471974", Gene_Name: "BRCA2", References: "10433620) ValidYN,CollectiveName,AffiliationInfo. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst.. 1999;91(15):1310-6.|12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|16825431) Alter BP,Rosenberg PS,Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet.. 2007;44(1):1-9.|18042939) Tai YC,Domchek S,Parmigiani G,Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst.. 2007;99(23):1811-4.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|26700119) van den Broek AJ,van 't Veer LJ,Hooning MJ,Cornelissen S,Broeks A,Rutgers EJ,Smit VT,Cornelisse CJ,van Beek M,Janssen-Heijnen ML,Seynaeve C,Westenend PJ,Jobsen JJ,Siesling S,Tollenaar RA,van Leeuwen FE,Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol.. 2016;34(5):409-18.|27306910) Streff H,Profato J,Ye Y,Nebgen D,Peterson SK,Singletary C,Arun BK,Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist.. 2016;21(7):869-74.|29922827) Hu C,Hart SN,Polley EC,Gnanaolivu R,Shimelis H,Lee KY,Lilyquist J,Na J,Moore R,Antwi SO,Bamlet WR,Chaffee KG,DiCarlo J,Wu Z,Samara R,Kasi PM,McWilliams RR,Petersen GM,Couch FJ. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA.. 2018;319(23):2401-2409.|30900310) Oh M,Alkhushaym N,Fallatah S,Althagafi A,Aljadeed R,Alsowaida Y,Jeter J,Martin JR,Babiker HM,McBride A,Abraham I. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate.. 2019;79(8):880-895.|32676552) Chen J,Bae E,Zhang L,Hughes K,Parmigiani G,Braun D,Rebbeck TR. Penetrance of Breast and Ovarian Cancer in Women Who Carry a  Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectr.. 2020;4(4):pkaa029.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The BRIP1 gene is associated with autosomal dominant predisposition to ovarian cancer (PMID: 30733081) and autosomal recessive Fanconi anemia (MedGen UID: 323015). There is also evidence suggesting BRIP1 is associated with autosomal dominant predisposition to breast and prostate cancer (PMID: 17033622, 28418444, 30733081, 32708810, 32853339). The data, however, are preliminary and insufficient to make a determination regarding these relationships.                                                          Females with a pathogenic BRIP1 variant have approximately a 6-13% risk of ovarian cancer (PMID: 26315354, 27296296, 32359370).   Autosomal recessive Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risk of leukemia and early onset solid tumors is significantly elevated (PMID: 20507306, 12393424, 12393516).", Pmids: "8986277|12393424|12393516|17033622|20417588|20507306|26315354|27296296|28418444|30733081|32359370|32708810|32853339", Gene_Name: "BRIP1", References: "12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|17033622) Seal S,Thompson D,Renwick A,Elliott A,Kelly P,Barfoot R,Chagtai T,Jayatilake H,Ahmed M,Spanova K,North B,McGuffog L,Evans DG,Eccles D, ,Easton DF,Stratton MR,Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet.. 2006;38(11):1239-41.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|26315354) Ramus SJ,Song H,Dicks E,Tyrer JP,Rosenthal AN,Intermaggio MP,Fraser L,Gentry-Maharaj A,Hayward J,Philpott S,Anderson C,Edlund CK,Conti D,Harrington P,Barrowdale D,Bowtell DD,Alsop K,Mitchell G, ,Cicek MS,Cunningham JM,Fridley BL,Alsop J,Jimenez-Linan M,Poblete S,Lele S,Sucheston-Campbell L,Moysich KB,Sieh W,McGuire V,Lester J,Bogdanova N,D√É¬ºrst M,Hillemanns P, ,Odunsi K,Whittemore AS,Karlan BY,D√É¬∂rk T,Goode EL,Menon U,Jacobs IJ,Antoniou AC,Pharoah PD,Gayther SA. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst.. 2015;107(11):.|27296296) Tung N,Domchek SM,Stadler Z,Nathanson KL,Couch F,Garber JE,Offit K,Robson ME. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol.. 2016;13(9):581-8.|28418444) Couch FJ,Shimelis H,Hu C,Hart SN,Polley EC,Na J,Hallberg E,Moore R,Thomas A,Lilyquist J,Feng B,McFarland R,Pesaran T,Huether R,LaDuca H,Chao EC,Goldgar DE,Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol.. 2017;3(9):1190-1196.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|32359370) Suszynska M,Ratajska M,Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res.. 2020;13(1):50.|32708810) Brand√É¬£o A,Paulo P,Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Mol Sci.. 2020;21(14):.|32853339) Darst BF,Dadaev T,Saunders E,Sheng X,Wan P,Pooler L,Xia LY,Chanock S,Berndt SI,Gapstur SM,Stevens V,Albanes D,Weinstein SJ,Gnanapragasam V,Giles GG,Nguyen-Dumont T,Milne RL,Pomerantz M,Schmidt JA,Mucci L,Catalona WJ,Hetrick KN,Doheny KF,MacInnis RJ,Southey MC,Eeles RA,Wiklund F,Kote-Jarai Z,Conti DV,Haiman CA. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. J Natl Cancer Inst.. 2021;113(5):616-625.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CASR gene is associated with a spectrum of disorders including autosomal dominant familial hypocalciuric hypercalcemia (FHH) (MedGen UID: 369200), autosomal dominant hypocalcemia (ADH) (MedGen UID: 87438), ADH with Bartter syndrome (MedGen UID: 811594), autosomal recessive neonatal severe hyperparathyroidism (NSHPT) (MedGen UID: 331326), and possibly familial isolated hyperparathyroidism (FIHP) (PMID: 14985373, 21521328). There is also evidence suggesting CASR is associated with autosomal dominant idiopathic generalized epilepsy (PMID: 18756473) and chronic pancreatitis (PMID: 14641934, 16497624). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  CASR-related conditions include multiple disorders resulting in abnormal calcium levels. Pathogenic loss-of-function (LOF) variants cause FHH, characterized by hypercalcemia and hypocalciuria, although most affected individuals are asymptomatic (PMID: 31189130). Individuals with FIHP often present with one or more hyperplastic parathyroid glands, resulting in elevated parathyroid hormone and hypercalemia; like FHH, most individuals are asymptomatic due to early diagnosis and treatment (PMID: 31189130). NSHPT presents in infancy with parathyroid hyperplasia, elevated parathyroid hormone levels and hypercalcemia, which can result in bone demineralization and failure to thrive. Untreated NSHPT may lead to a severe, life-threatening neurological disorder (PMID: 31189130). There are reports of homozygous CASR variants causing a milder FHH-like phenotype (PMID: 31189130).

Pathogenic gain-of-function (GOF) variants in CASR cause ADH. ADH is characterized by hypoparathyroidism, hypocalcemia and hypercalciuria although approximately half of affected individuals have no associated health problems (PMID: 31189130). A subset of GOF variants can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130).", Pmids: "14641934|14985373|16497624|18756473|21521328|31189130", Gene_Name: "CASR", References: "14641934) Felderbauer P,Hoffmann P,Einw√É¬§chter H,Bulut K,Ansorge N,Schmitz F,Schmidt WE. A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. BMC Gastroenterol.. 2003;3():34.|14985373) Warner J,Epstein M,Sweet A,Singh D,Burgess J,Stranks S,Hill P,Perry-Keene D,Learoyd D,Robinson B,Birdsey P,Mackenzie E,Teh BT,Prins JB,Cardinal J. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet.. 2004;41(3):155-60.|16497624) Felderbauer P,Klein W,Bulut K,Ansorge N,Dekomien G,Werner I,Epplen JT,Schmitz F,Schmidt WE. Mutations in the calcium-sensing receptor: a new genetic risk factor for chronic pancreatitis? Scand J Gastroenterol.. 2006;41(3):343-8.|18756473) Kapoor A,Satishchandra P,Ratnapriya R,Reddy R,Kadandale J,Shankar SK,Anand A. An idiopathic epilepsy syndrome linked to 3q13.3-q21 and missense mutations in the extracellular calcium sensing receptor gene. Ann Neurol.. 2008;64(2):158-67.|21521328) Frank-Raue K,Leidig-Bruckner G,Haag C,Schulze E,Lorenz A,Schmitz-Winnenthal H,Raue F. Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf).. 2011;75(1):50-5.|31189130) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Molecular and clinical insights from studies of calcium-sensing receptor mutations. J Mol Endocrinol.. 2019;63(2):R1-R16."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CDC73 gene is associated with autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid carcinoma, and familial isolated hyperparathyroidism (FIH) (MedGen UID: 310065, 146361, 333554), collectively referred to as CDC73-related conditions. There is also evidence suggesting CDC73 is associated with autosomal dominant predisposition to malignant uterine tumors (PMID: 23293331, 12434154, 23029104). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  CDC73-related conditions are characterized by primary hyperparathyroidism, which occurs in over 70% of cases (PMID: 16720667, 20301744). This primary hyperparathyroidism is typically caused by benign parathyroid adenomas, though it can also be due to an underlying parathyroid carcinoma (PMID: 20301744). Additional features include ossifying jaw fibromas, uterine fibroids, renal cysts, hamartomas and Wilms tumor.", Pmids: "12434154|16720667|20301744|23029104|23293331", Gene_Name: "CDC73", References: "12434154) Carpten JD,Robbins CM,Villablanca A,Forsberg L,Presciuttini S,Bailey-Wilson J,Simonds WF,Gillanders EM,Kennedy AM,Chen JD,Agarwal SK,Sood R,Jones MP,Moses TY,Haven C,Petillo D,Leotlela PD,Harding B,Cameron D,Pannett AA,H√É¬∂√É¬∂g A,Heath H,James-Newton LA,Robinson B,Zarbo RJ,Cavaco BM,Wassif W,Perrier ND,Rosen IB,Kristoffersson U,Turnpenny PD,Farnebo LO,Besser GM,Jackson CE,Morreau H,Trent JM,Thakker RV,Marx SJ,Teh BT,Larsson C,Hobbs MR. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet.. 2002;32(4):676-80.|16720667) Guarnieri V,Scillitani A,Muscarella LA,Battista C,Bonfitto N,Bisceglia M,Minisola S,Mascia ML,D'Agruma L,Cole DE. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab.. 2006;91(8):2827-32.|23029104) Wang O,Wang C,Nie M,Cui Q,Guan H,Jiang Y,Li M,Xia W,Meng X,Xing X. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PLoS One.. 2012;7(9):e45567.|23293331) Bricaire L,Odou MF,Cardot-Bauters C,Delemer B,North MO,Salenave S,Vezzosi D,Kuhn JM,Murat A,Caron P,Sadoul JL,Silve C,Chanson P,Barlier A,Clauser E,Porchet N,Groussin L, . Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab.. 2013;98(2):E403-8.|20301744) CDC73-Related Disorders"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CDH1 gene is associated with autosomal dominant predisposition to diffuse gastric cancer and lobular breast cancer, collectively known as hereditary diffuse gastric cancer (HDGC) syndrome (MedGen UID: 310839).  The estimated lifetime risk of diffuse gastric cancer in individuals with a pathogenic CDH1 variant is 67-83% (PMID: 11729114), although recent studies suggest the risk may be lower, at 33-42% (PMID: 31246251, 31296550). The lifetime risk of lobular cancer in females is 27%-52% (PMID: 17545690, 11729114, 33471974).", Pmids: "11729114|17545690|31246251|31296550|33471974", Gene_Name: "CDH1", References: "11729114) Pharoah PD,Guilford P,Caldas C, . Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology.. 2001;121(6):1348-53.|17545690) Kaurah P,MacMillan A,Boyd N,Senz J,De Luca A,Chun N,Suriano G,Zaor S,Van Manen L,Gilpin C,Nikkel S,Connolly-Wilson M,Weissman S,Rubinstein WS,Sebold C,Greenstein R,Stroop J,Yim D,Panzini B,McKinnon W,Greenblatt M,Wirtzfeld D,Fontaine D,Coit D,Yoon S,Chung D,Lauwers G,Pizzuti A,Vaccaro C,Redal MA,Oliveira C,Tischkowitz M,Olschwang S,Gallinger S,Lynch H,Green J,Ford J,Pharoah P,Fernandez B,Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA.. 2007;297(21):2360-72.|31246251) Roberts ME,Ranola JMO,Marshall ML,Susswein LR,Graceffo S,Bohnert K,Tsai G,Klein RT,Hruska KS,Shirts BH. Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers. JAMA Oncol.. 2019;5(9):1325-1331.|31296550) Xicola RM,Li S,Rodriguez N,Reinecke P,Karam R,Speare V,Black MH,LaDuca H,Llor X. Clinical features and cancer risk in families with pathogenic  variants irrespective of clinical criteria. J Med Genet.. 2019;56(12):838-843.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CDK4 gene is associated with autosomal dominant predisposition to cutaneous melanoma (MedGen UID: 268851).  CDK4-related cutaneous melanoma is characterized by early presentation of atypical nevi and early-onset melanoma (PMID: 15880589, 23384855, 30775140). In a study of individuals with pathogenic CDK4 variants, the penetrance at age 50 was 74% (PMID: 23384855). Additional risk factors including pale skin and excessive sun exposure may amplify lifetime risks.", Pmids: "15880589|23384855|30775140", Gene_Name: "CDK4", References: "15880589) Molven A,Grimstvedt MB,Steine SJ,Harland M,Avril MF,Hayward NK,Akslen LA. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer.. 2005;44(1):10-8.|23384855) Puntervoll HE,Yang XR,Vetti HH,Bachmann IM,Avril MF,Benfodda M,Catrical√É¬† C,Dalle S,Duval-Modeste AB,Ghiorzo P,Grammatico P,Harland M,Hayward NK,Hu HH,Jouary T,Martin-Denavit T,Ozola A,Palmer JM,Pastorino L,Pjanova D,Soufir N,Steine SJ,Stratigos AJ,Thomas L,Tinat J,Tsao H,Veinalde R,Tucker MA,Bressac-de Paillerets B,Newton-Bishop JA,Goldstein AM,Akslen LA,Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet.. 2013;50(4):264-70.|30775140) Rossi M,Pellegrini C,Cardelli L,Ciciarelli V,Di Nardo L,Fargnoli MC. Familial Melanoma: Diagnostic and Management Implications. Dermatol Pract Concept.. 2019;9(1):10-16."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CDKN1B gene is associated with autosomal dominant multiple endocrine neoplasia type 4 (MEN4) (MedGen UID: 373469).  MEN4 is characterized by parathyroid and pituitary tumors as well as tumors of the adrenal glands, kidney and reproductive organs (PMID: 23933118, 23140918).", Pmids: "23140918|23933118", Gene_Name: "CDKN1B", References: "23140918) Pasquali D,Di Matteo FM,Renzullo A,Accardo G,Esposito D,Barbato F,Colantuoni V,Circelli L,Conzo G. Multiple endocrine neoplasia, the old and the new: a mini review. G Chir.. ;33(11-12):370-3.|23933118) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol.. 2014;386(1-2):2-15."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CDKN1C gene is associated with autosomal dominant Beckwith-Wiedemann syndrome (BWS) (MedGen UID: 2562) and IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) (MedGen UID: 337364).  BWS is an overgrowth disorder characterized by macrosomia, macroglossia, visceromegaly, hemihyperplasia, omphalocele, neonatal hypoglycemia, and renal abnormalities. There is an increased risk for neoplasia, particularly Wilms tumor, hepatoblastoma, neuroblastoma, adrenocortical carcinoma and rhabdomyosarcoma; these risks are highest in the newborn period through eight years of age (PMID: 24335096, 24911853, 20301568).

IMAGe syndrome is also characterized by growth abnormality; however, unlike BWS, affected individuals present with growth restriction. In addition to the clinical findings indicated by the acronym (Intrauterine growth restriction, Metaphyseal dysplasia, congenital Adrenal hypoplasia, and Genital anomalies), some may present with craniofacial features such as low-set ears, flat nasal bridge and short nose (PMID: 24098681, 10599684, 14760276). Genital anomalies occur mostly in males and include micropenis, undescended testes and hypospadias (PMID: 14760276).", Pmids: "10599684|14760276|20301568|24098681|24335096|24911853", Gene_Name: "CDKN1C", References: "10599684) Vilain E,Le Merrer M,Lecointre C,Desangles F,Kay MA,Maroteaux P,McCabe ER. IMAGe, a new clinical association of intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies. J Clin Endocrinol Metab.. 1999;84(12):4335-40.|14760276) Pedreira CC,Savarirayan R,Zacharin MR. IMAGe syndrome: a complex disorder affecting growth, adrenal and gonadal function, and skeletal development. J Pediatr.. 2004;144(2):274-7.|24098681) Hamajima N,Johmura Y,Suzuki S,Nakanishi M,Saitoh S. Increased protein stability of CDKN1C causes a gain-of-function phenotype in patients with IMAGe syndrome. PLoS One.. 2013;8(9):e75137.|24335096) Brioude F,Lacoste A,Netchine I,Vazquez MP,Auber F,Audry G,Gauthier-Villars M,Brugieres L,Gicquel C,Le Bouc Y,Rossignol S. Beckwith-Wiedemann syndrome: growth pattern and tumor risk according to molecular mechanism, and guidelines for tumor surveillance. Horm Res Paediatr.. 2013;80(6):457-65.|24911853) Gizewska M,Wilk M,Patalan M,Mackay D,Peregud-Pegorzelski J,Gawrych E,Walczak M,Petriczko E,Brodkiewicz A. The significance of molecular studies in the long-term follow-up of children with beckwith- wiedemann syndrome. Turk J Pediatr.. 2014;56(2):177-82.|20301568) Beckwith wiedemann syndrome"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.  The variant identified in this individual impacts the p14ARF protein, which is associated with melanoma-NST syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and neural system tumors including astrocytoma and nerve sheath tumors (PMID: 9622062, 11136714, 17047042). Variants that only affect the p14ARF transcript are not known to be associated with pancreatic cancer. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants are currently unknown.", Pmids: "9622062|11136714|17047042", Gene_Name: "CDKN2A/p14", References: "11136714) Randerson-Moor JA,Harland M,Williams S,Cuthbert-Heavens D,Sheridan E,Aveyard J,Sibley K,Whitaker L,Knowles M,Bishop JN,Bishop DT. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet.. 2001;10(1):55-62.|17047042) Goldstein AM,Chan M,Harland M,Gillanders EM,Hayward NK,Avril MF,Azizi E,Bianchi-Scarra G,Bishop DT,Bressac-de Paillerets B,Bruno W,Calista D,Cannon Albright LA,Demenais F,Elder DE,Ghiorzo P,Gruis NA,Hansson J,Hogg D,Holland EA,Kanetsky PA,Kefford RF,Landi MT,Lang J,Leachman SA,Mackie RM,Magnusson V,Mann GJ,Niendorf K,Newton Bishop J,Palmer JM,Puig S,Puig-Butille JA,de Snoo FA,Stark M,Tsao H,Tucker MA,Whitaker L,Yakobson E, . High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res.. 2006;66(20):9818-28.|9622062) Bahuau M,Vidaud D,Jenkins RB,Bi√É¬®che I,Kimmel DW,Assouline B,Smith JS,Alderete B,Cayuela JM,Harpey JP,Caille B,Vidaud M. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res.. 1998;58(11):2298-303."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CDKN2A gene is associated with autosomal dominant melanoma-pancreatic cancer syndrome (MedGen UID: 325450) and melanoma-neural system tumor (NST) syndrome (MedGen UID: 331890). The CDKN2A gene encodes two main proteins, p16INK4a and p14ARF.  The variant identified in this individual impacts the p16INK4a protein, which is associated with melanoma-pancreatic cancer syndrome, also known as familial atypical multiple mole melanoma (FAMMM) syndrome. Affected individuals have an increased risk of developing multiple melanocytic nevi, cutaneous melanoma and pancreatic cancer. The lifetime risk of melanoma is 28-67%; the risk of pancreatic cancer is approximately 17% (PMID: 12072543, 16234564, 10956390, 24935963) although one study has suggested the risk may be up to 58% (PMID: 21150883). Variants affecting only the p16INK4a transcript are not known to be associated with neural system tumors. The cancer risks for individuals who have homozygous or compound heterozygous CDKN2A pathogenic variants is currently unknown.", Pmids: "10956390|12072543|16234564|21150883|24935963", Gene_Name: "CDKN2A/p16", References: "10956390) Vasen HF,Gruis NA,Frants RR,van Der Velden PA,Hille ET,Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer.. 2000;87(6):809-11.|12072543) Bishop DT,Demenais F,Goldstein AM,Bergman W,Bishop JN,Bressac-de Paillerets B,Chompret A,Ghiorzo P,Gruis N,Hansson J,Harland M,Hayward N,Holland EA,Mann GJ,Mantelli M,Nancarrow D,Platz A,Tucker MA, . Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst.. 2002;94(12):894-903.|16234564) Begg CB,Orlow I,Hummer AJ,Armstrong BK,Kricker A,Marrett LD,Millikan RC,Gruber SB,Anton-Culver H,Zanetti R,Gallagher RP,Dwyer T,Rebbeck TR,Mitra N,Busam K,From L,Berwick M, . Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst.. 2005;97(20):1507-15.|21150883) McWilliams RR,Wieben ED,Rabe KG,Pedersen KS,Wu Y,Sicotte H,Petersen GM. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet.. 2011;19(4):472-8.|24935963) Helgadottir H,H√É¬∂iom V,J√É¬∂nsson G,Tuominen R,Ingvar C,Borg A,Olsson H,Hansson J. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. J Med Genet.. 2014;51(8):545-52."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CEBPA gene is associated with autosomal dominant predisposition to familial acute myeloid leukemia (AML) (MedGen UID: 9730).  Familial AML is characterized by multiple diagnoses of this cancer type within a family. The age at diagnosis can be variable; however, it appears to have an earlier onset than sporadic cases (PMID: 18946494, 26162409).", Pmids: "18946494|26162409", Gene_Name: "CEBPA", References: "18946494) Renneville A,Mialou V,Philippe N,Kagialis-Girard S,Biggio V,Zabot MT,Thomas X,Bertrand Y,Preudhomme C. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia.. 2009;23(4):804-6.|26162409) Tawana K,Wang J,Renneville A,B√É¬∂d√É¬∂r C,Hills R,Loveday C,Savic A,Van Delft FW,Treleaven J,Georgiades P,Uglow E,Asou N,Uike N,Debeljak M,Jazbec J,Ancliff P,Gale R,Thomas X,Mialou V,D√É¬∂hner K,Bullinger L,Mueller B,Pabst T,Stelljes M,Schlegelberger B,Wozniak E,Iqbal S,Okosun J,Araf S,Frank AK,Lauridsen FB,Porse B,Nerlov C,Owen C,Dokal I,Gribben J,Smith M,Preudhomme C,Chelala C,Cavenagh J,Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood.. 2015;126(10):1214-23."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CFTR gene is associated with autosomal recessive cystic fibrosis (CF) (MedGen UID: 41393) and congenital bilateral absence of the vas deferens (CBAVD) (MedGen UID: 98021). Additionally, CFTR is associated with an increased risk for chronic pancreatitis (PMID: 17003641, 11729110).   Cystic fibrosis (CF) is usually a childhood onset disease characterized by the buildup of mucus that can damage the digestive and respiratory systems. Milder forms of CFTR-related disorders include congenital absence of the vas deferens (CAVD) (MedGen UID: 430259) associated with infertility, respiratory manifestations, and hereditary pancreatitis (MedGen UID: 116056). Pathogenic variants in CFTR may confer an approximately 4-10 fold increased risk for chronic pancreatitis in heterozygous carriers (PMID: 20977904, 21520337, 11729110), although the absolute risk of pancreatitis remains low (less than 1 in 100; PMID: 31882447). Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The combination of variants identified in an affected individual impacts the observed clinical features and severity of the disorders (PMID: 20301428, 24624459).", Pmids: "11729110|17003641|20301428|20977904|21520337|24624459|25170203|31882447", Gene_Name: "CFTR", References: "25170203) Becker AE,Hernandez YG,Frucht H,Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol.. 2014;20(32):11182-98.|11729110) Cystic fibrosis gene mutations and pancreatitis risk relation to epithelial ion transport and trypsin inhibitor gene mutations|17003641) Identification of cftr, prss1, and spink1 mutations in 381 patients with pancreatitis|20301428) Cystic fibrosis|20977904) Combined bicarbonate conductance impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis|21520337) Common icftri haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens|31882447) Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions|24624459) Pancreatitis Overview"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CHEK2 gene is associated with autosomal dominant predisposition to breast, colon, thyroid and prostate cancer (PMID: 15492928, 18759107, 21807500, 21876083, 25431674). Additionally, there is evidence supporting a correlation with CHEK2 and autosomal dominant predisposition to ovarian, renal and urinary tract cancer (PMID: 26681312, 27632928, 26424751, 11719428, 15492928, 29978187); however, the available evidence is insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with a pathogenic CHEK2 variant is 20-44% (PMID: 18172190, 21876083, 33471974). There is also an increased risk for male breast, colorectal, prostate and thyroid cancers; however, lifetime risks are not established (PMID: 18759107, 21807500, 23713947, 15492928, 25431674). While there is evidence to suggest an increased risk for various primary cancers among homozygotes and compound heterozygotes for most pathogenic CHEK2 variants, these risks are not established (PMID: 30858171, 27900359). For the well-studied c.1100del variant, homozygotes have approximately a 4-6 fold increased risk of breast cancer (PMID: 22058428, 23652375).", Pmids: "11719428|15492928|18172190|18759107|21807500|21876083|22058428|23652375|23713947|25431674|26424751|26681312|27632928|27900359|29978187|30858171|33471974", Gene_Name: "CHEK2", References: "11719428) Lee SB,Kim SH,Bell DW,Wahrer DC,Schiripo TA,Jorczak MM,Sgroi DC,Garber JE,Li FP,Nichols KE,Varley JM,Godwin AK,Shannon KM,Harlow E,Haber DA. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res.. 2001;61(22):8062-7.|15492928) Cybulski C,G√É¬≥rski B,Huzarski T,Masoj√Ñ‚Ä° B,Mierzejewski M,Debniak T,Teodorczyk U,Byrski T,Gronwald J,Matyjasik J,Zlowocka E,Lenner M,Grabowska E,Nej K,Castaneda J,Medrek K,Szyma√Ö‚Äûska A,Szyma√Ö‚Äûska J,Kurzawski G,Suchy J,Oszurek O,Witek A,Narod SA,Lubi√Ö‚Äûski J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet.. 2004;75(6):1131-5.|18172190) Weischer M,Bojesen SE,Ellervik C,Tybjaerg-Hansen A,Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol.. 2008;26(4):542-8.|18759107) Wasielewski M,den Bakker MA,van den Ouweland A,Meijer-van Gelder ME,Portengen H,Klijn JG,Meijers-Heijboer H,Foekens JA,Schutte M. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat.. 2009;116(2):397-400.|21807500) Xiang HP,Geng XP,Ge WW,Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer.. 2011;47(17):2546-51.|21876083) Cybulski C,Woko√Ö‚Äöorczyk D,Jakubowska A,Huzarski T,Byrski T,Gronwald J,Masoj√Ñ‚Ä° B,Deebniak T,G√É¬≥rski B,Blecharz P,Narod SA,Lubi√Ö‚Äûski J. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol.. 2011;29(28):3747-52.|22058428) Adank MA,Jonker MA,Kluijt I,van Mil SE,Oldenburg RA,Mooi WJ,Hogervorst FB,van den Ouweland AM,Gille JJ,Schmidt MK,van der Vaart AW,Meijers-Heijboer H,Waisfisz Q. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet.. 2011;48(12):860-3.|23652375) Huijts PE,Hollestelle A,Balliu B,Houwing-Duistermaat JJ,Meijers CM,Blom JC,Ozturk B,Krol-Warmerdam EM,Wijnen J,Berns EM,Martens JW,Seynaeve C,Kiemeney LA,van der Heijden HF,Tollenaar RA,Devilee P,van Asperen CJ. CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer. Eur J Hum Genet.. 2014;22(1):46-51.|23713947) Han FF,Guo CL,Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol.. 2013;32(6):329-35.|25431674) Hale V,Weischer M,Park JY. CHEK2 (√¢ÀÜ‚Äî) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer.. 2014;2014():294575.|26424751) Lawrenson K,Iversen ES,Tyrer J,Weber RP,Concannon P,Hazelett DJ,Li Q,Marks JR,Berchuck A,Lee JM,Aben KK,Anton-Culver H,Antonenkova N, , ,Bandera EV,Bean Y,Beckmann MW,Bisogna M,Bjorge L,Bogdanova N,Brinton LA,Brooks-Wilson A,Bruinsma F,Butzow R,Campbell IG,Carty K,Chang-Claude J,Chenevix-Trench G,Chen A,Chen Z,Cook LS,Cramer DW,Cunningham JM,Cybulski C,Plisiecka-Halasa J,Dennis J,Dicks E,Doherty JA,D√É¬∂rk T,du Bois A,Eccles D,Easton DT,Edwards RP,Eilber U,Ekici AB,Fasching PA,Fridley BL,Gao YT,Gentry-Maharaj A,Giles GG,Glasspool R,Goode EL,Goodman MT,Gronwald J,Harter P,Hasmad HN,Hein A,Heitz F,Hildebrandt MA,Hillemanns P,Hogdall E,Hogdall C,Hosono S,Jakubowska A,Paul J,Jensen A,Karlan BY,Kjaer SK,Kelemen LE,Kellar M,Kelley JL,Kiemeney LA,Krakstad C,Lambrechts D,Lambrechts S,Le ND,Lee AW,Cannioto R,Leminen A,Lester J,Levine DA,Liang D,Lissowska J,Lu K,Lubinski J,Lundvall L,Massuger LF,Matsuo K,McGuire V,McLaughlin JR,Nevanlinna H,McNeish I,Menon U,Modugno F,Moysich KB,Narod SA,Nedergaard L,Ness RB,Noor Azmi MA,Odunsi K,Olson SH,Orlow I,Orsulic S,Pearce CL,Pejovic T,Pelttari LM,Permuth-Wey J,Phelan CM,Pike MC,Poole EM,Ramus SJ,Risch HA,Rosen B,Rossing MA,Rothstein JH,Rudolph A,Runnebaum IB,Rzepecka IK,Salvesen HB,Budzilowska A,Sellers TA,Shu XO,Shvetsov YB,Siddiqui N,Sieh W,Song H,Southey MC,Sucheston L,Tangen IL,Teo SH,Terry KL,Thompson PJ,Timorek A,Tworoger SS,Van Nieuwenhuysen E,Vergote I,Vierkant RA,Wang-Gohrke S,Walsh C,Wentzensen N,Whittemore AS,Wicklund KG,Wilkens LR,Woo YL,Wu X,Wu AH,Yang H,Zheng W,Ziogas A,Coetzee GA,Freedman ML,Monteiro AN,Moes-Sosnowska J,Kupryjanczyk J,Pharoah PD,Gayther SA,Schildkraut JM. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis.. 2015;36(11):1341-53.|26681312) Susswein LR,Marshall ML,Nusbaum R,Vogel Postula KJ,Weissman SM,Yackowski L,Vaccari EM,Bissonnette J,Booker JK,Cremona ML,Gibellini F,Murphy PD,Pineda-Alvarez DE,Pollevick GD,Xu Z,Richard G,Bale S,Klein RT,Hruska KS,Chung WK. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med.. 2016;18(8):823-32.|27632928) Ge Y,Wang Y,Shao W,Jin J,Du M,Ma G,Chu H,Wang M,Zhang Z. Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers. Sci Rep.. 2016;6():33542.|27900359) Kukita Y,Okami J,Yoneda-Kato N,Nakamae I,Kawabata T,Higashiyama M,Kato J,Kodama K,Kato K. Homozygous inactivation of  is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs. Cold Spring Harb Mol Case Stud.. 2016;2(6):a001032.|29978187) Carlo MI,Mukherjee S,Mandelker D,Vijai J,Kemel Y,Zhang L,Knezevic A,Patil S,Ceyhan-Birsoy O,Huang KC,Redzematovic A,Coskey DT,Stewart C,Pradhan N,Arnold AG,Hakimi AA,Chen YB,Coleman JA,Hyman DM,Ladanyi M,Cadoo KA,Walsh MF,Stadler ZK,Lee CH,Feldman DR,Voss MH,Robson M,Motzer RJ,Offit K. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol.. 2018;4(9):1228-1235.|30858171) Paperna T,Sharon-Shwartzman N,Kurolap A,Goldberg Y,Moustafa N,Carasso Y,Feinstien M,Mory A,Reznick-Levi G,Gonzaga-Jauregui C,Shuldiner AR,Basel-Salmon L,Ofran Y,Half EE,Baris Feldman H. Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype. J Med Genet.. 2020;57(7):500-504.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CTNNA1 gene is associated with autosomal dominant butterfly-shaped pigmentary macular dystrophy (MedGen UID: 332348). Additionally, CTNNA1 has preliminary evidence supporting a correlation with autosomal dominant hereditary diffuse gastric cancer; however, the available evidence is insufficient to make a determination regarding this relationship (PMID: 23208944, 26182300, 32051609). This result should be considered in the context of personal and family history of diffuse gastric cancer and may warrant additional surveillance (PMID: 32758476). To date, loss-of-function variants in CTNNA1 have not been associated with butterfly-shaped pigmentary macular dystrophy.  Butterfly-shaped pigmentary macular dystrophy is a form of patterned dystrophies of the retinal pigment epithelium, characterized by accumulation of pigment in the macula that resembles the wings of a butterfly (PMID: 12724643). Affected individuals typically present from middle age with mildly reduced visual acuity and color vision. The activity of the RPE measured by electrooculogram (EOG) recordings may be abnormal (PMID: 26691986). Retinitis pigmentosa-like changes have been observed in some cases (PMID: 22466463). The disease is relatively benign, but can progress to atrophy of the choroid and retina, resulting in severe vision loss, though the severity of the disease is highly variable, even within the same family (PMID: 26691986).", Pmids: "12724643|22466463|23208944|26182300|26691986|32051609|32758476", Gene_Name: "CTNNA1", References: "23208944) Majewski IJ,Kluijt I,Cats A,Scerri TS,de Jong D,Kluin RJ,Hansford S,Hogervorst FB,Bosma AJ,Hofland I,Winter M,Huntsman D,Jonkers J,Bahlo M,Bernards R. An √é¬±-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol.. 2013;229(4):621-9.|26182300) Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor NM,Pennell E,MacMillan A,Fernandez B,Keller G,Lynch H,Shah SP,Guilford P,Gallinger S,Corso G,Roviello F,Caldas C,Oliveira C,Pharoah PD,Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol.. 2015;1(1):23-32.|26691986) Saksens NT,Krebs MP,Schoenmaker-Koller FE,Hicks W,Yu M,Shi L,Rowe L,Collin GB,Charette JR,Letteboer SJ,Neveling K,van Moorsel TW,Abu-Ltaif S,De Baere E,Walraedt S,Banfi S,Simonelli F,Cremers FP,Boon CJ,Roepman R,Leroy BP,Peachey NS,Hoyng CB,Nishina PM,den Hollander AI. Mutations in CTNNA1 cause butterfly-shaped pigment dystrophy and perturbed retinal pigment epithelium integrity. Nat Genet.. 2016;48(2):144-51.|32051609) Clark DF,Michalski ST,Tondon R,Nehoray B,Ebrahimzadeh J,Hughes SK,Soper ER,Domchek SM,Rustgi AK,Pineda-Alvarez D,Anderson MJ,Katona BW. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genet Med.. 2020;22(5):840-846.|32758476) Blair VR,McLeod M,Carneiro F,Coit DG,D'Addario JL,van Dieren JM,Harris KL,Hoogerbrugge N,Oliveira C,van der Post RS,Arnold J,Benusiglio PR,Bisseling TM,Boussioutas A,Cats A,Charlton A,Schreiber KEC,Davis JL,Pietro MD,Fitzgerald RC,Ford JM,Gamet K,Gullo I,Hardwick RH,Huntsman DG,Kaurah P,Kupfer SS,Latchford A,Mansfield PF,Nakajima T,Parry S,Rossaak J,Sugimura H,Svrcek M,Tischkowitz M,Ushijima T,Yamada H,Yang HK,Claydon A,Figueiredo J,Paringatai K,Seruca R,Bougen-Zhukov N,Brew T,Busija S,Carneiro P,DeGregorio L,Fisher H,Gardner E,Godwin TD,Holm KN,Humar B,Lintott CJ,Monroe EC,Muller MD,Norero E,Nouri Y,Paredes J,Sanches JM,Schulpen E,Ribeiro AS,Sporle A,Whitworth J,Zhang L,Reeve AE,Guilford P. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol.. 2020;21(8):e386-e397.|12724643) Genetic heterogeneity of butterfly shaped pigment dystrophy of the fovea|22466463) Pattern dystrophy with high intrafamilial variability associated with y141 c mutation in the peripherin rds gene and successful treatment of subfoveal cnv related to multifocal pattern type with anti vegf (ranibizumab) intravitreal injections"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The CTRC gene is associated with an increased risk for chronic pancreatitis (MedGen UID: 116056).  Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Penetrance and inheritance patterns of this gene are not well established, but individuals with a pathogenic loss-of-function CTRC variant may have an increased risk for chronic pancreatitis, particularly in the presence of other genetic and environmental risk factors (PMID: 18059268, 18172691, 22942235). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203).", Pmids: "18059268|18172691|22942235|25170203", Gene_Name: "CTRC", References: "25170203) Becker AE,Hernandez YG,Frucht H,Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol.. 2014;20(32):11182-98.|18059268) Chymotrypsin c (CTRC ) variants that diminish activity or secretion are associated with chronic pancreatitis|18172691) Association of rare chymotrypsinogen c (CTRC) gene variations in patients with idiopathic chronic pancreatitis|22942235) Comprehensive functional analysis of chymotrypsin C (CTRC)variants reveals distinct loss-of-function mechanisms associated with pancreatitis risk"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The DDX41 gene is associated with autosomal dominant familial myeloproliferative/lymphoproliferative neoplasms (MPLPF) (MedGen UID: 895780).  MPLPF is characterized by hereditary predisposition to adult-onset myeloid malignancies, particularly myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and in rare cases, lymphoma (PMID: 26712909). The disorder shows incomplete penetrance and the lifetime cancer risk is not known (PMID: 27133828). For information regarding management and surveillance suggestions for individuals with pathogenic variants in DDX41, please refer to PMID: 28600339.", Pmids: "26712909|27133828", Gene_Name: "DDX41", References: "26712909) Lewinsohn M,Brown AL,Weinel LM,Phung C,Rafidi G,Lee MK,Schreiber AW,Feng J,Babic M,Chong CE,Lee Y,Yong A,Suthers GK,Poplawski N,Altree M,Phillips K,Jaensch L,Fine M,D'Andrea RJ,Lewis ID,Medeiros BC,Pollyea DA,King MC,Walsh T,Keel S,Shimamura A,Godley LA,Hahn CN,Churpek JE,Scott HS. Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood.. 2016;127(8):1017-23.|27133828) Germline heterozygous DDX41 variants in a subset of familial myelodysplasia and acute myeloid leukemia"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The DICER1 gene is associated with autosomal dominant DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome (MedGen UID: 449020).  DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome is associated with an increased risk for certain types of rare tumors and cancers that may present in childhood. Noncancerous neoplasias include cystic nephroma, nasal chondromesenchymal hamartomas, thyroid adenomas and goiter. There is also an increased risk of certain malignancies including pleuropulmonary blastoma, ovarian sex cord-stromal tumors, Sertoli-Leydig cell tumors, genitourinary embryonal rhabdomyosarcoma, renal sarcoma, Wilms tumor, thyroid cancer, ciliary body medulloepithelioma, pituitary blastoma and pineoblastoma.", Pmids: "Unknown", Gene_Name: "DICER1", References: "Unknown"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The DIS3L2 gene is associated with autosomal recessive Perlman syndrome (MedGen UID: 162909).  Perlman syndrome is an overgrowth disorder characterized by macrosomia, renal dysplasia, nephroblastomatosis and Wilms tumor (PMID: 23613427). Affected infants have a high rate of neonatal morbidity; the incidence of Wilms tumor in those who survive the neonatal period has been estimated at 64% (PMID: 18780370).", Pmids: "18780370|23613427", Gene_Name: "DIS3L2", References: "18780370) Alessandri JL,Cuillier F,Ramful D,Ernould S,Robin S,de Napoli-Cocci S,Rivi√É¬®re JP,Rossignol S. Perlman syndrome: report, prenatal findings and review. Am J Med Genet A.. 2008;146A(19):2532-7.|23613427) Morris MR,Astuti D,Maher ER. Perlman syndrome: overgrowth, Wilms tumor predisposition and DIS3L2. Am J Med Genet C Semin Med Genet.. 2013;163C(2):106-13."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The EGFR gene is associated with autosomal dominant predisposition to lung cancer (MedGen UID: 472093) and autosomal recessive neonatal inflammatory skin and bowel disease (MedGen UID: 863567).  Pathogenic loss-of-function (LOF) variants in EGFR are associated with neonatal inflammatory skin and bowel disease, a rare condition affecting the skin, hair, kidney, growth, gastrointestinal and respiratory systems. Skin manifestations include erosions, scaling, inflammatory rash and infection. Recurrent respiratory and gastrointestinal infections as well as severe diarrhea and vomiting may occur (PMID: 32602142, 29899996, 26436111, 24691054). LOF variants in EGFR are not known to be associated with autosomal dominant predisposition to lung cancer.

Pathogenic gain-of-function (GOF) EGFR variants are associated with an increased risk of lung cancer (PMID: 16258541, 24736066, 24736080, 21252721, 23380224, 25176975, 18355544, 23358982). One study estimated the risk of lung cancer to be 15-31% (PMID: 24736066), although data are limited. GOF variants in EGFR are not known to be associated with autosomal recessive neonatal inflammatory skin and bowel disease.", Pmids: "16258541|18355544|21252721|23358982|23380224|24691054|24736066|24736080|25176975|26436111|29899996|32602142", Gene_Name: "EGFR", References: "16258541) Bell DW,Gore I,Okimoto RA,Godin-Heymann N,Sordella R,Mulloy R,Sharma SV,Brannigan BW,Mohapatra G,Settleman J,Haber DA. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet.. 2005;37(12):1315-6.|18355544) Ikeda K,Nomori H,Mori T,Sasaki J,Kobayashi T. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg.. 2008;85(4):1430-2.|23380224) Demierre N,Zoete V,Michielin O,Stauffer E,Zimmermann DR,Betticher DC,Peters S. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? Lung Cancer.. 2013;80(1):81-4.|24691054) Campbell P,Morton PE,Takeichi T,Salam A,Roberts N,Proudfoot LE,Mellerio JE,Aminu K,Wellington C,Patil SN,Akiyama M,Liu L,McMillan JR,Aristodemou S,Ishida-Yamamoto A,Abdul-Wahab A,Petrof G,Fong K,Harnchoowong S,Stone KL,Harper JI,Irwin McLean WH,Simpson MA,Parsons M,McGrath JA. Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol.. 2014;134(10):2570-2578.|24736066) Gazdar A,Robinson L,Oliver D,Xing C,Travis WD,Soh J,Toyooka S,Watumull L,Xie Y,Kernstine K,Schiller JH. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol.. 2014;9(4):456-63.|24736080) Yu HA,Arcila ME,Harlan Fleischut M,Stadler Z,Ladanyi M,Berger MF,Robson M,Riely GJ. Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol.. 2014;9(4):554-8.|25176975) Prim N,Legrain M,Guerin E,Mennecier B,Weingertner N,Voegeli AC,Guenot D,Maugard CM,Quoix AE,Beau-Faller M. Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients. Eur Respir Rev.. 2014;23(133):390-2.|26436111) Ganetzky R,Finn E,Bagchi A,Zollo O,Conlin L,Deardorff M,Harr M,Simpson MA,McGrath JA,Zackai E,Lemmon MA,Sondheimer N. EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features. Mol Genet Genomic Med.. 2015;3(5):452-8.|29899996) Hayashi S,Yokoi T,Hatano C,Enomoto Y,Tsurusaki Y,Naruto T,Kobayashi M,Ida H,Kurosawa K. Biallelic mutations of  in a compound heterozygous state cause ectodermal dysplasia with severe skin defects and gastrointestinal dysfunction. Hum Genome Var.. 2018;5():11.|32602142) Earl BR,Szybowska M,Marwaha A,Belostotsky V,Lara-Corrales I,Pope E,Kannu P. Epidermal growth factor receptor deficiency: Expanding the phenotype beyond infancy. J Dermatol.. 2020;47(8):898-902.|21252721) Inherited germline t790 m mutation and somatic epidermal growth factor receptor mutations in non small cell lung cancer patients|23358982) Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "Deletions that include exon 9 of the EPCAM gene are known to cause autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer, or HNPCC) (MedGen UID: 412966) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553). EPCAM is also associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031). The EPCAM gene is associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031).  Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the uterus/endometrium, ovary, stomach, bladder, biliary tract, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks for individuals with a pathogenic variant in MSH2 and/or EPCAM include a 33-52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain/central nervous system cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897). Congenital tufting enteropathy (CTE) is a gastrointestinal insufficiency syndrome presenting early in infancy as severe watery diarrhea. CTE is usually treated by daily nutritional supplements and occasionally, intestinal transplantation (PMID: 8057225, 18572020).", Pmids: "8057225|17539897|18398828|18572020|18709565|19900449|20442441|21642682|23091106|26657901|27013479|28754778|31337882", Gene_Name: "EPCAM", References: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18398828) Watson P,Vasen HFA,Mecklin JP,Bernstein I,Aarnio M,J√É¬§rvinen HJ,Myrh√É¬∏j T,Sunde L,Wijnen JT,Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer.. 2008;123(2):444-449.|18572020) Sivagnanam M,Mueller JL,Lee H,Chen Z,Nelson SF,Turner D,Zlotkin SH,Pencharz PB,Ngan BY,Libiger O,Schork NJ,Lavine JE,Taylor S,Newbury RO,Kolodner RD,Hoffman HM. Identification of EpCAM as the gene for congenital tufting enteropathy. Gastroenterology.. 2008;135(2):429-37.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|19900449) Capelle LG,Van Grieken NC,Lingsma HF,Steyerberg EW,Klokman WJ,Bruno MJ,Vasen HF,Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology.. 2010;138(2):487-92.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|23091106) Engel C,Loeffler M,Steinke V,Rahner N,Holinski-Feder E,Dietmaier W,Schackert HK,Goergens H,von Knebel Doeberitz M,Goecke TO,Schmiegel W,Buettner R,Moeslein G,Letteboer TG,G√É¬≥mez Garc√É¬≠a E,Hes FJ,Hoogerbrugge N,Menko FH,van Os TA,Sijmons RH,Wagner A,Kluijt I,Propping P,Vasen HF. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol.. 2012;30(35):4409-15.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|27013479) Dominguez-Valentin M,Joost P,Therkildsen C,Jonsson M,Rambech E,Nilbert M. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol.. 2016;16():15.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25.|8057225) Tufting enteropathy a newly recognized clinicopathological entity associated with refractory diarrhea in infants"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Since there is no effective screening for ovarian cancer, women should be educated on the symptoms that might be associated with the development of ovarian cancer, such as pelvic or abdominal pain, bloating, increased abdominal girth, difficulty eating, early satiety, or urinary frequency or urgency. Symptoms that persist for several weeks and are a change from a woman's baseline should prompt evaluation by her physician."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Since there is no effective screening for ovarian cancer, women should be educated on the symptoms that might be associated with the development of ovarian cancer, such as pelvic or abdominal pain, bloating, increased abdominal girth, difficulty eating, early satiety, or urinary frequency or urgency. Symptoms that persist for several weeks and are a change from a woman's baseline should prompt evaluation by her physician."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Since there is no effective screening for ovarian cancer, women should be educated on the symptoms that might be associated with the development of ovarian cancer, such as pelvic or abdominal pain, bloating, increased abdominal girth, difficulty eating, early satiety, or urinary frequency or urgency. Symptoms that persist for several weeks and are a change from a woman's baseline should prompt evaluation by her physician."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Since there is no effective screening for ovarian cancer, women should be educated on the symptoms that might be associated with the development of ovarian cancer, such as pelvic or abdominal pain, bloating, increased abdominal girth, difficulty eating, early satiety, or urinary frequency or urgency. Symptoms that persist for several weeks and are a change from a woman's baseline should prompt evaluation by her physician."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Reproductive", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "For patients of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic testing. Discussion should include known risks, limitations, and benefits of these technologies. Also advise about the risk of a rare recessive syndrome called constitutional MMR deficiency (CMMRD) syndrome. If both partners are a carriers of a pathogenic variant/s in the same MMR gene, then their future offspring will be at risk of having CMMRD syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Reproductive", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "For patients of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic testing. Discussion should include known risks, limitations, and benefits of these technologies. Also advise about the risk of a rare recessive syndrome called constitutional MMR deficiency (CMMRD) syndrome. If both partners are a carriers of a pathogenic variant/s in the same MMR gene, then their future offspring will be at risk of having CMMRD syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Reproductive", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "For patients of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic testing. Discussion should include known risks, limitations, and benefits of these technologies. Also advise about the risk of a rare recessive syndrome called constitutional MMR deficiency (CMMRD) syndrome. If both partners are a carriers of a pathogenic variant/s in the same MMR gene, then their future offspring will be at risk of having CMMRD syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Reproductive", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "For patients of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic testing. Discussion should include known risks, limitations, and benefits of these technologies. Also advise about the risk of a rare recessive syndrome called constitutional MMR deficiency (CMMRD) syndrome. If both partners are a carriers of a pathogenic variant/s in the same MMR gene, then their future offspring will be at risk of having CMMRD syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Reproductive", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "For patients of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic testing. Discussion should include known risks, limitations, and benefits of these technologies. Also advise about the risk of a rare recessive syndrome called constitutional MMR deficiency (CMMRD) syndrome. If both partners are a carriers of a pathogenic variant/s in the same MMR gene, then their future offspring will be at risk of having CMMRD syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Urothelial", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Urinalysis", OriginalAction: "There is no clear evidence to support surveillance for urothelial cancers in LS. Surveillance may be considered in selected individuals such as those with a family history of urothelial cancer. Surveillance options may include annual urinalysis starting at age 30-35 years. However, there is insufficient evidence to recommend a particular surveillance strategy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Urothelial", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Urinalysis", OriginalAction: "There is no clear evidence to support surveillance for urothelial cancers in LS. Surveillance may be considered in selected individuals such as those with a family history of urothelial cancer. Surveillance options may include annual urinalysis starting at age 30-35 years. However, there is insufficient evidence to recommend a particular surveillance strategy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Urothelial", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Urinalysis", OriginalAction: "There is no clear evidence to support surveillance for urothelial cancers in LS. Surveillance may be considered in selected individuals such as those with a family history of urothelial cancer. Surveillance options may include annual urinalysis starting at age 30-35 years. However, there is insufficient evidence to recommend a particular surveillance strategy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Urothelial", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Urinalysis", OriginalAction: "There is no clear evidence to support surveillance for urothelial cancers in LS. Surveillance may be considered in selected individuals such as those with a family history of urothelial cancer. Surveillance options may include annual urinalysis starting at age 30-35 years. However, there is insufficient evidence to recommend a particular surveillance strategy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Urothelial", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Urinalysis", OriginalAction: "There is no clear evidence to support surveillance for urothelial cancers in LS. Surveillance may be considered in selected individuals such as those with a family history of urothelial cancer. Surveillance options may include annual urinalysis starting at age 30-35 years. However, there is insufficient evidence to recommend a particular surveillance strategy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Endometrial Biopsy", GuidelineYear: "2021", OriginalAction: "Endometrial cancer screening does not have proven benefit in women with LS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1-2 years starting at age 30-35 years can be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Endometrial Biopsy", GuidelineYear: "2021", OriginalAction: "Endometrial cancer screening does not have proven benefit in women with LS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1-2 years starting at age 30-35 years can be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Endometrial Biopsy", GuidelineYear: "2021", OriginalAction: "Endometrial cancer screening does not have proven benefit in women with LS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1-2 years starting at age 30-35 years can be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Endometrial Biopsy", GuidelineYear: "2021", OriginalAction: "Endometrial cancer screening does not have proven benefit in women with LS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1-2 years starting at age 30-35 years can be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Endometrial Biopsy", GuidelineYear: "2021", OriginalAction: "Endometrial cancer screening does not have proven benefit in women with LS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1-2 years starting at age 30-35 years can be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Transvaginal ultrasound to screen for endometrial cancer in postmenopausal women has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician-s discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal women due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Transvaginal ultrasound to screen for endometrial cancer in postmenopausal women has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician-s discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal women due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Transvaginal ultrasound to screen for endometrial cancer in postmenopausal women has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician-s discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal women due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Transvaginal ultrasound to screen for endometrial cancer in postmenopausal women has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician-s discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal women due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Transvaginal ultrasound to screen for endometrial cancer in postmenopausal women has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician-s discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal women due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Hysterectomy", GuidelineYear: "2021", OriginalAction: "Hysterectomy has not been shown to reduce endometrial cancer mortality, but can reduce the incidence of endometrial cancer. Therefore, hysterectomy is a risk-reducing option that can be considered. Timing of hysterectomy can be individualized based on whether childbearing is complete, comorbidities, family history, and LS gene, as risks for endometrial cancer vary by pathogenic variant."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Hysterectomy", GuidelineYear: "2021", OriginalAction: "Hysterectomy has not been shown to reduce endometrial cancer mortality, but can reduce the incidence of endometrial cancer. Therefore, hysterectomy is a risk-reducing option that can be considered. Timing of hysterectomy can be individualized based on whether childbearing is complete, comorbidities, family history, and LS gene, as risks for endometrial cancer vary by pathogenic variant."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Hysterectomy", GuidelineYear: "2021", OriginalAction: "Hysterectomy has not been shown to reduce endometrial cancer mortality, but can reduce the incidence of endometrial cancer. Therefore, hysterectomy is a risk-reducing option that can be considered. Timing of hysterectomy can be individualized based on whether childbearing is complete, comorbidities, family history, and LS gene, as risks for endometrial cancer vary by pathogenic variant."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Hysterectomy", GuidelineYear: "2021", OriginalAction: "Hysterectomy has not been shown to reduce endometrial cancer mortality, but can reduce the incidence of endometrial cancer. Therefore, hysterectomy is a risk-reducing option that can be considered. Timing of hysterectomy can be individualized based on whether childbearing is complete, comorbidities, family history, and LS gene, as risks for endometrial cancer vary by pathogenic variant."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Hysterectomy", GuidelineYear: "2021", OriginalAction: "Hysterectomy has not been shown to reduce endometrial cancer mortality, but can reduce the incidence of endometrial cancer. Therefore, hysterectomy is a risk-reducing option that can be considered. Timing of hysterectomy can be individualized based on whether childbearing is complete, comorbidities, family history, and LS gene, as risks for endometrial cancer vary by pathogenic variant."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Because endometrial cancer can often be detected early based on symptoms, women should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Because endometrial cancer can often be detected early based on symptoms, women should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Because endometrial cancer can often be detected early based on symptoms, women should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Because endometrial cancer can often be detected early based on symptoms, women should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Because endometrial cancer can often be detected early based on symptoms, women should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "MLH1", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "No clear data exist to support surveillance for gastric, duodenal, and more distal small bowel cancer for LS. Individuals with a family history of these tumors may have increased risk but the benefit of surveillance is unknown. Regarding gastric cancer, risk factors include male sex, older age, MLH1 or MSH2 pathogenic variants, a first-degree relative with gastric cancer, Asian ethnicity, residing in or immigrant from countries with high background incidence of gastric cancer, chronic autoimmune gastritis, gastric intestinal metaplasia, and gastric adenomas. Consider baseline EGD with random biopsy of the proximal and distal stomach to evaluate for H. pylori, autoimmune gastritis, and intestinal metaplasia beginning at age 40 years and surveillance EGD every 3-5 years in those with above risk factors. Consider H. pylori testing. Treating H. pylori, if detected."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "No clear data exist to support surveillance for gastric, duodenal, and more distal small bowel cancer for LS. Individuals with a family history of these tumors may have increased risk but the benefit of surveillance is unknown. Regarding gastric cancer, risk factors include male sex, older age, MLH1 or MSH2 pathogenic variants, a first-degree relative with gastric cancer, Asian ethnicity, residing in or immigrant from countries with high background incidence of gastric cancer, chronic autoimmune gastritis, gastric intestinal metaplasia, and gastric adenomas. Consider baseline EGD with random biopsy of the proximal and distal stomach to evaluate for H. pylori, autoimmune gastritis, and intestinal metaplasia beginning at age 40 years and surveillance EGD every 3-5 years in those with above risk factors. Consider H. pylori testing. Treating H. pylori, if detected."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "No clear data exist to support surveillance for gastric, duodenal, and more distal small bowel cancer for LS. Individuals with a family history of these tumors may have increased risk but the benefit of surveillance is unknown. Regarding gastric cancer, risk factors include male sex, older age, MLH1 or MSH2 pathogenic variants, a first-degree relative with gastric cancer, Asian ethnicity, residing in or immigrant from countries with high background incidence of gastric cancer, chronic autoimmune gastritis, gastric intestinal metaplasia, and gastric adenomas. Consider baseline EGD with random biopsy of the proximal and distal stomach to evaluate for H. pylori, autoimmune gastritis, and intestinal metaplasia beginning at age 40 years and surveillance EGD every 3-5 years in those with above risk factors. Consider H. pylori testing. Treating H. pylori, if detected."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "No clear data exist to support surveillance for gastric, duodenal, and more distal small bowel cancer for LS. Individuals with a family history of these tumors may have increased risk but the benefit of surveillance is unknown. Regarding gastric cancer, risk factors include male sex, older age, MLH1 or MSH2 pathogenic variants, a first-degree relative with gastric cancer, Asian ethnicity, residing in or immigrant from countries with high background incidence of gastric cancer, chronic autoimmune gastritis, gastric intestinal metaplasia, and gastric adenomas. Consider baseline EGD with random biopsy of the proximal and distal stomach to evaluate for H. pylori, autoimmune gastritis, and intestinal metaplasia beginning at age 40 years and surveillance EGD every 3-5 years in those with above risk factors. Consider H. pylori testing. Treating H. pylori, if detected."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "EPCAM", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "No clear data exist to support surveillance for gastric, duodenal, and more distal small bowel cancer for LS. Individuals with a family history of these tumors may have increased risk but the benefit of surveillance is unknown. Regarding gastric cancer, risk factors include male sex, older age, MLH1 or MSH2 pathogenic variants, a first-degree relative with gastric cancer, Asian ethnicity, residing in or immigrant from countries with high background incidence of gastric cancer, chronic autoimmune gastritis, gastric intestinal metaplasia, and gastric adenomas. Consider baseline EGD with random biopsy of the proximal and distal stomach to evaluate for H. pylori, autoimmune gastritis, and intestinal metaplasia beginning at age 40 years and surveillance EGD every 3-5 years in those with above risk factors. Consider H. pylori testing. Treating H. pylori, if detected."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "MRE11A", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Surveillance", OriginalAction: "Lower penetrance genes that may be included as part of multi gene testing but for which there is currently insufficient evidence of an association with breast and/or ovarian cancer include: FANCC, MRE11A, MUTYH heterozygotes, RECQL4, RAD50, RINT1, SLX4, SMARCA4, and XRCC2. Risk management recommendations for these genes should take into account family history and other clinical factors."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "VHL", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHB", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHA", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHC", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "TMEM127", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "FH", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MDH2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "RNF43", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Surveillance", GuidelineYear: "2021", OriginalAction: "At this time the available data are insufficient to provide specialized colorectal cancer screening recommendations."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "RNF43", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Gene insight", GuidelineYear: "2021", OriginalAction: "Pathogenic variants in RNF43 have been identified as a rare cause of serrated polyposis syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "RPS20", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Data are insufficient to provide specialized colorectal cancer screening recommendations at this time."})
(:NCCN_GUIDELINES {GuidelineName: "Myelodysplastic Syndromes", OrganSystem: "General", Gene: "RUNX1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Gene Insight", GuidelineYear: "2021", OriginalAction: "Thrombocytopenia and abnormal platelet function/AML/MDS (highly penetrant). Other features: Typical age of onset of AML/MDS is 20-40 years. Anticipation may lead to occurrence in younger individuals in subsequent generations; eczema; ALL."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHA", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Biochemical Screening", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHB", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHC", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Skin", Gene: "MSH2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Dermatologic Exam", GuidelineYear: "2020", OriginalAction: "Frequency of malignant and benign skin tumors such as sebaceous adenocarcinomas, sebaceous adenomas, and keratoacanthomas has been reported to be increased among patients with Lynch syndrome, but cumulative lifetime risk and median age of presentation are uncertain. Consider skin exam every 1-2 years with a health care provider skilled in identifying Lynch syndrome-associated skin manifestations. Age to start surveillance is uncertain and can be individualized."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MSH3 biallelic", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Begin colonoscopy at age 25-30 years and every 2-3 years if negative. If polyps are found, colonoscopy every 1-2 years with consideration of surgery if the polyp burden becomes unmanageable by colonoscopy.

Surgical evaluation if appropriate.

The panel recognizes that data to support the surveillance recommendations for these particular genes are evolving at this time. Caution should be used when implementing final colonoscopy surveillance regimens in context of patient preferences and new knowledge that may emerge."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Advise patients to tell relatives about possible inherited cancer risk, options for risk assessment and management. Recommend genetic counseling and consideration of genetic testing for at-risk relatives."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Insufficient evidence exists to make a specific recommendation for risk-reducing Salpingo-oophorectomy (RRSO) in MSH6 pathogenic variant carriers. Bilateral Salpingo-oophorectomy (BSO) may reduce the incidence of ovarian cancer. The decision to have a BSO as a risk-reducing option should be individualized. Timing of BSO should be individualized based on whether childbearing is complete, menopause status, comorbidities, family history, and LS gene pathogenic variant, as risks for ovarian cancer vary by mutated gene. Estrogen replacement after premenopausal oophorectomy may be considered."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Skin", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Dermatologic Exam", GuidelineYear: "2021", OriginalAction: "Frequency of malignant and benign skin tumors such as sebaceous adenocarcinomas, sebaceous adenomas, and keratoacanthomas has been reported to be increased among patients with Lynch syndrome, but cumulative lifetime risk and median age of presentation are uncertain. Consider skin exam every 1-2 years with a health care provider skilled in identifying Lynch syndrome-associated skin manifestations. Age to start surveillance is uncertain and can be individualized."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MSH6", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "High-quality colonoscopy at age 30-35 years or 2-5 years prior to the earliest colon cancer if it is diagnosed before age 30 years and repeat every 1-2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "High-quality colonoscopy at age 30-35 years or 2-5 years prior to the earliest colon cancer if it is diagnosed before age 30 years and repeat every 1-2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Body", Gene: "MUTYH biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Annual physical examination."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MUTYH biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Begin colonoscopy at no later than age 25-30 years and every 1-2 years if negative. Earlier colonoscopy may be indicated based on family history. If positive, see below: 

1. Small adenoma burden that can be handled endoscopically:
Colonoscopy and polypectomy every 1-2 years. Surgical evaluation and counseling is appropriate. 

For patient with colectomy with IRA
Endoscopic evaluation of rectum every 6-12 months depending on polyp burden.

Small adenoma burden is defined (somewhat arbitrarily) as fewer than 20 adenomas, all <1 cm in diameter, and none with advanced histology, so that colonoscopy with polypectomy can be used to effectively eliminate the polyps. Colectomy may be indicated before this level of polyp burden, especially if colonoscopy is difficult and polyp control is uncertain. Surgery could be considered when polyp burden is >20 at any individual examination, when polyps have been previously ablated, when some polyps have reached a size >1 cm, or when advanced histology is encountered in any polyp. Extent of colectomy may be modified based on the burden and distribution of adenomas."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MUTYH biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Risk-Reducing Colectomy", GuidelineYear: "2021", OriginalAction: "For individuals with a personal history of MAP and an adenoma burden that cannot be handled endoscopically: 

Colectomy with IRA. 

Consider proctocolectomy with IPAA if dense rectal polyposis not manageable with polypectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Referral", Gene: "MUTYH biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "It is recommended that patients be managed by physicians or centers with expertise in MAP and that management be individualized to account for genotype, phenotype, and personal considerations."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "UGI", Gene: "MUTYH biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Baseline upper endoscopy (including complete visualization of the ampulla of Vater beginning at age 30-35 years.)

Surveillance for upper GI findings for MAP is similar to classical FAP. 

Cap-assisted endoscopy may be adequate for visualization of the ampulla. (Kallenberg F, et al. Endoscopy 2017;49:181-185.)"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MUTYH biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Chemoprevention", GuidelineYear: "2021", OriginalAction: "For individuals with a personal history of MUTYH-associated polyposis : Chemoprevention may be considered to facilitate management of the remaining rectum or pouch post-surgery in select patients (e.g., progressive polyp burden).There are no FDA-approved medications for this indication for individuals with MAP at present."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "MUTYH heterozygotes", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "For probands unaffected by CRC with a first-degree relative with CRC:
Colonoscopy screening every 5 years, beginning at age 40 years or 10 years prior to age of first-degree relative-s age at CRC diagnosis. See screening recommendations in NCCN Guidelines for Colorectal Cancer Screening.

There are no specific data available to determine screening recommendations for a patient with an MUTYH heterozygous pathogenic variant and a second-degree relative affected with CRC. See NCCN Guidelines for Colorectal Cancer Screening.

For probands unaffected by CRC with NO family history of CRC:
Data are unclear as to whether specialized screening is warranted for MUTYH heterozygous carriers unaffected by CRC with no family history of CRC.

Katona B, Yurgelun M, Garber J, et al. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 2018;20:1324-1327.

The panel recognizes that data to support the surveillance recommendations for these particular genes are evolving at this time. Caution should be used when
implementing final colonoscopy surveillance regimens in context of patient preferences and new knowledge that may emerge."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "NBN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: No established association."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "NBN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Limited

Absolute risk: Insufficient data to define

Management: 
Manage based on family history"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "NBN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "Counsel for risk of autosomal recessive condition in children. Nijmegen breakage syndrome (NBS) is characterized by microcephaly, growth retardation, immunodeficiency, predisposition to cancer, and premature ovarian failure in females. The highest malignancy risk is for T-cell and B-cell lymphomas. Affected children may experience developmental delays and hyperactivity. Targeted analysis for pathogenic variant c.657_661del5 can be performed first. This pathogenic variant is detected in ~100% of alleles in individuals of Slavic ancestry and in ~70% of alleles in individuals of North American ancestry."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong
. Absolute risk: 15-40%
. Management: Screening: Annual mammogram with consideration of tomosynthesis starting at age 30 years and consider breast MRI with contrast from ages 30-50 years. Risk reduction: Evidence insufficient for RRM, manage based on family history. Note: Screening recommendations only apply to individuals with a clinical diagnosis of NF. At this time, there are no data to suggest an increased breast cancer risk after age 50 years. Consider possibility of false-positive MRI results due to presence of breast neurofibromas.
 Screening and risk-reduction management is extrapolated from BRCA1/2 data based on levels of risk. May be modified based on family history (typically beginning screening 5-10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene pathogenic/likely pathogenic variant. For women with pathogenic/likely pathogenic variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Evidence of increased risk: No established association."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Referral", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "Recommend referral to NF1 specialist for evaluation and management."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "NTHL1 biallelic", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Begin colonoscopy at age 25-30 years and every 2-3 years if negative. If polyps are found, colonoscopy every 1-2 years with consideration of surgery if the polyp burden becomes unmanageable by colonoscopy.

Surgical evaluation if appropriate.

The panel recognizes that data to support the surveillance recommendations for these particular genes are evolving at this time. Caution should be used when
implementing final colonoscopy surveillance regimens in context of patient preferences and new knowledge that may emerge."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "PALB2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Evidence for increased risk: Strong (with overrepresentation of triple-negative disease). Absolute risk: 41-60%. Management: Screening: Annual mammogram with consideration of tomosynthesis and breast MRI with contrast at 30 years. Screening and risk-reduction management is extrapolated from BRCA1/2 data based on levels of risk. May be modified based on family history (typically beginning screening 5-10 years earlier than the youngest diagnosis in the family but not later than stated in the table) or specific gene pathogenic/likely pathogenic variant. For women with pathogenic/likely pathogenic variants who are treated for breast cancer and have not had bilateral mastectomy, screening should continue as described."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "PALB2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Risk Reducing Mastectomy", OriginalAction: "Discuss option of risk-reducing mastectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "PALB2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong. Absolute risk: 3-5%. Management: Risk reduction: Evidence insufficient; manage based on family history. Transvaginal ultrasound combined with serum CA-125 for ovarian cancer screening, although of uncertain benefit, may be considered at the clinician-s discretion"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "PALB2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Evidence for increased risk: Limited. Absolute risk: 5-10%. Management: Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in -1 first- or second-degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant. For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening. Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "PALB2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Genetic Testing", OriginalAction: "Counsel for risk of autosomal recessive condition in offspring. Fanconi anemia is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life. Pathogenic variants in PALB2 are associated with solid tumors, such as medulloblastomas and Wilms tumors."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "PMS2 carriers have not been shown to be at increased risk for pancreatic cancer. Patients with a family history of pancreatic cancer should be managed based on careful assessment and clinical judgement."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "General", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Advise patients to tell relatives about possible inherited cancer risk, options for risk assessment and management. Recommend genetic counseling and consideration of genetic testing for at-risk relatives."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Insufficient evidence exists to make a specific recommendation for risk-reducing Salpingo-oophorectomy (RRSO) for PMS2 pathogenic variant carriers. PMS2 pathogenic variant carriers appear to be at no greater than average risk for ovarian cancer, and may consider deferring surveillance and may reasonably elect not to have oophorectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Skin", Gene: "PMS2", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", Modality: "Dermatologic Exam", GuidelineYear: "2021", OriginalAction: "Frequency of malignant and benign skin tumors such as sebaceous adenocarcinomas, sebaceous adenomas, and keratoacanthomas has been reported to be increased among patients with Lynch syndrome, but cumulative lifetime risk and median age of presentation are uncertain. Further, an elevated risk of sebaceous tumors and keratoacanthoma has not been documented for PMS2 carriers. Consider skin exam every 1-2 years with a health care provider skilled in identifying Lynch syndrome-associated skin manifestations. Age to start surveillance is uncertain and can be individualized."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "POLD1", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Begin colonoscopy at age 25-30 years and every 2-3 years if negative. If polyps are found, colonoscopy every 1-2 years with consideration of surgery if the polyp burden becomes unmanageable by colonoscopy.

Surgical evaluation if appropriate.

The panel recognizes that data to support the surveillance recommendations for these particular genes are evolving at this time. Caution should be used when
implementing final colonoscopy surveillance regimens in context of patient preferences and new knowledge that may emerge."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "POLE", GuidelineVersion: "1.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Endoscopy", OriginalAction: "Begin colonoscopy at age 25-30 years and every 2-3 years if negative. If polyps are found, colonoscopy every 1-2 years with consideration of surgery if the polyp burden becomes unmanageable by colonoscopy.

Surgical evaluation if appropriate.

The panel recognizes that data to support the surveillance recommendations for these particular genes are evolving at this time. Caution should be used when
implementing final colonoscopy surveillance regimens in context of patient preferences and new knowledge that may emerge."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Body", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Education regarding the signs and symptoms of cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Body", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Annual comprehensive physical exam starting at age 18 years or 5 years before the youngest age of diagnosis of a component cancer in the family (whichever comes first), with particular attention to thyroid exam."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Breast awareness starting at age 18 years.

Women should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent BSE may facilitate breast self awareness. Premenopausal women may find BSE most informative when performed at the end of menses."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Clinical breast exam, every 6-12 months, starting at age 25 years or 5-10 years before the earliest known breast cancer in the family (whichever comes first)."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Breast screening
Annual mammography with consideration of tomosynthesis and breast MRI screening with contrast starting at age 35 years or 10 years before the earliest known breast cancer in the family (whichever comes first). Age >75 years, management should be considered on an individual basis. For women with a PTEN pathogenic/likely pathogenic variant who are treated for breast cancer, and have not had a bilateral mastectomy, screening with annual mammogram with consideration of tomosynthesis and breast MRI should continue as described above. The appropriateness of imaging modalities and scheduling is still under study. High-quality breast MRI limitations include having: a need for a dedicated breast coil, the ability to perform biopsy under MRI guidance by experienced radiologists in breast MRI, and regional availability. Breast MRI is preferably performed on days 7-15 of a menstrual cycle for premenopausal women."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Mastectomy", GuidelineYear: "2021", OriginalAction: "Discuss option of risk-reducing mastectomy in women with pathogenic/likely pathogenic variants identified. For those with clinical CS/PTHS syndrome, consideration of risk-reducing surgery should be based on family history. Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling. Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "CNS", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Consider psychomotor assessment in children at diagnosis and brain MRI if there are symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Colorectal", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Colonoscopy, starting at age 35 years unless symptomatic or if close relative with colon cancer before age 40 years, then start 5-10 years before the earliest known colon cancer in the family. Colonoscopy should be done every 5 years or more frequently if patient is symptomatic or polyps are found."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "General", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Advise about possible inherited cancer risk to relatives, options for risk assessment, and management. Recommend genetic counseling and consideration of genetic testing for at-risk relatives."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Kidney", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Renal Ultrasound", GuidelineYear: "2021", OriginalAction: "Consider renal ultrasound starting at age 40 years, then every 1-2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: None"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "For individuals of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Skin", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Dermatologic Exam", GuidelineYear: "2021", OriginalAction: "There may be an increased risk of melanoma, and the prevalence of other skin characteristics with CS/PTHS may independently make routine dermatology evaluations of value. Annual dermatology exams are recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Thyroid", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Annual thyroid ultrasound starting at age 7 years. This may also be considered for children at 50% risk of inheriting a known mutation whose parents wish to delay genetic testing until age 18 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Uterine", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Hysterectomy", GuidelineYear: "2021", OriginalAction: "Discuss option of hysterectomy upon completion of childbearing and counsel regarding degree of protection, extent of cancer risk, and reproductive desires. Address psychosocial and quality-of-life aspects of undergoing risk-reducing hysterectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Uterine", Gene: "PTEN", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "For endometrial cancer screening, consider starting by age 35 years. Encourage patient education and prompt response to symptoms (e.g., abnormal bleeding). Patients are encouraged to keep a calendar in order to identify irregularities in their menstrual cycle. Because endometrial cancer can often be detected early based on symptoms, women should be educated regarding the importance of prompt reporting and evaluation of any abnormal uterine bleeding or postmenopausal bleeding. The evaluation of these symptoms should include endometrial biopsy. Endometrial cancer screening does not have proven benefit in women with CS/PHTS. However, endometrial biopsy is both highly sensitive and highly specific as a diagnostic procedure. Screening via endometrial biopsy every 1 to 2 years can be considered. Transvaginal ultrasound to screen for endometrial cancer in postmenopausal individuals has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician's discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal individuals due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "RAD51C", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Evidence for increased risk: Strong for ER/PR-negative breast cancer.  Absolute risk: 15-40%. Management:  Insufficient data; managed based on family history"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "RAD51C", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong.  Absolute risk: >10%. Management: Risk reduction: Consider RRSO at 45-50 years.  Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of pathogenic/likely pathogenic variants in RAD51C appears to be sufficient to justify consideration of RRSO. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45-50 years or earlier based on a specific family history of an earlier onset ovarian cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "RAD51C", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", GuidelineYear: "2021", Modality: "Genetic Testing", OriginalAction: "Counsel for risk of autosomal recessive condition in offspring. Fanconi anemia is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "RAD51D", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Evidence for increased risk: Strong for ER/PR-negative breast cancer.  Absolute risk: 15-40%. Management:  Insufficient data; managed based on family history"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Ovary", Gene: "RAD51D", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Salpingo-Oophorectomy", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Strong.  Absolute risk: >10%. Management: Risk reduction: Consider RRSO at 45-50 years.  Based on estimates from available studies, the lifetime risk of ovarian cancer in carriers of pathogenic/likely pathogenic variants in RAD51C appears to be sufficient to justify consideration of RRSO. The current evidence is insufficient to make a firm recommendation as to the optimal age for this procedure. Based on the current, limited evidence base, a discussion about surgery should be held around age 45-50 years or earlier based on a specific family history of an earlier onset ovarian cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "RECQL", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "RECQL is found on some of the panels, but there is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Surveillance starting by age 11 years for children in the American Thyroid Association high risk (ATA-H) and highest risk (ATA-HST) categories and by age 16 years in children in the ATA-moderate risk (ATA-MOD) category: Adrenal imaging with CT or MRI is indicated in patients with positive biochemical results."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting by age 11 years for children in the American Thyroid Association high risk (ATA-H) and highest risk (ATA-HST) categories and by age 16 years in children in the ATA-moderate risk (ATA-MOD) category: Annual measurement of plasma free metanephrines or 24-hour urine for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with multiple endocrine neoplasia type 2 have an appreciable risk for bilateral tumors. Consideration should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Pheochromocytoma Evaluation of pheochromocytoma should be done before the administration of any anesthetic or invasive procedure. Pheochromocytoma (more likely to be multifocal in RET pathogenic variant carriers)For synchronous bilateral pheochromocytomas, a bilateral adrenalectomy is recommended."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Parathyroid", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Measure serum calcium levels annually If calcium elevated, measure PTH and 25-OH vitamin D levels and obtain imaging via neck ultrasound, parathyroid sestamibi with SPECT scan, or 4D-CT.Preference of scan will depend on institutional practice/protocol. Sestamibi may not be as sensitive since often the patient has hyperplasia."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Parathyroid", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Parathyroidectomy Subtotal parathyroidectomy is recommended when all the parathyroid glands are abnormal. Some thyroid surgeons recommend total parathyroidectomy with parathyroid autotransplantation, but others believe the risk of hypoparathyroidism (~6%) is too high to warrant this procedure."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Thyroid", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "To screen for medullary thyroid cancer: Measure calcitonin, CEA and perform a neck ultrasound of both thyroid and cervical lymph nodes"})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "VHL", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHB", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHA", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Education", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHC", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "TMEM127", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Education", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "FH", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MDH2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Consider medical alert ID for hormonally secreting pheochromocytomas and paragangliomas in situ or metastatic disease."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "RET", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "As appropriate, if metastatic or multifocal disease suspected: SSR-based imaging (e.g., 68 Ga-dotatate imaging preferred [PET/CT or PET/MRI] or SSR scintigraphy)FDG-PET/CT (skull base to mid-thigh)Chest CT with or without contrast MIBG scan Data on the role of functional imaging in pheochromocytoma/paraganglioma are evolving and the preferred method remains unclear. For cervical paraganglioma, consider measuring serum and/or 24-hour urine fractionated catecholamines (for dopamine). PET/CT or PET/MRI of skull base to mid-thigh with IV contrast when possible. Data are limited on the optimal timing of scans following administration of somatostatin analogs. MIBG scans are less sensitive than FDG-PET and 68Ga-dotatate for metastatic and multifocal paragangliomas/pheochromocytomas. Obtain MIBG scan if considering treatment with I131-MIBG."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "TMEM127", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Biochemical Screening", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "FH", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MDH2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Annual measurement of plasma free metanephrines or 24-hour for fractionated metanephrines."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHA", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHB", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHC", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "TMEM127", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "FH", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MDH2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Recommended beginning around ages 6 to 8 years. Cross-sectional imaging of skull base to pelvis every 2 years. Whole body MRI (if available) or other non-radiation-containing imaging procedures. If whole body MRI not available, may consider abdominal MRI, skull base and neck MRI, and chest CT."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHA", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Physical Examination", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHB", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHC", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "TMEM127", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Physical Examination", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "FH", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MDH2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Surveillance starting at 6-8 years of age: Blood pressure monitoring at all medical visits."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHA", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Surgery Alert", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHB", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHC", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "TMEM127", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Surgery Alert", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "FH", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MDH2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgery Alert", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of hereditary PGL/PCC syndrome should have blood and/or urine screening for tumors prior to any surgical procedures."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHA", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Surgical Management", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHB", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHC", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "TMEM127", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Surgical Management", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "FH", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MDH2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "NF1", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "MAX", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with hereditary PGL/PCC have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney", OrganSystem: "Kidney", Gene: "SDHA", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Female", Modality: "Pregnancy Considerations", GuidelineYear: "2021", OriginalAction: "Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney", OrganSystem: "Kidney", Gene: "SDHB", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Female", Modality: "Pregnancy Considerations", GuidelineYear: "2021", OriginalAction: "Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney", OrganSystem: "Kidney", Gene: "SDHC", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Female", Modality: "Pregnancy Considerations", GuidelineYear: "2021", OriginalAction: "Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney", OrganSystem: "Kidney", Gene: "SDHD", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Female", Modality: "Pregnancy Considerations", GuidelineYear: "2021", OriginalAction: "Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHA", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 4-6 y starting at age 12 y. If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23:e68-e75.Tufton N, Sahdev A, Akker SA. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 2017;1:897-907.Eijkelenkamp K, Osinga TE, de Jong MM, et al. Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers. Fam Cancer 2017;16:123-130."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHB", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 4-6 y starting at age 12 y. If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23:e68-e75.Tufton N, Sahdev A, Akker SA. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 2017;1:897-907.Eijkelenkamp K, Osinga TE, de Jong MM, et al. Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers. Fam Cancer 2017;16:123-130."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHC", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 4-6 y starting at age 12 y. If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23:e68-e75.Tufton N, Sahdev A, Akker SA. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 2017;1:897-907.Eijkelenkamp K, Osinga TE, de Jong MM, et al. Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers. Fam Cancer 2017;16:123-130."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHD", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 4-6 y starting at age 12 y. If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23:e68-e75.Tufton N, Sahdev A, Akker SA. Radiological surveillance screening in asymptomatic succinate dehydrogenase mutation carriers. J Endocr Soc 2017;1:897-907.Eijkelenkamp K, Osinga TE, de Jong MM, et al. Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers. Fam Cancer 2017;16:123-130."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHA", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Malignant tumors absent aggressive histology and early stage should undergo surgical resection; partial nephrectomy can be considered. For larger tumors and those with aggressive histology (e.g., high grade sarcomatoid), radical nephrectomy should be considered. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of tumors from 27 patients. Am J Surg Pathol 2014;38:1588-1602."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHB", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Malignant tumors absent aggressive histology and early stage should undergo surgical resection; partial nephrectomy can be considered. For larger tumors and those with aggressive histology (e.g., high grade sarcomatoid), radical nephrectomy should be considered. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of tumors from 27 patients. Am J Surg Pathol 2014;38:1588-1602."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHC", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Malignant tumors absent aggressive histology and early stage should undergo surgical resection; partial nephrectomy can be considered. For larger tumors and those with aggressive histology (e.g., high grade sarcomatoid), radical nephrectomy should be considered. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of tumors from 27 patients. Am J Surg Pathol 2014;38:1588-1602."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHD", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Malignant tumors absent aggressive histology and early stage should undergo surgical resection; partial nephrectomy can be considered. For larger tumors and those with aggressive histology (e.g., high grade sarcomatoid), radical nephrectomy should be considered. Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of tumors from 27 patients. Am J Surg Pathol 2014;38:1588-1602."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "SMAD4", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Initiation: 12-15 years. Endoscopy should be initiated at an earlier age or repeated more frequently if signs/symptoms of GI blood loss.  High-quality colonoscopy with polypectomy: If polyps are found, repeat every 2-3 years. Shorter intervals may be indicated based on polyp size, number and pathology. If no polyps, then resume at 18 years. At 18 years, increase colonoscopy frequency to every 1-3 years. 

If polyp burden or polyp-related symptoms (i.e., anemia) cannot be controlled endoscopically or prevent optimal surveillance for cancer considerations should be given to gastrectomy and/or colectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Referral", Gene: "SMAD4", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "For patients who meet clinical criteria for JPS or with a pathogenic variant in BMPR1A or SMAD4, we recommend referral to a specialized team and encourage participation in any available clinical trials."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Small Bowel", Gene: "SMAD4", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: Rare, undefined 


No recommendations have been made."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "SMAD4", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Initiation: 12-15 years.  Upper Endoscopy with polypectomy: If polyps are found, repeat every 2-3 years. Shorter intervals may be indicated based on polyp size, number, and pathology. If no polyps, then resume at 18 years.  at 18 years, resume upper endoscopy every 1-3 years. Intervals should be based on polyp size, number, and pathology. 

If polyp burden or polyp-related symptoms (i.e., anemia) cannot be controlled endoscopically or prevents optimal surveillance for cancer, consideration should be given to gastrectomy and/or colectomy.
SMAD4 pathogenic variant carriers often have severe upper gastrointestinal track involvement."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Vascular", Gene: "SMAD4", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "If there is a known SMAD4 pathogenic variant in the family, genetic testing should be performed within the first 6 months of life due to the coexistence of SMAD4-related JPS-hereditary hemorrhagic telangiectasia (HHT) overlap, which requires specialized surveillance."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Risk Reducing Mastectomy", OriginalAction: "Evidence for increased risk: Strong. Absolute risk: 40-60%. Management:  Risk reduction: Evidence insufficient RRM, manage based on family history."})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Breast", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 32-54%

Initiation Age: ~30 years

Screening Procedure and Interval: 
Mammogram and breast MRI annually
Clinical breast exam every 6 months

High-quality breast MRI limitations include having: a need for a dedicated breast coil, the ability to perform biopsy under MRI guidance, experienced radiologists in breast MRI, and regional availability. Breast MRI performed preferably days 7-15 of menstrual cycle for premenopausal women. The appropriateness of imaging modalities and scheduling is still under study. Lowry KP, et al. Cancer 2012; 118:2021-2030.

Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Cervix", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Female", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 10%

Typically cervical adenoma malignum

Screening Procedure and Interval: 
Initiation: ~18-20 years - Pelvic examination and Pap smear annually

Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Colorectal", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 39%

Initiation Age:8-10 years

Screening Procedure and Interval: 
High-quality colonoscopy with polypectomy: If polyps are found, repeat every 2-3 years. Shorter intervals may be indicated based on polyp size, number, and pathology. If no polyps, then resume at age 18 years. Endoscopy should be initiated at an earlier age or repeated more frequently if signs/symptoms of GI blood loss or intussuspection/obstruction. At 18 years, restart high-quality colonoscopy every 2-3 years. Shorter intervals may be indicated based on polyp size, number, and pathology. 


Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Lung", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Symptom Education", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 7-17%

Provide education about symptoms and smoking cessation. 

No other specific recommendations have been made.

Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Ovary", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Female", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 18-21%

Typically sec cord tumor with annular tubules (SCTAT)

Screening Procedure and Interval: 
Initiation: ~8 years - Annual physical examination for observation of precocious puberty

Initiation: ~18-20 years - Pelvic examination and Pap smear annually

Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Pancreas", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 11-36%


Initiation Age: ~ 30-35 years


Based on clinical judgment, early initiation age may be considered, such as 10 years younger than the earliest age of onset in the family.

Screening Procedure and Interval: 
Annual imaging of the pancreas with either endoscopic ultrasound or MRI/MCP (both ideally performed at center of expertise). 

Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Small Bowel", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 13%

Initiation Age: ~ 8-10 years  


Screening Procedure and Interval: 
Small bowel visualization (CT or MRI enterography or video capsule endoscopy baseline at age 8-10 years with follow-up interval based on findings but at least by age 18 years, then every 2-3 years, though this may be individualized. Repeat small intestinal exam is also indicated at any time based on symptoms.)
 Start at any earlier age or repeat more frequently if signs/symptoms of GI blood loss or intussusception/obstruction. 


Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Stomach", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 29%

Initiation Age: ~ 8-10 years (should be initiated at an earlier age or repeated more frequently if signs/symptoms of GI blood loss or intussusception/obstruction). 

Screening Procedure and Interval: 
Upper endoscopy with polypectomy: if polyps are found, repeat every 2-3 years. Shorter intervals may be indicated based on polyp size, number, and pathology. If no polyps, then resume at age 18 years. 


Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Testicular", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Male", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 9%

Typically sex cord/Sertoli cell tumors

Initiation age: ~ 10 years

Screening Procedure and Interval: 
Annual testicular exam and observation for feminizing changes

Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Colorectal", OrganSystem: "Uterine", Gene: "STK11", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Female", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Lifetime Risk: 9%

Screening Procedure and Interval: 
Initiation: ~18-20 years - Pelvic examination and Pap smear annually

Hearle N, et al. Clin Cancer Res 2006;12:3209-3215; Giardiello FM, et al. Gastroenterology 2000;119:1447-1453"})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Body", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Provide additional surveillance based on family history of cancer.

Provide education regarding signs and symptoms of cancer."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Body", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Comprehensive physical exam including neurologic examination with high index of suspicion for rare cancers and second malignancies in cancer survivors every 6-12 months.

Because of the remarkable risk of additional primary neoplasms, screening may be considered for cancer survivors with LFS and a good prognosis from their prior tumor(s)."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Body", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Annual whole body MRI (category 2B).

Whole body MRI is not uniformly available. If whole body MRI is not available, then individuals with LFS are encouraged to participate in clinical trials or consider alternate comprehensive imaging methods. Other components of screening are being evaluated in protocols, including biochemical screening and regular blood screening for hematologic malignancies.

Ballinger M, Best A, Mai P, et al. Baseline surveillance in Li-Fraumeni syndrome using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncol 2017;3:1634-1639.

Screening through whole body MRI has been broadly demonstrated to be feasible and of potential utility in the early detection of cancer among classic LFS families, though it also results in the detection of false-positive findings and possible cancer overdiagnosis. Furthermore, screening utility has not been evaluated among those with a germline TP53 pathogenic/likely pathogenic variant without a classic family history of LFS, who are increasingly identified through multi-gene panel tests."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Body", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Screening", GuidelineYear: "2021", OriginalAction: "There is controversy over how to manage cancer risk in incidental TP53 carriers who do not meet classic LFS criteria; some data suggest lower cancer risks in TP53 pathogenic/likely pathogenic carriers who do not have a family history consistent with LFS."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Self Breast Examination", GuidelineYear: "2021", OriginalAction: "Breast awareness starting at age 18 years.

Women should be familiar with their breasts and promptly report changes to their health care provider. Periodic, consistent BSE may facilitate breast self awareness. Premenopausal women may find BSE most informative when performed at the end of menses."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Examination", GuidelineYear: "2021", OriginalAction: "Clinical breast exam, every 6-12 months, starting at age 20 years.

Or at the age of the earliest diagnosed breast cancer in the family, if younger than age 20 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Breast screening
Age 20-29 years, annual breast MRI screening with contrast. Or at the age of the earliest diagnosed breast cancer in the family, if younger than age 20 y.  

Age 30-75 years, annual breast MRI screening with contrast and mammogram with consideration of tomosynthesis.  

Age >75 years, management should be considered on an individual basis.

For women with a TP53 pathogenic/likely pathogenic variant who are treated for breast cancer, and who have not had a bilateral mastectomy, screening with annual breast MRI and mammogram with consideration of tomosynthesis should continue as described above.

High-quality breast MRI limitations include having: a need for a dedicated breast coil, the ability to perform biopsy under MRI guidance by experienced radiologists in breast MRI, and regional availability. Breast MRI is preferably performed on days 7-15 of a menstrual cycle for premenopausal women.

Or mammogram with consideration of tomosynthesis, if MRI is unavailable. Breast MRI is preferred because of concerns regarding the risk of radiation exposure in
pathogenic/likely pathogenic variant carriers."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", Modality: "Risk Reducing Mastectomy", GuidelineYear: "2021", OriginalAction: "Discuss option of risk-reducing mastectomy

Counseling should include a discussion regarding degree of protection, reconstruction options, and risks. In addition, the family history and residual breast cancer risk with age and life expectancy should be considered during counseling.

Address psychosocial and quality-of-life aspects of undergoing risk-reducing mastectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "CNS", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Annual brain MRI (category 2B) may be performed as part of the whole body MRI or as a separate exam."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Colorectal", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Colonoscopy every 2-5 years starting at 25 years or 5 years before the earliest known colon cancer in the family."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "General", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Cascade Testing", GuidelineYear: "2021", OriginalAction: "Advise about possible inherited cancer risk to relatives, options for risk assessment, and management.

Recommend genetic counseling and consideration of genetic testing for at-risk relatives."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "General", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Pediatric Considerations", GuidelineYear: "2021", OriginalAction: "Pediatricians should be apprised of the risk of childhood cancers in affected families and review screening recommendations for children with LFS.

For additional information on the management of children with LFS, see Kratz C, et al. Clin Cancer Res 2017;23:e38-e45."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Pancreas", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Evidence for increased risk: Limited

Absolute risk: 5-10%

Management:
Consider pancreatic cancer screening beginning at age 50 years (or 10 years younger than the earliest exocrine pancreatic cancer diagnosis in the family, whichever is earlier) for individuals with exocrine pancreatic cancer in ?1 first- or second-degree relatives from the same side of (or presumed to be from the same side of) the family as the identified pathogenic/likely pathogenic germline variant.

Abe T, et al. J Clin Oncol 2019;37:1070-1080.

For individuals considering pancreatic cancer screening, the panel recommends that screening be performed in experienced high-volume centers, ideally under research conditions. The panel recommends that such screening only take place after an in-depth discussion about the potential limitations to screening, including cost, the high incidence of pancreatic abnormalities, and uncertainties about the potential benefits of pancreatic cancer screening.

Consider screening using annual contrast-enhanced MRI/MRCP and/or EUS, with consideration of shorter screening intervals, based on clinical judgment, for individuals found to have worrisome abnormalities on screening. The panel emphasizes that most small cystic lesions found on screening will not warrant biopsy, surgical resection, or any other intervention."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Psychosocial", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Education", GuidelineYear: "2021", OriginalAction: "Address psychosocial and quality-of-life aspects of the complex management of LFS. Address limitations of screening for many cancers associated with LFS."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Referral", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Referral", GuidelineYear: "2021", OriginalAction: "This screening and management of LFS is complex; it is preferred that individuals with LFS be followed at centers with expertise in the management of this syndrome."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Reproductive", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Genetic Testing", GuidelineYear: "2021", OriginalAction: "For individuals of reproductive age, advise about options for prenatal diagnosis and assisted reproduction including pre-implantation genetic diagnosis. Discussion should include known risks, limitations, and benefits of these technologies."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Skin", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Dermatologic Exam", GuidelineYear: "2021", OriginalAction: "Annual dermatologic examination starting at 18 years."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Treatment", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Personal Cancer Management", GuidelineYear: "2021", OriginalAction: "Therapeutic RT for cancer should be avoided when possible; diagnostic radiation should be minimized to the extent feasible without sacrificing accuracy."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "UGI", Gene: "TP53", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Both", Modality: "Endoscopy", GuidelineYear: "2021", OriginalAction: "Upper endoscopy every 2-5 years starting at 25 years or 5 years before the earliest known gastric cancer in the family."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "General", Gene: "TRIM37", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Both", Modality: "Gene Insight", GuidelineYear: "2021", OriginalAction: "MULIBREY (MUscle, LIver, BRain, and EYes) Nanism syndrome is a growth disorder with prenatal onset, including occasional progressive cardiomyopathy, characteristics facial features, failure of sexual maturation, insulin resistance with type 2 diabetes, and an increased risk for Wilms tumor."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "Kidney", Gene: "TRIM37", GuidelineBody: "NCCN", GuidelineVersion: "2.2021", Gender: "Both", Modality: "Ultrasound", GuidelineYear: "2021", OriginalAction: "The Pediatric Cancer Working Group of the American Association for Cancer Research recommends renal US every 3 months up to age 8 years."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 3-5 y starting at age 12 y. 

If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. 

Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2021 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurol 2013;49:255-265."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC2", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 3-5 y starting at age 12 y. 

If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. 

Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2021 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurol 2013;49:255-265."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Overview", OriginalAction: "Syndrome: Tuberous sclerosis complex (TSC)

Histology: angiomyolipoma, clear cell

Inheritance Pattern: Autosomal Dominant

Other specialists Involved in Screening: Neurology, dermatology"})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC2", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Overview", OriginalAction: "Syndrome: Tuberous sclerosis complex (TSC)

Histology: angiomyolipoma, clear cell

Inheritance Pattern: Autosomal Dominant

Other specialists Involved in Screening: Neurology, dermatology"})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "AML is a benign lesion associated with TSC and managed separately. 

Nephron-sparing surgery is the treatment of choice for renal tumors whenever possible, with consideration that an individual may have multiple tumors during their lifetime. 

Ablative treatment options may be considered for those with significant medical or surgical risk to undergo an operation. 

Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2021 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurol 2013;49:255-265.

Muller A, Rouviere O. Renal artery embolization-indications, technical approaches and outcomes. Nat Rev Nephrol 2015;11:288-301.

Nelson C, Sandra M. Contemporary diagnosis and management of renal angiomyolipoma. J Uro 2002;168:1315-1325."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC2", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "AML is a benign lesion associated with TSC and managed separately. 

Nephron-sparing surgery is the treatment of choice for renal tumors whenever possible, with consideration that an individual may have multiple tumors during their lifetime. 

Ablative treatment options may be considered for those with significant medical or surgical risk to undergo an operation. 

Krueger DA, Northrup H; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2021 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurol 2013;49:255-265.

Muller A, Rouviere O. Renal artery embolization-indications, technical approaches and outcomes. Nat Rev Nephrol 2015;11:288-301.

Nelson C, Sandra M. Contemporary diagnosis and management of renal angiomyolipoma. J Uro 2002;168:1315-1325."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "General", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Genotype-Phenotype Correlation", GuidelineYear: "2021", OriginalAction: "Available data suggests SDHAF2 patients are primarily at risk for head and neck tumors. Therefore, consideration can be given to more targeted imaging in these cohorts."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "General", Gene: "SDHAF2", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", GuidelineYear: "2021", Modality: "Parent of Origin Effect", OriginalAction: "SDHAF2 patients are most at risk if the pathogenic variant was paternally inherited. Recommend following screening recommendations if the parent of origin is unknown. Consider screening for patients with maternally inherited variants as case reports of tumor occurrence exist."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "General", Gene: "SDHD", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Parent of Origin Effect", GuidelineYear: "2021", OriginalAction: "SDHD patients are most at risk if the pathogenic variant was paternally inherited. Recommend following the screening recommendations if the patent of origin is unknown. Consider screening for patients with maternally inherited variants as case reports of tumor occurrence exist."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Therapy", OriginalAction: "Everolimus is an FDA-approved therapy for asymptomatic growing angiomyolipoma measuring >3 cm in diameter. 

Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicenter, randomized double-blind, placebo-controlled trial. Lancet 2013;381:817-824."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC2", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Therapy", OriginalAction: "Everolimus is an FDA-approved therapy for asymptomatic growing angiomyolipoma measuring >3 cm in diameter. 

Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicenter, randomized double-blind, placebo-controlled trial. Lancet 2013;381:817-824."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Body", Gene: "VHL", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "Abdominal MRI (preferred) or CT with and without contrast to assess kidneys, pancreas, and adrenals every 2 y starting at age 15 y. 

If there is a family member with an early diagnosis, screening should begin 10 y before earliest age of diagnosis in family member. 


Rednam SP, Erez A, Druker H, et al. Von Hippel-Lindau and hereditary pheochromocytoma/paraganglioma syndromes: Clinical features, genetics, and surveillance recommendations in childhood. Clin Cancer Res 2017;23:e68-e75."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "VHL", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Overview", OriginalAction: "Syndrome: von Hippel-Lindau (VHL)


Histology: Clear Cell


Inheritance Pattern: Autosomal Dominant


Other specialists Involved in Screening: Neurosurgery, ophthalmology, audiology, endocrinology, endocrine surgery"})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "VHL", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Management of localized renal masses in patients with VHL are typically guided under the \"3cm rule.\"

The idea is to intervene at a time point of maximal benefit to the patient to limit the chance of development of metastatic disease but also to consider the recurrent and multiple resections many of these patients will have over the course of their lifetime with subsequent development of chronic and progressive renal failure. 

Patient should undergo partial nephrectomy if at all possible and consider referral to centers with surgical expertise in complex partial nephrectomies and management of VHL patients. 

Ablative treatment options may be considered for those with significant medical or surgical risk to undergo an operation. 

Shuch B, et al. The surgical approach to multifocal renal cancers. Urol Clin North Am 2012;39:133-148.

Singer EA, Vourganti S, Lin KY, et al. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of follow up. J Urol 2021; 188:2084-2088."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "VHL", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Therapy", OriginalAction: "At this time there are no FDA-approved therapies for nonmetastic RCC arising in VHL disease. However, pazopanib was associated with >50% objective response rate in renal lesions in a 31-patient phase II study. 

Jonasch E, McCutcheon IE, Gombos DS, et al. Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-center, phase 2 trial. Lancet Oncol 2018;19:1351-1359."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "VHL", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Imaging", GuidelineYear: "2021", OriginalAction: "Abdominal MRI (preferred) or CT with and without IV contrast every 2 years starting at age 15 years."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "None_VUS", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "For individuals with a suspicious family history, beginning at age 40 years, start a risk and benefit discussion about offering prostate cancer early detection: Baseline PSA and strongly consider baseline digital rectal examination (DRE).The best evidence supports the use of serum PSA for the early detection of prostate cancer. DRE should not be used as a stand-alone test. DRE can be considered as a baseline test in addition to serum PSA in all patients, but has its greatest usefulness in those with elevated PSA. Consider referral for biopsy or further testing if DRE is suspicious for cancer at any PSA. Family or personal cancer history and/or family or personal history of high-risk germline mutations can inform when to begin shared decision-making regarding prostate cancer early detection. Family cancer history includes, but is not limited to, a first- or second-degree relative with metastatic prostate cancer, ovarian cancer, male breast cancer, female breast cancer ? 45 years, colorectal or endometrial cancer ? 50 years, or pancreatic cancer or two or more first- or second-degree relatives with breast, prostate (but not clinically localized Grade Group 1), colorectal or endometrial cancer at any age."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "None_VUS", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Beginning at age 40 years, start a risk and benefit discussion about offering prostate cancer early detection: Baseline PSA and strongly consider baseline digital rectal examination (DRE).The best evidence supports the use of serum PSA for the early detection of prostate cancer. DRE should not be used as a stand-alone test. DRE can be considered as a baseline test in addition to serum PSA in all patients, but has its greatest usefulness in those with elevated PSA. Consider referral for biopsy or further testing if DRE is suspicious for cancer at any PSA. Men of African ancestry have a higher incidence of prostate cancer, increased prostate cancer mortality, and earlier age of diagnosis compared to Caucasian men. This is attributable to a greater risk of developing preclinical prostate cancer and a higher likelihood that a preclinical tumor will spread. Although there are data suggesting a role for heritable genes linked to African ancestry, it is not known with certainty whether genetics rather than access to health care and other social determinants of health are the main drivers of increased risk in the patient population. Many support the recommendation for men of African ancestry to consider beginning shared decision-making about PSA screening at age 40 years and to consider screening at annual intervals rather than every other year. There is no current evidence to support that screening at an earlier age will result in decreased morbidity and mortality compared to testing at age 45 years."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "None_VUS", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Beginning at age 45 years, start a risk and benefit discussion about offering prostate cancer early detection: Baseline PSA and strongly consider baseline digital rectal examination (DRE).The best evidence supports the use of serum PSA for the early detection of prostate cancer. DRE should not be used as a stand-alone test. DRE can be considered as a baseline test in addition to serum PSA in all patients, but has its greatest usefulness in those with elevated PSA. Consider referral for biopsy or further testing if DRE is suspicious for cancer at any PSA."})
(:NCCN_GUIDELINES {GuidelineName: "Prostate Cancer Early Detection", OrganSystem: "Prostate", Gene: "None_VUS", GuidelineBody: "NCCN", GuidelineVersion: "1.2021", Gender: "Male", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "In select patients, start a risk and benefit discussion about offering prostate cancer early detection: Baseline PSA and strongly consider baseline digital rectal examination (DRE).Testing after 75 years of age should be done only in very healthy men with little or no comorbidity (especially if they have never undergone PSA testing or have a rising PSA) to detect the small number of aggressive cancers that pose a significant risk if left undetected until signs or symptoms develop. Widespread testing in this population would substantially increase rates of over detection and is not recommended. The best evidence supports the use of serum PSA for the early detection of prostate cancer. DRE should not be used as a stand-alone test. DRE can be considered as a baseline test in addition to serum PSA in all patients, but has its greatest usefulness in those with elevated PSA. Consider referral for biopsy or further testing if DRE is suspicious for cancer at any PSA."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "VHL", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Surgical Management", GuidelineYear: "2021", OriginalAction: "Patients with VHL have an appreciable risk for bilateral tumors. Considerations should be given to cortical-sparing adrenalectomy."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "VHL", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Physical Examination", GuidelineYear: "2021", OriginalAction: "Blood pressure monitoring at all medical visits starting at age 2 years."})
(:NCCN_GUIDELINES {GuidelineName: "Neuroendocrine and Adrenal Tumors", OrganSystem: "Endocrine", Gene: "VHL", GuidelineBody: "NCCN", GuidelineVersion: "3.2021", Gender: "Both", Modality: "Biochemical Screening", GuidelineYear: "2021", OriginalAction: "Annual measurement of plasma-free metanephrines (preferred) or 24-hour urine for fractionated metanephrines starting at age 5 years."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "VHL", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "MET", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FLCN", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "TSC2", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "FH", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "BAP1", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHA", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHB", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHC", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHD", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "Imaging frequency would be increased once lesions are detected based on growth rate and size of lesion(s). CT of the abdomen can be used for surgical planning but should be limited if possible for surveillance due to lifetime radiation exposure for hereditary syndromic patients. Whenever possible, screening should be coordinated with other specialists involved in patient's care. Women of childbearing age who are planning conception should consider renal imaging prior to pregnancy. Follow-up should be individualized based on treatment schedules, side effects, comorbidities, and symptoms."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "VHL", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of PGL/PCC or VHL are at increased risk of pheochromocytomas and should have blood and/or urine screening for this prior to any surgical procedure."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHA", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of PGL/PCC or VHL are at increased risk of pheochromocytomas and should have blood and/or urine screening for this prior to any surgical procedure."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHB", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of PGL/PCC or VHL are at increased risk of pheochromocytomas and should have blood and/or urine screening for this prior to any surgical procedure."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHC", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of PGL/PCC or VHL are at increased risk of pheochromocytomas and should have blood and/or urine screening for this prior to any surgical procedure."})
(:NCCN_GUIDELINES {GuidelineName: "Kidney Cancer", OrganSystem: "Kidney", Gene: "SDHD", GuidelineVersion: "1.2022", GuidelineBody: "NCCN", Gender: "Both", Modality: "Surgical Recommendation", GuidelineYear: "2021", OriginalAction: "Preoperative alert: Patients with a suspected or known diagnosis of PGL/PCC or VHL are at increased risk of pheochromocytomas and should have blood and/or urine screening for this prior to any surgical procedure."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "Kidney", Gene: "WT1", GuidelineVersion: "2.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "The Pediatric Cancer Working Group of the American Association for Cancer recommends renal US every 3 months up to age 8 years for individuals with Wilms Tumor Predisposition Syndromes."})
(:NCCN_GUIDELINES {GuidelineName: "Wilms Tumor", OrganSystem: "Kidney", Gene: "TP3", GuidelineVersion: "2.2021", GuidelineBody: "NCCN", Gender: "Both", GuidelineYear: "2021", Modality: "Imaging", OriginalAction: "The Pediatric Cancer Working Group of the American Association for Cancer recommends renal US every 3 months up to age 8 years for individuals with Wilms Tumor Predisposition Syndromes."})
(:NCCN_GUIDELINES {GuidelineName: "Breast, Ovarian, Pancreatic", OrganSystem: "Breast", Gene: "XRCC2", GuidelineBody: "NCCN", GuidelineVersion: "1.2022", Gender: "Female", GuidelineYear: "2021", Modality: "Screening", OriginalAction: "There is insufficient evidence to make any recommendations for breast MRI, RRSO, or RRM for XRCC2. Risk management recommendations should take into account family history and other clinical factors."})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrine Surgery", Organ_System: "Adrenal"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrinology", Organ_System: "Adrenal"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Bile Duct"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Hematology", Organ_System: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Thyroid cancer differentiated", GeneMasterName: "DICER1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Cervical Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Female", Organ: "Cervix"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Inflammatory Bowel Disease", GeneMasterName: "EPCAM", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Pelvis", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "ALL", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Sebaceous Adenoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sebaceous Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Keratoacanthoma", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "DIS3L2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "DOT1L", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "Unknown", GeneMasterName: "DOT1L", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Osteoarthritis", GeneMasterName: "DOT1L", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "EGFR", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "CHRPE", PredominantCancerSubtype: "Congenital retinal pigment epithelial hypertrophy", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Colorectal Polyps", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Duodenum Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Inflammatory Bowel Disease", GeneMasterName: "EGFR", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "NSCLC", GeneMasterName: "EGFR", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Upper Urinary Tract Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Upper Urinary Tract"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ureter Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "EPCAM", Gender: "Either", Organ: "Ureter"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "ALL", GeneMasterName: "ETV6", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "ETV6", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "ETV6", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ABRAXAS1", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ABRAXAS1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FANCC", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "FANCC", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Myelodysplasia", GeneMasterName: "FANCC", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FANCC", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "FANCC", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Tracheoesophageal Fistula¬†", GeneMasterName: "FANCC", Gender: "Either", Organ: "Mediastinum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FBXO24", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Adrenal Cortical (Benign)", PredominantCancerSubtype: "Primary Macronodular Adrenal Hyperplasia", GeneMasterName: "FH", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "FH", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Fumarase Deficiency", PredominantCancerSubtype: "Unknown", GeneMasterName: "FH", Gender: "Either", Organ: "Metabolic"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma, Aggressive", GeneMasterName: "FH", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "FH", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "FH", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Ovarian Neoplasm", PredominantCancerSubtype: "Ovarian Mucinous Cystadenoma", GeneMasterName: "FH", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Cutaneous Leiomyosarcoma", GeneMasterName: "FH", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Uterus Cancer", PredominantCancerSubtype: "Leiomyosarcoma", GeneMasterName: "FH", Gender: "Either", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Testicular Cancer", PredominantCancerSubtype: "Leydig Cell Tumour of the Testis", GeneMasterName: "FH", Gender: "Male", Organ: "Testes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma, hybrid oncocytic tumor, chromophobe renal cell carcinoma, clear cell renal carcinoma, renal cell oncocytoma, papillary renal carcinoma", GeneMasterName: "FLCN", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Lung Cyst", GeneMasterName: "FLCN", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Primary Spontaneous Pneumothorax", GeneMasterName: "FLCN", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Fibrofolliculoma", GeneMasterName: "FLCN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Basal Cell Carcinoma", GeneMasterName: "FLCN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "GALNT12", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "GATA2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "CMML", GeneMasterName: "GATA2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lymphedema", PredominantCancerSubtype: "Unknown", GeneMasterName: "GATA2", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Myelodysplastic syndrome", GeneMasterName: "GATA2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "GEN1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "GEN1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "GEN1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "GPC3", Gender: "Male", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Skin Neoplasm", PredominantCancerSubtype: "Cutaneous Myxoma", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pancreatic Neoplasm", PredominantCancerSubtype: "Intraductal pancreatic mucinous neoplasia (IPMN)", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Testicular Neoplasm", PredominantCancerSubtype: "Large Cell Calcifying Sertoli Cell Tumor", GeneMasterName: "PRKAR1A", Gender: "Male", Organ: "Testes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Breast (Benign)", PredominantCancerSubtype: "Myxoma", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Ovarian Neoplasm", PredominantCancerSubtype: "Non epithelial ovarian tumor", GeneMasterName: "STK11", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "DICER1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Multinodular Goiter", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Chorea", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Congenital septal defects", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intellectual Disability", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Global developmental delay
- Difficulty walking in childhood
- Choreoathetosis
- Hypotonia
- Ataxia
- Dysarthria
- Dystonia
- Symptoms of hypothalamic disturbances", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "Developmental"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Hypothyroid", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Neonatal respiratory distress", GeneMasterName: "NKX2-1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "CHEK2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Venous thrombosis", GeneMasterName: "HABP2", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Non-Medullary  thyroid carcinoma", GeneMasterName: "HABP2", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Blood Vessel (Benign)", PredominantCancerSubtype: "Carotid Stenosis", GeneMasterName: "HABP2", Gender: "Either", Organ: "Blood Vessel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Hair (Benign)", PredominantCancerSubtype: "Alopecia Mucinosa", GeneMasterName: "HABP2", Gender: "Either", Organ: "Hair"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Familial Isolated Pituitary Adenoma-somatotropinoma", GeneMasterName: "AIP", Gender: "Either", Organ: "Pituitary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "ATR", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "CFTR", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "CPA1", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "CTRC", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "MLH3", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "SPINK1", Gender: "Unknown", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Genitourinary (Benign)", PredominantCancerSubtype: "Streak ovaries, hypoplastic uterus", GeneMasterName: "WT1", Gender: "Female", Organ: "Genitals"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Genitourinary (Benign)", PredominantCancerSubtype: "Vaginal cysts
- Vulvar cysts
- Ovarian cysts
- Leiomyomas", GeneMasterName: "PTEN", Gender: "Female", Organ: "Genitals"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Breast (Benign)", PredominantCancerSubtype: "Gynecomastia", GeneMasterName: "PTEN", Gender: "Male", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Global Development Delay", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "GPC3", Gender: "Male", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "GPC3", Gender: "Male", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "GREM1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Adenomatous Polyps", GeneMasterName: "GREM1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Juvenile Polyps", GeneMasterName: "GREM1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Sclerosteosis", GeneMasterName: "GREM1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "HOXB13", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "HOXB13", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Gioma", GeneMasterName: "HOXB13", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "HOXB13", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "HOXB13", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Endocrine", PredominantCancerSubtype: "Type A insulin resistance, Diabetes Mellitus", GeneMasterName: "INSR", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "INSR", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Ovarian (Benign)", PredominantCancerSubtype: "Polycystic Ovary Disease", GeneMasterName: "INSR", Gender: "Either", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GIST", PredominantCancerSubtype: "Unknown", GeneMasterName: "KIT", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "KIT", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Piebaldism", GeneMasterName: "KIT", Gender: "Either", Organ: "Hair"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Systemic Mastocytosis", GeneMasterName: "KIT", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Testicular Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "KIT", Gender: "Male", Organ: "Testes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MAP3K6", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "MAX", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "MAX", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MCPH1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MCPH1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "MET", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Papillary renal Cell Carcinoma", GeneMasterName: "MET", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MET", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "MET", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "MET", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Osteofibrous Dysplasia", GeneMasterName: "MET", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Albinism", GeneMasterName: "MITF", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Coloboma", GeneMasterName: "MITF", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Ear (Benign)", PredominantCancerSubtype: "Hearing Loss", GeneMasterName: "MITF", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "MITF", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Macrocephaly", GeneMasterName: "MITF", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MITF", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Microphthalmia", GeneMasterName: "MITF", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Osteopetrosis", GeneMasterName: "MITF", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Basal Cell Carcinoma", GeneMasterName: "MLH1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "MLH1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Sebaceous Adenoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sebaceous Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Keratoacanthoma", GeneMasterName: "MLH1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Duodenum Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Upper Urinary Tract Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Upper Urinary Tract"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ureter Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1", Gender: "Either", Organ: "Ureter"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1-Biallelic", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1-Biallelic", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1-Biallelic", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neurofibroma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1-Biallelic", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Rhabdomyosarcoma", GeneMasterName: "MLH1-Biallelic", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Unknown", GeneMasterName: "MLH1-Biallelic", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MRE11A", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MRE11A", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MRE11A", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Basal Cell Carcinoma", GeneMasterName: "MSH2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "MSH2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Pelvis", GeneMasterName: "MSH2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Sebaceous Adenoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sebaceous Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Keratoacanthoma", GeneMasterName: "MSH2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Duodenum Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Upper Urinary Tract Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Upper Urinary Tract"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ureter Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2", Gender: "Either", Organ: "Ureter"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "ALL", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neurofibroma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Nerve"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The FANCA gene is associated with autosomal recessive Fanconi anemia type A (FA-A) (MedGen UID: 483333).  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).", Pmids: "8986277|12393424|12393516|20417588|20507306", Gene_Name: "FANCA", References: "12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The FANCC gene is associated with autosomal recessive Fanconi anemia (MedGen UID: 483324). There is also evidence suggesting FANCC is associated with autosomal dominant predisposition to breast, ovarian and pancreatic cancer (PMID: 30733081, 15695377, 12750283). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).", Pmids: "8986277|12393424|12393516|12750283|15695377|20417588|20507306|30733081", Gene_Name: "FANCC", References: "12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|12750283) van der Heijden MS,Yeo CJ,Hruban RH,Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res.. 2003;63(10):2585-8.|15695377) Couch FJ,Johnson MR,Rabe K,Boardman L,McWilliams R,de Andrade M,Petersen G. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res.. 2005;65(2):383-6.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The FANCM gene is associated with an autosomal recessive condition characterized by an increased risk for malignancy and infertility (OMIM: 618086). Additionally, there is preliminary evidence that FANCM is associated with autosomal dominant predisposition to breast cancer (PMID: 23409019, 25288723) and autosomal recessive Fanconi anemia (PMID: 16116422, 19423727, 21681190). The data, however, are insufficient to make a determination regarding these relationships.  Biallelic variants in FANCM have been described in individuals with variable features including malignancy, infertility and chromosome fragility (PMID: 30075111, 29231814, 28837162, 29895858, 28837157). The most common associated malignancies include cancers of the head, neck and breast; however, other cancer types have been reported (PMID: 28837162, 28837157). Several affected individuals have demonstrated reduced fertility (PMID: 30075111, 29231814, 28837162, 29895858). Chromosomal breakage due to hypersensitivity to crosslink-inducing agents has been observed (PMID: 29231814, 29895858, 28837157). Data regarding lifetime risks and management of autosomal recessive FANCM-related conditions are not yet established.", Pmids: "16116422|19423727|21681190|23409019|25288723|28837157|28837162|29231814|29895858|30075111", Gene_Name: "FANCM", References: "16116422) Meetei AR,Medhurst AL,Ling C,Xue Y,Singh TR,Bier P,Steltenpool J,Stone S,Dokal I,Mathew CG,Hoatlin M,Joenje H,de Winter JP,Wang W. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet.. 2005;37(9):958-63.|23409019) Gracia-Aznarez FJ,Fernandez V,Pita G,Peterlongo P,Dominguez O,de la Hoya M,Duran M,Osorio A,Moreno L,Gonzalez-Neira A,Rosa-Rosa JM,Sinilnikova O,Mazoyer S,Hopper J,Lazaro C,Southey M,Odefrey F,Manoukian S,Catucci I,Caldes T,Lynch HT,Hilbers FS,van Asperen CJ,Vasen HF,Goldgar D,Radice P,Devilee P,Benitez J. Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility alleles. PLoS One.. 2013;8(2):e55681.|25288723) Kiiski JI,Pelttari LM,Khan S,Freysteinsdottir ES,Reynisdottir I,Hart SN,Shimelis H,Vilske S,Kallioniemi A,Schleutker J,Leminen A,B√É¬ºtzow R,Blomqvist C,Barkardottir RB,Couch FJ,Aittom√É¬§ki K,Nevanlinna H. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc Natl Acad Sci U S A.. 2014;111(42):15172-7.|28837157) Bogliolo M,Bluteau D,Lespinasse J,Pujol R,Vasquez N,d'Enghien CD,Stoppa-Lyonnet D,Leblanc T,Soulier J,Surrall√É¬©s J. Biallelic truncating FANCM mutations cause early-onset cancer but not Fanconi anemia. Genet Med.. 2018;20(4):458-463.|28837162) Catucci I,Osorio A,Arver B,Neidhardt G,Bogliolo M,Zanardi F,Riboni M,Minardi S,Pujol R,Azzollini J,Peissel B,Manoukian S,De Vecchi G,Casola S,Hauke J,Richters L,Rhiem K,Schmutzler RK,Wallander K,T√É¬∂rngren T,Borg √É‚Ä¶,Radice P,Surrall√É¬©s J,Hahnen E,Ehrencrona H,Kvist A,Benitez J,Peterlongo P. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility. Genet Med.. 2018;20(4):452-457.|29231814) Fouquet B,Pawlikowska P,Caburet S,Guigon C,M√É¬§kinen M,Tanner L,Hietala M,Urbanska K,Bellutti L,Legois B,Bessieres B,Gougeon A,Benachi A,Livera G,Rosselli F,Veitia RA,Misrahi M. A homozygous  mutation underlies a familial case of non-syndromic primary ovarian insufficiency. Elife.. 2017;6():.|29895858) Yin H,Ma H,Hussain S,Zhang H,Xie X,Jiang L,Jiang X,Iqbal F,Bukhari I,Jiang H,Ali A,Zhong L,Li T,Fan S,Zhang B,Gao J,Li Y,Nazish J,Khan T,Khan M,Zubair M,Hao Q,Fang H,Huang J,Huleihel M,Sha J,Pandita TK,Zhang Y,Shi Q. A homozygous FANCM frameshift pathogenic variant causes male infertility. Genet Med.. 2019;21(1):62-70.|30075111) Kasak L,Punab M,Nagirnaja L,Grigorova M,Minajeva A,Lopes AM,Punab AM,Aston KI,Carvalho F,Laasik E,Smith LB, ,Conrad DF,Laan M. Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia. Am J Hum Genet.. 2018;103(2):200-212.|19423727) Impaired fancd2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize fanconi anemia complementation group m|21681190) Rare germline variants in regions of loss of heterozygosity may influence clinical course of hematological malignancies"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771) and autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).  HLRCC is characterized by cutaneous leiomyomas, early onset uterine leiomyomas, kidney tumors and kidney cancer. Uterine leiomyomas, also known as fibroids, are present in nearly all affected females. The lifetime risk for renal cell carcinoma is approximately 21% (PMID: 31831373). Some individuals with a clinically significant change in FH may also develop paragangliomas (PGL) and pheochromocytomas (PCC). PGL are nervous system tumors that often form in the head, neck, spine or abdomen. PCC are adrenal gland tumors that may cause symptoms including tachycardia and hypertension. Most PGL and PCC are benign and while there is malignant potential, lifetime cancer risks are not clear.  FHD is an inborn error of metabolism that causes infantile encephalopathy, failure to thrive, hypotonia, lethargy and seizures. Affected individuals often have microcephaly, distinctive facial features, structural brain abnormalities and developmental delay.", Pmids: "31831373", Gene_Name: "FH", References: "31831373) Forde C,Lim DHK,Alwan Y,Burghel G,Butland L,Cleaver R,Dixit A,Evans DG,Hanson H,Lalloo F,Oliveira P,Vialard L,Wallis Y,Maher ER,Woodward ER. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals. Eur Urol Oncol.. 2020;3(6):764-772."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The FLCN gene is associated with autosomal dominant Birt-Hogg-Dub√© (BHD) syndrome (MedGen UID: 91070). There is also evidence suggesting BHD is associated with an increased risk of colon polyps and colorectal cancer (PMID: 20522427, 20392993). The data, however, are preliminary and insufficient to made a determination regarding this relationship.  BHD is characterized by an increased risk to develop noncancerous cysts in the lungs (70% risk) and kidneys (12-34% risk) in addition to acrochordons, fibrofolliculomas and trichodiscomas on the face neck and upper body. There is a 24-38% risk of developing one or more spontaneous pneumothorax. Affected individuals also have an increased risk of kidney cancer; however, lifetime risks are not established (PMID: 25519092, 25519458, 18234728).", Pmids: "18234728|20392993|20522427|25519092|25519458", Gene_Name: "FLCN", References: "18234728) Toro JR,Wei MH,Glenn GM,Weinreich M,Toure O,Vocke C,Turner M,Choyke P,Merino MJ,Pinto PA,Steinberg SM,Schmidt LS,Linehan WM. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dub√É¬© syndrome: a new series of 50 families and a review of published reports. J Med Genet.. 2008;45(6):321-31.|20392993) Palmirotta R,Savonarola A,Ludovici G,Donati P,Cavaliere F,DE Marchis ML,Ferroni P,Guadagni F. Association between Birt Hogg Dube syndrome and cancer predisposition. Anticancer Res.. 2010;30(3):751-7.|20522427) Nahorski MS,Lim DH,Martin L,Gille JJ,McKay K,Rehal PK,Ploeger HM,van Steensel M,Tomlinson IP,Latif F,Menko FH,Maher ER. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer. J Med Genet.. 2010;47(6):385-90.|25519092) Dal Sasso AA,Bel√É¬©m LC,Zanetti G,Souza CA,Escuissato DL,Irion KL,Guimar√É¬£es MD,Marchiori E. Birt-Hogg-Dub√É¬© syndrome. State-of-the-art review with emphasis on pulmonary involvement. Respir Med.. 2015;109(3):289-96.|25519458) Benusiglio PR,Giraud S,Deveaux S,M√É¬©jean A,Correas JM,Joly D,Timsit MO,Ferlicot S,Verkarre V,Abadie C,Chauveau D,Leroux D,Avril MF,Cordier JF,Richard S, . Renal cell tumour characteristics in patients with the Birt-Hogg-Dub√É¬© cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet J Rare Dis.. 2014;9():163."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The GALNT12 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 19617566, 22461326, 29749045).", Pmids: "19617566|22461326|29749045", Gene_Name: "GALNT12", References: "19617566) Guda K,Moinova H,He J,Jamison O,Ravi L,Natale L,Lutterbaugh J,Lawrence E,Lewis S,Willson JK,Lowe JB,Wiesner GL,Parmigiani G,Barnholtz-Sloan J,Dawson DW,Velculescu VE,Kinzler KW,Papadopoulos N,Vogelstein B,Willis J,Gerken TA,Markowitz SD. Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci U S A.. 2009;106(31):12921-5.|22461326) Inherited deleterious variants inigalnt12 iare associated with crc susceptibility|29749045) Evidence for GALNT12 as a moderate penetrance gene for colorectal cancer"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The GATA2 gene is associated with autosomal dominant GATA2 deficiency (MedGen UID: 481660) and Emberger syndrome (MedGen UID: 481294).  GATA2 deficiency is an immunodeficiency syndrome that typically presents in late adolescence or early adulthood with neutropenia and recurrent infections. GATA2 deficiency is associated with an increased risk of myelodysplastic syndrome and acute myelogenous leukemia (AML). Emberger syndrome is a related GATA2 deficiency condition associated with lymphedema of the lower extremities and predisposition to AML; hearing loss has been reported in some cases (PMID: 23223431, 21892158, 20803646).", Pmids: "20803646|21892158|23223431", Gene_Name: "GATA2", References: "20803646) Mansour S,Connell F,Steward C,Ostergaard P,Brice G,Smithson S,Lunt P,Jeffery S,Dokal I,Vulliamy T,Gibson B,Hodgson S,Cottrell S,Kiely L,Tinworth L,Kalidas K,Mufti G,Cornish J,Keenan R,Mortimer P,Murday V, . Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases. Am J Med Genet A.. 2010;152A(9):2287-96.|21892158) Ostergaard P,Simpson MA,Connell FC,Steward CG,Brice G,Woollard WJ,Dafou D,Kilo T,Smithson S,Lunt P,Murday VA,Hodgson S,Keenan R,Pilz DT,Martinez-Corral I,Makinen T,Mortimer PS,Jeffery S,Trembath RC,Mansour S. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet.. 2011;43(10):929-31.|23223431) Pasquet M,Bellann√É¬©-Chantelot C,Tavitian S,Prade N,Beaupain B,Larochelle O,Petit A,Rohrlich P,Ferrand C,Van Den Neste E,Poirel HA,Lamy T,Ouach√É¬©e-Chardin M,Mansat-De Mas V,Corre J,R√É¬©cher C,Plat G,Bachelerie F,Donadieu J,Delabesse E. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood.. 2013;121(5):822-9."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The GEN1 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to prostate cancer (PMID: 27433846).", Pmids: "27433846", Gene_Name: "GEN1", References: "27433846) Pritchard CC,Mateo J,Walsh MF,De Sarkar N,Abida W,Beltran H,Garofalo A,Gulati R,Carreira S,Eeles R,Elemento O,Rubin MA,Robinson D,Lonigro R,Hussain M,Chinnaiyan A,Vinson J,Filipenko J,Garraway L,Taplin ME,AlDubayan S,Han GC,Beightol M,Morrissey C,Nghiem B,Cheng HH,Montgomery B,Walsh T,Casadei S,Berger M,Zhang L,Zehir A,Vijai J,Scher HI,Sawyers C,Schultz N,Kantoff PW,Solit D,Robson M,Van Allen EM,Offit K,de Bono J,Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.. 2016;375(5):443-53."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The GPC3 gene is associated with X-linked recessive Simpson-Golabi-Behmel syndrome (MedGen UID: 162917).  Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).

Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).", Pmids: "19372699|24115482|25238977", Gene_Name: "GPC3", References: "19372699) Li CC,McDonald SD. Increased nuchal translucency and other ultrasound findings in a case of simpson-golabi-behmel syndrome. Fetal Diagn Ther.. 2009;25(2):211-5.|24115482) Villarreal DD,Villarreal H,Paez AM,Peppas D,Lynch J,Roeder E,Powers GC. A patient with a unique frameshift mutation in GPC3, causing Simpson-Golabi-Behmel syndrome, presenting with craniosynostosis, penoscrotal hypospadias, and a large prostatic utricle. Am J Med Genet A.. 2013;161A(12):3121-5.|25238977) Tenorio J,Arias P,Mart√É¬≠nez-Glez V,Santos F,Garc√É¬≠a-Mi√É¬±aur S,Nevado J,Lapunzina P. Simpson-Golabi-Behmel syndrome types I and II. Orphanet J Rare Dis.. 2014;9():138."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The GREM1 gene is associated with autosomal dominant hereditary mixed polyposis syndrome (HMPS) in individuals who carry a duplication spanning the 3' end of the adjacent SCG5 gene and a region upstream of the GREM1 locus (MedGen UID: 430218, PMID: 22561515).  Hereditary mixed polyposis syndrome is an adult-onset condition associated with various types of colon polyps which may subsequently become malignant (PMID: 22561515). Lifetime cancer risks are currently not well established.", Pmids: "22561515", Gene_Name: "GREM1", References: "22561515) Jaeger E,Leedham S,Lewis A,Segditsas S,Becker M,Cuadrado PR,Davis H,Kaur K,Heinimann K,Howarth K, ,East J,Taylor J,Thomas H,Tomlinson I. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet.. 2012;44(6):699-703."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The HOXB13 gene is associated with autosomal dominant predisposition to prostate cancer (PMID: 31629417).", Pmids: "31629417", Gene_Name: "HOXB13", References: "31629417) Isaacs WB,Cooney KA,Xu J. Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13. Can J Urol.. 2019;26(5 Suppl 2):12-13."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The HRAS gene is associated with autosomal dominant Costello syndrome (MedGen UID: 108454).  Costello syndrome is characterized by intellectual disability, failure to thrive, cardiac malformations, short stature, loose skin with deep palmar and plantar creases, cerebellar overgrowth, predisposition to malignancy, and dysmorphic facial features including coarse facies, epicanthal folds, long eyelashes, sparse/curly hair, full lips, and a wide nasal bridge.", Pmids: "Unknown", Gene_Name: "HRAS", References: "Unknown"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The KIF1B gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (PMID: 24694336), neuroblastoma (PMID: 18614535, 18334619, 24469107), and Charcot-Marie-Tooth disease (CMT) (PMID: 30373780).", Pmids: "18334619|18614535|24469107|24694336|30373780", Gene_Name: "KIF1B", References: "18334619) Schlisio S,Kenchappa RS,Vredeveld LC,George RE,Stewart R,Greulich H,Shahriari K,Nguyen NV,Pigny P,Dahia PL,Pomeroy SL,Maris JM,Look AT,Meyerson M,Peeper DS,Carter BD,Kaelin WG. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev.. 2008;22(7):884-93.|18614535) Munirajan AK,Ando K,Mukai A,Takahashi M,Suenaga Y,Ohira M,Koda T,Hirota T,Ozaki T,Nakagawara A. KIF1Bbeta functions as a haploinsufficient tumor suppressor gene mapped to chromosome 1p36.2 by inducing apoptotic cell death. J Biol Chem.. 2008;283(36):24426-34.|24694336) Welander J,Andreasson A,Juhlin CC,Wiseman RW,B√É¬§ckdahl M,H√É¬∂√É¬∂g A,Larsson C,Gimm O,S√É¬∂derkvist P. Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab.. 2014;99(7):E1352-60.|24469107) RNA helicase A is a downstream mediator of KIF1B_ tumor-suppressor function in neuroblastoma|30373780) Molecular diagnosis of inherited peripheral neuropathies by targeted next-generation sequencing: molecular spectrum delineation"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The KIT gene is associated with autosomal dominant piebaldism (MedGen UID: 36361), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and familial mastocytosis (MedGen UID: 9902).  Pathogenic loss-of-function (LOF) variants in KIT are associated with piebaldism, a rare condition characterized by patchy absence of melanocytes in the skin and hair. These unpigmented areas are typically present at birth and do not increase in size or number (PMID: 19555431, 7529964, 7525736). LOF pathogenic KIT variants are generally not associated with familial GIST or mastocytosis (PMID: 15241338). 

Pathogenic gain-of-function (GOF) KIT variants are associated with familial GIST and familial mastocytosis. Familial GIST is a primarily adult-onset condition characterized by sarcomas of the stomach and small bowel that may be benign or malignant (PMID: 23648119, 26833487, 9438854). Familial mastocytosis causes abnormal accumulation of mast cells in the skin and bone marrow (PMID: 27777718, 28031180). In childhood, this condition is known as cutaneous mastocytosis because it manifests in the skin, often resolving by puberty. Adult-onset cases are known as systemic mastocytosis due to involvement of the bone marrow and skin, with potential risks for hematologic malignancy (PMID: 27777718, 28031180). Some individuals with pathogenic GOF KIT variants may present with features of both GIST and mastocytosis (PMID: 27777718). Pathogenic GOF variants in KIT are generally not associated with piebaldism (PMID: 15241338).", Pmids: "7525736|7529964|9438854|15241338|19555431|23648119|26833487|27777718|28031180", Gene_Name: "KIT", References: "15241338) Akin C,Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol.. 2004;114(1):13-9; quiz 20.|19555431) Dessinioti C,Stratigos AJ,Rigopoulos D,Katsambas AD. A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol.. 2009;18(9):741-9.|23648119) Bachet JB,Landi B,Laurent-Puig P,Italiano A,Le Cesne A,L√É¬©vy P,Safar V,Duffaud F,Blay JY,Emile JF. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. Eur J Cancer.. 2013;49(11):2531-41.|26833487) Watson GA,Kelly D,Melland-Smith M,Gleeson J,McEntee G,Kelly CM,McCaffrey JA. Get the GIST? An overview of gastrointestinal stromal tumours. Ir J Med Sci.. 2016;185(2):319-26.|27777718) Ke H,Kazi JU,Zhao H,Sun J. Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis. Cell Biosci.. 2016;6():55.|28031180) Valent P,Akin C,Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood.. 2017;129(11):1420-1427.|7525736) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Molecular basis of human piebaldism. J Invest Dermatol.. 1994;103(5 Suppl):137S-140S.|7529964) Ezoe K,Holmes SA,Ho L,Bennett CP,Bolognia JL,Brueton L,Burn J,Falabella R,Gatto EM,Ishii N. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. Am J Hum Genet.. 1995;56(1):58-66.|9438854) Hirota S,Isozaki K,Moriyama Y,Hashimoto K,Nishida T,Ishiguro S,Kawano K,Hanada M,Kurata A,Takeda M,Muhammad Tunio G,Matsuzawa Y,Kanakura Y,Shinomura Y,Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science.. 1998;279(5350):577-80."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).								  Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612).", Pmids: "10419612|23401320|24362817|24451042|25480913|26380542|26446362", Gene_Name: "LZTR1 - Gain of Function", References: "10419612) Nisbet DL,Griffin DR,Chitty LS. Prenatal features of Noonan syndrome. Prenat Diagn.. 1999;19(7):642-7.|23401320) Plotkin SR,Blakeley JO,Evans DG,Hanemann CO,Hulsebos TJ,Hunter-Schaedle K,Kalpana GV,Korf B,Messiaen L,Papi L,Ratner N,Sherman LS,Smith MJ,Stemmer-Rachamimov AO,Vitte J,Giovannini M. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A.. 2013;161A(3):405-16.|24362817) Piotrowski A,Xie J,Liu YF,Poplawski AB,Gomes AR,Madanecki P,Fu C,Crowley MR,Crossman DK,Armstrong L,Babovic-Vuksanovic D,Bergner A,Blakeley JO,Blumenthal AL,Daniels MS,Feit H,Gardner K,Hurst S,Kobelka C,Lee C,Nagy R,Rauen KA,Slopis JM,Suwannarat P,Westman JA,Zanko A,Korf BR,Messiaen LM. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet.. 2014;46(2):182-7.|24451042) Lepri FR,Scavelli R,Digilio MC,Gnazzo M,Grotta S,Dentici ML,Pisaneschi E,Sirleto P,Capolino R,Baban A,Russo S,Franchin T,Angioni A,Dallapiccola B. Diagnosis of Noonan syndrome and related disorders using target next generation sequencing. BMC Med Genet.. 2014;15():14.|25480913) Smith MJ,Isidor B,Beetz C,Williams SG,Bhaskar SS,Richer W,O'Sullivan J,Anderson B,Daly SB,Urquhart JE,Fryer A,Rustad CF,Mills SJ,Samii A,du Plessis D,Halliday D,Barbarot S,Bourdeaut F,Newman WG,Evans DG. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology.. 2015;84(2):141-7.|26380542) Gelb BD,Roberts AE,Tartaglia M. Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog Pediatr Cardiol.. 2015;39(1):13-19.|26446362) Aoki Y,Niihori T,Inoue S,Matsubara Y. Recent advances in RASopathies. J Hum Genet.. 2016;61(1):33-9."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The LZTR1 gene is associated with autosomal dominant schwannomatosis (MedGen UID: 816613). In addition, LZTR1 is associated with autosomal dominant and autosomal recessive Noonan spectrum disorders (NSDs) (MedGen UID: 902892, OMIM: 605275).								  Schwannomatosis is a distinct form of neurofibromatosis characterized by a predisposition to develop multiple nonintradermal and nonvestibular schwannomas in adulthood, often accompanied by chronic pain; meningiomas are seen in rare cases (PMID: 25480913, 23401320). Affected individuals have variable expression and/or reduced penetrance, even within the same family (PMID: 24362817, 23401320). Noonan Spectrum Disorders (NSDs), also known as RASopathies, are a class of pediatric developmental disorders that share a common spectrum of symptoms. These include cardiovascular abnormalities, especially congenital heart defects and hypertrophic cardiomyopathy, short stature, distinctive craniofacial features, cutaneous abnormalities affecting the skin and hair, varying degrees of developmental delay, and development of tumors, both benign and cancerous (PMID: 24451042, 26380542, 26446362). Features of NSDs are often variable even within members of the same family (PMID: 24451042). In some cases, individuals may have only subtle features, while others may present with symptoms perinatally (PMID: 10419612).", Pmids: "10419612|23401320|24362817|24451042|25480913|26380542|26446362", Gene_Name: "LZTR1 - Loss of Function", References: "10419612) Nisbet DL,Griffin DR,Chitty LS. Prenatal features of Noonan syndrome. Prenat Diagn.. 1999;19(7):642-7.|23401320) Plotkin SR,Blakeley JO,Evans DG,Hanemann CO,Hulsebos TJ,Hunter-Schaedle K,Kalpana GV,Korf B,Messiaen L,Papi L,Ratner N,Sherman LS,Smith MJ,Stemmer-Rachamimov AO,Vitte J,Giovannini M. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A.. 2013;161A(3):405-16.|24362817) Piotrowski A,Xie J,Liu YF,Poplawski AB,Gomes AR,Madanecki P,Fu C,Crowley MR,Crossman DK,Armstrong L,Babovic-Vuksanovic D,Bergner A,Blakeley JO,Blumenthal AL,Daniels MS,Feit H,Gardner K,Hurst S,Kobelka C,Lee C,Nagy R,Rauen KA,Slopis JM,Suwannarat P,Westman JA,Zanko A,Korf BR,Messiaen LM. Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas. Nat Genet.. 2014;46(2):182-7.|24451042) Lepri FR,Scavelli R,Digilio MC,Gnazzo M,Grotta S,Dentici ML,Pisaneschi E,Sirleto P,Capolino R,Baban A,Russo S,Franchin T,Angioni A,Dallapiccola B. Diagnosis of Noonan syndrome and related disorders using target next generation sequencing. BMC Med Genet.. 2014;15():14.|25480913) Smith MJ,Isidor B,Beetz C,Williams SG,Bhaskar SS,Richer W,O'Sullivan J,Anderson B,Daly SB,Urquhart JE,Fryer A,Rustad CF,Mills SJ,Samii A,du Plessis D,Halliday D,Barbarot S,Bourdeaut F,Newman WG,Evans DG. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology.. 2015;84(2):141-7.|26380542) Gelb BD,Roberts AE,Tartaglia M. Cardiomyopathies in Noonan syndrome and the other RASopathies. Prog Pediatr Cardiol.. 2015;39(1):13-19.|26446362) Aoki Y,Niihori T,Inoue S,Matsubara Y. Recent advances in RASopathies. J Hum Genet.. 2016;61(1):33-9."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MAX gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 313270). There is also evidence suggesting MAX is associated with autosomal dominant predisposition to renal cancer (PMID: 28973655) and pituitary adenomas (PMID: 32201880). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  MAX-associated PGL-PCC syndrome is characterized by malignant or benign PGL and PCC tumors. PGLs are nervous system tumors that often develop within the head, neck, spine, or abdomen. PCCs are adrenal gland tumors that may cause symptoms related to increased hormone secretion, such as rapid heartbeat and high blood pressure (PMID: 21685915, 22452945, 23666964). While both males and females can pass this variant on to their children, there is evidence suggesting the risks of developing MAX-associated tumors are greatest for those who inherit the variant from their father (PMID: 22452945, 33493868).", Pmids: "21685915|22452945|23666964|28973655|32201880|33493868", Gene_Name: "MAX", References: "21685915) Comino-M√É¬©ndez I,Gracia-Azn√É¬°rez FJ,Schiavi F,Landa I,Leandro-Garc√É¬≠a LJ,Let√É¬≥n R,Honrado E,Ramos-Medina R,Caronia D,Pita G,G√É¬≥mez-Gra√É¬±a A,de Cubas AA,Inglada-P√É¬©rez L,Maliszewska A,Taschin E,Bobisse S,Pica G,Loli P,Hern√É¬°ndez-Lavado R,D√É¬≠az JA,G√É¬≥mez-Morales M,Gonz√É¬°lez-Neira A,Roncador G,Rodr√É¬≠guez-Antona C,Ben√É¬≠tez J,Mannelli M,Opocher G,Robledo M,Casc√É¬≥n A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet.. 2011;43(7):663-7.|22452945) Burnichon N,Casc√É¬≥n A,Schiavi F,Morales NP,Comino-M√É¬©ndez I,Abermil N,Inglada-P√É¬©rez L,de Cubas AA,Amar L,Barontini M,de Quir√É¬≥s SB,Bertherat J,Bignon YJ,Blok MJ,Bobisse S,Borrego S,Castellano M,Chanson P,Chiara MD,Corssmit EP,Giacch√É¬® M,de Krijger RR,Ercolino T,Girerd X,G√É¬≥mez-Garc√É¬≠a EB,G√É¬≥mez-Gra√É¬±a A,Guilhem I,Hes FJ,Honrado E,Korpershoek E,Lenders JW,Let√É¬≥n R,Mensenkamp AR,Merlo A,Mori L,Murat A,Pierre P,Plouin PF,Prodanov T,Quesada-Charneco M,Qin N,Rapizzi E,Raymond V,Reisch N,Roncador G,Ruiz-Ferrer M,Schillo F,Stegmann AP,Suarez C,Taschin E,Timmers HJ,Tops CM,Urioste M,Beuschlein F,Pacak K,Mannelli M,Dahia PL,Opocher G,Eisenhofer G,Gimenez-Roqueplo AP,Robledo M. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res.. 2012;18(10):2828-37.|23666964) Rattenberry E,Vialard L,Yeung A,Bair H,McKay K,Jafri M,Canham N,Cole TR,Denes J,Hodgson SV,Irving R,Izatt L,Korbonits M,Kumar AV,Lalloo F,Morrison PJ,Woodward ER,Macdonald F,Wallis Y,Maher ER. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab.. 2013;98(7):E1248-56.|28973655) Casey RT,Warren AY,Martin JE,Challis BG,Rattenberry E,Whitworth J,Andrews KA,Roberts T,Clark GR,West H,Smith PS,Docquier FM,Rodger F,Murray V,Simpson HL,Wallis Y,Giger O,Tran M,Tomkins S,Stewart GD,Park SM,Woodward ER,Maher ER. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. J Clin Endocrinol Metab.. 2017;102(11):4013-4022.|33493868) Richter JE,Hines S,Selvam P,Atwal H,Farres H,Caulfield TR,Atwal PS. Clinical description & molecular modeling of novel MAX pathogenic variant causing pheochromocytoma in family, supports paternal parent-of-origin effect. Cancer Genet.. 2021;252-253():107-110.|32201880) Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MEN1 gene is associated with autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome (MedGen UID: 9957) and familial isolated hyperparathyroidism (FIHP) (OMIM: 145000). Studies also suggest the MEN1 gene may be associated with autosomal dominant predisposition to thyroid cancer (PMID: 30608029) and paraganglioma-pheochromocytoma syndrome (PGL-PCC) (PMID: 22723327, 27572829, 32130200). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Multiple endocrine neoplasia type 1 is a highly penetrant condition associated with endocrine tumors in the parathyroid, anterior pituitary, thymus, gastro-entero-pancreatic tract and adrenal glands. Affected individuals may also have facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. While most MEN1-associated tumors are noncancerous, there is an increased risk of malignant transformation. Parathyroid tumors are the primary MEN1-associated endocrinopathy with symptoms typically developing at 20-25 years of age (PMID: 32971521).  MEN1 is also associated with autosomal dominant familial isolated hyperparathyroidism (FIHP), characterized by parathyroid adenomas or hyperplasia without other associated tumors or endocrinopathies (PMID: 12213668, 12699448).", Pmids: "12213668|12699448|22723327|27572829|30608029|32130200|32971521", Gene_Name: "MEN1", References: "12213668) Villablanca A,Wassif WS,Smith T,H√É¬∂√É¬∂g A,Vierimaa O,Kassem M,Dwight T,Forsberg L,Du Q,Learoyd D,Jones K,Stranks S,Juhlin C,Teh BT,Carling T,Robinson B,Larsson C. Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. Eur J Endocrinol.. 2002;147(3):313-22.|12699448) Pannett AA,Kennedy AM,Turner JJ,Forbes SA,Cavaco BM,Bassett JH,Cianferotti L,Harding B,Shine B,Flinter F,Maidment CG,Trembath R,Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf).. 2003;58(5):639-46.|22723327) Thakker RV,Newey PJ,Walls GV,Bilezikian J,Dralle H,Ebeling PR,Melmed S,Sakurai A,Tonelli F,Brandi ML, . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab.. 2012;97(9):2990-3011.|27572829) Okada R,Shimura T,Tsukida S,Ando J,Kofunato Y,Momma T,Yashima R,Koyama Y,Suzuki S,Takenoshita S. Concomitant existence of pheochromocytoma in a patient with multiple endocrine neoplasia type 1. Surg Case Rep.. 2016;2(1):84.|30608029) Hill KA,Yip L,Carty SE,McCoy KL. Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. Thyroid.. 2019;29(2):252-257.|32130200) Tepede AA,Welch J,Lee M,Mandl A,Agarwal SK,Nilubol N,Patel D,Cochran C,Simonds WF,Weinstein LS,Jha A,Millo C,Pacak K,Blau JE. 18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinol Diabetes Metab Case Rep.. 2020;2020():.|32971521) Niederle B,Selberherr A,Bartsch DK,Brandi ML,Doherty GM,Falconi M,Goudet P,Halfdanarson TR,Ito T,Jensen RT,Larghi A,Lee L,√É‚Äìberg K,Pavel M,Perren A,Sadowski SM,Tonelli F,Triponez F,Valk GD,O'Toole D,Scott-Coombes D,Thakker RV,Thompson GB,Treglia G,Wiedenmann B. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology.. 2021;111(7):609-630."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MET gene is associated with autosomal dominant predisposition to hereditary papillary renal cell carcinoma (HPRCC) (MedGen UID: 766) and autosomal recessive deafness (MedGen UID: 899875). Additionally, the MET gene has preliminary evidence supporting a correlation with arthrogryposis involving the upper limbs (PMID: 30777867). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  HPRCC is a rare, highly penetrant hereditary cancer syndrome characterized by an increased lifetime risk of developing type 1 papillary renal cell carcinoma (PRCC) (PMID: 24710684, 9563489, 12647800). These tumors are typically multifocal and bilateral (PMID: 8308957).                           Nonsyndromic deafness does not affect any other part of the body. Affected individuals are born with mild to profound hearing loss that typically does not worsen over time. Severity of deafness may vary, even among members of the same family. Intellect and life span are not impacted.", Pmids: "8308957|9563489|12647800|24710684|30777867", Gene_Name: "MET", References: "12647800) Kuroda N,Toi M,Hiroi M,Enzan H. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol.. 2003;18(2):487-94.|30777867) Zhou H,Lian C,Wang T,Yang X,Xu C,Su D,Zheng S,Huang X,Liao Z,Zhou T,Qiu X,Chen Y,Gao B,Li Y,Wang X,You G,Fu Q,Gurnett C,Huang D,Su P. mutation causes muscular dysplasia and√Ç¬†arthrogryposis. EMBO Mol Med.. 2019;11(3):.|8308957) Zbar B,Tory K,Merino M,Schmidt L,Glenn G,Choyke P,Walther MM,Lerman M,Linehan WM. Hereditary papillary renal cell carcinoma. J Urol.. 1994;151(3):561-6.|9563489) Schmidt L,Junker K,Weirich G,Glenn G,Choyke P,Lubensky I,Zhuang Z,Jeffers M,Vande Woude G,Neumann H,Walther M,Linehan WM,Zbar B. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res.. 1998;58(8):1719-22.|24710684) Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MITF gene is associated with autosomal dominant Waardenburg syndrome, type 2a (MedGen UID: 349786) and autosomal recessive COMMAD syndrome (coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness) (MedGen UID: 934592). The c.952G>A (p.Glu318Lys) variant in MITF is associated with autosomal dominant predisposition to cutaneous malignant melanoma (MedGen UID: 463554).  Waardenburg syndrome, type 2a (WS2a) is characterized by congenital deafness and abnormal pigmentation of the iris, hair and skin. Additional neurologic manifestations including intellectual disability and myelination abnormalities have been described. WS2a is distinguished from Waardenburg type 1 by the absence of dystopia canthorum (PMID: 20127975).

COMMAD syndrome is a rare condition characterized by iris coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism and deafness. Due to the limited cases described in the literature, the clinical features and natural history of COMMAD are still unclear and will likely evolve over time. Clinical correlation is advised.", Pmids: "20127975", Gene_Name: "MITF", References: "20127975) Pingault V,Ente D,Dastot-Le Moal F,Goossens M,Marlin S,Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum Mutat.. 2010;31(4):391-406."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MLH1 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 232603) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MLH1-related Lynch syndrome is characterized by increased risk of various cancers including colorectal, endometrial, ovarian, urinary tract, gastrointestinal, brain and possibly prostate. Lifetime cancer risks include a 46‚Äì61% risk for colorectal cancer, a 5‚Äì7% risk for gastric cancer, a 6% risk for pancreatic cancer, up to an 11% risk for cancer of the small intestines, up to a 5% risk for urinary tract cancer, a 2‚Äì7% risk for bladder cancer, a 2‚Äì4% risk for cancer of the biliary tract and up to a 1.7% risk for brain/nervous system cancer. Affected females also have an increased risk of uterine/endometrial cancer (34-54%) and ovarian cancer (4‚Äì20%) (PMID: 21642682, 28754778, 28772289, 19900449, 26385421, 27013479, 18398828, 26657901,19900449, 31337882).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", Pmids: "17539897|18398828|18709565|19900449|20442441|21642682|26385421|26657901|27013479|28754778|28772289|31337882", Gene_Name: "MLH1", References: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18398828) Watson P,Vasen HFA,Mecklin JP,Bernstein I,Aarnio M,J√É¬§rvinen HJ,Myrh√É¬∏j T,Sunde L,Wijnen JT,Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer.. 2008;123(2):444-449.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|19900449) Capelle LG,Van Grieken NC,Lingsma HF,Steyerberg EW,Klokman WJ,Bruno MJ,Vasen HF,Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology.. 2010;138(2):487-92.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|26385421) Joost P,Therkildsen C,Dominguez-Valentin M,J√É¬∂nsson M,Nilbert M. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology.. 2015;86(6):1212-7.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|27013479) Dominguez-Valentin M,Joost P,Therkildsen C,Jonsson M,Rambech E,Nilbert M. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol.. 2016;16():15.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|28772289) Ryan NAJ,Morris J,Green K,Lalloo F,Woodward ER,Hill J,Crosbie EJ,Evans DG. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies. JAMA Oncol.. 2017;3(12):1702-1706.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MRE11 gene, formerly known as MRE11A, is associated with autosomal recessive ataxia-telangiectasia-like disorder (ATLD) (MedGen UID: 861227). There appears to be phenotypic overlap between ATLD and autosomal recessive Joubert syndrome (PMID: 22863007). Additionally, there are data supporting an association between MRE11 and autosomal dominant predisposition to breast and gynecologic cancer (PMID: 14684699, 24894818, 24549055, 25452441). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.                                                  ATLD is characterized by progressive cerebellar degeneration resulting in ataxia and oculomotor apraxia (PMID: 15279810). Studies have demonstrated an increased susceptibility to radiation, consistent with a defect in the DNA repair pathway. While this disorder shares some phenotypic features with ataxia-telangiectasia, telangiectasias and immunodeficiency are not present in ATLD (PMID: 15279810, 10612394, 18652530).", Pmids: "10612394|14684699|15279810|18652530|22863007|24549055|24894818|25452441", Gene_Name: "MRE11", References: "10612394) Stewart GS,Maser RS,Stankovic T,Bressan DA,Kaplan MI,Jaspers NG,Raams A,Byrd PJ,Petrini JH,Taylor AM. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell.. 1999;99(6):577-87.|14684699) Heikkinen K,Karppinen SM,Soini Y,M√É¬§kinen M,Winqvist R. Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet.. 2003;40(12):e131.|15279810) Taylor AM,Groom A,Byrd PJ. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair (Amst).. ;3(8-9):1219-25.|22863007) Chaki M,Airik R,Ghosh AK,Giles RH,Chen R,Slaats GG,Wang H,Hurd TW,Zhou W,Cluckey A,Gee HY,Ramaswami G,Hong CJ,Hamilton BA,Cervenka I,Ganji RS,Bryja V,Arts HH,van Reeuwijk J,Oud MM,Letteboer SJ,Roepman R,Husson H,Ibraghimov-Beskrovnaya O,Yasunaga T,Walz G,Eley L,Sayer JA,Schermer B,Liebau MC,Benzing T,Le Corre S,Drummond I,Janssen S,Allen SJ,Natarajan S,O'Toole JF,Attanasio M,Saunier S,Antignac C,Koenekoop RK,Ren H,Lopez I,Nayir A,Stoetzel C,Dollfus H,Massoudi R,Gleeson JG,Andreoli SP,Doherty DG,Lindstrad A,Golzio C,Katsanis N,Pape L,Abboud EB,Al-Rajhi AA,Lewis RA,Omran H,Lee EY,Wang S,Sekiguchi JM,Saunders R,Johnson CA,Garner E,Vanselow K,Andersen JS,Shlomai J,Nurnberg G,Nurnberg P,Levy S,Smogorzewska A,Otto EA,Hildebrandt F. Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell.. 2012;150(3):533-48.|24549055) Cast√É¬©ra L,Krieger S,Rousselin A,Legros A,Baumann JJ,Bruet O,Brault B,Fouillet R,Goardon N,Letac O,Baert-Desurmont S,Tinat J,Bera O,Dugast C,Berthet P,Polycarpe F,Layet V,Hardouin A,Fr√É¬©bourg T,Vaur D. Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes. Eur J Hum Genet.. 2014;22(11):1305-13.|24894818) Damiola F,Pertesi M,Oliver J,Le Calvez-Kelm F,Voegele C,Young EL,Robinot N,Forey N,Durand G,Vall√É¬©e MP,Tao K,Roane TC,Williams GJ,Hopper JL,Southey MC,Andrulis IL,John EM,Goldgar DE,Lesueur F,Tavtigian SV. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res.. 2014;16(3):R58.|25452441) Couch FJ,Hart SN,Sharma P,Toland AE,Wang X,Miron P,Olson JE,Godwin AK,Pankratz VS,Olswold C,Slettedahl S,Hallberg E,Guidugli L,Davila JI,Beckmann MW,Janni W,Rack B,Ekici AB,Slamon DJ,Konstantopoulou I,Fostira F,Vratimos A,Fountzilas G,Pelttari LM,Tapper WJ,Durcan L,Cross SS,Pilarski R,Shapiro CL,Klemp J,Yao S,Garber J,Cox A,Brauch H,Ambrosone C,Nevanlinna H,Yannoukakos D,Slager SL,Vachon CM,Eccles DM,Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol.. 2015;33(4):304-11.|18652530) Assessment of carriers' frequency of a novel IMRE11 I mutation responsible for the rare ataxia telangiectasialike disorder"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MSH2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 423615) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MSH2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovary, stomach, biliary tract, bladder, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks include a 33‚Äì52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", Pmids: "17539897|18398828|18709565|19900449|20442441|21642682|23091106|26657901|27013479|28754778|31337882", Gene_Name: "MSH2", References: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18398828) Watson P,Vasen HFA,Mecklin JP,Bernstein I,Aarnio M,J√É¬§rvinen HJ,Myrh√É¬∏j T,Sunde L,Wijnen JT,Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer.. 2008;123(2):444-449.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|19900449) Capelle LG,Van Grieken NC,Lingsma HF,Steyerberg EW,Klokman WJ,Bruno MJ,Vasen HF,Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology.. 2010;138(2):487-92.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|23091106) Engel C,Loeffler M,Steinke V,Rahner N,Holinski-Feder E,Dietmaier W,Schackert HK,Goergens H,von Knebel Doeberitz M,Goecke TO,Schmiegel W,Buettner R,Moeslein G,Letteboer TG,G√É¬≥mez Garc√É¬≠a E,Hes FJ,Hoogerbrugge N,Menko FH,van Os TA,Sijmons RH,Wagner A,Kluijt I,Propping P,Vasen HF. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol.. 2012;30(35):4409-15.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|27013479) Dominguez-Valentin M,Joost P,Therkildsen C,Jonsson M,Rambech E,Nilbert M. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol.. 2016;16():15.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653).", Pmids: "27476653", Gene_Name: "MSH3 - Monoallelic", References: "27476653) Adam R,Spier I,Zhao B,Kloth M,Marquez J,Hinrichsen I,Kirfel J,Tafazzoli A,Horpaopan S,Uhlhaas S,Stienen D,Friedrichs N,Altm√É¬ºller J,Laner A,Holzapfel S,Peters S,Kayser K,Thiele H,Holinski-Feder E,Marra G,Kristiansen G,N√É¬∂then MM,B√É¬ºttner R,M√É¬∂slein G,Betz RC,Brieger A,Lifton RP,Aretz S. Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. Am J Hum Genet.. 2016;99(2):337-51."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MSH3 gene is associated with autosomal recessive MSH3-associated polyposis (MedGen UID: 934686). This condition may also be associated with increased risks for other cancers (PMID: 27476653). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  MSH3-associated polyposis is an adult-onset hereditary cancer predisposition syndrome characterized by the development of multiple colonic adenomas, often with progression to colorectal cancer; lifetime cancer risks are not established (PMID: 27476653).", Pmids: "27476653", Gene_Name: "MSH3 - Biallelic", References: "27476653) Adam R,Spier I,Zhao B,Kloth M,Marquez J,Hinrichsen I,Kirfel J,Tafazzoli A,Horpaopan S,Uhlhaas S,Stienen D,Friedrichs N,Altm√É¬ºller J,Laner A,Holzapfel S,Peters S,Kayser K,Thiele H,Holinski-Feder E,Marra G,Kristiansen G,N√É¬∂then MM,B√É¬ºttner R,M√É¬∂slein G,Betz RC,Brieger A,Lifton RP,Aretz S. Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis. Am J Hum Genet.. 2016;99(2):337-51."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MSH6 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 318886) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MSH6-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract, bladder, brain, and possibly prostate, stomach and small bowel. Estimated lifetime risks include a 10‚Äì44% risk of colorectal cancer, up to 5.5% risk of urinary tract cancer, up to an 8% risk of bladder cancer and up to a 2% risk of brain cancer. Affected females also have an increased risk of uterine/endometrial cancer (16-49%) and ovarian cancer (up to 13%) (PMID: 20028993, 21642682, 28754778, 20028993, 31204389, 31337882).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", Pmids: "17539897|18709565|20028993|20442441|21642682|28754778|31204389|31337882", Gene_Name: "MSH6", References: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|20028993) Baglietto L,Lindor NM,Dowty JG,White DM,Wagner A,Gomez Garcia EB,Vriends AH, ,Cartwright NR,Barnetson RA,Farrington SM,Tenesa A,Hampel H,Buchanan D,Arnold S,Young J,Walsh MD,Jass J,Macrae F,Antill Y,Winship IM,Giles GG,Goldblatt J,Parry S,Suthers G,Leggett B,Butz M,Aronson M,Poynter JN,Baron JA,Le Marchand L,Haile R,Gallinger S,Hopper JL,Potter J,de la Chapelle A,Vasen HF,Dunlop MG,Thibodeau SN,Jenkins MA. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst.. 2010;102(3):193-201.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|31204389) Suerink M,Rodr√É¬≠guez-Girondo M,van der Klift HM,Colas C,Brugieres L,Lavoine N,Jongmans M,Munar GC,Evans DG,Farrell MP,Genuardi M,Goldberg Y,Gomez-Garcia E,Heinimann K,Hoell JI,Aretz S,Jasperson KW,Kedar I,Modi MB,Nikolaev S,van Os TAM,Ripperger T,Rueda D,Senter L,Sjursen W,Sunde L,Therkildsen C,Tibiletti MG,Trainer AH,Vos YJ,Wagner A,Winship I,Wimmer K,Zimmermann SY,Vasen HF,van Asperen CJ,Houwing-Duistermaat JJ,Ten Broeke SW,Nielsen M. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med.. 2019;21(12):2706-2712.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).  MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).  Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks.", Pmids: "16492921|17368238|19245865|19394335|19620482|19732775|23035301|24444654|26905905|33059073", Gene_Name: "MUTYH - Monoallelic", References: "16492921) Jenkins MA,Croitoru ME,Monga N,Cleary SP,Cotterchio M,Hopper JL,Gallinger S. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev.. 2006;15(2):312-4.|17368238) Balaguer F,Castellv√É¬≠-Bel S,Castells A,Andreu M,Mu√É¬±oz J,Gisbert JP,Llor X,Jover R,de Cid R,Gonzalo V,Bessa X,Xicola RM,Pons E,Alenda C,Pay√É¬° A,Piqu√É¬© JM, . Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol.. 2007;5(3):379-87.|19245865) Cleary SP,Cotterchio M,Jenkins MA,Kim H,Bristow R,Green R,Haile R,Hopper JL,LeMarchand L,Lindor N,Parfrey P,Potter J,Younghusband B,Gallinger S. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology.. 2009;136(4):1251-60.|19394335) Jones N,Vogt S,Nielsen M,Christian D,Wark PA,Eccles D,Edwards E,Evans DG,Maher ER,Vasen HF,Hes FJ,Aretz S,Sampson JR. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology.. 2009;137(2):489-94, 494.e1; quiz 725-6.|19620482) Lubbe SJ,Di Bernardo MC,Chandler IP,Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol.. 2009;27(24):3975-80.|19732775) Vogt S,Jones N,Christian D,Engel C,Nielsen M,Kaufmann A,Steinke V,Vasen HF,Propping P,Sampson JR,Hes FJ,Aretz S. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology.. 2009;137(6):1976-85.e1-10.|24444654) Win AK,Dowty JG,Cleary SP,Kim H,Buchanan DD,Young JP,Clendenning M,Rosty C,MacInnis RJ,Giles GG,Boussioutas A,Macrae FA,Parry S,Goldblatt J,Baron JA,Burnett T,Le Marchand L,Newcomb PA,Haile RW,Hopper JL,Cotterchio M,Gallinger S,Lindor NM,Tucker KM,Winship IM,Jenkins MA. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology.. 2014;146(5):1208-11.e1-5.|26905905) Walton SJ,Kallenberg FG,Clark SK,Dekker E,Latchford A. Frequency and Features of Duodenal Adenomas in Patients With√Ç¬†MUTYH-Associated Polyposis. Clin Gastroenterol Hepatol.. 2016;14(7):986-92.|33059073) Colas C,Bonadona V,Baert-Desurmont S,Bonnet D,Coulet F,Dhooge M,Saurin JC,Remenieras A,Bignon YJ,Caron O,De Pauw A,Buisine MP,Buecher B. MUTYH-associated polyposis: Review and update of the French recommendations established in 2012 under the auspices of the National Cancer institute (INCa). Eur J Med Genet.. 2020;63(12):104078.|23035301) MUTYH Polyposis"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The MUTYH gene is associated with autosomal recessive MUTYH-associated polyposis (MAP) (MedGen UID: 332993).  MAP is characterized by adult-onset multiple colorectal adenomas and increased lifetime risk for colorectal cancer, estimated to be 80-90% in untreated cases. Colorectal cancer has been reported in some affected individuals in the absence of polyposis (PMID: 23035301, 33059073). Duodenal adenomas are found in 17-34% of MAP cases (PMID: 19732775, 26905905), with a 4% risk of malignant transformation (PMID: 23035301).  Approximately 1.5-2% of the Northern European population carries a pathogenic variant in MUTYH (PMID: 16492921, 19245865). The risk of colorectal cancer among heterozygous carriers was found to be marginally increased in large population-based studies (OR: 1.07-1.2) (PMID: 17368238, 19620482) whereas, family-based studies found a higher risk compared to the general population (OR: 2-3) (PMID: 24444654, 16492921, 19394335). Being a carrier of a pathogenic MUTYH variant impacts reproductive risks.", Pmids: "16492921|17368238|19245865|19394335|19620482|19732775|23035301|24444654|26905905|33059073", Gene_Name: "MUTYH - Biallelic", References: "16492921) Jenkins MA,Croitoru ME,Monga N,Cleary SP,Cotterchio M,Hopper JL,Gallinger S. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev.. 2006;15(2):312-4.|17368238) Balaguer F,Castellv√É¬≠-Bel S,Castells A,Andreu M,Mu√É¬±oz J,Gisbert JP,Llor X,Jover R,de Cid R,Gonzalo V,Bessa X,Xicola RM,Pons E,Alenda C,Pay√É¬° A,Piqu√É¬© JM, . Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol.. 2007;5(3):379-87.|19245865) Cleary SP,Cotterchio M,Jenkins MA,Kim H,Bristow R,Green R,Haile R,Hopper JL,LeMarchand L,Lindor N,Parfrey P,Potter J,Younghusband B,Gallinger S. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology.. 2009;136(4):1251-60.|19394335) Jones N,Vogt S,Nielsen M,Christian D,Wark PA,Eccles D,Edwards E,Evans DG,Maher ER,Vasen HF,Hes FJ,Aretz S,Sampson JR. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology.. 2009;137(2):489-94, 494.e1; quiz 725-6.|19620482) Lubbe SJ,Di Bernardo MC,Chandler IP,Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol.. 2009;27(24):3975-80.|19732775) Vogt S,Jones N,Christian D,Engel C,Nielsen M,Kaufmann A,Steinke V,Vasen HF,Propping P,Sampson JR,Hes FJ,Aretz S. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology.. 2009;137(6):1976-85.e1-10.|24444654) Win AK,Dowty JG,Cleary SP,Kim H,Buchanan DD,Young JP,Clendenning M,Rosty C,MacInnis RJ,Giles GG,Boussioutas A,Macrae FA,Parry S,Goldblatt J,Baron JA,Burnett T,Le Marchand L,Newcomb PA,Haile RW,Hopper JL,Cotterchio M,Gallinger S,Lindor NM,Tucker KM,Winship IM,Jenkins MA. Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology.. 2014;146(5):1208-11.e1-5.|26905905) Walton SJ,Kallenberg FG,Clark SK,Dekker E,Latchford A. Frequency and Features of Duodenal Adenomas in Patients With√Ç¬†MUTYH-Associated Polyposis. Clin Gastroenterol Hepatol.. 2016;14(7):986-92.|33059073) Colas C,Bonadona V,Baert-Desurmont S,Bonnet D,Coulet F,Dhooge M,Saurin JC,Remenieras A,Bignon YJ,Caron O,De Pauw A,Buisine MP,Buecher B. MUTYH-associated polyposis: Review and update of the French recommendations established in 2012 under the auspices of the National Cancer institute (INCa). Eur J Med Genet.. 2020;63(12):104078.|23035301) MUTYH Polyposis"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The NBN gene is associated with autosomal recessive Nijmegen breakage syndrome (NBS) (MedGen UID: 140771). There is also evidence suggesting NBN may be associated with autosomal dominant predisposition to ovarian, endometrial and prostate cancer (PMID: 26720728, 29988077, 30733081, 31406321). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  NBS is a progressive multisystemic disorder characterized by physical abnormalities, immunodeficiency, increased cancer risk and cognitive impairment. Physical abnormalities may include progressive microcephaly, early growth restriction leading to short stature and distinctive facial features. Immunodeficiency often results in recurrent pulmonary infections. B-cell lymphomas are the most common malignancy, although T-cell lymphomas, medulloblastomas, gliomas and rhabdomyosarcomas may also occur (PMID: 22373003, 26271390).   Studies have previously suggested that females with a pathogenic variant in NBN may have autosomal dominant predisposition to breast cancer (PMID: 17957789, 21514219, 16770759, 23765759); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).", Pmids: "16770759|17957789|21514219|22373003|23765759|26271390|26720728|29988077|30733081|31406321|33471974|33471991", Gene_Name: "NBN", References: "16770759) Steffen J,Nowakowska D,Niwi√Ö‚Äûska A,Czapczak D,Kluska A,Piatkowska M,Wi√Ö‚Ä∫niewska A,Paszko Z. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer.. 2006;119(2):472-5.|17957789) Bogdanova N,Feshchenko S,Sch√É¬ºrmann P,Waltes R,Wieland B,Hillemanns P,Rogov YI,Dammann O,Bremer M,Karstens JH,Sohn C,Varon R,D√É¬∂rk T. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer.. 2008;122(4):802-6.|21514219) Zhang B,Beeghly-Fadiel A,Long J,Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol.. 2011;12(5):477-88.|22373003) Chrzanowska KH,Gregorek H,Dembowska-Bagi√Ö‚Äûska B,Kalina MA,Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis.. 2012;7():13.|23765759) Zhang G,Zeng Y,Liu Z,Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol.. 2013;34(5):2753-7.|26271390) Wolska-Ku√Ö‚Ä∫nierz B,Gregorek H,Chrzanowska K,Pi√Ñ‚Ä¶tosa B,Pietrucha B,Heropolita√Ö‚Äûska-Pliszka E,Pac M,Klaudel-Dreszler M,Kostyuchenko L,Pasic S,Marodi L,Belohradsky BH,√Ñ≈íi√Ö¬æn√É¬°r P,Shcherbina A,Kilic SS,Baumann U,Seidel MG,Gennery AR,Syczewska M,Miko√Ö‚Äöu√Ñ‚Ä° B,Ka√Ö‚Äöwak K,Styczy√Ö‚Äûski J,Pieczonka A,Drabko K,Wakuli√Ö‚Äûska A,Gathmann B,Albert MH,Skar√Ö¬ºy√Ö‚Äûska U,Bernatowska E, . Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options - a Retrospective Analysis. J Clin Immunol.. 2015;35(6):538-49.|26720728) Norquist BM,Harrell MI,Brady MF,Walsh T,Lee MK,Gulsuner S,Bernards SS,Casadei S,Yi Q,Burger RA,Chan JK,Davidson SA,Mannel RS,DiSilvestro PA,Lankes HA,Ramirez NC,King MC,Swisher EM,Birrer MJ. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol.. 2016;2(4):482-90.|29988077) Cast√É¬©ra L,Harter V,Muller E,Krieger S,Goardon N,Ricou A,Rousselin A,Paimparay G,Legros A,Bruet O,Quesnelle C,Domin F,San C,Brault B,Fouillet R,Abadie C,B√É¬©ra O,Berthet P, ,Fr√É¬©bourg T,Vaur D. Landscape of pathogenic variations in√Ç¬†a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genet Med.. 2018;20(12):1677-1686.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|31406321) LaDuca H,Polley EC,Yussuf A,Hoang L,Gutierrez S,Hart SN,Yadav S,Hu C,Na J,Goldgar DE,Fulk K,Smith LP,Horton C,Profato J,Pesaran T,Gau CL,Pronold M,Davis BT,Chao EC,Couch FJ,Dolinsky JS. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med.. 2020;22(2):407-415.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The NF1 gene is associated with autosomal dominant neurofibromatosis type 1 (NF1) (MedGen UID: 18013), neurofibromatosis-Noonan syndrome (NFNS) (MedGen UID: 419089) and Watson syndrome (MedGen UID: 107817).   NF1 is a neurocutaneous disorder associated with an increased risk of several types of benign and malignant tumors. Primary features include multiple cafe-au-lait spots, inguinal freckling and neurofibromas. NF1 is highly variable in its expression, even among affected members of the same family. There is an increased risk for tumors of the central nervous system neoplasms and other malignancies including female breast cancer, gastrointestinal stromal tumors, pheochromocytoma and soft tissue sarcomas (PMID: 20301288). Approximately one-half of NF1 cases are inherited, and the remainder are the result of de novo mutations (PMID: 20082463).             Allelic NF1 disorders include Watson syndrome and NFNS. Watson syndrome is characterized by pulmonic stenosis, cafe-au-lait spots, macrocephaly, Lisch nodules, intellectual disability and short stature (PMID: 1770531, 23047742). NFNS is characterized by classic neurofibromatosis in addition to short stature, distinctive facial features, broad neck, congenital heart defects, speech delay and pectus anomaly (PMID: 16542390, 24357598, 26178382). 

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results from blood or saliva specimens alone may not distinguish between germline and acquired variants in this gene and additional testing may be appropriate.", Pmids: "1770531|16542390|20082463|20301288|23047742|24357598|25426837|25426838|26178382|33864022", Gene_Name: "NF1", References: "16542390) Stevenson DA,Viskochil DH,Rope AF,Carey JC. Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. Clin Genet.. 2006;69(3):246-53.|1770531) Allanson JE,Upadhyaya M,Watson GH,Partington M,MacKenzie A,Lahey D,MacLeod H,Sarfarazi M,Broadhead W,Harper PS. Watson syndrome: is it a subtype of type 1 neurofibromatosis? J Med Genet.. 1991;28(11):752-6.|20082463) Evans DG,Howard E,Giblin C,Clancy T,Spencer H,Huson SM,Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A.. 2010;152A(2):327-32.|23047742) Ben-Shachar S,Constantini S,Hallevi H,Sach EK,Upadhyaya M,Evans GD,Huson SM. Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation. Eur J Hum Genet.. 2013;21(5):535-9.|24357598) Ekvall S,Sj√É¬∂rs K,Jonzon A,Vihinen M,Anner√É¬©n G,Bondeson ML. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome. Am J Med Genet A.. 2014;164A(3):579-87.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|26178382) Rojnueangnit K,Xie J,Gomes A,Sharp A,Callens T,Chen Y,Liu Y,Cochran M,Abbott MA,Atkin J,Babovic-Vuksanovic D,Barnett CP,Crenshaw M,Bartholomew DW,Basel L,Bellus G,Ben-Shachar S,Bialer MG,Bick D,Blumberg B,Cortes F,David KL,Destree A,Duat-Rodriguez A,Earl D,Escobar L,Eswara M,Ezquieta B,Frayling IM,Frydman M,Gardner K,Gripp KW,Hern√É¬°ndez-Chico C,Heyrman K,Ibrahim J,Janssens S,Keena BA,Llano-Rivas I,Leppig K,McDonald M,Misra VK,Mulbury J,Narayanan V,Orenstein N,Galvin-Parton P,Pedro H,Pivnick EK,Powell CM,Randolph L,Raskin S,Rosell J,Rubin K,Seashore M,Schaaf CP,Scheuerle A,Schultz M,Schorry E,Schnur R,Siqveland E,Tkachuk A,Tonsgard J,Upadhyaya M,Verma IC,Wallace S,Williams C,Zackai E,Zonana J,Lazaro C,Claes K,Korf B,Martin Y,Legius E,Messiaen L. High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat.. 2015;36(11):1052-63.|20301288) Neurofibromatosis1|25426837) Age-related clonal hematopoiesis associated with adverse outcomes|33864022) Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG)"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The NF2 gene is associated with autosomal dominant neurofibromatosis type 2 (NF2) (MedGen UID: 18014).										  Neurofibromatosis type 2 is a highly penetrant condition characterized by multiple tumors throughout the central and peripheral nervous systems including schwannomas, meningiomas, ependymomas and rarely, astrocytomas and neurofibromas (PMID: 20082463, 15699726, 19476995). The hallmark tumors associated with this condition are bilateral vestibular schwannomas causing symptoms of tinnitus, hearing loss, balance difficulties and facial nerve weakness (PMID: 19671848, 24724714). Neurofibromatosis type 2 generally presents in the third to fourth decade of life, although this may be influenced by mutation type (PMID: 19476995).", Pmids: "15699726|19476995|19671848|20082463|24724714", Gene_Name: "NF2", References: "15699726) Evans DG,Moran A,King A,Saeed S,Gurusinghe N,Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol.. 2005;26(1):93-7.|19476995) Asthagiri AR,Parry DM,Butman JA,Kim HJ,Tsilou ET,Zhuang Z,Lonser RR. Neurofibromatosis type 2. Lancet.. 2009;373(9679):1974-86.|19671848) Evans DG,Kalamarides M,Hunter-Schaedle K,Blakeley J,Allen J,Babovic-Vuskanovic D,Belzberg A,Bollag G,Chen R,DiTomaso E,Golfinos J,Harris G,Jacob A,Kalpana G,Karajannis M,Korf B,Kurzrock R,Law M,McClatchey A,Packer R,Roehm P,Rubenstein A,Slattery W,Tonsgard JH,Welling DB,Widemann B,Yohay K,Giovannini M. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res.. 2009;15(16):5032-5039.|20082463) Evans DG,Howard E,Giblin C,Clancy T,Spencer H,Huson SM,Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A.. 2010;152A(2):327-32.|24724714) Choi JW,Lee JY,Phi JH,Wang KC,Chung HT,Paek SH,Kim DG,Park SH,Kim SK. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2. J Neurosurg Pediatr.. 2014;13(6):650-7."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).  NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593).", Pmids: "25938944|26559593", Gene_Name: "NTHL1 - Monoallelic", References: "25938944) Weren RD,Ligtenberg MJ,Kets CM,de Voer RM,Verwiel ET,Spruijt L,van Zelst-Stams WA,Jongmans MC,Gilissen C,Hehir-Kwa JY,Hoischen A,Shendure J,Boyle EA,Kamping EJ,Nagtegaal ID,Tops BB,Nagengast FM,Geurts van Kessel A,van Krieken JH,Kuiper RP,Hoogerbrugge N. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet.. 2015;47(6):668-71.|26559593) Rivera B,Castellsagu√É¬© E,Bah I,van Kempen LC,Foulkes WD. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. N Engl J Med.. 2015;373(20):1985-6."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The NTHL1 gene is associated with autosomal recessive NTHL1-associated polyposis (MedGen UID: 902388).  NTHL1-associated polyposis is characterized by the development of multiple colonic adenomas in adulthood, often with progression to colorectal cancer. Lifetime cancer risks are not established (PMID: 25938944, 26559593).", Pmids: "25938944|26559593", Gene_Name: "NTHL1 - Biallelic", References: "25938944) Weren RD,Ligtenberg MJ,Kets CM,de Voer RM,Verwiel ET,Spruijt L,van Zelst-Stams WA,Jongmans MC,Gilissen C,Hehir-Kwa JY,Hoischen A,Shendure J,Boyle EA,Kamping EJ,Nagtegaal ID,Tops BB,Nagengast FM,Geurts van Kessel A,van Krieken JH,Kuiper RP,Hoogerbrugge N. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet.. 2015;47(6):668-71.|26559593) Rivera B,Castellsagu√É¬© E,Bah I,van Kempen LC,Foulkes WD. Biallelic NTHL1 Mutations in a Woman with Multiple Primary Tumors. N Engl J Med.. 2015;373(20):1985-6."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PALB2 gene is associated with autosomal dominant predisposition to breast, pancreatic (PMID: 25099575, 31841383) and ovarian cancer (PMID: 30733081) in addition to autosomal recessive Fanconi anemia (MedGen UID: 372133). Studies have also suggested PALB2 may be associated with autosomal dominant predisposition to prostate (PMID: 17287723), male breast cancer (PMID: 31841383) and colorectal cancer (PMID: 29478780). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with a pathogenic PALB2 variant is 33-58% (PMID: 25099575, 33471974). There is also a 2-5% risk of pancreatic cancer (PMID: 21285249, 31841383) and a 3-5% risk of ovarian cancer (PMID: 31841383, 28888541, 35172496).  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).", Pmids: "8986277|12393424|12393516|17287723|20417588|20507306|21285249|25099575|28888541|29478780|30733081|31841383|33471974|35172496", Gene_Name: "PALB2", References: "12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|17287723) Erkko H,Xia B,Nikkil√É¬§ J,Schleutker J,Syrj√É¬§koski K,Mannermaa A,Kallioniemi A,Pylk√É¬§s K,Karppinen SM,Rapakko K,Miron A,Sheng Q,Li G,Mattila H,Bell DW,Haber DA,Grip M,Reiman M,Jukkola-Vuorinen A,Mustonen A,Kere J,Aaltonen LA,Kosma VM,Kataja V,Soini Y,Drapkin RI,Livingston DM,Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature.. 2007;446(7133):316-9.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|21285249) Casadei S,Norquist BM,Walsh T,Stray S,Mandell JB,Lee MK,Stamatoyannopoulos JA,King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res.. 2011;71(6):2222-9.|25099575) Antoniou AC,Casadei S,Heikkinen T,Barrowdale D,Pylk√É¬§s K,Roberts J,Lee A,Subramanian D,De Leeneer K,Fostira F,Tomiak E,Neuhausen SL,Teo ZL,Khan S,Aittom√É¬§ki K,Moilanen JS,Turnbull C,Seal S,Mannermaa A,Kallioniemi A,Lindeman GJ,Buys SS,Andrulis IL,Radice P,Tondini C,Manoukian S,Toland AE,Miron P,Weitzel JN,Domchek SM,Poppe B,Claes KB,Yannoukakos D,Concannon P,Bernstein JL,James PA,Easton DF,Goldgar DE,Hopper JL,Rahman N,Peterlongo P,Nevanlinna H,King MC,Couch FJ,Southey MC,Winqvist R,Foulkes WD,Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med.. 2014;371(6):497-506.|28888541) Lilyquist J,LaDuca H,Polley E,Davis BT,Shimelis H,Hu C,Hart SN,Dolinsky JS,Couch FJ,Goldgar DE. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol.. 2017;147(2):375-380.|29478780) AlDubayan SH,Giannakis M,Moore ND,Han GC,Reardon B,Hamada T,Mu XJ,Nishihara R,Qian Z,Liu L,Yurgelun MB,Syngal S,Garraway LA,Ogino S,Fuchs CS,Van Allen EM. Inherited DNA-Repair Defects in Colorectal Cancer. Am J Hum Genet.. 2018;102(3):401-414.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|31841383) Yang X,Leslie G,Doroszuk A,Schneider S,Allen J,Decker B,Dunning AM,Redman J,Scarth J,Plaskocinska I,Luccarini C,Shah M,Pooley K,Dorling L,Lee A,Adank MA,Adlard J,Aittom√É¬§ki K,Andrulis IL,Ang P,Barwell J,Bernstein JL,Bobolis K,Borg √É‚Ä¶,Blomqvist C,Claes KBM,Concannon P,Cuggia A,Culver JO,Damiola F,de Pauw A,Diez O,Dolinsky JS,Domchek SM,Engel C,Evans DG,Fostira F,Garber J,Golmard L,Goode EL,Gruber SB,Hahnen E,Hake C,Heikkinen T,Hurley JE,Janavicius R,Kleibl Z,Kleiblova P,Konstantopoulou I,Kvist A,Laduca H,Lee ASG,Lesueur F,Maher ER,Mannermaa A,Manoukian S,McFarland R,McKinnon W,Meindl A,Metcalfe K,Mohd Taib NA,Moilanen J,Nathanson KL,Neuhausen S,Ng PS,Nguyen-Dumont T,Nielsen SM,Obermair F,Offit K,Olopade OI,Ottini L,Penkert J,Pylk√É¬§s K,Radice P,Ramus SJ,Rudaitis V,Side L,Silva-Smith R,Silvestri V,Skytte AB,Slavin T,Soukupova J,Tondini C,Trainer AH,Unzeitig G,Usha L,van Overeem Hansen T,Whitworth J,Wood M,Yip CH,Yoon SY,Yussuf A,Zogopoulos G,Goldgar D,Hopper JL,Chenevix-Trench G,Pharoah P,George SHL,Balma√É¬±a J,Houdayer C,James P,El-Haffaf Z,Ehrencrona H,Janatova M,Peterlongo P,Nevanlinna H,Schmutzler R,Teo SH,Robson M,Pal T,Couch F,Weitzel JN,Elliott A,Southey M,Winqvist R,Easton DF,Foulkes WD,Antoniou AC,Tischkowitz M. Cancer Risks Associated With Germline  Pathogenic Variants: An International Study of 524 Families. J Clin Oncol.. 2020;38(7):674-685.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes|35172496) Kurian AW,Hughes E,Handorf EA,Gutin A,Allen B,Hartman AR,Hall MJ. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precis Oncol.. 2017;1():1-12."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PDGFRA gene is associated with autosomal dominant GIST-plus syndrome (MedGen UID: 357402).  GIST-plus syndrome is associated with inflammatory fibroid polyps and fibroid tumors in the gastrointestinal tract in addition to gastrointestinal stromal tumors (GIST) that most often develop in the stomach and small intestines. GIST may be noncancerous but have malignant potential; however, specific lifetime cancer risks are not established. Some affected individuals may also have coarse skin and facial features in addition to broad hands and feet (PMID: 14699510, 18670346, 17087943).", Pmids: "14699510|17087943|18670346", Gene_Name: "PDGFRA", References: "14699510) Chompret A,Kannengiesser C,Barrois M,Terrier P,Dahan P,Tursz T,Lenoir GM,Bressac-De Paillerets B. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology.. 2004;126(1):318-21.|17087943) de Raedt T,Cools J,Debiec-Rychter M,Brems H,Mentens N,Sciot R,Himpens J,de Wever I,Sch√É¬∂ffski P,Marynen P,Legius E. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology.. 2006;131(6):1907-12.|18670346) Carney JA,Stratakis CA. Stromal, fibrous, and fatty gastrointestinal tumors in a patient with a PDGFRA gene mutation. Am J Surg Pathol.. 2008;32(9):1412-20."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PHOX2B gene is associated with autosomal dominant congenital central hypoventilation syndrome (CCHS) (MedGen UID: 347052). Most cases of CCHS are due to a polyalanine repeat expansion, which is not analyzed by this test.											  CCHS is a disorder of autonomic regulation characterized by alveolar hypoventilation and symptoms of autonomic dysregulation presenting in the newborn period. Dysmorphic features include downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears (PMID: 23465774,18579454, 20208042). A subset of affected individuals may develop Hirschsprung disease and/or tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma).", Pmids: "18579454|20208042|23465774", Gene_Name: "PHOX2B", References: "18579454) Weese-Mayer DE,Berry-Kravis EM,Ceccherini I,Rand CM. Congenital central hypoventilation syndrome (CCHS) and sudden infant death syndrome (SIDS): kindred disorders of autonomic regulation. Respir Physiol Neurobiol.. 2008;164(1-2):38-48.|20208042) Weese-Mayer DE,Berry-Kravis EM,Ceccherini I,Keens TG,Loghmanee DA,Trang H, . An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. Am J Respir Crit Care Med.. 2010;181(6):626-44.|23465774) Rand CM,Patwari PP,Carroll MS,Weese-Mayer DE. Congenital central hypoventilation syndrome and sudden infant death syndrome: disorders of autonomic regulation. Semin Pediatr Neurol.. 2013;20(1):44-55."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PMS2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 325005) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  PMS2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract and possibly prostate. Estimated lifetime cancer risks appear to be lower than those seen with other mismatch repair genes and include a 9-20% risk for colorectal cancer and up to a 3.7% risk of urinary tract cancer. Affected females also have an increased risk of uterine/endometrial cancer (13‚Äì26%) and ovarian cancer (3%) (PMID: 18602922, 30161022, 31204389, 28754778, 26657901, 31337882).  CMMR-D is a cancer syndrome characterized by childhood cancers, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", Pmids: "17539897|18602922|18709565|20442441|26657901|28754778|30161022|31204389|31337882", Gene_Name: "PMS2", References: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18602922) Senter L,Clendenning M,Sotamaa K,Hampel H,Green J,Potter JD,Lindblom A,Lagerstedt K,Thibodeau SN,Lindor NM,Young J,Winship I,Dowty JG,White DM,Hopper JL,Baglietto L,Jenkins MA,de la Chapelle A. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology.. 2008;135(2):419-28.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|30161022) Ten Broeke SW,van der Klift HM,Tops CMJ,Aretz S,Bernstein I,Buchanan DD,de la Chapelle A,Capella G,Clendenning M,Engel C,Gallinger S,Gomez Garcia E,Figueiredo JC,Haile R,Hampel HL,Hopper JL,Hoogerbrugge N,von Knebel Doeberitz M,Le Marchand L,Letteboer TGW,Jenkins MA,Lindblom A,Lindor NM,Mensenkamp AR,M√É¬∏ller P,Newcomb PA,van Os TAM,Pearlman R,Pineda M,Rahner N,Redeker EJW,Olderode-Berends MJW,Rosty C,Schackert HK,Scott R,Senter L,Spruijt L,Steinke-Lange V,Suerink M,Thibodeau S,Vos YJ,Wagner A,Winship I,Hes FJ,Vasen HFA,Wijnen JT,Nielsen M,Win AK. Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol.. 2018;36(29):2961-2968.|31204389) Suerink M,Rodr√É¬≠guez-Girondo M,van der Klift HM,Colas C,Brugieres L,Lavoine N,Jongmans M,Munar GC,Evans DG,Farrell MP,Genuardi M,Goldberg Y,Gomez-Garcia E,Heinimann K,Hoell JI,Aretz S,Jasperson KW,Kedar I,Modi MB,Nikolaev S,van Os TAM,Ripperger T,Rueda D,Senter L,Sjursen W,Sunde L,Therkildsen C,Tibiletti MG,Trainer AH,Vos YJ,Wagner A,Winship I,Wimmer K,Zimmermann SY,Vasen HF,van Asperen CJ,Houwing-Duistermaat JJ,Ten Broeke SW,Nielsen M. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med.. 2019;21(12):2706-2712.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The POLD1 gene is associated with autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 436445) and autosomal dominant MDPL syndrome (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) (MedGen UID: 811623). There is also preliminary evidence supporting a correlation with autosomal dominant predisposition to endometrial cancer (PMID: 23263490, 26133394), autosomal recessive combined immunodeficiency syndrome (PMID: 31629014) and autosomal recessive non-syndromic deafness (PMID: 31944473). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Individuals with a pathogenic POLD1 variant typically presents with 10-100 colonic polyps and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 23263490, 26133394, 24501277). MDPL syndrome is a rare, systemic disorder characterized by loss of subcutaneous fat, distinctive facial features and metabolic abnormalities including insulin resistance and diabetes. Sensorineural hearing loss is also a common finding, typically presenting in the first or second decades of life (PMID: 25131834, 23770608).", Pmids: "23263490|23770608|24501277|25131834|26133394|31629014|31944473", Gene_Name: "POLD1", References: "23263490) Palles C,Cazier JB,Howarth KM,Domingo E,Jones AM,Broderick P,Kemp Z,Spain SL,Guarino E,Guarino Almeida E,Salguero I,Sherborne A,Chubb D,Carvajal-Carmona LG,Ma Y,Kaur K,Dobbins S,Barclay E,Gorman M,Martin L,Kovac MB,Humphray S, , ,Lucassen A,Holmes CC,Bentley D,Donnelly P,Taylor J,Petridis C,Roylance R,Sawyer EJ,Kerr DJ,Clark S,Grimes J,Kearsey SE,Thomas HJ,McVean G,Houlston RS,Tomlinson I. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet.. 2013;45(2):136-44.|23770608) Weedon MN,Ellard S,Prindle MJ,Caswell R,Lango Allen H,Oram R,Godbole K,Yajnik CS,Sbraccia P,Novelli G,Turnpenny P,McCann E,Goh KJ,Wang Y,Fulford J,McCulloch LJ,Savage DB,O'Rahilly S,Kos K,Loeb LA,Semple RK,Hattersley AT. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet.. 2013;45(8):947-50.|24501277) Valle L,Hern√É¬°ndez-Ill√É¬°n E,Bellido F,Aiza G,Castillejo A,Castillejo MI,Navarro M,Segu√É¬≠ N,Vargas G,Guarinos C,Juarez M,Sanju√É¬°n X,Iglesias S,Alenda C,Egoavil C,Segura √É¬Å,Juan MJ,Rodriguez-Soler M,Brunet J,Gonz√É¬°lez S,Jover R,L√É¬°zaro C,Capell√É¬° G,Pineda M,Soto JL,Blanco I. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet.. 2014;23(13):3506-12.|25131834) Pelosini C,Martinelli S,Ceccarini G,Magno S,Barone I,Basolo A,Fierabracci P,Vitti P,Maffei M,Santini F. Identification of a novel mutation in the polymerase delta 1 (POLD1) gene in a lipodystrophic patient affected by mandibular hypoplasia, deafness, progeroid features (MDPL) syndrome. Metabolism.. 2014;63(11):1385-9.|26133394) Bellido F,Pineda M,Aiza G,Vald√É¬©s-Mas R,Navarro M,Puente DA,Pons T,Gonz√É¬°lez S,Iglesias S,Darder E,Pi√É¬±ol V,Soto JL,Valencia A,Blanco I,Urioste M,Brunet J,L√É¬°zaro C,Capell√É¬° G,Puente XS,Valle L. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med.. 2016;18(4):325-32.|31629014) Cui Y,Keles S,Charbonnier LM,Jul√É¬© AM,Henderson L,Celik SC,Reisli I,Shen C,Xie WJ,Schmitz-Abe K,Wu H,Chatila TA. Combined immunodeficiency caused by a loss-of-function mutation in DNA polymerase delta 1. J Allergy Clin Immunol.. 2020;145(1):391-401.e8.|31944473) Oh DY,Matsumoto Y,Kitajiri SI,Kim NKD,Kim MY,Kim AR,Lee M,Lee C,Tomkinson AE,Katsuno T,Kim SY,Shin HW,Han JH,Lee S,Park WY,Choi BY. POLD1 variants leading to reduced polymerase activity can cause hearing loss without syndromic features. Hum Mutat.. 2020;41(5):913-920."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The POLE gene is associated with an autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 767374) and autosomal recessive FILS syndrome (facial dysmorphism, immunodeficiency, livedo, and short stature) (MedGen UID: 767490).  Individuals with a pathogenic POLE variant typically present with 10-100 adenomas and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 26133394, 29120461, 32424176).  FILS syndrome is characterized by mild facial dysmorphism and immunodeficiency resulting in recurrent infections, livedo on the skin present at birth and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001).", Pmids: "23230001|26133394|29120461|32424176", Gene_Name: "POLE", References: "23230001) Pachlopnik Schmid J,Lemoine R,Nehme N,Cormier-Daire V,Revy P,Debeurme F,Debr√É¬© M,Nitschke P,Bole-Feysot C,Legeai-Mallet L,Lim A,de Villartay JP,Picard C,Durandy A,Fischer A,de Saint Basile G. Polymerase √é¬µ1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature ('FILS syndrome'). J Exp Med.. 2012;209(13):2323-30.|26133394) Bellido F,Pineda M,Aiza G,Vald√É¬©s-Mas R,Navarro M,Puente DA,Pons T,Gonz√É¬°lez S,Iglesias S,Darder E,Pi√É¬±ol V,Soto JL,Valencia A,Blanco I,Urioste M,Brunet J,L√É¬°zaro C,Capell√É¬° G,Puente XS,Valle L. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med.. 2016;18(4):325-32.|29120461) Buchanan DD,Stewart JR,Clendenning M,Rosty C,Mahmood K,Pope BJ,Jenkins MA,Hopper JL,Southey MC,Macrae FA,Winship IM,Win AK. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genet Med.. 2018;20(8):890-895.|32424176) Hamzaoui N,Alarcon F,Leulliot N,Guimbaud R,Buecher B,Colas C,Corsini C,Nuel G,Terris B,Laurent-Puig P,Chaussade S,Dhooge M,Madru C,Clauser E. Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. Genet Med.. 2020;22(9):1533-1541."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The POT1 gene is associated with autosomal dominant POT1 tumor predisposition syndrome (MedGen UID: 862913).  POT1 tumor predisposition syndrome is associated with predisposition to familial malignant melanoma (PMID: 24686846, 24686849, 26337759). Melanoma most often occurs in the skin, but may also develop in the eyes, ears, gastrointestinal tract, and oral and genital membranes. POT1 has also been associated with a susceptibility to additional cancers including glioma and angiosarcoma, among others; specific lifetime cancer risks are not clear (PMID: 25482530, 30165405, 25252913, 28853721, 27528712). Although consensus guidelines have not been published for individuals with pathogenic variants in POT1, evaluation and surveillance considerations are available in PMID: 33119245.", Pmids: "24686846|24686849|25252913|25482530|26337759|27528712|28853721|30165405", Gene_Name: "POT1", References: "24686846) Shi J,Yang XR,Ballew B,Rotunno M,Calista D,Fargnoli MC,Ghiorzo P,Bressac-de Paillerets B,Nagore E,Avril MF,Caporaso NE,McMaster ML,Cullen M,Wang Z,Zhang X, , , ,Bruno W,Pastorino L,Queirolo P,Banuls-Roca J,Garcia-Casado Z,Vaysse A,Mohamdi H,Riazalhosseini Y,Foglio M,Jouenne F,Hua X,Hyland PL,Yin J,Vallabhaneni H,Chai W,Minghetti P,Pellegrini C,Ravichandran S,Eggermont A,Lathrop M,Peris K,Scarra GB,Landi G,Savage SA,Sampson JN,He J,Yeager M,Goldin LR,Demenais F,Chanock SJ,Tucker MA,Goldstein AM,Liu Y,Landi MT. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet.. 2014;46(5):482-6.|24686849) Robles-Espinoza CD,Harland M,Ramsay AJ,Aoude LG,Quesada V,Ding Z,Pooley KA,Pritchard AL,Tiffen JC,Petljak M,Palmer JM,Symmons J,Johansson P,Stark MS,Gartside MG,Snowden H,Montgomery GW,Martin NG,Liu JZ,Choi J,Makowski M,Brown KM,Dunning AM,Keane TM,L√É¬≥pez-Ot√É¬≠n C,Gruis NA,Hayward NK,Bishop DT,Newton-Bishop JA,Adams DJ. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet.. 2014;46(5):478-481.|25252913) Kunze K,Spieker T,Gamerdinger U,Nau K,Berger J,Dreyer T,Sindermann JR,Hoffmeier A,Gattenl√É¬∂hner S,Br√É¬§uninger A. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells. Cancer Res.. 2014;74(21):6173-83.|25482530) Bainbridge MN,Armstrong GN,Gramatges MM,Bertuch AA,Jhangiani SN,Doddapaneni H,Lewis L,Tombrello J,Tsavachidis S,Liu Y,Jalali A,Plon SE,Lau CC,Parsons DW,Claus EB,Barnholtz-Sloan J,Il'yasova D,Schildkraut J,Ali-Osman F,Sadetzki S,Johansen C,Houlston RS,Jenkins RB,Lachance D,Olson SH,Bernstein JL,Merrell RT,Wrensch MR,Walsh KM,Davis FG,Lai R,Shete S,Aldape K,Amos CI,Thompson PA,Muzny DM,Gibbs RA,Melin BS,Bondy ML, . Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst.. 2015;107(1):384.|26337759) Read J,Wadt KA,Hayward NK. Melanoma genetics. J Med Genet.. 2016;53(1):1-14.|27528712) Speedy HE,Kinnersley B,Chubb D,Broderick P,Law PJ,Litchfield K,Jayne S,Dyer MJS,Dearden C,Follows GA,Catovsky D,Houlston RS. Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood.. 2016;128(19):2319-2326.|28853721) Calvete O,Garcia-Pavia P,Dom√É¬≠nguez F,Bougeard G,Kunze K,Braeuninger A,Teule A,Lasa A,Ram√É¬≥n Y Cajal T,Llort G,Fern√É¬°ndez V,L√É¬°zaro C,Urioste M,Benitez J. The wide spectrum of POT1 gene variants correlates with multiple cancer types. Eur J Hum Genet.. 2017;25(11):1278-1281.|30165405) Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PRKAR1A gene is associated with autosomal dominant Carney complex (CNC) (MedGen UID: 388559) and acrodysostosis (MedGen UID: 477858).			  CNC is characterized by myxomas, endocrine tumors and schwannomas. Pigmentary skin lesions are a defining feature, present in over 80% of cases. Primary pigmented nodular adrenocortical disease (PPNAD), which can lead to Cushing's syndrome, develops in 25-60% of affected individuals. CNC is associated with an increased risk of developing thyroid nodules, thyroid cancer, myxomas in the heart, breast, skin, throat and female genital tract in addition to psammomatous melanotic schwannomas (PMS) and ovarian tumors. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in nearly all affected males (PMID: 26130139, 16756677).

Autosomal dominant acrodysostosis is characterized by variable skeletal, endocrine, and neurological abnormalities that are present in childhood (PMID: 22464252). The most common features include brachydactyly, dysmorphic facies, short stature, and intellectual disability and/or developmental delays (PMID: 26763073). Other symptoms may include advanced bone age, peripheral dysostosis with shortened bones of the hands and feet, cone-shaped epiphyses, lumbar stenosis, hypothyroidism, multiple hormone resistance, cryptorchidism, hypospadias, deafness and rhinitis (PMID: 22464252, 23033274, 26763073).

Loss of function variants are associated with CNC (PMID: 19293268, 11115848). Some further genotype-phenotype correlations have been suggested for acrodysostosis versus CNC (PMID: 10974026, 10973256, 22464250, 22464252), but these correlations remain preliminary.", Pmids: "10973256|10974026|11115848|16756677|19293268|22464250|22464252|23033274|26130139|26763073", Gene_Name: "PRKAR1A", References: "10973256) Kirschner LS,Carney JA,Pack SD,Taymans SE,Giatzakis C,Cho YS,Cho-Chung YS,Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet.. 2000;26(1):89-92.|10974026) Casey M,Vaughan CJ,He J,Hatcher CJ,Winter JM,Weremowicz S,Montgomery K,Kucherlapati R,Morton CC,Basson CT. Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest.. 2000;106(5):R31-8.|11115848) Kirschner LS,Sandrini F,Monbo J,Lin JP,Carney JA,Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum Mol Genet.. 2000;9(20):3037-46.|16756677) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Carney complex (CNC). Orphanet J Rare Dis.. 2006;1():21.|19293268) Bertherat J,Horvath A,Groussin L,Grabar S,Boikos S,Cazabat L,Libe R,Ren√É¬©-Corail F,Stergiopoulos S,Bourdeau I,Bei T,Clauser E,Calender A,Kirschner LS,Bertagna X,Carney JA,Stratakis CA. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab.. 2009;94(6):2085-91.|22464250) Michot C,Le Goff C,Goldenberg A,Abhyankar A,Klein C,Kinning E,Guerrot AM,Flahaut P,Duncombe A,Baujat G,Lyonnet S,Thalassinos C,Nitschke P,Casanova JL,Le Merrer M,Munnich A,Cormier-Daire V. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet.. 2012;90(4):740-5.|22464252) Lee H,Graham JM,Rimoin DL,Lachman RS,Krejci P,Tompson SW,Nelson SF,Krakow D,Cohn DH. Exome sequencing identifies PDE4D mutations in acrodysostosis. Am J Hum Genet.. 2012;90(4):746-51.|23033274) Lynch DC,Dyment DA,Huang L,Nikkel SM,Lacombe D,Campeau PM,Lee B,Bacino CA,Michaud JL,Bernier FP, ,Parboosingh JS,Innes AM. Identification of novel mutations confirms PDE4D as a major gene causing acrodysostosis. Hum Mutat.. 2013;34(1):97-102.|26130139) Correa R,Salpea P,Stratakis CA. Carney complex: an update. Eur J Endocrinol.. 2015;173(4):M85-97.|26763073) Elli FM,Bordogna P,de Sanctis L,Giachero F,Verrua E,Segni M,Mazzanti L,Boldrin V,Toromanovic A,Spada A,Mantovani G. Screening of PRKAR1A and PDE4D in a Large Italian Series of Patients Clinically Diagnosed With Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism. J Bone Miner Res.. 2016;31(6):1215-24."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PRSS1 gene is associated with autosomal dominant hereditary pancreatitis (Medgen UID: 116056).  Hereditary pancreatitis is characterized by recurrent episodes of acute inflammation of the pancreas (pancreatitis) beginning in childhood or adolescence leading to chronic pancreatitis. Chronic pancreatitis is a risk factor pancreatic cancer. Other associated symptoms include exocrine pancreatic insufficiency and diabetes mellitus (PMID: 19453252, 18755888, 12120221, 21844754).", Pmids: "12120221|18755888|19453252|21844754", Gene_Name: "PRSS1", References: "19453252) Chen JM,F√É¬©rec C. Chronic pancreatitis: genetics and pathogenesis. Annu Rev Genomics Hum Genet.. 2009;10():63-87.|21844754) LaRusch J,Whitcomb DC. Genetics of pancreatitis. Curr Opin Gastroenterol.. 2011;27(5):467-74.|12120221) Hereditary pancreatitis in north america the pittsburgh midwest multi center pancreatic study group study|18755888) The natural history of hereditary pancreatitis a national series"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PTCH1 gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554). There is also evidence suggesting PTCH1 is associated with autosomal dominant holoprosencephaly (HPE) (MedGen: 372134). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  PTCH1-associated BCNS is an early-onset condition characterized by up to a 90% risk of developing multiple skin cancers, specifically basal cell carcinomas (BCCs). Approximately 90% will develop odontogenic keratocysts. BCNS is also associated with cardiac fibromas and ovarian fibromas in affected females. Additional findings include palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. Medulloblastomas occur in up to 5% of children with PTCH1-associated BCNS (PMID: 33066274).", Pmids: "33066274", Gene_Name: "PTCH1", References: "33066274) Onodera S,Nakamura Y,Azuma T. Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research. Int J Mol Sci.. 2020;21(20):."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The PTEN gene is associated with autosomal dominant PTEN hamartoma tumor syndrome (PHTS), including the clinical subtypes of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and PTEN-related autism spectrum disorder (MedGen UID: 368366). Other PTEN-associated conditions have also been described (PMID: 11755638, 17392703, 27890237).  PHTS is a highly variable hamartomatous condition characterized by macrocephaly, Lhermitte-Duclos disease, mucocutaneous lesions, gastrointestinal hamartomas, lipomas, benign thyroid lesions, macular pigmentation of the glans penis, cerebrovascular malformations and several types of cancer. Associated cancers include breast (up to 85% risk), thyroid (typically follicular, up to 38% risk), renal (up to 34%), endometrial (up to 28% risk), colorectal (9-16% risk) and melanoma (6% risk) (PMID: 31216739, 33471991). PHTS is also associated with developmental delay, intellectual disability and autism spectrum disorder (PMID: 26564076, 19265751, 25288137).", Pmids: "11755638|17392703|19265751|25288137|26564076|27890237|31216739|33471991", Gene_Name: "PTEN", References: "11755638) Biesecker LG,Rosenberg MJ,Vacha S,Turner JT,Cohen MM. PTEN mutations and proteus syndrome. Lancet.. 2001;358(9298):2079-80.|17392703) Caux F,Plauchu H,Chibon F,Faivre L,Fain O,Vabres P,Bonnet F,Selma ZB,Laroche L,G√É¬©rard M,Longy M. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet.. 2007;15(7):767-73.|19265751) Varga EA,Pastore M,Prior T,Herman GE,McBride KL. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med.. 2009;11(2):111-7.|25288137) Frazier TW,Embacher R,Tilot AK,Koenig K,Mester J,Eng C. Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism. Mol Psychiatry.. 2015;20(9):1132-8.|26564076) Mester J,Charis E. PTEN hamartoma tumor syndrome. Handb Clin Neurol.. 2015;132():129-37.|27890237) Nathan N,Keppler-Noreuil KM,Biesecker LG,Moss J,Darling TN. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway. Dermatol Clin.. 2017;35(1):51-60.|31216739) ValidYN,LastName,ForeName,Initials,Identifier,AffiliationInfo. Hamartoma Tumor Syndrome: A Clinical Overview. Cancers (Basel).. 2019;11(6):.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RAD50 gene is associated with autosomal recessive Nijmegen breakage syndrome-like disorder (NBSLD) (PMID: 19409520).  NBSLD is characterized by a clinical phenotype resembling Nijmegen breakage syndrome including chromosomal instability, radiosensitivity, neurodevelopmental disease, and immunodeficiency but with a milder clinical presentation.  Studies had previously suggested that females with a pathogenic variant in RAD50 may have autosomal dominant predisposition to breast cancer (PMID: 21356067, 24894818); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).", Pmids: "19409520|21356067|24894818|33471974|33471991", Gene_Name: "RAD50", References: "19409520) Waltes R,Kalb R,Gatei M,Kijas AW,Stumm M,Sobeck A,Wieland B,Varon R,Lerenthal Y,Lavin MF,Schindler D,D√É¬∂rk T. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet.. 2009;84(5):605-16.|21356067) Kuusisto KM,Bebel A,Vihinen M,Schleutker J,Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res.. 2011;13(1):R20.|24894818) Damiola F,Pertesi M,Oliver J,Le Calvez-Kelm F,Voegele C,Young EL,Robinot N,Forey N,Durand G,Vall√É¬©e MP,Tao K,Roane TC,Williams GJ,Hopper JL,Southey MC,Andrulis IL,John EM,Goldgar DE,Lesueur F,Tavtigian SV. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res.. 2014;16(3):R58.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RAD51C gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 462009). Studies have also suggested RAD51C may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846) and autosomal recessive Fanconi anemia (PMID: 20400963). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  The lifetime risks among females with a pathogenic RAD51C variant are estimated to be 5-11% for ovarian cancer (PMID: 30733081, 32107557, Kurian et al. 2017) and 21-25% for breast cancer (PMID: 33471991, 32107557, 32091585).", Pmids: "20400963|27433846|30733081|32091585|32107557|33471991", Gene_Name: "RAD51C", References: "20400963) Vaz F,Hanenberg H,Schuster B,Barker K,Wiek C,Erven V,Neveling K,Endt D,Kesterton I,Autore F,Fraternali F,Freund M,Hartmann L,Grimwade D,Roberts RG,Schaal H,Mohammed S,Rahman N,Schindler D,Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet.. 2010;42(5):406-9.|27433846) Pritchard CC,Mateo J,Walsh MF,De Sarkar N,Abida W,Beltran H,Garofalo A,Gulati R,Carreira S,Eeles R,Elemento O,Rubin MA,Robinson D,Lonigro R,Hussain M,Chinnaiyan A,Vinson J,Filipenko J,Garraway L,Taplin ME,AlDubayan S,Han GC,Beightol M,Morrissey C,Nghiem B,Cheng HH,Montgomery B,Walsh T,Casadei S,Berger M,Zhang L,Zehir A,Vijai J,Scher HI,Sawyers C,Schultz N,Kantoff PW,Solit D,Robson M,Van Allen EM,Offit K,de Bono J,Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.. 2016;375(5):443-53.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|32091585) Hu C,Polley EC,Yadav S,Lilyquist J,Shimelis H,Na J,Hart SN,Goldgar DE,Shah S,Pesaran T,Dolinsky JS,LaDuca H,Couch FJ. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. J Natl Cancer Inst.. 2020;112(12):1231-1241.|32107557) Yang X,Song H,Leslie G,Engel C,Hahnen E,Auber B,Horv√É¬°th J,Kast K,Niederacher D,Turnbull C,Houlston R,Hanson H,Loveday C,Dolinsky JS,LaDuca H,Ramus SJ,Menon U,Rosenthal AN,Jacobs I,Gayther SA,Dicks E,Nevanlinna H,Aittom√É¬§ki K,Pelttari LM,Ehrencrona H,Borg √É‚Ä¶,Kvist A,Rivera B,Hansen TVO,Djursby M,Lee A,Dennis J,Bowtell DD,Traficante N,Diez O,Balma√É¬±a J,Gruber SB,Chenevix-Trench G,Investigators K,Jensen A,Kj√É¬¶r SK,H√É¬∏gdall E,Cast√É¬©ra L,Garber J,Janavicius R,Osorio A,Golmard L,Vega A,Couch FJ,Robson M,Gronwald J,Domchek SM,Culver JO,de la Hoya M,Easton DF,Foulkes WD,Tischkowitz M,Meindl A,Schmutzler RK,Pharoah PDP,Antoniou AC. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst.. 2020;112(12):1242-1250.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RAD51D gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 481975). Studies have also suggested RAD51D may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846). The data, however, are preliminary and  insufficient to make a determination regarding this relationship.   The lifetime risks among females with a pathogenic RAD51D variant are estimated to be 8-13% for ovarian cancer (PMID: 30733081, 32107557) and 20-31% for breast cancer (PMID: 28418444, 32091585, 33471974).", Pmids: "27433846|28418444|30733081|32091585|32107557|33471974", Gene_Name: "RAD51D", References: "27433846) Pritchard CC,Mateo J,Walsh MF,De Sarkar N,Abida W,Beltran H,Garofalo A,Gulati R,Carreira S,Eeles R,Elemento O,Rubin MA,Robinson D,Lonigro R,Hussain M,Chinnaiyan A,Vinson J,Filipenko J,Garraway L,Taplin ME,AlDubayan S,Han GC,Beightol M,Morrissey C,Nghiem B,Cheng HH,Montgomery B,Walsh T,Casadei S,Berger M,Zhang L,Zehir A,Vijai J,Scher HI,Sawyers C,Schultz N,Kantoff PW,Solit D,Robson M,Van Allen EM,Offit K,de Bono J,Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.. 2016;375(5):443-53.|28418444) Couch FJ,Shimelis H,Hu C,Hart SN,Polley EC,Na J,Hallberg E,Moore R,Thomas A,Lilyquist J,Feng B,McFarland R,Pesaran T,Huether R,LaDuca H,Chao EC,Goldgar DE,Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol.. 2017;3(9):1190-1196.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|32091585) Hu C,Polley EC,Yadav S,Lilyquist J,Shimelis H,Na J,Hart SN,Goldgar DE,Shah S,Pesaran T,Dolinsky JS,LaDuca H,Couch FJ. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. J Natl Cancer Inst.. 2020;112(12):1231-1241.|32107557) Yang X,Song H,Leslie G,Engel C,Hahnen E,Auber B,Horv√É¬°th J,Kast K,Niederacher D,Turnbull C,Houlston R,Hanson H,Loveday C,Dolinsky JS,LaDuca H,Ramus SJ,Menon U,Rosenthal AN,Jacobs I,Gayther SA,Dicks E,Nevanlinna H,Aittom√É¬§ki K,Pelttari LM,Ehrencrona H,Borg √É‚Ä¶,Kvist A,Rivera B,Hansen TVO,Djursby M,Lee A,Dennis J,Bowtell DD,Traficante N,Diez O,Balma√É¬±a J,Gruber SB,Chenevix-Trench G,Investigators K,Jensen A,Kj√É¬¶r SK,H√É¬∏gdall E,Cast√É¬©ra L,Garber J,Janavicius R,Osorio A,Golmard L,Vega A,Couch FJ,Robson M,Gronwald J,Domchek SM,Culver JO,de la Hoya M,Easton DF,Foulkes WD,Tischkowitz M,Meindl A,Schmutzler RK,Pharoah PDP,Antoniou AC. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst.. 2020;112(12):1242-1250.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RB1 gene is associated with autosomal dominant retinoblastoma (MedGen UID: 20552). There is also evidence suggesting RB1 is associated with predisposition to several cancer types in retinoblastoma survivors (PMID: 14996857, 22355046).  Retinoblastoma (Rb) is a rare, early-childhood cancer that forms in the retina of the eye. The majority of individuals with hereditary Rb develop multiple tumors in both eyes with nearly complete penetrance; however, unilateral disease is not uncommon. A small subset of cases show a reduced penetrance phenotype with variable expressivity (PMID: 32422154). Affected individuals also appear to have an increased risk of developing secondary extra-ocular primary cancers including pinealoma, osteosarcoma, soft tissue sarcomas, and melanoma. The specific risk of these extra-ocular cancers is unknown, but is significantly increased among those who have received prior external beam radiation therapy (PMID: 32422154).", Pmids: "14996857|22355046|32422154", Gene_Name: "RB1", References: "14996857) Fletcher O,Easton D,Anderson K,Gilham C,Jay M,Peto J. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst.. 2004;96(5):357-63.|22355046) Kleinerman RA,Yu CL,Little MP,Li Y,Abramson D,Seddon J,Tucker MA. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol.. 2012;30(9):950-7.|32422154) Tonorezos ES,Friedman DN,Barnea D,Bosscha MI,Chantada G,Dommering CJ,de Graaf P,Dunkel IJ,Fabius AWM,Francis JH,Greer MC,Kleinerman RA,Kors WA,Laughlin S,Moll AC,Morton LM,Temming P,Tucker MA,van Leeuwen FE,Walsh MF,Oeffinger KC,Abramson DH. Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Ophthalmology.. 2020;127(11):1549-1557."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RECQL gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to breast cancer (PMID: 28724667, 30610487).", Pmids: "28724667|30610487", Gene_Name: "RECQL", References: "28724667) Sun J,Meng H,Yao L,Lv M,Bai J,Zhang J,Wang L,Ouyang T,Li J,Wang T,Fan Z,Fan T,Lin B,Xie Y. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Clin Cancer Res.. 2017;23(20):6113-6119.|30610487) Bowden AR,Tischkowitz M. Clinical implications of germline mutations in breast cancer genes: RECQL. Breast Cancer Res Treat.. 2019;174(3):553-560."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RECQL4 gene is associated with autosomal recessive Rothmund-Thomson syndrome (RTS) (MedGen UID: 10819), RAPADILINO syndrome (MedGen UID: 336602) and Baller-Gerold syndrome (BGS) (MedGen UID: 120532).  RECQL4-related disorders include RTS, RAPADILINO syndrome and BGS. These rare disorders are characterized by epithelial features (poikiloderma, except in RAPADILINO), congenital skeletal malformations, and occasionally abnormalities of the teeth and nails. Coronal craniosynostosis is a feature unique only to BGS. RECQL4-related disorders are also associated with an increased susceptibility to specific cancers including osteosarcoma, hematological malignancy, and skin cancer (PMID: 20503338, 24960165, 11471165).", Pmids: "11471165|20503338|24960165", Gene_Name: "RECQL4 - Monoallelic", References: "11471165) Wang LL,Levy ML,Lewis RA,Chintagumpala MM,Lev D,Rogers M,Plon SE. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet.. 2001;102(1):11-7.|20503338) Simon T,Kohlhase J,Wilhelm C,Kochanek M,De Carolis B,Berthold F. Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review. Am J Med Genet A.. 2010;152A(6):1575-9.|24960165) Smeets MF,DeLuca E,Wall M,Quach JM,Chalk AM,Deans AJ,Heierhorst J,Purton LE,Izon DJ,Walkley CR. The Rothmund-Thomson syndrome helicase RECQL4 is essential for hematopoiesis. J Clin Invest.. 2014;124(8):3551-65."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501). In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area. 

Pathogenic loss-of-function (LOF) RET variants are associated with Hirschsprung disease (HD), a condition characterized by congenital agenesis of ganglion in the colon. HD is typically diagnosed in early infancy, although less severe cases may be diagnosed later in childhood (PMID: 16448984).", Pmids: "16448984|21552134|31390501|33812987", Gene_Name: "RET", References: "16448984) Lantieri F,Griseri P,Ceccherini I. Molecular mechanisms of RET-induced Hirschsprung pathogenesis. Ann Med.. 2006;38(1):11-9.|21552134) Moline J,Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med.. 2011;13(9):755-64.|33812987) Mathiesen JS,Effraimidis G,Rossing M,Rasmussen √É‚Ä¶K,Hoejberg L,Bastholt L,Godballe C,Oturai P,Feldt-Rasmussen U. Multiple endocrine neoplasia type 2: A reveiw. Semin Cancer Biol.. 2021;():.|31390501) Pheochromocytoma and Paraganglioma"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RINT1 gene is associated with autosomal recessive Infantile liver failure syndrome (MedGen UID: 1684678). There is also preliminary evidence supporting a correlation with breast cancer (PMID: 25050558, 33099839). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Infantile liver failure syndrome is characterized by episodic acute liver failure usually triggered by an intercurrent illness. The first event typically occurs in early childhood with episodic liver dysfunction, hyperammonemia and coagulopathy. With supportive treatment, the episodes resolve, though liver function may not normalize entirely (PMID: 31204009). Accumulated liver injury in the form of steatosis, bridging fibrosis, and increased Kupffer cells, caused at least one child to undergo liver transplant. Laboratory findings include elevated liver enzymes, total and direct hyperbilirubinemia, with increased prothrombin time and INRs (PMID: 31204009). Additional features of RALF include short stature and vertebral anomalies, with platyspondyly, hypoplastic, beaked and/or irregular vertebrae. Irregular femoral head epiphyses have also been described. Though only a few affected individuals have been reported to date, thus far all have had normal development and cognitive function (PMID: 31204009).", Pmids: "25050558|31204009|33099839", Gene_Name: "RINT1", References: "25050558) Park DJ,Tao K,Le Calvez-Kelm F,Nguyen-Dumont T,Robinot N,Hammet F,Odefrey F,Tsimiklis H,Teo ZL,Thingholm LB,Young EL,Voegele C,Lonie A,Pope BJ,Roane TC,Bell R,Hu H,Shankaracharya ,Huff CD,Ellis J,Li J,Makunin IV,John EM,Andrulis IL,Terry MB,Daly M,Buys SS,Snyder C,Lynch HT,Devilee P,Giles GG,Hopper JL,Feng BJ,Lesueur F,Tavtigian SV,Southey MC,Goldgar DE. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. Cancer Discov.. 2014;4(7):804-15.|33099839) Cavaill√É¬© M,Uhrhammer N,Privat M,Ponelle-Chachuat F,Gay-Bellile M,Lepage M,Molnar I,Viala S,Bidet Y,Bignon YJ. Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition. Genes Chromosomes Cancer.. 2021;60(2):73-78.|31204009) RINT1 Bi-allelic Variations Cause Infantile-Onset Recurrent Acute Liver Failure and Skeletal Abnormalities"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RNF43 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant predisposition to colorectal cancer (PMID: 31243857).", Pmids: "31243857", Gene_Name: "RNF43", References: "31243857) Terradas M,Munoz-Torres PM,Belhadj S,Aiza G,Navarro M,Brunet J,Capell√É¬° G,Valle L. Contribution to colonic polyposis of recently proposed predisposing genes and assessment of the prevalence of NTHL1- and MSH3-associated polyposes. Hum Mutat.. 2019;40(11):1910-1923."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RPS20 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant hereditary nonpolyposis colorectal cancer (HNPCC) (PMID: 24941021).", Pmids: "24941021", Gene_Name: "RPS20", References: "24941021) Nieminen TT,O'Donohue MF,Wu Y,Lohi H,Scherer SW,Paterson AD,Ellonen P,Abdel-Rahman WM,Valo S,Mecklin JP,J√É¬§rvinen HJ,Gleizes PE,Peltom√É¬§ki P. Germline mutation of RPS20, encoding a ribosomal protein, causes predisposition to hereditary nonpolyposis colorectal carcinoma without DNA mismatch repair deficiency. Gastroenterology.. 2014;147(3):595-598.e5."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The RUNX1 gene is associated with autosomal dominant familial platelet disorder with associated myeloid malignancy (MedGen UID: 321945).  Familial platelet disorder is characterized by mild to moderate thrombocytopenia, platelet abnormalities, and a predisposition to develop myelodysplasia and/or acute myeloid leukemia (PMID: 19357396, 18723428). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired RUNX1 variants and additional testing may be appropriate.", Pmids: "18723428|19357396|25426837|25426838|31490007|31881331", Gene_Name: "RUNX1", References: "18723428) Owen CJ,Toze CL,Koochin A,Forrest DL,Smith CA,Stevens JM,Jackson SC,Poon MC,Sinclair GD,Leber B,Johnson PR,Macheta A,Yin JA,Barnett MJ,Lister TA,Fitzgibbon J. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood.. 2008;112(12):4639-45.|19357396) Preudhomme C,Renneville A,Bourdon V,Philippe N,Roche-Lestienne C,Boissel N,Dhedin N,Andr√É¬© JM,Cornillet-Lefebvre P,Baruchel A,Mozziconacci MJ,Sobol H. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood.. 2009;113(22):5583-7.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|31490007) Coffee B,Cox HC,Bernhisel R,Manley S,Bowles K,Roa BB,Mancini-DiNardo D. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Hum Mutat.. 2020;41(1):203-211.|31881331) Mester JL,Jackson SA,Postula K,Stettner A,Solomon S,Bissonnette J,Murphy PD,Klein RT,Hruska KS. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. J Mol Diagn.. 2020;22(3):396-404.|25426837) Age-related clonal hematopoiesis associated with adverse outcomes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SDHA gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 481622), gastrointestinal stromal tumors (GIST) (PMID: 20301715), and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHA may also be associated with autosomal dominant predisposition to renal cancer (PMID: 26722403) and pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  SDHA-associated PGL-PCC syndrome due to loss-of-function (LOF) variants is characterized by an increased risk of developing PGL and PCC. Germline LOF SDHA variants have also been identified in individuals and families with GIST (PMID: 21505157, 22974104, 23060355) and Carney-Stratakis syndrome, which is associated with both PGL and GIST. The lifetime risk to develop a SDHA-related tumor is estimated to be 1-10% (PMID: 29177515, 29978154, 30201732); however, the risk of malignant transformation is unclear. While the SDHA gene is associated with autosomal dominant mitochondrial complex II deficiency, LOF variants in this gene have not been observed in individuals with this condition.  Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy (PMID: 22972948, 23322652, 27683074). Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy (PMID: 22972948, 23322652). The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 23322652). Clinical correlation is advised.", Pmids: "20301715|21505157|22972948|22974104|23060355|23322652|26259135|26722403|27683074|29177515|29978154|30201732", Gene_Name: "SDHA", References: "21505157) Pantaleo MA,Astolfi A,Indio V,Moore R,Thiessen N,Heinrich MC,Gnocchi C,Santini D,Catena F,Formica S,Martelli PL,Casadio R,Pession A,Biasco G. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst.. 2011;103(12):983-7.|22972948) Alston CL,Davison JE,Meloni F,van der Westhuizen FH,He L,Hornig-Do HT,Peet AC,Gissen P,Goffrini P,Ferrero I,Wassmer E,McFarland R,Taylor RW. Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet.. 2012;49(9):569-77.|22974104) Italiano A,Chen CL,Sung YS,Singer S,DeMatteo RP,LaQuaglia MP,Besmer P,Socci N,Antonescu CR. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer.. 2012;12():408.|23060355) Dwight T,Benn DE,Clarkson A,Vilain R,Lipton L,Robinson BG,Clifton-Bligh RJ,Gill AJ. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol.. 2013;37(2):226-33.|23322652) Jain-Ghai S,Cameron JM,Al Maawali A,Blaser S,MacKay N,Robinson B,Raiman J. Complex II deficiency--a case report and review of the literature. Am J Med Genet A.. 2013;161A(2):285-94.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|26722403) Jiang Q,Zhang Y,Zhou YH,Hou YY,Wang JY,Li JL,Li M,Tong HX,Lu WQ. A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. Int J Clin Exp Pathol.. 2015;8(10):12188-97.|27683074) Courage C,Jackson CB,Hahn D,Euro L,Nuoffer JM,Gallati S,Schaller A. SDHA mutation with dominant transmission results in complex II deficiency with ocular, cardiac, and neurologic involvement. Am J Med Genet A.. 2017;173(1):225-230.|29177515) van der Tuin K,Mensenkamp AR,Tops CMJ,Corssmit EPM,Dinjens WN,van de Horst-Schrivers ANA,Jansen JC,de Jong MM,Kunst HPM,Kusters B,Leter EM,Morreau H,van Nesselrooij BMP,Oldenburg RA,Spruijt L,Hes FJ,Timmers HJLM. Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. J Clin Endocrinol Metab.. 2018;103(2):438-445.|29978154) Maniam P,Zhou K,Lonergan M,Berg JN,Goudie DR,Newey PJ. Pathogenicity and Penetrance of Germline  Variants in Pheochromocytoma and Paraganglioma (PPGL). J Endocr Soc.. 2018;2(7):806-816.|30201732) Benn DE,Zhu Y,Andrews KA,Wilding M,Duncan EL,Dwight T,Tothill RW,Burgess J,Crook A,Gill AJ,Hicks RJ,Kim E,Luxford C,Marfan H,Richardson AL,Robinson B,Schlosberg A,Susman R,Tacon L,Trainer A,Tucker K,Maher ER,Field M,Clifton-Bligh RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet.. 2018;55(11):729-734.|20301715) Hereditary Paraganglioma-Pheochromocytoma Syndromes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SDHAF2 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 357076).  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGLs and PCCs. Pathogenic SDHAF2 variants predispose individuals to multiple head and neck paragangliomas, especially at early ages, although the lifetime risk of developing these tumors is unclear (PMID: 21224366, 20071235, 22241717). While the SDHAF2 gene follows traditional Mendelian inheritance, there is evidence suggesting a parent-of-origin effect; it appears that the risk of disease may be limited to paternally inherited pathogenic variants (PMID: 28099933, 21224366).", Pmids: "20071235|21224366|22241717|28099933", Gene_Name: "SDHAF2", References: "20071235) Bayley JP,Kunst HP,Cascon A,Sampietro ML,Gaal J,Korpershoek E,Hinojar-Gutierrez A,Timmers HJ,Hoefsloot LH,Hermsen MA,Su√É¬°rez C,Hussain AK,Vriends AH,Hes FJ,Jansen JC,Tops CM,Corssmit EP,de Knijff P,Lenders JW,Cremers CW,Devilee P,Dinjens WN,de Krijger RR,Robledo M. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol.. 2010;11(4):366-72.|21224366) Kunst HP,Rutten MH,de M√É¬∂nnink JP,Hoefsloot LH,Timmers HJ,Marres HA,Jansen JC,Kremer H,Bayley JP,Cremers CW. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res.. 2011;17(2):247-54.|22241717) Piccini V,Rapizzi E,Bacca A,Di Trapani G,Pulli R,Giach√É¬® V,Zampetti B,Lucci-Cordisco E,Canu L,Corsini E,Faggiano A,Deiana L,Carrara D,Tantardini V,Mariotti S,Ambrosio MR,Zatelli MC,Parenti G,Colao A,Pratesi C,Bernini G,Ercolino T,Mannelli M. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer.. 2012;19(2):149-55.|28099933) Hoekstra AS,Hensen EF,Jordanova ES,Korpershoek E,van der Horst-Schrivers AN,Cornelisse C,Corssmit EP,Hes FJ,Jansen JC,Kunst HP,Timmers HJ,Bateman A,Eccles D,Bov√É¬©e JV,Devilee P,Bayley JP. Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. Oncotarget.. 2017;8(9):14525-14536."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SDHB gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 349380), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049), renal cancer (PMID: 29386252, 23083876) and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHB may also be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGL and PCC. SDHB is also associated with autosomal dominant predisposition to renal cancer (PMID: 18728283, 23083876), GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). The lifetime risk of developing PGL and/or PCC is 22-49% (PMID: 28374168, 29386252, 30201732). PGL, PCC and GIST are typically benign but have a risk of malignant transformation; lifetime cancer risks are not clear (PMID: 30536464, 29386252). There is approximately a 5% risk of kidney cancer to age 60 (PMID: 29386252, 23083876).  Mitochondrial complex II deficiency is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy. Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy. The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 22972948, 23322652).", Pmids: "17667967|18728283|22972948|23083876|23322652|26259135|28374168|29386252|30201732|30536464", Gene_Name: "SDHB", References: "17667967) Pasini B,McWhinney SR,Bei T,Matyakhina L,Stergiopoulos S,Muchow M,Boikos SA,Ferrando B,Pacak K,Assie G,Baudin E,Chompret A,Ellison JW,Briere JJ,Rustin P,Gimenez-Roqueplo AP,Eng C,Carney JA,Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet.. 2008;16(1):79-88.|18728283) Ricketts C,Woodward ER,Killick P,Morris MR,Astuti D,Latif F,Maher ER. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst.. 2008;100(17):1260-2.|22972948) Alston CL,Davison JE,Meloni F,van der Westhuizen FH,He L,Hornig-Do HT,Peet AC,Gissen P,Goffrini P,Ferrero I,Wassmer E,McFarland R,Taylor RW. Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet.. 2012;49(9):569-77.|23083876) Ricketts CJ,Shuch B,Vocke CD,Metwalli AR,Bratslavsky G,Middelton L,Yang Y,Wei MH,Pautler SE,Peterson J,Stolle CA,Zbar B,Merino MJ,Schmidt LS,Pinto PA,Srinivasan R,Pacak K,Linehan WM. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.. 2012;188(6):2063-71.|23322652) Jain-Ghai S,Cameron JM,Al Maawali A,Blaser S,MacKay N,Robinson B,Raiman J. Complex II deficiency--a case report and review of the literature. Am J Med Genet A.. 2013;161A(2):285-94.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|28374168) Jochmanova I,Wolf KI,King KS,Nambuba J,Wesley R,Martucci V,Raygada M,Adams KT,Prodanov T,Fojo AT,Lazurova I,Pacak K. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol.. 2017;143(8):1421-1435.|29386252) Andrews KA,Ascher DB,Pires DEV,Barnes DR,Vialard L,Casey RT,Bradshaw N,Adlard J,Aylwin S,Brennan P,Brewer C,Cole T,Cook JA,Davidson R,Donaldson A,Fryer A,Greenhalgh L,Hodgson SV,Irving R,Lalloo F,McConachie M,McConnell VPM,Morrison PJ,Murday V,Park SM,Simpson HL,Snape K,Stewart S,Tomkins SE,Wallis Y,Izatt L,Goudie D,Lindsay RS,Perry CG,Woodward ER,Antoniou AC,Maher ER. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes ,  and . J Med Genet.. 2018;55(6):384-394.|30201732) Benn DE,Zhu Y,Andrews KA,Wilding M,Duncan EL,Dwight T,Tothill RW,Burgess J,Crook A,Gill AJ,Hicks RJ,Kim E,Luxford C,Marfan H,Richardson AL,Robinson B,Schlosberg A,Susman R,Tacon L,Trainer A,Tucker K,Maher ER,Field M,Clifton-Bligh RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet.. 2018;55(11):729-734.|30536464) Muth A,Crona J,Gimm O,Elmgren A,Filipsson K,Stenmark Askmalm M,Sandstedt J,Tengvar M,Tham E. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med.. 2019;285(2):187-204."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SDHC gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 340200), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and renal cancer (PMID: 23083876).  Studies also suggest SDHC may be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and available evidence is insufficient to make a determination regarding this relationship.  SDHC-associated hereditary PGL-PCC syndrome is associated with an 8-25% risk of developing PGL and/or PCC that are typically benign (PMID: 30201732, 29386252). Affected individuals will more often develop PGL in the head and neck. SDHC is also associated with autosomal dominant predisposition to to renal cancer (PMID: 23083876), GIST and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967, 21173220). PGL, PCC and GIST may become malignant; however, lifetime cancer risks are not clear. The lifetime risk of renal cancer is not established.", Pmids: "17667967|21173220|23083876|26259135|29386252|30201732", Gene_Name: "SDHC", References: "17667967) Pasini B,McWhinney SR,Bei T,Matyakhina L,Stergiopoulos S,Muchow M,Boikos SA,Ferrando B,Pacak K,Assie G,Baudin E,Chompret A,Ellison JW,Briere JJ,Rustin P,Gimenez-Roqueplo AP,Eng C,Carney JA,Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet.. 2008;16(1):79-88.|21173220) Janeway KA,Kim SY,Lodish M,Nos√É¬© V,Rustin P,Gaal J,Dahia PL,Liegl B,Ball ER,Raygada M,Lai AH,Kelly L,Hornick JL, ,O'Sullivan M,de Krijger RR,Dinjens WN,Demetri GD,Antonescu CR,Fletcher JA,Helman L,Stratakis CA. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A.. 2011;108(1):314-8.|23083876) Ricketts CJ,Shuch B,Vocke CD,Metwalli AR,Bratslavsky G,Middelton L,Yang Y,Wei MH,Pautler SE,Peterson J,Stolle CA,Zbar B,Merino MJ,Schmidt LS,Pinto PA,Srinivasan R,Pacak K,Linehan WM. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.. 2012;188(6):2063-71.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|29386252) Andrews KA,Ascher DB,Pires DEV,Barnes DR,Vialard L,Casey RT,Bradshaw N,Adlard J,Aylwin S,Brennan P,Brewer C,Cole T,Cook JA,Davidson R,Donaldson A,Fryer A,Greenhalgh L,Hodgson SV,Irving R,Lalloo F,McConachie M,McConnell VPM,Morrison PJ,Murday V,Park SM,Simpson HL,Snape K,Stewart S,Tomkins SE,Wallis Y,Izatt L,Goudie D,Lindsay RS,Perry CG,Woodward ER,Antoniou AC,Maher ER. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes ,  and . J Med Genet.. 2018;55(6):384-394.|30201732) Benn DE,Zhu Y,Andrews KA,Wilding M,Duncan EL,Dwight T,Tothill RW,Burgess J,Crook A,Gill AJ,Hicks RJ,Kim E,Luxford C,Marfan H,Richardson AL,Robinson B,Schlosberg A,Susman R,Tacon L,Trainer A,Tucker K,Maher ER,Field M,Clifton-Bligh RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet.. 2018;55(11):729-734."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SDHD gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 358258) and gastrointestinal stromal tumors (GIST) (PMID: 24886695). Studies suggest SDHD is also associated with autosomal dominant predisposition to renal cancer (PMID: 19802898, 23083876) and pituitary adenomas (PMID: 26259135), as well as autosomal recessive mitochondrial complex II deficiency (PMID: 24367056; 26008905). The data, however, are preliminary and available evidence is insufficient to make a determination regarding these relationships.  Individuals with SDHD-associated hereditary PGL-PCC syndrome have a 43-70% risk of developing a PGL by age 60 (PMID: 29386252) and these tumors most often develop in the head and neck. SDHD is also associated with GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). SDHD-associated PGL, PCC and GIST have a risk of malignant transformation; however, lifetime risks are not clear. While both males and females can pass this variant on to their children, there is evidence suggesting that only those who inherit it from their father are at risk of developing SDHD-associated tumors (PMID: 25300370, 21937622, 19205158, 18211978).", Pmids: "17667967|18211978|19205158|19802898|21937622|23083876|24367056|24886695|25300370|26008905|26259135|28374168|29386252", Gene_Name: "SDHD", References: "17667967) Pasini B,McWhinney SR,Bei T,Matyakhina L,Stergiopoulos S,Muchow M,Boikos SA,Ferrando B,Pacak K,Assie G,Baudin E,Chompret A,Ellison JW,Briere JJ,Rustin P,Gimenez-Roqueplo AP,Eng C,Carney JA,Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet.. 2008;16(1):79-88.|18211978) Pigny P,Vincent A,Cardot Bauters C,Bertrand M,de Montpreville VT,Crepin M,Porchet N,Caron P. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J Clin Endocrinol Metab.. 2008;93(5):1609-15.|19205158) Hartzell LD,McKelvey KD,Van Hemert RL,Dornhoffer J. Cerebellopontine angle tumor in a patient with a maternally inherited SDHD gene mutation. Int Tinnitus J.. 2008;14(2):97-100.|19802898) Ricketts CJ,Forman JR,Rattenberry E,Bradshaw N,Lalloo F,Izatt L,Cole TR,Armstrong R,Kumar VK,Morrison PJ,Atkinson AB,Douglas F,Ball SG,Cook J,Srirangalingam U,Killick P,Kirby G,Aylwin S,Woodward ER,Evans DG,Hodgson SV,Murday V,Chew SL,Connell JM,Blundell TL,Macdonald F,Maher ER. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat.. 2010;31(1):41-51.|21937622) Yeap PM,Tobias ES,Mavraki E,Fletcher A,Bradshaw N,Freel EM,Cooke A,Murday VA,Davidson HR,Perry CG,Lindsay RS. Molecular analysis of pheochromocytoma after maternal transmission of SDHD mutation elucidates mechanism of parent-of-origin effect. J Clin Endocrinol Metab.. 2011;96(12):E2009-13.|23083876) Ricketts CJ,Shuch B,Vocke CD,Metwalli AR,Bratslavsky G,Middelton L,Yang Y,Wei MH,Pautler SE,Peterson J,Stolle CA,Zbar B,Merino MJ,Schmidt LS,Pinto PA,Srinivasan R,Pacak K,Linehan WM. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.. 2012;188(6):2063-71.|24367056) Jackson CB,Nuoffer JM,Hahn D,Prokisch H,Haberberger B,Gautschi M,H√É¬§berli A,Gallati S,Schaller A. Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency. J Med Genet.. 2014;51(3):170-5.|24886695) Miettinen M,Lasota J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol.. 2014;53():514-9.|25300370) Bayley JP,Oldenburg RA,Nuk J,Hoekstra AS,van der Meer CA,Korpershoek E,McGillivray B,Corssmit EP,Dinjens WN,de Krijger RR,Devilee P,Jansen JC,Hes FJ. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet.. 2014;15():111.|26008905) Alston CL,Ceccatelli Berti C,Blakely EL,Ol√É¬°hov√É¬° M,He L,McMahon CJ,Olpin SE,Hargreaves IP,Nolli C,McFarland R,Goffrini P,O'Sullivan MJ,Taylor RW. A recessive homozygous p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy and a severe mitochondrial complex II deficiency. Hum Genet.. 2015;134(8):869-79.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|28374168) Jochmanova I,Wolf KI,King KS,Nambuba J,Wesley R,Martucci V,Raygada M,Adams KT,Prodanov T,Fojo AT,Lazurova I,Pacak K. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol.. 2017;143(8):1421-1435.|29386252) Andrews KA,Ascher DB,Pires DEV,Barnes DR,Vialard L,Casey RT,Bradshaw N,Adlard J,Aylwin S,Brennan P,Brewer C,Cole T,Cook JA,Davidson R,Donaldson A,Fryer A,Greenhalgh L,Hodgson SV,Irving R,Lalloo F,McConachie M,McConnell VPM,Morrison PJ,Murday V,Park SM,Simpson HL,Snape K,Stewart S,Tomkins SE,Wallis Y,Izatt L,Goudie D,Lindsay RS,Perry CG,Woodward ER,Antoniou AC,Maher ER. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes ,  and . J Med Genet.. 2018;55(6):384-394."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SLX4 gene is associated with autosomal recessive Fanconi anemia, type P (FA-P) (MedGen UID: 450103).  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).", Pmids: "8986277|12393424|12393516|20417588|20507306", Gene_Name: "SLX4", References: "12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400) and Myhre syndrome (MedGen UID: 167103).  Loss-of-function (LOF) variants in SMAD4 are associated with juvenile polyposis syndrome (JPS), a condition characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469). LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.   Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT.", Pmids: "2705469|9869523|12221036|20859198|22846733|24424121|24715504|26636501|27302097|27562837", Gene_Name: "SMAD4", References: "12221036) Dunlop MG, , . Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut.. 2002;51 Suppl 5():V21-7.|20859198) Pollock J,Welsh JS. Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol.. 2011;34(3):332-6.|22846733) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Genetic testing by cancer site: colon (polyposis syndromes). Cancer J.. ;18(4):328-33.|24424121) Michot C,Le Goff C,Mahaut C,Afenjar A,Brooks AS,Campeau PM,Destree A,Di Rocco M,Donnai D,Hennekam R,Heron D,Jacquemont S,Kannu P,Lin AE,Manouvrier-Hanu S,Mansour S,Marlin S,McGowan R,Murphy H,Raas-Rothschild A,Rio M,Simon M,Stolte-Dijkstra I,Stone JR,Sznajer Y,Tolmie J,Touraine R,van den Ende J,Van der Aa N,van Essen T,Verloes A,Munnich A,Cormier-Daire V. Myhre and LAPS syndromes: clinical and molecular review of 32 patients. Eur J Hum Genet.. 2014;22(11):1272-7.|24715504) Caputo V,Bocchinfuso G,Castori M,Traversa A,Pizzuti A,Stella L,Grammatico P,Tartaglia M. Novel SMAD4 mutation causing Myhre syndrome. Am J Med Genet A.. 2014;164A(7):1835-40.|26636501) Bassett JK,Douzgou S,Kerr B. Severe constipation in a patient with Myhre syndrome: a case report. Clin Dysmorphol.. 2016;25(2):54-7.|2705469) Walpole IR,Cullity G. Juvenile polyposis: a case with early presentation and death attributable to adenocarcinoma of the pancreas. Am J Med Genet.. 1989;32(1):1-8.|27302097) Lin AE,Michot C,Cormier-Daire V,L'Ecuyer TJ,Matherne GP,Barnes BH,Humberson JB,Edmondson AC,Zackai E,O'Connor MJ,Kaplan JD,Ebeid MR,Krier J,Krieg E,Ghoshhajra B,Lindsay ME. Gain-of-function mutations in SMAD4 cause a distinctive repertoire of cardiovascular phenotypes in patients with Myhre syndrome. Am J Med Genet A.. 2016;170(10):2617-31.|27562837) Garavelli L,Maini I,Baccilieri F,Ivanovski I,Pollazzon M,Rosato S,Iughetti L,Unger S,Superti-Furga A,Tartaglia M. Natural history and life-threatening complications in Myhre syndrome and review of the literature. Eur J Pediatr.. 2016;175(10):1307-15.|9869523) Howe JR,Mitros FA,Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol.. 1998;5(8):751-6."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SMARCA4 gene is associated with rhabdoid tumor predisposition syndrome, type 2, autosomal dominant small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PMID: 24658002, 24658001) and Coffin-Siris syndrome (CSS) (MedGen UID: 766163).  Loss-of-function (LOF) variants in SMARCA4 are associated with RTPS2, a childhood-onset condition associated with rhabdoid tumors that typically develop in the kidneys and central nervous system. SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established.

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays.", Pmids: "24658001|24658002", Gene_Name: "SMARCA4", References: "24658001) Ramos P,Karnezis AN,Craig DW,Sekulic A,Russell ML,Hendricks WP,Corneveaux JJ,Barrett MT,Shumansky K,Yang Y,Shah SP,Prentice LM,Marra MA,Kiefer J,Zismann VL,McEachron TA,Salhia B,Prat J,D'Angelo E,Clarke BA,Pressey JG,Farley JH,Anthony SP,Roden RB,Cunliffe HE,Huntsman DG,Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet.. 2014;46(5):427-9.|24658002) Witkowski L,Carrot-Zhang J,Albrecht S,Fahiminiya S,Hamel N,Tomiak E,Grynspan D,Saloustros E,Nadaf J,Rivera B,Gilpin C,Castellsagu√É¬© E,Silva-Smith R,Plourde F,Wu M,Saskin A,Arseneault M,Karabakhtsian RG,Reilly EA,Ueland FR,Margiolaki A,Pavlakis K,Castellino SM,Lamovec J,Mackay HJ,Roth LM,Ulbright TM,Bender TA,Georgoulias V,Longy M,Berchuck A,Tischkowitz M,Nagel I,Siebert R,Stewart CJ,Arseneau J,McCluggage WG,Clarke BA,Riazalhosseini Y,Hasselblatt M,Majewski J,Foulkes WD. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet.. 2014;46(5):438-43."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SMARCB1 gene is associated with autosomal dominant rhabdoid tumor predisposition syndrome 1 (RTPS1) (MedGen UID: 322892), schwannomatosis (MedGen UID: 234775) and Coffin-Siris syndrome (MedGen UID: 766162).  RTPS is associated with an increased risk of rhabdoid tumors, a rare type of childhood cancer that most often develops in the kidneys and central nervous system. Schwannomatosis is characterized by the development of multiple spinal, peripheral, and cranial nerve schwannomas. The absence of vestibular schwannomas distinguishes schwannomatosis from neurofibromatosis type 2 (PMID: 24933152, 19898272, 21208904). 

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 25168959, 25169878, 23929686).", Pmids: "19898272|21208904|23929686|24933152|25168959|25169878", Gene_Name: "SMARCB1", References: "19898272) Lu-Emerson C,Plotkin SR. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis.. 2009;6(3):E81-6.|21208904) Bourdeaut F,Lequin D,Brugi√É¬®res L,Reynaud S,Dufour C,Doz F,Andr√É¬© N,Stephan JL,P√É¬©rel Y,Oberlin O,Orbach D,Bergeron C,Rialland X,Fr√É¬©neaux P,Ranchere D,Figarella-Branger D,Audry G,Puget S,Evans DG,Pinas JC,Capra V,Mosseri V,Coupier I,Gauthier-Villars M,Pierron G,Delattre O. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res.. 2011;17(1):31-8.|23929686) Santen GW,Aten E,Vulto-van Silfhout AT,Pottinger C,van Bon BW,van Minderhout IJ,Snowdowne R,van der Lans CA,Boogaard M,Linssen MM,Vijfhuizen L,van der Wielen MJ,Vollebregt MJ, ,Breuning MH,Kriek M,van Haeringen A,den Dunnen JT,Hoischen A,Clayton-Smith J,de Vries BB,Hennekam RC,van Belzen MJ. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat.. 2013;34(11):1519-28.|24933152) Smith MJ,Wallace AJ,Bowers NL,Eaton H,Evans DG. SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genet.. 2014;207(9):373-8.|25168959) Kosho T,Okamoto N, . Genotype-phenotype correlation of Coffin-Siris syndrome caused by mutations in SMARCB1, SMARCA4, SMARCE1, and ARID1A. Am J Med Genet C Semin Med Genet.. 2014;166C(3):262-75.|25169878) Kosho T,Miyake N,Carey JC. Coffin-Siris syndrome and related disorders involving components of the BAF (mSWI/SNF) complex: historical review and recent advances using next generation sequencing. Am J Med Genet C Semin Med Genet.. 2014;166C(3):241-51."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SMARCE1 gene is associated with autosomal dominant familial meningioma (MedGen UID: 232281) and Coffin-Siris syndrome (MedGen UID: 934755).  Pathogenic loss-of-function (LOF) SMARCE1 variants are associated with familial meningioma. Meningiomas are typically slow growing benign tumors derived from the meningeal tissue of the brain and spinal cord (PMID: 23377182, 25143307).

Coffin-Siris syndrome (CSS) is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 23929686, 27264197, 30499906, 25168959, 25169878, 23929686). While SMARCE1 is also associated with autosomal dominant CSS, to date, LOF variants in this gene have not been observed in individuals affected with CSS.", Pmids: "23377182|23929686|25143307|25168959|25169878|27264197|30499906", Gene_Name: "SMARCE1", References: "23377182) Smith MJ,O'Sullivan J,Bhaskar SS,Hadfield KD,Poke G,Caird J,Sharif S,Eccles D,Fitzpatrick D,Rawluk D,du Plessis D,Newman WG,Evans DG. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet.. 2013;45(3):295-8.|23929686) Santen GW,Aten E,Vulto-van Silfhout AT,Pottinger C,van Bon BW,van Minderhout IJ,Snowdowne R,van der Lans CA,Boogaard M,Linssen MM,Vijfhuizen L,van der Wielen MJ,Vollebregt MJ, ,Breuning MH,Kriek M,van Haeringen A,den Dunnen JT,Hoischen A,Clayton-Smith J,de Vries BB,Hennekam RC,van Belzen MJ. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat.. 2013;34(11):1519-28.|25143307) Smith MJ,Wallace AJ,Bennett C,Hasselblatt M,Elert-Dobkowska E,Evans LT,Hickey WF,van Hoff J,Bauer D,Lee A,Hevner RF,Beetz C,du Plessis D,Kilday JP,Newman WG,Evans DG. Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol.. 2014;234(4):436-40.|25168959) Kosho T,Okamoto N, . Genotype-phenotype correlation of Coffin-Siris syndrome caused by mutations in SMARCB1, SMARCA4, SMARCE1, and ARID1A. Am J Med Genet C Semin Med Genet.. 2014;166C(3):262-75.|25169878) Kosho T,Miyake N,Carey JC. Coffin-Siris syndrome and related disorders involving components of the BAF (mSWI/SNF) complex: historical review and recent advances using next generation sequencing. Am J Med Genet C Semin Med Genet.. 2014;166C(3):241-51.|27264197) Zarate YA,Bhoj E,Kaylor J,Li D,Tsurusaki Y,Miyake N,Matsumoto N,Phadke S,Escobar L,Irani A,Hakonarson H,Schrier Vergano SA. SMARCE1, a rare cause of Coffin-Siris Syndrome: Clinical description of three additional cases. Am J Med Genet A.. 2016;170(8):1967-73.|30499906) Lin B,Kesserwan C,Quinn EA,Einhaus SL,Wright KD,Azzato EM,Orr BA,Upadhyaya SA. Anaplastic Astrocytoma in a Child With Coffin-Siris Syndrome and a Germline SMARCE1 Mutation: A Case Report. J Pediatr Hematol Oncol.. 2020;42(3):e177-e180."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SPINK1 gene is associated with autosomal dominant predisposition to hereditary pancreatitis (MedGen UID: 116056).  Chronic and/or hereditary pancreatitis is characterized by recurrent episodes of inflammation of the pancreas (pancreatitis). Pathogenic variants in SPINK1 are associated with increased susceptibility to chronic pancreatitis (PMID: 25206283, 24522117). Chronic pancreatitis is a risk factor for pancreatic cancer (PMID: 25170203). The phenotype of individuals with the same allelic variant may differ due to other genetic and environmental risk factors. Individuals with a pathogenic variant or increased risk variant identified in both CFTR and SPINK1 have been reported to have more than a 65-fold increased risk for pancreatitis (PMID: 11729110, 17003641, 17681820, 20977904). The clinical presentation, severity and prognosis depends on the specific variants identified along with additional environmental factors.", Pmids: "11729110|17003641|17681820|20977904|24522117|25170203|25206283", Gene_Name: "SPINK1", References: "25170203) Becker AE,Hernandez YG,Frucht H,Lucas AL. Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol.. 2014;20(32):11182-98.|11729110) Cystic fibrosis gene mutations and pancreatitis risk relation to epithelial ion transport and trypsin inhibitor gene mutations|17003641) Identification of cftr, prss1, and spink1 mutations in 381 patients with pancreatitis|17681820) Co inheritance of a novel deletion of the entire spink1 gene with a cftr missense mutation (l997 f) in a family with chronic pancreatitis|20977904) Combined bicarbonate conductance impairing variants in CFTR and SPINK1 variants are associated with chronic pancreatitis in patients without cystic fibrosis|24522117) Genetics of pancreatitis: the 2014 update|25206283) PRSS1 and SPINK1 mutations in idiopathic chronic and recurrent acute pancreatitis"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The STK11 gene is associated with autosomal dominant Peutz-Jeghers syndrome (PJS) (MedGen UID: 18404).  PJS is characterized by gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation of the lips, and increased risk of cancer. Affected individuals have increased risk of developing a wide variety of cancers including breast (19-54% risk), ovarian (18-21% risk), testicular (9% risk), endometrial/uterine (9% risk), cervical (10% risk), colon (39% risk), gastric (29% risk), small bowel (13% risk), pancreatic (11-36% risk) and lung (7-17% risk) (PMID: 11113065, 33471991).", Pmids: "11113065|33471991", Gene_Name: "STK11", References: "11113065) Giardiello FM,Brensinger JD,Tersmette AC,Goodman SN,Petersen GM,Booker SV,Cruz-Correa M,Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology.. 2000;119(6):1447-53.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The SUFU gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554), autosomal recessive Joubert syndrome (MedGen UID: 1626697), and autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).  Pathogenic loss-of-function (LOF) SUFU variants are associated with BCNS. BCNS is an early-onset condition characterized by the development of multiple basal cell carcinomas, cardiac and ovarian fibromas, palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. SUFU-related BCNS is associated with up to a 33% risk of medulloblastoma (PMID: 29186568, 25403219, 33066274).

Joubert syndrome (JS) is a highly variable condition associated with a specific anomaly of the cerebellar vermis and brainstem causing the characteristic \"molar tooth sign\" (MTS) on magnetic resonance imaging. Additional findings include ataxia, polydactyly, distinctive facial features, episodic tachypnea or apnea and abnormal eye movements (PMID: 24360807). Cognitive abilities may range from normal to severely impaired. The term \"Joubert syndrome and related disorders (JSRD)\" is used to describe JS and other conditions that have MTS as well as other overlapping clinical features (PMID: 17603801, 14981712). While the SUFU gene is associated with JS, LOF variants in this gene have not been observed in individuals with this condition.", Pmids: "14981712|17603801|24360807|25403219|29186568|33024317|33066274", Gene_Name: "SUFU", References: "14981712) Gleeson JG,Keeler LC,Parisi MA,Marsh SE,Chance PF,Glass IA,Graham JM,Maria BL,Barkovich AJ,Dobyns WB. Molar tooth sign of the midbrain-hindbrain junction: occurrence in multiple distinct syndromes. Am J Med Genet A.. 2004;125A(2):125-34; discussion 117.|17603801) Boycott KM,Parboosingh JS,Scott JN,McLeod DR,Greenberg CR,Fujiwara TM,Mah JK,Midgley J,Wade A,Bernier FP,Chodirker BN,Bunge M,Innes AM. Meckel syndrome in the Hutterite population is actually a Joubert-related cerebello-oculo-renal syndrome. Am J Med Genet A.. 2007;143A(15):1715-25.|24360807) Akizu N,Silhavy JL,Rosti RO,Scott E,Fenstermaker AG,Schroth J,Zaki MS,Sanchez H,Gupta N,Kabra M,Kara M,Ben-Omran T,Rosti B,Guemez-Gamboa A,Spencer E,Pan R,Cai N,Abdellateef M,Gabriel S,Halbritter J,Hildebrandt F,van Bokhoven H,Gunel M,Gleeson JG. Mutations in CSPP1 lead to classical Joubert syndrome. Am J Hum Genet.. 2014;94(1):80-6.|25403219) Smith MJ,Beetz C,Williams SG,Bhaskar SS,O'Sullivan J,Anderson B,Daly SB,Urquhart JE,Bholah Z,Oudit D,Cheesman E,Kelsey A,McCabe MG,Newman WG,Evans DG. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol.. 2014;32(36):4155-61.|29186568) Guerrini-Rousseau L,Dufour C,Varlet P,Masliah-Planchon J,Bourdeaut F,Guillaud-Bataille M,Abbas R,Bertozzi AI,Fouyssac F,Huybrechts S,Puget S,Bressac-De Paillerets B,Caron O,Sevenet N,Dimaria M,Villebasse S,Delattre O,Valteau-Couanet D,Grill J,Brugi√É¬®res L. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro Oncol.. 2018;20(8):1122-1132.|33024317) Schr√É¬∂der S,Li Y,Yigit G,Altm√É¬ºller J,Bader I,Bevot A,Biskup S,Dreha-Kulaczewski S,Christoph Korenke G,Kottke R,Mayr JA,Preisel M,Toelle SP,Wente-Schulz S,Wortmann SB,Hahn H,Boltshauser E,Uhmann A,Wollnik B,Brockmann K. Heterozygous truncating variants in SUFU cause congenital ocular motor apraxia. Genet Med.. 2021;23(2):341-351.|33066274) Onodera S,Nakamura Y,Azuma T. Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research. Int J Mol Sci.. 2020;21(20):."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TERC gene is associated with autosomal dominant TERC-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 338831).  DC is a telomere disorder characterized by abnormal skin pigmentation, nail dystrophy and oral leukoplakia. Affected individuals have a predisposition to progressive bone marrow failure, pulmonary fibrosis and cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). There is some evidence of genetic anticipation due to telomere shortening in which older generations present with adult-onset pulmonary fibrosis and subsequent generations present in childhood with bone marrow failure (PMID: 15098033).", Pmids: "15098033|25170286", Gene_Name: "TERC", References: "15098033) Vulliamy T,Marrone A,Szydlo R,Walne A,Mason PJ,Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet.. 2004;36(5):447-9.|25170286) Fern√É¬°ndez Garc√É¬≠a MS,Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med.. 2014;5():157-67."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793  Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual‚Äôs telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200).", Pmids: "17392301|21436073|23335200|25170286|25237198|25940403|26022962|27836952|32923861|33184060", Gene_Name: "TERT", References: "17392301) Armanios MY,Chen JJ,Cogan JD,Alder JK,Ingersoll RG,Markin C,Lawson WE,Xie M,Vulto I,Phillips JA,Lansdorp PM,Greider CW,Loyd JE. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med.. 2007;356(13):1317-26.|21436073) Parry EM,Alder JK,Qi X,Chen JJ,Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood.. 2011;117(21):5607-11.|23335200) Vogiatzi P,Perdigones N,Mason PJ,Wilson DB,Bessler M. A family with Hoyeraal-Hreidarsson syndrome and four variants in two genes of the telomerase core complex. Pediatr Blood Cancer.. 2013;60(6):E4-6.|25170286) Fern√É¬°ndez Garc√É¬≠a MS,Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med.. 2014;5():157-67.|25237198) Townsley DM,Dumitriu B,Young NS. Bone marrow failure and the telomeropathies. Blood.. 2014;124(18):2775-83.|25940403) Glousker G,Touzot F,Revy P,Tzfati Y,Savage SA. Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol.. 2015;170(4):457-71.|26022962) Kannengiesser C,Borie R,M√É¬©nard C,R√É¬©ocreux M,Nitschk√É¬© P,Gazal S,Mal H,Taill√É¬© C,Cadranel J,Nunes H,Valeyre D,Cordier JF,Callebaut I,Boileau C,Cottin V,Grandchamp B,Revy P,Crestani B. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J.. 2015;46(2):474-85.|27836952) Borie R,Tab√É¬®ze L,Thabut G,Nunes H,Cottin V,Marchand-Adam S,Prevot G,Tazi A,Cadranel J,Mal H,Wemeau-Stervinou L,Bergeron Lafaurie A,Israel-Biet D,Picard C,Reynaud Gaubert M,Jouneau S,Naccache JM,Mankikian J,M√É¬©nard C,Cordier JF,Valeyre D,Reocreux M,Grandchamp B,Revy P,Kannengiesser C,Crestani B. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J.. 2016;48(6):1721-1731.|32923861) Walsh MF,Sacca R,Wildman T,Amoroso K,Kennedy J,Zhang L,Birsoy O,Mandelker D,Steinsnyder Z,Latham A,Carlo MI,Cadoo K,Kemel Y,Robson M,Stadler ZK,Offit K. Pathogenic Loss-of-Function Germline  Mutations in Patients With Solid Tumors. JCO Precis Oncol.. 2019;3():."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TMEM127 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 18419). There is also evidence suggesting TMEM127 is associated with autosomal dominant predisposition to renal cancer (PMID: 33051659, 28973655). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk to develop PGLs and PCCs. Most evidence suggests TMEM127 is associated with primarily PCC; however, cases of extra-adrenal PGLs have also been reported (PMID: 33051659). The risk of malignant transformation appears to be low (PMID: 24899893, 26347711, 20301715).", Pmids: "20301715|24899893|26347711|28973655|33051659", Gene_Name: "TMEM127", References: "24899893) Martins R,Bugalho MJ. Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol.. 2014;2014():794187.|26347711) Costa MH,Ortiga-Carvalho TM,Violante AD,Vaisman M. Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Front Endocrinol (Lausanne).. 2015;6():126.|28973655) Casey RT,Warren AY,Martin JE,Challis BG,Rattenberry E,Whitworth J,Andrews KA,Roberts T,Clark GR,West H,Smith PS,Docquier FM,Rodger F,Murray V,Simpson HL,Wallis Y,Giger O,Tran M,Tomkins S,Stewart GD,Park SM,Woodward ER,Maher ER. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. J Clin Endocrinol Metab.. 2017;102(11):4013-4022.|33051659) Armaiz-Pena G,Flores SK,Cheng ZM,Zhang X,Esquivel E,Poullard N,Vaidyanathan A,Liu Q,Michalek J,Santillan-Gomez AA,Liss M,Ahmadi S,Katselnik D,Maldonado E,Salgado SA,Jimenez C,Fishbein L,Hamidi O,Else T,Lechan R,Tischler AS,Benn DE,Dwight T,Clifton-Bligh R,Sanso G,Barontini M,Vincent D,Aronin N,Biondi B,Koops M,Bowhay-Carnes E,Gimenez-Roqueplo AP,Alvarez-Eslava A,Bruder JM,Kitano M,Burnichon N,Ding Y,Dahia PLM. Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. J Clin Endocrinol Metab.. 2021;106(1):e350-e364.|20301715) Hereditary Paraganglioma-Pheochromocytoma Syndromes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TP53 gene is associated with autosomal dominant Li-Fraumeni syndrome (LFS) (MedGen UID: 322656).  LFS is a cancer predisposition syndrome associated with sarcoma, brain cancer, breast cancer, adrenocortical carcinoma and other malignancies. Affected individuals often develop cancers in childhood or early adulthood, and are at increased risk for multiple primary cancers. Overall lifetime cancer risks have been reported as high as 73% for males and nearly 100% for females (PMID: 10864200). It is estimated that 7-20% of LFS cases are due to a de novo pathogenic variant (PMID: 19556618). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired TP53 variants and additional testing may be appropriate.", Pmids: "10864200|19556618|25426837|25426838|31490007|31881331", Gene_Name: "TP53", References: "10864200) Chompret A,Brugi√É¬®res L,Ronsin M,Gardes M,Dessarps-Freichey F,Abel A,Hua D,Ligot L,Dondon MG,Bressac-de Paillerets B,Fr√É¬©bourg T,Lemerle J,Bona√É¬Øti-Pelli√É¬© C,Feunteun J. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer.. 2000;82(12):1932-7.|19556618) Gonzalez KD,Buzin CH,Noltner KA,Gu D,Li W,Malkin D,Sommer SS. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet.. 2009;46(10):689-93.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|31490007) Coffee B,Cox HC,Bernhisel R,Manley S,Bowles K,Roa BB,Mancini-DiNardo D. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Hum Mutat.. 2020;41(1):203-211.|31881331) Mester JL,Jackson SA,Postula K,Stettner A,Solomon S,Bissonnette J,Murphy PD,Klein RT,Hruska KS. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. J Mol Diagn.. 2020;22(3):396-404.|25426837) Age-related clonal hematopoiesis associated with adverse outcomes"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).  Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms‚Äô tumor (PMID: 14757854).", Pmids: "14757854", Gene_Name: "TRIM37 - Monoallelic", References: "14757854) Mulibrey nanism clinical features and diagnostic criteria"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TRIM37 gene is associated with autosomal recessive mulibrey nanism (MedGen UID: 99347).  Mulibrey nanism generally presents in infancy with severe growth deficiency and characteristic craniofacial features. Other features can vary greatly but can include short limbs, constrictive pericarditis, hepatomegaly, thin extremities, high pitched voice, and yellow dots on the fundus. A small number of affected individuals may develop Wilms‚Äô tumor (PMID: 14757854).", Pmids: "14757854", Gene_Name: "TRIM37 - Biallelic", References: "14757854) Mulibrey nanism clinical features and diagnostic criteria"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TSC1 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 344288).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).", Pmids: "2069856|11920808|32953421", Gene_Name: "TSC1", References: "11920808) Armada RC,Longchong Ramos M,Marrero P,Pascual J. Embryonal rhabdomyosarcoma associated with tuberous sclerosis. Med Pediatr Oncol.. 2002;38(4):302.|2069856) Narod SA,Stiller C,Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer.. 1991;63(6):993-9.|32953421) Nair N,Chakraborty R,Mahajan Z,Sharma A,Sethi SK,Raina R. Renal Manifestations of Tuberous Sclerosis Complex. J Kidney Cancer VHL.. 2020;7(3):5-19."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The TSC2 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 348170).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).", Pmids: "2069856|11920808|32953421", Gene_Name: "TSC2", References: "11920808) Armada RC,Longchong Ramos M,Marrero P,Pascual J. Embryonal rhabdomyosarcoma associated with tuberous sclerosis. Med Pediatr Oncol.. 2002;38(4):302.|2069856) Narod SA,Stiller C,Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer.. 1991;63(6):993-9.|32953421) Nair N,Chakraborty R,Mahajan Z,Sharma A,Sethi SK,Raina R. Renal Manifestations of Tuberous Sclerosis Complex. J Kidney Cancer VHL.. 2020;7(3):5-19."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The VHL gene is associated with autosomal dominant von Hippel-Lindau (VHL) syndrome (MedGen UID: 42458) and autosomal recessive familial erythrocytosis, type 2 (MedGen UID: 332974).  von Hippel-Lindau syndrome is associated with an increased risk of developing various noncancerous tumors throughout the body including hemangioblastomas of the central nervous system and retina, head and neck paragangliomas, pheochromocytomas, endolymphatic sac tumors and epididymal cystadenomas. Although most tumors are benign, there is a 17-70% risk of developing clear cell renal cell carcinoma and an 8-17% risk for pancreatic neuroendocrine tumors (PMID: 20301636, 28620007, 31095066). Approximately 20% of VHL cases are de novo (PMID: 21386872, 25611110). Although genotype-phenotype correlations have been suggested, their diagnostic relevance is unclear and therefore should not impact medical management (PMID: 21386872, 20301636).  Familial erythrocytosis is characterized by the abnormally high production of red blood cells (erythrocytes), which can cause headaches, dizziness, nosebleeds, shortness of breath and predisposition to excessive clotting. Familial erythrocytosis has incomplete penetrance; many individuals with biallelic pathogenic variants will never develop clinical symptoms (PMID: 24115288, 23733342).", Pmids: "20301636|21386872|23733342|24115288|25611110|28620007|31095066", Gene_Name: "VHL", References: "21386872) Maher ER,Neumann HP,Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet.. 2011;19(6):617-23.|23733342) Franke K,Gassmann M,Wielockx B. Erythrocytosis: the HIF pathway in control. Blood.. 2013;122(7):1122-8.|24115288) Bento C,Percy MJ,Gardie B,Maia TM,van Wijk R,Perrotta S,Della Ragione F,Almeida H,Rossi C,Girodon F,Astr√É¬∂m M,Neumann D,Schnittger S,Landin B,Minkov M,Randi ML,Richard S,Casadevall N,Vainchenker W,Rives S,Hermouet S,Ribeiro ML,McMullin MF,Cario H, ,Chauveau A,Gimenez-Roqueplo AP,Bressac-de-Paillerets B,Altindirek D,Lorenzo F,Lambert F,Dan H,Gad-Lapiteau S,Catarina Oliveira A,Rossi C,Fraga C,Taradin G,Martin-Nu√É¬±ez G,Vit√É¬≥ria H,Diaz Aguado H,Palmblad J,Vid√É¬°n J,Relvas L,Ribeiro ML,Luigi Larocca M,Luigia Randi M,Pedro Silveira M,Percy M,Gross M,Marques da Costa R,Beshara S,Ben-Ami T,Ugo V, . Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat.. 2014;35(1):15-26.|25611110) Cassol C,Mete O. Endocrine manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med.. 2015;139(2):263-8.|28620007) Rednam SP,Erez A,Druker H,Janeway KA,Kamihara J,Kohlmann WK,Nathanson KL,States LJ,Tomlinson GE,Villani A,Voss SD,Schiffman JD,Wasserman JD. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res.. 2017;23(12):e68-e75.|31095066) Aronow ME,Wiley HE,Gaudric A,Krivosic V,Gorin MB,Shields CL,Shields JA,Jonasch EW,Singh AD,Chew EY. VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects. Retina.. 2019;39(12):2243-2253.|20301636) Von Hippel-Lindau Syndrome"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).  WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204).", Pmids: "16673358|20301687|24401204", Gene_Name: "WRN - Monoallelic", References: "16673358) Huang S,Lee L,Hanson NB,Lenaerts C,Hoehn H,Poot M,Rubin CD,Chen DF,Yang CC,Juch H,Dorn T,Spiegel R,Oral EA,Abid M,Battisti C,Lucci-Cordisco E,Neri G,Steed EH,Kidd A,Isley W,Showalter D,Vittone JL,Konstantinow A,Ring J,Meyer P,Wenger SL,von Herbay A,Wollina U,Schuelke M,Huizenga CR,Leistritz DF,Martin GM,Mian IS,Oshima J. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat.. 2006;27(6):558-67.|24401204) Oshima J,Hisama FM. Search and insights into novel genetic alterations leading to classical and atypical Werner syndrome. Gerontology.. 2014;60(3):239-46.|20301687) Werner Syndrome"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The WRN gene is associated with autosomal recessive Werner syndrome (WS) (MedGen UID: 12147).  WS is a progeroid syndrome characterized by premature aging affecting multiple organ systems. Affected individuals have increased predisposition to age-related diseases such as cataracts, cardiovascular disease and certain cancers (PMID: 24401204, 20301687, 16673358). Sarcoma and other rare cancers occur more frequently; however, more common cancers have also been reported (PMID: 24401204).", Pmids: "16673358|20301687|24401204", Gene_Name: "WRN - Biallelic", References: "16673358) Huang S,Lee L,Hanson NB,Lenaerts C,Hoehn H,Poot M,Rubin CD,Chen DF,Yang CC,Juch H,Dorn T,Spiegel R,Oral EA,Abid M,Battisti C,Lucci-Cordisco E,Neri G,Steed EH,Kidd A,Isley W,Showalter D,Vittone JL,Konstantinow A,Ring J,Meyer P,Wenger SL,von Herbay A,Wollina U,Schuelke M,Huizenga CR,Leistritz DF,Martin GM,Mian IS,Oshima J. The spectrum of WRN mutations in Werner syndrome patients. Hum Mutat.. 2006;27(6):558-67.|24401204) Oshima J,Hisama FM. Search and insights into novel genetic alterations leading to classical and atypical Werner syndrome. Gerontology.. 2014;60(3):239-46.|20301687) Werner Syndrome"})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The WT1 gene is associated with autosomal dominant Denys-Drash syndrome (MedGen UID: 181980), Wilms tumor predisposition syndrome (MedGen UID: 447509), WAGR syndrome (MedGen UID: 64512) and Frasier syndrome (MedGen UID: 215533).  WT1-related disorders are associated with an increased risk for Wilms tumor, a type of renal cancer, which typically presents in early childhood. WT1-related Wilms tumor may occur as an isolated finding or as part of a syndrome. Deletions of WT1 along with the neighboring PAX6 gene are associated with WAGR (Wilms tumor-aniridia-genital anomalies-retardation) syndrome, characterized by Wilms tumor, genitourinary anomalies, intellectual disability, and aniridia (PMID: 22692063).  Other WT1-related disorders include Denys-Drash syndrome, which has a high risk of Wilms tumor and genitourinary anomalies, and Frasier syndrome, which is more often associated with gonadoblastoma and less often with Wilms tumor (PMID: 23295293, 9529364). Nephrotic syndrome has also been linked to pathogenic variants in WT1 (PMID: 25818337).", Pmids: "9529364|22692063|23295293|25818337", Gene_Name: "WT1", References: "22692063) Hingorani M,Hanson I,van Heyningen V. Aniridia. Eur J Hum Genet.. 2012;20(10):1011-7.|23295293) Guaragna MS,Lutaif AC,Bittencourt VB,Piveta CS,Soardi FC,Castro LC,Belangero VM,Maciel-Guerra AT,Guerra-Junior G,Mello MP. Frasier syndrome: four new cases with unusual presentations. Arq Bras Endocrinol Metabol.. 2012;56(8):525-32.|25818337) Lehnhardt A,Karnatz C,Ahlenstiel-Grunow T,Benz K,Benz MR,Budde K,B√É¬ºscher AK,Fehr T,Feldk√É¬∂tter M,Graf N,H√É¬∂cker B,Jungraithmayr T,Klaus G,Koehler B,Konrad M,Kranz B,Montoya CR,M√É¬ºller D,Neuhaus TJ,Oh J,Pape L,Pohl M,Royer-Pokora B,Querfeld U,Schneppenheim R,Staude H,Spart√É¬† G,Timmermann K,Wilkening F,Wygoda S,Bergmann C,Kemper MJ. Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1. Clin J Am Soc Nephrol.. 2015;10(5):825-31.|9529364) Jeanpierre C,Denamur E,Henry I,Cabanis MO,Luce S,C√É¬©cille A,Elion J,Peuchmaur M,Loirat C,Niaudet P,Gubler MC,Junien C. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet.. 1998;62(4):824-33."})
(:LKP_GENE_DISEASE_ASSOCIATION {Concatenated: "The XRCC2 gene currently has no well-established disease association; however, there is preliminary evidence supporting a correlation with autosomal dominant susceptibility to breast cancer (PMID: 22464251, 25452441) and autosomal recessive Fanconi anemia (PMID: 22232082).", Pmids: "22232082|22464251|25452441", Gene_Name: "XRCC2", References: "22464251) Park DJ,Lesueur F,Nguyen-Dumont T,Pertesi M,Odefrey F,Hammet F,Neuhausen SL,John EM,Andrulis IL,Terry MB,Daly M,Buys S,Le Calvez-Kelm F,Lonie A,Pope BJ,Tsimiklis H,Voegele C,Hilbers FM,Hoogerbrugge N,Barroso A,Osorio A, , ,Giles GG,Devilee P,Benitez J,Hopper JL,Tavtigian SV,Goldgar DE,Southey MC. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet.. 2012;90(4):734-9.|25452441) Couch FJ,Hart SN,Sharma P,Toland AE,Wang X,Miron P,Olson JE,Godwin AK,Pankratz VS,Olswold C,Slettedahl S,Hallberg E,Guidugli L,Davila JI,Beckmann MW,Janni W,Rack B,Ekici AB,Slamon DJ,Konstantopoulou I,Fostira F,Vratimos A,Fountzilas G,Pelttari LM,Tapper WJ,Durcan L,Cross SS,Pilarski R,Shapiro CL,Klemp J,Yao S,Garber J,Cox A,Brauch H,Ambrosone C,Nevanlinna H,Yannoukakos D,Slager SL,Vachon CM,Eccles DM,Fasching PA. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol.. 2015;33(4):304-11.|22232082) Exome sequencing reveals a novel fanconi group defined by xrcc2 mutation"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRRAP", GeneMasterName: "TRRAP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MYD88", GeneMasterName: "MYD88"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NTRK", GeneMasterName: "NTRK"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PCAP", GeneMasterName: "PCAP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS2P1", GeneMasterName: "PMS2P1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RINT1", GeneMasterName: "RINT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MCPH1", GeneMasterName: "MCPH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ARA9", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FKBP16", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XAP2", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PITA1", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XAP-2", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FKBP37", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMTPHN", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD246", GeneMasterName: "ALK"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBLST3", GeneMasterName: "ALK"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CAR", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FHH", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PCAR1", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCasR", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GPRC2A", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HYPOC1", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FIH", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HHC", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EIG8", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NSHPT", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HHC1", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HYX", GeneMasterName: "CDC73"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FIHP", GeneMasterName: "CDC73"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HPTJT", GeneMasterName: "CDC73"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HRPT1", GeneMasterName: "CDC73"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HRPT2", GeneMasterName: "CDC73"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C1orf28", GeneMasterName: "CDC73"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CEBP", GeneMasterName: "CEBPA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C/EBP-alpha", GeneMasterName: "CEBPA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BWS", GeneMasterName: "CDKN1C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WBS", GeneMasterName: "CDKN1C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "p57", GeneMasterName: "CDKN1C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BWCR", GeneMasterName: "CDKN1C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KIP2", GeneMasterName: "CDKN1C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "p57Kip2", GeneMasterName: "CDKN1C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CF", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRP7", GeneMasterName: "CFTR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AT mutated", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AT protein", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AT1", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATA", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "ataxia telangiectasia mutated", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ataxia telangiectasia mutated protein", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ataxia telangiectasia mutated (includes complementation groups A, C and D)", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATD", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATC", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATDC", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATE", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATM_HUMAN", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "human phosphatidylinositol 3-kinase homolog", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "serine-protein kinase ATM", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TEL1", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TELO1", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1 Associated RING Domain 1", GeneMasterName: "BARD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RING-Type E3 Ubiquitin Transferase BARD1", GeneMasterName: "BARD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BARD-1", GeneMasterName: "BARD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.3.2.27", GeneMasterName: "BARD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Protein Phosphatase 1, Regulatory Subunit 46", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Deleted In Polyposis 2.5", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Adenomatosis Polyposis Coli Tumor Suppressor", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Truncated Adenomatosis Polyposis Coli", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BTPS2", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11.1", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATM Serine/Threonine Kinase", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ACVRLK3", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ALK3", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BMR1A_HUMAN", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "bone morphogenetic protein receptor type IA", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD292", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SKR5", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "serine/threonine-protein kinase receptor R5", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Activin Receptor-Like Kinase 3", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BMP Type-1A Receptor", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11.30", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BMPR-1A", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ALK-3", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Activin A Receptor, Type II-Like Kinase 3", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD292 Antigen", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCC1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 1 gene", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 1, early onset gene", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer type 1 susceptibility gene", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer type 1 susceptibility protein", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IRIS", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PPP1R53", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PSCP", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RNF53", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1, DNA Repair Associated", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Protein Phosphatase 1, Regulatory Subunit 53", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1/BRCA2-Containing Complex, Subunit 1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Fanconi Anemia, Complementation Group S", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RING Finger Protein 53", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1_HUMAN", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Breast And Ovarian Cancer Susceptibility Protein 1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RING-Type E3 Ubiquitin Transferase BRCA1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.3.2.27", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 6.3.2", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BROVCA1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCAI", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCS", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PNCA4", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA2_HUMAN
BRCC2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 2 gene", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer 2, early onset gene", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer type 2 susceptibility protein", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "breast cancer type 2 susceptibility gene", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FACD", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAD", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAD1", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "FANCB", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA2, DNA Repair Associated", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1/BRCA2-Containing Complex, Subunit 2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Fanconi Anemia Group D1 Protein", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Breast And Ovarian Cancer Susceptibility Gene, Early Onset", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Breast And Ovarian Cancer Susceptibility Protein 2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Fanconi Anemia, Complementation Group D1", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Truncated Breast Cancer 2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Breast Cancer 2 Tumor Suppressor", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BROVCA2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XRCC11", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCC2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PNCA2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "FANCD", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GLM3", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "BACH1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1-Interacting Protein C-Terminal Helicase 1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1-Associated C-Terminal Helicase 1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1/BRCA2-Associated Helicase 1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATP-Dependent RNA Helicase BRIP1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCA1-Binding Helicase-Like Protein BACH1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Fanconi Anemia Group J Protein", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.6.4.13", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.6.1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Arc-1", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CADH1_HUMAN", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cadherin 1, type 1", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Calcium-Dependent Adhesion Protein, Epithelial", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CAM 120/80", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD324", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDHE", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cell-CAM 120/80", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ECAD", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LCAM", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "liver cell adhesion molecule", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "UVO", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "uvomorulin", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cadherin 1, type 1, E-cadherin (epithelial)", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD324 Antigen", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "multiple tumor suppressor 1", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase 4 inhibitor A", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase inhibitor 2A", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase inhibitor 2A isoform p12", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase inhibitor 2A isoform p14ARF", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase inhibitor 2A isoform p16INK4a", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cyclin-dependent kinase inhibitor 2A isoform p16gamma", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cell Cycle Negative Regulator Beta", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Alternative Reading Frame", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CMM3", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PSK-J3", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cyclin Dependent Kinase 4", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cell Division Protein Kinase 4", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11.22", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cyclin-Dependent Kinase 4", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDS1", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cds1 kinase", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Checkpoint-Like Protein CHK2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CHK2 checkpoint homolog (S. pombe)", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Chk2 protein kinase", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CHK2_HUMAN", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCds1 protein", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCHK2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HuCds1", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD53", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Serine/Threonine-Protein Kinase CHK2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HCds1", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CHK2 (Checkpoint, S.Pombe) Homolog", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11.1", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PP1425", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LFS2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "17-1A", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "323/A3", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CD326", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CO-17A", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGP-2", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGP34", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGP40", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Ep-CAM", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "epithelial cell adhesion molecule precursor", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "epithelial glycoprotein 314", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ESA", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GA733-2", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HEA125", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "human epithelial glycoprotein-2", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KS1/4", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KSA", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Ly74", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "M4S1", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MH99", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MIC18", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MK-1", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MOC31", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TACST-1", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TACSTD1", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TROP1", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "tumor-associated calcium signal transducer 1", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Major Gastrointestinal Tumor-Associated Protein GA733-2", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Adenocarcinoma-Associated Antigen", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Membrane Component, Chromosome 4, Surface Marker (35kD Glycoprotein)", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Antigen Identified By Monoclonal Antibody AUA1", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Epithelial Cell Surface Antigen", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Epithelial Glycoprotein", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KS 1/4 Antigen", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HEGP314", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC8", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DIAR5", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "M1S2", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGP", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PSGD", GeneMasterName: "HOXB13"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "C15DUPq", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CKTSF1B1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CRAC1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CRCS4", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DAND2", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DRM", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DUP15q", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GREMLIN", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HMPS", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HMPS1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IHG-2", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MPSH", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PIG2", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Gremlin 1, DAN Family BMP Antagonist", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cysteine Knot Superfamily 1, BMP Antagonist 1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Down-Regulated In Mos-Transformed Cells Protein", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cell Proliferation-Inducing Gene 2 Protein", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Colorectal Adenoma And Carcinoma 1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DAN Domain Family Member 2", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Gremlin 1, Cysteine Knot Superfamily, Homolog (Xenopus Laevis)", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Increased In High Glucose Protein 2", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Increased In High Glucose-2", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Gremlin 1-Like Protein", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Gremlin 1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Gremlin-1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Homeobox Protein Hox-B13", GeneMasterName: "HOXB13"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HXB13_HUMAN", GeneMasterName: "HOXB13"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Homeobox B13", GeneMasterName: "HOXB13"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Homeo Box B13", GeneMasterName: "HOXB13"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "COCA2", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FCC2", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC2", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MLH1_HUMAN", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutL (E. coli) homolog 1 (colon cancer, nonpolyposis type 2)", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MutL protein homolog 1", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MutL Homolog 1", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Mismatch Repair Protein Mlh1", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "COCA1", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC1", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH2_HUMAN", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutS (E. coli) homolog 2 (colon cancer, nonpolyposis type 1)", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutS (E. coli) homolog 2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MutS Homolog 2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FCC1", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LCFS2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MutS Protein Homolog 2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Mismatch Repair Protein MSH2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Mismatch Repair Protein MSH6", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "G/T mismatch-binding protein", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GTBP", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GTMBP", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC5", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH6_HUMAN", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutS (E. coli) homolog 6", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MutS-alpha 160 kDa subunit", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutS homolog 6 (E. coli)", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P160", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MutS Protein Homolog 6", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Sperm-Associated Protein", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HSAP", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hMYH", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MUTYH_HUMAN", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "mutY homolog", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutY homolog (E. coli)", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutY (E. coli) homolog", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.2.2", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MutY-Like Protein", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Adenine DNA Glycosylase", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "A/G-Specific Adenine DNA Glycosylase", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MutY DNA Glycosylase", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AT-V1", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AT-V2", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATV", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBN_HUMAN", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBS", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "p95 protein of the MRE11/RAD50 complex", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Nijmegen breakage syndrome 1", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Nibrin", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Cell Cycle Regulatory Protein P95", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P95", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PNCA3", GeneMasterName: "PALB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Fanconi Anemia, Complementation Group N", GeneMasterName: "PALB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA mismatch repair gene homologue", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HNPCC4", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MLH4", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS2-C terminal -like", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS2 postmeiotic segregation increased 2 (S. cerevisiae)", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS2_HUMAN", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS2CL", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMSL2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "postmeiotic segregation increased (S. cerevisiae) 2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "PMS1 Homolog 2, Mismatch Repair System Component", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS1 Homolog 2, Mismatch Repair Protein", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS1 Protein Homolog 2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Postmeiotic Segregation Increased 2 Nirs Variant 6", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mismatch Repair Endonuclease PMS2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.1.-.-", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDC2", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CRCS10", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MDPL", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "POLD", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "DNA Polymerase Delta 1, Catalytic Subunit", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Polymerase (DNA) Delta 1, Catalytic Subunit", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Polymerase Subunit Delta P125", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.7.7", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Polymerase (DNA Directed), Delta 1, Catalytic Subunit (125kD)", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDC2 Homolog (S. Cerevisiae)", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDC2 Homolog", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.1.11.-", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CRCS12", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FILS", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "POLE1", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Polymerase Epsilon, Catalytic Subunit", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Polymerase Epsilon Catalytic Subunit A", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Polymerase II Subunit A", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.7.7", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.7", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Polymerase (DNA Directed), Epsilon, Catalytic Subunit", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Polymerase (DNA Directed), Epsilon", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Polymerase Epsilon Catalytic Subunit Protein", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MMAC1", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mutated in multiple advanced cancers 1", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "phosphatase and tensin homolog (mutated in multiple advanced cancers 1)", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "phosphatase and tensin homolog deleted on chromosome 10", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "protein-tyrosine phosphatase PTEN", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTEN-MMAC1 protein", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTEN1", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTEN_HUMAN", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TEP1", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TEP1 phosphatase", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Phosphatase And Tensin Homolog", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Phosphatidylinositol-3,4,5-Trisphosphate 3-Phosphatase And Dual-Specificity Protein Phosphatase PTEN", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MMAC1 Phosphatase And Tensin Homolog Deleted On Chromosome 10", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mitochondrial Phosphatase And Tensin Protein Alpha", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Phosphatase And Tensin-Like Protein", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mitochondrial PTENalpha", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.1.3.16", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.1.3.48", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.1.3.67", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTENbeta", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GLM2", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MHAM", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DEC", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BZS", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CWS1", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBSLD", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD502", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD50 Double Strand Break Repair Protein", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RAD50 Homolog, Double Strand Break Repair Protein", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD50 (S. Cerevisiae) Homolog", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA Repair Protein RAD50", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.6.3.27", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.6.1.15", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.6.-.-", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 3.6.3", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BROVCA3", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCO", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "R51H3", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51L2", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51 Paralog C", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51-Like Protein 2", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "DNA Repair Protein RAD51 Homolog 3", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51 (S. Cerevisiae) Homolog C", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51 Homolog C (S. Cerevisiae)", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Yeast RAD51 Homolog 3", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RAD51 Homolog C", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BROVCA4", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "R51H3", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51L3", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "DNA Repair Protein RAD51 Homolog 4", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RAD51 Paralog D", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Recombination Repair Protein", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51-Like Protein D", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51 Homolog D", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRAD", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51 Homolog D (S. Cerevisiae)", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51 (S. Cerevisiae)-Like 3", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51-Like 3 (S. Cerevisiae)", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DPC4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "JIP", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MAD (mothers against decapentaplegic, Drosophila) homolog 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MAD, mothers against decapentaplegic homolog 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MAD, mothers against decapentaplegic homolog 4 (Drosophila)", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MADH4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Mothers against decapentaplegic, Drosophila, homolog of, 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "SMAD, mothers against DPP homolog 4 (Drosophila)", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMAD4_HUMAN", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMAD Family Member 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Deletion Target In Pancreatic Carcinoma 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MAD Homolog 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mothers Against Decapentaplegic Homolog 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Deleted In Pancreatic Carcinoma Locus 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMAD, Mothers Against DPP Homolog 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mothers Against DPP Homolog 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMAD 4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MYHRS", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LKB1", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PJS", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "STK11_HUMAN", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "serine/threonine kinase 11 (Peutz-Jeghers syndrome)", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Serine/threonine-protein kinase 11", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Serine/Threonine Kinase 11", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Polarization-Related Protein LKB1", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Renal Carcinoma Antigen NY-REN-19", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Liver Kinase B1", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EC 2.7.11.1", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HLKB1", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Serine/Threonine-Protein Kinase STK11", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Serine/Threonine-Protein Kinase LKB11", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cellular tumor antigen p53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P53 tumor suppressor", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P53_HUMAN", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "phosphoprotein p53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "transformation-related protein 53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TRP53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "tumor protein p53 (Li-Fraumeni syndrome)", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "tumor suppressor p53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Tumor Protein P53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Antigen NY-CO-13", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mutant Tumor Protein 53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Li-Fraumeni Syndrome", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Tumor Supressor P53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Tumor Protein 53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BCC7", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LFS1", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "FANCD1", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "DNA-mismatch-repair", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "HNPCC", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "lynch syndrome", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "retinoblastoma 1", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "retinoblastoma-1", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RB1", GeneMasterName: "RB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CHEK2/1100delC", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MUTYH-Biallelic", GeneMasterName: "MUTYH-Biallelic"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MUTYH-Biallelic/Compound Heterozygous
MUTYH-Biallelic/Compound Heterozygous", GeneMasterName: "MUTYH-Biallelic/Compound Heterozygous
MUTYH-Biallelic/Compound Heterozygous"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MUTYH-Biallelic/G396D", GeneMasterName: "MUTYH-Biallelic/G396D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MUTYH-Monoallelic", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBN/657del5", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ataxia-telangiectasia (A-T) gene", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "LKB1", GeneMasterName: "LKB1"})
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ABCC9", GeneMasterName: "ABCC9"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ACTC", GeneMasterName: "ACTC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ACTN2", GeneMasterName: "ACTN2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "APC", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hAPC", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "ATM", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hATM", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "A-T mutation", GeneMasterName: "ATM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "BARD1", GeneMasterName: "BARD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hBARD1", GeneMasterName: "BARD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "BMPR1A", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hBMPR1A", GeneMasterName: "BMPR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "BRCA", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hBRCA", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "BRCA1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "17q-linked", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hBRCA1", GeneMasterName: "BRCA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "BRCA2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hBRCA2", GeneMasterName: "BRCA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "FANCJ", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "BRIP1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hBRIP1", GeneMasterName: "BRIP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "epithelial cadherin", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CDH1", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "e-cadherin", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "epithelial-cadherin", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cadherin", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCDH1", GeneMasterName: "CDH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CDK4", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCDK4", GeneMasterName: "CDK4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CDKN1B", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "P14", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "ARF", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CMM2", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "INK4A", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MLM", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MTS1", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CDK4I", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CDKN2A", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "P16", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "TP16", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "P19", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P14ARF", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDKN2", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "INK4", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P16INK4A", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P16INK4", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MTS-1", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P16-INK4A", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P19ARF", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCDKN2A/p14", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDKN2A/p14", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCDKN2A/p16", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDKN2A/p16", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "p16", GeneMasterName: "CDKN2A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CHEK1", GeneMasterName: "CHEK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "CHEK2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Checkpoint kinase 2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CHK2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hCHEK2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cell cycle checkpoint kinase 2", GeneMasterName: "CHEK2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CSRP3", GeneMasterName: "CSRP3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTF1", GeneMasterName: "CTF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DES", GeneMasterName: "DES"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DSC2", GeneMasterName: "DSC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DSG2", GeneMasterName: "DSG2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DSP", GeneMasterName: "DSP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EMD", GeneMasterName: "EMD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "EPCAM", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Epithelial cell adhesion molecule", GeneMasterName: "EPCAM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hEPCAM", GeneMasterName: "EPCAM"})
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GLA", GeneMasterName: "GLA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "GREM1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hGREM1", GeneMasterName: "GREM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HOXB13", GeneMasterName: "HOXB13"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LAMP2", GeneMasterName: "LAMP2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LDB3", GeneMasterName: "LDB3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LMNA", GeneMasterName: "LMNA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MMR", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "DNA Mismatch Repair gene", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mismatch repair mmr genes", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mismatch repair", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "mismatch repair (mmr) genes", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mismatch Repair genes", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "dna mismatch-repair", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "dna mismatch repair mmr", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA mismatch repair", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DNA-mismatch repair", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "Mismatch Repair gene", GeneMasterName: "Lynch Gene"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Menin", GeneMasterName: "MEN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MEN1", GeneMasterName: "MEN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MLH1", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Mutl Homolog", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hMLH1", GeneMasterName: "MLH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MLH3", GeneMasterName: "MLH3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MSH2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hMSH2", GeneMasterName: "MSH2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MSH6", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hMSH6", GeneMasterName: "MSH6"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MSI", GeneMasterName: "MSI"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Microsatellite Instability", GeneMasterName: "MSI"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "msi-h", GeneMasterName: "MSI"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "microsatellite-stable", GeneMasterName: "MSI"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MUTYH Biallelic", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MYH", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MUTYH Monoallelic", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "MUTYH", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hMUTYH Monoallelic", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hMUTYH Biallelic", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hmutyh", GeneMasterName: "MUTYH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MYBPC3", GeneMasterName: "MYBPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MYH7", GeneMasterName: "MYH7"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MYL2", GeneMasterName: "MYL2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MYL3", GeneMasterName: "MYL3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "NBS1", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "NBN", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NBN/NBS1", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hNBN", GeneMasterName: "NBN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "NF1", GeneMasterName: "NF1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "NF2", GeneMasterName: "NF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "FANCN", GeneMasterName: "PALB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Partner and Localizer Of BRCA2", GeneMasterName: "PALB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PALB2", GeneMasterName: "PALB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hPALB2", GeneMasterName: "PALB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PKP2", GeneMasterName: "PKP2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PLN", GeneMasterName: "PLN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "PMS1", GeneMasterName: "PMS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hPMS1", GeneMasterName: "PMS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "PMS2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hPMS2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "POLD1", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hPOLD1", GeneMasterName: "POLD1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "POLE", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hPOLE", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PRKAG2", GeneMasterName: "PRKAG2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "PTEN", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hPTEN", GeneMasterName: "PTEN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RAD50", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hRAD50", GeneMasterName: "RAD50"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RAD51", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RAD51C", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hRAD51C", GeneMasterName: "RAD51C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RAD51D", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hRAD51D", GeneMasterName: "RAD51D"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "RET", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "SDHA", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "SDHAF2", GeneMasterName: "SDHAF2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "SDHB", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "SDHC", GeneMasterName: "SDHC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "SDHD", GeneMasterName: "SDHD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SGCD", GeneMasterName: "SGCD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "SMAD4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hSMAD4", GeneMasterName: "SMAD4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "STK11", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hSTK11", GeneMasterName: "STK11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TAZ", GeneMasterName: "TAZ"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TCAP", GeneMasterName: "TCAP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TMEM43", GeneMasterName: "TMEM43"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TNNI3", GeneMasterName: "TNNI3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TNNT2", GeneMasterName: "TNNT2"})
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
()
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "TP53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "P53", GeneMasterName: "TP53"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TPM1", GeneMasterName: "TPM1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "VCL", GeneMasterName: "VCL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "VHL", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "adenomatous polyposis coli", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "APC_HUMAN", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DP2", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DP2.5", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DP3", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "FAP", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FPC", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GS", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PPP1R46", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WNT signaling pathway regulator", GeneMasterName: "APC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BAP1", GeneMasterName: "BAP1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MITF", GeneMasterName: "MITF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BLM", GeneMasterName: "BLM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DICER1", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCC", GeneMasterName: "FANCC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FH", GeneMasterName: "FH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GALNT12", GeneMasterName: "GALNT12"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MAX", GeneMasterName: "MAX"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MET", GeneMasterName: "MET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MRE11A", GeneMasterName: "MRE11"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMARCA4", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TMEM127", GeneMasterName: "TMEM127"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TSC1", GeneMasterName: "TSC1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TSC2", GeneMasterName: "TSC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "XRCC2", GeneMasterName: "XRCC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ALK", GeneMasterName: "ALK"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PHOX2B", GeneMasterName: "PHOX2B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PRKAR1A", GeneMasterName: "PRKAR1A"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PTCH1", GeneMasterName: "PTCH1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMARCB1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SUFU", GeneMasterName: "SUFU"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "POT1", GeneMasterName: "POT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SMARCE1", GeneMasterName: "SMARCE1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AIP", GeneMasterName: "AIP"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "NTHL1", GeneMasterName: "NTHL1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "AXIN2", GeneMasterName: "AXIN2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDC73", GeneMasterName: "CDC73"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTNNA1", GeneMasterName: "CTNNA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PIK3CA", GeneMasterName: "PIK3CA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCA", GeneMasterName: "FANCA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCE", GeneMasterName: "FANCE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCF", GeneMasterName: "FANCF"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCG", GeneMasterName: "FANCG"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCI", GeneMasterName: "FANCI"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCL", GeneMasterName: "FANCL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "KIT", GeneMasterName: "KIT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PDGFRA", GeneMasterName: "PDGFRA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SLX4", GeneMasterName: "SLX4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PRSS1", GeneMasterName: "PRSS1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MSH3", GeneMasterName: "MSH3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RPS20", GeneMasterName: "RPS20"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CASR", GeneMasterName: "CASR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WT1", GeneMasterName: "WT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCD2", GeneMasterName: "FANCD2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BUB1B", GeneMasterName: "BUB1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CEBPA", GeneMasterName: "CEBPA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DIS3L2", GeneMasterName: "DIS3L2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EGFR", GeneMasterName: "EGFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC4", GeneMasterName: "ERCC4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FANCM", GeneMasterName: "FANCM"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GATA2", GeneMasterName: "GATA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HRAS", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECQL4", GeneMasterName: "RECQL4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RUNX1", GeneMasterName: "RUNX1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "WRN", GeneMasterName: "WRN"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TERC", GeneMasterName: "TERC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "TERT", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "GPC3", GeneMasterName: "GPC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDKN1C", GeneMasterName: "CDKN1C"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "SPINK1", GeneMasterName: "SPINK1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTFR", GeneMasterName: "CTFR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CTRC", GeneMasterName: "CTRC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CPA1", GeneMasterName: "CPA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ATR", GeneMasterName: "ATR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CYLD", GeneMasterName: "CYLD"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "DDB2", GeneMasterName: "DDB2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC2", GeneMasterName: "ERCC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC3", GeneMasterName: "ERCC3"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ERCC5", GeneMasterName: "ERCC5"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EXT1", GeneMasterName: "EXT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "EXT2", GeneMasterName: "EXT2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "FAH", GeneMasterName: "FAH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LDLR", GeneMasterName: "LDLR"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "PMS2 postmeiotic segregation increased 2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "postmeiotic segregation increased 2", GeneMasterName: "PMS2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IMAGEI", GeneMasterName: "POLE"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "BRCC5", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "DNA repair protein RAD51 homolog 1", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HRAD51", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HsRAD51", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51 homolog", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51_HUMAN", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RAD51A", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RECA", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RecA-like protein", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "RecA, E. coli, homolog of", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "recombination protein A", GeneMasterName: "RAD51"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "cadherin family member 12", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "cadherin-related family member 16", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDHF12", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "CDHR16", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HSCR1", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hydroxyaryl-protein kinase", GeneMasterName: "RET"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MEN2A", GeneMasterName: "RET"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Neurosurgery", Organ_System: "Brain"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Neurology", Organ_System: "Brain"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Breast Surgery", Organ_System: "Breast"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Medical Oncology", Organ_System: "Breast"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gynecologic Oncology", Organ_System: "Cervix"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Neurology", Organ_System: "CNS"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Neurosurgery", Organ_System: "CNS"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Colorectal surgery", Organ_System: "Colorectal"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Colorectal"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Duodenal"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Duodenal"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrine Surgery", Organ_System: "Endocrine"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrinology", Organ_System: "Endocrine"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Esophagus"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Ophthalmology", Organ_System: "Eye"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Gallbladder"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Gallbladder"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Gastric"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Gastric"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Genitals"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gynecology", Organ_System: "Genitals"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "GI"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "GI"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Medical Oncology", Organ_System: "Kidney"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Kidney"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Liver"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Medical Oncology", Organ_System: "Lung"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Pulmonology", Organ_System: "Lung"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Mediastinum"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Mesothelium"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrinology", Organ_System: "Metabolic"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrinology", Organ_System: "Neuroendocrine"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrine Surgery", Organ_System: "Neuroendocrine"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Hematology", Organ_System: "Nodes"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gynecologic Oncology", Organ_System: "Ovary"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Pancreas"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Hepatobiliary Surgery", Organ_System: "Pancreas"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrinology", Organ_System: "Parathyroid"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrine Surgery", Organ_System: "Parathyroid"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Prostate"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Genetic Counselor", Organ_System: "Psychosocial"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Dermatology", Organ_System: "Skin"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Dentist/Orthodontist", Organ_System: "Teeth"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Dentist", Organ_System: "Teeth"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Testes"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Upper Urinary Tract"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Ureter"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Urinary Bladder"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gynecologic Oncology", Organ_System: "Uterus"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gynecologic Oncology", Organ_System: "Uterine"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Orthopedic Oncology", Organ_System: "Bone"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Desmoid"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Diaphragm"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Head and Neck", Organ_System: "Ear"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Head and Neck", Organ_System: "ENT"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Thoracic", Organ_System: "Heart"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Hematologist", Organ_System: "Hematologic"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Hematologist", Organ_System: "Lymphatic"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrinology", Organ_System: "Neural Crest"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrinology", Organ_System: "Pituitary"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "PNS"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Orthopedics", Organ_System: "Skeletal"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Small Bowel"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "SNS"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Soft Tissue"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Testicular"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Thoracic", Organ_System: "Thymus"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Thoracic", Organ_System: "Thyroid"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "UGI"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Urology", Organ_System: "Urothelial"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Unknown", Organ_System: "Vascular"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Pediatric surgery", Organ_System: "Kidney"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Endocrine Surgery", Organ_System: "Neural Crest"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Neurosurgery", Organ_System: "Pituitary"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "Small Bowel"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "UGI"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Surgical Oncology", Organ_System: "UGI-Small Bowel"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "UGI-Small Bowel"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "Gastroenterology", Organ_System: "Bile Duct"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "All", Organ_System: "General"})
(:LKP_SPECIALISTS_BY_ORGAN {PrimarySpecialist: "All", Organ_System: "Referral"})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Unknown", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Breast Surgery", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Colorectal surgery", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Dentist", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Dentist/Orthodontist", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Dermatology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Endocrine Surgery", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Endocrinology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Gastroenterology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Genetic Counselor", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Gynecologic Oncology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Gynecology", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Head and Neck", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Hematologist", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Hematology", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Hepatobiliary Surgery", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Medical Oncology", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Neurology", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Neurosurgery", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Ophthalmology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Orthopedic Oncology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Orthopedics", ShowAsWebsite_1Yes: 0})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Pediatric surgery", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Pulmonology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Surgical Oncology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Thoracic", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_WEBSITE {PrimarySpecialist: "Urology", ShowAsWebsite_1Yes: 1})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Breast Surgery", GeneMasterName: "BRCA2"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Breast Surgery", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Colorectal surgery", GeneMasterName: "CHEK2"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Colorectal surgery", GeneMasterName: "EPCAM"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Dermatology", GeneMasterName: "BRCA2"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Dermatology", GeneMasterName: "PMS2"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Endocrine Surgery	", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Endocrinology", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Gastroenterology	", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Gynecologic Oncology	", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Hepatobiliary Surgery	", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Neurosurgery	BRCA1", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Ophthalmology	BRCA1", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Orthopedic Oncology	BRCA1", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Pediatric surgery	BRCA1", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Pulmonology	BRCA1", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Surgical Oncology", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Thoracic", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Urology", GeneMasterName: "MLH1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Urology", GeneMasterName: "MSH2"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Generic", GeneMasterName: "BRCA1"})
(:LKP_SPECIALIST_PREFERREDGENES {PrimarySpecialist: "Generic", GeneMasterName: "BRCA2"})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 39.61, gender: "Female", gene: "ATM", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 8.34, organ: "Colorectal", gender: "Male", gene: "ATM", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 7.08, gender: "Female", gene: "ATM", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 4.32, organ: "Gastric", gender: "Male", gene: "ATM", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 2.51, gender: "Female", gene: "ATM", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 5.02, organ: "Pancreas", gender: "Male", gene: "ATM", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 4.47, gender: "Female", gene: "ATM", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 28.87, organ: "Prostate", gender: "Male", gene: "ATM", cancer: "Prostate", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 26.17, gender: "Female", gene: "BARD1", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 4.76, gender: "Female", gene: "BARD1", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 68.57, gender: "Female", gene: "BRCA1", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 67.76, gender: "Female", gene: "BRCA1", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 5.43, gender: "Male", gene: "BRCA1", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 4.82, gender: "Female", gene: "BRCA1", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 61.1, gender: "Female", gene: "BRCA2", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 12.86, gender: "Male", gene: "BRCA2", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 36.46, gender: "Female", gene: "BRCA2", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 7.64, gender: "Male", gene: "BRCA2", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 6.8, gender: "Female", gene: "BRCA2", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Prostate", maxofcr85: 21.46, gender: "Male", gene: "BRCA2", cancer: "Prostate", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 5.55, gender: "Female", gene: "BRIP1", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 57.03, gender: "Female", gene: "CDH1", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 70.63, organ: "Gastric", gender: "Male", gene: "CDH1", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 55.48, gender: "Female", gene: "CDH1", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 46.59, organ: "Unknown", gender: "Male", gene: "CDK4", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 37.94, gender: "Female", gene: "CDK4", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 46.29, gender: "Male", gene: "CDKN2A/p16", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 37.63, gender: "Female", gene: "CDKN2A/p16", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 28.61, gender: "Male", gene: "CDKN2A/p16", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 24.39, gender: "Female", gene: "CDKN2A/p16", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 23.47, organ: "Breast", gender: "Female", gene: "CHEK2/1100delC", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 7.96, organ: "Colorectal", gender: "Male", gene: "CHEK2/1100delC", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 6.75, organ: "Colorectal", gender: "Female", gene: "CHEK2/1100delC", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 6.58, organ: "Kidney", gender: "Female", gene: "CHEK2/1100delC", cancer: "Kidney", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 3.81, organ: "Kidney", gender: "Male", gene: "CHEK2/1100delC", cancer: "Kidney", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 46.61, organ: "Prostate", gender: "Male", gene: "CHEK2/1100delC", cancer: "Prostate", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 89.8, organ: "Colorectal", gender: "Male", gene: "EPCAM", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 79.5, gender: "Female", gene: "EPCAM", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Prostate", maxofcr85: 53.47, gender: "Male", gene: "HOXB13", cancer: "Prostate", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 1.41, organ: "Brain", gender: "Male", gene: "MLH1", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Brain", maxofcr85: 1.02, gender: "Female", gene: "MLH1", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 51.13, gender: "Female", gene: "MLH1", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 41.65, organ: "Colorectal", gender: "Male", gene: "MLH1", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 21.13, gender: "Female", gene: "MLH1", cancer: "Endometrial", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 28.27, organ: "Gastric", gender: "Male", gene: "MLH1", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 13.71, gender: "Female", gene: "MLH1", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 5.26, gender: "Female", gene: "MLH1", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 6.83, organ: "Pancreas", gender: "Male", gene: "MLH1", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 6.56, gender: "Female", gene: "MLH1", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 9.88, gender: "Male", gene: "MLH1", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 8.6, gender: "Female", gene: "MLH1", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 6.51, gender: "Male", gene: "MLH1", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 3.68, gender: "Female", gene: "MLH1", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 7.87, gender: "Male", gene: "MLH1", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 2.35, gender: "Female", gene: "MLH1", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Brain", maxofcr85: 3.24, gender: "Female", gene: "MSH2", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 2.64, organ: "Brain", gender: "Male", gene: "MSH2", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 60.93, organ: "Colorectal", gender: "Male", gene: "MSH2", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 45.74, gender: "Female", gene: "MSH2", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 30.71, gender: "Female", gene: "MSH2", cancer: "Endometrial", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 16.96, gender: "Female", gene: "MSH2", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 10.95, gender: "Female", gene: "MSH2", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 21.5, organ: "Pancreas", gender: "Male", gene: "MSH2", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 5.4, gender: "Female", gene: "MSH2", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 10.43, gender: "Male", gene: "MSH2", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 9.09, gender: "Female", gene: "MSH2", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 24.06, gender: "Male", gene: "MSH2", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 13.11, gender: "Female", gene: "MSH2", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 14.12, gender: "Male", gene: "MSH2", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 4.24, gender: "Female", gene: "MSH2", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Brain", maxofcr85: 3.24, gender: "Female", gene: "MSH6", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 2.64, organ: "Brain", gender: "Male", gene: "MSH6", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 40.72, organ: "Colorectal", gender: "Male", gene: "MSH6", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 32.82, gender: "Female", gene: "MSH6", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 17.46, gender: "Female", gene: "MSH6", cancer: "Endometrial", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 2.85, gender: "Female", gene: "MSH6", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 2.14, organ: "Gastric", gender: "Male", gene: "MSH6", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 13.76, gender: "Female", gene: "MSH6", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 3.47, gender: "Male", gene: "MSH6", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 2.93, gender: "Female", gene: "MSH6", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 4.69, gender: "Male", gene: "MSH6", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 2.57, gender: "Female", gene: "MSH6", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 14.27, gender: "Male", gene: "MSH6", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 4.28, gender: "Female", gene: "MSH6", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 14.27, organ: "Ovary", gender: "Female", gene: "MUTYH-Biallelic", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 37.73, gender: "Male", gene: "MUTYH-Biallelic", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 8.23, gender: "Female", gene: "MUTYH-Biallelic", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 58.39, gender: "Female", gene: "MUTYH-Biallelic/Compound Heterozygous", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 29.07, organ: "Colorectal", gender: "Male", gene: "MUTYH-Biallelic/Compound Heterozygous", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 55.01, organ: "Colorectal", gender: "Female", gene: "MUTYH-Biallelic/G396D", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 36.28, organ: "Colorectal", gender: "Male", gene: "MUTYH-Biallelic/G396D", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 14.02, organ: "Colorectal", gender: "Female", gene: "MUTYH-Monoallelic", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 11.27, organ: "Colorectal", gender: "Male", gene: "MUTYH-Monoallelic", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 4.26, organ: "Unknown", gender: "Female", gene: "MUTYH-Monoallelic", cancer: "Endometrial", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 5.62, organ: "Gastric", gender: "Male", gene: "MUTYH-Monoallelic", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 2.63, organ: "Gastric", gender: "Female", gene: "MUTYH-Monoallelic", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 3.39, organ: "Unknown", gender: "Male", gene: "MUTYH-Monoallelic", cancer: "Hepatobiliary", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 1.63, organ: "Unknown", gender: "Female", gene: "MUTYH-Monoallelic", cancer: "Hepatobiliary", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 35.77, gender: "Female", gene: "NBN/657del5", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Prostate", maxofcr85: 33.35, gender: "Male", gene: "NBN/657del5", cancer: "Prostate", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 22.09, organ: "Brain", gender: "Male", gene: "NF1", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Brain", maxofcr85: 16.35, gender: "Female", gene: "NF1", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 38.54, gender: "Female", gene: "NF1", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 14.68, organ: "Unknown", gender: "Female", gene: "NF1", cancer: "Malignant peripheral nerve sheath tumor", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 14.59, organ: "Unknown", gender: "Male", gene: "NF1", cancer: "Malignant peripheral nerve sheath tumor", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 44.53, gender: "Female", gene: "PALB2", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 7.64, gender: "Male", gene: "PALB2", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 6.8, gender: "Female", gene: "PALB2", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 21.39, organ: "Colorectal", gender: "Male", gene: "PMS2", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 12.81, gender: "Female", gene: "PMS2", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 12.9, gender: "Female", gene: "PMS2", cancer: "Endometrial", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 5.26, gender: "Female", gene: "PMS2", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 100.0, gender: "Male", gene: "POLD1", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 100.0, gender: "Female", gene: "POLD1", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 58.02, organ: "Colorectal", gender: "Male", gene: "POLE", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 48.02, gender: "Female", gene: "POLE", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Brain", maxofcr85: 0.57, gender: "Male", gene: "Population", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Brain", maxofcr85: 0.43, gender: "Female", gene: "Population", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 13.66, gender: "Female", gene: "Population", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 0.13, gender: "Male", gene: "Population", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 4.24, gender: "Male", gene: "Population", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 3.6, gender: "Female", gene: "Population", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 2.63, gender: "Female", gene: "Population", cancer: "Endometrial", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 0.91, gender: "Male", gene: "Population", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 0.53, gender: "Female", gene: "Population", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 1.22, gender: "Male", gene: "Population", cancer: "Hepatobiliary", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 0.46, gender: "Female", gene: "Population", cancer: "Hepatobiliary", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Kidney", maxofcr85: 1.88, gender: "Male", gene: "Population", cancer: "Kidney", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Kidney", maxofcr85: 1.87, gender: "Female", gene: "Population", cancer: "Kidney", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 1.39, gender: "Male", gene: "Population", cancer: "Leukemia", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 0.9, gender: "Female", gene: "Population", cancer: "Leukemia", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 0.0, gender: "Female", gene: "Population", cancer: "Malignant peripheral nerve sheath tumor", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 0.0, organ: "Unknown", gender: "Male", gene: "Population", cancer: "Malignant peripheral nerve sheath tumor", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 3.85, gender: "Male", gene: "Population", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 2.5, gender: "Female", gene: "Population", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 0.06, gender: "Male", gene: "Population", cancer: "Osteosarcoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 0.04, gender: "Female", gene: "Population", cancer: "Osteosarcoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 1.13, gender: "Female", gene: "Population", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 1.32, gender: "Male", gene: "Population", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Pancreas", maxofcr85: 1.17, gender: "Female", gene: "Population", cancer: "Pancreatic", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Prostate", maxofcr85: 13.31, gender: "Male", gene: "Population", cancer: "Prostate", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 0.25, gender: "Male", gene: "Population", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 0.21, organ: "Unknown", gender: "Female", gene: "Population", cancer: "Small Intestine", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 0.31, gender: "Male", gene: "Population", cancer: "Soft Tissue Sarcoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 0.23, organ: "Unknown", gender: "Female", gene: "Population", cancer: "Soft Tissue Sarcoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Thyroid", maxofcr85: 1.61, gender: "Female", gene: "Population", cancer: "Thyroid", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Thyroid", maxofcr85: 0.57, gender: "Male", gene: "Population", cancer: "Thyroid", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 1.88, gender: "Male", gene: "Population", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Upper Urinary Tract", maxofcr85: 1.06, gender: "Female", gene: "Population", cancer: "Upper Urinary Tract", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 3.14, gender: "Male", gene: "Population", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Urinary Bladder", maxofcr85: 0.89, gender: "Female", gene: "Population", cancer: "Urinary Bladder", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 92.54, gender: "Female", gene: "PTEN", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 13.96, organ: "Colorectal", gender: "Male", gene: "PTEN", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 12.29, gender: "Female", gene: "PTEN", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Endometrial", maxofcr85: 30.18, gender: "Female", gene: "PTEN", cancer: "Endometrial", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 39.45, organ: "Kidney", gender: "Male", gene: "PTEN", cancer: "Kidney", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Kidney", maxofcr85: 21.87, gender: "Female", gene: "PTEN", cancer: "Kidney", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 10.25, organ: "Unknown", gender: "Male", gene: "PTEN", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 7.59, gender: "Female", gene: "PTEN", cancer: "Melanoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Thyroid", maxofcr85: 51.92, gender: "Female", gene: "PTEN", cancer: "Thyroid", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 15.1, organ: "Thyroid", gender: "Male", gene: "PTEN", cancer: "Thyroid", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 5.89, gender: "Female", gene: "RAD51C", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Ovary", maxofcr85: 13.59, gender: "Female", gene: "RAD51D", cancer: "Ovarian", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 38.42, gender: "Female", gene: "STK11", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 16.6, gender: "Male", gene: "STK11", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Colorectal", maxofcr85: 14.27, gender: "Female", gene: "STK11", cancer: "Colorectal", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 37.76, gender: "Male", gene: "STK11", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Gastric", maxofcr85: 21.99, gender: "Female", gene: "STK11", cancer: "Gastric", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Brain", maxofcr85: 12.07, gender: "Female", gene: "TP53", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 1.49, organ: "Brain", gender: "Male", gene: "TP53", cancer: "Brain", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Breast", maxofcr85: 62.23, gender: "Female", gene: "TP53", cancer: "Breast", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 1.48, organ: "Unknown", gender: "Male", gene: "TP53", cancer: "Leukemia", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 1.4, gender: "Female", gene: "TP53", cancer: "Leukemia", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 2.03, gender: "Female", gene: "TP53", cancer: "Osteosarcoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {maxofcr85: 0.67, organ: "Unknown", gender: "Male", gene: "TP53", cancer: "Osteosarcoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 17.86, gender: "Male", gene: "TP53", cancer: "Soft Tissue Sarcoma", age: 25})
(:LKP_MASTER_RISKTO85FORGRAPH {organ: "Unknown", maxofcr85: 10.17, gender: "Female", gene: "TP53", cancer: "Soft Tissue Sarcoma", age: 25})
(:gene {name: "MLH1, MSH2, PMS2, MSH6", fullName: "LynchGenesMinusEPCAM_ForPrevalenceQueryUse", mechanism: "Unknown"})
(:gene {name: "TSC1/2", fullName: "_ForPrevalenceQueryUse", mechanism: "Unknown"})
(:gene {references: "19372699) Li CC,McDonald SD. Increased nuchal translucency and other ultrasound findings in a case of simpson-golabi-behmel syndrome. Fetal Diagn Ther.. 2009;25(2):211-5.|24115482) Villarreal DD,Villarreal H,Paez AM,Peppas D,Lynch J,Roeder E,Powers GC. A patient with a unique frameshift mutation in GPC3, causing Simpson-Golabi-Behmel syndrome, presenting with craniosynostosis, penoscrotal hypospadias, and a large prostatic utricle. Am J Med Genet A.. 2013;161A(12):3121-5.|25238977) Tenorio J,Arias P,Mart√É¬≠nez-Glez V,Santos F,Garc√É¬≠a-Mi√É¬±aur S,Nevado J,Lapunzina P. Simpson-Golabi-Behmel syndrome types I and II. Orphanet J Rare Dis.. 2014;9():138.", pmids: "19372699|24115482|25238977", name: "GPC3", description: "The GPC3 gene is associated with X-linked recessive Simpson-Golabi-Behmel syndrome (MedGen UID: 162917).  Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).

Simpson-Golabi-Behmel syndrome (SGBS) is characterized by pre- and postnatal overgrowth, characteristic facial features and visceromegaly. Clinical features include cleft lip or palate, heart defects and anomalies of the skeleton, kidneys and genitourinary system. SGBS is associated with an increased risk of Wilms tumor and other embryonal tumors such as hepatoblastoma, adrenal neuroblastoma, gonadoblastoma and hepatocellular carcinoma. Craniosynostosis has been reported in rare cases (PMID: 24115482, 19372699). All males are expected to have features of SGBS; however, there is variability in the clinical severity. Females are frequently unaffected but may also have clinical features of SGBS due to skewed X-inactivation (PMID: 25238977).", fullName: "Glypican 3", altName: "Glypican 3", mechanism: "Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2009]"})
(:gene {references: "Unknown", pmids: "Unknown", name: "HRAS", description: "The HRAS gene is associated with autosomal dominant Costello syndrome (MedGen UID: 108454).  Costello syndrome is characterized by intellectual disability, failure to thrive, cardiac malformations, short stature, loose skin with deep palmar and plantar creases, cerebellar overgrowth, predisposition to malignancy, and dysmorphic facial features including coarse facies, epicanthal folds, long eyelashes, sparse/curly hair, full lips, and a wide nasal bridge.", fullName: "GTPase Hras", mechanism: "HRAS encodes a protein part of the RAS/MAPK pathway. This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus."})
(:gene {references: "15241338) Akin C,Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol.. 2004;114(1):13-9; quiz 20.|19555431) Dessinioti C,Stratigos AJ,Rigopoulos D,Katsambas AD. A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol.. 2009;18(9):741-9.|23648119) Bachet JB,Landi B,Laurent-Puig P,Italiano A,Le Cesne A,L√É¬©vy P,Safar V,Duffaud F,Blay JY,Emile JF. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. Eur J Cancer.. 2013;49(11):2531-41.|26833487) Watson GA,Kelly D,Melland-Smith M,Gleeson J,McEntee G,Kelly CM,McCaffrey JA. Get the GIST? An overview of gastrointestinal stromal tumours. Ir J Med Sci.. 2016;185(2):319-26.|27777718) Ke H,Kazi JU,Zhao H,Sun J. Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis. Cell Biosci.. 2016;6():55.|28031180) Valent P,Akin C,Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood.. 2017;129(11):1420-1427.|7525736) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Molecular basis of human piebaldism. J Invest Dermatol.. 1994;103(5 Suppl):137S-140S.|7529964) Ezoe K,Holmes SA,Ho L,Bennett CP,Bolognia JL,Brueton L,Burn J,Falabella R,Gatto EM,Ishii N. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. Am J Hum Genet.. 1995;56(1):58-66.|9438854) Hirota S,Isozaki K,Moriyama Y,Hashimoto K,Nishida T,Ishiguro S,Kawano K,Hanada M,Kurata A,Takeda M,Muhammad Tunio G,Matsuzawa Y,Kanakura Y,Shinomura Y,Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science.. 1998;279(5350):577-80.", pmids: "7525736|7529964|9438854|15241338|19555431|23648119|26833487|27777718|28031180", name: "KIT", fullName: "KIT Proto-Oncogene, Receptor Tyrosine Kinase", description: "The KIT gene is associated with autosomal dominant piebaldism (MedGen UID: 36361), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and familial mastocytosis (MedGen UID: 9902).  Pathogenic loss-of-function (LOF) variants in KIT are associated with piebaldism, a rare condition characterized by patchy absence of melanocytes in the skin and hair. These unpigmented areas are typically present at birth and do not increase in size or number (PMID: 19555431, 7529964, 7525736). LOF pathogenic KIT variants are generally not associated with familial GIST or mastocytosis (PMID: 15241338). 

Pathogenic gain-of-function (GOF) KIT variants are associated with familial GIST and familial mastocytosis. Familial GIST is a primarily adult-onset condition characterized by sarcomas of the stomach and small bowel that may be benign or malignant (PMID: 23648119, 26833487, 9438854). Familial mastocytosis causes abnormal accumulation of mast cells in the skin and bone marrow (PMID: 27777718, 28031180). In childhood, this condition is known as cutaneous mastocytosis because it manifests in the skin, often resolving by puberty. Adult-onset cases are known as systemic mastocytosis due to involvement of the bone marrow and skin, with potential risks for hematologic malignancy (PMID: 27777718, 28031180). Some individuals with pathogenic GOF KIT variants may present with features of both GIST and mastocytosis (PMID: 27777718). Pathogenic GOF variants in KIT are generally not associated with piebaldism (PMID: 15241338).", mechanism: "This gene encodes a receptor tyrosine kinase. This gene was initially identified as a homolog of the feline sarcoma viral oncogene v-kit and is often referred to as proto-oncogene c-Kit. The canonical form of this glycosylated transmembrane protein has an N-terminal extracellular region with five immunoglobulin-like domains, a transmembrane region, and an intracellular tyrosine kinase domain at the C-terminus. Upon activation by its cytokine ligand, stem cell factor (SCF), this protein phosphorylates multiple intracellular proteins that play a role in in the proliferation, differentiation, migration and apoptosis of many cell types and thereby plays an important role in hematopoiesis, stem cell maintenance, gametogenesis, melanogenesis, and in mast cell development, migration and function. This protein can be a membrane-bound or soluble protein. Mutations in this gene are associated with gastrointestinal stromal tumors, mast cell disease, acute myelogenous leukemia, and piebaldism. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2020]"})
(:gene {references: "10433620) ValidYN,CollectiveName,AffiliationInfo. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst.. 1999;91(15):1310-6.|12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|16825431) Alter BP,Rosenberg PS,Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet.. 2007;44(1):1-9.|18042939) Tai YC,Domchek S,Parmigiani G,Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst.. 2007;99(23):1811-4.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|26700119) van den Broek AJ,van 't Veer LJ,Hooning MJ,Cornelissen S,Broeks A,Rutgers EJ,Smit VT,Cornelisse CJ,van Beek M,Janssen-Heijnen ML,Seynaeve C,Westenend PJ,Jobsen JJ,Siesling S,Tollenaar RA,van Leeuwen FE,Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol.. 2016;34(5):409-18.|27306910) Streff H,Profato J,Ye Y,Nebgen D,Peterson SK,Singletary C,Arun BK,Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist.. 2016;21(7):869-74.|29922827) Hu C,Hart SN,Polley EC,Gnanaolivu R,Shimelis H,Lee KY,Lilyquist J,Na J,Moore R,Antwi SO,Bamlet WR,Chaffee KG,DiCarlo J,Wu Z,Samara R,Kasi PM,McWilliams RR,Petersen GM,Couch FJ. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA.. 2018;319(23):2401-2409.|30900310) Oh M,Alkhushaym N,Fallatah S,Althagafi A,Aljadeed R,Alsowaida Y,Jeter J,Martin JR,Babiker HM,McBride A,Abraham I. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate.. 2019;79(8):880-895.|32676552) Chen J,Bae E,Zhang L,Hughes K,Parmigiani G,Braun D,Rebbeck TR. Penetrance of Breast and Ovarian Cancer in Women Who Carry a  Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectr.. 2020;4(4):pkaa029.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes", pmids: "8986277|10433620|12393424|12393516|16825431|18042939|20417588|20507306|26700119|27306910|29922827|30900310|32676552|33471974", name: "BRCA2", description: "The BRCA2 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793) and autosomal recessive Fanconi anemia, type D1 (FA-D1) (MedGen UID: 325420).  Females with a pathogenic BRCA2 variant have a 44-80% lifetime risk of breast cancer (PMID: 32676552, 33471974). The risk for contralateral breast cancer 10 years after primary diagnosis is 10-30% (PMID: 26700119). The lifetime risk for ovarian, fallopian tube or peritoneal cancer is 19-46% (PMID: 32676552). Males have a 7-8% risk of breast cancer (PMID: 18042939) and a 22-32% risk of prostate cancer (PMID: 30900310). Both males and females have an increased risk of pancreatic cancer (4-9% lifetime risk) (PMID: 29922827, 27306910) and melanoma (lifetime risks are not established) (PMID: 10433620).  Biallelic pathogenic variants in BRCA2 are associated with a particularly severe form of Fanconi anemia (PMID: 16825431) characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). Risks of leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516), with up to a 97% risk of malignancy by 5 years of age (PMID: 16825431).", fullName: "Breast Cancer 2 Early Onset Protein", altName: "FANCB,FANCD,FANCD1,BRCA2", mechanism: "The protein product of BRCA2 is a nuclear phosphoprotein which forms part of the homologous recombination pathway for double-stranded DNA repair via binding with RAD51."})
(:gene {references: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18398828) Watson P,Vasen HFA,Mecklin JP,Bernstein I,Aarnio M,J√É¬§rvinen HJ,Myrh√É¬∏j T,Sunde L,Wijnen JT,Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer.. 2008;123(2):444-449.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|19900449) Capelle LG,Van Grieken NC,Lingsma HF,Steyerberg EW,Klokman WJ,Bruno MJ,Vasen HF,Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology.. 2010;138(2):487-92.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|23091106) Engel C,Loeffler M,Steinke V,Rahner N,Holinski-Feder E,Dietmaier W,Schackert HK,Goergens H,von Knebel Doeberitz M,Goecke TO,Schmiegel W,Buettner R,Moeslein G,Letteboer TG,G√É¬≥mez Garc√É¬≠a E,Hes FJ,Hoogerbrugge N,Menko FH,van Os TA,Sijmons RH,Wagner A,Kluijt I,Propping P,Vasen HF. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol.. 2012;30(35):4409-15.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|27013479) Dominguez-Valentin M,Joost P,Therkildsen C,Jonsson M,Rambech E,Nilbert M. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol.. 2016;16():15.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25.", pmids: "17539897|18398828|18709565|19900449|20442441|21642682|23091106|26657901|27013479|28754778|31337882", name: "MSH2", description: "The MSH2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 423615) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MSH2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovary, stomach, biliary tract, bladder, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks include a 33‚Äì52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", fullName: "MutS Homolog 2", altName: "MutS Homolog 2,MSH2", mechanism: "Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Recruits DNA helicase MCM9 to chromatin which unwinds the mismatch containing DNA strand (PubMed:26300262). ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis"})
(:gene {references: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|20028993) Baglietto L,Lindor NM,Dowty JG,White DM,Wagner A,Gomez Garcia EB,Vriends AH, ,Cartwright NR,Barnetson RA,Farrington SM,Tenesa A,Hampel H,Buchanan D,Arnold S,Young J,Walsh MD,Jass J,Macrae F,Antill Y,Winship IM,Giles GG,Goldblatt J,Parry S,Suthers G,Leggett B,Butz M,Aronson M,Poynter JN,Baron JA,Le Marchand L,Haile R,Gallinger S,Hopper JL,Potter J,de la Chapelle A,Vasen HF,Dunlop MG,Thibodeau SN,Jenkins MA. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst.. 2010;102(3):193-201.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|31204389) Suerink M,Rodr√É¬≠guez-Girondo M,van der Klift HM,Colas C,Brugieres L,Lavoine N,Jongmans M,Munar GC,Evans DG,Farrell MP,Genuardi M,Goldberg Y,Gomez-Garcia E,Heinimann K,Hoell JI,Aretz S,Jasperson KW,Kedar I,Modi MB,Nikolaev S,van Os TAM,Ripperger T,Rueda D,Senter L,Sjursen W,Sunde L,Therkildsen C,Tibiletti MG,Trainer AH,Vos YJ,Wagner A,Winship I,Wimmer K,Zimmermann SY,Vasen HF,van Asperen CJ,Houwing-Duistermaat JJ,Ten Broeke SW,Nielsen M. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med.. 2019;21(12):2706-2712.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25.", pmids: "17539897|18709565|20028993|20442441|21642682|28754778|31204389|31337882", name: "MSH6", description: "The MSH6 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 318886) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MSH6-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract, bladder, brain, and possibly prostate, stomach and small bowel. Estimated lifetime risks include a 10‚Äì44% risk of colorectal cancer, up to 5.5% risk of urinary tract cancer, up to an 8% risk of bladder cancer and up to a 2% risk of brain cancer. Affected females also have an increased risk of uterine/endometrial cancer (16-49%) and ovarian cancer (up to 13%) (PMID: 20028993, 21642682, 28754778, 20028993, 31204389, 31337882).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", fullName: "MutS Homolog 6", altName: "mutS homolog 6,MSH6", mechanism: "This gene encodes a member of the DNA mismatch repair MutS family. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein heterodimerizes with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene may be associated with hereditary nonpolyposis colon cancer, colorectal cancer, and endometrial cancer. Transcripts variants encoding different isoforms have been described. [provided by RefSeq, Jul 2013]"})
(:gene {name: "MUTYH", fullName: "MutY DNA Glycosylase", altName: "mutY homolog,MUTYH Biallelic,MYH,MUTYH Monoallelic,MUTYH", mechanism: "This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene."})
(:gene {references: "16770759) Steffen J,Nowakowska D,Niwi√Ö‚Äûska A,Czapczak D,Kluska A,Piatkowska M,Wi√Ö‚Ä∫niewska A,Paszko Z. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland. Int J Cancer.. 2006;119(2):472-5.|17957789) Bogdanova N,Feshchenko S,Sch√É¬ºrmann P,Waltes R,Wieland B,Hillemanns P,Rogov YI,Dammann O,Bremer M,Karstens JH,Sohn C,Varon R,D√É¬∂rk T. Nijmegen Breakage Syndrome mutations and risk of breast cancer. Int J Cancer.. 2008;122(4):802-6.|21514219) Zhang B,Beeghly-Fadiel A,Long J,Zheng W. Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Lancet Oncol.. 2011;12(5):477-88.|22373003) Chrzanowska KH,Gregorek H,Dembowska-Bagi√Ö‚Äûska B,Kalina MA,Digweed M. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis.. 2012;7():13.|23765759) Zhang G,Zeng Y,Liu Z,Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol.. 2013;34(5):2753-7.|26271390) Wolska-Ku√Ö‚Ä∫nierz B,Gregorek H,Chrzanowska K,Pi√Ñ‚Ä¶tosa B,Pietrucha B,Heropolita√Ö‚Äûska-Pliszka E,Pac M,Klaudel-Dreszler M,Kostyuchenko L,Pasic S,Marodi L,Belohradsky BH,√Ñ≈íi√Ö¬æn√É¬°r P,Shcherbina A,Kilic SS,Baumann U,Seidel MG,Gennery AR,Syczewska M,Miko√Ö‚Äöu√Ñ‚Ä° B,Ka√Ö‚Äöwak K,Styczy√Ö‚Äûski J,Pieczonka A,Drabko K,Wakuli√Ö‚Äûska A,Gathmann B,Albert MH,Skar√Ö¬ºy√Ö‚Äûska U,Bernatowska E, . Nijmegen Breakage Syndrome: Clinical and Immunological Features, Long-Term Outcome and Treatment Options - a Retrospective Analysis. J Clin Immunol.. 2015;35(6):538-49.|26720728) Norquist BM,Harrell MI,Brady MF,Walsh T,Lee MK,Gulsuner S,Bernards SS,Casadei S,Yi Q,Burger RA,Chan JK,Davidson SA,Mannel RS,DiSilvestro PA,Lankes HA,Ramirez NC,King MC,Swisher EM,Birrer MJ. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol.. 2016;2(4):482-90.|29988077) Cast√É¬©ra L,Harter V,Muller E,Krieger S,Goardon N,Ricou A,Rousselin A,Paimparay G,Legros A,Bruet O,Quesnelle C,Domin F,San C,Brault B,Fouillet R,Abadie C,B√É¬©ra O,Berthet P, ,Fr√É¬©bourg T,Vaur D. Landscape of pathogenic variations in√Ç¬†a panel of 34 genes and cancer risk estimation from 5131 HBOC families. Genet Med.. 2018;20(12):1677-1686.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|31406321) LaDuca H,Polley EC,Yussuf A,Hoang L,Gutierrez S,Hart SN,Yadav S,Hu C,Na J,Goldgar DE,Fulk K,Smith LP,Horton C,Profato J,Pesaran T,Gau CL,Pronold M,Davis BT,Chao EC,Couch FJ,Dolinsky JS. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med.. 2020;22(2):407-415.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439.", pmids: "16770759|17957789|21514219|22373003|23765759|26271390|26720728|29988077|30733081|31406321|33471974|33471991", name: "NBN", description: "The NBN gene is associated with autosomal recessive Nijmegen breakage syndrome (NBS) (MedGen UID: 140771). There is also evidence suggesting NBN may be associated with autosomal dominant predisposition to ovarian, endometrial and prostate cancer (PMID: 26720728, 29988077, 30733081, 31406321). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  NBS is a progressive multisystemic disorder characterized by physical abnormalities, immunodeficiency, increased cancer risk and cognitive impairment. Physical abnormalities may include progressive microcephaly, early growth restriction leading to short stature and distinctive facial features. Immunodeficiency often results in recurrent pulmonary infections. B-cell lymphomas are the most common malignancy, although T-cell lymphomas, medulloblastomas, gliomas and rhabdomyosarcomas may also occur (PMID: 22373003, 26271390).   Studies have previously suggested that females with a pathogenic variant in NBN may have autosomal dominant predisposition to breast cancer (PMID: 17957789, 21514219, 16770759, 23765759); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).", fullName: "Nibrin", altName: "Nibrin,NBS1,NBN", mechanism: "Nibrin, the protein product of NBN, plays a role in the cellular response to DNA double-strand damage, in addition to regulating cell division and cell proliferation."})
(:gene {references: "12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|17287723) Erkko H,Xia B,Nikkil√É¬§ J,Schleutker J,Syrj√É¬§koski K,Mannermaa A,Kallioniemi A,Pylk√É¬§s K,Karppinen SM,Rapakko K,Miron A,Sheng Q,Li G,Mattila H,Bell DW,Haber DA,Grip M,Reiman M,Jukkola-Vuorinen A,Mustonen A,Kere J,Aaltonen LA,Kosma VM,Kataja V,Soini Y,Drapkin RI,Livingston DM,Winqvist R. A recurrent mutation in PALB2 in Finnish cancer families. Nature.. 2007;446(7133):316-9.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|21285249) Casadei S,Norquist BM,Walsh T,Stray S,Mandell JB,Lee MK,Stamatoyannopoulos JA,King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res.. 2011;71(6):2222-9.|25099575) Antoniou AC,Casadei S,Heikkinen T,Barrowdale D,Pylk√É¬§s K,Roberts J,Lee A,Subramanian D,De Leeneer K,Fostira F,Tomiak E,Neuhausen SL,Teo ZL,Khan S,Aittom√É¬§ki K,Moilanen JS,Turnbull C,Seal S,Mannermaa A,Kallioniemi A,Lindeman GJ,Buys SS,Andrulis IL,Radice P,Tondini C,Manoukian S,Toland AE,Miron P,Weitzel JN,Domchek SM,Poppe B,Claes KB,Yannoukakos D,Concannon P,Bernstein JL,James PA,Easton DF,Goldgar DE,Hopper JL,Rahman N,Peterlongo P,Nevanlinna H,King MC,Couch FJ,Southey MC,Winqvist R,Foulkes WD,Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med.. 2014;371(6):497-506.|28888541) Lilyquist J,LaDuca H,Polley E,Davis BT,Shimelis H,Hu C,Hart SN,Dolinsky JS,Couch FJ,Goldgar DE. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol.. 2017;147(2):375-380.|29478780) AlDubayan SH,Giannakis M,Moore ND,Han GC,Reardon B,Hamada T,Mu XJ,Nishihara R,Qian Z,Liu L,Yurgelun MB,Syngal S,Garraway LA,Ogino S,Fuchs CS,Van Allen EM. Inherited DNA-Repair Defects in Colorectal Cancer. Am J Hum Genet.. 2018;102(3):401-414.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|31841383) Yang X,Leslie G,Doroszuk A,Schneider S,Allen J,Decker B,Dunning AM,Redman J,Scarth J,Plaskocinska I,Luccarini C,Shah M,Pooley K,Dorling L,Lee A,Adank MA,Adlard J,Aittom√É¬§ki K,Andrulis IL,Ang P,Barwell J,Bernstein JL,Bobolis K,Borg √É‚Ä¶,Blomqvist C,Claes KBM,Concannon P,Cuggia A,Culver JO,Damiola F,de Pauw A,Diez O,Dolinsky JS,Domchek SM,Engel C,Evans DG,Fostira F,Garber J,Golmard L,Goode EL,Gruber SB,Hahnen E,Hake C,Heikkinen T,Hurley JE,Janavicius R,Kleibl Z,Kleiblova P,Konstantopoulou I,Kvist A,Laduca H,Lee ASG,Lesueur F,Maher ER,Mannermaa A,Manoukian S,McFarland R,McKinnon W,Meindl A,Metcalfe K,Mohd Taib NA,Moilanen J,Nathanson KL,Neuhausen S,Ng PS,Nguyen-Dumont T,Nielsen SM,Obermair F,Offit K,Olopade OI,Ottini L,Penkert J,Pylk√É¬§s K,Radice P,Ramus SJ,Rudaitis V,Side L,Silva-Smith R,Silvestri V,Skytte AB,Slavin T,Soukupova J,Tondini C,Trainer AH,Unzeitig G,Usha L,van Overeem Hansen T,Whitworth J,Wood M,Yip CH,Yoon SY,Yussuf A,Zogopoulos G,Goldgar D,Hopper JL,Chenevix-Trench G,Pharoah P,George SHL,Balma√É¬±a J,Houdayer C,James P,El-Haffaf Z,Ehrencrona H,Janatova M,Peterlongo P,Nevanlinna H,Schmutzler R,Teo SH,Robson M,Pal T,Couch F,Weitzel JN,Elliott A,Southey M,Winqvist R,Easton DF,Foulkes WD,Antoniou AC,Tischkowitz M. Cancer Risks Associated With Germline  Pathogenic Variants: An International Study of 524 Families. J Clin Oncol.. 2020;38(7):674-685.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes|35172496) Kurian AW,Hughes E,Handorf EA,Gutin A,Allen B,Hartman AR,Hall MJ. Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women. JCO Precis Oncol.. 2017;1():1-12.", pmids: "8986277|12393424|12393516|17287723|20417588|20507306|21285249|25099575|28888541|29478780|30733081|31841383|33471974|35172496", name: "PALB2", description: "The PALB2 gene is associated with autosomal dominant predisposition to breast, pancreatic (PMID: 25099575, 31841383) and ovarian cancer (PMID: 30733081) in addition to autosomal recessive Fanconi anemia (MedGen UID: 372133). Studies have also suggested PALB2 may be associated with autosomal dominant predisposition to prostate (PMID: 17287723), male breast cancer (PMID: 31841383) and colorectal cancer (PMID: 29478780). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with a pathogenic PALB2 variant is 33-58% (PMID: 25099575, 33471974). There is also a 2-5% risk of pancreatic cancer (PMID: 21285249, 31841383) and a 3-5% risk of ovarian cancer (PMID: 31841383, 28888541, 35172496).  Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risks for leukemia and early onset solid tumors are significantly elevated (PMID: 20507306, 12393424, 12393516).", fullName: "Partner And Localizer Of BRCA2", altName: "FANCN,Partner and Localizer Of BRCA2", mechanism: "This gene encodes a protein that may function in tumor suppression. This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2) in nuclear foci and likely permits the stable intranuclear localization and accumulation of BRCA2. [provided by RefSeq, Jul 2008]"})
(:gene {references: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18602922) Senter L,Clendenning M,Sotamaa K,Hampel H,Green J,Potter JD,Lindblom A,Lagerstedt K,Thibodeau SN,Lindor NM,Young J,Winship I,Dowty JG,White DM,Hopper JL,Baglietto L,Jenkins MA,de la Chapelle A. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology.. 2008;135(2):419-28.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|30161022) Ten Broeke SW,van der Klift HM,Tops CMJ,Aretz S,Bernstein I,Buchanan DD,de la Chapelle A,Capella G,Clendenning M,Engel C,Gallinger S,Gomez Garcia E,Figueiredo JC,Haile R,Hampel HL,Hopper JL,Hoogerbrugge N,von Knebel Doeberitz M,Le Marchand L,Letteboer TGW,Jenkins MA,Lindblom A,Lindor NM,Mensenkamp AR,M√É¬∏ller P,Newcomb PA,van Os TAM,Pearlman R,Pineda M,Rahner N,Redeker EJW,Olderode-Berends MJW,Rosty C,Schackert HK,Scott R,Senter L,Spruijt L,Steinke-Lange V,Suerink M,Thibodeau S,Vos YJ,Wagner A,Winship I,Hes FJ,Vasen HFA,Wijnen JT,Nielsen M,Win AK. Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol.. 2018;36(29):2961-2968.|31204389) Suerink M,Rodr√É¬≠guez-Girondo M,van der Klift HM,Colas C,Brugieres L,Lavoine N,Jongmans M,Munar GC,Evans DG,Farrell MP,Genuardi M,Goldberg Y,Gomez-Garcia E,Heinimann K,Hoell JI,Aretz S,Jasperson KW,Kedar I,Modi MB,Nikolaev S,van Os TAM,Ripperger T,Rueda D,Senter L,Sjursen W,Sunde L,Therkildsen C,Tibiletti MG,Trainer AH,Vos YJ,Wagner A,Winship I,Wimmer K,Zimmermann SY,Vasen HF,van Asperen CJ,Houwing-Duistermaat JJ,Ten Broeke SW,Nielsen M. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome. Genet Med.. 2019;21(12):2706-2712.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25.", pmids: "17539897|18602922|18709565|20442441|26657901|28754778|30161022|31204389|31337882", name: "PMS2", description: "The PMS2 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 325005) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  PMS2-related Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the endometrium, ovaries, urinary tract and possibly prostate. Estimated lifetime cancer risks appear to be lower than those seen with other mismatch repair genes and include a 9-20% risk for colorectal cancer and up to a 3.7% risk of urinary tract cancer. Affected females also have an increased risk of uterine/endometrial cancer (13‚Äì26%) and ovarian cancer (3%) (PMID: 18602922, 30161022, 31204389, 28754778, 26657901, 31337882).  CMMR-D is a cancer syndrome characterized by childhood cancers, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", fullName: "PMS1 Homolog 2, Mismatch Repair System Component", altName: "PMS1 Homolog 2, Mismatch Repair System Component,PMS2", mechanism: "The protein encoded by this gene is a key component of the mismatch repair system that functions to correct DNA mismatches and small insertions and deletions that can occur during DNA replication and homologous recombination. This protein forms heterodimers with the gene product of the mutL homolog 1 (MLH1) gene to form the MutL-alpha heterodimer. The MutL-alpha heterodimer possesses an endonucleolytic activity that is activated following recognition of mismatches and insertion/deletion loops by the MutS-alpha and MutS-beta heterodimers, and is necessary for removal of the mismatched DNA. There is a DQHA(X)2E(X)4E motif found at the C-terminus of the protein encoded by this gene that forms part of the active site of the nuclease. Mutations in this gene have been associated with hereditary nonpolyposis colorectal cancer (HNPCC; also known as Lynch syndrome) and Turcot syndrome. [provided by RefSeq, Apr 2016]"})
(:gene {references: "23263490) Palles C,Cazier JB,Howarth KM,Domingo E,Jones AM,Broderick P,Kemp Z,Spain SL,Guarino E,Guarino Almeida E,Salguero I,Sherborne A,Chubb D,Carvajal-Carmona LG,Ma Y,Kaur K,Dobbins S,Barclay E,Gorman M,Martin L,Kovac MB,Humphray S, , ,Lucassen A,Holmes CC,Bentley D,Donnelly P,Taylor J,Petridis C,Roylance R,Sawyer EJ,Kerr DJ,Clark S,Grimes J,Kearsey SE,Thomas HJ,McVean G,Houlston RS,Tomlinson I. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet.. 2013;45(2):136-44.|23770608) Weedon MN,Ellard S,Prindle MJ,Caswell R,Lango Allen H,Oram R,Godbole K,Yajnik CS,Sbraccia P,Novelli G,Turnpenny P,McCann E,Goh KJ,Wang Y,Fulford J,McCulloch LJ,Savage DB,O'Rahilly S,Kos K,Loeb LA,Semple RK,Hattersley AT. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet.. 2013;45(8):947-50.|24501277) Valle L,Hern√É¬°ndez-Ill√É¬°n E,Bellido F,Aiza G,Castillejo A,Castillejo MI,Navarro M,Segu√É¬≠ N,Vargas G,Guarinos C,Juarez M,Sanju√É¬°n X,Iglesias S,Alenda C,Egoavil C,Segura √É¬Å,Juan MJ,Rodriguez-Soler M,Brunet J,Gonz√É¬°lez S,Jover R,L√É¬°zaro C,Capell√É¬° G,Pineda M,Soto JL,Blanco I. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet.. 2014;23(13):3506-12.|25131834) Pelosini C,Martinelli S,Ceccarini G,Magno S,Barone I,Basolo A,Fierabracci P,Vitti P,Maffei M,Santini F. Identification of a novel mutation in the polymerase delta 1 (POLD1) gene in a lipodystrophic patient affected by mandibular hypoplasia, deafness, progeroid features (MDPL) syndrome. Metabolism.. 2014;63(11):1385-9.|26133394) Bellido F,Pineda M,Aiza G,Vald√É¬©s-Mas R,Navarro M,Puente DA,Pons T,Gonz√É¬°lez S,Iglesias S,Darder E,Pi√É¬±ol V,Soto JL,Valencia A,Blanco I,Urioste M,Brunet J,L√É¬°zaro C,Capell√É¬° G,Puente XS,Valle L. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med.. 2016;18(4):325-32.|31629014) Cui Y,Keles S,Charbonnier LM,Jul√É¬© AM,Henderson L,Celik SC,Reisli I,Shen C,Xie WJ,Schmitz-Abe K,Wu H,Chatila TA. Combined immunodeficiency caused by a loss-of-function mutation in DNA polymerase delta 1. J Allergy Clin Immunol.. 2020;145(1):391-401.e8.|31944473) Oh DY,Matsumoto Y,Kitajiri SI,Kim NKD,Kim MY,Kim AR,Lee M,Lee C,Tomkinson AE,Katsuno T,Kim SY,Shin HW,Han JH,Lee S,Park WY,Choi BY. POLD1 variants leading to reduced polymerase activity can cause hearing loss without syndromic features. Hum Mutat.. 2020;41(5):913-920.", pmids: "23263490|23770608|24501277|25131834|26133394|31629014|31944473", name: "POLD1", description: "The POLD1 gene is associated with autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 436445) and autosomal dominant MDPL syndrome (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) (MedGen UID: 811623). There is also preliminary evidence supporting a correlation with autosomal dominant predisposition to endometrial cancer (PMID: 23263490, 26133394), autosomal recessive combined immunodeficiency syndrome (PMID: 31629014) and autosomal recessive non-syndromic deafness (PMID: 31944473). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Individuals with a pathogenic POLD1 variant typically presents with 10-100 colonic polyps and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 23263490, 26133394, 24501277). MDPL syndrome is a rare, systemic disorder characterized by loss of subcutaneous fat, distinctive facial features and metabolic abnormalities including insulin resistance and diabetes. Sensorineural hearing loss is also a common finding, typically presenting in the first or second decades of life (PMID: 25131834, 23770608).", fullName: "Polymerase (DNA-Directed), Delta 1, Catalytic Subunit; POLD1", altName: "DNA Polymerase Delta 1, Catalytic Subunit,POLD1", mechanism: "POLD1 codes for the catalytic subunit of DNA polymerase delta, which is essential for DNA replication."})
(:gene {references: "12393516) Kutler DI,Singh B,Satagopan J,Batish SD,Berwick M,Giampietro PF,Hanenberg H,Auerbach AD. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood.. 2003;101(4):1249-56.|17033622) Seal S,Thompson D,Renwick A,Elliott A,Kelly P,Barfoot R,Chagtai T,Jayatilake H,Ahmed M,Spanova K,North B,McGuffog L,Evans DG,Eccles D, ,Easton DF,Stratton MR,Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet.. 2006;38(11):1239-41.|20507306) Alter BP,Giri N,Savage SA,Peters JA,Loud JT,Leathwood L,Carr AG,Greene MH,Rosenberg PS. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol.. 2010;150(2):179-88.|26315354) Ramus SJ,Song H,Dicks E,Tyrer JP,Rosenthal AN,Intermaggio MP,Fraser L,Gentry-Maharaj A,Hayward J,Philpott S,Anderson C,Edlund CK,Conti D,Harrington P,Barrowdale D,Bowtell DD,Alsop K,Mitchell G, ,Cicek MS,Cunningham JM,Fridley BL,Alsop J,Jimenez-Linan M,Poblete S,Lele S,Sucheston-Campbell L,Moysich KB,Sieh W,McGuire V,Lester J,Bogdanova N,D√É¬ºrst M,Hillemanns P, ,Odunsi K,Whittemore AS,Karlan BY,D√É¬∂rk T,Goode EL,Menon U,Jacobs IJ,Antoniou AC,Pharoah PD,Gayther SA. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst.. 2015;107(11):.|27296296) Tung N,Domchek SM,Stadler Z,Nathanson KL,Couch F,Garber JE,Offit K,Robson ME. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol.. 2016;13(9):581-8.|28418444) Couch FJ,Shimelis H,Hu C,Hart SN,Polley EC,Na J,Hallberg E,Moore R,Thomas A,Lilyquist J,Feng B,McFarland R,Pesaran T,Huether R,LaDuca H,Chao EC,Goldgar DE,Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol.. 2017;3(9):1190-1196.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|32359370) Suszynska M,Ratajska M,Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~30,000 cases. J Ovarian Res.. 2020;13(1):50.|32708810) Brand√É¬£o A,Paulo P,Teixeira MR. Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications. Int J Mol Sci.. 2020;21(14):.|32853339) Darst BF,Dadaev T,Saunders E,Sheng X,Wan P,Pooler L,Xia LY,Chanock S,Berndt SI,Gapstur SM,Stevens V,Albanes D,Weinstein SJ,Gnanapragasam V,Giles GG,Nguyen-Dumont T,Milne RL,Pomerantz M,Schmidt JA,Mucci L,Catalona WJ,Hetrick KN,Doheny KF,MacInnis RJ,Southey MC,Eeles RA,Wiklund F,Kote-Jarai Z,Conti DV,Haiman CA. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. J Natl Cancer Inst.. 2021;113(5):616-625.|8986277) Diagnosis of fanconi anemia in patients without congenital malformations an international fanconi anemia registry study|12393424) Cancer incidence in persons with fanconi anemia|20417588) Pathophysiology and management of inherited bone marrow failure syndromes", pmids: "8986277|12393424|12393516|17033622|20417588|20507306|26315354|27296296|28418444|30733081|32359370|32708810|32853339", name: "BRIP1", description: "The BRIP1 gene is associated with autosomal dominant predisposition to ovarian cancer (PMID: 30733081) and autosomal recessive Fanconi anemia (MedGen UID: 323015). There is also evidence suggesting BRIP1 is associated with autosomal dominant predisposition to breast and prostate cancer (PMID: 17033622, 28418444, 30733081, 32708810, 32853339). The data, however, are preliminary and insufficient to make a determination regarding these relationships.                                                          Females with a pathogenic BRIP1 variant have approximately a 6-13% risk of ovarian cancer (PMID: 26315354, 27296296, 32359370).   Autosomal recessive Fanconi anemia is characterized by bone marrow failure, short stature, abnormal skin pigmentation, developmental delay and malformations of the thumbs, skeletal and central nervous systems (PMID: 20417588, 8986277). The risk of leukemia and early onset solid tumors is significantly elevated (PMID: 20507306, 12393424, 12393516).", fullName: "BRCA1 Interacting Protein C-Terminal Helicase 1", altName: "BACH1,FANCJ,BRIP1", mechanism: "The protein product of BRIP1 is a helicase which interacts with BRCA1 via BRCT repeats. It is essential to the role of BRCA1 in double-stranded DNA repair."})
(:gene {references: "11729114) Pharoah PD,Guilford P,Caldas C, . Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology.. 2001;121(6):1348-53.|17545690) Kaurah P,MacMillan A,Boyd N,Senz J,De Luca A,Chun N,Suriano G,Zaor S,Van Manen L,Gilpin C,Nikkel S,Connolly-Wilson M,Weissman S,Rubinstein WS,Sebold C,Greenstein R,Stroop J,Yim D,Panzini B,McKinnon W,Greenblatt M,Wirtzfeld D,Fontaine D,Coit D,Yoon S,Chung D,Lauwers G,Pizzuti A,Vaccaro C,Redal MA,Oliveira C,Tischkowitz M,Olschwang S,Gallinger S,Lynch H,Green J,Ford J,Pharoah P,Fernandez B,Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA.. 2007;297(21):2360-72.|31246251) Roberts ME,Ranola JMO,Marshall ML,Susswein LR,Graceffo S,Bohnert K,Tsai G,Klein RT,Hruska KS,Shirts BH. Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers. JAMA Oncol.. 2019;5(9):1325-1331.|31296550) Xicola RM,Li S,Rodriguez N,Reinecke P,Karam R,Speare V,Black MH,LaDuca H,Llor X. Clinical features and cancer risk in families with pathogenic  variants irrespective of clinical criteria. J Med Genet.. 2019;56(12):838-843.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.", pmids: "11729114|17545690|31246251|31296550|33471974", name: "CDH1", description: "The CDH1 gene is associated with autosomal dominant predisposition to diffuse gastric cancer and lobular breast cancer, collectively known as hereditary diffuse gastric cancer (HDGC) syndrome (MedGen UID: 310839).  The estimated lifetime risk of diffuse gastric cancer in individuals with a pathogenic CDH1 variant is 67-83% (PMID: 11729114), although recent studies suggest the risk may be lower, at 33-42% (PMID: 31246251, 31296550). The lifetime risk of lobular cancer in females is 27%-52% (PMID: 17545690, 11729114, 33471974).", fullName: "Cadherin 1", altName: "Calcium-Dependent Adhesion Protein, Epithelial,epithelial cadherin,CDH1", mechanism: "CDH1 codes for a transmembrane epithelial cadherin protein which plays a role in cell adhesion. Loss of function can lead to cancer through heightened cell proliferation and mobility."})
(:gene {references: "15880589) Molven A,Grimstvedt MB,Steine SJ,Harland M,Avril MF,Hayward NK,Akslen LA. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer.. 2005;44(1):10-8.|23384855) Puntervoll HE,Yang XR,Vetti HH,Bachmann IM,Avril MF,Benfodda M,Catrical√É¬† C,Dalle S,Duval-Modeste AB,Ghiorzo P,Grammatico P,Harland M,Hayward NK,Hu HH,Jouary T,Martin-Denavit T,Ozola A,Palmer JM,Pastorino L,Pjanova D,Soufir N,Steine SJ,Stratigos AJ,Thomas L,Tinat J,Tsao H,Veinalde R,Tucker MA,Bressac-de Paillerets B,Newton-Bishop JA,Goldstein AM,Akslen LA,Molven A. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. J Med Genet.. 2013;50(4):264-70.|30775140) Rossi M,Pellegrini C,Cardelli L,Ciciarelli V,Di Nardo L,Fargnoli MC. Familial Melanoma: Diagnostic and Management Implications. Dermatol Pract Concept.. 2019;9(1):10-16.", pmids: "15880589|23384855|30775140", name: "CDK4", description: "The CDK4 gene is associated with autosomal dominant predisposition to cutaneous melanoma (MedGen UID: 268851).  CDK4-related cutaneous melanoma is characterized by early presentation of atypical nevi and early-onset melanoma (PMID: 15880589, 23384855, 30775140). In a study of individuals with pathogenic CDK4 variants, the penetrance at age 50 was 74% (PMID: 23384855). Additional risk factors including pale skin and excessive sun exposure may amplify lifetime risks.", fullName: "Cyclin Dependent Kinase 4", altName: "CDK4", mechanism: "CDK4 encodes cyclin-dependent kinase 4, a serine/threonine kinase which helps regulate the cell cycle at the G1 phase."})
(:gene {name: "CDKN2A", fullName: "Cyclin Dependent Kinase Inhibitor 2A", altName: "P14,ARF,CMM2,INK4A,MLM,MTS1,CDK4I,CDKN2A,P16,TP16,P19", mechanism: "Via alternative splicing, CDKN2A can produce two major proteins, p14 and p16. Both act as tumor suppressors: p14 activates the p53 tumor suppressor protein, while p16 helps regulate the cell cycle by activating the RB1 protein via inhibition of CDK4 and CDK6. Thus, p16 helps keep the cell in the G1 phase of the cell cycle."})
(:gene {references: "11719428) Lee SB,Kim SH,Bell DW,Wahrer DC,Schiripo TA,Jorczak MM,Sgroi DC,Garber JE,Li FP,Nichols KE,Varley JM,Godwin AK,Shannon KM,Harlow E,Haber DA. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res.. 2001;61(22):8062-7.|15492928) Cybulski C,G√É¬≥rski B,Huzarski T,Masoj√Ñ‚Ä° B,Mierzejewski M,Debniak T,Teodorczyk U,Byrski T,Gronwald J,Matyjasik J,Zlowocka E,Lenner M,Grabowska E,Nej K,Castaneda J,Medrek K,Szyma√Ö‚Äûska A,Szyma√Ö‚Äûska J,Kurzawski G,Suchy J,Oszurek O,Witek A,Narod SA,Lubi√Ö‚Äûski J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet.. 2004;75(6):1131-5.|18172190) Weischer M,Bojesen SE,Ellervik C,Tybjaerg-Hansen A,Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol.. 2008;26(4):542-8.|18759107) Wasielewski M,den Bakker MA,van den Ouweland A,Meijer-van Gelder ME,Portengen H,Klijn JG,Meijers-Heijboer H,Foekens JA,Schutte M. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat.. 2009;116(2):397-400.|21807500) Xiang HP,Geng XP,Ge WW,Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer.. 2011;47(17):2546-51.|21876083) Cybulski C,Woko√Ö‚Äöorczyk D,Jakubowska A,Huzarski T,Byrski T,Gronwald J,Masoj√Ñ‚Ä° B,Deebniak T,G√É¬≥rski B,Blecharz P,Narod SA,Lubi√Ö‚Äûski J. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol.. 2011;29(28):3747-52.|22058428) Adank MA,Jonker MA,Kluijt I,van Mil SE,Oldenburg RA,Mooi WJ,Hogervorst FB,van den Ouweland AM,Gille JJ,Schmidt MK,van der Vaart AW,Meijers-Heijboer H,Waisfisz Q. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. J Med Genet.. 2011;48(12):860-3.|23652375) Huijts PE,Hollestelle A,Balliu B,Houwing-Duistermaat JJ,Meijers CM,Blom JC,Ozturk B,Krol-Warmerdam EM,Wijnen J,Berns EM,Martens JW,Seynaeve C,Kiemeney LA,van der Heijden HF,Tollenaar RA,Devilee P,van Asperen CJ. CHEK2*1100delC homozygosity in the Netherlands--prevalence and risk of breast and lung cancer. Eur J Hum Genet.. 2014;22(1):46-51.|23713947) Han FF,Guo CL,Liu LH. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol.. 2013;32(6):329-35.|25431674) Hale V,Weischer M,Park JY. CHEK2 (√¢ÀÜ‚Äî) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer.. 2014;2014():294575.|26424751) Lawrenson K,Iversen ES,Tyrer J,Weber RP,Concannon P,Hazelett DJ,Li Q,Marks JR,Berchuck A,Lee JM,Aben KK,Anton-Culver H,Antonenkova N, , ,Bandera EV,Bean Y,Beckmann MW,Bisogna M,Bjorge L,Bogdanova N,Brinton LA,Brooks-Wilson A,Bruinsma F,Butzow R,Campbell IG,Carty K,Chang-Claude J,Chenevix-Trench G,Chen A,Chen Z,Cook LS,Cramer DW,Cunningham JM,Cybulski C,Plisiecka-Halasa J,Dennis J,Dicks E,Doherty JA,D√É¬∂rk T,du Bois A,Eccles D,Easton DT,Edwards RP,Eilber U,Ekici AB,Fasching PA,Fridley BL,Gao YT,Gentry-Maharaj A,Giles GG,Glasspool R,Goode EL,Goodman MT,Gronwald J,Harter P,Hasmad HN,Hein A,Heitz F,Hildebrandt MA,Hillemanns P,Hogdall E,Hogdall C,Hosono S,Jakubowska A,Paul J,Jensen A,Karlan BY,Kjaer SK,Kelemen LE,Kellar M,Kelley JL,Kiemeney LA,Krakstad C,Lambrechts D,Lambrechts S,Le ND,Lee AW,Cannioto R,Leminen A,Lester J,Levine DA,Liang D,Lissowska J,Lu K,Lubinski J,Lundvall L,Massuger LF,Matsuo K,McGuire V,McLaughlin JR,Nevanlinna H,McNeish I,Menon U,Modugno F,Moysich KB,Narod SA,Nedergaard L,Ness RB,Noor Azmi MA,Odunsi K,Olson SH,Orlow I,Orsulic S,Pearce CL,Pejovic T,Pelttari LM,Permuth-Wey J,Phelan CM,Pike MC,Poole EM,Ramus SJ,Risch HA,Rosen B,Rossing MA,Rothstein JH,Rudolph A,Runnebaum IB,Rzepecka IK,Salvesen HB,Budzilowska A,Sellers TA,Shu XO,Shvetsov YB,Siddiqui N,Sieh W,Song H,Southey MC,Sucheston L,Tangen IL,Teo SH,Terry KL,Thompson PJ,Timorek A,Tworoger SS,Van Nieuwenhuysen E,Vergote I,Vierkant RA,Wang-Gohrke S,Walsh C,Wentzensen N,Whittemore AS,Wicklund KG,Wilkens LR,Woo YL,Wu X,Wu AH,Yang H,Zheng W,Ziogas A,Coetzee GA,Freedman ML,Monteiro AN,Moes-Sosnowska J,Kupryjanczyk J,Pharoah PD,Gayther SA,Schildkraut JM. Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis.. 2015;36(11):1341-53.|26681312) Susswein LR,Marshall ML,Nusbaum R,Vogel Postula KJ,Weissman SM,Yackowski L,Vaccari EM,Bissonnette J,Booker JK,Cremona ML,Gibellini F,Murphy PD,Pineda-Alvarez DE,Pollevick GD,Xu Z,Richard G,Bale S,Klein RT,Hruska KS,Chung WK. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med.. 2016;18(8):823-32.|27632928) Ge Y,Wang Y,Shao W,Jin J,Du M,Ma G,Chu H,Wang M,Zhang Z. Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers. Sci Rep.. 2016;6():33542.|27900359) Kukita Y,Okami J,Yoneda-Kato N,Nakamae I,Kawabata T,Higashiyama M,Kato J,Kodama K,Kato K. Homozygous inactivation of  is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs. Cold Spring Harb Mol Case Stud.. 2016;2(6):a001032.|29978187) Carlo MI,Mukherjee S,Mandelker D,Vijai J,Kemel Y,Zhang L,Knezevic A,Patil S,Ceyhan-Birsoy O,Huang KC,Redzematovic A,Coskey DT,Stewart C,Pradhan N,Arnold AG,Hakimi AA,Chen YB,Coleman JA,Hyman DM,Ladanyi M,Cadoo KA,Walsh MF,Stadler ZK,Lee CH,Feldman DR,Voss MH,Robson M,Motzer RJ,Offit K. Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncol.. 2018;4(9):1228-1235.|30858171) Paperna T,Sharon-Shwartzman N,Kurolap A,Goldberg Y,Moustafa N,Carasso Y,Feinstien M,Mory A,Reznick-Levi G,Gonzaga-Jauregui C,Shuldiner AR,Basel-Salmon L,Ofran Y,Half EE,Baris Feldman H. Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype. J Med Genet.. 2020;57(7):500-504.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.", pmids: "11719428|15492928|18172190|18759107|21807500|21876083|22058428|23652375|23713947|25431674|26424751|26681312|27632928|27900359|29978187|30858171|33471974", name: "CHEK2", description: "The CHEK2 gene is associated with autosomal dominant predisposition to breast, colon, thyroid and prostate cancer (PMID: 15492928, 18759107, 21807500, 21876083, 25431674). Additionally, there is evidence supporting a correlation with CHEK2 and autosomal dominant predisposition to ovarian, renal and urinary tract cancer (PMID: 26681312, 27632928, 26424751, 11719428, 15492928, 29978187); however, the available evidence is insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with a pathogenic CHEK2 variant is 20-44% (PMID: 18172190, 21876083, 33471974). There is also an increased risk for male breast, colorectal, prostate and thyroid cancers; however, lifetime risks are not established (PMID: 18759107, 21807500, 23713947, 15492928, 25431674). While there is evidence to suggest an increased risk for various primary cancers among homozygotes and compound heterozygotes for most pathogenic CHEK2 variants, these risks are not established (PMID: 30858171, 27900359). For the well-studied c.1100del variant, homozygotes have approximately a 4-6 fold increased risk of breast cancer (PMID: 22058428, 23652375).", fullName: "Checkpoint Kinase 2", altName: "CHEK2,Checkpoint kinase 2", mechanism: "When DNA double-stranded breaks occur, the protein product of CHEK2 inhibits CDC25C phosphatase and stabilizes the p53 tumor suppressor protein, thus keeping the cell in the G1 phase of the cell cycle. CHEK2 also phosphorylates BRCA1, which allows BRCA1 to ensure survival after DNA damage."})
(:gene {references: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18398828) Watson P,Vasen HFA,Mecklin JP,Bernstein I,Aarnio M,J√É¬§rvinen HJ,Myrh√É¬∏j T,Sunde L,Wijnen JT,Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer.. 2008;123(2):444-449.|18572020) Sivagnanam M,Mueller JL,Lee H,Chen Z,Nelson SF,Turner D,Zlotkin SH,Pencharz PB,Ngan BY,Libiger O,Schork NJ,Lavine JE,Taylor S,Newbury RO,Kolodner RD,Hoffman HM. Identification of EpCAM as the gene for congenital tufting enteropathy. Gastroenterology.. 2008;135(2):429-37.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|19900449) Capelle LG,Van Grieken NC,Lingsma HF,Steyerberg EW,Klokman WJ,Bruno MJ,Vasen HF,Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology.. 2010;138(2):487-92.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|23091106) Engel C,Loeffler M,Steinke V,Rahner N,Holinski-Feder E,Dietmaier W,Schackert HK,Goergens H,von Knebel Doeberitz M,Goecke TO,Schmiegel W,Buettner R,Moeslein G,Letteboer TG,G√É¬≥mez Garc√É¬≠a E,Hes FJ,Hoogerbrugge N,Menko FH,van Os TA,Sijmons RH,Wagner A,Kluijt I,Propping P,Vasen HF. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol.. 2012;30(35):4409-15.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|27013479) Dominguez-Valentin M,Joost P,Therkildsen C,Jonsson M,Rambech E,Nilbert M. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol.. 2016;16():15.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25.|8057225) Tufting enteropathy a newly recognized clinicopathological entity associated with refractory diarrhea in infants", pmids: "8057225|17539897|18398828|18572020|18709565|19900449|20442441|21642682|23091106|26657901|27013479|28754778|31337882", name: "EPCAM", description: "Deletions that include exon 9 of the EPCAM gene are known to cause autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer, or HNPCC) (MedGen UID: 412966) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553). EPCAM is also associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031). The EPCAM gene is associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031).  Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the uterus/endometrium, ovary, stomach, bladder, biliary tract, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks for individuals with a pathogenic variant in MSH2 and/or EPCAM include a 33-52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain/central nervous system cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897). Congenital tufting enteropathy (CTE) is a gastrointestinal insufficiency syndrome presenting early in infancy as severe watery diarrhea. CTE is usually treated by daily nutritional supplements and occasionally, intestinal transplantation (PMID: 8057225, 18572020).", fullName: "Epithelial Cell Adhesion Molecule", altName: "EPCAM", mechanism: "EPCAM codes for a cellular adhesion antigen molecule which is involved in embryonic stem cell proliferation and differentiation. 3' deletions cause EPCAM mRNA to be combined with mRNA of the downstream MSH2 gene, causing loss of function of MSH2."})
(:gene {references: "22561515) Jaeger E,Leedham S,Lewis A,Segditsas S,Becker M,Cuadrado PR,Davis H,Kaur K,Heinimann K,Howarth K, ,East J,Taylor J,Thomas H,Tomlinson I. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet.. 2012;44(6):699-703.", pmids: "22561515", name: "GREM1", description: "The GREM1 gene is associated with autosomal dominant hereditary mixed polyposis syndrome (HMPS) in individuals who carry a duplication spanning the 3' end of the adjacent SCG5 gene and a region upstream of the GREM1 locus (MedGen UID: 430218, PMID: 22561515).  Hereditary mixed polyposis syndrome is an adult-onset condition associated with various types of colon polyps which may subsequently become malignant (PMID: 22561515). Lifetime cancer risks are currently not well established.", fullName: "Gremlin 1, DAN Family BMP Antagonis", altName: "GREM1", mechanism: "This gene encodes a member of the BMP (bone morphogenic protein) antagonist family. Like BMPs, BMP antagonists contain cystine knots and typically form homo- and heterodimers. The CAN (cerberus and dan) subfamily of BMP antagonists, to which this gene belongs, is characterized by a C-terminal cystine knot with an eight-membered ring. The antagonistic effect of the secreted glycosylated protein encoded by this gene is likely due to its direct binding to BMP proteins. As an antagonist of BMP, this gene may play a role in regulating organogenesis, body patterning, and tissue differentiation. In mouse, this protein has been shown to relay the sonic hedgehog (SHH) signal from the polarizing region to the apical ectodermal ridge during limb bud outgrowth. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2010]"})
(:gene {references: "17539897) Felton KE,Gilchrist DM,Andrew SE. Constitutive deficiency in DNA mismatch repair. Clin Genet.. 2007;71(6):483-98.|18398828) Watson P,Vasen HFA,Mecklin JP,Bernstein I,Aarnio M,J√É¬§rvinen HJ,Myrh√É¬∏j T,Sunde L,Wijnen JT,Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer.. 2008;123(2):444-449.|18709565) Wimmer K,Etzler J. Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet.. 2008;124(2):105-22.|19900449) Capelle LG,Van Grieken NC,Lingsma HF,Steyerberg EW,Klokman WJ,Bruno MJ,Vasen HF,Kuipers EJ. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology.. 2010;138(2):487-92.|20442441) Wimmer K,Kratz CP. Constitutional mismatch repair-deficiency syndrome. Haematologica.. 2010;95(5):699-701.|21642682) Bonadona V,Bona√É¬Øti B,Olschwang S,Grandjouan S,Huiart L,Longy M,Guimbaud R,Buecher B,Bignon YJ,Caron O,Colas C,Nogu√É¬®s C,Lejeune-Dumoulin S,Olivier-Faivre L,Polycarpe-Osaer F,Nguyen TD,Desseigne F,Saurin JC,Berthet P,Leroux D,Duffour J,Manouvrier S,Fr√É¬©bourg T,Sobol H,Lasset C,Bona√É¬Øti-Pelli√É¬© C, . Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA.. 2011;305(22):2304-10.|26385421) Joost P,Therkildsen C,Dominguez-Valentin M,J√É¬∂nsson M,Nilbert M. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology.. 2015;86(6):1212-7.|26657901) M√É¬∏ller P,Sepp√É¬§l√É¬§ T,Bernstein I,Holinski-Feder E,Sala P,Evans DG,Lindblom A,Macrae F,Blanco I,Sijmons R,Jeffries J,Vasen H,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen J,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Frayling IM,Plazzer JP,Pylvanainen K,Sampson JR,Capella G,Mecklin JP,M√É¬∂slein G, . Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut.. 2017;66(3):464-472.|27013479) Dominguez-Valentin M,Joost P,Therkildsen C,Jonsson M,Rambech E,Nilbert M. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol.. 2016;16():15.|28754778) M√É¬∏ller P,Sepp√É¬§l√É¬§ TT,Bernstein I,Holinski-Feder E,Sala P,Gareth Evans D,Lindblom A,Macrae F,Blanco I,Sijmons RH,Jeffries J,Vasen HFA,Burn J,Nakken S,Hovig E,R√É¬∏dland EA,Tharmaratnam K,de Vos Tot Nederveen Cappel WH,Hill J,Wijnen JT,Jenkins MA,Green K,Lalloo F,Sunde L,Mints M,Bertario L,Pineda M,Navarro M,Morak M,Renkonen-Sinisalo L,Valentin MD,Frayling IM,Plazzer JP,Pylvanainen K,Genuardi M,Mecklin JP,Moeslein G,Sampson JR,Capella G, . Cancer risk and survival in  carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut.. 2018;67(7):1306-1316.|28772289) Ryan NAJ,Morris J,Green K,Lalloo F,Woodward ER,Hill J,Crosbie EJ,Evans DG. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies. JAMA Oncol.. 2017;3(12):1702-1706.|31337882) Dominguez-Valentin M,Sampson JR,Sepp√É¬§l√É¬§ TT,Ten Broeke SW,Plazzer JP,Nakken S,Engel C,Aretz S,Jenkins MA,Sunde L,Bernstein I,Capella G,Balaguer F,Thomas H,Evans DG,Burn J,Greenblatt M,Hovig E,de Vos Tot Nederveen Cappel WH,Sijmons RH,Bertario L,Tibiletti MG,Cavestro GM,Lindblom A,Della Valle A,Lopez-K√É¬∂stner F,Gluck N,Katz LH,Heinimann K,Vaccaro CA,B√É¬ºttner R,G√É¬∂rgens H,Holinski-Feder E,Morak M,Holzapfel S,H√É¬ºneburg R,Knebel Doeberitz MV,Loeffler M,Rahner N,Schackert HK,Steinke-Lange V,Schmiegel W,Vangala D,Pylv√É¬§n√É¬§inen K,Renkonen-Sinisalo L,Hopper JL,Win AK,Haile RW,Lindor NM,Gallinger S,Le Marchand L,Newcomb PA,Figueiredo JC,Thibodeau SN,Wadt K,Therkildsen C,Okkels H,Ketabi Z,Moreira L,S√É¬°nchez A,Serra-Burriel M,Pineda M,Navarro M,Blanco I,Green K,Lalloo F,Crosbie EJ,Hill J,Denton OG,Frayling IM,R√É¬∏dland EA,Vasen H,Mints M,Neffa F,Esperon P,Alvarez K,Kariv R,Rosner G,Pinero TA,Gonzalez ML,Kalfayan P,Tjandra D,Winship IM,Macrae F,M√É¬∂slein G,Mecklin JP,Nielsen M,M√É¬∏ller P. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med.. 2020;22(1):15-25.", pmids: "17539897|18398828|18709565|19900449|20442441|21642682|26385421|26657901|27013479|28754778|28772289|31337882", name: "MLH1", description: "The MLH1 gene is associated with autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 232603) and autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  MLH1-related Lynch syndrome is characterized by increased risk of various cancers including colorectal, endometrial, ovarian, urinary tract, gastrointestinal, brain and possibly prostate. Lifetime cancer risks include a 46‚Äì61% risk for colorectal cancer, a 5‚Äì7% risk for gastric cancer, a 6% risk for pancreatic cancer, up to an 11% risk for cancer of the small intestines, up to a 5% risk for urinary tract cancer, a 2‚Äì7% risk for bladder cancer, a 2‚Äì4% risk for cancer of the biliary tract and up to a 1.7% risk for brain/nervous system cancer. Affected females also have an increased risk of uterine/endometrial cancer (34-54%) and ovarian cancer (4‚Äì20%) (PMID: 21642682, 28754778, 28772289, 19900449, 26385421, 27013479, 18398828, 26657901,19900449, 31337882).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical findings reminiscent of neurofibromatosis type 1 (NF1) such as cafe-au-lait spots (PMID: 18709565, 20442441, 17539897).", fullName: "MutL Homolog 1", altName: "MLH1,Mutl Homolog", mechanism: "The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]"})
(:gene {references: "15098033) Vulliamy T,Marrone A,Szydlo R,Walne A,Mason PJ,Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet.. 2004;36(5):447-9.|25170286) Fern√É¬°ndez Garc√É¬≠a MS,Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med.. 2014;5():157-67.", pmids: "15098033|25170286", name: "TERC", description: "The TERC gene is associated with autosomal dominant TERC-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 338831).  DC is a telomere disorder characterized by abnormal skin pigmentation, nail dystrophy and oral leukoplakia. Affected individuals have a predisposition to progressive bone marrow failure, pulmonary fibrosis and cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). There is some evidence of genetic anticipation due to telomere shortening in which older generations present with adult-onset pulmonary fibrosis and subsequent generations present in childhood with bone marrow failure (PMID: 15098033).", fullName: "Telomerase RNA Component", mechanism: "TERC encodes a component of telomerase which is involved with maintaining telomeric integrity"})
(:gene {references: "21685915) Comino-M√É¬©ndez I,Gracia-Azn√É¬°rez FJ,Schiavi F,Landa I,Leandro-Garc√É¬≠a LJ,Let√É¬≥n R,Honrado E,Ramos-Medina R,Caronia D,Pita G,G√É¬≥mez-Gra√É¬±a A,de Cubas AA,Inglada-P√É¬©rez L,Maliszewska A,Taschin E,Bobisse S,Pica G,Loli P,Hern√É¬°ndez-Lavado R,D√É¬≠az JA,G√É¬≥mez-Morales M,Gonz√É¬°lez-Neira A,Roncador G,Rodr√É¬≠guez-Antona C,Ben√É¬≠tez J,Mannelli M,Opocher G,Robledo M,Casc√É¬≥n A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet.. 2011;43(7):663-7.|22452945) Burnichon N,Casc√É¬≥n A,Schiavi F,Morales NP,Comino-M√É¬©ndez I,Abermil N,Inglada-P√É¬©rez L,de Cubas AA,Amar L,Barontini M,de Quir√É¬≥s SB,Bertherat J,Bignon YJ,Blok MJ,Bobisse S,Borrego S,Castellano M,Chanson P,Chiara MD,Corssmit EP,Giacch√É¬® M,de Krijger RR,Ercolino T,Girerd X,G√É¬≥mez-Garc√É¬≠a EB,G√É¬≥mez-Gra√É¬±a A,Guilhem I,Hes FJ,Honrado E,Korpershoek E,Lenders JW,Let√É¬≥n R,Mensenkamp AR,Merlo A,Mori L,Murat A,Pierre P,Plouin PF,Prodanov T,Quesada-Charneco M,Qin N,Rapizzi E,Raymond V,Reisch N,Roncador G,Ruiz-Ferrer M,Schillo F,Stegmann AP,Suarez C,Taschin E,Timmers HJ,Tops CM,Urioste M,Beuschlein F,Pacak K,Mannelli M,Dahia PL,Opocher G,Eisenhofer G,Gimenez-Roqueplo AP,Robledo M. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res.. 2012;18(10):2828-37.|23666964) Rattenberry E,Vialard L,Yeung A,Bair H,McKay K,Jafri M,Canham N,Cole TR,Denes J,Hodgson SV,Irving R,Izatt L,Korbonits M,Kumar AV,Lalloo F,Morrison PJ,Woodward ER,Macdonald F,Wallis Y,Maher ER. A comprehensive next generation sequencing-based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. J Clin Endocrinol Metab.. 2013;98(7):E1248-56.|28973655) Casey RT,Warren AY,Martin JE,Challis BG,Rattenberry E,Whitworth J,Andrews KA,Roberts T,Clark GR,West H,Smith PS,Docquier FM,Rodger F,Murray V,Simpson HL,Wallis Y,Giger O,Tran M,Tomkins S,Stewart GD,Park SM,Woodward ER,Maher ER. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. J Clin Endocrinol Metab.. 2017;102(11):4013-4022.|33493868) Richter JE,Hines S,Selvam P,Atwal H,Farres H,Caulfield TR,Atwal PS. Clinical description & molecular modeling of novel MAX pathogenic variant causing pheochromocytoma in family, supports paternal parent-of-origin effect. Cancer Genet.. 2021;252-253():107-110.|32201880) Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms", pmids: "21685915|22452945|23666964|28973655|32201880|33493868", name: "MAX", description: "The MAX gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 313270). There is also evidence suggesting MAX is associated with autosomal dominant predisposition to renal cancer (PMID: 28973655) and pituitary adenomas (PMID: 32201880). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  MAX-associated PGL-PCC syndrome is characterized by malignant or benign PGL and PCC tumors. PGLs are nervous system tumors that often develop within the head, neck, spine, or abdomen. PCCs are adrenal gland tumors that may cause symptoms related to increased hormone secretion, such as rapid heartbeat and high blood pressure (PMID: 21685915, 22452945, 23666964). While both males and females can pass this variant on to their children, there is evidence suggesting the risks of developing MAX-associated tumors are greatest for those who inherit the variant from their father (PMID: 22452945, 33493868).", fullName: "MYC-Associated Factor X", mechanism: "MAX encodes a tumor suppressor part of the MYC-MAX-MXD2 complex, which regulates cell proliferation, differentiation, and apoptosis."})
(:gene {name: "APC", fullName: "APC regulator of WNT signaling pathway", altName: "Adenomatosis Polyposis Coli Tumor Suppressor,Truncated Adenomatosis Polyposis Coli,APC,FAP", mechanism: "APC functions as an antagonist to the Wnt (Wingless-related integration site) signaling pathway. It regulates cell division, adhesion, migration, and apoptosis, among other processes."})
(:gene {references: "15279807) Chun HH,Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst).. ;3(8-9):1187-96.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|26050521) Teive HA,Moro A,Moscovich M,Arruda WO,Munhoz RP,Raskin S,Ashizawa T. Ataxia-telangiectasia - A historical review and a proposal for a new designation: ATM syndrome. J Neurol Sci.. 2015;355(1-2):3-6.|26182300) Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor NM,Pennell E,MacMillan A,Fernandez B,Keller G,Lynch H,Shah SP,Guilford P,Gallinger S,Corso G,Roviello F,Caldas C,Oliveira C,Pharoah PD,Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol.. 2015;1(1):23-32.|26483394) Hu C,Hart SN,Bamlet WR,Moore RM,Nandakumar K,Eckloff BW,Lee YK,Petersen GM,McWilliams RR,Couch FJ. Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. Cancer Epidemiol Biomarkers Prev.. 2016;25(1):207-11.|27112364) Marabelli M,Cheng SC,Parmigiani G. Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk. Genet Epidemiol.. 2016;40(5):425-31.|27989354) Na R,Zheng SL,Han M,Yu H,Jiang D,Shah S,Ewing CM,Zhang L,Novakovic K,Petkewicz J,Gulukota K,Helseth DL,Quinn M,Humphries E,Wiley KE,Isaacs SD,Wu Y,Liu X,Zhang N,Wang CH,Khandekar J,Hulick PJ,Shevrin DH,Cooney KA,Shen Z,Partin AW,Carter HB,Carducci MA,Eisenberger MA,Denmeade SR,McGuire M,Walsh PC,Helfand BT,Brendler CB,Ding Q,Xu J,Isaacs WB. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol.. 2017;71(5):740-747.|28657667) Pili√É¬© PG,Johnson AM,Hanson KL,Dayno ME,Kapron AL,Stoffel EM,Cooney KA. Germline genetic variants in men with prostate cancer and one or more additional cancers. Cancer.. 2017;123(20):3925-3932.|28767289) Shindo K,Yu J,Suenaga M,Fesharakizadeh S,Cho C,Macgregor-Das A,Siddiqui A,Witmer PD,Tamura K,Song TJ,Navarro Almario JA,Brant A,Borges M,Ford M,Barkley T,He J,Weiss MJ,Wolfgang CL,Roberts NJ,Hruban RH,Klein AP,Goggins M. Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. J Clin Oncol.. 2017;35(30):3382-3390.|28888541) Lilyquist J,LaDuca H,Polley E,Davis BT,Shimelis H,Hu C,Hart SN,Dolinsky JS,Couch FJ,Goldgar DE. Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. Gynecol Oncol.. 2017;147(2):375-380.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|30862463) Valle L,de Voer RM,Goldberg Y,Sjursen W,F√É¬∂rsti A,Ruiz-Ponte C,Cald√É¬©s T,Garr√É¬© P,Olsen MF,Nordling M,Castellvi-Bel S,Hemminki K. Update on genetic predisposition to colorectal cancer and polyposis. Mol Aspects Med.. 2019;69():10-26.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|25426837) Age-related clonal hematopoiesis associated with adverse outcomes|33864022) Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG)", pmids: "15279807|25426837|25426838|26050521|26182300|26483394|27112364|27989354|28657667|28767289|28888541|30733081|30862463|33471974|33864022", name: "ATM", description: "The ATM gene is associated with autosomal dominant predisposition to breast, ovarian, pancreatic (PMID: 26483394, 28888541, 30733081) and prostate cancer (PMID: 27989354, 28657667). ATM is also associated with autosomal recessive ataxia-telangiectasia (A-T) (MedGen UID: 439). Additionally, there is evidence suggesting ATM is associated with autosomal dominant predisposition to gastric (PMID: 26182300) and colon cancer (PMID: 30862463). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  The lifetime risk of breast cancer in females with one pathogenic ATM variant is approximately 21-33% (PMID: 30733081, 33471974, 27112364). There is also an increased risk of ovarian, pancreatic and prostate cancer; however, lifetime risks are not established (PMID: 30733081, 28767289, 27989354).  A-T is characterized by progressive cerebellar ataxia beginning in early childhood, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections and increased malignancy risk, particularly leukemia and lymphoma (PMID: 15279807, 26050521).

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results using specimens containing leukocytes may not distinguish between germline and acquired variants and additional testing may be appropriate.", fullName: "Ataxia Telangiectasia Mutated", altName: "ataxia telangiectasia mutated,ATM", mechanism: "ATM encodes a phosphorylating cell cycle checkpoint kinase in the PI3/PI4-kinase family which regulates downstream tumor suppressor proteins. It is involved with the cellular response to DNA damage."})
(:gene {references: "22006311) Walsh T,Casadei S,Lee MK,Pennil CC,Nord AS,Thornton AM,Roeb W,Agnew KJ,Stray SM,Wickramanayake A,Norquist B,Pennington KP,Garcia RL,King MC,Swisher EM. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A.. 2011;108(44):18032-7.|23334666) Pugh TJ,Morozova O,Attiyeh EF,Asgharzadeh S,Wei JS,Auclair D,Carter SL,Cibulskis K,Hanna M,Kiezun A,Kim J,Lawrence MS,Lichenstein L,McKenna A,Pedamallu CS,Ramos AH,Shefler E,Sivachenko A,Sougnez C,Stewart C,Ally A,Birol I,Chiu R,Corbett RD,Hirst M,Jackman SD,Kamoh B,Khodabakshi AH,Krzywinski M,Lo A,Moore RA,Mungall KL,Qian J,Tam A,Thiessen N,Zhao Y,Cole KA,Diamond M,Diskin SJ,Mosse YP,Wood AC,Ji L,Sposto R,Badgett T,London WB,Moyer Y,Gastier-Foster JM,Smith MA,Guidry Auvil JM,Gerhard DS,Hogarty MD,Jones SJ,Lander ES,Gabriel SB,Getz G,Seeger RC,Khan J,Marra MA,Meyerson M,Maris JM. The genetic landscape of high-risk neuroblastoma. Nat Genet.. 2013;45(3):279-84.|28418444) Couch FJ,Shimelis H,Hu C,Hart SN,Polley EC,Na J,Hallberg E,Moore R,Thomas A,Lilyquist J,Feng B,McFarland R,Pesaran T,Huether R,LaDuca H,Chao EC,Goldgar DE,Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol.. 2017;3(9):1190-1196.|32091585) Hu C,Polley EC,Yadav S,Lilyquist J,Shimelis H,Na J,Hart SN,Goldgar DE,Shah S,Pesaran T,Dolinsky JS,LaDuca H,Couch FJ. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. J Natl Cancer Inst.. 2020;112(12):1231-1241.", pmids: "22006311|23334666|28418444|32091585", name: "BARD1", description: "The BARD1 gene is associated with autosomal dominant predisposition to breast cancer (MedGen UID: 87542). Elevated risks for ovarian cancer and neuroblastoma have also been suggested (PMID: 22006311, 23334666). The evidence, however, is preliminary and insufficient to make a determination regarding these relationships.  Females with a pathogenic BARD1 variant have an increased risk of breast cancer; the lifetime risk is 22-29% (PMID: 28418444, 32091585, Kurian et al. 2017).", fullName: "BRCA-Associated RING Domain 1", altName: "BARD1", mechanism: "The protein product of BARD1 forms a heterodimer with BRCA1 at the N-terminal to regulate various processes, including transcriptional regulation, DNA damage repair, and ubiquitination."})
(:gene {references: "12221036) Dunlop MG, , . Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut.. 2002;51 Suppl 5():V21-7.|20859198) Pollock J,Welsh JS. Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol.. 2011;34(3):332-6.|22846733) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Genetic testing by cancer site: colon (polyposis syndromes). Cancer J.. ;18(4):328-33.|2705469) Walpole IR,Cullity G. Juvenile polyposis: a case with early presentation and death attributable to adenocarcinoma of the pancreas. Am J Med Genet.. 1989;32(1):1-8.|9869523) Howe JR,Mitros FA,Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol.. 1998;5(8):751-6.", pmids: "2705469|9869523|12221036|20859198|22846733", name: "BMPR1A", description: "The BMPR1A gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518).  JPS is characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. There is an increased risk of developing colon cancer and stomach cancer (PMID: 20859198, 2705469). The risk of colon cancer is 40-50% (PMID: 22846733, 9869523) and the risk of gastric cancer is up to 21% (PMID: 12221036).", fullName: "Bone Morphogenetic Protein Receptor Type 1A", altName: "BMPR1A", mechanism: "BMPR1A encodes transmembrane serine/threonine kinases which repress the Wnt (Wingless-related integration site) signaling pathway."})
(:gene {references: "18042939) Tai YC,Domchek S,Parmigiani G,Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst.. 2007;99(23):1811-4.|26700119) van den Broek AJ,van 't Veer LJ,Hooning MJ,Cornelissen S,Broeks A,Rutgers EJ,Smit VT,Cornelisse CJ,van Beek M,Janssen-Heijnen ML,Seynaeve C,Westenend PJ,Jobsen JJ,Siesling S,Tollenaar RA,van Leeuwen FE,Schmidt MK. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. J Clin Oncol.. 2016;34(5):409-18.|27306910) Streff H,Profato J,Ye Y,Nebgen D,Peterson SK,Singletary C,Arun BK,Litton JK. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist.. 2016;21(7):869-74.|29922827) Hu C,Hart SN,Polley EC,Gnanaolivu R,Shimelis H,Lee KY,Lilyquist J,Na J,Moore R,Antwi SO,Bamlet WR,Chaffee KG,DiCarlo J,Wu Z,Samara R,Kasi PM,McWilliams RR,Petersen GM,Couch FJ. Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. JAMA.. 2018;319(23):2401-2409.|30900310) Oh M,Alkhushaym N,Fallatah S,Althagafi A,Aljadeed R,Alsowaida Y,Jeter J,Martin JR,Babiker HM,McBride A,Abraham I. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate.. 2019;79(8):880-895.|32676552) Chen J,Bae E,Zhang L,Hughes K,Parmigiani G,Braun D,Rebbeck TR. Penetrance of Breast and Ovarian Cancer in Women Who Carry a  Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectr.. 2020;4(4):pkaa029.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.", pmids: "18042939|26700119|27306910|29922827|30900310|32676552|33471974", name: "BRCA1", description: "The BRCA1 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793). Additionally, the BRCA1 gene has preliminary evidence supporting a correlation with autosomal recessive Fanconi anemia (MedGen UID: 1632414).  HBOC due to a clinically significant change in the BRCA1 gene is characterized by an increased risk of breast cancer (in both females and males), ovarian cancer, prostate cancer, pancreatic cancer and possibly melanoma when compared to individuals in the general population. The lifetime risk of breast cancer for females with a positive BRCA1 variant is 53-78% (PMID: 32676552, 33471974) and the chance of developing breast cancer again in their other breast (contralateral breast cancer) within 10 years after the first diagnosis is estimated to be 20-42% (PMID: 26700119). The lifetime risk to develop ovarian or fallopian tube cancer is 44-65% (PMID: 32676552). Males with HBOC due to a change in the BRCA1 gene have a 1-2% lifetime risk of developing breast cancer (PMID: 18042939) and an increased risk of prostate cancer, although specific lifetime risks are not clear (PMID: 30900310). Both males and females with a positive BRCA1 variant have a 3-4% lifetime risk of pancreatic cancer (PMID: 29922827, 27306910).", fullName: "Breast Cancer 1 Early Onset Protein", altName: "BRCA,BRCA1,17q-linked", mechanism: "The protein product of BRCA1 is a nuclear phosphoprotein which forms the BRCA1-associated genome surveillance complex (BASC) with other proteins and can also form a heterodimer with BARD1. BRCA1 helps regulate the cell cycle and plays a role in homologous recombination repair of double-stranded DNA breaks, transcription, recombination, and ubiquitination."})
(:gene {references: "16258541) Bell DW,Gore I,Okimoto RA,Godin-Heymann N,Sordella R,Mulloy R,Sharma SV,Brannigan BW,Mohapatra G,Settleman J,Haber DA. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet.. 2005;37(12):1315-6.|18355544) Ikeda K,Nomori H,Mori T,Sasaki J,Kobayashi T. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg.. 2008;85(4):1430-2.|23380224) Demierre N,Zoete V,Michielin O,Stauffer E,Zimmermann DR,Betticher DC,Peters S. A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable? Lung Cancer.. 2013;80(1):81-4.|24691054) Campbell P,Morton PE,Takeichi T,Salam A,Roberts N,Proudfoot LE,Mellerio JE,Aminu K,Wellington C,Patil SN,Akiyama M,Liu L,McMillan JR,Aristodemou S,Ishida-Yamamoto A,Abdul-Wahab A,Petrof G,Fong K,Harnchoowong S,Stone KL,Harper JI,Irwin McLean WH,Simpson MA,Parsons M,McGrath JA. Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol.. 2014;134(10):2570-2578.|24736066) Gazdar A,Robinson L,Oliver D,Xing C,Travis WD,Soh J,Toyooka S,Watumull L,Xie Y,Kernstine K,Schiller JH. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol.. 2014;9(4):456-63.|24736080) Yu HA,Arcila ME,Harlan Fleischut M,Stadler Z,Ladanyi M,Berger MF,Robson M,Riely GJ. Germline EGFR T790M mutation found in multiple members of a familial cohort. J Thorac Oncol.. 2014;9(4):554-8.|25176975) Prim N,Legrain M,Guerin E,Mennecier B,Weingertner N,Voegeli AC,Guenot D,Maugard CM,Quoix AE,Beau-Faller M. Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients. Eur Respir Rev.. 2014;23(133):390-2.|26436111) Ganetzky R,Finn E,Bagchi A,Zollo O,Conlin L,Deardorff M,Harr M,Simpson MA,McGrath JA,Zackai E,Lemmon MA,Sondheimer N. EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features. Mol Genet Genomic Med.. 2015;3(5):452-8.|29899996) Hayashi S,Yokoi T,Hatano C,Enomoto Y,Tsurusaki Y,Naruto T,Kobayashi M,Ida H,Kurosawa K. Biallelic mutations of  in a compound heterozygous state cause ectodermal dysplasia with severe skin defects and gastrointestinal dysfunction. Hum Genome Var.. 2018;5():11.|32602142) Earl BR,Szybowska M,Marwaha A,Belostotsky V,Lara-Corrales I,Pope E,Kannu P. Epidermal growth factor receptor deficiency: Expanding the phenotype beyond infancy. J Dermatol.. 2020;47(8):898-902.|21252721) Inherited germline t790 m mutation and somatic epidermal growth factor receptor mutations in non small cell lung cancer patients|23358982) Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation", pmids: "16258541|18355544|21252721|23358982|23380224|24691054|24736066|24736080|25176975|26436111|29899996|32602142", name: "EGFR", description: "The EGFR gene is associated with autosomal dominant predisposition to lung cancer (MedGen UID: 472093) and autosomal recessive neonatal inflammatory skin and bowel disease (MedGen UID: 863567).  Pathogenic loss-of-function (LOF) variants in EGFR are associated with neonatal inflammatory skin and bowel disease, a rare condition affecting the skin, hair, kidney, growth, gastrointestinal and respiratory systems. Skin manifestations include erosions, scaling, inflammatory rash and infection. Recurrent respiratory and gastrointestinal infections as well as severe diarrhea and vomiting may occur (PMID: 32602142, 29899996, 26436111, 24691054). LOF variants in EGFR are not known to be associated with autosomal dominant predisposition to lung cancer.

Pathogenic gain-of-function (GOF) EGFR variants are associated with an increased risk of lung cancer (PMID: 16258541, 24736066, 24736080, 21252721, 23380224, 25176975, 18355544, 23358982). One study estimated the risk of lung cancer to be 15-31% (PMID: 24736066), although data are limited. GOF variants in EGFR are not known to be associated with autosomal recessive neonatal inflammatory skin and bowel disease.", fullName: "Epidermal Growth Factor Receptor", mechanism: "The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. EGFR is a component of the cytokine storm that sometimes results from a severe form of human infection of SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). [provided by RefSeq, Jun 2020]"})
(:gene {references: "31831373) Forde C,Lim DHK,Alwan Y,Burghel G,Butland L,Cleaver R,Dixit A,Evans DG,Hanson H,Lalloo F,Oliveira P,Vialard L,Wallis Y,Maher ER,Woodward ER. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals. Eur Urol Oncol.. 2020;3(6):764-772.", pmids: "31831373", name: "FH", description: "The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771) and autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).  HLRCC is characterized by cutaneous leiomyomas, early onset uterine leiomyomas, kidney tumors and kidney cancer. Uterine leiomyomas, also known as fibroids, are present in nearly all affected females. The lifetime risk for renal cell carcinoma is approximately 21% (PMID: 31831373). Some individuals with a clinically significant change in FH may also develop paragangliomas (PGL) and pheochromocytomas (PCC). PGL are nervous system tumors that often form in the head, neck, spine or abdomen. PCC are adrenal gland tumors that may cause symptoms including tachycardia and hypertension. Most PGL and PCC are benign and while there is malignant potential, lifetime cancer risks are not clear.  FHD is an inborn error of metabolism that causes infantile encephalopathy, failure to thrive, hypotonia, lethargy and seizures. Affected individuals often have microcephaly, distinctive facial features, structural brain abnormalities and developmental delay.", fullName: "Fumerate Hydratase", mechanism: "The protein encoded by this gene is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extended form, differing only in the translation start site used. The N-terminal extended form is targeted to the mitochondrion, where the removal of the extension generates the same form as in the cytoplasm. It is similar to some thermostable class II fumarases and functions as a homotetramer. Mutations in this gene can cause fumarase deficiency and lead to progressive encephalopathy. [provided by RefSeq, Jul 2008]"})
(:gene {references: "18234728) Toro JR,Wei MH,Glenn GM,Weinreich M,Toure O,Vocke C,Turner M,Choyke P,Merino MJ,Pinto PA,Steinberg SM,Schmidt LS,Linehan WM. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dub√É¬© syndrome: a new series of 50 families and a review of published reports. J Med Genet.. 2008;45(6):321-31.|20392993) Palmirotta R,Savonarola A,Ludovici G,Donati P,Cavaliere F,DE Marchis ML,Ferroni P,Guadagni F. Association between Birt Hogg Dube syndrome and cancer predisposition. Anticancer Res.. 2010;30(3):751-7.|20522427) Nahorski MS,Lim DH,Martin L,Gille JJ,McKay K,Rehal PK,Ploeger HM,van Steensel M,Tomlinson IP,Latif F,Menko FH,Maher ER. Investigation of the Birt-Hogg-Dube tumour suppressor gene (FLCN) in familial and sporadic colorectal cancer. J Med Genet.. 2010;47(6):385-90.|25519092) Dal Sasso AA,Bel√É¬©m LC,Zanetti G,Souza CA,Escuissato DL,Irion KL,Guimar√É¬£es MD,Marchiori E. Birt-Hogg-Dub√É¬© syndrome. State-of-the-art review with emphasis on pulmonary involvement. Respir Med.. 2015;109(3):289-96.|25519458) Benusiglio PR,Giraud S,Deveaux S,M√É¬©jean A,Correas JM,Joly D,Timsit MO,Ferlicot S,Verkarre V,Abadie C,Chauveau D,Leroux D,Avril MF,Cordier JF,Richard S, . Renal cell tumour characteristics in patients with the Birt-Hogg-Dub√É¬© cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet J Rare Dis.. 2014;9():163.", pmids: "18234728|20392993|20522427|25519092|25519458", name: "FLCN", description: "The FLCN gene is associated with autosomal dominant Birt-Hogg-Dub√© (BHD) syndrome (MedGen UID: 91070). There is also evidence suggesting BHD is associated with an increased risk of colon polyps and colorectal cancer (PMID: 20522427, 20392993). The data, however, are preliminary and insufficient to made a determination regarding this relationship.  BHD is characterized by an increased risk to develop noncancerous cysts in the lungs (70% risk) and kidneys (12-34% risk) in addition to acrochordons, fibrofolliculomas and trichodiscomas on the face neck and upper body. There is a 24-38% risk of developing one or more spontaneous pneumothorax. Affected individuals also have an increased risk of kidney cancer; however, lifetime risks are not established (PMID: 25519092, 25519458, 18234728).", fullName: "Folliculin", mechanism: "FLCN encodes a tumor suppressor involved in the AMPK and mTOR pathways"})
(:gene {references: "20803646) Mansour S,Connell F,Steward C,Ostergaard P,Brice G,Smithson S,Lunt P,Jeffery S,Dokal I,Vulliamy T,Gibson B,Hodgson S,Cottrell S,Kiely L,Tinworth L,Kalidas K,Mufti G,Cornish J,Keenan R,Mortimer P,Murday V, . Emberger syndrome-primary lymphedema with myelodysplasia: report of seven new cases. Am J Med Genet A.. 2010;152A(9):2287-96.|21892158) Ostergaard P,Simpson MA,Connell FC,Steward CG,Brice G,Woollard WJ,Dafou D,Kilo T,Smithson S,Lunt P,Murday VA,Hodgson S,Keenan R,Pilz DT,Martinez-Corral I,Makinen T,Mortimer PS,Jeffery S,Trembath RC,Mansour S. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet.. 2011;43(10):929-31.|23223431) Pasquet M,Bellann√É¬©-Chantelot C,Tavitian S,Prade N,Beaupain B,Larochelle O,Petit A,Rohrlich P,Ferrand C,Van Den Neste E,Poirel HA,Lamy T,Ouach√É¬©e-Chardin M,Mansat-De Mas V,Corre J,R√É¬©cher C,Plat G,Bachelerie F,Donadieu J,Delabesse E. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood.. 2013;121(5):822-9.", pmids: "20803646|21892158|23223431", name: "GATA2", description: "The GATA2 gene is associated with autosomal dominant GATA2 deficiency (MedGen UID: 481660) and Emberger syndrome (MedGen UID: 481294).  GATA2 deficiency is an immunodeficiency syndrome that typically presents in late adolescence or early adulthood with neutropenia and recurrent infections. GATA2 deficiency is associated with an increased risk of myelodysplastic syndrome and acute myelogenous leukemia (AML). Emberger syndrome is a related GATA2 deficiency condition associated with lymphedema of the lower extremities and predisposition to AML; hearing loss has been reported in some cases (PMID: 23223431, 21892158, 20803646).", fullName: "GATA Binding Protein 2", mechanism: "This gene encodes a member of the GATA family of zinc-finger transcription factors that are named for the consensus nucleotide sequence they bind in the promoter regions of target genes. The encoded protein plays an essential role in regulating transcription of genes involved in the development and proliferation of hematopoietic and endocrine cell lineages. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Mar 2009].GATA2 encodes a transcription factor that regulates transcription of genes involved in development and proliferation of hematopoietic and endocrine cells."})
(:gene {references: "23230001) Pachlopnik Schmid J,Lemoine R,Nehme N,Cormier-Daire V,Revy P,Debeurme F,Debr√É¬© M,Nitschke P,Bole-Feysot C,Legeai-Mallet L,Lim A,de Villartay JP,Picard C,Durandy A,Fischer A,de Saint Basile G. Polymerase √é¬µ1 mutation in a human syndrome with facial dysmorphism, immunodeficiency, livedo, and short stature ('FILS syndrome'). J Exp Med.. 2012;209(13):2323-30.|26133394) Bellido F,Pineda M,Aiza G,Vald√É¬©s-Mas R,Navarro M,Puente DA,Pons T,Gonz√É¬°lez S,Iglesias S,Darder E,Pi√É¬±ol V,Soto JL,Valencia A,Blanco I,Urioste M,Brunet J,L√É¬°zaro C,Capell√É¬° G,Puente XS,Valle L. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med.. 2016;18(4):325-32.|29120461) Buchanan DD,Stewart JR,Clendenning M,Rosty C,Mahmood K,Pope BJ,Jenkins MA,Hopper JL,Southey MC,Macrae FA,Winship IM,Win AK. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genet Med.. 2018;20(8):890-895.|32424176) Hamzaoui N,Alarcon F,Leulliot N,Guimbaud R,Buecher B,Colas C,Corsini C,Nuel G,Terris B,Laurent-Puig P,Chaussade S,Dhooge M,Madru C,Clauser E. Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. Genet Med.. 2020;22(9):1533-1541.", pmids: "23230001|26133394|29120461|32424176", name: "POLE", description: "The POLE gene is associated with an autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 767374) and autosomal recessive FILS syndrome (facial dysmorphism, immunodeficiency, livedo, and short stature) (MedGen UID: 767490).  Individuals with a pathogenic POLE variant typically present with 10-100 adenomas and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 26133394, 29120461, 32424176).  FILS syndrome is characterized by mild facial dysmorphism and immunodeficiency resulting in recurrent infections, livedo on the skin present at birth and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001).", fullName: "DNA Polymerase Epsilon, Catalytic Subunit", altName: "POLE", mechanism: "POLE codes for the catalytic subunit of DNA polymerase epsilon, which is essential for DNA replication."})
(:gene {references: "11755638) Biesecker LG,Rosenberg MJ,Vacha S,Turner JT,Cohen MM. PTEN mutations and proteus syndrome. Lancet.. 2001;358(9298):2079-80.|17392703) Caux F,Plauchu H,Chibon F,Faivre L,Fain O,Vabres P,Bonnet F,Selma ZB,Laroche L,G√É¬©rard M,Longy M. Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet.. 2007;15(7):767-73.|19265751) Varga EA,Pastore M,Prior T,Herman GE,McBride KL. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med.. 2009;11(2):111-7.|25288137) Frazier TW,Embacher R,Tilot AK,Koenig K,Mester J,Eng C. Molecular and phenotypic abnormalities in individuals with germline heterozygous PTEN mutations and autism. Mol Psychiatry.. 2015;20(9):1132-8.|26564076) Mester J,Charis E. PTEN hamartoma tumor syndrome. Handb Clin Neurol.. 2015;132():129-37.|27890237) Nathan N,Keppler-Noreuil KM,Biesecker LG,Moss J,Darling TN. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway. Dermatol Clin.. 2017;35(1):51-60.|31216739) ValidYN,LastName,ForeName,Initials,Identifier,AffiliationInfo. Hamartoma Tumor Syndrome: A Clinical Overview. Cancers (Basel).. 2019;11(6):.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439.", pmids: "11755638|17392703|19265751|25288137|26564076|27890237|31216739|33471991", name: "PTEN", description: "The PTEN gene is associated with autosomal dominant PTEN hamartoma tumor syndrome (PHTS), including the clinical subtypes of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and PTEN-related autism spectrum disorder (MedGen UID: 368366). Other PTEN-associated conditions have also been described (PMID: 11755638, 17392703, 27890237).  PHTS is a highly variable hamartomatous condition characterized by macrocephaly, Lhermitte-Duclos disease, mucocutaneous lesions, gastrointestinal hamartomas, lipomas, benign thyroid lesions, macular pigmentation of the glans penis, cerebrovascular malformations and several types of cancer. Associated cancers include breast (up to 85% risk), thyroid (typically follicular, up to 38% risk), renal (up to 34%), endometrial (up to 28% risk), colorectal (9-16% risk) and melanoma (6% risk) (PMID: 31216739, 33471991). PHTS is also associated with developmental delay, intellectual disability and autism spectrum disorder (PMID: 26564076, 19265751, 25288137).", fullName: "Phosphatase and Tensin Homolog", altName: "Phosphatase And Tensin-Like Protein,PTEN", mechanism: "PTEN codes for a phosphatase which is an antagonist for intracellular phosphatidylinositol-3,4,5-triphosphate levels and for the AKT/PKB signaling pathway. It is involved in cellular migration, adhesion, and angiogenesis."})
(:gene {references: "19409520) Waltes R,Kalb R,Gatei M,Kijas AW,Stumm M,Sobeck A,Wieland B,Varon R,Lerenthal Y,Lavin MF,Schindler D,D√É¬∂rk T. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet.. 2009;84(5):605-16.|21356067) Kuusisto KM,Bebel A,Vihinen M,Schleutker J,Sallinen SL. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Res.. 2011;13(1):R20.|24894818) Damiola F,Pertesi M,Oliver J,Le Calvez-Kelm F,Voegele C,Young EL,Robinot N,Forey N,Durand G,Vall√É¬©e MP,Tao K,Roane TC,Williams GJ,Hopper JL,Southey MC,Andrulis IL,John EM,Goldgar DE,Lesueur F,Tavtigian SV. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res.. 2014;16(3):R58.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439.", pmids: "19409520|21356067|24894818|33471974|33471991", name: "RAD50", description: "The RAD50 gene is associated with autosomal recessive Nijmegen breakage syndrome-like disorder (NBSLD) (PMID: 19409520).  NBSLD is characterized by a clinical phenotype resembling Nijmegen breakage syndrome including chromosomal instability, radiosensitivity, neurodevelopmental disease, and immunodeficiency but with a milder clinical presentation.  Studies had previously suggested that females with a pathogenic variant in RAD50 may have autosomal dominant predisposition to breast cancer (PMID: 21356067, 24894818); however, more recent data have not supported this assertion (PMID: 33471974, 33471991).", fullName: "RAD50 Double Strand Break Repair Protein", altName: "RAD50 Homolog, Double Strand Break Repair Protein,RAD50", mechanism: "The protein product for RAD50 forms the MRN complex with MRE11 and NBS1. It plays a role in nonhomologous repair of double-stranded DNA breaks, as well as serving as a checkpoint in the cell cycle."})
(:gene {references: "20400963) Vaz F,Hanenberg H,Schuster B,Barker K,Wiek C,Erven V,Neveling K,Endt D,Kesterton I,Autore F,Fraternali F,Freund M,Hartmann L,Grimwade D,Roberts RG,Schaal H,Mohammed S,Rahman N,Schindler D,Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet.. 2010;42(5):406-9.|27433846) Pritchard CC,Mateo J,Walsh MF,De Sarkar N,Abida W,Beltran H,Garofalo A,Gulati R,Carreira S,Eeles R,Elemento O,Rubin MA,Robinson D,Lonigro R,Hussain M,Chinnaiyan A,Vinson J,Filipenko J,Garraway L,Taplin ME,AlDubayan S,Han GC,Beightol M,Morrissey C,Nghiem B,Cheng HH,Montgomery B,Walsh T,Casadei S,Berger M,Zhang L,Zehir A,Vijai J,Scher HI,Sawyers C,Schultz N,Kantoff PW,Solit D,Robson M,Van Allen EM,Offit K,de Bono J,Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.. 2016;375(5):443-53.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|32091585) Hu C,Polley EC,Yadav S,Lilyquist J,Shimelis H,Na J,Hart SN,Goldgar DE,Shah S,Pesaran T,Dolinsky JS,LaDuca H,Couch FJ. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. J Natl Cancer Inst.. 2020;112(12):1231-1241.|32107557) Yang X,Song H,Leslie G,Engel C,Hahnen E,Auber B,Horv√É¬°th J,Kast K,Niederacher D,Turnbull C,Houlston R,Hanson H,Loveday C,Dolinsky JS,LaDuca H,Ramus SJ,Menon U,Rosenthal AN,Jacobs I,Gayther SA,Dicks E,Nevanlinna H,Aittom√É¬§ki K,Pelttari LM,Ehrencrona H,Borg √É‚Ä¶,Kvist A,Rivera B,Hansen TVO,Djursby M,Lee A,Dennis J,Bowtell DD,Traficante N,Diez O,Balma√É¬±a J,Gruber SB,Chenevix-Trench G,Investigators K,Jensen A,Kj√É¬¶r SK,H√É¬∏gdall E,Cast√É¬©ra L,Garber J,Janavicius R,Osorio A,Golmard L,Vega A,Couch FJ,Robson M,Gronwald J,Domchek SM,Culver JO,de la Hoya M,Easton DF,Foulkes WD,Tischkowitz M,Meindl A,Schmutzler RK,Pharoah PDP,Antoniou AC. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst.. 2020;112(12):1242-1250.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439.", pmids: "20400963|27433846|30733081|32091585|32107557|33471991", name: "RAD51C", description: "The RAD51C gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 462009). Studies have also suggested RAD51C may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846) and autosomal recessive Fanconi anemia (PMID: 20400963). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  The lifetime risks among females with a pathogenic RAD51C variant are estimated to be 5-11% for ovarian cancer (PMID: 30733081, 32107557, Kurian et al. 2017) and 21-25% for breast cancer (PMID: 33471991, 32107557, 32091585).", fullName: "RAD51 Paralog C", altName: "DNA Repair Protein RAD51 Homolog 3,RAD51 Homolog C,RAD51C", mechanism: "The protein product of RAD51C is pivotal in homologous recombination repair of double-stranded DNA breaks. In collaboration with other proteins, it plays a role in Holliday junction resolution."})
(:gene {references: "27433846) Pritchard CC,Mateo J,Walsh MF,De Sarkar N,Abida W,Beltran H,Garofalo A,Gulati R,Carreira S,Eeles R,Elemento O,Rubin MA,Robinson D,Lonigro R,Hussain M,Chinnaiyan A,Vinson J,Filipenko J,Garraway L,Taplin ME,AlDubayan S,Han GC,Beightol M,Morrissey C,Nghiem B,Cheng HH,Montgomery B,Walsh T,Casadei S,Berger M,Zhang L,Zehir A,Vijai J,Scher HI,Sawyers C,Schultz N,Kantoff PW,Solit D,Robson M,Van Allen EM,Offit K,de Bono J,Nelson PS. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.. 2016;375(5):443-53.|28418444) Couch FJ,Shimelis H,Hu C,Hart SN,Polley EC,Na J,Hallberg E,Moore R,Thomas A,Lilyquist J,Feng B,McFarland R,Pesaran T,Huether R,LaDuca H,Chao EC,Goldgar DE,Dolinsky JS. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol.. 2017;3(9):1190-1196.|30733081) Suszynska M,Klonowska K,Jasinska AJ,Kozlowski P. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes. Gynecol Oncol.. 2019;153(2):452-462.|32091585) Hu C,Polley EC,Yadav S,Lilyquist J,Shimelis H,Na J,Hart SN,Goldgar DE,Shah S,Pesaran T,Dolinsky JS,LaDuca H,Couch FJ. The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. J Natl Cancer Inst.. 2020;112(12):1231-1241.|32107557) Yang X,Song H,Leslie G,Engel C,Hahnen E,Auber B,Horv√É¬°th J,Kast K,Niederacher D,Turnbull C,Houlston R,Hanson H,Loveday C,Dolinsky JS,LaDuca H,Ramus SJ,Menon U,Rosenthal AN,Jacobs I,Gayther SA,Dicks E,Nevanlinna H,Aittom√É¬§ki K,Pelttari LM,Ehrencrona H,Borg √É‚Ä¶,Kvist A,Rivera B,Hansen TVO,Djursby M,Lee A,Dennis J,Bowtell DD,Traficante N,Diez O,Balma√É¬±a J,Gruber SB,Chenevix-Trench G,Investigators K,Jensen A,Kj√É¬¶r SK,H√É¬∏gdall E,Cast√É¬©ra L,Garber J,Janavicius R,Osorio A,Golmard L,Vega A,Couch FJ,Robson M,Gronwald J,Domchek SM,Culver JO,de la Hoya M,Easton DF,Foulkes WD,Tischkowitz M,Meindl A,Schmutzler RK,Pharoah PDP,Antoniou AC. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. J Natl Cancer Inst.. 2020;112(12):1242-1250.|33471974) Hu C,Hart SN,Gnanaolivu R,Huang H,Lee KY,Na J,Gao C,Lilyquist J,Yadav S,Boddicker NJ,Samara R,Klebba J,Ambrosone CB,Anton-Culver H,Auer P,Bandera EV,Bernstein L,Bertrand KA,Burnside ES,Carter BD,Eliassen H,Gapstur SM,Gaudet M,Haiman C,Hodge JM,Hunter DJ,Jacobs EJ,John EM,Kooperberg C,Kurian AW,Le Marchand L,Lindstroem S,Lindstrom T,Ma H,Neuhausen S,Newcomb PA,O'Brien KM,Olson JE,Ong IM,Pal T,Palmer JR,Patel AV,Reid S,Rosenberg L,Sandler DP,Scott C,Tamimi R,Taylor JA,Trentham-Dietz A,Vachon CM,Weinberg C,Yao S,Ziogas A,Weitzel JN,Goldgar DE,Domchek SM,Nathanson KL,Kraft P,Polley EC,Couch FJ. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med.. 2021;384(5):440-451.", pmids: "27433846|28418444|30733081|32091585|32107557|33471974", name: "RAD51D", description: "The RAD51D gene is associated with autosomal dominant predisposition to breast and ovarian cancer (MedGen UID: 481975). Studies have also suggested RAD51D may be associated with autosomal dominant predisposition to prostate cancer (PMID: 27433846). The data, however, are preliminary and  insufficient to make a determination regarding this relationship.   The lifetime risks among females with a pathogenic RAD51D variant are estimated to be 8-13% for ovarian cancer (PMID: 30733081, 32107557) and 20-31% for breast cancer (PMID: 28418444, 32091585, 33471974).", fullName: "RAD51 Paralog D", altName: "DNA Repair Protein RAD51 Homolog 4,RAD51 Paralog D,RAD51D", mechanism: "The protein product of RAD51D is pivotal in homologous recombination repair of double-stranded DNA breaks. In collaboration with other proteins, it plays a role in Holliday junction resolution."})
(:gene {references: "12221036) Dunlop MG, , . Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut.. 2002;51 Suppl 5():V21-7.|20859198) Pollock J,Welsh JS. Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol.. 2011;34(3):332-6.|22846733) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Genetic testing by cancer site: colon (polyposis syndromes). Cancer J.. ;18(4):328-33.|24424121) Michot C,Le Goff C,Mahaut C,Afenjar A,Brooks AS,Campeau PM,Destree A,Di Rocco M,Donnai D,Hennekam R,Heron D,Jacquemont S,Kannu P,Lin AE,Manouvrier-Hanu S,Mansour S,Marlin S,McGowan R,Murphy H,Raas-Rothschild A,Rio M,Simon M,Stolte-Dijkstra I,Stone JR,Sznajer Y,Tolmie J,Touraine R,van den Ende J,Van der Aa N,van Essen T,Verloes A,Munnich A,Cormier-Daire V. Myhre and LAPS syndromes: clinical and molecular review of 32 patients. Eur J Hum Genet.. 2014;22(11):1272-7.|24715504) Caputo V,Bocchinfuso G,Castori M,Traversa A,Pizzuti A,Stella L,Grammatico P,Tartaglia M. Novel SMAD4 mutation causing Myhre syndrome. Am J Med Genet A.. 2014;164A(7):1835-40.|26636501) Bassett JK,Douzgou S,Kerr B. Severe constipation in a patient with Myhre syndrome: a case report. Clin Dysmorphol.. 2016;25(2):54-7.|2705469) Walpole IR,Cullity G. Juvenile polyposis: a case with early presentation and death attributable to adenocarcinoma of the pancreas. Am J Med Genet.. 1989;32(1):1-8.|27302097) Lin AE,Michot C,Cormier-Daire V,L'Ecuyer TJ,Matherne GP,Barnes BH,Humberson JB,Edmondson AC,Zackai E,O'Connor MJ,Kaplan JD,Ebeid MR,Krier J,Krieg E,Ghoshhajra B,Lindsay ME. Gain-of-function mutations in SMAD4 cause a distinctive repertoire of cardiovascular phenotypes in patients with Myhre syndrome. Am J Med Genet A.. 2016;170(10):2617-31.|27562837) Garavelli L,Maini I,Baccilieri F,Ivanovski I,Pollazzon M,Rosato S,Iughetti L,Unger S,Superti-Furga A,Tartaglia M. Natural history and life-threatening complications in Myhre syndrome and review of the literature. Eur J Pediatr.. 2016;175(10):1307-15.|9869523) Howe JR,Mitros FA,Summers RW. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol.. 1998;5(8):751-6.", pmids: "2705469|9869523|12221036|20859198|22846733|24424121|24715504|26636501|27302097|27562837", name: "SMAD4", description: "The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400) and Myhre syndrome (MedGen UID: 167103).  Loss-of-function (LOF) variants in SMAD4 are associated with juvenile polyposis syndrome (JPS), a condition characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469). LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.   Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT.", fullName: "SMAD Family Member 4", altName: "MAD (mothers against decapentaplegic, Drosophila) homolog 4,Mothers against decapentaplegic, Drosophila, homolog of, 4,SMAD, mothers against DPP homolog 4 (Drosophila),Deletion Target In Pancreatic Carcinoma 4,SMAD4", mechanism: "SMAD4 codes for a signal transduction protein in the SMAD family, which is activated by transmembrane serine-threonine kinases. SMAD4 conglomerates with other SMAD proteins, building up in the nucleus. SMAD4 also helps regulate cell growth and proliferati"})
(:gene {references: "11113065) Giardiello FM,Brensinger JD,Tersmette AC,Goodman SN,Petersen GM,Booker SV,Cruz-Correa M,Offerhaus JA. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology.. 2000;119(6):1447-53.|33471991)  ,Dorling L,Carvalho S,Allen J,Gonz√É¬°lez-Neira A,Luccarini C,Wahlstr√É¬∂m C,Pooley KA,Parsons MT,Fortuno C,Wang Q,Bolla MK,Dennis J,Keeman R,Alonso MR,√É¬Ålvarez N,Herraez B,Fernandez V,N√É¬∫√É¬±ez-Torres R,Osorio A,Valcich J,Li M,T√É¬∂rngren T,Harrington PA,Baynes C,Conroy DM,Decker B,Fachal L,Mavaddat N,Ahearn T,Aittom√É¬§ki K,Antonenkova NN,Arnold N,Arveux P,Ausems MGEM,Auvinen P,Becher H,Beckmann MW,Behrens S,Bermisheva M,Bia√Ö‚Äökowska K,Blomqvist C,Bogdanova NV,Bogdanova-Markov N,Bojesen SE,Bonanni B,B√É¬∏rresen-Dale AL,Brauch H,Bremer M,Briceno I,Br√É¬ºning T,Burwinkel B,Cameron DA,Camp NJ,Campbell A,Carracedo A,Castelao JE,Cessna MH,Chanock SJ,Christiansen H,Coll√É¬©e JM,Cordina-Duverger E,Cornelissen S,Czene K,D√É¬∂rk T,Ekici AB,Engel C,Eriksson M,Fasching PA,Figueroa J,Flyger H,F√É¬∂rsti A,Gabrielson M,Gago-Dominguez M,Georgoulias V,Gil F,Giles GG,Glendon G,Garcia EBG,Aln√É¬¶s GIG,Gu√É¬©nel P,Hadjisavvas A,Haeberle L,Hahnen E,Hall P,Hamann U,Harkness EF,Hartikainen JM,Hartman M,He W,Heemskerk-Gerritsen BAM,Hillemanns P,Hogervorst FBL,Hollestelle A,Ho WK,Hooning MJ,Howell A,Humphreys K,Idris F,Jakubowska A,Jung A,Kapoor PM,Kerin MJ,Khusnutdinova E,Kim SW,Ko YD,Kosma VM,Kristensen VN,Kyriacou K,Lakeman IMM,Lee JW,Lee MH,Li J,Lindblom A,Lo WY,Loizidou MA,Lophatananon A,Lubi√Ö‚Äûski J,MacInnis RJ,Madsen MJ,Mannermaa A,Manoochehri M,Manoukian S,Margolin S,Martinez ME,Maurer T,Mavroudis D,McLean C,Meindl A,Mensenkamp AR,Michailidou K,Miller N,Mohd Taib NA,Muir K,Mulligan AM,Nevanlinna H,Newman WG,Nordestgaard BG,Ng PS,Oosterwijk JC,Park SK,Park-Simon TW,Perez JIA,Peterlongo P,Porteous DJ,Prajzendanc K,Prokofyeva D,Radice P,Rashid MU,Rhenius V,Rookus MA,R√É¬ºdiger T,Saloustros E,Sawyer EJ,Schmutzler RK,Schneeweiss A,Sch√É¬ºrmann P,Shah M,Sohn C,Southey MC,Surowy H,Suvanto M,Thanasitthichai S,Tomlinson I,Torres D,Truong T,Tzardi M,Valova Y,van Asperen CJ,Van Dam RM,van den Ouweland AMW,van der Kolk LE,van Veen EM,Wendt C,Williams JA,Yang XR,Yoon SY,Zamora MP,Evans DG,de la Hoya M,Simard J,Antoniou AC,Borg √É‚Ä¶,Andrulis IL,Chang-Claude J,Garc√É¬≠a-Closas M,Chenevix-Trench G,Milne RL,Pharoah PDP,Schmidt MK,Spurdle AB,Vreeswijk MPG,Benitez J,Dunning AM,Kvist A,Teo SH,Devilee P,Easton DF. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med.. 2021;384(5):428-439.", pmids: "11113065|33471991", name: "STK11", description: "The STK11 gene is associated with autosomal dominant Peutz-Jeghers syndrome (PJS) (MedGen UID: 18404).  PJS is characterized by gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation of the lips, and increased risk of cancer. Affected individuals have increased risk of developing a wide variety of cancers including breast (19-54% risk), ovarian (18-21% risk), testicular (9% risk), endometrial/uterine (9% risk), cervical (10% risk), colon (39% risk), gastric (29% risk), small bowel (13% risk), pancreatic (11-36% risk) and lung (7-17% risk) (PMID: 11113065, 33471991).", fullName: "Serine/Threonine Kinase 11", altName: "Serine/threonine-protein kinase 11,STK11", mechanism: "STK11 codes for a serine/threonine protein kinase which regulates AMP-activated protein kinases. As a result, STK11 plays a role in controlling cell apoptosis, division, metabolism, and polarization, along with DNA damage repair."})
(:gene {references: "10864200) Chompret A,Brugi√É¬®res L,Ronsin M,Gardes M,Dessarps-Freichey F,Abel A,Hua D,Ligot L,Dondon MG,Bressac-de Paillerets B,Fr√É¬©bourg T,Lemerle J,Bona√É¬Øti-Pelli√É¬© C,Feunteun J. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer.. 2000;82(12):1932-7.|19556618) Gonzalez KD,Buzin CH,Noltner KA,Gu D,Li W,Malkin D,Sommer SS. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet.. 2009;46(10):689-93.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|31490007) Coffee B,Cox HC,Bernhisel R,Manley S,Bowles K,Roa BB,Mancini-DiNardo D. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Hum Mutat.. 2020;41(1):203-211.|31881331) Mester JL,Jackson SA,Postula K,Stettner A,Solomon S,Bissonnette J,Murphy PD,Klein RT,Hruska KS. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. J Mol Diagn.. 2020;22(3):396-404.|25426837) Age-related clonal hematopoiesis associated with adverse outcomes", pmids: "10864200|19556618|25426837|25426838|31490007|31881331", name: "TP53", description: "The TP53 gene is associated with autosomal dominant Li-Fraumeni syndrome (LFS) (MedGen UID: 322656).  LFS is a cancer predisposition syndrome associated with sarcoma, brain cancer, breast cancer, adrenocortical carcinoma and other malignancies. Affected individuals often develop cancers in childhood or early adulthood, and are at increased risk for multiple primary cancers. Overall lifetime cancer risks have been reported as high as 73% for males and nearly 100% for females (PMID: 10864200). It is estimated that 7-20% of LFS cases are due to a de novo pathogenic variant (PMID: 19556618). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired TP53 variants and additional testing may be appropriate.", fullName: "Tumor Protein P53", altName: "transformation-related protein 53,tumor suppressor p53,TP53", mechanism: "TP53 codes for a regulatory protein which controls expression of other genes. In this capacity, TP53 plays a role in the cell cycle, apoptosis, DNA repair, cell metabolism, and cellular senescence."})
(:gene {references: "31629417) Isaacs WB,Cooney KA,Xu J. Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13. Can J Urol.. 2019;26(5 Suppl 2):12-13.", pmids: "31629417", name: "HOXB13", fullName: "Homeobox B13", description: "The HOXB13 gene is associated with autosomal dominant predisposition to prostate cancer (PMID: 31629417).", altName: "Homeo Box B13", mechanism: "This gene encodes a transcription factor that belongs to the homeobox gene family. Genes of this family are highly conserved among vertebrates and essential for vertebrate embryonic development. This gene has been implicated to play a role in fetal skin development and cutaneous regeneration. In mice, a similar gene was shown to exhibit temporal and spatial colinearity in the main body axis of the embryo, but was not expressed in the secondary axes, which suggests functions in body patterning along the axis. This gene and other HOXB genes form a gene cluster at chromosome the 17q21-22 region."})
(:gene {references: "23140918) Pasquali D,Di Matteo FM,Renzullo A,Accardo G,Esposito D,Barbato F,Colantuoni V,Circelli L,Conzo G. Multiple endocrine neoplasia, the old and the new: a mini review. G Chir.. ;33(11-12):370-3.|23933118) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol.. 2014;386(1-2):2-15.", pmids: "23140918|23933118", name: "CDKN1B", description: "The CDKN1B gene is associated with autosomal dominant multiple endocrine neoplasia type 4 (MEN4) (MedGen UID: 373469).  MEN4 is characterized by parathyroid and pituitary tumors as well as tumors of the adrenal glands, kidney and reproductive organs (PMID: 23933118, 23140918).", fullName: "Cyclin Dependent Kinase Inhibitor 1B", altName: "CDKN1B", mechanism: "This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state."})
(:gene {references: "10599684) Vilain E,Le Merrer M,Lecointre C,Desangles F,Kay MA,Maroteaux P,McCabe ER. IMAGe, a new clinical association of intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies. J Clin Endocrinol Metab.. 1999;84(12):4335-40.|14760276) Pedreira CC,Savarirayan R,Zacharin MR. IMAGe syndrome: a complex disorder affecting growth, adrenal and gonadal function, and skeletal development. J Pediatr.. 2004;144(2):274-7.|24098681) Hamajima N,Johmura Y,Suzuki S,Nakanishi M,Saitoh S. Increased protein stability of CDKN1C causes a gain-of-function phenotype in patients with IMAGe syndrome. PLoS One.. 2013;8(9):e75137.|24335096) Brioude F,Lacoste A,Netchine I,Vazquez MP,Auber F,Audry G,Gauthier-Villars M,Brugieres L,Gicquel C,Le Bouc Y,Rossignol S. Beckwith-Wiedemann syndrome: growth pattern and tumor risk according to molecular mechanism, and guidelines for tumor surveillance. Horm Res Paediatr.. 2013;80(6):457-65.|24911853) Gizewska M,Wilk M,Patalan M,Mackay D,Peregud-Pegorzelski J,Gawrych E,Walczak M,Petriczko E,Brodkiewicz A. The significance of molecular studies in the long-term follow-up of children with beckwith- wiedemann syndrome. Turk J Pediatr.. 2014;56(2):177-82.|20301568) Beckwith wiedemann syndrome", pmids: "10599684|14760276|20301568|24098681|24335096|24911853", name: "CDKN1C", description: "The CDKN1C gene is associated with autosomal dominant Beckwith-Wiedemann syndrome (BWS) (MedGen UID: 2562) and IMAGe syndrome (intrauterine growth restriction, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies) (MedGen UID: 337364).  BWS is an overgrowth disorder characterized by macrosomia, macroglossia, visceromegaly, hemihyperplasia, omphalocele, neonatal hypoglycemia, and renal abnormalities. There is an increased risk for neoplasia, particularly Wilms tumor, hepatoblastoma, neuroblastoma, adrenocortical carcinoma and rhabdomyosarcoma; these risks are highest in the newborn period through eight years of age (PMID: 24335096, 24911853, 20301568).

IMAGe syndrome is also characterized by growth abnormality; however, unlike BWS, affected individuals present with growth restriction. In addition to the clinical findings indicated by the acronym (Intrauterine growth restriction, Metaphyseal dysplasia, congenital Adrenal hypoplasia, and Genital anomalies), some may present with craniofacial features such as low-set ears, flat nasal bridge and short nose (PMID: 24098681, 10599684, 14760276). Genital anomalies occur mostly in males and include micropenis, undescended testes and hypospadias (PMID: 14760276).", fullName: "Cyclin Dependent Kinase Inhibitor 1C", mechanism: "This gene is imprinted, with preferential expression of the maternal allele. The encoded protein is a tight-binding, strong inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation. Mutations in this gene are implicated in sporadic cancers and Beckwith-Wiedemann syndorome, suggesting that this gene is a tumor suppressor candidate. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Oct 2010]"})
(:gene {references: "18946494) Renneville A,Mialou V,Philippe N,Kagialis-Girard S,Biggio V,Zabot MT,Thomas X,Bertrand Y,Preudhomme C. Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia.. 2009;23(4):804-6.|26162409) Tawana K,Wang J,Renneville A,B√É¬∂d√É¬∂r C,Hills R,Loveday C,Savic A,Van Delft FW,Treleaven J,Georgiades P,Uglow E,Asou N,Uike N,Debeljak M,Jazbec J,Ancliff P,Gale R,Thomas X,Mialou V,D√É¬∂hner K,Bullinger L,Mueller B,Pabst T,Stelljes M,Schlegelberger B,Wozniak E,Iqbal S,Okosun J,Araf S,Frank AK,Lauridsen FB,Porse B,Nerlov C,Owen C,Dokal I,Gribben J,Smith M,Preudhomme C,Chelala C,Cavenagh J,Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood.. 2015;126(10):1214-23.", pmids: "18946494|26162409", name: "CEBPA", description: "The CEBPA gene is associated with autosomal dominant predisposition to familial acute myeloid leukemia (AML) (MedGen UID: 9730).  Familial AML is characterized by multiple diagnoses of this cancer type within a family. The age at diagnosis can be variable; however, it appears to have an earlier onset than sporadic cases (PMID: 18946494, 26162409).", fullName: "CAAT Enhancer Binding Protein Alpha", mechanism: "This intronless gene encodes a transcription factor that contains a basic leucine zipper (bZIP) domain and recognizes the CCAAT motif in the promoters of target genes. The encoded protein functions in homodimers and also heterodimers with CCAAT/enhancer-binding proteins beta and gamma. Activity of this protein can modulate the expression of genes involved in cell cycle regulation as well as in body weight homeostasis. Mutation of this gene is associated with acute myeloid leukemia. The use of alternative in-frame non-AUG (GUG) and AUG start codons results in protein isoforms with different lengths. Differential translation initiation is mediated by an out-of-frame, upstream open reading frame which is located between the GUG and the first AUG start codons. [provided by RefSeq, Dec 2013]"})
(:gene {references: "23208944) Majewski IJ,Kluijt I,Cats A,Scerri TS,de Jong D,Kluin RJ,Hansford S,Hogervorst FB,Bosma AJ,Hofland I,Winter M,Huntsman D,Jonkers J,Bahlo M,Bernards R. An √é¬±-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol.. 2013;229(4):621-9.|26182300) Hansford S,Kaurah P,Li-Chang H,Woo M,Senz J,Pinheiro H,Schrader KA,Schaeffer DF,Shumansky K,Zogopoulos G,Santos TA,Claro I,Carvalho J,Nielsen C,Padilla S,Lum A,Talhouk A,Baker-Lange K,Richardson S,Lewis I,Lindor NM,Pennell E,MacMillan A,Fernandez B,Keller G,Lynch H,Shah SP,Guilford P,Gallinger S,Corso G,Roviello F,Caldas C,Oliveira C,Pharoah PD,Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol.. 2015;1(1):23-32.|26691986) Saksens NT,Krebs MP,Schoenmaker-Koller FE,Hicks W,Yu M,Shi L,Rowe L,Collin GB,Charette JR,Letteboer SJ,Neveling K,van Moorsel TW,Abu-Ltaif S,De Baere E,Walraedt S,Banfi S,Simonelli F,Cremers FP,Boon CJ,Roepman R,Leroy BP,Peachey NS,Hoyng CB,Nishina PM,den Hollander AI. Mutations in CTNNA1 cause butterfly-shaped pigment dystrophy and perturbed retinal pigment epithelium integrity. Nat Genet.. 2016;48(2):144-51.|32051609) Clark DF,Michalski ST,Tondon R,Nehoray B,Ebrahimzadeh J,Hughes SK,Soper ER,Domchek SM,Rustgi AK,Pineda-Alvarez D,Anderson MJ,Katona BW. Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer. Genet Med.. 2020;22(5):840-846.|32758476) Blair VR,McLeod M,Carneiro F,Coit DG,D'Addario JL,van Dieren JM,Harris KL,Hoogerbrugge N,Oliveira C,van der Post RS,Arnold J,Benusiglio PR,Bisseling TM,Boussioutas A,Cats A,Charlton A,Schreiber KEC,Davis JL,Pietro MD,Fitzgerald RC,Ford JM,Gamet K,Gullo I,Hardwick RH,Huntsman DG,Kaurah P,Kupfer SS,Latchford A,Mansfield PF,Nakajima T,Parry S,Rossaak J,Sugimura H,Svrcek M,Tischkowitz M,Ushijima T,Yamada H,Yang HK,Claydon A,Figueiredo J,Paringatai K,Seruca R,Bougen-Zhukov N,Brew T,Busija S,Carneiro P,DeGregorio L,Fisher H,Gardner E,Godwin TD,Holm KN,Humar B,Lintott CJ,Monroe EC,Muller MD,Norero E,Nouri Y,Paredes J,Sanches JM,Schulpen E,Ribeiro AS,Sporle A,Whitworth J,Zhang L,Reeve AE,Guilford P. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol.. 2020;21(8):e386-e397.|12724643) Genetic heterogeneity of butterfly shaped pigment dystrophy of the fovea|22466463) Pattern dystrophy with high intrafamilial variability associated with y141 c mutation in the peripherin rds gene and successful treatment of subfoveal cnv related to multifocal pattern type with anti vegf (ranibizumab) intravitreal injections", pmids: "12724643|22466463|23208944|26182300|26691986|32051609|32758476", name: "CTNNA1", description: "The CTNNA1 gene is associated with autosomal dominant butterfly-shaped pigmentary macular dystrophy (MedGen UID: 332348). Additionally, CTNNA1 has preliminary evidence supporting a correlation with autosomal dominant hereditary diffuse gastric cancer; however, the available evidence is insufficient to make a determination regarding this relationship (PMID: 23208944, 26182300, 32051609). This result should be considered in the context of personal and family history of diffuse gastric cancer and may warrant additional surveillance (PMID: 32758476). To date, loss-of-function variants in CTNNA1 have not been associated with butterfly-shaped pigmentary macular dystrophy.  Butterfly-shaped pigmentary macular dystrophy is a form of patterned dystrophies of the retinal pigment epithelium, characterized by accumulation of pigment in the macula that resembles the wings of a butterfly (PMID: 12724643). Affected individuals typically present from middle age with mildly reduced visual acuity and color vision. The activity of the RPE measured by electrooculogram (EOG) recordings may be abnormal (PMID: 26691986). Retinitis pigmentosa-like changes have been observed in some cases (PMID: 22466463). The disease is relatively benign, but can progress to atrophy of the choroid and retina, resulting in severe vision loss, though the severity of the disease is highly variable, even within the same family (PMID: 26691986).", fullName: "Catenin Alpha 1", mechanism: "CTNNA1 encodes a protein of the same name that may play a role in cell differentiation."})
(:gene {references: "12213668) Villablanca A,Wassif WS,Smith T,H√É¬∂√É¬∂g A,Vierimaa O,Kassem M,Dwight T,Forsberg L,Du Q,Learoyd D,Jones K,Stranks S,Juhlin C,Teh BT,Carling T,Robinson B,Larsson C. Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. Eur J Endocrinol.. 2002;147(3):313-22.|12699448) Pannett AA,Kennedy AM,Turner JJ,Forbes SA,Cavaco BM,Bassett JH,Cianferotti L,Harding B,Shine B,Flinter F,Maidment CG,Trembath R,Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) germline mutations in familial isolated primary hyperparathyroidism. Clin Endocrinol (Oxf).. 2003;58(5):639-46.|22723327) Thakker RV,Newey PJ,Walls GV,Bilezikian J,Dralle H,Ebeling PR,Melmed S,Sakurai A,Tonelli F,Brandi ML, . Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab.. 2012;97(9):2990-3011.|27572829) Okada R,Shimura T,Tsukida S,Ando J,Kofunato Y,Momma T,Yashima R,Koyama Y,Suzuki S,Takenoshita S. Concomitant existence of pheochromocytoma in a patient with multiple endocrine neoplasia type 1. Surg Case Rep.. 2016;2(1):84.|30608029) Hill KA,Yip L,Carty SE,McCoy KL. Concomitant Thyroid Cancer in Patients with Multiple Endocrine Neoplasia Type 1 Undergoing Surgery for Primary Hyperparathyroidism. Thyroid.. 2019;29(2):252-257.|32130200) Tepede AA,Welch J,Lee M,Mandl A,Agarwal SK,Nilubol N,Patel D,Cochran C,Simonds WF,Weinstein LS,Jha A,Millo C,Pacak K,Blau JE. 18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinol Diabetes Metab Case Rep.. 2020;2020():.|32971521) Niederle B,Selberherr A,Bartsch DK,Brandi ML,Doherty GM,Falconi M,Goudet P,Halfdanarson TR,Ito T,Jensen RT,Larghi A,Lee L,√É‚Äìberg K,Pavel M,Perren A,Sadowski SM,Tonelli F,Triponez F,Valk GD,O'Toole D,Scott-Coombes D,Thakker RV,Thompson GB,Treglia G,Wiedenmann B. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome - An International Consensus Statement. Neuroendocrinology.. 2021;111(7):609-630.", pmids: "12213668|12699448|22723327|27572829|30608029|32130200|32971521", name: "MEN1", description: "The MEN1 gene is associated with autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome (MedGen UID: 9957) and familial isolated hyperparathyroidism (FIHP) (OMIM: 145000). Studies also suggest the MEN1 gene may be associated with autosomal dominant predisposition to thyroid cancer (PMID: 30608029) and paraganglioma-pheochromocytoma syndrome (PGL-PCC) (PMID: 22723327, 27572829, 32130200). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  Multiple endocrine neoplasia type 1 is a highly penetrant condition associated with endocrine tumors in the parathyroid, anterior pituitary, thymus, gastro-entero-pancreatic tract and adrenal glands. Affected individuals may also have facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. While most MEN1-associated tumors are noncancerous, there is an increased risk of malignant transformation. Parathyroid tumors are the primary MEN1-associated endocrinopathy with symptoms typically developing at 20-25 years of age (PMID: 32971521).  MEN1 is also associated with autosomal dominant familial isolated hyperparathyroidism (FIHP), characterized by parathyroid adenomas or hyperplasia without other associated tumors or endocrinopathies (PMID: 12213668, 12699448).", fullName: "Menin¬†", altName: "multiple endocrine neoplasia I,Menin,MEN1", mechanism: "MEN1 encodes a tumor suppressor that plays a role in cell proliferation, genomic stability, and cell cycle control."})
(:gene {references: "12647800) Kuroda N,Toi M,Hiroi M,Enzan H. Review of papillary renal cell carcinoma with focus on clinical and pathobiological aspects. Histol Histopathol.. 2003;18(2):487-94.|30777867) Zhou H,Lian C,Wang T,Yang X,Xu C,Su D,Zheng S,Huang X,Liao Z,Zhou T,Qiu X,Chen Y,Gao B,Li Y,Wang X,You G,Fu Q,Gurnett C,Huang D,Su P. mutation causes muscular dysplasia and√Ç¬†arthrogryposis. EMBO Mol Med.. 2019;11(3):.|8308957) Zbar B,Tory K,Merino M,Schmidt L,Glenn G,Choyke P,Walther MM,Lerman M,Linehan WM. Hereditary papillary renal cell carcinoma. J Urol.. 1994;151(3):561-6.|9563489) Schmidt L,Junker K,Weirich G,Glenn G,Choyke P,Lubensky I,Zhuang Z,Jeffers M,Vande Woude G,Neumann H,Walther M,Linehan WM,Zbar B. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res.. 1998;58(8):1719-22.|24710684) Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations", pmids: "8308957|9563489|12647800|24710684|30777867", name: "MET", fullName: "MET Proto-Oncogene, Receptor Tyrosine Kinase", description: "The MET gene is associated with autosomal dominant predisposition to hereditary papillary renal cell carcinoma (HPRCC) (MedGen UID: 766) and autosomal recessive deafness (MedGen UID: 899875). Additionally, the MET gene has preliminary evidence supporting a correlation with arthrogryposis involving the upper limbs (PMID: 30777867). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  HPRCC is a rare, highly penetrant hereditary cancer syndrome characterized by an increased lifetime risk of developing type 1 papillary renal cell carcinoma (PRCC) (PMID: 24710684, 9563489, 12647800). These tumors are typically multifocal and bilateral (PMID: 8308957).                           Nonsyndromic deafness does not affect any other part of the body. Affected individuals are born with mild to profound hearing loss that typically does not worsen over time. Severity of deafness may vary, even among members of the same family. Intellect and life span are not impacted.", mechanism: "This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]"})
(:gene {references: "16448984) Lantieri F,Griseri P,Ceccherini I. Molecular mechanisms of RET-induced Hirschsprung pathogenesis. Ann Med.. 2006;38(1):11-9.|21552134) Moline J,Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med.. 2011;13(9):755-64.|33812987) Mathiesen JS,Effraimidis G,Rossing M,Rasmussen √É‚Ä¶K,Hoejberg L,Bastholt L,Godballe C,Oturai P,Feldt-Rasmussen U. Multiple endocrine neoplasia type 2: A reveiw. Semin Cancer Biol.. 2021;():.|31390501) Pheochromocytoma and Paraganglioma", pmids: "16448984|21552134|31390501|33812987", name: "RET", description: "The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501). In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area. 

Pathogenic loss-of-function (LOF) RET variants are associated with Hirschsprung disease (HD), a condition characterized by congenital agenesis of ganglion in the colon. HD is typically diagnosed in early infancy, although less severe cases may be diagnosed later in childhood (PMID: 16448984).", fullName: "Ret Proto-Oncogene", altName: "RET,cadherin-related family member 16", mechanism: "This gene encodes a transmembrane receptor and member of the tyrosine protein kinase family of proteins. Binding of ligands such as GDNF (glial cell-line derived neurotrophic factor) and other related proteins to the encoded receptor stimulates receptor dimerization and activation of downstream signaling pathways that play a role in cell differentiation, growth, migration and survival. The encoded receptor is important in development of the nervous system, and the development of organs and tissues derived from the neural crest. This proto-oncogene can undergo oncogenic activation through both cytogenetic rearrangement and activating point mutations. Mutations in this gene are associated with Hirschsprung disease and central hypoventilation syndrome and have been identified in patients with renal agenesis. [provided by RefSeq, Sep 2017]"})
(:gene {references: "26186299) Hern√É¬°ndez-Ram√É¬≠rez LC,Gabrovska P,D√É¬©nes J,Stals K,Trivellin G,Tilley D,Ferrau F,Evanson J,Ellard S,Grossman AB,Roncaroli F,Gadelha MR,Korbonits M, . Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab.. 2015;100(9):E1242-54.|22720333) AIP Familial Isolated Pituitary Adenomas", pmids: "22720333|26186299", name: "AIP", fullName: "Aryl Hydrocarbon Receptor Interacting Protein", description: "The AIP gene is associated with autosomal dominant predisposition to familial isolated pituitary adenoma (FIPA) (MedGen UID: 489979).  FIPA presents in early adulthood with the development of pituitary adenomas in the absence of other syndromic findings. These pituitary adenomas may be of various types including somatotropinoma (growth hormone-secreting), prolactinoma (prolactin-secreting), somatomammotropinoma (growth hormone and prolactin co-secreting) and nonfunctioning pituitary adenomas (NFPA). Other types of adenomas have also been observed (PMID: 22720333, 26186299).", mechanism: "The protein encoded by this gene is a receptor for aryl hydrocarbons and a ligand-activated transcription factor. The encoded protein is found in the cytoplasm as part of a multiprotein complex, but upon binding of ligand is transported to the nucleus. This protein can regulate the expression of many xenobiotic metabolizing enzymes. Also, the encoded protein can bind specifically to and inhibit the activity of hepatitis B virus. Three transcript variants encoding different isoforms have been found for this gene. AIP encodes a protein that binds and stabilizes the AHR in the cytoplasm, and helps to regulate its subcellular localization."})
(:gene {references: "18724359) Moss√É¬© YP,Laudenslager M,Longo L,Cole KA,Wood A,Attiyeh EF,Laquaglia MJ,Sennett R,Lynch JE,Perri P,Laureys G,Speleman F,Kim C,Hou C,Hakonarson H,Torkamani A,Schork NJ,Brodeur GM,Tonini GP,Rappaport E,Devoto M,Maris JM. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature.. 2008;455(7215):930-5.|18923523) Janoueix-Lerosey I,Lequin D,Brugi√É¬®res L,Ribeiro A,de Pontual L,Combaret V,Raynal V,Puisieux A,Schleiermacher G,Pierron G,Valteau-Couanet D,Frebourg T,Michon J,Lyonnet S,Amiel J,Delattre O. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature.. 2008;455(7215):967-70.|22071890) Bourdeaut F,Ferrand S,Brugi√É¬®res L,Hilbert M,Ribeiro A,Lacroix L,B√É¬©nard J,Combaret V,Michon J,Valteau-Couanet D,Isidor B,Rialland X,Poir√É¬©e M,Defachelles AS,Peuchmaur M,Schleiermacher G,Pierron G,Gauthier-Villars M,Janoueix-Lerosey I,Delattre O, . ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. Eur J Hum Genet.. 2012;20(3):291-7.|18242317) Neuroblastoma biology,prognosis,and treatment|18923503) Cancer a ringleader identified", pmids: "18242317|18724359|18923503|18923523|22071890", name: "ALK", fullName: "Anaplastic Lymphoma Receptor Tyrosine Kinase", description: "The ALK gene is associated with autosomal dominant predisposition to neuroblastoma (MedGen UID: 414083).  Neuroblastoma is a tumor affecting developing nerve cells, and therefore most often affects infants and young children (PMID: 18242317). Studies have identified pathogenic ALK variants in families exhibiting a predisposition to neuroblastoma (PMID: 18724359, 18923523, 22071890) with incomplete penetrance (PMID: 18923503).", mechanism: "This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system.. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011] ALK encodes a tyrosine kinase receptor which plays a role in brain development."})
(:gene {references: "15699726) Evans DG,Moran A,King A,Saeed S,Gurusinghe N,Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol.. 2005;26(1):93-7.|19476995) Asthagiri AR,Parry DM,Butman JA,Kim HJ,Tsilou ET,Zhuang Z,Lonser RR. Neurofibromatosis type 2. Lancet.. 2009;373(9679):1974-86.|19671848) Evans DG,Kalamarides M,Hunter-Schaedle K,Blakeley J,Allen J,Babovic-Vuskanovic D,Belzberg A,Bollag G,Chen R,DiTomaso E,Golfinos J,Harris G,Jacob A,Kalpana G,Karajannis M,Korf B,Kurzrock R,Law M,McClatchey A,Packer R,Roehm P,Rubenstein A,Slattery W,Tonsgard JH,Welling DB,Widemann B,Yohay K,Giovannini M. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res.. 2009;15(16):5032-5039.|20082463) Evans DG,Howard E,Giblin C,Clancy T,Spencer H,Huson SM,Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A.. 2010;152A(2):327-32.|24724714) Choi JW,Lee JY,Phi JH,Wang KC,Chung HT,Paek SH,Kim DG,Park SH,Kim SK. Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2. J Neurosurg Pediatr.. 2014;13(6):650-7.", pmids: "15699726|19476995|19671848|20082463|24724714", name: "NF2", description: "The NF2 gene is associated with autosomal dominant neurofibromatosis type 2 (NF2) (MedGen UID: 18014).										  Neurofibromatosis type 2 is a highly penetrant condition characterized by multiple tumors throughout the central and peripheral nervous systems including schwannomas, meningiomas, ependymomas and rarely, astrocytomas and neurofibromas (PMID: 20082463, 15699726, 19476995). The hallmark tumors associated with this condition are bilateral vestibular schwannomas causing symptoms of tinnitus, hearing loss, balance difficulties and facial nerve weakness (PMID: 19671848, 24724714). Neurofibromatosis type 2 generally presents in the third to fourth decade of life, although this may be influenced by mutation type (PMID: 19476995).", fullName: "Neurofibromin 2", altName: "NF2", mechanism: "This gene encodes a protein that is similar to some members of the ERM (ezrin, radixin, moesin) family of proteins that are thought to link cytoskeletal components with proteins in the cell membrane. This gene product has been shown to interact with cell-surface proteins, proteins involved in cytoskeletal dynamics and proteins involved in regulating ion transport. This gene is expressed at high levels during embryonic development; in adults, significant expression is found in Schwann cells, meningeal cells, lens and nerve."})
(:gene {name: "NTHL1", fullName: "Nth Like DNA Glycosylase 1", mechanism: "The protein encoded by this gene is a DNA N-glycosylase of the endonuclease III family. Like a similar protein in E. coli, the encoded protein has DNA glycosylase activity on DNA substrates containing oxidized pyrimidine residues and has apurinic/apyrimidinic lyase activity. [provided by RefSeq, Oct 2008]"})
(:gene {references: "14699510) Chompret A,Kannengiesser C,Barrois M,Terrier P,Dahan P,Tursz T,Lenoir GM,Bressac-De Paillerets B. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology.. 2004;126(1):318-21.|17087943) de Raedt T,Cools J,Debiec-Rychter M,Brems H,Mentens N,Sciot R,Himpens J,de Wever I,Sch√É¬∂ffski P,Marynen P,Legius E. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology.. 2006;131(6):1907-12.|18670346) Carney JA,Stratakis CA. Stromal, fibrous, and fatty gastrointestinal tumors in a patient with a PDGFRA gene mutation. Am J Surg Pathol.. 2008;32(9):1412-20.", pmids: "14699510|17087943|18670346", name: "PDGFRA", description: "The PDGFRA gene is associated with autosomal dominant GIST-plus syndrome (MedGen UID: 357402).  GIST-plus syndrome is associated with inflammatory fibroid polyps and fibroid tumors in the gastrointestinal tract in addition to gastrointestinal stromal tumors (GIST) that most often develop in the stomach and small intestines. GIST may be noncancerous but have malignant potential; however, specific lifetime cancer risks are not established. Some affected individuals may also have coarse skin and facial features in addition to broad hands and feet (PMID: 14699510, 18670346, 17087943).", fullName: "Platelet Derived Growth Factor Receptor Alpha", mechanism: "This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers. [provided by RefSeq, Mar 2012]"})
(:gene {references: "18579454) Weese-Mayer DE,Berry-Kravis EM,Ceccherini I,Rand CM. Congenital central hypoventilation syndrome (CCHS) and sudden infant death syndrome (SIDS): kindred disorders of autonomic regulation. Respir Physiol Neurobiol.. 2008;164(1-2):38-48.|20208042) Weese-Mayer DE,Berry-Kravis EM,Ceccherini I,Keens TG,Loghmanee DA,Trang H, . An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. Am J Respir Crit Care Med.. 2010;181(6):626-44.|23465774) Rand CM,Patwari PP,Carroll MS,Weese-Mayer DE. Congenital central hypoventilation syndrome and sudden infant death syndrome: disorders of autonomic regulation. Semin Pediatr Neurol.. 2013;20(1):44-55.", pmids: "18579454|20208042|23465774", name: "PHOX2B", description: "The PHOX2B gene is associated with autosomal dominant congenital central hypoventilation syndrome (CCHS) (MedGen UID: 347052). Most cases of CCHS are due to a polyalanine repeat expansion, which is not analyzed by this test.											  CCHS is a disorder of autonomic regulation characterized by alveolar hypoventilation and symptoms of autonomic dysregulation presenting in the newborn period. Dysmorphic features include downslanting palpebral fissures, small nose and low-set, posteriorly rotated ears (PMID: 23465774,18579454, 20208042). A subset of affected individuals may develop Hirschsprung disease and/or tumors of neural crest origin (neuroblastoma, ganglioneuroblastoma, and ganglioneuroma).", fullName: "Paired Like Homeobox 2B", mechanism: "The DNA-associated protein encoded by this gene is a member of the paired family of homeobox proteins localized to the nucleus. The protein functions as a transcription factor involved in the development of several major noradrenergic neuron populations and the determination of neurotransmitter phenotype. The gene product is linked to enhancement of second messenger-mediated activation of the dopamine beta-hydroylase, c-fos promoters and several enhancers, including cyclic amp-response element and serum-response element. Expansion of a 20 amino acid polyalanine tract in this protein by 5-13 aa has been associated with congenital central hypoventilation syndrome. [provided by RefSeq, Jul 2016]"})
(:gene {references: "24686846) Shi J,Yang XR,Ballew B,Rotunno M,Calista D,Fargnoli MC,Ghiorzo P,Bressac-de Paillerets B,Nagore E,Avril MF,Caporaso NE,McMaster ML,Cullen M,Wang Z,Zhang X, , , ,Bruno W,Pastorino L,Queirolo P,Banuls-Roca J,Garcia-Casado Z,Vaysse A,Mohamdi H,Riazalhosseini Y,Foglio M,Jouenne F,Hua X,Hyland PL,Yin J,Vallabhaneni H,Chai W,Minghetti P,Pellegrini C,Ravichandran S,Eggermont A,Lathrop M,Peris K,Scarra GB,Landi G,Savage SA,Sampson JN,He J,Yeager M,Goldin LR,Demenais F,Chanock SJ,Tucker MA,Goldstein AM,Liu Y,Landi MT. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. Nat Genet.. 2014;46(5):482-6.|24686849) Robles-Espinoza CD,Harland M,Ramsay AJ,Aoude LG,Quesada V,Ding Z,Pooley KA,Pritchard AL,Tiffen JC,Petljak M,Palmer JM,Symmons J,Johansson P,Stark MS,Gartside MG,Snowden H,Montgomery GW,Martin NG,Liu JZ,Choi J,Makowski M,Brown KM,Dunning AM,Keane TM,L√É¬≥pez-Ot√É¬≠n C,Gruis NA,Hayward NK,Bishop DT,Newton-Bishop JA,Adams DJ. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet.. 2014;46(5):478-481.|25252913) Kunze K,Spieker T,Gamerdinger U,Nau K,Berger J,Dreyer T,Sindermann JR,Hoffmeier A,Gattenl√É¬∂hner S,Br√É¬§uninger A. A recurrent activating PLCG1 mutation in cardiac angiosarcomas increases apoptosis resistance and invasiveness of endothelial cells. Cancer Res.. 2014;74(21):6173-83.|25482530) Bainbridge MN,Armstrong GN,Gramatges MM,Bertuch AA,Jhangiani SN,Doddapaneni H,Lewis L,Tombrello J,Tsavachidis S,Liu Y,Jalali A,Plon SE,Lau CC,Parsons DW,Claus EB,Barnholtz-Sloan J,Il'yasova D,Schildkraut J,Ali-Osman F,Sadetzki S,Johansen C,Houlston RS,Jenkins RB,Lachance D,Olson SH,Bernstein JL,Merrell RT,Wrensch MR,Walsh KM,Davis FG,Lai R,Shete S,Aldape K,Amos CI,Thompson PA,Muzny DM,Gibbs RA,Melin BS,Bondy ML, . Germline mutations in shelterin complex genes are associated with familial glioma. J Natl Cancer Inst.. 2015;107(1):384.|26337759) Read J,Wadt KA,Hayward NK. Melanoma genetics. J Med Genet.. 2016;53(1):1-14.|27528712) Speedy HE,Kinnersley B,Chubb D,Broderick P,Law PJ,Litchfield K,Jayne S,Dyer MJS,Dearden C,Follows GA,Catovsky D,Houlston RS. Germ line mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia. Blood.. 2016;128(19):2319-2326.|28853721) Calvete O,Garcia-Pavia P,Dom√É¬≠nguez F,Bougeard G,Kunze K,Braeuninger A,Teule A,Lasa A,Ram√É¬≥n Y Cajal T,Llort G,Fern√É¬°ndez V,L√É¬°zaro C,Urioste M,Benitez J. The wide spectrum of POT1 gene variants correlates with multiple cancer types. Eur J Hum Genet.. 2017;25(11):1278-1281.|30165405) Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series", pmids: "24686846|24686849|25252913|25482530|26337759|27528712|28853721|30165405", name: "POT1", description: "The POT1 gene is associated with autosomal dominant POT1 tumor predisposition syndrome (MedGen UID: 862913).  POT1 tumor predisposition syndrome is associated with predisposition to familial malignant melanoma (PMID: 24686846, 24686849, 26337759). Melanoma most often occurs in the skin, but may also develop in the eyes, ears, gastrointestinal tract, and oral and genital membranes. POT1 has also been associated with a susceptibility to additional cancers including glioma and angiosarcoma, among others; specific lifetime cancer risks are not clear (PMID: 25482530, 30165405, 25252913, 28853721, 27528712). Although consensus guidelines have not been published for individuals with pathogenic variants in POT1, evaluation and surveillance considerations are available in PMID: 33119245.", fullName: "Protection Of Telomeres 1", mechanism: "This gene is a member of the telombin family and encodes a nuclear protein involved in telomere maintenance. Specifically, this protein functions as a member of a multi-protein complex that binds to the TTAGGG repeats of telomeres, regulating telomere length and protecting chromosome ends from illegitimate recombination, catastrophic chromosome instability, and abnormal chromosome segregation. Increased transcriptional expression of this gene is associated with stomach carcinogenesis and its progression. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008]"})
(:gene {references: "10973256) Kirschner LS,Carney JA,Pack SD,Taymans SE,Giatzakis C,Cho YS,Cho-Chung YS,Stratakis CA. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet.. 2000;26(1):89-92.|10974026) Casey M,Vaughan CJ,He J,Hatcher CJ,Winter JM,Weremowicz S,Montgomery K,Kucherlapati R,Morton CC,Basson CT. Mutations in the protein kinase A R1alpha regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest.. 2000;106(5):R31-8.|11115848) Kirschner LS,Sandrini F,Monbo J,Lin JP,Carney JA,Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. Hum Mol Genet.. 2000;9(20):3037-46.|16756677) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Carney complex (CNC). Orphanet J Rare Dis.. 2006;1():21.|19293268) Bertherat J,Horvath A,Groussin L,Grabar S,Boikos S,Cazabat L,Libe R,Ren√É¬©-Corail F,Stergiopoulos S,Bourdeau I,Bei T,Clauser E,Calender A,Kirschner LS,Bertagna X,Carney JA,Stratakis CA. Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab.. 2009;94(6):2085-91.|22464250) Michot C,Le Goff C,Goldenberg A,Abhyankar A,Klein C,Kinning E,Guerrot AM,Flahaut P,Duncombe A,Baujat G,Lyonnet S,Thalassinos C,Nitschke P,Casanova JL,Le Merrer M,Munnich A,Cormier-Daire V. Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis. Am J Hum Genet.. 2012;90(4):740-5.|22464252) Lee H,Graham JM,Rimoin DL,Lachman RS,Krejci P,Tompson SW,Nelson SF,Krakow D,Cohn DH. Exome sequencing identifies PDE4D mutations in acrodysostosis. Am J Hum Genet.. 2012;90(4):746-51.|23033274) Lynch DC,Dyment DA,Huang L,Nikkel SM,Lacombe D,Campeau PM,Lee B,Bacino CA,Michaud JL,Bernier FP, ,Parboosingh JS,Innes AM. Identification of novel mutations confirms PDE4D as a major gene causing acrodysostosis. Hum Mutat.. 2013;34(1):97-102.|26130139) Correa R,Salpea P,Stratakis CA. Carney complex: an update. Eur J Endocrinol.. 2015;173(4):M85-97.|26763073) Elli FM,Bordogna P,de Sanctis L,Giachero F,Verrua E,Segni M,Mazzanti L,Boldrin V,Toromanovic A,Spada A,Mantovani G. Screening of PRKAR1A and PDE4D in a Large Italian Series of Patients Clinically Diagnosed With Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism. J Bone Miner Res.. 2016;31(6):1215-24.", pmids: "10973256|10974026|11115848|16756677|19293268|22464250|22464252|23033274|26130139|26763073", name: "PRKAR1A", description: "The PRKAR1A gene is associated with autosomal dominant Carney complex (CNC) (MedGen UID: 388559) and acrodysostosis (MedGen UID: 477858).			  CNC is characterized by myxomas, endocrine tumors and schwannomas. Pigmentary skin lesions are a defining feature, present in over 80% of cases. Primary pigmented nodular adrenocortical disease (PPNAD), which can lead to Cushing's syndrome, develops in 25-60% of affected individuals. CNC is associated with an increased risk of developing thyroid nodules, thyroid cancer, myxomas in the heart, breast, skin, throat and female genital tract in addition to psammomatous melanotic schwannomas (PMS) and ovarian tumors. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in nearly all affected males (PMID: 26130139, 16756677).

Autosomal dominant acrodysostosis is characterized by variable skeletal, endocrine, and neurological abnormalities that are present in childhood (PMID: 22464252). The most common features include brachydactyly, dysmorphic facies, short stature, and intellectual disability and/or developmental delays (PMID: 26763073). Other symptoms may include advanced bone age, peripheral dysostosis with shortened bones of the hands and feet, cone-shaped epiphyses, lumbar stenosis, hypothyroidism, multiple hormone resistance, cryptorchidism, hypospadias, deafness and rhinitis (PMID: 22464252, 23033274, 26763073).

Loss of function variants are associated with CNC (PMID: 19293268, 11115848). Some further genotype-phenotype correlations have been suggested for acrodysostosis versus CNC (PMID: 10974026, 10973256, 22464250, 22464252), but these correlations remain preliminary.", fullName: "Protein Kinase CAMP-Dependent Type I Regulatory Subunit Alpha", mechanism: "cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. This gene encodes one of the regulatory subunits. This protein was found to be a tissue-specific extinguisher that down-regulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Mutations in this gene cause Carney complex (CNC). This gene can fuse to the RET protooncogene by gene rearrangement and form the thyroid tumor-specific chimeric oncogene known as PTC2. A nonconventional nuclear localization sequence (NLS) has been found for this protein which suggests a role in DNA replication via the protein serving as a nuclear transport protein for the second subunit of the Replication Factor C (RFC40). Several alternatively spliced transcript variants encoding two different isoforms have been observed. [provided by RefSeq, Jan 2013]"})
(:gene {references: "20071235) Bayley JP,Kunst HP,Cascon A,Sampietro ML,Gaal J,Korpershoek E,Hinojar-Gutierrez A,Timmers HJ,Hoefsloot LH,Hermsen MA,Su√É¬°rez C,Hussain AK,Vriends AH,Hes FJ,Jansen JC,Tops CM,Corssmit EP,de Knijff P,Lenders JW,Cremers CW,Devilee P,Dinjens WN,de Krijger RR,Robledo M. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol.. 2010;11(4):366-72.|21224366) Kunst HP,Rutten MH,de M√É¬∂nnink JP,Hoefsloot LH,Timmers HJ,Marres HA,Jansen JC,Kremer H,Bayley JP,Cremers CW. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res.. 2011;17(2):247-54.|22241717) Piccini V,Rapizzi E,Bacca A,Di Trapani G,Pulli R,Giach√É¬® V,Zampetti B,Lucci-Cordisco E,Canu L,Corsini E,Faggiano A,Deiana L,Carrara D,Tantardini V,Mariotti S,Ambrosio MR,Zatelli MC,Parenti G,Colao A,Pratesi C,Bernini G,Ercolino T,Mannelli M. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocr Relat Cancer.. 2012;19(2):149-55.|28099933) Hoekstra AS,Hensen EF,Jordanova ES,Korpershoek E,van der Horst-Schrivers AN,Cornelisse C,Corssmit EP,Hes FJ,Jansen JC,Kunst HP,Timmers HJ,Bateman A,Eccles D,Bov√É¬©e JV,Devilee P,Bayley JP. Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas. Oncotarget.. 2017;8(9):14525-14536.", pmids: "20071235|21224366|22241717|28099933", name: "SDHAF2", description: "The SDHAF2 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 357076).  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGLs and PCCs. Pathogenic SDHAF2 variants predispose individuals to multiple head and neck paragangliomas, especially at early ages, although the lifetime risk of developing these tumors is unclear (PMID: 21224366, 20071235, 22241717). While the SDHAF2 gene follows traditional Mendelian inheritance, there is evidence suggesting a parent-of-origin effect; it appears that the risk of disease may be limited to paternally inherited pathogenic variants (PMID: 28099933, 21224366).", fullName: "Succinate Dehydrogenase Complex Assembly Factor 2", altName: "SDHAF2", mechanism: "SDHAF2 encodes a protein involved with the flavination of a succinate dehydrogenase complex subunit."})
(:gene {references: "17667967) Pasini B,McWhinney SR,Bei T,Matyakhina L,Stergiopoulos S,Muchow M,Boikos SA,Ferrando B,Pacak K,Assie G,Baudin E,Chompret A,Ellison JW,Briere JJ,Rustin P,Gimenez-Roqueplo AP,Eng C,Carney JA,Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet.. 2008;16(1):79-88.|18728283) Ricketts C,Woodward ER,Killick P,Morris MR,Astuti D,Latif F,Maher ER. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst.. 2008;100(17):1260-2.|22972948) Alston CL,Davison JE,Meloni F,van der Westhuizen FH,He L,Hornig-Do HT,Peet AC,Gissen P,Goffrini P,Ferrero I,Wassmer E,McFarland R,Taylor RW. Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet.. 2012;49(9):569-77.|23083876) Ricketts CJ,Shuch B,Vocke CD,Metwalli AR,Bratslavsky G,Middelton L,Yang Y,Wei MH,Pautler SE,Peterson J,Stolle CA,Zbar B,Merino MJ,Schmidt LS,Pinto PA,Srinivasan R,Pacak K,Linehan WM. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.. 2012;188(6):2063-71.|23322652) Jain-Ghai S,Cameron JM,Al Maawali A,Blaser S,MacKay N,Robinson B,Raiman J. Complex II deficiency--a case report and review of the literature. Am J Med Genet A.. 2013;161A(2):285-94.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|28374168) Jochmanova I,Wolf KI,King KS,Nambuba J,Wesley R,Martucci V,Raygada M,Adams KT,Prodanov T,Fojo AT,Lazurova I,Pacak K. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol.. 2017;143(8):1421-1435.|29386252) Andrews KA,Ascher DB,Pires DEV,Barnes DR,Vialard L,Casey RT,Bradshaw N,Adlard J,Aylwin S,Brennan P,Brewer C,Cole T,Cook JA,Davidson R,Donaldson A,Fryer A,Greenhalgh L,Hodgson SV,Irving R,Lalloo F,McConachie M,McConnell VPM,Morrison PJ,Murday V,Park SM,Simpson HL,Snape K,Stewart S,Tomkins SE,Wallis Y,Izatt L,Goudie D,Lindsay RS,Perry CG,Woodward ER,Antoniou AC,Maher ER. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes ,  and . J Med Genet.. 2018;55(6):384-394.|30201732) Benn DE,Zhu Y,Andrews KA,Wilding M,Duncan EL,Dwight T,Tothill RW,Burgess J,Crook A,Gill AJ,Hicks RJ,Kim E,Luxford C,Marfan H,Richardson AL,Robinson B,Schlosberg A,Susman R,Tacon L,Trainer A,Tucker K,Maher ER,Field M,Clifton-Bligh RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet.. 2018;55(11):729-734.|30536464) Muth A,Crona J,Gimm O,Elmgren A,Filipsson K,Stenmark Askmalm M,Sandstedt J,Tengvar M,Tham E. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. J Intern Med.. 2019;285(2):187-204.", pmids: "17667967|18728283|22972948|23083876|23322652|26259135|28374168|29386252|30201732|30536464", name: "SDHB", description: "The SDHB gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 349380), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049), renal cancer (PMID: 29386252, 23083876) and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHB may also be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk for PGL and PCC. SDHB is also associated with autosomal dominant predisposition to renal cancer (PMID: 18728283, 23083876), GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). The lifetime risk of developing PGL and/or PCC is 22-49% (PMID: 28374168, 29386252, 30201732). PGL, PCC and GIST are typically benign but have a risk of malignant transformation; lifetime cancer risks are not clear (PMID: 30536464, 29386252). There is approximately a 5% risk of kidney cancer to age 60 (PMID: 29386252, 23083876).  Mitochondrial complex II deficiency is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy. Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy. The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 22972948, 23322652).", fullName: "Succinate Dehydrogenase Complex Iron Sulfur Subunit B", altName: "succinate dehydrogenase complex, subunit B, iron sulfur,SDHB", mechanism: "SDHB encodes a tumor suppressor involved in complex II of the mitochondrial electron transport chain."})
(:gene {references: "17667967) Pasini B,McWhinney SR,Bei T,Matyakhina L,Stergiopoulos S,Muchow M,Boikos SA,Ferrando B,Pacak K,Assie G,Baudin E,Chompret A,Ellison JW,Briere JJ,Rustin P,Gimenez-Roqueplo AP,Eng C,Carney JA,Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet.. 2008;16(1):79-88.|21173220) Janeway KA,Kim SY,Lodish M,Nos√É¬© V,Rustin P,Gaal J,Dahia PL,Liegl B,Ball ER,Raygada M,Lai AH,Kelly L,Hornick JL, ,O'Sullivan M,de Krijger RR,Dinjens WN,Demetri GD,Antonescu CR,Fletcher JA,Helman L,Stratakis CA. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A.. 2011;108(1):314-8.|23083876) Ricketts CJ,Shuch B,Vocke CD,Metwalli AR,Bratslavsky G,Middelton L,Yang Y,Wei MH,Pautler SE,Peterson J,Stolle CA,Zbar B,Merino MJ,Schmidt LS,Pinto PA,Srinivasan R,Pacak K,Linehan WM. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.. 2012;188(6):2063-71.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|29386252) Andrews KA,Ascher DB,Pires DEV,Barnes DR,Vialard L,Casey RT,Bradshaw N,Adlard J,Aylwin S,Brennan P,Brewer C,Cole T,Cook JA,Davidson R,Donaldson A,Fryer A,Greenhalgh L,Hodgson SV,Irving R,Lalloo F,McConachie M,McConnell VPM,Morrison PJ,Murday V,Park SM,Simpson HL,Snape K,Stewart S,Tomkins SE,Wallis Y,Izatt L,Goudie D,Lindsay RS,Perry CG,Woodward ER,Antoniou AC,Maher ER. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes ,  and . J Med Genet.. 2018;55(6):384-394.|30201732) Benn DE,Zhu Y,Andrews KA,Wilding M,Duncan EL,Dwight T,Tothill RW,Burgess J,Crook A,Gill AJ,Hicks RJ,Kim E,Luxford C,Marfan H,Richardson AL,Robinson B,Schlosberg A,Susman R,Tacon L,Trainer A,Tucker K,Maher ER,Field M,Clifton-Bligh RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet.. 2018;55(11):729-734.", pmids: "17667967|21173220|23083876|26259135|29386252|30201732", name: "SDHC", description: "The SDHC gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 340200), gastrointestinal stromal tumors (GIST) (MedGen UID: 116049) and renal cancer (PMID: 23083876).  Studies also suggest SDHC may be associated with autosomal dominant predisposition to pituitary adenomas (PMID: 26259135). The data, however, are preliminary and available evidence is insufficient to make a determination regarding this relationship.  SDHC-associated hereditary PGL-PCC syndrome is associated with an 8-25% risk of developing PGL and/or PCC that are typically benign (PMID: 30201732, 29386252). Affected individuals will more often develop PGL in the head and neck. SDHC is also associated with autosomal dominant predisposition to to renal cancer (PMID: 23083876), GIST and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967, 21173220). PGL, PCC and GIST may become malignant; however, lifetime cancer risks are not clear. The lifetime risk of renal cancer is not established.", fullName: "Succinate Dehydrogenase Complex Subunit C", altName: "integral membrane protein CII-3,succinate-ubiquinone oxidoreducatase cytochrome B large subunit,SDHC", mechanism: "SDHC encodes a component of the succinate dehydrogenase enzyme which is involved in the electron transport chain."})
(:gene {references: "17667967) Pasini B,McWhinney SR,Bei T,Matyakhina L,Stergiopoulos S,Muchow M,Boikos SA,Ferrando B,Pacak K,Assie G,Baudin E,Chompret A,Ellison JW,Briere JJ,Rustin P,Gimenez-Roqueplo AP,Eng C,Carney JA,Stratakis CA. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet.. 2008;16(1):79-88.|18211978) Pigny P,Vincent A,Cardot Bauters C,Bertrand M,de Montpreville VT,Crepin M,Porchet N,Caron P. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J Clin Endocrinol Metab.. 2008;93(5):1609-15.|19205158) Hartzell LD,McKelvey KD,Van Hemert RL,Dornhoffer J. Cerebellopontine angle tumor in a patient with a maternally inherited SDHD gene mutation. Int Tinnitus J.. 2008;14(2):97-100.|19802898) Ricketts CJ,Forman JR,Rattenberry E,Bradshaw N,Lalloo F,Izatt L,Cole TR,Armstrong R,Kumar VK,Morrison PJ,Atkinson AB,Douglas F,Ball SG,Cook J,Srirangalingam U,Killick P,Kirby G,Aylwin S,Woodward ER,Evans DG,Hodgson SV,Murday V,Chew SL,Connell JM,Blundell TL,Macdonald F,Maher ER. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat.. 2010;31(1):41-51.|21937622) Yeap PM,Tobias ES,Mavraki E,Fletcher A,Bradshaw N,Freel EM,Cooke A,Murday VA,Davidson HR,Perry CG,Lindsay RS. Molecular analysis of pheochromocytoma after maternal transmission of SDHD mutation elucidates mechanism of parent-of-origin effect. J Clin Endocrinol Metab.. 2011;96(12):E2009-13.|23083876) Ricketts CJ,Shuch B,Vocke CD,Metwalli AR,Bratslavsky G,Middelton L,Yang Y,Wei MH,Pautler SE,Peterson J,Stolle CA,Zbar B,Merino MJ,Schmidt LS,Pinto PA,Srinivasan R,Pacak K,Linehan WM. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol.. 2012;188(6):2063-71.|24367056) Jackson CB,Nuoffer JM,Hahn D,Prokisch H,Haberberger B,Gautschi M,H√É¬§berli A,Gallati S,Schaller A. Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency. J Med Genet.. 2014;51(3):170-5.|24886695) Miettinen M,Lasota J. Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) - a review. Int J Biochem Cell Biol.. 2014;53():514-9.|25300370) Bayley JP,Oldenburg RA,Nuk J,Hoekstra AS,van der Meer CA,Korpershoek E,McGillivray B,Corssmit EP,Dinjens WN,de Krijger RR,Devilee P,Jansen JC,Hes FJ. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations. BMC Med Genet.. 2014;15():111.|26008905) Alston CL,Ceccatelli Berti C,Blakely EL,Ol√É¬°hov√É¬° M,He L,McMahon CJ,Olpin SE,Hargreaves IP,Nolli C,McFarland R,Goffrini P,O'Sullivan MJ,Taylor RW. A recessive homozygous p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy and a severe mitochondrial complex II deficiency. Hum Genet.. 2015;134(8):869-79.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|28374168) Jochmanova I,Wolf KI,King KS,Nambuba J,Wesley R,Martucci V,Raygada M,Adams KT,Prodanov T,Fojo AT,Lazurova I,Pacak K. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations. J Cancer Res Clin Oncol.. 2017;143(8):1421-1435.|29386252) Andrews KA,Ascher DB,Pires DEV,Barnes DR,Vialard L,Casey RT,Bradshaw N,Adlard J,Aylwin S,Brennan P,Brewer C,Cole T,Cook JA,Davidson R,Donaldson A,Fryer A,Greenhalgh L,Hodgson SV,Irving R,Lalloo F,McConachie M,McConnell VPM,Morrison PJ,Murday V,Park SM,Simpson HL,Snape K,Stewart S,Tomkins SE,Wallis Y,Izatt L,Goudie D,Lindsay RS,Perry CG,Woodward ER,Antoniou AC,Maher ER. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes ,  and . J Med Genet.. 2018;55(6):384-394.", pmids: "17667967|18211978|19205158|19802898|21937622|23083876|24367056|24886695|25300370|26008905|26259135|28374168|29386252", name: "SDHD", description: "The SDHD gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 358258) and gastrointestinal stromal tumors (GIST) (PMID: 24886695). Studies suggest SDHD is also associated with autosomal dominant predisposition to renal cancer (PMID: 19802898, 23083876) and pituitary adenomas (PMID: 26259135), as well as autosomal recessive mitochondrial complex II deficiency (PMID: 24367056; 26008905). The data, however, are preliminary and available evidence is insufficient to make a determination regarding these relationships.  Individuals with SDHD-associated hereditary PGL-PCC syndrome have a 43-70% risk of developing a PGL by age 60 (PMID: 29386252) and these tumors most often develop in the head and neck. SDHD is also associated with GIST (PMID: 28374168, 29386252) and Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967). SDHD-associated PGL, PCC and GIST have a risk of malignant transformation; however, lifetime risks are not clear. While both males and females can pass this variant on to their children, there is evidence suggesting that only those who inherit it from their father are at risk of developing SDHD-associated tumors (PMID: 25300370, 21937622, 19205158, 18211978).", fullName: "Succinate Dehydrogenase Complex Subunit D", altName: "succinate dehydrogenase complex subunit D, integral membrane protein,SDHD", mechanism: "SDHD encodes a tumor-suppressor that is involved in complex II of the mitochondrial electron transport chain."})
(:gene {references: "24658001) Ramos P,Karnezis AN,Craig DW,Sekulic A,Russell ML,Hendricks WP,Corneveaux JJ,Barrett MT,Shumansky K,Yang Y,Shah SP,Prentice LM,Marra MA,Kiefer J,Zismann VL,McEachron TA,Salhia B,Prat J,D'Angelo E,Clarke BA,Pressey JG,Farley JH,Anthony SP,Roden RB,Cunliffe HE,Huntsman DG,Trent JM. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet.. 2014;46(5):427-9.|24658002) Witkowski L,Carrot-Zhang J,Albrecht S,Fahiminiya S,Hamel N,Tomiak E,Grynspan D,Saloustros E,Nadaf J,Rivera B,Gilpin C,Castellsagu√É¬© E,Silva-Smith R,Plourde F,Wu M,Saskin A,Arseneault M,Karabakhtsian RG,Reilly EA,Ueland FR,Margiolaki A,Pavlakis K,Castellino SM,Lamovec J,Mackay HJ,Roth LM,Ulbright TM,Bender TA,Georgoulias V,Longy M,Berchuck A,Tischkowitz M,Nagel I,Siebert R,Stewart CJ,Arseneau J,McCluggage WG,Clarke BA,Riazalhosseini Y,Hasselblatt M,Majewski J,Foulkes WD. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet.. 2014;46(5):438-43.", pmids: "24658001|24658002", name: "SMARCA4", description: "The SMARCA4 gene is associated with rhabdoid tumor predisposition syndrome, type 2, autosomal dominant small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PMID: 24658002, 24658001) and Coffin-Siris syndrome (CSS) (MedGen UID: 766163).  Loss-of-function (LOF) variants in SMARCA4 are associated with RTPS2, a childhood-onset condition associated with rhabdoid tumors that typically develop in the kidneys and central nervous system. SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established.

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays.", fullName: "SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 4", mechanism: "Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structur"})
(:gene {references: "19898272) Lu-Emerson C,Plotkin SR. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis.. 2009;6(3):E81-6.|21208904) Bourdeaut F,Lequin D,Brugi√É¬®res L,Reynaud S,Dufour C,Doz F,Andr√É¬© N,Stephan JL,P√É¬©rel Y,Oberlin O,Orbach D,Bergeron C,Rialland X,Fr√É¬©neaux P,Ranchere D,Figarella-Branger D,Audry G,Puget S,Evans DG,Pinas JC,Capra V,Mosseri V,Coupier I,Gauthier-Villars M,Pierron G,Delattre O. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. Clin Cancer Res.. 2011;17(1):31-8.|23929686) Santen GW,Aten E,Vulto-van Silfhout AT,Pottinger C,van Bon BW,van Minderhout IJ,Snowdowne R,van der Lans CA,Boogaard M,Linssen MM,Vijfhuizen L,van der Wielen MJ,Vollebregt MJ, ,Breuning MH,Kriek M,van Haeringen A,den Dunnen JT,Hoischen A,Clayton-Smith J,de Vries BB,Hennekam RC,van Belzen MJ. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat.. 2013;34(11):1519-28.|24933152) Smith MJ,Wallace AJ,Bowers NL,Eaton H,Evans DG. SMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors. Cancer Genet.. 2014;207(9):373-8.|25168959) Kosho T,Okamoto N, . Genotype-phenotype correlation of Coffin-Siris syndrome caused by mutations in SMARCB1, SMARCA4, SMARCE1, and ARID1A. Am J Med Genet C Semin Med Genet.. 2014;166C(3):262-75.|25169878) Kosho T,Miyake N,Carey JC. Coffin-Siris syndrome and related disorders involving components of the BAF (mSWI/SNF) complex: historical review and recent advances using next generation sequencing. Am J Med Genet C Semin Med Genet.. 2014;166C(3):241-51.", pmids: "19898272|21208904|23929686|24933152|25168959|25169878", name: "SMARCB1", description: "The SMARCB1 gene is associated with autosomal dominant rhabdoid tumor predisposition syndrome 1 (RTPS1) (MedGen UID: 322892), schwannomatosis (MedGen UID: 234775) and Coffin-Siris syndrome (MedGen UID: 766162).  RTPS is associated with an increased risk of rhabdoid tumors, a rare type of childhood cancer that most often develops in the kidneys and central nervous system. Schwannomatosis is characterized by the development of multiple spinal, peripheral, and cranial nerve schwannomas. The absence of vestibular schwannomas distinguishes schwannomatosis from neurofibromatosis type 2 (PMID: 24933152, 19898272, 21208904). 

Coffin-Siris syndrome is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 25168959, 25169878, 23929686).", fullName: "SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1", mechanism: "Core component of the BAF (hSWI/SNF) complex. This ATP-dependent chromatin-remodeling complex plays important roles in cell proliferation and differentiation, in cellular antiviral activities and inhibition of tumor formation. The BAF complex is able to c"})
(:gene {references: "23377182) Smith MJ,O'Sullivan J,Bhaskar SS,Hadfield KD,Poke G,Caird J,Sharif S,Eccles D,Fitzpatrick D,Rawluk D,du Plessis D,Newman WG,Evans DG. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet.. 2013;45(3):295-8.|23929686) Santen GW,Aten E,Vulto-van Silfhout AT,Pottinger C,van Bon BW,van Minderhout IJ,Snowdowne R,van der Lans CA,Boogaard M,Linssen MM,Vijfhuizen L,van der Wielen MJ,Vollebregt MJ, ,Breuning MH,Kriek M,van Haeringen A,den Dunnen JT,Hoischen A,Clayton-Smith J,de Vries BB,Hennekam RC,van Belzen MJ. Coffin-Siris syndrome and the BAF complex: genotype-phenotype study in 63 patients. Hum Mutat.. 2013;34(11):1519-28.|25143307) Smith MJ,Wallace AJ,Bennett C,Hasselblatt M,Elert-Dobkowska E,Evans LT,Hickey WF,van Hoff J,Bauer D,Lee A,Hevner RF,Beetz C,du Plessis D,Kilday JP,Newman WG,Evans DG. Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol.. 2014;234(4):436-40.|25168959) Kosho T,Okamoto N, . Genotype-phenotype correlation of Coffin-Siris syndrome caused by mutations in SMARCB1, SMARCA4, SMARCE1, and ARID1A. Am J Med Genet C Semin Med Genet.. 2014;166C(3):262-75.|25169878) Kosho T,Miyake N,Carey JC. Coffin-Siris syndrome and related disorders involving components of the BAF (mSWI/SNF) complex: historical review and recent advances using next generation sequencing. Am J Med Genet C Semin Med Genet.. 2014;166C(3):241-51.|27264197) Zarate YA,Bhoj E,Kaylor J,Li D,Tsurusaki Y,Miyake N,Matsumoto N,Phadke S,Escobar L,Irani A,Hakonarson H,Schrier Vergano SA. SMARCE1, a rare cause of Coffin-Siris Syndrome: Clinical description of three additional cases. Am J Med Genet A.. 2016;170(8):1967-73.|30499906) Lin B,Kesserwan C,Quinn EA,Einhaus SL,Wright KD,Azzato EM,Orr BA,Upadhyaya SA. Anaplastic Astrocytoma in a Child With Coffin-Siris Syndrome and a Germline SMARCE1 Mutation: A Case Report. J Pediatr Hematol Oncol.. 2020;42(3):e177-e180.", pmids: "23377182|23929686|25143307|25168959|25169878|27264197|30499906", name: "SMARCE1", description: "The SMARCE1 gene is associated with autosomal dominant familial meningioma (MedGen UID: 232281) and Coffin-Siris syndrome (MedGen UID: 934755).  Pathogenic loss-of-function (LOF) SMARCE1 variants are associated with familial meningioma. Meningiomas are typically slow growing benign tumors derived from the meningeal tissue of the brain and spinal cord (PMID: 23377182, 25143307).

Coffin-Siris syndrome (CSS) is characterized by varying degrees of intellectual disability, agenesis of the corpus callosum, seizures, absent speech, hearing and vision deficits, coarse facial features, hypertrichosis, frequent infections, hypoplastic fifth fingers and nails and growth delays (PMID: 23929686, 27264197, 30499906, 25168959, 25169878, 23929686). While SMARCE1 is also associated with autosomal dominant CSS, to date, LOF variants in this gene have not been observed in individuals affected with CSS.", fullName: "SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily E, Member 1", mechanism: "Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Component of SWI/SNF chromatin remodeling complexes that carry out key enzymatic activities, changing chromatin structur"})
(:gene {references: "14981712) Gleeson JG,Keeler LC,Parisi MA,Marsh SE,Chance PF,Glass IA,Graham JM,Maria BL,Barkovich AJ,Dobyns WB. Molar tooth sign of the midbrain-hindbrain junction: occurrence in multiple distinct syndromes. Am J Med Genet A.. 2004;125A(2):125-34; discussion 117.|17603801) Boycott KM,Parboosingh JS,Scott JN,McLeod DR,Greenberg CR,Fujiwara TM,Mah JK,Midgley J,Wade A,Bernier FP,Chodirker BN,Bunge M,Innes AM. Meckel syndrome in the Hutterite population is actually a Joubert-related cerebello-oculo-renal syndrome. Am J Med Genet A.. 2007;143A(15):1715-25.|24360807) Akizu N,Silhavy JL,Rosti RO,Scott E,Fenstermaker AG,Schroth J,Zaki MS,Sanchez H,Gupta N,Kabra M,Kara M,Ben-Omran T,Rosti B,Guemez-Gamboa A,Spencer E,Pan R,Cai N,Abdellateef M,Gabriel S,Halbritter J,Hildebrandt F,van Bokhoven H,Gunel M,Gleeson JG. Mutations in CSPP1 lead to classical Joubert syndrome. Am J Hum Genet.. 2014;94(1):80-6.|25403219) Smith MJ,Beetz C,Williams SG,Bhaskar SS,O'Sullivan J,Anderson B,Daly SB,Urquhart JE,Bholah Z,Oudit D,Cheesman E,Kelsey A,McCabe MG,Newman WG,Evans DG. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol.. 2014;32(36):4155-61.|29186568) Guerrini-Rousseau L,Dufour C,Varlet P,Masliah-Planchon J,Bourdeaut F,Guillaud-Bataille M,Abbas R,Bertozzi AI,Fouyssac F,Huybrechts S,Puget S,Bressac-De Paillerets B,Caron O,Sevenet N,Dimaria M,Villebasse S,Delattre O,Valteau-Couanet D,Grill J,Brugi√É¬®res L. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. Neuro Oncol.. 2018;20(8):1122-1132.|33024317) Schr√É¬∂der S,Li Y,Yigit G,Altm√É¬ºller J,Bader I,Bevot A,Biskup S,Dreha-Kulaczewski S,Christoph Korenke G,Kottke R,Mayr JA,Preisel M,Toelle SP,Wente-Schulz S,Wortmann SB,Hahn H,Boltshauser E,Uhmann A,Wollnik B,Brockmann K. Heterozygous truncating variants in SUFU cause congenital ocular motor apraxia. Genet Med.. 2021;23(2):341-351.|33066274) Onodera S,Nakamura Y,Azuma T. Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research. Int J Mol Sci.. 2020;21(20):.", pmids: "14981712|17603801|24360807|25403219|29186568|33024317|33066274", name: "SUFU", fullName: "SUFU negative regulator of hedgehog signaling", description: "The SUFU gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554), autosomal recessive Joubert syndrome (MedGen UID: 1626697), and autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).  Pathogenic loss-of-function (LOF) SUFU variants are associated with BCNS. BCNS is an early-onset condition characterized by the development of multiple basal cell carcinomas, cardiac and ovarian fibromas, palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. SUFU-related BCNS is associated with up to a 33% risk of medulloblastoma (PMID: 29186568, 25403219, 33066274).

Joubert syndrome (JS) is a highly variable condition associated with a specific anomaly of the cerebellar vermis and brainstem causing the characteristic \"molar tooth sign\" (MTS) on magnetic resonance imaging. Additional findings include ataxia, polydactyly, distinctive facial features, episodic tachypnea or apnea and abnormal eye movements (PMID: 24360807). Cognitive abilities may range from normal to severely impaired. The term \"Joubert syndrome and related disorders (JSRD)\" is used to describe JS and other conditions that have MTS as well as other overlapping clinical features (PMID: 17603801, 14981712). While the SUFU gene is associated with JS, LOF variants in this gene have not been observed in individuals with this condition.", mechanism: "The SUFU gene is important  in early development as it plays a role in pattern formation and cellular proliferation.  This gene encodes a negative regulator of the hedgehog signaling pathway."})
(:gene {references: "17392301) Armanios MY,Chen JJ,Cogan JD,Alder JK,Ingersoll RG,Markin C,Lawson WE,Xie M,Vulto I,Phillips JA,Lansdorp PM,Greider CW,Loyd JE. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med.. 2007;356(13):1317-26.|21436073) Parry EM,Alder JK,Qi X,Chen JJ,Armanios M. Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood.. 2011;117(21):5607-11.|23335200) Vogiatzi P,Perdigones N,Mason PJ,Wilson DB,Bessler M. A family with Hoyeraal-Hreidarsson syndrome and four variants in two genes of the telomerase core complex. Pediatr Blood Cancer.. 2013;60(6):E4-6.|25170286) Fern√É¬°ndez Garc√É¬≠a MS,Teruya-Feldstein J. The diagnosis and treatment of dyskeratosis congenita: a review. J Blood Med.. 2014;5():157-67.|25237198) Townsley DM,Dumitriu B,Young NS. Bone marrow failure and the telomeropathies. Blood.. 2014;124(18):2775-83.|25940403) Glousker G,Touzot F,Revy P,Tzfati Y,Savage SA. Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder. Br J Haematol.. 2015;170(4):457-71.|26022962) Kannengiesser C,Borie R,M√É¬©nard C,R√É¬©ocreux M,Nitschk√É¬© P,Gazal S,Mal H,Taill√É¬© C,Cadranel J,Nunes H,Valeyre D,Cordier JF,Callebaut I,Boileau C,Cottin V,Grandchamp B,Revy P,Crestani B. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J.. 2015;46(2):474-85.|27836952) Borie R,Tab√É¬®ze L,Thabut G,Nunes H,Cottin V,Marchand-Adam S,Prevot G,Tazi A,Cadranel J,Mal H,Wemeau-Stervinou L,Bergeron Lafaurie A,Israel-Biet D,Picard C,Reynaud Gaubert M,Jouneau S,Naccache JM,Mankikian J,M√É¬©nard C,Cordier JF,Valeyre D,Reocreux M,Grandchamp B,Revy P,Kannengiesser C,Crestani B. Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. Eur Respir J.. 2016;48(6):1721-1731.|32923861) Walsh MF,Sacca R,Wildman T,Amoroso K,Kennedy J,Zhang L,Birsoy O,Mandelker D,Steinsnyder Z,Latham A,Carlo MI,Cadoo K,Kemel Y,Robson M,Stadler ZK,Offit K. Pathogenic Loss-of-Function Germline  Mutations in Patients With Solid Tumors. JCO Precis Oncol.. 2019;3():.", pmids: "17392301|21436073|23335200|25170286|25237198|25940403|26022962|27836952|32923861|33184060", name: "TERT", description: "The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793  Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual‚Äôs telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200).", fullName: "Telomerase Reverse Transcriptase", mechanism: "Telomerase is a ribonucleoprotein enzyme essential for the replication of chromosome termini in most eukaryotes. Active in progenitor and cancer cells. Inactive, or very low activity, in normal somatic cells. Catalytic component of the teleromerase holoen"})
(:gene {references: "24899893) Martins R,Bugalho MJ. Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol.. 2014;2014():794187.|26347711) Costa MH,Ortiga-Carvalho TM,Violante AD,Vaisman M. Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches. Front Endocrinol (Lausanne).. 2015;6():126.|28973655) Casey RT,Warren AY,Martin JE,Challis BG,Rattenberry E,Whitworth J,Andrews KA,Roberts T,Clark GR,West H,Smith PS,Docquier FM,Rodger F,Murray V,Simpson HL,Wallis Y,Giger O,Tran M,Tomkins S,Stewart GD,Park SM,Woodward ER,Maher ER. Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review. J Clin Endocrinol Metab.. 2017;102(11):4013-4022.|33051659) Armaiz-Pena G,Flores SK,Cheng ZM,Zhang X,Esquivel E,Poullard N,Vaidyanathan A,Liu Q,Michalek J,Santillan-Gomez AA,Liss M,Ahmadi S,Katselnik D,Maldonado E,Salgado SA,Jimenez C,Fishbein L,Hamidi O,Else T,Lechan R,Tischler AS,Benn DE,Dwight T,Clifton-Bligh R,Sanso G,Barontini M,Vincent D,Aronin N,Biondi B,Koops M,Bowhay-Carnes E,Gimenez-Roqueplo AP,Alvarez-Eslava A,Bruder JM,Kitano M,Burnichon N,Ding Y,Dahia PLM. Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. J Clin Endocrinol Metab.. 2021;106(1):e350-e364.|20301715) Hereditary Paraganglioma-Pheochromocytoma Syndromes", pmids: "20301715|24899893|26347711|28973655|33051659", name: "TMEM127", description: "The TMEM127 gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 18419). There is also evidence suggesting TMEM127 is associated with autosomal dominant predisposition to renal cancer (PMID: 33051659, 28973655). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  Hereditary PGL-PCC syndrome is characterized by an increased lifetime risk to develop PGLs and PCCs. Most evidence suggests TMEM127 is associated with primarily PCC; however, cases of extra-adrenal PGLs have also been reported (PMID: 33051659). The risk of malignant transformation appears to be low (PMID: 24899893, 26347711, 20301715).", fullName: "Transmembrane Protein 127", mechanism: "Controls cell proliferation acting as a negative regulator of TOR signaling pathway mediated by mTORC1. May act as a tumor suppressor."})
(:gene {references: "11920808) Armada RC,Longchong Ramos M,Marrero P,Pascual J. Embryonal rhabdomyosarcoma associated with tuberous sclerosis. Med Pediatr Oncol.. 2002;38(4):302.|2069856) Narod SA,Stiller C,Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer.. 1991;63(6):993-9.|32953421) Nair N,Chakraborty R,Mahajan Z,Sharma A,Sethi SK,Raina R. Renal Manifestations of Tuberous Sclerosis Complex. J Kidney Cancer VHL.. 2020;7(3):5-19.", pmids: "2069856|11920808|32953421", name: "TSC1", description: "The TSC1 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 344288).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).", fullName: "TSC Complex Subunit 1", mechanism: "This gene is a tumor suppressor gene that encodes the growth inhibitory protein hamartin. The encoded protein interacts with and stabilizes the GTPase activating protein tuberin. This hamartin-tuberin complex negatively regulates mammalian target of rapam"})
(:gene {references: "11920808) Armada RC,Longchong Ramos M,Marrero P,Pascual J. Embryonal rhabdomyosarcoma associated with tuberous sclerosis. Med Pediatr Oncol.. 2002;38(4):302.|2069856) Narod SA,Stiller C,Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer.. 1991;63(6):993-9.|32953421) Nair N,Chakraborty R,Mahajan Z,Sharma A,Sethi SK,Raina R. Renal Manifestations of Tuberous Sclerosis Complex. J Kidney Cancer VHL.. 2020;7(3):5-19.", pmids: "2069856|11920808|32953421", name: "TSC2", description: "The TSC2 gene is associated with autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 348170).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421).", fullName: "TSC Complex Subunit 2", mechanism: "In complex with TSC1, this tumor suppressor inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling (PubMed:12271141, PubMed:28215400). Acts as a GTPase-activating protein ("})
(:gene {references: "21386872) Maher ER,Neumann HP,Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet.. 2011;19(6):617-23.|23733342) Franke K,Gassmann M,Wielockx B. Erythrocytosis: the HIF pathway in control. Blood.. 2013;122(7):1122-8.|24115288) Bento C,Percy MJ,Gardie B,Maia TM,van Wijk R,Perrotta S,Della Ragione F,Almeida H,Rossi C,Girodon F,Astr√É¬∂m M,Neumann D,Schnittger S,Landin B,Minkov M,Randi ML,Richard S,Casadevall N,Vainchenker W,Rives S,Hermouet S,Ribeiro ML,McMullin MF,Cario H, ,Chauveau A,Gimenez-Roqueplo AP,Bressac-de-Paillerets B,Altindirek D,Lorenzo F,Lambert F,Dan H,Gad-Lapiteau S,Catarina Oliveira A,Rossi C,Fraga C,Taradin G,Martin-Nu√É¬±ez G,Vit√É¬≥ria H,Diaz Aguado H,Palmblad J,Vid√É¬°n J,Relvas L,Ribeiro ML,Luigi Larocca M,Luigia Randi M,Pedro Silveira M,Percy M,Gross M,Marques da Costa R,Beshara S,Ben-Ami T,Ugo V, . Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat.. 2014;35(1):15-26.|25611110) Cassol C,Mete O. Endocrine manifestations of von Hippel-Lindau disease. Arch Pathol Lab Med.. 2015;139(2):263-8.|28620007) Rednam SP,Erez A,Druker H,Janeway KA,Kamihara J,Kohlmann WK,Nathanson KL,States LJ,Tomlinson GE,Villani A,Voss SD,Schiffman JD,Wasserman JD. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res.. 2017;23(12):e68-e75.|31095066) Aronow ME,Wiley HE,Gaudric A,Krivosic V,Gorin MB,Shields CL,Shields JA,Jonasch EW,Singh AD,Chew EY. VON HIPPEL-LINDAU DISEASE: Update on Pathogenesis and Systemic Aspects. Retina.. 2019;39(12):2243-2253.|20301636) Von Hippel-Lindau Syndrome", pmids: "20301636|21386872|23733342|24115288|25611110|28620007|31095066", name: "VHL", description: "The VHL gene is associated with autosomal dominant von Hippel-Lindau (VHL) syndrome (MedGen UID: 42458) and autosomal recessive familial erythrocytosis, type 2 (MedGen UID: 332974).  von Hippel-Lindau syndrome is associated with an increased risk of developing various noncancerous tumors throughout the body including hemangioblastomas of the central nervous system and retina, head and neck paragangliomas, pheochromocytomas, endolymphatic sac tumors and epididymal cystadenomas. Although most tumors are benign, there is a 17-70% risk of developing clear cell renal cell carcinoma and an 8-17% risk for pancreatic neuroendocrine tumors (PMID: 20301636, 28620007, 31095066). Approximately 20% of VHL cases are de novo (PMID: 21386872, 25611110). Although genotype-phenotype correlations have been suggested, their diagnostic relevance is unclear and therefore should not impact medical management (PMID: 21386872, 20301636).  Familial erythrocytosis is characterized by the abnormally high production of red blood cells (erythrocytes), which can cause headaches, dizziness, nosebleeds, shortness of breath and predisposition to excessive clotting. Familial erythrocytosis has incomplete penetrance; many individuals with biallelic pathogenic variants will never develop clinical symptoms (PMID: 24115288, 23733342).", fullName: "Von Hippel-Lindau Tumor Suppressor", altName: "VHL", mechanism: "VHL encodes a tumor suppressor that is involved in transcriptional repression."})
(:gene {name: "WRN", fullName: "ATP-dependent helicase", mechanism: "Multifunctional enzyme that has both magnesium and ATP-dependent DNA-helicase activity and 3'->5' exonuclease activity towards double-stranded DNA with a 5'-overhang. Has no nuclease activity towards single-stranded DNA or blunt-ended double-stranded DNA."})
(:gene {references: "22692063) Hingorani M,Hanson I,van Heyningen V. Aniridia. Eur J Hum Genet.. 2012;20(10):1011-7.|23295293) Guaragna MS,Lutaif AC,Bittencourt VB,Piveta CS,Soardi FC,Castro LC,Belangero VM,Maciel-Guerra AT,Guerra-Junior G,Mello MP. Frasier syndrome: four new cases with unusual presentations. Arq Bras Endocrinol Metabol.. 2012;56(8):525-32.|25818337) Lehnhardt A,Karnatz C,Ahlenstiel-Grunow T,Benz K,Benz MR,Budde K,B√É¬ºscher AK,Fehr T,Feldk√É¬∂tter M,Graf N,H√É¬∂cker B,Jungraithmayr T,Klaus G,Koehler B,Konrad M,Kranz B,Montoya CR,M√É¬ºller D,Neuhaus TJ,Oh J,Pape L,Pohl M,Royer-Pokora B,Querfeld U,Schneppenheim R,Staude H,Spart√É¬† G,Timmermann K,Wilkening F,Wygoda S,Bergmann C,Kemper MJ. Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1. Clin J Am Soc Nephrol.. 2015;10(5):825-31.|9529364) Jeanpierre C,Denamur E,Henry I,Cabanis MO,Luce S,C√É¬©cille A,Elion J,Peuchmaur M,Loirat C,Niaudet P,Gubler MC,Junien C. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet.. 1998;62(4):824-33.", pmids: "9529364|22692063|23295293|25818337", name: "WT1", description: "The WT1 gene is associated with autosomal dominant Denys-Drash syndrome (MedGen UID: 181980), Wilms tumor predisposition syndrome (MedGen UID: 447509), WAGR syndrome (MedGen UID: 64512) and Frasier syndrome (MedGen UID: 215533).  WT1-related disorders are associated with an increased risk for Wilms tumor, a type of renal cancer, which typically presents in early childhood. WT1-related Wilms tumor may occur as an isolated finding or as part of a syndrome. Deletions of WT1 along with the neighboring PAX6 gene are associated with WAGR (Wilms tumor-aniridia-genital anomalies-retardation) syndrome, characterized by Wilms tumor, genitourinary anomalies, intellectual disability, and aniridia (PMID: 22692063).  Other WT1-related disorders include Denys-Drash syndrome, which has a high risk of Wilms tumor and genitourinary anomalies, and Frasier syndrome, which is more often associated with gonadoblastoma and less often with Wilms tumor (PMID: 23295293, 9529364). Nephrotic syndrome has also been linked to pathogenic variants in WT1 (PMID: 25818337).", fullName: "WT1 Transcription Factor", mechanism: "Transcription factor that plays an important role in cellular development and cell survival (PubMed:7862533). Recognizes and binds to the DNA sequence 5'-GCG(T/G)GGGCG-3' (PubMed:7862533, PubMed:17716689, PubMed:25258363). Regulates the expression of nume"})
(:gene {references: "15042511) Lammi L,Arte S,Somer M,Jarvinen H,Lahermo P,Thesleff I,Pirinen S,Nieminen P. Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal cancer. Am J Hum Genet.. 2004;74(5):1043-50.|21416598) Marvin ML,Mazzoni SM,Herron CM,Edwards S,Gruber SB,Petty EM. AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic syndrome. Am J Med Genet A.. 2011;155A(4):898-902.|21626677) Bergendal B,Klar J,Stecks√É¬©n-Blicks C,Norderyd J,Dahl N. Isolated oligodontia associated with mutations in EDARADD, AXIN2, MSX1, and PAX9 genes. Am J Med Genet A.. 2011;155A(7):1616-22.", pmids: "15042511|21416598|21626677", name: "AXIN2", description: "The AXIN2 gene is associated with autosomal dominant oligodontia-colorectal cancer syndrome (MedGen UID: 324868).								  Oligodontia-colorectal cancer syndrome is associated with colon polyps and colorectal cancer as well as features of ectodermal dysplasia including severe oligodontia and sparse eyebrows, scalp and body hair (PMID: 15042511, 21416598, 21626677).", fullName: "Axis Inhibitor 2", mechanism: "The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin. Apparently, the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair. [provided by RefSeq, Jul 2008]"})
(:gene {references: "22935333) Carbone M,Ferris LK,Baumann F,Napolitano A,Lum CA,Flores EG,Gaudino G,Powers A,Bryant-Greenwood P,Krausz T,Hyjek E,Tate R,Friedberg J,Weigel T,Pass HI,Yang H. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med.. 2012;10():179.|23684012) Popova T,Hebert L,Jacquemin V,Gad S,Caux-Moncoutier V,Dubois-d'Enghien C,Richaudeau B,Renaudin X,Sellers J,Nicolas A,Sastre-Garau X,Desjardins L,Gyapay G,Raynal V,Sinilnikova OM,Andrieu N,Mani√É¬© E,de Pauw A,Gesta P,Bonadona V,Maugard CM,Penet C,Avril MF,Barillot E,Cabaret O,Delattre O,Richard S,Caron O,Benfodda M,Hu HH,Soufir N,Bressac-de Paillerets B,Stoppa-Lyonnet D,Stern MH. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet.. 2013;92(6):974-80.|30517737) Walpole S,Pritchard AL,Cebulla CM,Pilarski R,Stautberg M,Davidorf FH,de la Fouchardi√É¬®re A,Cabaret O,Golmard L,Stoppa-Lyonnet D,Garfield E,Njauw CN,Cheung M,Turunen JA,Repo P,J√É¬§rvinen RS,van Doorn R,Jager MJ,Luyten GPM,Marinkovic M,Chau C,Potrony M,H√É¬∂iom V,Helgadottir H,Pastorino L,Bruno W,Andreotti V,Dalmasso B,Ciccarese G,Queirolo P,Mastracci L,Wadt K,Kiilgaard JF,Speicher MR,van Poppelen N,Kilic E,Al-Jamal RT,Dianzani I,Betti M,Bergmann C,Santagata S,Dahiya S,Taibjee S,Burke J,Poplawski N,O'Shea SJ,Newton-Bishop J,Adlard J,Adams DJ,Lane AM,Kim I,Klebe S,Racher H,Harbour JW,Nickerson ML,Murali R,Palmer JM,Howlie M,Symmons J,Hamilton H,Warrier S,Glasson W,Johansson P,Robles-Espinoza CD,Ossio R,de Klein A,Puig S,Ghiorzo P,Nielsen M,Kivel√É¬§ TT,Tsao H,Testa JR,Gerami P,Stern MH,Paillerets BB,Abdel-Rahman MH,Hayward NK. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. J Natl Cancer Inst.. 2018;110(12):1328-1341.", pmids: "22935333|23684012|30517737", name: "BAP1", description: "The BAP1 gene is associated with autosomal dominant BAP1 tumor predisposition syndrome (MedGen UID: 482122). There is also evidence suggesting BAP1 is associated with autosomal dominant predisposition to meningioma (PMID: 30517737). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  BAP1 tumor predisposition syndrome is associated with an increased risk for cutaneous and uveal melanoma, malignant pleural mesothelioma and renal cell carcinoma; lifetime cancer risks are unclear (PMID: 22935333, 23684012).", fullName: "BRCA1 associated protein 1", mechanism: "This gene belongs to the ubiquitin C-terminal hydrolase subfamily of deubiquitinating enzymes that are involved in the removal of ubiquitin from proteins. The encoded enzyme binds to the breast cancer type 1 susceptibility protein (BRCA1) via the RING finger domain of the latter and acts as a tumor suppressor. In addition, the enzyme may be involved in regulation of transcription, regulation of cell cycle and growth, response to DNA damage and chromatin dynamics."})
(:gene {references: "12242432) Gruber SB,Ellis NA,Scott KK,Almog R,Kolachana P,Bonner JD,Kirchhoff T,Tomsho LP,Nafa K,Pierce H,Low M,Satagopan J,Rennert H,Huang H,Greenson JK,Groden J,Rapaport B,Shia J,Johnson S,Gregersen PK,Harris CC,Boyd J,Rennert G,Offit K. BLM heterozygosity and the risk of colorectal cancer. Science.. 2002;297(5589):2013.|16763388) Diaz A,Vogiatzi MG,Sanz MM,German J. Evaluation of short stature, carbohydrate metabolism and other endocrinopathies in Bloom's syndrome. Horm Res.. 2006;66(3):111-7.|26358404) de Voer RM,Hahn MM,Mensenkamp AR,Hoischen A,Gilissen C,Henkes A,Spruijt L,van Zelst-Stams WA,Kets CM,Verwiel ET,Nagtegaal ID,Schackert HK,van Kessel AG,Hoogerbrugge N,Ligtenberg MJ,Kuiper RP. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep.. 2015;5():14060.|5770175) ValidYN,LastName,ForeName,Initials. Bloom's syndrome. I. Genetical and clinical observations in the first twenty-seven patients. Am J Hum Genet.. 1969;21(2):196-227.", pmids: "5770175|12242432|16763388|26358404", name: "BLM", description: "The BLM gene is associated with autosomal recessive Bloom syndrome (MedGen UID: 2685). Studies have also suggested BLM may be associated with autosomal dominant predisposition to colorectal cancer (PMID: 12242432, 26358404). The evidence, however, is preliminary and insufficient to make a determination regarding this relationship.                                                                          Bloom syndrome is characterized by proportionate small stature, microcephaly, abnormal skin pigmentation, facial anomalies, sun-sensitive facial erythema, infertility, immunodeficiency, and a predisposition to a wide variety of cancers (PMID: 16763388, 5770175).", fullName: "BLM RecQ Like Helicase", mechanism: "BLM encodes a helicase that works to maintain genomic stability."})
(:gene {references: "14641934) Felderbauer P,Hoffmann P,Einw√É¬§chter H,Bulut K,Ansorge N,Schmitz F,Schmidt WE. A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. BMC Gastroenterol.. 2003;3():34.|14985373) Warner J,Epstein M,Sweet A,Singh D,Burgess J,Stranks S,Hill P,Perry-Keene D,Learoyd D,Robinson B,Birdsey P,Mackenzie E,Teh BT,Prins JB,Cardinal J. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet.. 2004;41(3):155-60.|16497624) Felderbauer P,Klein W,Bulut K,Ansorge N,Dekomien G,Werner I,Epplen JT,Schmitz F,Schmidt WE. Mutations in the calcium-sensing receptor: a new genetic risk factor for chronic pancreatitis? Scand J Gastroenterol.. 2006;41(3):343-8.|18756473) Kapoor A,Satishchandra P,Ratnapriya R,Reddy R,Kadandale J,Shankar SK,Anand A. An idiopathic epilepsy syndrome linked to 3q13.3-q21 and missense mutations in the extracellular calcium sensing receptor gene. Ann Neurol.. 2008;64(2):158-67.|21521328) Frank-Raue K,Leidig-Bruckner G,Haag C,Schulze E,Lorenz A,Schmitz-Winnenthal H,Raue F. Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf).. 2011;75(1):50-5.|31189130) ValidYN,LastName,ForeName,Initials,AffiliationInfo. Molecular and clinical insights from studies of calcium-sensing receptor mutations. J Mol Endocrinol.. 2019;63(2):R1-R16.", pmids: "14641934|14985373|16497624|18756473|21521328|31189130", name: "CASR", description: "The CASR gene is associated with a spectrum of disorders including autosomal dominant familial hypocalciuric hypercalcemia (FHH) (MedGen UID: 369200), autosomal dominant hypocalcemia (ADH) (MedGen UID: 87438), ADH with Bartter syndrome (MedGen UID: 811594), autosomal recessive neonatal severe hyperparathyroidism (NSHPT) (MedGen UID: 331326), and possibly familial isolated hyperparathyroidism (FIHP) (PMID: 14985373, 21521328). There is also evidence suggesting CASR is associated with autosomal dominant idiopathic generalized epilepsy (PMID: 18756473) and chronic pancreatitis (PMID: 14641934, 16497624). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  CASR-related conditions include multiple disorders resulting in abnormal calcium levels. Pathogenic loss-of-function (LOF) variants cause FHH, characterized by hypercalcemia and hypocalciuria, although most affected individuals are asymptomatic (PMID: 31189130). Individuals with FIHP often present with one or more hyperplastic parathyroid glands, resulting in elevated parathyroid hormone and hypercalemia; like FHH, most individuals are asymptomatic due to early diagnosis and treatment (PMID: 31189130). NSHPT presents in infancy with parathyroid hyperplasia, elevated parathyroid hormone levels and hypercalcemia, which can result in bone demineralization and failure to thrive. Untreated NSHPT may lead to a severe, life-threatening neurological disorder (PMID: 31189130). There are reports of homozygous CASR variants causing a milder FHH-like phenotype (PMID: 31189130).

Pathogenic gain-of-function (GOF) variants in CASR cause ADH. ADH is characterized by hypoparathyroidism, hypocalcemia and hypercalciuria although approximately half of affected individuals have no associated health problems (PMID: 31189130). A subset of GOF variants can lead ADH with Bartter syndrome, type V, a renal tubular disorder causing excessive loss of sodium, chloride, and potassium in the urine (PMID: 31189130).", fullName: "Calcium Sensing Receptor", mechanism: "The protein encoded by this gene is a plasma membrane G protein-coupled receptor that senses small changes in circulating calcium concentration. The encoded protein couples this information to intracellular signaling pathways that modify parathyroid hormone secretion or renal cation handling, and thus this protein plays an essential role in maintaining mineral ion homeostasis."})
(:gene {references: "12434154) Carpten JD,Robbins CM,Villablanca A,Forsberg L,Presciuttini S,Bailey-Wilson J,Simonds WF,Gillanders EM,Kennedy AM,Chen JD,Agarwal SK,Sood R,Jones MP,Moses TY,Haven C,Petillo D,Leotlela PD,Harding B,Cameron D,Pannett AA,H√É¬∂√É¬∂g A,Heath H,James-Newton LA,Robinson B,Zarbo RJ,Cavaco BM,Wassif W,Perrier ND,Rosen IB,Kristoffersson U,Turnpenny PD,Farnebo LO,Besser GM,Jackson CE,Morreau H,Trent JM,Thakker RV,Marx SJ,Teh BT,Larsson C,Hobbs MR. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet.. 2002;32(4):676-80.|16720667) Guarnieri V,Scillitani A,Muscarella LA,Battista C,Bonfitto N,Bisceglia M,Minisola S,Mascia ML,D'Agruma L,Cole DE. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab.. 2006;91(8):2827-32.|23029104) Wang O,Wang C,Nie M,Cui Q,Guan H,Jiang Y,Li M,Xia W,Meng X,Xing X. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PLoS One.. 2012;7(9):e45567.|23293331) Bricaire L,Odou MF,Cardot-Bauters C,Delemer B,North MO,Salenave S,Vezzosi D,Kuhn JM,Murat A,Caron P,Sadoul JL,Silve C,Chanson P,Barlier A,Clauser E,Porchet N,Groussin L, . Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab.. 2013;98(2):E403-8.|20301744) CDC73-Related Disorders", pmids: "12434154|16720667|20301744|23029104|23293331", name: "CDC73", description: "The CDC73 gene is associated with autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid carcinoma, and familial isolated hyperparathyroidism (FIH) (MedGen UID: 310065, 146361, 333554), collectively referred to as CDC73-related conditions. There is also evidence suggesting CDC73 is associated with autosomal dominant predisposition to malignant uterine tumors (PMID: 23293331, 12434154, 23029104). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  CDC73-related conditions are characterized by primary hyperparathyroidism, which occurs in over 70% of cases (PMID: 16720667, 20301744). This primary hyperparathyroidism is typically caused by benign parathyroid adenomas, though it can also be due to an underlying parathyroid carcinoma (PMID: 20301744). Additional features include ossifying jaw fibromas, uterine fibroids, renal cysts, hamartomas and Wilms tumor.", fullName: "Cell Division Cycle 73", mechanism: "This gene encodes a tumor suppressor that is involved in transcriptional and post-transcriptional control pathways. The protein is a component of the the PAF protein complex, which associates with the RNA polymerase II subunit POLR2A and with a histone methyltransferase complex. This protein appears to facilitate the association of 3' mRNA processing factors with actively-transcribed chromatin. Mutations in this gene have been linked to hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism, and parathyroid carcinoma. [provided by RefSeq, Jul 2009]"})
(:gene {references: "20127975) Pingault V,Ente D,Dastot-Le Moal F,Goossens M,Marlin S,Bondurand N. Review and update of mutations causing Waardenburg syndrome. Hum Mutat.. 2010;31(4):391-406.", pmids: "20127975", name: "MITF", fullName: "Melanocyte Inducing Transcription Factor", description: "The MITF gene is associated with autosomal dominant Waardenburg syndrome, type 2a (MedGen UID: 349786) and autosomal recessive COMMAD syndrome (coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism, and deafness) (MedGen UID: 934592). The c.952G>A (p.Glu318Lys) variant in MITF is associated with autosomal dominant predisposition to cutaneous malignant melanoma (MedGen UID: 463554).  Waardenburg syndrome, type 2a (WS2a) is characterized by congenital deafness and abnormal pigmentation of the iris, hair and skin. Additional neurologic manifestations including intellectual disability and myelination abnormalities have been described. WS2a is distinguished from Waardenburg type 1 by the absence of dystopia canthorum (PMID: 20127975).

COMMAD syndrome is a rare condition characterized by iris coloboma, osteopetrosis, microphthalmia, macrocephaly, albinism and deafness. Due to the limited cases described in the literature, the clinical features and natural history of COMMAD are still unclear and will likely evolve over time. Clinical correlation is advised.", mechanism: "The protein encoded by this gene is a transcription factor that contains both basic helix-loop-helix and leucine zipper structural features. The encoded protein regulates melanocyte development and is responsible for pigment cell-specific transcription of the melanogenesis enzyme genes. Heterozygous mutations in the this gene cause auditory-pigmentary syndromes, such as Waardenburg syndrome type 2 and Tietz syndrome. [provided by RefSeq, Aug 2017]"})
(:gene {name: "MSH3", fullName: "MutS Homolog 3", mechanism: "MSH3 encodes a protein involved in DNA mismatch repair.The protein encoded by this gene forms a heterodimer with MSH2 to form MutS beta, part of the post-replicative DNA mismatch repair system. MutS beta initiates mismatch repair by binding to a mismatch and then forming a complex with MutL alpha heterodimer. This gene contains a polymorphic 9 bp tandem repeat sequence in the first exon. The repeat is present 6 times in the reference genome sequence and 3-7 repeats have been reported. Defects in this gene are a cause of susceptibility to endometrial cancer."})
(:gene {references: "16542390) Stevenson DA,Viskochil DH,Rope AF,Carey JC. Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype. Clin Genet.. 2006;69(3):246-53.|1770531) Allanson JE,Upadhyaya M,Watson GH,Partington M,MacKenzie A,Lahey D,MacLeod H,Sarfarazi M,Broadhead W,Harper PS. Watson syndrome: is it a subtype of type 1 neurofibromatosis? J Med Genet.. 1991;28(11):752-6.|20082463) Evans DG,Howard E,Giblin C,Clancy T,Spencer H,Huson SM,Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A.. 2010;152A(2):327-32.|23047742) Ben-Shachar S,Constantini S,Hallevi H,Sach EK,Upadhyaya M,Evans GD,Huson SM. Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation. Eur J Hum Genet.. 2013;21(5):535-9.|24357598) Ekvall S,Sj√É¬∂rs K,Jonzon A,Vihinen M,Anner√É¬©n G,Bondeson ML. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome. Am J Med Genet A.. 2014;164A(3):579-87.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|26178382) Rojnueangnit K,Xie J,Gomes A,Sharp A,Callens T,Chen Y,Liu Y,Cochran M,Abbott MA,Atkin J,Babovic-Vuksanovic D,Barnett CP,Crenshaw M,Bartholomew DW,Basel L,Bellus G,Ben-Shachar S,Bialer MG,Bick D,Blumberg B,Cortes F,David KL,Destree A,Duat-Rodriguez A,Earl D,Escobar L,Eswara M,Ezquieta B,Frayling IM,Frydman M,Gardner K,Gripp KW,Hern√É¬°ndez-Chico C,Heyrman K,Ibrahim J,Janssens S,Keena BA,Llano-Rivas I,Leppig K,McDonald M,Misra VK,Mulbury J,Narayanan V,Orenstein N,Galvin-Parton P,Pedro H,Pivnick EK,Powell CM,Randolph L,Raskin S,Rosell J,Rubin K,Seashore M,Schaaf CP,Scheuerle A,Schultz M,Schorry E,Schnur R,Siqveland E,Tkachuk A,Tonsgard J,Upadhyaya M,Verma IC,Wallace S,Williams C,Zackai E,Zonana J,Lazaro C,Claes K,Korf B,Martin Y,Legius E,Messiaen L. High Incidence of Noonan Syndrome Features Including Short Stature and Pulmonic Stenosis in Patients carrying NF1 Missense Mutations Affecting p.Arg1809: Genotype-Phenotype Correlation. Hum Mutat.. 2015;36(11):1052-63.|20301288) Neurofibromatosis1|25426837) Age-related clonal hematopoiesis associated with adverse outcomes|33864022) Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG)", pmids: "1770531|16542390|20082463|20301288|23047742|24357598|25426837|25426838|26178382|33864022", name: "NF1", description: "The NF1 gene is associated with autosomal dominant neurofibromatosis type 1 (NF1) (MedGen UID: 18013), neurofibromatosis-Noonan syndrome (NFNS) (MedGen UID: 419089) and Watson syndrome (MedGen UID: 107817).   NF1 is a neurocutaneous disorder associated with an increased risk of several types of benign and malignant tumors. Primary features include multiple cafe-au-lait spots, inguinal freckling and neurofibromas. NF1 is highly variable in its expression, even among affected members of the same family. There is an increased risk for tumors of the central nervous system neoplasms and other malignancies including female breast cancer, gastrointestinal stromal tumors, pheochromocytoma and soft tissue sarcomas (PMID: 20301288). Approximately one-half of NF1 cases are inherited, and the remainder are the result of de novo mutations (PMID: 20082463).             Allelic NF1 disorders include Watson syndrome and NFNS. Watson syndrome is characterized by pulmonic stenosis, cafe-au-lait spots, macrocephaly, Lisch nodules, intellectual disability and short stature (PMID: 1770531, 23047742). NFNS is characterized by classic neurofibromatosis in addition to short stature, distinctive facial features, broad neck, congenital heart defects, speech delay and pectus anomaly (PMID: 16542390, 24357598, 26178382). 

It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 33864022). Results from blood or saliva specimens alone may not distinguish between germline and acquired variants in this gene and additional testing may be appropriate.", fullName: "Neurofibromin 1", altName: "Neurofibromatosis Type 1 Protein,NF1", mechanism: "This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]"})
(:gene {references: "33066274) Onodera S,Nakamura Y,Azuma T. Gorlin Syndrome: Recent Advances in Genetic Testing and Molecular and Cellular Biological Research. Int J Mol Sci.. 2020;21(20):.", pmids: "33066274", name: "PTCH1", description: "The PTCH1 gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554). There is also evidence suggesting PTCH1 is associated with autosomal dominant holoprosencephaly (HPE) (MedGen: 372134). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  PTCH1-associated BCNS is an early-onset condition characterized by up to a 90% risk of developing multiple skin cancers, specifically basal cell carcinomas (BCCs). Approximately 90% will develop odontogenic keratocysts. BCNS is also associated with cardiac fibromas and ovarian fibromas in affected females. Additional findings include palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. Medulloblastomas occur in up to 5% of children with PTCH1-associated BCNS (PMID: 33066274).", fullName: "serine protease 1", mechanism: "This gene encodes a trypsinogen, which is a member of the trypsin family of serine proteases. This enzyme is secreted by the pancreas and cleaved to its active form in the small intestine. It is active on peptide linkages involving the carboxyl group of lysine or arginine. Mutations in this gene are associated with hereditary pancreatitis. This gene and several other trypsinogen genes are localized to the T cell receptor beta locus on chromosome 7"})
(:gene {references: "14996857) Fletcher O,Easton D,Anderson K,Gilham C,Jay M,Peto J. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst.. 2004;96(5):357-63.|22355046) Kleinerman RA,Yu CL,Little MP,Li Y,Abramson D,Seddon J,Tucker MA. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol.. 2012;30(9):950-7.|32422154) Tonorezos ES,Friedman DN,Barnea D,Bosscha MI,Chantada G,Dommering CJ,de Graaf P,Dunkel IJ,Fabius AWM,Francis JH,Greer MC,Kleinerman RA,Kors WA,Laughlin S,Moll AC,Morton LM,Temming P,Tucker MA,van Leeuwen FE,Walsh MF,Oeffinger KC,Abramson DH. Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Ophthalmology.. 2020;127(11):1549-1557.", pmids: "14996857|22355046|32422154", name: "RB1", description: "The RB1 gene is associated with autosomal dominant retinoblastoma (MedGen UID: 20552). There is also evidence suggesting RB1 is associated with predisposition to several cancer types in retinoblastoma survivors (PMID: 14996857, 22355046).  Retinoblastoma (Rb) is a rare, early-childhood cancer that forms in the retina of the eye. The majority of individuals with hereditary Rb develop multiple tumors in both eyes with nearly complete penetrance; however, unilateral disease is not uncommon. A small subset of cases show a reduced penetrance phenotype with variable expressivity (PMID: 32422154). Affected individuals also appear to have an increased risk of developing secondary extra-ocular primary cancers including pinealoma, osteosarcoma, soft tissue sarcomas, and melanoma. The specific risk of these extra-ocular cancers is unknown, but is significantly increased among those who have received prior external beam radiation therapy (PMID: 32422154).", fullName: "RB Transcriptional Corepressor 1", altName: "retinoblastoma 1,retinoblastoma-1,RB1", mechanism: "The protein encoded by this gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma. [provided by RefSeq, Jul 2008]"})
(:gene {name: "RECQL4", fullName: "RecQ like helicase¬†4", mechanism: "The protein encoded by this gene is a DNA helicase that belongs to the RecQ helicase family. DNA helicases unwind double-stranded DNA into single-stranded DNAs and may modulate chromosome segregation. This gene is predominantly expressed in thymus and testis. Mutations in this gene are associated with Rothmund-Thomson, RAPADILINO and Baller-Gerold syndromes. [provided by RefSeq, Jan 2010]"})
(:gene {references: "18723428) Owen CJ,Toze CL,Koochin A,Forrest DL,Smith CA,Stevens JM,Jackson SC,Poon MC,Sinclair GD,Leber B,Johnson PR,Macheta A,Yin JA,Barnett MJ,Lister TA,Fitzgibbon J. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood.. 2008;112(12):4639-45.|19357396) Preudhomme C,Renneville A,Bourdon V,Philippe N,Roche-Lestienne C,Boissel N,Dhedin N,Andr√É¬© JM,Cornillet-Lefebvre P,Baruchel A,Mozziconacci MJ,Sobol H. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood.. 2009;113(22):5583-7.|25426838) Genovese G,K√É¬§hler AK,Handsaker RE,Lindberg J,Rose SA,Bakhoum SF,Chambert K,Mick E,Neale BM,Fromer M,Purcell SM,Svantesson O,Land√É¬©n M,H√É¬∂glund M,Lehmann S,Gabriel SB,Moran JL,Lander ES,Sullivan PF,Sklar P,Gr√É¬∂nberg H,Hultman CM,McCarroll SA. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med.. 2014;371(26):2477-87.|31490007) Coffee B,Cox HC,Bernhisel R,Manley S,Bowles K,Roa BB,Mancini-DiNardo D. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically. Hum Mutat.. 2020;41(1):203-211.|31881331) Mester JL,Jackson SA,Postula K,Stettner A,Solomon S,Bissonnette J,Murphy PD,Klein RT,Hruska KS. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing. J Mol Diagn.. 2020;22(3):396-404.|25426837) Age-related clonal hematopoiesis associated with adverse outcomes", pmids: "18723428|19357396|25426837|25426838|31490007|31881331", name: "RUNX1", description: "The RUNX1 gene is associated with autosomal dominant familial platelet disorder with associated myeloid malignancy (MedGen UID: 321945).  Familial platelet disorder is characterized by mild to moderate thrombocytopenia, platelet abnormalities, and a predisposition to develop myelodysplasia and/or acute myeloid leukemia (PMID: 19357396, 18723428). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired RUNX1 variants and additional testing may be appropriate.", fullName: "RUNX Family Transcription Factor 1", mechanism: "Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory"})
(:gene {references: "21505157) Pantaleo MA,Astolfi A,Indio V,Moore R,Thiessen N,Heinrich MC,Gnocchi C,Santini D,Catena F,Formica S,Martelli PL,Casadio R,Pession A,Biasco G. SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst.. 2011;103(12):983-7.|22972948) Alston CL,Davison JE,Meloni F,van der Westhuizen FH,He L,Hornig-Do HT,Peet AC,Gissen P,Goffrini P,Ferrero I,Wassmer E,McFarland R,Taylor RW. Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet.. 2012;49(9):569-77.|22974104) Italiano A,Chen CL,Sung YS,Singer S,DeMatteo RP,LaQuaglia MP,Besmer P,Socci N,Antonescu CR. SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors. BMC Cancer.. 2012;12():408.|23060355) Dwight T,Benn DE,Clarkson A,Vilain R,Lipton L,Robinson BG,Clifton-Bligh RJ,Gill AJ. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumors. Am J Surg Pathol.. 2013;37(2):226-33.|23322652) Jain-Ghai S,Cameron JM,Al Maawali A,Blaser S,MacKay N,Robinson B,Raiman J. Complex II deficiency--a case report and review of the literature. Am J Med Genet A.. 2013;161A(2):285-94.|26259135) Niemeijer ND,Papathomas TG,Korpershoek E,de Krijger RR,Oudijk L,Morreau H,Bayley JP,Hes FJ,Jansen JC,Dinjens WN,Corssmit EP. Succinate Dehydrogenase (SDH)-Deficient Pancreatic Neuroendocrine Tumor Expands the SDH-Related Tumor Spectrum. J Clin Endocrinol Metab.. 2015;100(10):E1386-93.|26722403) Jiang Q,Zhang Y,Zhou YH,Hou YY,Wang JY,Li JL,Li M,Tong HX,Lu WQ. A novel germline mutation in SDHA identified in a rare case of gastrointestinal stromal tumor complicated with renal cell carcinoma. Int J Clin Exp Pathol.. 2015;8(10):12188-97.|27683074) Courage C,Jackson CB,Hahn D,Euro L,Nuoffer JM,Gallati S,Schaller A. SDHA mutation with dominant transmission results in complex II deficiency with ocular, cardiac, and neurologic involvement. Am J Med Genet A.. 2017;173(1):225-230.|29177515) van der Tuin K,Mensenkamp AR,Tops CMJ,Corssmit EPM,Dinjens WN,van de Horst-Schrivers ANA,Jansen JC,de Jong MM,Kunst HPM,Kusters B,Leter EM,Morreau H,van Nesselrooij BMP,Oldenburg RA,Spruijt L,Hes FJ,Timmers HJLM. Clinical Aspects of SDHA-Related Pheochromocytoma and Paraganglioma: A Nationwide Study. J Clin Endocrinol Metab.. 2018;103(2):438-445.|29978154) Maniam P,Zhou K,Lonergan M,Berg JN,Goudie DR,Newey PJ. Pathogenicity and Penetrance of Germline  Variants in Pheochromocytoma and Paraganglioma (PPGL). J Endocr Soc.. 2018;2(7):806-816.|30201732) Benn DE,Zhu Y,Andrews KA,Wilding M,Duncan EL,Dwight T,Tothill RW,Burgess J,Crook A,Gill AJ,Hicks RJ,Kim E,Luxford C,Marfan H,Richardson AL,Robinson B,Schlosberg A,Susman R,Tacon L,Trainer A,Tucker K,Maher ER,Field M,Clifton-Bligh RJ. Bayesian approach to determining penetrance of pathogenic SDH variants. J Med Genet.. 2018;55(11):729-734.|20301715) Hereditary Paraganglioma-Pheochromocytoma Syndromes", pmids: "20301715|21505157|22972948|22974104|23060355|23322652|26259135|26722403|27683074|29177515|29978154|30201732", name: "SDHA", description: "The SDHA gene is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 481622), gastrointestinal stromal tumors (GIST) (PMID: 20301715), and autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Studies suggest SDHA may also be associated with autosomal dominant predisposition to renal cancer (PMID: 26722403) and pituitary adenomas (PMID: 26259135). The data, however, are preliminary and insufficient to make a determination regarding these relationships.  SDHA-associated PGL-PCC syndrome due to loss-of-function (LOF) variants is characterized by an increased risk of developing PGL and PCC. Germline LOF SDHA variants have also been identified in individuals and families with GIST (PMID: 21505157, 22974104, 23060355) and Carney-Stratakis syndrome, which is associated with both PGL and GIST. The lifetime risk to develop a SDHA-related tumor is estimated to be 1-10% (PMID: 29177515, 29978154, 30201732); however, the risk of malignant transformation is unclear. While the SDHA gene is associated with autosomal dominant mitochondrial complex II deficiency, LOF variants in this gene have not been observed in individuals with this condition.  Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy (PMID: 22972948, 23322652, 27683074). Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy (PMID: 22972948, 23322652). The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 23322652). Clinical correlation is advised.", fullName: "Succinate Dehydrogenase Complex Flavoprotein Subunit A", altName: "succinate dehydrogenase complex, subunit A, flavoprotein,SDHA", mechanism: "SDHA encodes a component of the succinate dehydrogenase enzyme which is involved in the electron transport chain"})
(:gene {references: "Unknown", pmids: "Unknown", name: "DICER1", description: "The DICER1 gene is associated with autosomal dominant DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome (MedGen UID: 449020).  DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome is associated with an increased risk for certain types of rare tumors and cancers that may present in childhood. Noncancerous neoplasias include cystic nephroma, nasal chondromesenchymal hamartomas, thyroid adenomas and goiter. There is also an increased risk of certain malignancies including pleuropulmonary blastoma, ovarian sex cord-stromal tumors, Sertoli-Leydig cell tumors, genitourinary embryonal rhabdomyosarcoma, renal sarcoma, Wilms tumor, thyroid cancer, ciliary body medulloepithelioma, pituitary blastoma and pineoblastoma.", fullName: "dicer 1, ribonuclease III", mechanism: "This gene encodes a protein possessing an RNA helicase motif containing a DEXH box in its amino terminus and an RNA motif in the carboxy terminus. The encoded protein functions as a ribonuclease and is required by the RNA interference and small temporal RNA (stRNA) pathways to produce the active small RNA component that represses gene expression. Alternative splicing results in multiple transcript variants."})
(:gene {references: "18780370) Alessandri JL,Cuillier F,Ramful D,Ernould S,Robin S,de Napoli-Cocci S,Rivi√É¬®re JP,Rossignol S. Perlman syndrome: report, prenatal findings and review. Am J Med Genet A.. 2008;146A(19):2532-7.|23613427) Morris MR,Astuti D,Maher ER. Perlman syndrome: overgrowth, Wilms tumor predisposition and DIS3L2. Am J Med Genet C Semin Med Genet.. 2013;163C(2):106-13.", pmids: "18780370|23613427", name: "DIS3L2", description: "The DIS3L2 gene is associated with autosomal recessive Perlman syndrome (MedGen UID: 162909).  Perlman syndrome is an overgrowth disorder characterized by macrosomia, renal dysplasia, nephroblastomatosis and Wilms tumor (PMID: 23613427). Affected infants have a high rate of neonatal morbidity; the incidence of Wilms tumor in those who survive the neonatal period has been estimated at 64% (PMID: 18780370).", fullName: "DIS3 Like 3'-5' Exoribonuclease 2", mechanism: "The protein encoded by this gene is similar in sequence to 3'/5' exonucleolytic subunits of the RNA exosome. The exosome is a large multimeric ribonucleotide complex responsible for degrading various RNA substrates. Several transcript variants, some protein-coding and some not, have been found for this gene. [provided by RefSeq, Mar 2012]"})
(:organ {name: "Kidney"})
(:organ {name: "Diaphragm"})
(:organ {name: "Genitals"})
(:organ {name: "CNS"})
(:organ {name: "Blood"})
(:organ {name: "Mesothelium"})
(:organ {name: "Prostate"})
(:organ {name: "Breast"})
(:organ {name: "Ovary"})
(:organ {name: "Endocrine"})
(:organ {name: "Skin"})
(:organ {name: "Heart"})
(:organ {name: "Liver"})
(:organ {name: "Colorectal"})
(:organ {name: "Brain"})
(:organ {name: "Unknown"})
(:organ {name: "Eye"})
(:organ {name: "Pancreas"})
(:organ {name: "Multiple organs"})
(:organ {name: "Lymphatic"})
(:organ {name: "Oropharynx"})
(:organ {name: "General"})
(:organ {name: "Lung"})
(:organ {name: "Metabolic"})
(:organ {name: "Nerve"})
(:organ {name: "Uterus"})
(:organ {name: "Face"})
(:organ {name: "Thyroid"})
(:organ {name: "Adrenal"})
(:organ {name: "PNS"})
(:organ {name: "Parathyroid"})
(:organ {name: "Pituitary"})
(:organ {name: "Connective Tissue"})
(:organ {name: "Bone"})
(:organ {name: "Soft Tissue"})
(:organ {name: "Urinary Bladder"})
(:organ {name: "Bile Duct"})
(:organ {name: "Auditory"})
(:organ {name: "GI"})
(:organ {name: "Colon"})
(:organ {name: "Head and neck"})
(:organ {name: "Lipid"})
(:organ {name: "Hand"})
(:organ {name: "Nails"})
(:organ {name: "Hair"})
(:organ {name: "Blood Vessel"})
(:organ {name: "Duodenum"})
(:organ {name: "Neuroendocrine"})
(:organ {name: "Connective tissue"})
(:organ {name: "Thymus"})
(:organ {name: "Wound healing"})
(:organ {name: "Nodes"})
(:organ {name: "Soft tissue"})
(:organ {name: "Gastric"})
(:organ {name: "Small Bowel"})
(:organ {name: "Spleen"})
(:organ {name: "Cervix"})
(:organ {name: "Esophagus"})
(:organ {name: "Developmental"})
(:organ {name: "Upper Urinary Tract"})
(:organ {name: "Ureter"})
(:organ {name: "Mediastinum"})
(:organ {name: "Testes"})
(:organ {name: "Muscle"})
(:organ {name: "Gallbladder"})
(:disease {name: "Kidney (Benign)"})
(:disease {name: "Gastrointestinal (Benign)"})
(:disease {name: "Genitourinary (Benign)"})
(:disease {name: "Developmental"})
(:disease {name: "Leukemia"})
(:disease {name: "Mesothelioma"})
(:disease {name: "Prostate Cancer"})
(:disease {name: "Wilms Tumor"})
(:disease {name: "Breast Cancer"})
(:disease {name: "Ovarian Cancer"})
(:disease {name: "Endocrine"})
(:disease {name: "Skin (Benign)"})
(:disease {name: "Cardiovascular Neoplasm"})
(:disease {name: "Skin Neoplasm"})
(:disease {name: "Hepatobiliary Cancer"})
(:disease {name: "Colorectal Cancer"})
(:disease {name: "Brain Tumor"})
(:disease {name: "Angiomyolipomas"})
(:disease {name: "Hamartoma"})
(:disease {name: "Neuroendocrine"})
(:disease {name: "Lymphangiomyomatosis"})
(:disease {name: "Oropharynx (Benign)"})
(:disease {name: "Tuberous sclerosis complex (TSC)"})
(:disease {name: "Lung (Benign)"})
(:disease {name: "Cystic fibrosis"})
(:disease {name: "Blood (Benign)"})
(:disease {name: "Pheochromocytoma/Paraganglioma"})
(:disease {name: "Uterus Neoplasm"})
(:disease {name: "Kidney Neoplasm"})
(:disease {name: "Dysmorphic Feature"})
(:disease {name: "Thyroid Cancer"})
(:disease {name: "Adrenal Cortical Carcinoma"})
(:disease {name: "Peripheral Nervous System Benign"})
(:disease {name: "Peripheral Nervous System Cancer"})
(:disease {name: "Parathyroid Neoplasm"})
(:disease {name: "Peripheral Nervous System Neoplasm"})
(:disease {name: "Lipoma"})
(:disease {name: "Thyroid (Benign)"})
(:disease {name: "Simpson-Golabi-Behmel syndrome"})
(:disease {name: "Cardiovascular (Benign)"})
(:disease {name: "Melanoma"})
(:disease {name: "Sarcoma"})
(:disease {name: "Metabolic"})
(:disease {name: "Bladder Cancer"})
(:disease {name: "Hearing loss"})
(:disease {name: "Arthrogryposis"})
(:disease {name: "Inflammatory fibroid polyps"})
(:disease {name: "Fibroid tumors"})
(:disease {name: "Coarse skin and facial features in addition to broad hands and feet"})
(:disease {name: "Coffin-Siris syndrome"})
(:disease {name: "Rhabdoid Tumour"})
(:disease {name: "Polyp"})
(:disease {name: "Kidney Cysts"})
(:disease {name: "Cirrhosis"})
(:disease {name: "Pancreas (Benign)"})
(:disease {name: "Thyroid Neoplasm"})
(:disease {name: "Kidney Cancer"})
(:disease {name: "Eye Neoplasm"})
(:disease {name: "Nasopharyngeal Neoplasm"})
(:disease {name: "Eye (Benign)"})
(:disease {name: "Parathyroid (Benign)"})
(:disease {name: "Adrenal Neoplasm"})
(:disease {name: "Nose (Benign)"})
(:disease {name: "Teeth (Benign)"})
(:disease {name: "Bone (Benign)"})
(:disease {name: "Nails (Benign)"})
(:disease {name: "Hair (Benign)"})
(:disease {name: "CNS (Benign)"})
(:disease {name: "Blood Vessel (Benign)"})
(:disease {name: "Lung Cancer"})
(:disease {name: "GI Neoplasm"})
(:disease {name: "Adrenal Cortical (Benign)"})
(:disease {name: "Pancreatic Cancer"})
(:disease {name: "Skin Cancer (Non-Melanoma)"})
(:disease {name: "Inflammatory Myofibroblastic Tumor"})
(:disease {name: "Lymphoma"})
(:disease {name: "Bone Neoplasm"})
(:disease {name: "CHRPE"})
(:disease {name: "Colorectal Neoplasia"})
(:disease {name: "Soft Tissue Neoplasm"})
(:disease {name: "Duodenum Neoplasm"})
(:disease {name: "Duodenum Cancer"})
(:disease {name: "Facial Palsy"})
(:disease {name: "Gastric Cancer"})
(:disease {name: "Gastric Neoplasm"})
(:disease {name: "Small Intestine Cancer"})
(:disease {name: "Endometrial Cancer"})
(:disease {name: "Ear (Benign)"})
(:disease {name: "Liver (Benign)"})
(:disease {name: "Spleen (Benign)"})
(:disease {name: "Cervical Cancer"})
(:disease {name: "Ovarian (Benign)"})
(:disease {name: "Bladder (Benign)"})
(:disease {name: "CNS Tumor"})
(:disease {name: "Psychiatric"})
(:disease {name: "Esophageal Cancer"})
(:disease {name: "Parathyroid Carcinoma"})
(:disease {name: "Nasopharyngeal Cancer"})
(:disease {name: "Breast (Benign)"})
(:disease {name: "Uterus (Benign)"})
(:disease {name: "Head And Neck Cancer"})
(:disease {name: "Plasma Cell Cancer"})
(:disease {name: "Orolaryngeal Carcinoma"})
(:disease {name: "Ovarian Neoplasm"})
(:disease {name: "Sebaceous Adenoma"})
(:disease {name: "Sebaceous Cancer"})
(:disease {name: "Upper Urinary Tract Cancer"})
(:disease {name: "Ureter Cancer"})
(:disease {name: "Fumarase Deficiency"})
(:disease {name: "Uterus Cancer"})
(:disease {name: "Testicular Cancer"})
(:disease {name: "Lymphedema"})
(:disease {name: "Pancreatic Neoplasm"})
(:disease {name: "Testicular Neoplasm"})
(:disease {name: "GIST"})
(:disease {name: "Neurofibroma"})
(:disease {name: "Plasma Cell Neoplasm"})
(:disease {name: "Endocrine Abnormalities"})
(:disease {name: "Hypereosinophilic Syndrome"})
(:disease {name: "MDPL syndrome"})
(:disease {name: "Myopathy"})
(:disease {name: "Lymphomesentric Cyst"})
(:disease {name: "Facial Papules"})
(:disease {name: "Retinoblastoma"})
(:disease {name: "Lymphadenopathy"})
(:syndrome {name: "FAMM", types: ["Dominant"], verbiages: ["Autosomal dominant predisposition to cutaneous melanoma (MedGen UID: 268851).  CDK4-related cutaneous melanoma is characterized by early presentation of atypical nevi and early-onset melanoma (PMID: 15880589, 23384855, 30775140). In a study of individuals with pathogenic CDK4 variants, the penetrance at age 50 was 74% (PMID: 23384855). Additional risk factors including pale skin and excessive sun exposure may amplify lifetime risks."]})
(:syndrome {name: "Congenital tufting enteropathy", types: ["Recessive"], verbiages: ["The EPCAM gene is associated with autosomal recessive congenital tufting enteropathy (CTE) (MedGen UID: 413031).  Congenital tufting enteropathy (CTE) is a gastrointestinal insufficiency syndrome presenting early in infancy as severe watery diarrhea. CTE is usually treated by daily nutritional supplements and occasionally, intestinal transplantation (PMID: 8057225, 18572020)."]})
(:syndrome {name: "Constitutional Mismatch Repair Deficiency Syndrome", types: ["Recessive"], verbiages: ["Autosomal recessive constitutional mismatch repair deficiency syndrome (CMMR-D) (MedGen UID: 78553).  CMMR-D is a cancer syndrome characterized by childhood malignancies, most commonly hematological malignancies and/or brain tumors, as well as very early-onset colorectal cancer. Nearly all affected individuals have clinical signs reminiscent of neurofibromatosis type 1 (NF1) such as caf√©-au-lait spots (PMID: 18709565, 20442441, 17539897)."]})
(:syndrome {name: "MDPL Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant MDPL syndrome (mandibular hypoplasia, deafness, progeroid features, and lipodystrophy) (MedGen UID: 811623). MDPL syndrome is a rare, systemic disorder characterized by loss of subcutaneous fat, distinctive facial features and metabolic abnormalities including insulin resistance and diabetes. Sensorineural hearing loss is also a common finding, typically presenting in the first or second decades of life (PMID: 25131834, 23770608)."]})
(:syndrome {name: "FILS Syndrome", types: ["Recessive"], verbiages: ["Autosomal recessive FILS syndrome (facial dysmorphism, immunodeficiency, livedo, and short stature) (MedGen UID: 767490).  FILS syndrome is characterized by mild facial dysmorphism and immunodeficiency resulting in recurrent infections, livedo on the skin present at birth and short stature. Malignancies have not been observed in affected individuals (PMID: 23230001)."]})
(:syndrome {name: "Myhre Syndrome", types: ["Dominant"], verbiages: ["Myhre syndrome (MedGen UID: 167103).  Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT."]})
(:syndrome {name: "Watson Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Watson syndrome (MedGen UID: 107817).   Watson syndrome is characterized by pulmonic stenosis, cafe-au-lait spots, macrocephaly, Lisch nodules, intellectual disability and short stature (PMID: 1770531, 23047742)."]})
(:syndrome {name: "Nijmegen Breakage Syndrome", types: ["Recessive"], verbiages: ["Autosomal recessive Nijmegen breakage syndrome (NBS) (MedGen UID: 140771).  NBS is a progressive multisystemic disorder characterized by physical abnormalities, immunodeficiency, increased cancer risk and cognitive impairment. Physical abnormalities may include progressive microcephaly, early growth restriction leading to short stature and distinctive facial features. Immunodeficiency often results in recurrent pulmonary infections. B-cell lymphomas are the most common malignancy, although T-cell lymphomas, medulloblastomas, gliomas and rhabdomyosarcomas may also occur (PMID: 22373003, 26271390)."]})
(:syndrome {name: "Marinesco-Sj√∂gren syndrome"})
(:syndrome {name: "Cowden Syndrome", types: ["Dominant"], verbiages: ["The PTEN gene is associated with autosomal dominant PTEN hamartoma tumor syndrome (PHTS), including the clinical subtypes of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome and PTEN-related autism spectrum disorder (MedGen UID: 368366). Other PTEN-associated conditions have also been described (PMID: 11755638, 17392703, 27890237).  PHTS is a highly variable hamartomatous condition characterized by macrocephaly, Lhermitte-Duclos disease, mucocutaneous lesions, gastrointestinal hamartomas, lipomas, benign thyroid lesions, macular pigmentation of the glans penis, cerebrovascular malformations and several types of cancer. Associated cancers include breast (up to 85% risk), thyroid (typically follicular, up to 38% risk), renal (up to 34%), endometrial (up to 28% risk), colorectal (9-16% risk) and melanoma (6% risk) (PMID: 31216739, 33471991). PHTS is also associated with developmental delay, intellectual disability and autism spectrum disorder (PMID: 26564076, 19265751, 25288137)."]})
(:syndrome {name: "Fanconi Anemia", types: ["Recessive"], verbiages: ["Fanconi anemia is characterized by developmental abnormalities in major organ systems, early-onset bone marrow failure, and a high predisposition to cancer. Bone marrow failure with pancytopenia often presents in the first decade of life."]})
(:syndrome {name: "Hereditary Diffuse Gastric Cancer Syndrome", types: ["Dominant"], verbiages: ["The CDH1 gene is associated with autosomal dominant predisposition to diffuse gastric cancer and lobular breast cancer, collectively known as hereditary diffuse gastric cancer (HDGC) syndrome (MedGen UID: 310839).  The estimated lifetime risk of diffuse gastric cancer in individuals with a pathogenic CDH1 variant is 67-83% (PMID: 11729114), although recent studies suggest the risk may be lower, at 33-42% (PMID: 31246251, 31296550). The lifetime risk of lobular cancer in females is 27%-52% (PMID: 17545690, 11729114, 33471974)."]})
(:syndrome {name: "Lynch Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Lynch syndrome (also called hereditary nonpolyposis colorectal cancer syndrome, or HNPCC) (MedGen UID: 232603).  Lynch syndrome is characterized by an increased risk of colorectal cancer as well as cancers of the uterus/endometrium, ovary, stomach, bladder, biliary tract, urinary tract, prostate, brain and possibly small intestines. Estimated lifetime risks for individuals with a pathogenic variant in MSH2 and/or EPCAM include a 33-52% risk for colorectal cancer, up to a 9% risk for gastric cancer, up to a 1.7% risk for cancer of the biliary tract, a 2-28% risk for urinary tract cancer, a 4-13% risk for bladder cancer and a 3-8% risk for brain/central nervous system cancer. Affected females also have an increased risk of uterine cancer (21-57%) and ovarian cancer (8-38%) while affected males have an elevated risk for prostate cancer (up to 24%) (PMID: 21642682, 28754778, 19900449, 26657901, 31337882, 23091106, 18398828, 27013479)."]})
(:syndrome {name: "Hereditary Hemorrhagic Telangiectasia (HHT)", types: ["Dominant"], verbiages: ["Hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400).  HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias."]})
(:syndrome {name: "Neurofibromatosis, type 2", types: ["Dominant"], verbiages: ["Autosomal dominant neurofibromatosis type 2 (NF2) (MedGen UID: 18014).										  Neurofibromatosis type 2 is a highly penetrant condition characterized by multiple tumors throughout the central and peripheral nervous systems including schwannomas, meningiomas, ependymomas and rarely, astrocytomas and neurofibromas (PMID: 20082463, 15699726, 19476995). The hallmark tumors associated with this condition are bilateral vestibular schwannomas causing symptoms of tinnitus, hearing loss, balance difficulties and facial nerve weakness (PMID: 19671848, 24724714). Neurofibromatosis type 2 generally presents in the third to fourth decade of life, although this may be influenced by mutation type (PMID: 19476995)."]})
(:syndrome {name: "Nijmegen Breakage Syndrome-Like Disorder", types: ["Recessive"], verbiages: ["Autosomal recessive Nijmegen breakage syndrome-like disorder (NBSLD) (PMID: 19409520).  NBSLD is characterized by a clinical phenotype resembling Nijmegen breakage syndrome including chromosomal instability, radiosensitivity, neurodevelopmental disease, and immunodeficiency but with a milder clinical presentation."]})
(:syndrome {name: "Peutz-Jeghers Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Peutz-Jeghers syndrome (PJS) (MedGen UID: 18404).  PJS is characterized by gastrointestinal hamartomatous polyposis, mucocutaneous pigmentation of the lips, and increased risk of cancer. Affected individuals have increased risk of developing a wide variety of cancers including breast (19-54% risk), ovarian (18-21% risk), testicular (9% risk), endometrial/uterine (9% risk), cervical (10% risk), colon (39% risk), gastric (29% risk), small bowel (13% risk), pancreatic (11-36% risk) and lung (7-17% risk) (PMID: 11113065, 33471991)."]})
(:syndrome {name: "Birt-Hogg-Dube Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Birt-Hogg-Dub√© (BHD) syndrome (MedGen UID: 91070). There is also evidence suggesting BHD is associated with an increased risk of colon polyps and colorectal cancer (PMID: 20522427, 20392993). The data, however, are preliminary and insufficient to made a determination regarding this relationship.  BHD is characterized by an increased risk to develop noncancerous cysts in the lungs (70% risk) and kidneys (12-34% risk) in addition to acrochordons, fibrofolliculomas and trichodiscomas on the face neck and upper body. There is a 24-38% risk of developing one or more spontaneous pneumothorax. Affected individuals also have an increased risk of kidney cancer; however, lifetime risks are not established (PMID: 25519092, 25519458, 18234728)."]})
(:syndrome {name: "Gardner Syndrome"})
(:syndrome {name: "Hereditary Mixed Polyposis Syndrome", types: ["Dominant"], verbiages: ["The GREM1 gene is associated with autosomal dominant hereditary mixed polyposis syndrome (HMPS) in individuals who carry a duplication spanning the 3' end of the adjacent SCG5 gene and a region upstream of the GREM1 locus (MedGen UID: 430218, PMID: 22561515).  Hereditary mixed polyposis syndrome is an adult-onset condition associated with various types of colon polyps which may subsequently become malignant (PMID: 22561515). Lifetime cancer risks are currently not well established."]})
(:syndrome {name: "Juvenile Polyposis Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518)  .  JPS is characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469)."]})
(:syndrome {name: "Hereditary Paraganglioma-Pheochromocytoma Syndrome", types: ["Dominant"], verbiages: ["Hereditary paraganglioma-pheochromocytoma (PGL-PCC) syndrome (MedGen UID: 313270). PGL-PCC syndrome is characterized by malignant or benign PGL and PCC tumors. PGLs are nervous system tumors that often develop within the head, neck, spine, or abdomen. PCCs are adrenal gland tumors that may cause symptoms related to increased hormone secretion, such as rapid heartbeat and high blood pressure (PMID: 21685915, 22452945, 23666964)."]})
(:syndrome {name: "Ataxia telangiectasia", types: ["Recessive"], verbiages: ["A-T is characterized by progressive cerebellar ataxia beginning in early childhood, oculomotor apraxia, choreoathetosis, telangiectasias of the conjunctivae, immunodeficiency, frequent infections and increased malignancy risk, particularly leukemia and lymphoma (PMID: 15279807, 26050521)."]})
(:syndrome {name: "Carney-Stratakis Syndrome", types: ["Dominant"], verbiages: ["Carney-Stratakis syndrome, which is associated with both GIST and PGL (PMID: 17667967)."]})
(:syndrome {name: "Hereditary Breast and Ovary Cancer Syndrome", types: ["Dominant"], verbiages: ["The BRCA2 gene is associated with autosomal dominant hereditary breast and ovarian cancer (HBOC) syndrome (MedGen UID: 151793)"]})
(:syndrome {name: "Li-Fraumeni Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Li-Fraumeni syndrome (LFS) (MedGen UID: 322656).  LFS is a cancer predisposition syndrome associated with sarcoma, brain cancer, breast cancer, adrenocortical carcinoma and other malignancies. Affected individuals often develop cancers in childhood or early adulthood, and are at increased risk for multiple primary cancers. Overall lifetime cancer risks have been reported as high as 73% for males and nearly 100% for females (PMID: 10864200). It is estimated that 7-20% of LFS cases are due to a de novo pathogenic variant (PMID: 19556618). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired TP53 variants and additional testing may be appropriate."]})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Rhabdomyosarcoma", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH2-Biallelic", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH3", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Neoplasm", DiseaseName: "Gastric Neoplasm", PredominantCancerSubtype: "Gastric Leiomyoma", GeneMasterName: "MSH3", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "MSH6", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Pelvis", GeneMasterName: "MSH6", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Sebaceous Adenoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sebaceous Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Keratoacanthoma", GeneMasterName: "MSH6", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Upper Urinary Tract Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Upper Urinary Tract"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ureter Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6", Gender: "Either", Organ: "Ureter"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6-Biallelic", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6-Biallelic", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6-Biallelic", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neurofibroma", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6-Biallelic", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Rhabdomyosarcoma", GeneMasterName: "MSH6-Biallelic", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSH6-Biallelic", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Barrett Esophagus", GeneMasterName: "MSR1", Gender: "Either", Organ: "Esophagus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSR1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSR1", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Liver (Benign)", PredominantCancerSubtype: "Non-Alcoholic Fatty Liver Disease", GeneMasterName: "MSR1", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Ovarian (Benign)", PredominantCancerSubtype: "Polycystic Ovary Disease", GeneMasterName: "MSR1", Gender: "Either", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MSR1", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Duodenum Neoplasm", PredominantCancerSubtype: "Duodenal Polyps", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic/Compound Heterozygous
MUTYH-Biallelic/Compound Heterozygous", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic/G396D", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "CNS", GeneMasterName: "MYD88", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Neoplasm", DiseaseName: "Plasma Cell Neoplasm", PredominantCancerSubtype: "Macroglobulinemia", GeneMasterName: "MYD88", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "NBN", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "NBN", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "ALL", GeneMasterName: "NBN", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Nasopharyngeal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NBN", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Astrocytoma", GeneMasterName: "NF1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NF1", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Cafe-Au-Lait Spots", GeneMasterName: "NF1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GIST", PredominantCancerSubtype: "Unknown", GeneMasterName: "NF1", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Lisch nodule (Iris Hamartoma)", GeneMasterName: "NF1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intellectual Disability", GeneMasterName: "NF1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Endocrine Abnormalities", PredominantCancerSubtype: "Unknown", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Endocrine"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Nevi", GeneMasterName: "SRGAP1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Jaw Lesions", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Pilomatrixoma", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "MUTYH-Biallelic", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NF1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Malignant Peripheral Nerve Sheath Tumor", GeneMasterName: "NF1", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "NF1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "NF1", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "NF1", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neurofibroma", PredominantCancerSubtype: "Unknown", GeneMasterName: "NF1", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Optic Glioma", GeneMasterName: "NF1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "NF1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Pulmonary Stenosis", GeneMasterName: "NF1", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Rhabdomyosarcoma", GeneMasterName: "NF1", Gender: "Either", Organ: "Soft tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Skin Freckling -Axillary and Inguinal", GeneMasterName: "NF1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "NF2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Meningioma", GeneMasterName: "NF2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Pancreatic Neoplasm", PredominantCancerSubtype: "Periampullary Adenoma", GeneMasterName: "NTHL1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Lipoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Either", Organ: "Lipid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "PALB2", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Either", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PALB2", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Tracheoesophageal Fistula¬†", GeneMasterName: "PALB2", Gender: "Either", Organ: "Mediastinum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "PALB2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PARK2", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Parkinsons", GeneMasterName: "PARK2", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GIST", PredominantCancerSubtype: "Unknown", GeneMasterName: "PDGFRA", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Hypereosinophilic Syndrome", PredominantCancerSubtype: "Unknown", GeneMasterName: "PDGFRA", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "Chronic Eosinophilic Leukemia", GeneMasterName: "PDGFRA", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Central Hypoventilation", GeneMasterName: "PHOX2B", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Hirschsprung Disease", GeneMasterName: "PHOX2B", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Peripheral Nervous System Cancer", PredominantCancerSubtype: "Neuroblastoma", GeneMasterName: "PHOX2B", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PIK3CA", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PIK3CA", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Hair (Benign)", PredominantCancerSubtype: "Alopecia Areata", GeneMasterName: "PMS2", Gender: "Either", Organ: "Hair"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "PMS2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Pelvis", GeneMasterName: "PMS2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Sebaceous Adenoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sebaceous Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Keratoacanthoma", GeneMasterName: "PMS2", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Upper Urinary Tract Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2", Gender: "Either", Organ: "Upper Urinary Tract"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2-Biallelic", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2-Biallelic", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2-Biallelic", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Lymphoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2-Biallelic", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neurofibroma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2-Biallelic", Gender: "Either", Organ: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Rhabdomyosarcoma", GeneMasterName: "PMS2-Biallelic", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Unknown", GeneMasterName: "PMS2-Biallelic", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Cholangiocarcinoma", GeneMasterName: "PMS2P1", Gender: "Either", Organ: "Bile Duct"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "POLD1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLD1", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLD1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLD1", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Syndrome", DiseaseName: "MDPL syndrome", PredominantCancerSubtype: "Lipodystrophy, Deafness, Mandibular Hypoplasia", GeneMasterName: "POLD1", Gender: "Either", Organ: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLD1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLD1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Adenomatous Polyps", GeneMasterName: "POLD1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLD1", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioblastoma Multiforme", GeneMasterName: "POLE", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLE", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLE", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Adenomatous Polyps", GeneMasterName: "POLE", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLE", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Myopathy", PredominantCancerSubtype: "Nemaline Myopathy¬†", GeneMasterName: "POLE", Gender: "Either", Organ: "Muscle"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLE", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLE", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "POLE", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Acrodysostosis", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Adrenal Cortical (Benign)", PredominantCancerSubtype: "Pigmented Nodular Adrenocortical Disease", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Bone Neoplasm", PredominantCancerSubtype: "Osteochondromyxoma", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Cardiovascular Neoplasm", PredominantCancerSubtype: "Cardiac Myxoma", GeneMasterName: "PRKAR1A", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatitis", GeneMasterName: "PRSS1", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PRSS1", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Coloboma", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Holoprosencephaly", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Bone Neoplasm", PredominantCancerSubtype: "Keratocystic Odontogenic Tumor", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lymphomesentric Cyst", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Cataract", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Ovarian (Benign)", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTCH1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Palmoplantar Pits", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Pleural Cyst", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Vertebral Defects", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Nevi", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Basal Cell Carcinoma", GeneMasterName: "PTCH1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Psychiatric", PredominantCancerSubtype: "Autism", GeneMasterName: "PTEN", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Cerebellar Gangliocytoma", GeneMasterName: "PTEN", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Breast (Benign)", PredominantCancerSubtype: "Virginal hyperplasia
- Fibrocystic breast disease
- Breast fibroadenomas", GeneMasterName: "PTEN", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Cerebrovascular Malformations", GeneMasterName: "PTEN", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Facial Papules", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GI Neoplasm", PredominantCancerSubtype: "Hamartomatous Polyps", GeneMasterName: "PTEN", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Head And Neck Cancer", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "PTEN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "PTEN", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lipoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Lipid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Macrocephaly", GeneMasterName: "PTEN", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Oral Mucosal Papillomatosis", GeneMasterName: "PTEN", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Palmoplantar Keratoses - Multiple facial papules
- Acral keratoses
- Multiple skin tags
- Facial trichilemmomas
- Subcutaneous lipomas", GeneMasterName: "PTEN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Trichilemmoma", GeneMasterName: "PTEN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Macular Pigmentation Of Glans Penis", GeneMasterName: "PTEN", Gender: "Male", Organ: "Genitals"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Acral Keratoses", GeneMasterName: "PTEN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "PTEN", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Thyroid (Benign)", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "PTEN", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Uterus (Benign)", PredominantCancerSubtype: "Uterine Fibroids", GeneMasterName: "PTEN", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD50", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD50", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Ovarian (Benign)", PredominantCancerSubtype: "Polycystic Ovary Disease", GeneMasterName: "RAD50", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD50", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51C", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51C", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51C", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Head And Neck Cancer", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "RAD51C", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51C", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51C", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Tracheoesophageal Fistula¬†", GeneMasterName: "RAD51C", Gender: "Either", Organ: "Mediastinum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51D", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51D", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RAD51D", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RB1", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Pineoblastoma", GeneMasterName: "RB1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RB1", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Head And Neck Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RB1", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RB1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "RB1", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RB1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Retinoblastoma", PredominantCancerSubtype: "Retinoblastoma", GeneMasterName: "RB1", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Soft Tissue Sarcoma", GeneMasterName: "RB1", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Adamantinoma", GeneMasterName: "RB1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Osteosarcoma", GeneMasterName: "RB1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RECQL", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RECQL", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Central Hypoventilation", GeneMasterName: "RET", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Gastrointestinal (Benign)", PredominantCancerSubtype: "Hirschsprung Disease", GeneMasterName: "RET", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RET", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "RET", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "RET", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Medullary Thyroid Cancer", GeneMasterName: "RET", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RINT1", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RINT1", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "RPS20", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "RUNX1", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Platelet disorder", GeneMasterName: "RUNX1", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Rheumatoid Arthritis", GeneMasterName: "RUNX1", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Systemic Mastocytosis", GeneMasterName: "RUNX1", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GIST", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHA", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "SDHA", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "SDHA", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Neural crest tumor", GeneMasterName: "SDHAF2", Gender: "Either", Organ: "Neuroendocrine"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "SDHAF2", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "SDHAF2", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Neoplasm", DiseaseName: "Adrenal Cortical (Benign)", PredominantCancerSubtype: "Adrenal Medulla Hyperplasia", GeneMasterName: "SDHB", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHB", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHB", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GIST", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHB", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "SDHB", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "SDHB", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "SDHB", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHB", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GIST", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHC", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "SDHC", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "SDHC", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "SDHC", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHD", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GIST", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHD", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "SDHD", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Merkel Cell Carcinoma", GeneMasterName: "SDHD", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "SDHD", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "SDHD", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SDHD", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SLX4", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SLX4", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood Vessel (Benign)", PredominantCancerSubtype: "Aortic Dilation", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Blood Vessel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMAD4", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Duodenum Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Duodenum"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioma", GeneMasterName: "BRCA2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Ependymoma", GeneMasterName: "HOXB13", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Adrenal Neoplasm", PredominantCancerSubtype: "Adrenal Adenoma", GeneMasterName: "APC", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Testicular Neoplasm", PredominantCancerSubtype: "Epididymal Cystadenomas", GeneMasterName: "VHL", Gender: "Male", Organ: "Testes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Neuroendocrine tumors", GeneMasterName: "VHL", Gender: "Either", Organ: "Neuroendocrine"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Pancreas (Benign)", PredominantCancerSubtype: "Pancreatic Cysts", GeneMasterName: "VHL", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Kidney Neoplasm", PredominantCancerSubtype: "Renal Angioma", GeneMasterName: "VHL", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Vertebral Defects", GeneMasterName: "SUFU", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Cholangiocarcinoma", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Bile Duct"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Colorectal Neoplasia", PredominantCancerSubtype: "Juvenile Polyps", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Laryngotracheal Stenosis", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Psychiatric", PredominantCancerSubtype: "Obsessive-Compulsive Disorder", GeneMasterName: "SMAD4", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Prognathism", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood Vessel (Benign)", PredominantCancerSubtype: "Pulmonary Arterial Hypertension", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Blood Vessel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Dysmorphic Feature", PredominantCancerSubtype: "Short Stature", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMAD4", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCA4", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intellectual Disability", GeneMasterName: "SMARCA4", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCA4", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)", GeneMasterName: "SMARCA4", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Thoracic Sarcomas", GeneMasterName: "SMARCA4", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Rhabdoid Tumour", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCA4", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Developmental", PredominantCancerSubtype: "Intellectual Disability", GeneMasterName: "SMARCB1", Gender: "Either", Organ: "CNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Peripheral Nervous System Neoplasm", PredominantCancerSubtype: "Schwannoma", GeneMasterName: "SMARCB1", Gender: "Either", Organ: "PNS"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Rhabdoid Tumour", PredominantCancerSubtype: "Unknown", GeneMasterName: "SMARCB1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Meningioma", GeneMasterName: "SMARCE1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Cholangiocarcinoma", GeneMasterName: "STK11", Gender: "Either", Organ: "Bile Duct"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Cervical Cancer", PredominantCancerSubtype: "Cervical Adenoma Malignum", GeneMasterName: "STK11", Gender: "Female", Organ: "Cervix"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "GI Neoplasm", PredominantCancerSubtype: "Hamartomatous Polyps", GeneMasterName: "STK11", Gender: "Either", Organ: "GI"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "STK11", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Orofacial Cleft", GeneMasterName: "STK11", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Ovarian Neoplasm", PredominantCancerSubtype: "Sex Cord Tumor", GeneMasterName: "STK11", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Perioral Freckling", GeneMasterName: "STK11", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Small Intestine Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Either", Organ: "Small Bowel"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Testicular Neoplasm", PredominantCancerSubtype: "Sertoli Cell Tumor", GeneMasterName: "STK11", Gender: "Male", Organ: "Testes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Thyroid Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "STK11", Gender: "Either", Organ: "Thyroid"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Meningioma", GeneMasterName: "SUFU", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "SUFU", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Bone Neoplasm", PredominantCancerSubtype: "Keratocystic Odontogenic Tumor", GeneMasterName: "SUFU", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lymphomesentric Cyst", PredominantCancerSubtype: "Unknown", GeneMasterName: "SUFU", Gender: "Either", Organ: "Unknown"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Cataract", GeneMasterName: "SUFU", Gender: "Either", Organ: "Eye"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Ovarian (Benign)", PredominantCancerSubtype: "Unknown", GeneMasterName: "SUFU", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Palmoplantar Pits", GeneMasterName: "SUFU", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Pleural Cyst", GeneMasterName: "SUFU", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Bifid Rib", GeneMasterName: "SUFU", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Nevi", GeneMasterName: "SUFU", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Basal Cell Carcinoma", GeneMasterName: "SUFU", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Aplastic Anemia, bone marrow failure", GeneMasterName: "TERC", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Abnormal skin pigmentation, nail dystrophy", GeneMasterName: "TERC", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "TERC", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Prostate Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Male", Organ: "Prostate"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Soft Tissue Sarcoma", GeneMasterName: "TP53", Gender: "Either", Organ: "Soft Tissue"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Sarcoma", PredominantCancerSubtype: "Osteosarcoma", GeneMasterName: "TP53", Gender: "Either", Organ: "Bone"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "TP53", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Basal Cell Carcinoma", GeneMasterName: "TP53", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Wilms Tumor", PredominantCancerSubtype: "Nephroblastoma", GeneMasterName: "TP53", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC1", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Cardiovascular Neoplasm", PredominantCancerSubtype: "Rhabdomyomas", GeneMasterName: "TSC1", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Cortical Dysplasia", GeneMasterName: "TSC1", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Leukoplakia", GeneMasterName: "TERC", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Pulmonary Fibrosis", GeneMasterName: "TERC", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "TERC", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Blood (Benign)", PredominantCancerSubtype: "Aplastic Anemia", GeneMasterName: "TERT", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TERT", Gender: "Either", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Skin (Benign)", PredominantCancerSubtype: "Dyskeratosis Congenita", GeneMasterName: "TERT", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Gallbladder Cancer", GeneMasterName: "TERT", Gender: "Either", Organ: "Gallbladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "AML", GeneMasterName: "TERT", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "TERT", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lung (Benign)", PredominantCancerSubtype: "Pulmonary Fibrosis", GeneMasterName: "TERT", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Skin Cancer (Non-Melanoma)", PredominantCancerSubtype: "Squamous Cell Carcinoma", GeneMasterName: "TERT", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Lymphadenopathy", PredominantCancerSubtype: "Generalized", GeneMasterName: "TMEM127", Gender: "Either", Organ: "Nodes"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "TMEM127", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "TMEM127", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Cardiovascular (Benign)", PredominantCancerSubtype: "Tricuspid Atresia", GeneMasterName: "TMEM127", Gender: "Either", Organ: "Heart"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Adrenal Cortical Carcinoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Cholangiocarcinoma", GeneMasterName: "TP53", Gender: "Either", Organ: "Bile Duct"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Bladder Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Urinary Bladder"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Glioma", GeneMasterName: "TP53", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Choroid Plexus Papilloma", GeneMasterName: "TP53", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "Medulloblastoma", GeneMasterName: "TP53", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Breast Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Female", Organ: "Breast"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Colorectal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Colorectal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Endometrial Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Female", Organ: "Uterus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Esophageal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Esophagus"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Gastric Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Gastric"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 0, DiseaseType: "Cancer", DiseaseName: "Head And Neck Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Hepatobiliary Cancer", PredominantCancerSubtype: "Hepatocellular Cancer", GeneMasterName: "TP53", Gender: "Either", Organ: "Liver"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Leukemia", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Blood"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Melanoma", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Skin"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Nasopharyngeal Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Head and neck"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Ovarian Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Female", Organ: "Ovary"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Pancreatic Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TP53", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Oropharynx (Benign)", PredominantCancerSubtype: "Hamartomas Of Tongue", GeneMasterName: "TSC1", Gender: "Either", Organ: "Oropharynx"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "TSC1", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC1", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Lymphangiomyomatosis", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC1", Gender: "Either", Organ: "Lymphatic"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "Bone (Benign)", PredominantCancerSubtype: "Polysyndactyly", GeneMasterName: "TSC1", Gender: "Either", Organ: "Hand"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Benign", DiseaseName: "CNS (Benign)", PredominantCancerSubtype: "Cortical Dysplasia", GeneMasterName: "TSC2", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "TSC2", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 9, DiseaseType: "Cancer", DiseaseName: "Lung Cancer", PredominantCancerSubtype: "Unknown", GeneMasterName: "TSC2", Gender: "Either", Organ: "Lung"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Brain Tumor", PredominantCancerSubtype: "CNS Hemangioblastoma", GeneMasterName: "VHL", Gender: "Either", Organ: "Brain"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Cancer", DiseaseName: "Kidney Cancer", PredominantCancerSubtype: "Renal Cell Carcinoma", GeneMasterName: "VHL", Gender: "Either", Organ: "Kidney"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Pheochromocytoma", GeneMasterName: "VHL", Gender: "Either", Organ: "Adrenal"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Pheochromocytoma/Paraganglioma", PredominantCancerSubtype: "Paraganglioma", GeneMasterName: "VHL", Gender: "Either", Organ: "Nerve"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Neoplasm", DiseaseName: "Neuroendocrine", PredominantCancerSubtype: "Pancreatic Neuroendocrine Tumor", GeneMasterName: "VHL", Gender: "Either", Organ: "Pancreas"})
(:LKP_GENECANCERFORPRINTOUT {FinalVerdict: 1, DiseaseType: "Benign", DiseaseName: "Eye (Benign)", PredominantCancerSubtype: "Anirida", GeneMasterName: "WT1", Gender: "Either", Organ: "Eye"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hNTH1", GeneMasterName: "NTHL1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HPC9", GeneMasterName: "HOXB13"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HPH-2", GeneMasterName: "EGLN1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HPOT1", GeneMasterName: "POT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HRAS1", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "H-RASIDX", GeneMasterName: "HRAS"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HRCA1", GeneMasterName: "VHL"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "HsFH", GeneMasterName: "FH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hSNF2b", GeneMasterName: "SMARCA4"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hSNFS", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hTR", GeneMasterName: "TERC"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "hTRT", GeneMasterName: "TERT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "ILFS3", GeneMasterName: "RINT1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "IMD21", GeneMasterName: "GATA2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "INI1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "INI-1", GeneMasterName: "SMARCB1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "JBTS32", GeneMasterName: "SUFU"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "K12H4.8-LIKE", GeneMasterName: "DICER1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LAM", GeneMasterName: "TSC1"})
(:syndrome {name: "MEN1", types: ["Dominant"], verbiages: ["Autosomal dominant multiple endocrine neoplasia type 1 (MEN1) syndrome (MedGen UID: 9957). Multiple endocrine neoplasia type 1 is a highly penetrant condition associated with endocrine tumors in the parathyroid, anterior pituitary, thymus, gastro-entero-pancreatic tract and adrenal glands. Affected individuals may also have facial angiofibromas, collagenomas, lipomas, meningiomas, ependymomas and leiomyomas. While most MEN1-associated tumors are noncancerous, there is an increased risk of malignant transformation. Parathyroid tumors are the primary MEN1-associated endocrinopathy with symptoms typically developing at 20-25 years of age (PMID: 32971521)."]})
(:syndrome {name: "MEN2b", types: ["Dominant"], verbiages: ["The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B.  In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area."]})
(:syndrome {name: "MEN4", types: ["Dominant"], verbiages: ["Autosomal dominant multiple endocrine neoplasia type 4 (MEN4) (MedGen UID: 373469).  MEN4 is characterized by parathyroid and pituitary tumors as well as tumors of the adrenal glands, kidney and reproductive organs (PMID: 23933118, 23140918)."]})
(:syndrome {name: "Neurofibromatosis, type 1", types: ["Dominant"], verbiages: ["Autosomal dominant neurofibromatosis type 1 (NF1) (MedGen UID: 18013).   NF1 is a neurocutaneous disorder associated with an increased risk of several types of benign and malignant tumors. Primary features include multiple cafe-au-lait spots, inguinal freckling and neurofibromas. NF1 is highly variable in its expression, even among affected members of the same family. There is an increased risk for tumors of the central nervous system neoplasms and other malignancies including female breast cancer, gastrointestinal stromal tumors, pheochromocytoma and soft tissue sarcomas (PMID: 20301288). Approximately one-half of NF1 cases are inherited, and the remainder are the result of de novo mutations (PMID: 20082463)."]})
(:syndrome {name: "Von Hippel Lindau Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant von Hippel-Lindau (VHL) syndrome (MedGen UID: 42458).  Von Hippel-Lindau syndrome is associated with an increased risk of developing various noncancerous tumors throughout the body including hemangioblastomas of the central nervous system and retina, head and neck paragangliomas, pheochromocytomas, endolymphatic sac tumors and epididymal cystadenomas. Although most tumors are benign, there is a 17-70% risk of developing clear cell renal cell carcinoma and an 8-17% risk for pancreatic neuroendocrine tumors (PMID: 20301636, 28620007, 31095066). Approximately 20% of VHL cases are de novo (PMID: 21386872, 25611110). Although genotype-phenotype correlations have been suggested, their diagnostic relevance is unclear and therefore should not impact medical management (PMID: 21386872, 20301636)."]})
(:syndrome {name: "Attenuated FAP", types: ["Dominant"], verbiages: ["Genotype-phenotype studies have suggested that pathogenic variants in the 5' and 3' areas of the APC gene may result in AFAP; however clinical symptoms may not be accurately predicted by genotype alone (PMID: 16461775, 8522331, 8655134)."]})
(:syndrome {name: "Hereditary Breast Cancer Syndrome"})
(:syndrome {name: "MUTYH-Associated Polyposis Syndrome"})
(:syndrome {name: "Neurofibromatosis-Noonan syndrome", types: ["Dominant"], verbiages: ["Neurofibromatosis-Noonan syndrome (NFNS) (MedGen UID: 419089).  NFNS is characterized by classic neurofibromatosis in addition to short stature, distinctive facial features, broad neck, congenital heart defects, speech delay and pectus anomaly (PMID: 16542390, 24357598, 26178382)."]})
(:syndrome {name: "FAP", types: ["Dominant"], verbiages: ["FAP is characterized by the development of hundreds to thousands of adenomatous colon polyps, with 70-100% penetrance. Extracolonic cancers include duodenal, stomach, hepatic, brain, pancreatic, and thyroid. AFAP is associated with fewer colon polyps, reduced penetrance and later cancer onset (PMID: 31070935)"]})
(:syndrome {name: "MEN2a", types: ["Dominant"], verbiages: ["The RET gene is associated with autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958) and nonsyndromic Hirschsprung disease (MedGen UID: 419188).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501)."]})
(:syndrome {name: "Bannayan-Riley-Ruvalcaba syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Bannayan-Riley-Ruvalcaba syndrome"]})
(:syndrome {name: "Familial Medullary Thyroid Carcinoma Syndrome"})
(:syndrome {name: "Blepharocheilodontic Syndrome"})
(:syndrome {name: "Juvenile polyposis_hereditary hemorrhagic telangiectasia syndrome", types: ["Dominant"], verbiages: ["Hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400).  LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.      The SMAD4 gene is associated with autosomal dominant juvenile polyposis syndrome (JPS) (MedGen UID: 87518), hereditary hemorrhagic telangiectasia (HHT) (MedGen UID: 331400) and Myhre syndrome (MedGen UID: 167103).  Loss-of-function (LOF) variants in SMAD4 are associated with juvenile polyposis syndrome (JPS), a condition characterized by the development of numerous hamartomatous polyps in the gastrointestinal (GI) tract. The risk of developing GI cancer is 40-50% (PMID: 22846733, 9869523). There is also a 21% risk of gastric cancer (PMID: 12221036) and an increased risk of pancreatic cancer; although, lifetime risks are not established (PMID: 20859198, 2705469). LOF SMAD4 variants have been reported in individuals with symptoms of both JPS and hereditary hemorrhagic telangiectasia (HHT). HHT is characterized by multiple arteriovenous malformations (AVMs), including small AVMs called telangiectasias.   Gain-of-function (GOF) variants in SMAD4 are associated with Myhre syndrome, a rare, severe connective tissue disorder that is diagnosed in childhood. This condition is characterized by short stature, distinctive facial features, hearing loss and intellectual disability. Additional findings include arthropathy, muscle hypertrophy, cardiovascular abnormalities and progressive fibrosis and airway compromise (PMID: 27302097, 24424121, 24715504, 27562837). To date, all reported cases are de novo (PMID: 26636501, 27302097). Individuals with Myhre syndrome have not been described as having features of JPS or HHT."]})
(:syndrome {name: "Melanoma astrocytoma syndrome"})
(:syndrome {name: "Muir-Torre syndrome"})
(:syndrome {name: "MUTYH-related AFAP"})
(:syndrome {name: "Atrial fibrillation, familial"})
(:syndrome {name: "Dilated Cardiomyopathy"})
(:syndrome {name: "Cantu Syndrome"})
(:syndrome {name: "Hypertrophic Cardiomyopathy"})
(:syndrome {name: "Bloom Syndrome", types: ["Recessive"], verbiages: ["Bloom syndrome is characterized by proportionate small stature, microcephaly, abnormal skin pigmentation, facial anomalies, sun-sensitive facial erythema, infertility, immunodeficiency, and a predisposition to a wide variety of cancers (PMID: 16763388, 5770175)."]})
(:syndrome {name: "Mosaic Variegated Aneuploidy Syndrome"})
(:syndrome {name: "Neonatal Severe Hyperparathyroidism", types: ["Recessive"], verbiages: ["NSHPT presents in infancy with parathyroid hyperplasia, elevated parathyroid hormone levels and hypercalcemia, which can result in bone demineralization and failure to thrive. Untreated NSHPT may lead to a severe, life-threatening neurological disorder (PMID: 31189130). There are reports of homozygous CASR variants causing a milder FHH-like phenotype (PMID: 31189130)."]})
(:syndrome {name: "Cystic Fibrosis & Congenital Absence Of The Vas Deferens (CAVD),"})
(:syndrome {name: "Dyskeratosis Congenita", types: ["Dominant", "Recessive"], verbiages: ["The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793  Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual‚Äôs telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200).", "The TERT gene is associated with both autosomal dominant and autosomal recessive TERT-related dyskeratosis congenita (DC) spectrum disorders (MedGen UID: 462793  Autosomal dominant TERT-related conditions encompass a broad spectrum of features with varying degrees of severity complicated by reduced penetrance, variable expressivity, anticipation, delayed age of onset and multifactorial effects (PMID: 32923861, 25237198). Symptoms, if present, may include aplastic anemia, idiopathic pulmonary fibrosis and/or liver cirrhosis, among others (PMID: 17392301, 27836952, 21436073, 26022962). Genotype-phenotype correlation is unclear but may be influenced by an individual‚Äôs telomere length (PMID: 33184060).

Autosomal recessive TERT-related conditions include those associated with dominant disease, but may also have features of dyskeratosis congenita (DC). DC is characterized by abnormal skin pigmentation, nail dystrophy, oral leukoplakia, progressive bone marrow failure and increased risk for certain cancers such as squamous cell carcinoma and hematolymphoid neoplasms (PMID: 25170286). Some affected individuals may have a severe form of DC called Hoyeraal-Hreidarsson syndrome (HHS) that typically presents in the first year of life with intrauterine growth restriction, cerebellar hypoplasia, immunodeficiency and bone marrow failure in addition to features of DC (PMID: 25940403, 23335200)."]})
(:syndrome {name: "Perlman Syndrome", types: ["Recessive"], verbiages: ["The DIS3L2 gene is associated with autosomal recessive Perlman syndrome (MedGen UID: 162909).  Perlman syndrome is an overgrowth disorder characterized by macrosomia, renal dysplasia, nephroblastomatosis and Wilms tumor (PMID: 23613427). Affected infants have a high rate of neonatal morbidity; the incidence of Wilms tumor in those who survive the neonatal period has been estimated at 64% (PMID: 18780370)."]})
(:syndrome {name: "Cockayne Syndrome"})
(:syndrome {name: "fumarate hydratase deficiency", types: ["Recessive"], verbiages: ["Autosomal recessive fumarate hydratase deficiency (FHD) (MedGen UID: 87458).  FHD is an inborn error of metabolism that causes infantile encephalopathy, failure to thrive, hypotonia, lethargy and seizures. Affected individuals often have microcephaly, distinctive facial features, structural brain abnormalities and developmental delay."]})
(:syndrome {name: "Ataxia-Telangiectasia-Like Disorder (ATLD)"})
(:syndrome {name: "Colonic Polyposis And Colorectal Cancer", types: ["Dominant"], verbiages: ["Autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 436445). Individuals with a pathogenic POLD1 variant typically presents with 10-100 colonic polyps and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 23263490, 26133394, 24501277)."]})
(:syndrome {name: "Tuberous Sclerosis Complex", types: ["Dominant"], verbiages: ["Autosomal dominant tuberous sclerosis complex (TSC) (MedGen UID: 344288).  (MedGen UID: 348170).  TSC is characterized by benign hamartomas of multiple organ systems, skin abnormalities including hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques and ungual fibromas. Affected individuals often develop benign brain tumors including cortical tubers, subependymal nodules and subependymal giant cell astrocytomas that may result neurological and neurodevelopmental symptoms such as headaches, nausea, seizures, behavioral changes and learning difficulties. TSC is also associated with cardiac rhabdomyomas, renal angiomyolipomas, retinal nodular hamartomas, lymphangioleiomyomas and pancreatic neuroendocrine tumors. These tumors are typically benign; however, malignant transformation has been described (PMID: 2069856, 11920808), particularly in the kidneys (PMID: 32953421)."]})
(:syndrome {name: "NTHL1 Tumor Syndrome"})
(:syndrome {name: "Baller-Gerold Syndrome"})
(:syndrome {name: "Rapadilino Syndrome"})
(:syndrome {name: "Turcot Syndrome"})
(:syndrome {name: "Arrhythmogenic right ventricular dysplasia"})
(:syndrome {name: "arrhythmogenic right ventricular dysplasia"})
(:syndrome {name: "Carney Complex", types: ["Dominant"], verbiages: ["Autosomal dominant Carney complex (CNC) (MedGen UID: 388559).			  CNC is characterized by myxomas, endocrine tumors and schwannomas. Pigmentary skin lesions are a defining feature, present in over 80% of cases. Primary pigmented nodular adrenocortical disease (PPNAD), which can lead to Cushing's syndrome, develops in 25-60% of affected individuals. CNC is associated with an increased risk of developing thyroid nodules, thyroid cancer, myxomas in the heart, breast, skin, throat and female genital tract in addition to psammomatous melanotic schwannomas (PMS) and ovarian tumors. Large-cell calcifying Sertoli cell tumors (LCCSCTs) are observed in nearly all affected males (PMID: 26130139, 16756677)."]})
(:syndrome {name: "Trichohepatoenteric Syndrome"})
(:syndrome {name: "Rothmund-Thomson Syndrome"})
(:syndrome {name: "Mitochondrial Complex II Deficiency", types: ["Recessive"], verbiages: ["Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy (MedGen UID: 344401). Autosomal recessive mitochondrial complex II deficiency with or without cardiomyopathy is characterized by progressive encephalopathy, myopathy, hypotonia and leukodystrophy (PMID: 22972948, 23322652, 27683074). Poor growth, short stature and joint contractures are common findings while only a subset of affected individuals also develop cardiomyopathy (PMID: 22972948, 23322652). The severity of features is highly variable, ranging from adult-onset of milder symptoms with normal cognition to severe, life-threatening infantile onset (PMID: 23322652). Clinical correlation is advised."]})
(:syndrome {name: "Hereditary Pancreatitis"})
(:syndrome {name: "Familial Erythrocytosis Type 2", types: ["Recessive"], verbiages: ["Autosomal recessive familial erythrocytosis, type 2 (MedGen UID: 332974).  Familial erythrocytosis is characterized by the abnormally high production of red blood cells (erythrocytes), which can cause headaches, dizziness, nosebleeds, shortness of breath and predisposition to excessive clotting. Familial erythrocytosis has incomplete penetrance; many individuals with biallelic pathogenic variants will never develop clinical symptoms (PMID: 24115288, 23733342)."]})
(:syndrome {name: "Werner Syndrome"})
(:syndrome {name: "Androgen Insensitivity Syndrome"})
(:syndrome {name: "Blepharocheilodontic syndrome"})
(:syndrome {name: "Brugada syndrome"})
(:syndrome {name: "Clouston syndrome"})
(:syndrome {name: "Danon disease"})
(:syndrome {name: "Fabry disease"})
(:syndrome {name: "HUTCHINSON-GILFORD PROGERIA SYNDROME"})
(:syndrome {name: "CDC73-related conditions", types: ["Dominant"], verbiages: ["Autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), parathyroid carcinoma, and familial isolated hyperparathyroidism (FIH) (MedGen UID: 310065, 146361, 333554), collectively referred to as CDC73-related conditions. There is also evidence suggesting CDC73 is associated with autosomal dominant predisposition to malignant uterine tumors (PMID: 23293331, 12434154, 23029104). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  CDC73-related conditions are characterized by primary hyperparathyroidism, which occurs in over 70% of cases (PMID: 16720667, 20301744). This primary hyperparathyroidism is typically caused by benign parathyroid adenomas, though it can also be due to an underlying parathyroid carcinoma (PMID: 20301744). Additional features include ossifying jaw fibromas, uterine fibroids, renal cysts, hamartomas and Wilms tumor."]})
(:syndrome {name: "immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome"})
(:syndrome {name: "McLeod neuroacanthocytosis syndrome"})
(:syndrome {name: "Cutaneous telangiectasia and cancer syndrome, familial"})
(:syndrome {name: "Seckel syndrome 1"})
(:syndrome {name: "Oligodontia-Colorectal Cancer Syndrome", types: ["Dominant"], verbiages: ["(MedGen UID: 324868).								  Oligodontia-colorectal cancer syndrome is associated with colon polyps and colorectal cancer as well as features of ectodermal dysplasia including severe oligodontia and sparse eyebrows, scalp and body hair (PMID: 15042511, 21416598, 21626677)."]})
(:syndrome {name: "BAP1 Tumor Predisposition Syndrome", types: ["Dominant"], verbiages: ["(MedGen UID: 482122). BAP1 tumor predisposition syndrome is associated with an increased risk for cutaneous and uveal melanoma, malignant pleural mesothelioma and renal cell carcinoma; lifetime cancer risks are unclear (PMID: 22935333, 23684012)."]})
(:syndrome {name: "Familial Hypocalciuric Hypercalcemia", types: ["Dominant"], verbiages: ["Characterized by hypercalcemia and hypocalciuria, although most affected individuals are asymptomatic (PMID: 31189130)."]})
(:syndrome {name: "Familial Isolated Hyperparathyroidism", types: ["Dominant"], verbiages: ["Familial isolated hyperparathyroidism (FIHP) (OMIM: 145000). Autosomal dominant familial isolated hyperparathyroidism (FIHP), characterized by parathyroid adenomas or hyperplasia without other associated tumors or endocrinopathies (PMID: 12213668, 12699448). Individuals with FIHP often present with one or more hyperplastic parathyroid glands, resulting in elevated parathyroid hormone and hypercalemia; like FHH, most individuals are asymptomatic due to early diagnosis and treatment (PMID: 31189130)."]})
(:syndrome {name: "Beckwith-Wiedemann Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Beckwith-Wiedemann syndrome (BWS) (MedGen UID: 2562).  BWS is an overgrowth disorder characterized by macrosomia, macroglossia, visceromegaly, hemihyperplasia, omphalocele, neonatal hypoglycemia, and renal abnormalities. There is an increased risk for neoplasia, particularly Wilms tumor, hepatoblastoma, neuroblastoma, adrenocortical carcinoma and rhabdomyosarcoma; these risks are highest in the newborn period through eight years of age (PMID: 24335096, 24911853, 20301568)."]})
(:syndrome {name: "Familial Acute Myeloid Leukemia", types: ["Dominant"], verbiages: ["(MedGen UID: 9730).  Familial AML is characterized by multiple diagnoses of this cancer type within a family. The age at diagnosis can be variable; however, it appears to have an earlier onset than sporadic cases (PMID: 18946494, 26162409)."]})
(:syndrome {name: "Spiegler-Brooke syndrome"})
(:syndrome {name: "Scapuloperoneal syndrome, neurogenic, Kaeser type"})
(:syndrome {name: "DICER1-Pleuropulmonary Blastoma Familial Tumor Predisposition Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome (MedGen UID: 449020).  DICER1-related pleuropulmonary blastoma familial tumor predisposition syndrome is associated with an increased risk for certain types of rare tumors and cancers that may present in childhood. Noncancerous neoplasias include cystic nephroma, nasal chondromesenchymal hamartomas, thyroid adenomas and goiter. There is also an increased risk of certain malignancies including pleuropulmonary blastoma, ovarian sex cord-stromal tumors, Sertoli-Leydig cell tumors, genitourinary embryonal rhabdomyosarcoma, renal sarcoma, Wilms tumor, thyroid cancer, ciliary body medulloepithelioma, pituitary blastoma and pineoblastoma."]})
(:syndrome {name: "X-Linked Dyskeratosis Congenita"})
(:syndrome {name: "Skin fragility woolly hair syndrome"})
(:syndrome {name: "neonatal inflammatory skin and bowel disease", types: ["Recessive"], verbiages: ["Pathogenic loss-of-function (LOF) variants in EGFR are associated with neonatal inflammatory skin and bowel disease, a rare condition affecting the skin, hair, kidney, growth, gastrointestinal and respiratory systems. Skin manifestations include erosions, scaling, inflammatory rash and infection. Recurrent respiratory and gastrointestinal infections as well as severe diarrhea and vomiting may occur (PMID: 32602142, 29899996, 26436111, 24691054). GOF variants in EGFR are not known to be associated with autosomal recessive neonatal inflammatory skin and bowel disease."]})
(:syndrome {name: "Hereditary Pulmonary Arterial Hypertension (PAH)"})
(:syndrome {name: "Cerebrooculofacioskeletal syndrome"})
(:syndrome {name: "MEN2", types: ["Dominant"], verbiages: ["Autosomal dominant multiple endocrine neoplasia type 2 (MEN2) syndrome (MedGen UID: 9958).  Pathogenic gain-of-function (GOF) RET variants cause MEN2, a condition associated with cancers of the endocrine glands that has two clinical subtypes: MEN2A and MEN2B. MEN2A is characterized by medullary thyroid carcinoma (MTC) (up to 95% of cases), pheochromocytoma (20-50% of cases) and hyperparathyroidism (10-30% of cases). Clinical variability within and among families has been described (PMID: 33812987). Some individuals with MEN2A may only develop medullary thyroid carcinoma, which is also known as familial medullary thyroid carcinoma (FMTC) (PMID: 21552134, 31390501). In addition to the same risks for medullary thyroid cancer and pheochromocytoma, MEN2B is also associated with tall stature, arachnodactyly, hypermobility, scoliosis and neuromas in the intestines and perioral area. 

Pathogenic loss-of-function (LOF) RET variants are associated with Hirschsprung disease (HD), a condition characterized by congenital agenesis of ganglion in the colon. HD is typically diagnosed in early infancy, although less severe cases may be diagnosed later in childhood (PMID: 16448984)."]})
(:syndrome {name: "Howel-Evans syndrome"})
(:syndrome {name: "Sessile serrated polyposis cancer syndrome"})
(:syndrome {name: "Familial Platelet Disorder With Associated Myeloid Malignancy", types: ["Dominant"], verbiages: ["Autosomal dominant familial platelet disorder with associated myeloid malignancy (MedGen UID: 321945).  Familial platelet disorder is characterized by mild to moderate thrombocytopenia, platelet abnormalities, and a predisposition to develop myelodysplasia and/or acute myeloid leukemia (PMID: 19357396, 18723428). It should be noted that acquired (somatic) variants may arise in the blood, particularly with advancing age, and may even appear heterozygous (PMID: 25426837, 25426838, 31490007, 31881331). Results from blood or saliva specimens alone may not distinguish between germline and acquired RUNX1 variants and additional testing may be appropriate."]})
(:syndrome {name: "Shwachman syndrome"})
(:syndrome {name: "Leigh Syndrome"})
(:syndrome {name: "Cowden-Like Syndrome"})
(:syndrome {name: "Rhabdoid Tumor Predisposition Syndrome 2", types: ["Dominant"], verbiages: ["Rhabdoid tumor predisposition syndrome, type 2.  Loss-of-function (LOF) variants in SMARCA4 are associated with RTPS2, a childhood-onset condition associated with rhabdoid tumors that typically develop in the kidneys and central nervous system. SCCOHT, which is considered part of the RTPS2 clinical spectrum, is a specific type of ovarian cancer associated with hypercalcemia, early age of onset (average 25 years), and small, hyperchromatic cells with brisk mitotic activity. The lifetime risk of ovarian cancer is not well-established."]})
(:syndrome {name: "Rhabdoid Tumor Predisposition Syndrome 1", types: ["Dominant"], verbiages: ["Autosomal dominant rhabdoid tumor predisposition syndrome 1 (RTPS1) (MedGen UID: 322892)  RTPS is associated with an increased risk of rhabdoid tumors, a rare type of childhood cancer that most often develops in the kidneys and central nervous system."]})
(:syndrome {name: "Schwannomatosis", types: ["Dominant"], verbiages: ["Schwannomatosis (MedGen UID: 234775). Schwannomatosis is characterized by the development of multiple spinal, peripheral, and cranial nerve schwannomas. The absence of vestibular schwannomas distinguishes schwannomatosis from neurofibromatosis type 2 (PMID: 24933152, 19898272, 21208904)."]})
(:syndrome {name: "Coffin-Siris Syndrome"})
(:syndrome {name: "Familial Meningioma", types: ["Dominant"], verbiages: ["Autosomal dominant familial meningioma (MedGen UID: 232281)  Pathogenic loss-of-function (LOF) SMARCE1 variants are associated with familial meningioma. Meningiomas are typically slow growing benign tumors derived from the meningeal tissue of the brain and spinal cord (PMID: 23377182, 25143307)."]})
(:syndrome {name: "Legius Syndrome"})
(:syndrome {name: "Gorlin Syndrome", types: ["Dominant"], verbiages: ["The PTCH1 gene is associated with autosomal dominant basal cell nevus syndrome (BCNS), also known as Gorlin syndrome (MedGen UID: 2554). There is also evidence suggesting PTCH1 is associated with autosomal dominant holoprosencephaly (HPE) (MedGen: 372134). The data, however, are preliminary and insufficient to make a determination regarding this relationship.  PTCH1-associated BCNS is an early-onset condition characterized by up to a 90% risk of developing multiple skin cancers, specifically basal cell carcinomas (BCCs). Approximately 90% will develop odontogenic keratocysts. BCNS is also associated with cardiac fibromas and ovarian fibromas in affected females. Additional findings include palmar and plantar pits, calcification of the falx cerebri, abnormalities of the ribs and vertebrae, cleft lip and/or palate, macrocephaly and polydactyly. Medulloblastomas occur in up to 5% of children with PTCH1-associated BCNS (PMID: 33066274)."]})
(:syndrome {name: "Joubert Syndrome", types: ["Recessive"], verbiages: ["Autosomal recessive Joubert syndrome (MedGen UID: 1626697), and autosomal dominant congenital ocular motor apraxia (COMA) (PMID: 33024317).  

Joubert syndrome (JS) is a highly variable condition associated with a specific anomaly of the cerebellar vermis and brainstem causing the characteristic \"molar tooth sign\" (MTS) on magnetic resonance imaging. Additional findings include ataxia, polydactyly, distinctive facial features, episodic tachypnea or apnea and abnormal eye movements (PMID: 24360807). Cognitive abilities may range from normal to severely impaired. The term \"Joubert syndrome and related disorders (JSRD)\" is used to describe JS and other conditions that have MTS as well as other overlapping clinical features (PMID: 17603801, 14981712). While the SUFU gene is associated with JS, LOF variants in this gene have not been observed in individuals with this condition."]})
(:syndrome {name: "Denys-Drash Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Denys-Drash syndrome (MedGen UID: 181980)  Denys-Drash syndrome, which has a high risk of Wilms tumor and genitourinary anomalies"]})
(:syndrome {name: "Frasier Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant Frasier syndrome (MedGen UID: 215533).  Frasier syndrome, which is more often associated with gonadoblastoma and less often with Wilms tumor (PMID: 23295293, 9529364)."]})
(:syndrome {name: "Meacham syndrome"})
(:syndrome {name: "WAGR Syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant WAGR syndrome (MedGen UID: 64512) Deletions of WT1 along with the neighboring PAX6 gene are associated with WAGR (Wilms tumor-aniridia-genital anomalies-retardation) syndrome, characterized by Wilms tumor, genitourinary anomalies, intellectual disability, and aniridia (PMID: 22692063)."]})
(:syndrome {name: "Macular dystrophy, patterned, 2", types: ["Dominant"], verbiages: ["Autosomal dominant butterfly-shaped pigmentary macular dystrophy (MedGen UID: 332348). To date, loss-of-function variants in CTNNA1 have not been associated with butterfly-shaped pigmentary macular dystrophy.  Butterfly-shaped pigmentary macular dystrophy is a form of patterned dystrophies of the retinal pigment epithelium, characterized by accumulation of pigment in the macula that resembles the wings of a butterfly (PMID: 12724643). Affected individuals typically present from middle age with mildly reduced visual acuity and color vision. The activity of the RPE measured by electrooculogram (EOG) recordings may be abnormal (PMID: 26691986). Retinitis pigmentosa-like changes have been observed in some cases (PMID: 22466463). The disease is relatively benign, but can progress to atrophy of the choroid and retina, resulting in severe vision loss, though the severity of the disease is highly variable, even within the same family (PMID: 26691986)."]})
(:syndrome {name: "xeroderma pigmentosum complementation group E"})
(:syndrome {name: "Dilated cardiomyopathy"})
(:syndrome {name: "Arrhythmogenic right ventricular cardiomyopathy"})
(:syndrome {name: "XFE progeroid syndrome"})
(:syndrome {name: "Seizures, scoliosis, and macrocephaly syndrome"})
(:syndrome {name: "Weaver Syndrome"})
(:syndrome {name: "X-Linked Fanconi Anemia"})
(:syndrome {name: "Hereditary Leiomyomatosis And Renal Cell Cancer (HLRCC)", types: ["Dominant"], verbiages: ["The FH gene is associated with autosomal dominant hereditary leiomyomatosis and renal cell cancer (HLRCC) (MedGen UID: 353771).  HLRCC is characterized by cutaneous leiomyomas, early onset uterine leiomyomas, kidney tumors and kidney cancer. Uterine leiomyomas, also known as fibroids, are present in nearly all affected females. The lifetime risk for renal cell carcinoma is approximately 21% (PMID: 31831373). Some individuals with a clinically significant change in FH may also develop paragangliomas (PGL) and pheochromocytomas (PCC). PGL are nervous system tumors that often form in the head, neck, spine or abdomen. PCC are adrenal gland tumors that may cause symptoms including tachycardia and hypertension. Most PGL and PCC are benign and while there is malignant potential, lifetime cancer risks are not clear."]})
(:syndrome {name: "Diamond-Blackfan Anemia"})
(:syndrome {name: "X-Linked GATA1-Related Cytopenia"})
(:syndrome {name: "GATA2 Deficiency", types: ["Dominant"], verbiages: ["The GATA2 gene is associated with autosomal dominant GATA2 deficiency (MedGen UID: 481660) and Emberger syndrome (MedGen UID: 481294).  GATA2 deficiency is an immunodeficiency syndrome that typically presents in late adolescence or early adulthood with neutropenia and recurrent infections. GATA2 deficiency is associated with an increased risk of myelodysplastic syndrome and acute myelogenous leukemia (AML)."]})
(:syndrome {name: "Simpson-Golabi-Behmel syndrome"})
(:syndrome {name: "Costello Syndrome", types: ["Dominant"], verbiages: ["Costello syndrome (MedGen UID: 108454).  Costello syndrome is characterized by intellectual disability, failure to thrive, cardiac malformations, short stature, loose skin with deep palmar and plantar creases, cerebellar overgrowth, predisposition to malignancy, and dysmorphic facial features including coarse facies, epicanthal folds, long eyelashes, sparse/curly hair, full lips, and a wide nasal bridge."]})
(:syndrome {name: "Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome"})
(:syndrome {name: "Heart-hand syndrome, Slovenian type"})
(:syndrome {name: "Lethal tight skin contracture syndrome"})
(:syndrome {name: "Hereditary Papillary Renal Cell Carcinoma", types: ["Dominant"], verbiages: ["Autosomal dominant predisposition to hereditary papillary renal cell carcinoma (HPRCC) (MedGen UID: 766). HPRCC is a rare, highly penetrant hereditary cancer syndrome characterized by an increased lifetime risk of developing type 1 papillary renal cell carcinoma (PRCC) (PMID: 24710684, 9563489, 12647800). These tumors are typically multifocal and bilateral (PMID: 8308957)."]})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LAM", GeneMasterName: "TSC2"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "LRCC", GeneMasterName: "FH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MASTC", GeneMasterName: "KIT"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MC2DN1", GeneMasterName: "SDHA"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MC2DN4", GeneMasterName: "SDHB"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MCL", GeneMasterName: "FH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MCUL1", GeneMasterName: "FH"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MDPT2", GeneMasterName: "CTNNA1"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MEN1B", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MEN4", GeneMasterName: "CDKN1B"})
(:LKP_GENE_AKA {DisplayAltNameGene: 0, AltNameGene: "MGRISCE1", GeneMasterName: "BLM"})
(:syndrome {name: "Tietz syndrome"})
(:syndrome {name: "Waardenburg syndrome type 2A", types: ["Dominant"], verbiages: ["Waardenburg syndrome, type 2a (MedGen UID: 349786).  Waardenburg syndrome, type 2a (WS2a) is characterized by congenital deafness and abnormal pigmentation of the iris, hair and skin. Additional neurologic manifestations including intellectual disability and myelination abnormalities have been described. WS2a is distinguished from Waardenburg type 1 by the absence of dystopia canthorum (PMID: 20127975)."]})
(:syndrome {name: "GIST-plus syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant GIST-plus syndrome (MedGen UID: 357402).  GIST-plus syndrome is associated with inflammatory fibroid polyps and fibroid tumors in the gastrointestinal tract in addition to gastrointestinal stromal tumors (GIST) that most often develop in the stomach and small intestines. GIST may be noncancerous but have malignant potential; however, specific lifetime cancer risks are not established. Some affected individuals may also have coarse skin and facial features in addition to broad hands and feet (PMID: 14699510, 18670346, 17087943)."]})
(:syndrome {name: "Macrocephaly/autism syndrome"})
(:syndrome {name: "Proteus Syndrome"})
(:syndrome {name: "Proteus-Like Syndrome"})
(:syndrome {name: "Cardiomyopathy, dilated, with woolly hair, keratoderma, and tooth agenesis"})
(:syndrome {name: "Dilated cardiomyopathy with woolly hair and keratoderma"})
(:syndrome {name: "Emery-Dreifuss muscular dystrophy 1, X-linked"})
(:syndrome {name: "Trichothiodystrophy 1, photosensitive"})
(:syndrome {name: "Xeroderma Pigmentosa"})
(:syndrome {name: "Trichothiodystrophy 2, photosensitive"})
(:syndrome {name: "Hereditary Prostate Cancer", types: ["Dominant"], verbiages: ["The HOXB13 gene is associated with autosomal dominant predisposition to prostate cancer (PMID: 31629417)."]})
(:syndrome {name: "Partial albinism"})
(:syndrome {name: "Hypercholesterolemia, autosomal recessive"})
(:syndrome {name: "Benign scapuloperoneal muscular dystrophy with cardiomyopathy"})
(:syndrome {name: "Congenital muscular dystrophy, LMNA-related"})
(:syndrome {name: "Emery-Dreifuss muscular dystrophy 3, autosomal recessive"})
(:syndrome {name: "Familial partial lipodystrophy 2"})
(:syndrome {name: "Myopathy, myosin storage, autosomal recessive"})
(:syndrome {name: "Myosin storage myopathy"})
(:syndrome {name: "Scapuloperoneal myopathy, MYH7-related"})
(:syndrome {name: "Hereditary insensitivity to pain with anhidrosis"})
(:syndrome {name: "Hypercholesterolemia, autosomal dominant, 3"})
(:syndrome {name: "CRC12", types: ["Dominant"], verbiages: ["The POLE gene is associated with an autosomal dominant predisposition to colonic adenomatous polyps and colon cancer (MedGen UID: 767374).  Individuals with a pathogenic POLE variant typically present with 10-100 adenomas and/or colorectal cancer, which is often microsatellite stable; specific lifetime cancer risks are not established (PMID: 26133394, 29120461, 32424176)."]})
(:syndrome {name: "POT1 tumor predisposition syndrome", types: ["Dominant"], verbiages: ["Autosomal dominant POT1 tumor predisposition syndrome (MedGen UID: 862913).  POT1 tumor predisposition syndrome is associated with predisposition to familial malignant melanoma (PMID: 24686846, 24686849, 26337759). Melanoma most often occurs in the skin, but may also develop in the eyes, ears, gastrointestinal tract, and oral and genital membranes. POT1 has also been associated with a susceptibility to additional cancers including glioma and angiosarcoma, among others; specific lifetime cancer risks are not clear (PMID: 25482530, 30165405, 25252913, 28853721, 27528712). Although consensus guidelines have not been published for individuals with pathogenic variants in POT1, evaluation and surveillance considerations are available in PMID: 33119245."]})
(:LKP_GENE_AKA {DisplayAltNameGene: 1, AltNameGene: "Glypican 3", GeneMasterName: "GPC3"})
